{"1ef4261ae10941a5c40556ab578fabc2d8f46b6f": [["Systemic Injustice for End-of-Life Careby ALAN ELBAUM I f George Floyd had died of Covid-19, the world would not know his name.", [["Covid", "TEST", 83, 88], ["Injustice", "OBSERVATION", 9, 18]]], ["If he had lived another thirty years and then died of cardiovascular disease, the world would not know his name.", [["cardiovascular", "ANATOMY", 54, 68], ["cardiovascular disease", "DISEASE", 54, 76], ["cardiovascular", "ANATOMICAL_SYSTEM", 54, 68], ["cardiovascular disease", "PROBLEM", 54, 76], ["cardiovascular", "ANATOMY", 54, 68], ["disease", "OBSERVATION", 69, 76]]], ["It is the particular brutality of the racism that killed him, a police officer kneeling on his neck for eight minutes and forty-six seconds as Floyd pleaded for breath, that has finally brought the United States to reckon with the racism that has never ceased terrorizing African Americans.", [["neck", "ANATOMY", 95, 99], ["neck", "ORGANISM_SUBDIVISION", 95, 99], ["breath", "PROBLEM", 161, 167], ["neck", "ANATOMY", 95, 99]]], ["Yet even if this atrocity had not occurred-even if Floyd had died of Covid-19, or even if he had died at age seventy-four from diabetes-related complications-the underlying cause of death would be the same: racism.Systemic Injustice for End-of-Life CareThe pandemic has rendered human life more precarious than it has been in decades.", [["diabetes", "DISEASE", 127, 135], ["death", "DISEASE", 182, 187], ["human", "ORGANISM", 279, 284], ["human", "SPECIES", 279, 284], ["human", "SPECIES", 279, 284], ["Covid", "TEST", 69, 74], ["diabetes", "PROBLEM", 127, 135], ["related complications", "PROBLEM", 136, 157], ["death", "PROBLEM", 182, 187], ["End-of-Life Care", "TREATMENT", 237, 253], ["Injustice", "OBSERVATION", 223, 232]]], ["All medical providers now practice palliative care.", [["practice palliative care", "TREATMENT", 26, 50]]], ["Asking patients about their visions of the good life and the good death has long been a standard practice, but this has taken on new urgency.", [["death", "DISEASE", 66, 71], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["new urgency", "PROBLEM", 129, 140]]], ["As a medical trainee, I have found palliative care to be the most uplifting of disciplines.", [["palliative care", "TREATMENT", 35, 50]]], ["To empower a patient to define her own trajectory, to prevent and to relieve suffering-these are gifts for patients and providers alike.", [["patient", "ORGANISM", 13, 20], ["patients", "ORGANISM", 107, 115], ["patient", "SPECIES", 13, 20], ["patients", "SPECIES", 107, 115]]], ["Here, I explore what it means to offer genuine palliative care when patients' illnesses are rooted in systemic injustice.Systemic Injustice for End-of-Life CareThe movement for palliative and hospice care emerged to offer an alternative to dying in intensive care, sedated or bristling with lines and tubes.", [["patients", "ORGANISM", 68, 76], ["tubes", "TISSUE", 301, 306], ["patients", "SPECIES", 68, 76], ["genuine palliative care", "TREATMENT", 39, 62], ["patients' illnesses", "PROBLEM", 68, 87], ["End-of-Life Care", "TREATMENT", 144, 160], ["palliative and hospice care", "TREATMENT", 177, 204], ["sedated", "TREATMENT", 265, 272], ["lines and tubes", "TREATMENT", 291, 306], ["Injustice", "OBSERVATION", 130, 139], ["tubes", "OBSERVATION", 301, 306]]], ["One of the movement's fundamental premises is that patients have the right to decline aggressive interventions.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["aggressive interventions", "TREATMENT", 86, 110], ["right", "ANATOMY_MODIFIER", 69, 74]]], ["Many patients now carry standing physicians' orders of \"do not intubate\" or \"do not resuscitate\" (\"DNR\").", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Underneath the ideology of patient choice lies a tacit and widespread complex of beliefs about the good death-for example, that medical interventions with little chance of success merely increase suffering and that one should die at home, surrounded by loved ones.", [["death", "DISEASE", 104, 109], ["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["medical interventions", "TREATMENT", 128, 149]]], ["This is the death most of my older family members would choose for themselves.", [["death", "DISEASE", 12, 17]]], ["If they contracted Covid-19, they would receive treatment in prestigious, well-resourced hospitals.", [["treatment", "TREATMENT", 48, 57]]], ["If their prognoses were grim, they may feel that they have \"lived a complete life.\" 1 Few would fight for a miracle in intensive care if hospice could guarantee a comfortable, peaceful death at home.", [["death", "DISEASE", 185, 190], ["hospice", "TREATMENT", 137, 144]]], ["Though several carry their parents' trauma from the Holocaust, they no longer have to fear racial discrimination in the United States.Systemic Injustice for End-of-Life CareAfrican Americans, statistically, tend to make different choices about medical care than whites do.", [["trauma", "DISEASE", 36, 42], ["Injustice", "OBSERVATION", 143, 152]]], ["Repeated studies have found that, relative to white Americans, African Americans more often choose therapies such as prolonged ventilation and feeding tubes, less often elect to receive hospice care, and less often engage in advance care planning.", [["Repeated studies", "TEST", 0, 16], ["therapies", "TREATMENT", 99, 108], ["prolonged ventilation", "TREATMENT", 117, 138], ["feeding tubes", "TREATMENT", 143, 156], ["hospice care", "TREATMENT", 186, 198]]], ["To the extent that these patterns are attributable to knowledge and access gaps, they should be considered health care disparities in their own right.", [["right", "ANATOMY_MODIFIER", 144, 149]]], ["But there is also a trend in the literature and in clinical practice to identify \"barriers\" between African Americans and palliative care-such as patients' religious faith or \"mistrust\" of the medical system-and to overcome them.", [["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["palliative care", "TREATMENT", 122, 137]]], ["2 Even in the best of times, many African Americans fear that accepting DNR status is tantamount to giving up and inviting their physicians to give up on them.", [["DNR", "CHEMICAL", 72, 75]]], ["An ethnographic study conducted by LaVera Crawley illuminates why trust is something medical providers must earn, not something patients must give.", [["LaVera Crawley", "ORGANISM", 35, 49], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["An ethnographic study", "TEST", 0, 21]]], ["Crawley's study participants, African American adults in the San Francisco Bay Area making decisions in the face of serious illness over a period of two years, spoke of their \"struggle\" against unjust conditions, in medical systems as in society at large.", [["participants", "SPECIES", 16, 28], ["large", "OBSERVATION_MODIFIER", 249, 254]]], ["Many had experienced clinicians acting on racial biases, making decisions on their behalf; these patients were not given \"a say\" in their own end-of-life care.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105]]], ["3 One way to understand the unjust conditions invoked by Crawley's study participants is to look at the unsurprising and unacceptable burden of Covid-19 in black communities across the country.", [["participants", "SPECIES", 73, 85]]], ["In every single state reporting demographic data, African Americans are overrepresented in Covid-19 cases, deaths, or both.", [["deaths", "DISEASE", 107, 113]]], ["5 This is why the cause of death would still be structural racism if George Floyd had died of Covid-19.Systemic Injustice for End-of-Life CareFor my family members who have the privilege to shelter in place and work from home, contracting Covid-19 would be a case of terrible luck.", [["death", "DISEASE", 27, 32], ["death", "PROBLEM", 27, 32], ["Covid", "TEST", 94, 99], ["Injustice", "OBSERVATION", 112, 121]]], ["By contrast, \"essential\" workers, disproportionately people of color, have been forced to choose between supporting their families and protecting themselves from Covid-19, largely as a result of deliberate social planning.", [["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59]]], ["Another telling contrast: residents of the wealthy white enclave of Bolinas, California, received free tests for Covid-19 antibodies as soon as they became publicly available.", [["Covid-19 antibodies", "PROTEIN", 113, 132], ["free tests", "TEST", 98, 108], ["Covid", "TEST", 113, 118], ["Bolinas", "ANATOMY", 68, 75]]], ["In the nearby San Quentin State Prison, where African Americans are represented at five times their rate in the general population, 6 inmates cannot even achieve social isolation.Systemic Injustice for End-of-Life CareThese racial fault lines of illness are nothing new.", [["illness", "DISEASE", 246, 253], ["End-of-Life", "TREATMENT", 202, 213], ["illness", "PROBLEM", 246, 253], ["Injustice", "OBSERVATION", 188, 197], ["fault lines", "OBSERVATION", 231, 242], ["new", "OBSERVATION_MODIFIER", 266, 269]]], ["7 Similar disparities afflict urban areas across the country.", [["Similar", "OBSERVATION_MODIFIER", 2, 9], ["disparities", "OBSERVATION_MODIFIER", 10, 21], ["afflict", "OBSERVATION_MODIFIER", 22, 29]]], ["The average life expectancy for men in Houston ranges from eighty-eight years in the most affluent ZIP codes to seventy-four years in the historically black Third Ward, where George Floyd grew up.", [["men", "ORGANISM", 32, 35], ["men", "SPECIES", 32, 35]]], ["8 This amounts to an epidemic of premature black death.", [["premature black death", "DISEASE", 33, 54], ["premature black death", "PROBLEM", 33, 54], ["epidemic", "OBSERVATION_MODIFIER", 21, 29], ["premature", "OBSERVATION_MODIFIER", 33, 42], ["black death", "OBSERVATION", 43, 54]]], ["This is why the cause of death would still be structural racism if Floyd had died of almost any cause at the age of seventy-four-as opposed to eighty-eight.Systemic Injustice for End-of-Life CareSocial and structural determinants of health are by now integrated into medical school curricula.", [["death", "DISEASE", 25, 30], ["death", "PROBLEM", 25, 30], ["Injustice", "OBSERVATION", 165, 174]]], ["Is there such a thing as a \"good\" or \"dignified\" death when African Americans are dying not merely of Covid-19 but of structural racism?Systemic Injustice for End-of-Life CareOne dominant philosophy of rationing scarce medical resources, including mechanical ventilation and dialysis, merely amplifies the problem.", [["death", "DISEASE", 49, 54], ["Covid", "TEST", 102, 107], ["mechanical ventilation", "TREATMENT", 248, 270], ["dialysis", "TREATMENT", 275, 283], ["mechanical ventilation", "OBSERVATION", 248, 270]]], ["Early on in the pandemic, the Journal of the American Medical Association published a framework for rationing intensive care that has since been adopted by several states and over one hundred hospitals.", [["rationing intensive care", "TREATMENT", 100, 124]]], ["9 Like nearly all rationing plans, it prioritizes patients with a higher likelihood of surviving until hospital discharge.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58]]], ["Thus, patients who have a life expectancy under five years are deemed less deserving of a ventilator.Systemic Injustice for End-of-Life CareThe framework's authors do not engage with the issue of the unjust disparity in life expectancy across racial groups.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["a ventilator", "TREATMENT", 88, 100], ["End-of-Life Care", "TREATMENT", 124, 140], ["Injustice", "OBSERVATION", 110, 119]]], ["(They have also misrepresented an intensive community engagement study as finding \"broad endorsement\" for their framework among people of diverse cultural and religious identities.", [["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134]]], ["10 ) The net result of this colorblind rationing scheme is predictably asymmetric: black lives are sacrificed to preserve the lives of the more privileged.", [["this colorblind rationing scheme", "TREATMENT", 23, 55]]], ["According to this utilitarian philosophy, the very hospital that would extend curative options to my relatives, should they fall sick with Covid-19, would deny the same options to an age-matched but sicker-at-baseline African American patient.Systemic Injustice for End-of-Life CareIf George Floyd had died of Covid-19, the cause of death would still be structural racism.Systemic Injustice for End-of-Life CareWith some success, civil rights advocates have since brought numerous lawsuits against states that have adopted guidelines similar to the framework in JAMA.", [["death", "DISEASE", 333, 338], ["patient", "ORGANISM", 235, 242], ["patient", "SPECIES", 235, 242], ["Covid", "TEST", 310, 315], ["death", "PROBLEM", 333, 338], ["structural racism", "OBSERVATION", 354, 371]]], ["Whereas Pennsylvania's version of the algorithm initially penalized patients with a prognosis under ten years and those with chronic illnesses such as dependency on renal dialysis, the references to specific illnesses and disabilities were later removed.", [["renal", "ANATOMY", 165, 170], ["patients", "ORGANISM", 68, 76], ["renal", "ORGAN", 165, 170], ["patients", "SPECIES", 68, 76], ["chronic illnesses", "PROBLEM", 125, 142], ["renal dialysis", "TREATMENT", 165, 179], ["renal", "ANATOMY", 165, 170], ["dialysis", "OBSERVATION", 171, 179]]], ["11 California has gone further in response to community advocacy, announcing on June 9, 2020, that incorporating age, disability, or preexisting conditions into ventilator rationing is unacceptable.", [["disability", "DISEASE", 118, 128], ["ventilator rationing", "TREATMENT", 161, 181]]], ["12 But these are piecemeal successes: utilitarianism remains a dominant framework.Systemic Injustice for End-of-Life CareCovid-19 has sharpened the problem of disparate health outcomes and medical treatments, worsening the epidemic of premature black deaths.", [["premature black deaths", "DISEASE", 235, 257], ["utilitarianism", "PROBLEM", 38, 52], ["medical treatments", "TREATMENT", 189, 207], ["premature black deaths", "PROBLEM", 235, 257], ["piecemeal", "OBSERVATION", 17, 26]]], ["As patients face the end of life, medical providers have one final chance to honor their values and identities-this is the essence of palliative care.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["palliative care", "TREATMENT", 134, 149]]], ["Clinicians must also seek to understand African Americans' perceptions of death and dying.Systemic Injustice for End-of-Life CareThe experiences of Crawley's ethnography participants, who were denied a say in their own care, the disproportionate toll of black deaths from Covid-19, and the murders of George Floyd and other black people-these phenomena are related.", [["death", "DISEASE", 74, 79], ["deaths", "DISEASE", 260, 266], ["people", "ORGANISM", 330, 336], ["participants", "SPECIES", 170, 182], ["people", "SPECIES", 330, 336], ["death", "PROBLEM", 74, 79], ["End-of-Life Care", "TREATMENT", 113, 129], ["black deaths", "PROBLEM", 254, 266], ["Covid", "TEST", 272, 277], ["these phenomena", "PROBLEM", 337, 352], ["Injustice", "OBSERVATION", 99, 108]]], ["The preliminary report of Floyd's autopsy by the Hennepin County medical examiner's office found no evidence of asphyxia and falsely overstated the role of Floyd's cardiovascular disease in his death.", [["cardiovascular", "ANATOMY", 164, 178], ["asphyxia", "DISEASE", 112, 120], ["cardiovascular disease", "DISEASE", 164, 186], ["death", "DISEASE", 194, 199], ["cardiovascular", "ANATOMICAL_SYSTEM", 164, 178], ["asphyxia", "PROBLEM", 112, 120], ["Floyd's cardiovascular disease", "PROBLEM", 156, 186], ["his death", "PROBLEM", 190, 199], ["no evidence of", "UNCERTAINTY", 97, 111], ["asphyxia", "OBSERVATION", 112, 120]]], ["Three days later, the official autopsy report retracted the surreal implication-that Floyd was not killed.", [["the official autopsy", "TEST", 18, 38]]], ["13 But imagine if Floyd had needed intensive care for Covid-19 and if he had been denied such care because of his underlying health issues, which were secondary to a lifetime of experiencing racism.", [["intensive care", "TREATMENT", 35, 49], ["Covid", "TEST", 54, 59], ["his underlying health issues", "PROBLEM", 110, 138]]], ["No such admission-that he had been killed-would have been forthcoming.Systemic Injustice for End-of-Life CareHow can medical providers work against racism and heal the continual breaches of trust that endanger black lives?", [["End-of-Life Care", "TREATMENT", 93, 109], ["Injustice", "OBSERVATION", 79, 88]]], ["At a minimum, we must eliminate all forms of utilitarian rationing with eugenic outcomes.", [["utilitarian rationing", "TREATMENT", 45, 66]]], ["Providers must also be prepared to make the diagnosis of exposure to racism when that is the underlying cause of injury, illness, or death.", [["injury", "DISEASE", 113, 119], ["illness", "DISEASE", 121, 128], ["death", "DISEASE", 133, 138], ["injury", "PROBLEM", 113, 119], ["illness", "PROBLEM", 121, 128], ["death", "PROBLEM", 133, 138], ["injury", "OBSERVATION", 113, 119]]], ["Others are working to change their institutions from within, challenging medicine's complicity with police violence and the carceral state.Systemic Injustice for End-of-Life CareCovid-19 had already focused national attention on structural racism when the killing of George Floyd made more devastatingly clear that radical change cannot wait.Systemic Injustice for End-of-Life CareHealth professionals, health educators, bioethicists, and policy-makers must all take up the struggle to fight racism, and they must not abandon it once the pandemic begins to lift and if the protests die down.", [["radical change", "PROBLEM", 315, 329], ["radical", "OBSERVATION", 315, 322], ["Injustice", "OBSERVATION", 351, 360]]], ["Only when African Americans no longer die of systemic injustice will a \"good death\" cease being a contradiction.", [["death", "DISEASE", 77, 82]]]], "94dba39633cd8521b83bd8cc004d5e1a09b73326": [["R&D, Sigma-Tau, Pomezia 2 Department of Chemistry Chemical Engineering and Materials, University of L'Aquila, Coppito, L'Aquila, ItalyBackground and aims: Homodimerization of MyD88 adapter protein is essential for NF-kB activation in the inflammatory pathway triggered by IL-1 and TLR [1] .", [["Sigma-Tau", "GENE_OR_GENE_PRODUCT", 5, 14], ["MyD88", "GENE_OR_GENE_PRODUCT", 175, 180], ["NF-kB", "GENE_OR_GENE_PRODUCT", 214, 219], ["IL-1", "GENE_OR_GENE_PRODUCT", 272, 276], ["TLR [1]", "GENE_OR_GENE_PRODUCT", 281, 288], ["MyD88 adapter protein", "PROTEIN", 175, 196], ["NF-kB", "PROTEIN", 214, 219], ["IL", "PROTEIN", 272, 274], ["TLR", "PROTEIN", 281, 284], ["Coppito", "TREATMENT", 110, 117], ["Homodimerization of MyD88 adapter protein", "TREATMENT", 155, 196], ["NF", "PROBLEM", 214, 216], ["kB activation", "PROBLEM", 217, 230]]], ["We designed a peptidomimetic of the MyD88 TIR domain consensus peptide Arg-Asp-Val-Leu-Pro-Gly-Thr [2] , named ST2825.", [["Arg-Asp-Val-Leu-Pro-Gly-Thr", "CHEMICAL", 71, 98], ["Arg-Asp-Val-Leu-Pro-Gly-Thr", "CHEMICAL", 71, 98], ["ST2825", "CHEMICAL", 111, 117], ["MyD88", "GENE_OR_GENE_PRODUCT", 36, 41], ["ST2825", "SIMPLE_CHEMICAL", 111, 117], ["MyD88 TIR domain", "PROTEIN", 36, 52], ["peptide", "TEST", 63, 70], ["Arg", "TEST", 71, 74], ["Asp", "TEST", 75, 78], ["Val", "TEST", 79, 82], ["Leu", "TEST", 83, 86]]], ["Here, we report its synthesis and biological activity.", [["its synthesis", "PROBLEM", 16, 29]]], ["We also report the synthesis and biological activity of its enantiomer, ST3511, and its diastereoisomers, ST3489 and ST3558.", [["ST3511", "CHEMICAL", 72, 78], ["ST3489", "CHEMICAL", 106, 112], ["ST3558", "CHEMICAL", 117, 123], ["ST3511", "CHEMICAL", 72, 78], ["ST3489", "CHEMICAL", 106, 112], ["ST3558", "CHEMICAL", 117, 123], ["ST3511", "SIMPLE_CHEMICAL", 72, 78], ["ST3489", "SIMPLE_CHEMICAL", 106, 112], ["ST3558", "SIMPLE_CHEMICAL", 117, 123], ["the synthesis", "PROBLEM", 15, 28]]], ["Methods: The structure of the MyD88 TIR domain consensus peptide is subdivided into three distinct portions, the most important of which is a b-turn.", [["MyD88", "GENE_OR_GENE_PRODUCT", 30, 35], ["MyD88 TIR domain", "PROTEIN", 30, 46]]], ["In the peptidomimetic design we changed the b-turn with a tricyclic spirolactam [3] , already known [4] .", [["spirolactam", "CHEMICAL", 68, 79], ["tricyclic spirolactam", "CHEMICAL", 58, 79], ["tricyclic spirolactam [3]", "SIMPLE_CHEMICAL", 58, 83], ["the b-turn", "TREATMENT", 40, 50], ["a tricyclic spirolactam", "TREATMENT", 56, 79]]], ["We synthesized this building block, its enantiomer and two of 8 possible diastereoisomers by \"in solution\" synthesis.", [["this building block", "TREATMENT", 15, 34], ["diastereoisomers", "TREATMENT", 73, 89]]], ["Based on semiempirical calculation of heat of formation [5] , we could predict the right stereochemistry of the 4 products selectively obtained in the last cyclization step.", [["the last cyclization step", "TREATMENT", 147, 172], ["right", "ANATOMY_MODIFIER", 83, 88]]], ["Some coimmunoprecipitation experiments were also carried out and we report their results.R&D, Sigma-Tau, Pomezia 2 Department of Chemistry Chemical Engineering and Materials, University of L'Aquila, Coppito, L'Aquila, ItalyConclusions: The results show the activity of ST2825 and its isomers on our target, with limited specificity towards their stereostructure.", [["ST2825", "CHEMICAL", 269, 275], ["ST2825", "CHEMICAL", 269, 275], ["Sigma-Tau", "GENE_OR_GENE_PRODUCT", 94, 103], ["ST2825", "SIMPLE_CHEMICAL", 269, 275], ["Some coimmunoprecipitation experiments", "TEST", 0, 38]]], ["Introduction of a methylene bridge between the C\u03b1(i+1) and the N(i+2) atoms in an open peptide (I) to mimic simultaneously the C\u03b1H(i+1) and HN(i+2) protons (\u03b2-Lactam Scaffold Assisted Design -\u03b2-LSAD) has proven to be a practical tool for the preparation of monotopic \u03b2-turn peptidomimetics (II, R2 = R3 = H), according to the principle of separation of constraint and recognition elements1.", [["methylene", "CHEMICAL", 18, 27], ["C\u03b1", "CHEMICAL", 47, 49], ["methylene", "CHEMICAL", 18, 27], ["C\u03b1", "CHEMICAL", 47, 49], ["N(i+2)", "CHEMICAL", 63, 69], ["HN(i+2)", "CHEMICAL", 140, 147], ["H", "CHEMICAL", 305, 306], ["methylene", "SIMPLE_CHEMICAL", 18, 27], ["C\u03b1H", "SIMPLE_CHEMICAL", 127, 130], ["HN(i+2) protons", "SIMPLE_CHEMICAL", 140, 155], ["\u03b2-Lactam", "SIMPLE_CHEMICAL", 157, 165], ["monotopic \u03b2-turn peptidomimetics", "SIMPLE_CHEMICAL", 257, 289], ["N(i+2) atoms", "PROTEIN", 63, 75], ["recognition elements", "DNA", 368, 388], ["a methylene bridge", "TREATMENT", 16, 34], ["the C\u03b1(i+", "TREATMENT", 43, 52], ["the N(i+2) atoms", "TREATMENT", 59, 75], ["an open peptide", "TREATMENT", 79, 94], ["the C\u03b1H", "TEST", 123, 130], ["HN(i+2) protons (\u03b2-Lactam Scaffold Assisted Design -\u03b2-LSAD", "TREATMENT", 140, 198], ["monotopic \u03b2-turn peptidomimetics", "TREATMENT", 257, 289]]], ["In this work we report a short, general, and stereocontrolled synthesis of multitopic \u03b2-lactam scaffolds of type VI. \u03b1-Alkyl serinates III are converted into the corresponding enantiopure Nnosyl-aziridines IV which undergo \"in situ\" ring-opening with amino acids V. Subsequent base-promoted cyclization affords the N-protected \u03b1-alkyl-\u03b1-amino-\u03b2-lactams VII.", [["\u03b1-Alkyl serinates", "CHEMICAL", 117, 134], ["Nnosyl-aziridines", "CHEMICAL", 188, 205], ["amino acids", "CHEMICAL", 251, 262], ["\u03b1-alkyl-\u03b1-amino-\u03b2-lactams", "CHEMICAL", 327, 352], ["\u03b2-lactam", "CHEMICAL", 86, 94], ["\u03b1-Alkyl serinates III", "CHEMICAL", 117, 138], ["Nnosyl-aziridines IV", "CHEMICAL", 188, 208], ["amino acids", "CHEMICAL", 251, 262], ["N", "CHEMICAL", 315, 316], ["\u03b1-alkyl-\u03b1-amino", "CHEMICAL", 327, 342], ["\u03b1-Alkyl serinates III", "SIMPLE_CHEMICAL", 117, 138], ["Nnosyl-aziridines IV", "SIMPLE_CHEMICAL", 188, 208], ["amino acids", "AMINO_ACID", 251, 262], ["N-protected \u03b1-alkyl-\u03b1-amino-\u03b2-lactams VII", "SIMPLE_CHEMICAL", 315, 356], ["N-protected \u03b1-alkyl-\u03b1-amino-\u03b2-lactams VII", "PROTEIN", 315, 356], ["a short, general, and stereocontrolled synthesis", "PROBLEM", 23, 71], ["multitopic \u03b2-lactam scaffolds", "TREATMENT", 75, 104], ["the corresponding enantiopure Nnosyl-aziridines IV", "TREATMENT", 158, 208], ["amino acids", "TREATMENT", 251, 262], ["promoted cyclization", "TREATMENT", 282, 302], ["the N", "TREATMENT", 311, 316], ["type VI", "OBSERVATION_MODIFIER", 108, 115]]], ["Incorporation of the novel scaffolds into linear and cyclic peptides and their conformational features are also presented, most of them showing stabilized \u03b2-and \u03b3-turn conformations.", [["the novel scaffolds into linear and cyclic peptides", "PROBLEM", 17, 68], ["cyclic peptides", "OBSERVATION", 53, 68], ["stabilized", "OBSERVATION", 144, 154]]], ["Poly(amino acids) are emerging as promising therapeutic carriers finding widespread application in the field of drug delivery.", [["Poly(amino acids", "CHEMICAL", 0, 16], ["Poly(amino acids", "CHEMICAL", 0, 16], ["Poly(amino acids", "SIMPLE_CHEMICAL", 0, 16], ["Poly(amino acids", "TREATMENT", 0, 16], ["drug delivery", "TREATMENT", 112, 125], ["widespread", "OBSERVATION_MODIFIER", 73, 83]]], ["In this context, polyproline polymers have been used to solubilize poorly water-soluble proteins, in affinity chromatography for the purification of platelet profilin, and more recently, in the design of dendrimers.", [["platelet", "ANATOMY", 149, 157], ["polyproline polymers", "SIMPLE_CHEMICAL", 17, 37], ["platelet profilin", "GENE_OR_GENE_PRODUCT", 149, 166], ["soluble proteins", "PROTEIN", 80, 96], ["platelet profilin", "PROTEIN", 149, 166], ["polyproline polymers", "TREATMENT", 17, 37], ["affinity chromatography", "TEST", 101, 124], ["platelet profilin", "TREATMENT", 149, 166]]], ["Poly(amino acids) are most conveniently synthesized by polymerization of the corresponding amino acid N-carboxyanhydride (NCA).", [["Poly(amino acids", "CHEMICAL", 0, 16], ["amino acid N-carboxyanhydride", "CHEMICAL", 91, 120], ["Poly(amino acids", "CHEMICAL", 0, 16], ["amino acid N-carboxyanhydride", "CHEMICAL", 91, 120], ["NCA", "CHEMICAL", 122, 125], ["Poly(amino acids", "SIMPLE_CHEMICAL", 0, 16], ["amino acid N-carboxyanhydride", "SIMPLE_CHEMICAL", 91, 120], ["NCA", "SIMPLE_CHEMICAL", 122, 125], ["Poly(amino acids", "TREATMENT", 0, 16], ["the corresponding amino acid N", "TREATMENT", 73, 103], ["carboxyanhydride (NCA)", "TREATMENT", 104, 126]]], ["In spite of the interest of polyproline, the preparation of proline N-carboxyanhydride (Pro-NCA) renders poor synthetic yields.", [["proline N-carboxyanhydride", "CHEMICAL", 60, 86], ["Pro-NCA", "CHEMICAL", 88, 95], ["polyproline", "CHEMICAL", 28, 39], ["proline N-carboxyanhydride", "CHEMICAL", 60, 86], ["Pro-NCA", "CHEMICAL", 88, 95], ["polyproline", "AMINO_ACID", 28, 39], ["proline N-carboxyanhydride", "SIMPLE_CHEMICAL", 60, 86], ["Pro-NCA", "SIMPLE_CHEMICAL", 88, 95], ["polyproline", "TREATMENT", 28, 39], ["proline N", "TREATMENT", 60, 69], ["carboxyanhydride (Pro-NCA)", "TREATMENT", 70, 96], ["poor synthetic yields", "PROBLEM", 105, 126]]], ["In this work a new method for the preparation of Pro-NCA in high yields and purities is described.", [["Pro-NCA", "CHEMICAL", 49, 56], ["Pro-NCA", "CHEMICAL", 49, 56], ["Pro-NCA", "SIMPLE_CHEMICAL", 49, 56], ["Pro-NCA in high yields and purities", "TREATMENT", 49, 84]]], ["Amino acid N-carboxyanhydrides are obtained by the method described by Fuchs.", [["Amino acid N-carboxyanhydrides", "CHEMICAL", 0, 30], ["Amino acid N-carboxyanhydrides", "CHEMICAL", 0, 30], ["Amino acid N-carboxyanhydrides", "SIMPLE_CHEMICAL", 0, 30], ["Amino acid N", "TREATMENT", 0, 12], ["carboxyanhydrides", "TREATMENT", 13, 30], ["Fuchs", "OBSERVATION", 71, 76]]], ["But, in the case of proline, the N-carbamoyl chloride does not cyclise spontaneously as it takes place with other amino acids, and the use of a non-nucleophilic base is required for the cyclisation.", [["proline", "CHEMICAL", 20, 27], ["N-carbamoyl chloride", "CHEMICAL", 33, 53], ["amino acids", "CHEMICAL", 114, 125], ["proline", "CHEMICAL", 20, 27], ["N-carbamoyl chloride", "CHEMICAL", 33, 53], ["amino acids", "CHEMICAL", 114, 125], ["proline", "AMINO_ACID", 20, 27], ["N-carbamoyl chloride", "SIMPLE_CHEMICAL", 33, 53], ["amino acids", "AMINO_ACID", 114, 125], ["the N-carbamoyl chloride", "TREATMENT", 29, 53], ["other amino acids", "TREATMENT", 108, 125], ["a non-nucleophilic base", "TREATMENT", 142, 165], ["the cyclisation", "TREATMENT", 182, 197]]], ["A tertiary amine, such as triethylamine, is commonly used but it renders a low conversion of the N-carbamoyl chloride to the expected Pro-NCA, together with the presence of the Pro-Pro diketopiperazine byproduct.", [["amine", "CHEMICAL", 11, 16], ["triethylamine", "CHEMICAL", 26, 39], ["N-carbamoyl chloride", "CHEMICAL", 97, 117], ["Pro-NCA", "CHEMICAL", 134, 141], ["diketopiperazine", "CHEMICAL", 185, 201], ["tertiary amine", "CHEMICAL", 2, 16], ["triethylamine", "CHEMICAL", 26, 39], ["N-carbamoyl chloride", "CHEMICAL", 97, 117], ["Pro-NCA", "CHEMICAL", 134, 141], ["Pro-Pro diketopiperazine", "CHEMICAL", 177, 201], ["amine", "SIMPLE_CHEMICAL", 11, 16], ["triethylamine", "SIMPLE_CHEMICAL", 26, 39], ["N-carbamoyl chloride", "SIMPLE_CHEMICAL", 97, 117], ["Pro-NCA", "SIMPLE_CHEMICAL", 134, 141], ["Pro-Pro diketopiperazine", "SIMPLE_CHEMICAL", 177, 201], ["A tertiary amine", "TREATMENT", 0, 16], ["triethylamine", "TREATMENT", 26, 39], ["a low conversion of the N-carbamoyl chloride", "TREATMENT", 73, 117], ["the Pro-Pro diketopiperazine byproduct", "TREATMENT", 173, 211]]], ["In the present work, polymer-supported bases have been used instead of triethylamine.", [["triethylamine", "CHEMICAL", 71, 84], ["triethylamine", "CHEMICAL", 71, 84], ["triethylamine", "SIMPLE_CHEMICAL", 71, 84], ["polymer-supported bases", "TREATMENT", 21, 44], ["triethylamine", "TREATMENT", 71, 84]]], ["Higher yields of Pro-NCA, and very low percentages of diketopiperazine have been obtained.", [["Pro-NCA", "CHEMICAL", 17, 24], ["diketopiperazine", "CHEMICAL", 54, 70], ["Pro-NCA", "CHEMICAL", 17, 24], ["diketopiperazine", "CHEMICAL", 54, 70], ["Pro-NCA", "SIMPLE_CHEMICAL", 17, 24], ["diketopiperazine", "SIMPLE_CHEMICAL", 54, 70], ["Pro-NCA", "TEST", 17, 24], ["very low percentages of diketopiperazine", "PROBLEM", 30, 70]]], ["In addition, no tertiary amine contamination was observed.", [["amine", "CHEMICAL", 25, 30], ["tertiary amine", "CHEMICAL", 16, 30], ["amine", "SIMPLE_CHEMICAL", 25, 30], ["tertiary amine contamination", "PROBLEM", 16, 44], ["no", "UNCERTAINTY", 13, 15]]], ["Polymer-supported bases could also be recycled and Pro-NCA yields were reproducible.", [["Pro-NCA", "SIMPLE_CHEMICAL", 51, 58], ["bases", "ANATOMY_MODIFIER", 18, 23]]], ["In conclusion, we have developed an efficient method for Pro-NCA preparation with polymer-supported bases.Faculty of Chemistry, University of Wroclaw, PolandThe introduction of novel nonproteinaceous heterocyclic amino acids into peptides results in new compounds with interesting structural, physicochemical and biological properties.", [["amino acids", "CHEMICAL", 213, 224], ["amino acids", "CHEMICAL", 213, 224], ["Pro-NCA", "SIMPLE_CHEMICAL", 57, 64], ["nonproteinaceous heterocyclic", "SIMPLE_CHEMICAL", 183, 212], ["amino acids", "AMINO_ACID", 213, 224], ["Pro-NCA preparation", "TREATMENT", 57, 76], ["novel nonproteinaceous heterocyclic amino acids", "TREATMENT", 177, 224], ["bases", "ANATOMY_MODIFIER", 100, 105]]], ["The transformation of amino acid side chains after the peptide assembly is a convenient method of generating such modified peptides.", [["amino acid", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 22, 32], ["amino acid", "AMINO_ACID", 22, 32], ["amino acid side chains", "TREATMENT", 22, 44], ["such modified peptides", "TREATMENT", 109, 131], ["amino acid", "OBSERVATION", 22, 32]]], ["Taking into account the biological activity and complexing abilities of nitrogen-containing heterocycles, we investigated the formation of imidazole, benzimidazole and quinoxaline moieties using condensation with various aldehydes and \u03b1-dicarbonyl compounds after classical peptide synthesis on solid support.", [["nitrogen", "CHEMICAL", 72, 80], ["imidazole", "CHEMICAL", 139, 148], ["benzimidazole", "CHEMICAL", 150, 163], ["quinoxaline", "CHEMICAL", 168, 179], ["aldehydes", "CHEMICAL", 221, 230], ["\u03b1-dicarbonyl", "CHEMICAL", 235, 247], ["nitrogen", "CHEMICAL", 72, 80], ["heterocycles", "CHEMICAL", 92, 104], ["imidazole", "CHEMICAL", 139, 148], ["benzimidazole", "CHEMICAL", 150, 163], ["quinoxaline", "CHEMICAL", 168, 179], ["aldehydes", "CHEMICAL", 221, 230], ["\u03b1-dicarbonyl", "CHEMICAL", 235, 247], ["nitrogen-containing heterocycles", "SIMPLE_CHEMICAL", 72, 104], ["imidazole", "SIMPLE_CHEMICAL", 139, 148], ["benzimidazole", "SIMPLE_CHEMICAL", 150, 163], ["quinoxaline moieties", "SIMPLE_CHEMICAL", 168, 188], ["aldehydes", "SIMPLE_CHEMICAL", 221, 230], ["\u03b1-dicarbonyl compounds", "SIMPLE_CHEMICAL", 235, 257], ["nitrogen-containing heterocycles", "TREATMENT", 72, 104], ["imidazole", "TREATMENT", 139, 148], ["benzimidazole", "TREATMENT", 150, 163], ["quinoxaline moieties", "TREATMENT", 168, 188], ["condensation", "TREATMENT", 195, 207], ["various aldehydes", "TREATMENT", 213, 230], ["\u03b1-dicarbonyl compounds", "TREATMENT", 235, 257], ["classical peptide synthesis on solid support", "TREATMENT", 264, 308]]], ["The imidazole synthesis utilizes the N-terminal or side chain amino group of amino acids, whereas a derivative of phenylalanine, \u03b2-(4-amino-3-nitrophenyl)alanine, was developed for benzimidazole and quinoxaline synthesis.", [["imidazole", "CHEMICAL", 4, 13], ["N-terminal", "CHEMICAL", 37, 47], ["amino acids", "CHEMICAL", 77, 88], ["phenylalanine", "CHEMICAL", 114, 127], ["\u03b2-(4-amino-3-nitrophenyl)alanine", "CHEMICAL", 129, 161], ["benzimidazole", "CHEMICAL", 181, 194], ["quinoxaline", "CHEMICAL", 199, 210], ["imidazole", "CHEMICAL", 4, 13], ["N", "CHEMICAL", 37, 38], ["amino", "CHEMICAL", 62, 67], ["amino acids", "CHEMICAL", 77, 88], ["phenylalanine", "CHEMICAL", 114, 127], ["\u03b2-(4-amino-3-nitrophenyl)alanine", "CHEMICAL", 129, 161], ["benzimidazole", "CHEMICAL", 181, 194], ["quinoxaline", "CHEMICAL", 199, 210], ["imidazole", "SIMPLE_CHEMICAL", 4, 13], ["amino acids", "AMINO_ACID", 77, 88], ["phenylalanine", "SIMPLE_CHEMICAL", 114, 127], ["\u03b2-(4-amino-3-nitrophenyl)alanine", "SIMPLE_CHEMICAL", 129, 161], ["benzimidazole", "SIMPLE_CHEMICAL", 181, 194], ["quinoxaline", "SIMPLE_CHEMICAL", 199, 210], ["The imidazole synthesis", "TREATMENT", 0, 23], ["the N-terminal or side chain amino group of amino acids", "TREATMENT", 33, 88], ["a derivative of phenylalanine", "TREATMENT", 98, 127], ["amino-3-nitrophenyl)alanine", "TREATMENT", 134, 161], ["benzimidazole", "TREATMENT", 181, 194], ["quinoxaline synthesis", "TREATMENT", 199, 220]]], ["The modified peptides were purified by preparative HPLC and characterized by ESI-MS, UV and NMR.Faculty of Chemistry, University of Wroclaw, PolandIn conclusion, we developed a straightforward method of synthesis of peptides with specific ion affinity and spectral characteristic.", [["The modified peptides", "TREATMENT", 0, 21], ["preparative HPLC", "TEST", 39, 55], ["NMR", "TEST", 92, 95], ["synthesis of peptides", "TREATMENT", 203, 224]]], ["The broad range of commercially available aromatic aldehydes and dicarbonyl compounds makes possible the synthesis of combinatorial libraries of modified amino acids and peptides.", [["aromatic aldehydes", "CHEMICAL", 42, 60], ["dicarbonyl", "CHEMICAL", 65, 75], ["amino acids", "CHEMICAL", 154, 165], ["aromatic aldehydes", "CHEMICAL", 42, 60], ["dicarbonyl", "CHEMICAL", 65, 75], ["amino acids", "CHEMICAL", 154, 165], ["aromatic aldehydes", "SIMPLE_CHEMICAL", 42, 60], ["dicarbonyl compounds", "SIMPLE_CHEMICAL", 65, 85], ["amino acids", "AMINO_ACID", 154, 165], ["aromatic aldehydes", "TREATMENT", 42, 60], ["dicarbonyl compounds", "TREATMENT", 65, 85], ["combinatorial libraries", "TREATMENT", 118, 141], ["modified amino acids", "TREATMENT", 145, 165], ["broad", "OBSERVATION_MODIFIER", 4, 9], ["range", "OBSERVATION_MODIFIER", 10, 15]]], ["Part of this work was supported by a grant No. 3T09A 110 28 from the Ministry of Education and Science.Faculty of Chemistry, University of Wroclaw, PolandNMDA receptors belong to the ionotropic group of glutamate receptors.", [["glutamate", "CHEMICAL", 203, 212], ["glutamate", "CHEMICAL", 203, 212], ["glutamate receptors", "GENE_OR_GENE_PRODUCT", 203, 222], ["PolandNMDA receptors", "PROTEIN", 148, 168], ["glutamate receptors", "PROTEIN", 203, 222], ["glutamate receptors", "TREATMENT", 203, 222]]], ["The activity of the receptor can be altered by compounds acting at binding sites.", [["activity", "OBSERVATION_MODIFIER", 4, 12]]], ["The (R,S)-(Tetrazol-5-yl)glycine (TG) has been shown to be a highly potent NMDA (N-methyl-d-aspartic acid) receptor agonist with exitotoxic effects [1] .", [["(R,S)-(Tetrazol-5-yl", "CHEMICAL", 4, 24], ["glycine", "CHEMICAL", 25, 32], ["TG", "CHEMICAL", 34, 36], ["NMDA", "CHEMICAL", 75, 79], ["N-methyl-d-aspartic acid", "CHEMICAL", 81, 105], ["(R,S)-(Tetrazol-5-yl)glycine", "CHEMICAL", 4, 32], ["NMDA", "CHEMICAL", 75, 79], ["N-methyl-d-aspartic acid", "CHEMICAL", 81, 105], ["(R,S)-(Tetrazol-5-yl)glycine", "SIMPLE_CHEMICAL", 4, 32], ["TG", "SIMPLE_CHEMICAL", 34, 36], ["NMDA", "SIMPLE_CHEMICAL", 75, 79], ["N-methyl-d-aspartic acid", "SIMPLE_CHEMICAL", 81, 105], ["The (R,S)", "TREATMENT", 0, 9], ["Tetrazol-5-yl)glycine (TG)", "TREATMENT", 11, 37], ["a highly potent NMDA", "TREATMENT", 59, 79], ["methyl-d-aspartic acid) receptor agonist", "TREATMENT", 83, 123], ["exitotoxic effects", "TREATMENT", 129, 147]]], ["The aim of our studies was to investigate the chelating ability of TG towards copper(II) ions.", [["TG", "DISEASE", 67, 69], ["copper(II", "CHEMICAL", 78, 87], ["copper(II)", "CHEMICAL", 78, 88], ["TG", "SIMPLE_CHEMICAL", 67, 69], ["copper(II) ions", "SIMPLE_CHEMICAL", 78, 93], ["our studies", "TEST", 11, 22]]], ["Copper is widely distributed throughout the body with a distinct concentration in the brain.", [["body", "ANATOMY", 44, 48], ["brain", "ANATOMY", 86, 91], ["Copper", "CHEMICAL", 0, 6], ["Copper", "CHEMICAL", 0, 6], ["Copper", "SIMPLE_CHEMICAL", 0, 6], ["body", "ORGANISM_SUBDIVISION", 44, 48], ["brain", "ORGAN", 86, 91], ["a distinct concentration in the brain", "PROBLEM", 54, 91], ["widely", "OBSERVATION_MODIFIER", 10, 16], ["body", "ANATOMY_MODIFIER", 44, 48], ["distinct", "OBSERVATION_MODIFIER", 56, 64], ["concentration", "OBSERVATION", 65, 78], ["brain", "ANATOMY", 86, 91]]], ["Copper enters cells as complex and seeks out targets requiring it to function.", [["cells", "ANATOMY", 14, 19], ["Copper", "CHEMICAL", 0, 6], ["Copper", "CHEMICAL", 0, 6], ["Copper", "SIMPLE_CHEMICAL", 0, 6], ["cells", "CELL", 14, 19], ["Copper enters cells", "PROBLEM", 0, 19]]], ["For these reasons it was interesting to evaluate stability and structure of TG -copper(II) complexes.", [["TG -copper", "CHEMICAL", 76, 86], ["TG -copper(II)", "CHEMICAL", 76, 90], ["TG -copper(II)", "SIMPLE_CHEMICAL", 76, 90], ["TG", "PROTEIN", 76, 78], ["copper(II) complexes", "PROTEIN", 80, 100], ["TG", "TEST", 76, 78]]], ["The equilibrium and structural properties of complex species were characterized by pH-metric and spectroscopic (UV-VIS and EPR) methods.", [["complex species", "PROBLEM", 45, 60], ["pH", "TEST", 83, 85], ["spectroscopic (UV-VIS and EPR) methods", "TREATMENT", 97, 135], ["equilibrium", "OBSERVATION_MODIFIER", 4, 15], ["complex species", "OBSERVATION", 45, 60]]], ["In the system, polymeric species are dominant at acidic pH range having { NH2, COO-} coordination with possible Ntetr bridging elements.", [["NH2", "CHEMICAL", 74, 77], ["COO", "CHEMICAL", 79, 82], ["Ntetr", "CHEMICAL", 112, 117], ["polymeric species", "SIMPLE_CHEMICAL", 15, 32], ["{ NH2, COO-}", "SIMPLE_CHEMICAL", 72, 84], ["Ntetr", "SIMPLE_CHEMICAL", 112, 117], ["Ntetr bridging elements", "PROTEIN", 112, 135], ["polymeric species", "TEST", 15, 32], ["COO", "TEST", 79, 82], ["Ntetr bridging elements", "PROBLEM", 112, 135], ["polymeric species", "OBSERVATION", 15, 32], ["dominant", "OBSERVATION_MODIFIER", 37, 45], ["bridging elements", "OBSERVATION", 118, 135]]], ["Monomeric complexes were found at physiological pH.", [["Monomeric complexes", "PROTEIN", 0, 19], ["complexes", "OBSERVATION", 10, 19]]], ["The two TG molecules are bound to copper ion via four nitrogen donors.", [["TG", "DISEASE", 8, 10], ["copper", "CHEMICAL", 34, 40], ["nitrogen", "CHEMICAL", 54, 62], ["copper", "CHEMICAL", 34, 40], ["nitrogen", "CHEMICAL", 54, 62], ["copper ion", "SIMPLE_CHEMICAL", 34, 44], ["TG molecules", "PROTEIN", 8, 20], ["four nitrogen donors", "TREATMENT", 49, 69]]], ["The formation of two {NH2, Ntetr} donor sets results in very strong metal-ligand interactions and the complex species are very stable over a wide pH region.", [["Ntetr}", "CHEMICAL", 27, 33], ["NH2", "CHEMICAL", 22, 25], ["Ntetr}", "CHEMICAL", 27, 33], ["{NH2", "SIMPLE_CHEMICAL", 21, 25], ["NH2", "PROTEIN", 22, 25], ["donor sets", "TEST", 34, 44], ["the complex species", "PROBLEM", 98, 117], ["a wide pH region", "TREATMENT", 139, 155], ["very", "OBSERVATION_MODIFIER", 122, 126], ["stable", "OBSERVATION_MODIFIER", 127, 133]]], ["We have also performed an investigation on similar tetrazole compounds in order to compare the chelating ability of the tetrazole moiety .", [["tetrazole", "CHEMICAL", 51, 60], ["tetrazole", "CHEMICAL", 120, 129], ["tetrazole", "CHEMICAL", 51, 60], ["tetrazole", "CHEMICAL", 120, 129], ["tetrazole", "SIMPLE_CHEMICAL", 51, 60], ["tetrazole moiety", "SIMPLE_CHEMICAL", 120, 136], ["an investigation", "TEST", 23, 39], ["similar tetrazole compounds", "TREATMENT", 43, 70], ["the tetrazole moiety", "TREATMENT", 116, 136]]], ["The targets of our studies were 1,5-diamino-1H-1,2,3,4-tetrazole [2] and tetrazole aspartic acid.", [["1,5-diamino-1H-1,2,3,4-tetrazole [2] and tetrazole aspartic acid", "CHEMICAL", 32, 96], ["1,5-diamino-1H-1,2,3,4-tetrazole", "CHEMICAL", 32, 64], ["tetrazole aspartic acid", "CHEMICAL", 73, 96], ["1,5-diamino-1H-1,2,3,4-tetrazole [2]", "SIMPLE_CHEMICAL", 32, 68], ["tetrazole aspartic acid", "SIMPLE_CHEMICAL", 73, 96], ["our studies", "TEST", 15, 26], ["diamino", "TEST", 36, 43], ["tetrazole", "TREATMENT", 55, 64], ["tetrazole aspartic acid", "TREATMENT", 73, 96]]], ["References Continuing work in that field, we synthesized oxytocins containing tetrazole analogues of amino acids.", [["oxytocins", "CHEMICAL", 57, 66], ["tetrazole", "CHEMICAL", 78, 87], ["amino acids", "CHEMICAL", 101, 112], ["oxytocins", "CHEMICAL", 57, 66], ["tetrazole", "CHEMICAL", 78, 87], ["amino acids", "CHEMICAL", 101, 112], ["oxytocins", "SIMPLE_CHEMICAL", 57, 66], ["tetrazole analogues", "SIMPLE_CHEMICAL", 78, 97], ["amino acids", "AMINO_ACID", 101, 112], ["we synthesized oxytocins", "TREATMENT", 42, 66], ["tetrazole analogues", "TREATMENT", 78, 97], ["amino acids", "TREATMENT", 101, 112]]], ["The 5-tetrazolyl group is widely used in medicinal chemistry as an isostere of the carboxyl group.", [["5-tetrazolyl", "CHEMICAL", 4, 16], ["5-tetrazolyl", "CHEMICAL", 4, 16], ["carboxyl", "CHEMICAL", 83, 91], ["5-tetrazolyl", "SIMPLE_CHEMICAL", 4, 16], ["The 5-tetrazolyl group", "TREATMENT", 0, 22], ["medicinal chemistry", "TREATMENT", 41, 60], ["an isostere of the carboxyl group", "TREATMENT", 64, 97]]], ["Compounds containing tetrazole ring appear to be metabolically more stable than their carboxylic analogues and have comparable acidity.", [["tetrazole", "CHEMICAL", 21, 30], ["tetrazole", "CHEMICAL", 21, 30], ["carboxylic", "CHEMICAL", 86, 96], ["tetrazole ring", "SIMPLE_CHEMICAL", 21, 35], ["carboxylic analogues", "SIMPLE_CHEMICAL", 86, 106], ["tetrazole ring", "TREATMENT", 21, 35], ["tetrazole ring", "OBSERVATION", 21, 35], ["acidity", "OBSERVATION", 127, 134]]], ["We synthesized derivatives of aspartic, glutamic, and alpha-aminoadipic acids containing 1H-tetrazole ring in side chains.", [["aspartic, glutamic, and alpha-aminoadipic acids", "CHEMICAL", 30, 77], ["1H-tetrazole", "CHEMICAL", 89, 101], ["aspartic, glutamic, and alpha-aminoadipic acids", "CHEMICAL", 30, 77], ["1H-tetrazole", "CHEMICAL", 89, 101], ["aspartic", "AMINO_ACID", 30, 38], ["glutamic", "AMINO_ACID", 40, 48], ["alpha-aminoadipic acids", "SIMPLE_CHEMICAL", 54, 77], ["1H-tetrazole ring", "SIMPLE_CHEMICAL", 89, 106], ["aspartic, glutamic", "TREATMENT", 30, 48], ["alpha-aminoadipic acids", "TREATMENT", 54, 77], ["1H-tetrazole ring in side chains", "TREATMENT", 89, 121]]], ["These derivatives were then used for syntheses of oxytocin analogues substituted in position 4.", [["oxytocin", "CHEMICAL", 50, 58], ["oxytocin", "CHEMICAL", 50, 58], ["oxytocin analogues", "SIMPLE_CHEMICAL", 50, 68], ["These derivatives", "TREATMENT", 0, 17], ["syntheses of oxytocin analogues", "TREATMENT", 37, 68]]], ["Apart from above we also obtained two analogues with tetrazole analogue of glycine in position 9.", [["tetrazole", "CHEMICAL", 53, 62], ["glycine", "CHEMICAL", 75, 82], ["tetrazole", "CHEMICAL", 53, 62], ["glycine", "CHEMICAL", 75, 82], ["tetrazole", "SIMPLE_CHEMICAL", 53, 62], ["glycine", "SIMPLE_CHEMICAL", 75, 82], ["two analogues", "TREATMENT", 34, 47], ["tetrazole analogue of glycine in position", "TREATMENT", 53, 94]]], ["The first one contains 1H-tetrazole ring, the second one has tetrazole ring substituted with methyl group in position 1.", [["1H-tetrazole", "CHEMICAL", 23, 35], ["tetrazole", "CHEMICAL", 61, 70], ["methyl", "CHEMICAL", 93, 99], ["1H-tetrazole", "CHEMICAL", 23, 35], ["tetrazole", "CHEMICAL", 61, 70], ["methyl", "CHEMICAL", 93, 99], ["1H-tetrazole ring", "SIMPLE_CHEMICAL", 23, 40], ["tetrazole ring", "SIMPLE_CHEMICAL", 61, 75], ["methyl", "SIMPLE_CHEMICAL", 93, 99], ["1H-tetrazole ring", "TREATMENT", 23, 40], ["tetrazole ring", "TREATMENT", 61, 75], ["methyl group in position", "TREATMENT", 93, 117], ["tetrazole ring", "OBSERVATION", 26, 40], ["tetrazole ring", "OBSERVATION", 61, 75]]], ["Oxytocin analogues possessing amino acids with tetrazole ring in side chains were synthesized on amide resin using Fmoc methodology.", [["Oxytocin", "CHEMICAL", 0, 8], ["amino acids", "CHEMICAL", 30, 41], ["tetrazole", "CHEMICAL", 47, 56], ["Oxytocin", "CHEMICAL", 0, 8], ["amino acids", "CHEMICAL", 30, 41], ["tetrazole", "CHEMICAL", 47, 56], ["amide", "CHEMICAL", 97, 102], ["Fmoc", "CHEMICAL", 115, 119], ["Oxytocin", "SIMPLE_CHEMICAL", 0, 8], ["amino acids", "AMINO_ACID", 30, 41], ["tetrazole ring", "SIMPLE_CHEMICAL", 47, 61], ["amide resin", "SIMPLE_CHEMICAL", 97, 108], ["Oxytocin analogues", "TREATMENT", 0, 18], ["amino acids", "TREATMENT", 30, 41], ["tetrazole ring in side chains", "TREATMENT", 47, 76], ["amide resin", "TREATMENT", 97, 108], ["Fmoc methodology", "TREATMENT", 115, 131]]], ["In the case of analogues with C-terminal tetrazole ring, fragments 1-7 were synthesized on resin and then coupled with suitable dipeptides in solution.", [["C-terminal tetrazole", "CHEMICAL", 30, 50], ["C", "CHEMICAL", 30, 31], ["tetrazole", "CHEMICAL", 41, 50], ["dipeptides", "CHEMICAL", 128, 138], ["1-7", "SIMPLE_CHEMICAL", 67, 70], ["analogues", "TREATMENT", 15, 24], ["C-terminal tetrazole ring", "TREATMENT", 30, 55], ["fragments", "PROBLEM", 57, 66], ["resin", "TREATMENT", 91, 96], ["suitable dipeptides in solution", "TREATMENT", 119, 150], ["tetrazole ring", "OBSERVATION", 41, 55]]], ["All obtained peptides show no pressor and rather low uteronic activity.", [["All obtained peptides", "TEST", 0, 21], ["pressor", "TREATMENT", 30, 37], ["rather low uteronic activity", "PROBLEM", 42, 70], ["no", "UNCERTAINTY", 27, 29], ["low", "OBSERVATION_MODIFIER", 49, 52], ["uteronic activity", "OBSERVATION", 53, 70]]], ["However, for some analogues the uterotonic activity when measured in the presence of magnesium ions was several times higher.", [["magnesium", "CHEMICAL", 85, 94], ["magnesium", "CHEMICAL", 85, 94], ["magnesium ions", "SIMPLE_CHEMICAL", 85, 99], ["some analogues the uterotonic activity", "PROBLEM", 13, 51], ["magnesium ions", "PROBLEM", 85, 99], ["uterotonic activity", "OBSERVATION", 32, 51]]], ["In humans, two classes of defensins, \u03b1-defensin and \u03b2-defensin, have been identified on the basis of tissue specificities and structural features including their modes of disulfide pairing.", [["tissue", "ANATOMY", 101, 107], ["\u03b1-defensin", "CHEMICAL", 37, 47], ["\u03b2-defensin", "CHEMICAL", 52, 62], ["disulfide", "CHEMICAL", 171, 180], ["humans", "ORGANISM", 3, 9], ["defensins", "GENE_OR_GENE_PRODUCT", 26, 35], ["\u03b1-defensin", "GENE_OR_GENE_PRODUCT", 37, 47], ["\u03b2-defensin", "GENE_OR_GENE_PRODUCT", 52, 62], ["tissue", "TISSUE", 101, 107], ["defensins", "PROTEIN", 26, 35], ["\u03b1-defensin", "PROTEIN", 37, 47], ["\u03b2-defensin", "PROTEIN", 52, 62], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["defensins", "TREATMENT", 26, 35], ["\u03b2-defensin", "TREATMENT", 52, 62], ["tissue specificities", "TEST", 101, 121], ["two", "OBSERVATION_MODIFIER", 11, 14], ["classes", "OBSERVATION_MODIFIER", 15, 22], ["defensins", "OBSERVATION", 26, 35]]], ["In general, particular combinations with disulfide bonding in cysteine-containing peptides are critical for expressing their intrinsic biological activities.", [["cysteine", "CHEMICAL", 62, 70], ["disulfide", "CHEMICAL", 41, 50], ["cysteine", "CHEMICAL", 62, 70], ["cysteine", "AMINO_ACID", 62, 70], ["disulfide bonding in cysteine", "TREATMENT", 41, 70]]], ["In the case of human \u03b1-and \u03b2-defensins, however, disulfide isomers without the native pairing were demonstrated to exhibit similar antimicrobial activity to that of the native defensins.", [["disulfide", "CHEMICAL", 49, 58], ["human", "ORGANISM", 15, 20], ["\u03b2-defensins", "GENE_OR_GENE_PRODUCT", 27, 38], ["disulfide isomers", "SIMPLE_CHEMICAL", 49, 66], ["human \u03b1-and \u03b2-defensins", "PROTEIN", 15, 38], ["native defensins", "PROTEIN", 169, 185], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["antimicrobial activity", "OBSERVATION", 131, 153], ["native defensins", "OBSERVATION", 169, 185]]], ["Therefore, to assess the biological activities of defensins as well as defensin-based therapeutics, extreme care is required in the chemical synthesis of these peptides to avoid ambiguity in quality.", [["defensin", "GENE_OR_GENE_PRODUCT", 71, 79], ["defensins", "PROTEIN", 50, 59], ["defensin", "PROTEIN", 71, 79], ["defensins", "TREATMENT", 50, 59], ["defensin-based therapeutics", "TREATMENT", 71, 98], ["extreme care", "TREATMENT", 100, 112], ["these peptides", "TREATMENT", 154, 168]]], ["In the present study, we synthesized human \u03b1-defensin-1, -2 and -4, and human \u03b2-defensin-1, -2, -3 and -4 by employing Boc chemistry, and determined the optimal conditions for folding the respective reduced peptides preferentially into a native conformation.", [["\u03b2-defensin-1, -2, -3 and -4", "CHEMICAL", 78, 105], ["Boc", "CHEMICAL", 119, 122], ["human", "ORGANISM", 37, 42], ["\u03b1-defensin-1", "GENE_OR_GENE_PRODUCT", 43, 55], ["-2", "SIMPLE_CHEMICAL", 57, 59], ["-4", "SIMPLE_CHEMICAL", 64, 66], ["human", "ORGANISM", 72, 77], ["\u03b2-defensin-1, -2, -3", "SIMPLE_CHEMICAL", 78, 98], ["-4", "SIMPLE_CHEMICAL", 103, 105], ["Boc", "SIMPLE_CHEMICAL", 119, 122], ["human \u03b2-defensin-1, -2, -3 and -4", "DNA", 72, 105], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 72, 77], ["human \u03b2-defensin", "TREATMENT", 72, 88], ["Boc chemistry", "TEST", 119, 132], ["folding the respective reduced peptides", "TREATMENT", 176, 215]]], ["Among the factors affecting the oxidative folding in the presence of reduced and oxidized glutathione, the buffer concentration and reaction temperature were essential.", [["glutathione", "CHEMICAL", 90, 101], ["glutathione", "CHEMICAL", 90, 101], ["glutathione", "SIMPLE_CHEMICAL", 90, 101], ["the oxidative folding", "PROBLEM", 28, 49], ["reduced and oxidized glutathione", "TREATMENT", 69, 101], ["the buffer concentration", "TREATMENT", 103, 127], ["reaction temperature", "TEST", 132, 152], ["reduced", "OBSERVATION_MODIFIER", 69, 76], ["oxidized glutathione", "OBSERVATION", 81, 101]]], ["All the synthetic human \u03b1-and \u03b2-defensins were confirmed to have the respective native disulfide pairing by sequential analyses and mass measurements with cystine segments obtained by enzymatic digestion.", [["cystine", "CHEMICAL", 155, 162], ["disulfide", "CHEMICAL", 87, 96], ["cystine", "CHEMICAL", 155, 162], ["human", "ORGANISM", 18, 23], ["\u03b2-defensins", "GENE_OR_GENE_PRODUCT", 30, 41], ["cystine", "SIMPLE_CHEMICAL", 155, 162], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["sequential analyses", "TEST", 108, 127], ["mass measurements", "TEST", 132, 149], ["cystine segments", "TREATMENT", 155, 171]]], ["All the human \u03b1-and \u03b2-defensins could be efficiently oxidized to the \u03b1-and \u03b2-defensin-type disulfide structure, respectively, under several conditions determined in the present study.", [["\u03b2-defensin", "CHEMICAL", 75, 85], ["\u03b2-defensin", "CHEMICAL", 75, 85], ["disulfide", "CHEMICAL", 91, 100], ["human", "ORGANISM", 8, 13], ["\u03b1-and \u03b2-defensins", "SIMPLE_CHEMICAL", 14, 31], ["human \u03b1-and \u03b2-defensins", "PROTEIN", 8, 31], ["\u03b2-defensin", "PROTEIN", 75, 85], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13], ["All the human \u03b1-and \u03b2-defensins", "TREATMENT", 0, 31], ["the present study", "TEST", 165, 182]]], ["These synthetic peptides of high homogeneity were used to accurately assess the antimicrobial activity.UMR 8161-Service de Chimie des Biomol\u00e9cules, Institut De Biologie de Lille, Lille 2 Laboratoire de Chimie Bioorganique, UFR-Sciences, Reims, FranceNative chemical ligation is based on the reaction of a peptide bearing a C-terminal thioester group with an N-terminal cysteinyl peptide, leading to the formation of an amide bond at the AA-Cys junction.UMR 8161-Service de Chimie des Biomol\u00e9cules, Institut De Biologie de Lille, Lille 2 Laboratoire de Chimie Bioorganique, UFR-Sciences, Reims, FranceThe key starting materials for native chemical ligation are unprotected C-terminal thioester peptides.", [["UMR 8161", "CHEMICAL", 103, 111], ["AA", "CHEMICAL", 437, 439], ["UMR 8161", "CHEMICAL", 453, 461], ["C", "CHEMICAL", 323, 324], ["thioester", "CHEMICAL", 334, 343], ["N", "CHEMICAL", 358, 359], ["cysteinyl", "CHEMICAL", 369, 378], ["amide", "CHEMICAL", 419, 424], ["Cys", "CHEMICAL", 440, 443], ["C", "CHEMICAL", 672, 673], ["thioester", "CHEMICAL", 683, 692], ["high homogeneity", "PROBLEM", 28, 44], ["FranceNative chemical ligation", "TREATMENT", 244, 274], ["a peptide bearing a C-terminal thioester group", "TREATMENT", 303, 349], ["an N-terminal cysteinyl peptide", "TREATMENT", 355, 386], ["an amide bond at the AA-Cys junction", "TREATMENT", 416, 452], ["The key starting materials", "TREATMENT", 600, 626], ["native chemical ligation", "TREATMENT", 631, 655], ["C-terminal thioester peptides", "TREATMENT", 672, 701], ["high homogeneity", "OBSERVATION", 28, 44], ["antimicrobial activity", "OBSERVATION", 80, 102], ["ligation", "OBSERVATION", 266, 274], ["cysteinyl peptide", "OBSERVATION", 369, 386], ["Cys junction", "OBSERVATION", 440, 452], ["chemical ligation", "OBSERVATION", 638, 655]]], ["Thioester peptides are often prepared using Boc/benzyl solidphase peptide chemistry.", [["Boc/benzyl", "CHEMICAL", 44, 54], ["Boc", "CHEMICAL", 44, 47], ["benzyl", "CHEMICAL", 48, 54], ["Thioester peptides", "GENE_OR_GENE_PRODUCT", 0, 18], ["benzyl solidphase peptide", "SIMPLE_CHEMICAL", 48, 73], ["Thioester peptides", "PROBLEM", 0, 18], ["Boc/benzyl solidphase peptide", "TREATMENT", 44, 73]]], ["However, the widespread use of the Fmoc/tert-butyl chemistry for peptide synthesis, over the Boc/benzyl method, has stimulated the development of methods allowing the preparation of thioester peptides that are compatible with the basic treatments used to remove the Fmoc alpha-amino protecting group.UMR 8161-Service de Chimie des Biomol\u00e9cules, Institut De Biologie de Lille, Lille 2 Laboratoire de Chimie Bioorganique, UFR-Sciences, Reims, FranceWe report here a novel method for thioester peptide synthesis that is based on the use of the sulfonamide safety-catch linker.", [["Fmoc", "CHEMICAL", 35, 39], ["tert-butyl", "CHEMICAL", 40, 50], ["Boc/benzyl", "CHEMICAL", 93, 103], ["Fmoc alpha-amino", "CHEMICAL", 266, 282], ["UMR 8161", "CHEMICAL", 300, 308], ["sulfonamide", "CHEMICAL", 541, 552], ["Fmoc", "CHEMICAL", 35, 39], ["tert-butyl", "CHEMICAL", 40, 50], ["Boc", "CHEMICAL", 93, 96], ["benzyl", "CHEMICAL", 97, 103], ["thioester", "CHEMICAL", 182, 191], ["Fmoc alpha-amino", "CHEMICAL", 266, 282], ["thioester peptide", "CHEMICAL", 481, 498], ["sulfonamide", "CHEMICAL", 541, 552], ["tert-butyl", "SIMPLE_CHEMICAL", 40, 50], ["thioester peptide", "SIMPLE_CHEMICAL", 481, 498], ["sulfonamide", "SIMPLE_CHEMICAL", 541, 552], ["the Fmoc/tert-butyl chemistry", "TREATMENT", 31, 60], ["peptide synthesis", "TREATMENT", 65, 82], ["the Boc/benzyl method", "TREATMENT", 89, 110], ["the preparation of thioester peptides", "TREATMENT", 163, 200], ["the basic treatments", "TREATMENT", 226, 246], ["the Fmoc alpha-amino protecting group", "TREATMENT", 262, 299], ["a novel method", "TREATMENT", 462, 476], ["thioester peptide synthesis", "TREATMENT", 481, 508], ["the sulfonamide safety", "TREATMENT", 537, 559], ["catch linker", "TREATMENT", 560, 572], ["widespread", "OBSERVATION_MODIFIER", 13, 23]]], ["Once the peptidyl chain is assembled by Fmoc/tert-butyl chemistry, the thioester function is generated on the solid-phase through an intramolecular N,S-acyl shift.UMR 8161-Service de Chimie des Biomol\u00e9cules, Institut De Biologie de Lille, Lille 2 Laboratoire de Chimie Bioorganique, UFR-Sciences, Reims, FranceThe procedure seems to be insensitive to the bulkiness of the amino acid directly attached to the sulfonamide linker.", [["Fmoc/tert-butyl", "CHEMICAL", 40, 55], ["UMR 8161", "CHEMICAL", 163, 171], ["amino acid", "CHEMICAL", 372, 382], ["sulfonamide", "CHEMICAL", 408, 419], ["Fmoc", "CHEMICAL", 40, 44], ["tert-butyl", "CHEMICAL", 45, 55], ["thioester", "CHEMICAL", 71, 80], ["N,S-acyl", "CHEMICAL", 148, 156], ["amino acid", "CHEMICAL", 372, 382], ["sulfonamide", "CHEMICAL", 408, 419], ["tert-butyl", "SIMPLE_CHEMICAL", 45, 55], ["amino acid", "AMINO_ACID", 372, 382], ["peptidyl chain", "PROTEIN", 9, 23], ["the peptidyl chain", "TREATMENT", 5, 23], ["the thioester function", "TEST", 67, 89], ["The procedure", "TREATMENT", 310, 323], ["the amino acid", "TREATMENT", 368, 382], ["the sulfonamide linker", "TREATMENT", 404, 426], ["acyl shift", "OBSERVATION", 152, 162], ["sulfonamide linker", "OBSERVATION", 408, 426]]], ["The thioesters were successfully used for native chemical ligations in solution or on the solid support.", [["thioesters", "CHEMICAL", 4, 14], ["The thioesters", "TREATMENT", 0, 14], ["native chemical ligations in solution", "TREATMENT", 42, 79], ["the solid support", "TREATMENT", 86, 103], ["chemical ligations", "OBSERVATION", 49, 67]]], ["We optimized the recognition sequence of the substrate and the reaction conditions with respect to the yield.", [["the reaction conditions", "PROBLEM", 59, 82]]], ["The sortase-mediated ligation was successfully applied to the synthesis of cellpenetrating peptide-PNA conjugates which showed enhanced activity in antisense experiments compared to PNA alone.", [["PNA", "CHEMICAL", 182, 185], ["sortase", "GENE_OR_GENE_PRODUCT", 4, 11], ["cellpenetrating peptide-PNA conjugates", "SIMPLE_CHEMICAL", 75, 113], ["PNA", "SIMPLE_CHEMICAL", 182, 185], ["The sortase-mediated ligation", "TREATMENT", 0, 29], ["cellpenetrating peptide", "TREATMENT", 75, 98], ["PNA conjugates", "PROBLEM", 99, 113], ["enhanced activity in antisense experiments", "PROBLEM", 127, 169], ["PNA", "PROBLEM", 182, 185], ["PNA", "OBSERVATION", 99, 102], ["enhanced", "OBSERVATION_MODIFIER", 127, 135], ["activity", "OBSERVATION_MODIFIER", 136, 144], ["PNA", "OBSERVATION", 182, 185]]], ["This ligation strategy was also employed for the coupling of a chemically synthesized construct of the extracellular loops of the CRF-receptor with the corresponding N-terminal receptor domain, which was expressed in E. coli.", [["extracellular", "ANATOMY", 103, 116], ["N", "CHEMICAL", 166, 167], ["extracellular loops", "CELLULAR_COMPONENT", 103, 122], ["CRF-receptor", "GENE_OR_GENE_PRODUCT", 130, 142], ["E. coli", "ORGANISM", 217, 224], ["extracellular loops", "PROTEIN", 103, 122], ["CRF-receptor", "PROTEIN", 130, 142], ["N-terminal receptor domain", "PROTEIN", 166, 192], ["E. coli", "SPECIES", 217, 224], ["E. coli", "SPECIES", 217, 224], ["This ligation strategy", "TREATMENT", 0, 22], ["the corresponding N-terminal receptor domain", "PROBLEM", 148, 192], ["E. coli", "PROBLEM", 217, 224], ["extracellular loops", "OBSERVATION", 103, 122], ["E. coli", "OBSERVATION", 217, 224]]], ["This 23 kDa protein behaves like an artificial receptor, binding specifically natural ligands.UMR 8161-Service de Chimie des Biomol\u00e9cules, Institut De Biologie de Lille, Lille 2 Laboratoire de Chimie Bioorganique, UFR-Sciences, Reims, FranceLinear gramicidins represent the most investigated family of antibiotic peptides forming ionic channels.", [["UMR 8161", "CHEMICAL", 94, 102], ["23 kDa protein", "PROTEIN", 5, 19], ["artificial receptor", "PROTEIN", 36, 55], ["This 23 kDa protein", "TEST", 0, 19], ["antibiotic peptides", "TREATMENT", 302, 321], ["natural ligands", "OBSERVATION", 78, 93]]], ["Gramicidins produced by Bacillus Brevis are hydrophobic peptides composed of 15 amino-acids with D and L configuration strictly alternate.", [["Gramicidins", "CHEMICAL", 0, 11], ["amino-acids", "CHEMICAL", 80, 91], ["Gramicidins", "CHEMICAL", 0, 11], ["amino-acids", "CHEMICAL", 80, 91], ["Gramicidins", "SIMPLE_CHEMICAL", 0, 11], ["Bacillus Brevis", "ORGANISM", 24, 39], ["amino-acids", "SIMPLE_CHEMICAL", 80, 91], ["D", "SIMPLE_CHEMICAL", 97, 98], ["Bacillus Brevis", "SPECIES", 24, 39], ["Bacillus Brevis", "SPECIES", 24, 39], ["Gramicidins", "TREATMENT", 0, 11], ["hydrophobic peptides", "TREATMENT", 44, 64], ["15 amino-acids", "TREATMENT", 77, 91], ["D and L configuration", "TREATMENT", 97, 118], ["Bacillus Brevis", "ANATOMY", 24, 39]]], ["The presence of D-amino acids in the sequence of gramicidin A (HCO-Val-Gly-Ala-DLeu-Ala-DVal-Val-DVal-Trp-DLeu-Trp-DLeu-Trp-DLeu-Trp-NHCH2CH2OH) should possible make the peptide highly resistant to proteolysis [1] .", [["D-amino acids", "CHEMICAL", 16, 29], ["gramicidin", "CHEMICAL", 49, 59], ["DVal-Val-DVal-Trp", "CHEMICAL", 88, 105], ["D-amino acids", "CHEMICAL", 16, 29], ["gramicidin A", "CHEMICAL", 49, 61], ["HCO-Val-Gly-Ala-DLeu-Ala-DVal-Val-DVal-Trp-DLeu-Trp-DLeu-Trp-DLeu-Trp-NHCH2CH2OH", "CHEMICAL", 63, 143], ["D-amino acids", "AMINO_ACID", 16, 29], ["gramicidin A", "SIMPLE_CHEMICAL", 49, 61], ["HCO-Val-Gly", "SIMPLE_CHEMICAL", 63, 74], ["D-amino acids", "TREATMENT", 16, 29], ["gramicidin", "TEST", 49, 59], ["HCO", "TEST", 63, 66], ["Val-", "TEST", 67, 71], ["Gly", "TEST", 71, 74], ["Ala-", "TEST", 75, 79], ["DLeu-", "TEST", 79, 84], ["Ala-", "TEST", 84, 88], ["DVal", "TEST", 88, 92], ["DVal-Trp-DLeu-Trp-DLeu-Trp-DLeu-Trp-NHCH2CH2OH)", "TREATMENT", 97, 144], ["the peptide", "PROBLEM", 166, 177], ["D-amino acids", "OBSERVATION", 16, 29]]], ["Striking features like ethanolamine group in C-terminus, the N-terminal N-formylated valine and the high hydrophobicity of the peptide sequence, make the solid-phase synthesis of gramicidin A very tricky.", [["ethanolamine", "CHEMICAL", 23, 35], ["N-formylated valine", "CHEMICAL", 72, 91], ["gramicidin", "CHEMICAL", 179, 189], ["ethanolamine", "CHEMICAL", 23, 35], ["C", "CHEMICAL", 45, 46], ["N-formylated valine", "CHEMICAL", 72, 91], ["ethanolamine", "SIMPLE_CHEMICAL", 23, 35], ["valine", "AMINO_ACID", 85, 91], ["gramicidin A", "SIMPLE_CHEMICAL", 179, 191], ["C-terminus", "PROTEIN", 45, 55], ["N-terminal N-formylated valine", "PROTEIN", 61, 91], ["Striking features", "PROBLEM", 0, 17], ["ethanolamine group in C-terminus", "PROBLEM", 23, 55], ["the N-terminal N-formylated valine", "TREATMENT", 57, 91], ["the high hydrophobicity of the peptide sequence", "PROBLEM", 96, 143], ["ethanolamine group", "OBSERVATION", 23, 41], ["formylated valine", "OBSERVATION", 74, 91], ["high hydrophobicity", "OBSERVATION_MODIFIER", 100, 119]]], ["Therefore, we followed a new synthetic strategy for peptide chain elongation assisted by microwave energy.", [["a new synthetic strategy", "TREATMENT", 23, 47], ["peptide chain elongation", "TREATMENT", 52, 76]]], ["In fact, microwave energy has been demonstrated to produce highpurity compounds with more rapid reaction times, enhancing coupling rates and efficiency in difficult syntheses [2] .", [["highpurity compounds", "PROBLEM", 59, 79], ["more rapid reaction times", "PROBLEM", 85, 110], ["enhancing coupling rates", "PROBLEM", 112, 136]]], ["However, microwave-assisted solid phase peptide synthesis (MW-SPPS) has not been yet extensively investigated.", [["microwave-assisted solid phase peptide synthesis", "TREATMENT", 9, 57]]], ["In this context, we synthesized gramicidin A by MW-SPPS in high yield and purity, enhancing reaction rate compared to the traditional SPPS.", [["gramicidin A", "CHEMICAL", 32, 44], ["MW-SPPS", "CHEMICAL", 48, 55], ["gramicidin A", "CHEMICAL", 32, 44], ["gramicidin A", "SIMPLE_CHEMICAL", 32, 44], ["MW-SPPS", "SIMPLE_CHEMICAL", 48, 55], ["enhancing reaction rate", "PROBLEM", 82, 105]]], ["Thermal disruption of peptide aggregation, induced by microwaves, is possible favorable for obtaining this particularly difficult sequence.", [["Thermal disruption of peptide aggregation", "PROBLEM", 0, 41], ["peptide aggregation", "OBSERVATION", 22, 41]]], ["Gramicidin A was incorporated in synthetic lipid bilayers, self-assembled on mercury electrodes, characterized by hydrophilic spacers interposed between the metal and the lipid bilayer.", [["Gramicidin A", "CHEMICAL", 0, 12], ["mercury", "CHEMICAL", 77, 84], ["Gramicidin A", "CHEMICAL", 0, 12], ["mercury", "CHEMICAL", 77, 84], ["Gramicidin A", "SIMPLE_CHEMICAL", 0, 12], ["lipid bilayers", "SIMPLE_CHEMICAL", 43, 57], ["mercury", "SIMPLE_CHEMICAL", 77, 84], ["lipid bilayer", "CELLULAR_COMPONENT", 171, 184], ["Gramicidin A", "TREATMENT", 0, 12], ["mercury electrodes", "TREATMENT", 77, 95], ["hydrophilic spacers interposed between the metal and the lipid bilayer", "TREATMENT", 114, 184], ["hydrophilic spacers", "OBSERVATION", 114, 133], ["metal", "ANATOMY_MODIFIER", 157, 162], ["lipid bilayer", "OBSERVATION", 171, 184]]], ["We tested the behaviour of gramicidin A in biomimetic membranes using Electrochemical Impedance Spectroscopy (EIS), AC voltammetry and other electrochemical techniques [3] .", [["membranes", "ANATOMY", 54, 63], ["gramicidin A", "CHEMICAL", 27, 39], ["gramicidin A", "CHEMICAL", 27, 39], ["gramicidin A", "SIMPLE_CHEMICAL", 27, 39], ["gramicidin A in biomimetic membranes", "TREATMENT", 27, 63], ["Electrochemical Impedance Spectroscopy", "TEST", 70, 108], ["AC voltammetry", "TEST", 116, 130]]], ["[ CSF114(Glc) is an N-glucosylated peptide to be produced in large scale by PeptLab because it is the active molecule of the first specific diagnostic/prognostic test for monitoring disease activity and guiding therapeutic treatments of multiple sclerosis patients [1] .UMR 8161-Service de Chimie des Biomol\u00e9cules, Institut De Biologie de Lille, Lille 2 Laboratoire de Chimie Bioorganique, UFR-Sciences, Reims, FranceIn order to develop a synthetic protocol by an automated instrumentation, increasing yield, purity of the crude, and reaction time, a microwave-assisted solid phase peptide synthesis was validated comparing the use of the new generation of Triazine-Based Coupling Reagents (TBCRs) with a series of commonly used ones.", [["Glc", "CHEMICAL", 9, 12], ["multiple sclerosis", "DISEASE", 237, 255], ["UMR 8161", "CHEMICAL", 270, 278], ["Triazine", "CHEMICAL", 657, 665], ["CSF114", "CHEMICAL", 2, 8], ["Glc", "CHEMICAL", 9, 12], ["N", "CHEMICAL", 20, 21], ["Triazine", "CHEMICAL", 657, 665], ["CSF114(Glc)", "GENE_OR_GENE_PRODUCT", 2, 13], ["PeptLab", "GENE_OR_GENE_PRODUCT", 76, 83], ["patients", "ORGANISM", 256, 264], ["Triazine", "SIMPLE_CHEMICAL", 657, 665], ["PeptLab", "PROTEIN", 76, 83], ["patients", "SPECIES", 256, 264], ["CSF114", "TEST", 2, 8], ["Glc", "TEST", 9, 12], ["an N", "TEST", 17, 21], ["prognostic test", "TEST", 151, 166], ["monitoring disease activity", "PROBLEM", 171, 198], ["therapeutic treatments", "TREATMENT", 211, 233], ["multiple sclerosis patients", "PROBLEM", 237, 264], ["a synthetic protocol", "TREATMENT", 437, 457], ["an automated instrumentation", "TREATMENT", 461, 489], ["a microwave-assisted solid phase peptide synthesis", "TREATMENT", 549, 599], ["the new generation of Triazine", "TREATMENT", 635, 665], ["multiple", "OBSERVATION_MODIFIER", 237, 245], ["sclerosis", "OBSERVATION", 246, 255]]], ["Activation of carboxylic acids by TBCRs is particularly effective because of formation of triazine \"superactive esters\".", [["carboxylic acids", "CHEMICAL", 14, 30], ["TBCRs", "CHEMICAL", 34, 39], ["triazine", "CHEMICAL", 90, 98], ["carboxylic acids", "CHEMICAL", 14, 30], ["triazine", "CHEMICAL", 90, 98], ["esters", "CHEMICAL", 112, 118], ["carboxylic acids", "SIMPLE_CHEMICAL", 14, 30], ["TBCRs", "SIMPLE_CHEMICAL", 34, 39], ["triazine \"superactive esters", "SIMPLE_CHEMICAL", 90, 118], ["Activation of carboxylic acids", "TREATMENT", 0, 30]]], ["The usefulness of TBCRs as coupling reagents has been recently confirmed in the synthesis of Z-, Boc-, and Fmoc-protected dipeptides, sterically hindered amino acids, in the synthesis of esters, in manual and automated SPPS of difficult peptide sequences, and head-to-tail constrained cyclopeptide analogues [2] .", [["TBCRs", "CHEMICAL", 18, 23], ["Boc-", "CHEMICAL", 97, 101], ["Fmoc", "CHEMICAL", 107, 111], ["amino acids", "CHEMICAL", 154, 165], ["Z-, Boc-, and Fmoc-protected dipeptides", "CHEMICAL", 93, 132], ["amino acids", "CHEMICAL", 154, 165], ["esters", "CHEMICAL", 187, 193], ["cyclopeptide", "CHEMICAL", 285, 297], ["TBCRs", "SIMPLE_CHEMICAL", 18, 23], ["Z-, Boc-", "SIMPLE_CHEMICAL", 93, 101], ["Fmoc-protected dipeptides", "SIMPLE_CHEMICAL", 107, 132], ["sterically hindered amino acids", "SIMPLE_CHEMICAL", 134, 165], ["esters", "SIMPLE_CHEMICAL", 187, 193], ["cyclopeptide", "SIMPLE_CHEMICAL", 285, 297], ["Z", "TEST", 93, 94], ["Boc-", "TEST", 97, 101], ["Fmoc", "TEST", 107, 111], ["sterically hindered amino acids", "PROBLEM", 134, 165], ["difficult peptide sequences", "PROBLEM", 227, 254], ["head", "TEST", 260, 264], ["cyclopeptide analogues", "TREATMENT", 285, 307], ["head", "ANATOMY", 260, 264], ["tail", "ANATOMY", 268, 272]]], ["Moreover, we also demonstrated TBCRs efficient in a microwave-assisted solution synthesis of the N-glucosylated building block Fmoc-Asn(GlcOAc4)-OH using a manual monomode microwave instrument [3] .", [["Fmoc-Asn", "CHEMICAL", 127, 135], ["GlcOAc4)-OH", "CHEMICAL", 136, 147], ["N", "CHEMICAL", 97, 98], ["Fmoc-Asn(GlcOAc4)-OH", "CHEMICAL", 127, 147], ["TBCRs", "SIMPLE_CHEMICAL", 31, 36], ["Fmoc-Asn(GlcOAc4)-OH", "SIMPLE_CHEMICAL", 127, 147], ["TBCRs", "PROBLEM", 31, 36], ["a microwave-assisted solution synthesis", "TREATMENT", 50, 89], ["the N-glucosylated building block Fmoc", "TREATMENT", 93, 131], ["Asn(GlcOAc4)", "TREATMENT", 132, 144], ["a manual monomode microwave instrument", "TREATMENT", 154, 192]]], ["This building block was used to obtain CSF114(Glc) comparing the efficacy of a monomode microwave automatic instrument with the traditional solid-phase peptide synthesizers such as the manual and automatic in batch systems, as well as the continuous-flow one.", [["Glc", "CHEMICAL", 46, 49], ["CSF114", "CHEMICAL", 39, 45], ["Glc", "CHEMICAL", 46, 49], ["CSF114", "SIMPLE_CHEMICAL", 39, 45], ["Glc", "SIMPLE_CHEMICAL", 46, 49], ["This building block", "TREATMENT", 0, 19], ["Glc", "TEST", 46, 49], ["a monomode microwave automatic instrument", "TREATMENT", 77, 118], ["the traditional solid-phase peptide synthesizers", "TREATMENT", 124, 172], ["automatic in batch systems", "TREATMENT", 196, 222]]], ["It is known that enzymatic peptide synthesis is more advantageous than chemical synthesis in many aspects; it is highly stereoselective, racemization-free and requires minimal side-chain protection.", [["enzymatic peptide synthesis", "PROBLEM", 17, 44], ["chemical synthesis", "TREATMENT", 71, 89], ["minimal side-chain protection", "TREATMENT", 168, 197], ["minimal", "OBSERVATION_MODIFIER", 168, 175]]], ["The method is, however, limited to the use of amino acid derivatives which meet the enzymatic specificity as a coupling component.", [["amino acid", "CHEMICAL", 46, 56], ["amino acid", "CHEMICAL", 46, 56], ["amino acid derivatives", "SIMPLE_CHEMICAL", 46, 68], ["amino acid derivatives", "TREATMENT", 46, 68], ["a coupling component", "PROBLEM", 109, 129]]], ["This problem may be solved using enzymes which have wide specificity of substrate.", [["enzymes", "PROTEIN", 33, 40], ["enzymes", "TEST", 33, 40]]], ["But in this case, secondary hydrolysis of the resulting peptide may arise from the inherent nature of the protease.", [["protease", "PROTEIN", 106, 114], ["secondary hydrolysis", "PROBLEM", 18, 38], ["the resulting peptide", "PROBLEM", 42, 63], ["the protease", "TREATMENT", 102, 114]]], ["In this matter, ficin and ficin-like enzymes were used as cysteine protease to analyze the diminishment of specificity for the substrate.", [["ficin", "CHEMICAL", 16, 21], ["ficin", "CHEMICAL", 26, 31], ["ficin", "CHEMICAL", 16, 21], ["cysteine", "CHEMICAL", 58, 66], ["ficin", "SIMPLE_CHEMICAL", 16, 21], ["ficin", "SIMPLE_CHEMICAL", 26, 31], ["ficin and ficin-like enzymes", "PROTEIN", 16, 44], ["cysteine protease", "PROTEIN", 58, 75], ["enzymes", "TEST", 37, 44], ["cysteine protease", "TREATMENT", 58, 75]]], ["The cysteine protease-catalyzed peptide coupling reaction has been studied by using synthetic fourteen Boc-amino acid phenyl and naphthyl esters as acyl donor.", [["cysteine", "CHEMICAL", 4, 12], ["Boc-amino acid phenyl", "CHEMICAL", 103, 124], ["naphthyl esters", "CHEMICAL", 129, 144], ["acyl", "CHEMICAL", 148, 152], ["cysteine", "CHEMICAL", 4, 12], ["Boc-amino acid phenyl", "CHEMICAL", 103, 124], ["naphthyl esters", "CHEMICAL", 129, 144], ["acyl", "CHEMICAL", 148, 152], ["cysteine", "AMINO_ACID", 4, 12], ["Boc-amino acid phenyl", "SIMPLE_CHEMICAL", 103, 124], ["naphthyl esters", "SIMPLE_CHEMICAL", 129, 144], ["acyl donor", "SIMPLE_CHEMICAL", 148, 158], ["The cysteine protease", "TREATMENT", 0, 21], ["coupling reaction", "PROBLEM", 40, 57], ["synthetic fourteen Boc-amino acid phenyl and naphthyl esters", "TREATMENT", 84, 144], ["acyl donor", "TREATMENT", 148, 158]]], ["The reaction conditions were optimized for organic solvent, pH, and concentration of acceptor.", [["The reaction conditions", "PROBLEM", 0, 23], ["organic solvent", "TREATMENT", 43, 58], ["concentration of acceptor", "TREATMENT", 68, 93]]], ["The coupling reaction was carried out by incubating an acyl donor (1 mM) with an acyl acceptor (Ala p-nitroanilide, 35 mM) and enzyme (0.1U) in a mixture of GTA buffer (50 mM, pH 9.0) and DMSO (3:2) at 37\u0652C.", [["acyl", "CHEMICAL", 55, 59], ["Ala p-nitroanilide", "CHEMICAL", 96, 114], ["0.1U", "CHEMICAL", 135, 139], ["DMSO", "CHEMICAL", 188, 192], ["acyl", "CHEMICAL", 55, 59], ["acyl", "CHEMICAL", 81, 85], ["Ala p-nitroanilide", "CHEMICAL", 96, 114], ["DMSO", "CHEMICAL", 188, 192], ["Ala p-nitroanilide", "SIMPLE_CHEMICAL", 96, 114], ["GTA", "SIMPLE_CHEMICAL", 157, 160], ["DMSO", "SIMPLE_CHEMICAL", 188, 192], ["The coupling reaction", "PROBLEM", 0, 21], ["an acyl donor", "TREATMENT", 52, 65], ["an acyl acceptor (Ala p-nitroanilide", "TREATMENT", 78, 114], ["enzyme", "TEST", 127, 133], ["GTA buffer", "TREATMENT", 157, 167], ["pH", "TEST", 176, 178], ["DMSO", "TEST", 188, 192]]], ["The progress of the coupling reaction was monitored by RP-HPLC.", [["the coupling reaction", "PROBLEM", 16, 37]]], ["The products were obtained in satisfactory yields.Bioanalytics, Center for Biotechnology and Biomedicine (BBZ), Faculty of Chemistry and Mineralogy, University of Leipzig, GermanyNon-enzymatic glycosylation, also called glycation, is a common modification in living organisms formed by the reaction of carbohydrates with free amino groups of peptides and proteins.", [["carbohydrates", "CHEMICAL", 302, 315], ["amino", "CHEMICAL", 326, 331], ["carbohydrates", "SIMPLE_CHEMICAL", 302, 315], ["GermanyNon-enzymatic glycosylation", "TREATMENT", 172, 206], ["a common modification in living organisms", "PROBLEM", 234, 275], ["free amino groups of peptides", "TREATMENT", 321, 350], ["enzymatic glycosylation", "OBSERVATION", 183, 206]]], ["It is a slow chemical reaction yielding Amadori products undergoing further oxidation and degradation reactions finally leading to advanced glycation end-products (AGE).", [["Amadori", "CHEMICAL", 40, 47], ["Amadori products", "SIMPLE_CHEMICAL", 40, 56], ["advanced glycation end-products", "SIMPLE_CHEMICAL", 131, 162], ["AGE", "SIMPLE_CHEMICAL", 164, 167], ["AGE", "PROTEIN", 164, 167], ["a slow chemical reaction", "PROBLEM", 6, 30], ["Amadori products", "TREATMENT", 40, 56], ["further oxidation", "TREATMENT", 68, 85], ["degradation reactions", "PROBLEM", 90, 111], ["advanced glycation end-products", "TREATMENT", 131, 162], ["slow", "OBSERVATION_MODIFIER", 8, 12], ["chemical reaction", "OBSERVATION", 13, 30], ["Amadori products", "OBSERVATION", 40, 56]]], ["Amadori products are early markers for ageing, diabetes mellitus and Alzheimer's disease.", [["diabetes mellitus", "DISEASE", 47, 64], ["Alzheimer's disease", "DISEASE", 69, 88], ["Amadori products", "TREATMENT", 0, 16], ["diabetes mellitus", "PROBLEM", 47, 64], ["Alzheimer's disease", "PROBLEM", 69, 88]]], ["Despite the clinical importance of these Amadori products, universal protocols to synthesize Amadori modified peptides are still missing.Bioanalytics, Center for Biotechnology and Biomedicine (BBZ), Faculty of Chemistry and Mineralogy, University of Leipzig, GermanyHere we describe a solid phase strategy for the glycation of specific amino groups on partially protected resin bound peptides using a global post synthetic approach.", [["amino", "CHEMICAL", 336, 341], ["amino", "AMINO_ACID", 336, 341], ["these Amadori products", "TREATMENT", 35, 57], ["universal protocols", "TREATMENT", 59, 78], ["Amadori modified peptides", "TREATMENT", 93, 118], ["a solid phase strategy", "TREATMENT", 283, 305], ["the glycation of specific amino groups", "TREATMENT", 310, 348], ["resin bound peptides", "TREATMENT", 372, 392], ["a global post synthetic approach", "TREATMENT", 399, 431]]], ["The peptides were synthesized by standard Fmoc/tBu-chemistry using carbodiimide activation.", [["Fmoc", "CHEMICAL", 42, 46], ["carbodiimide", "CHEMICAL", 67, 79], ["Fmoc", "CHEMICAL", 42, 46], ["tBu-", "CHEMICAL", 47, 51], ["carbodiimide", "CHEMICAL", 67, 79], ["tBu-", "SIMPLE_CHEMICAL", 47, 51], ["carbodiimide", "SIMPLE_CHEMICAL", 67, 79], ["The peptides", "TREATMENT", 0, 12], ["standard Fmoc/tBu-chemistry", "TREATMENT", 33, 60], ["carbodiimide activation", "TREATMENT", 67, 90]]], ["The lysine position to be modified was incorporated with a methyltrityl protected \u03b5-amino group, which can be selectively cleaved after completion of the peptide synthesis with 1% TFA in dichloromethane.", [["lysine", "CHEMICAL", 4, 10], ["methyltrityl", "CHEMICAL", 59, 71], ["\u03b5-amino", "CHEMICAL", 82, 89], ["TFA", "CHEMICAL", 180, 183], ["dichloromethane", "CHEMICAL", 187, 202], ["lysine", "CHEMICAL", 4, 10], ["methyltrityl", "CHEMICAL", 59, 71], ["\u03b5-amino", "CHEMICAL", 82, 89], ["TFA", "CHEMICAL", 180, 183], ["dichloromethane", "CHEMICAL", 187, 202], ["lysine", "AMINO_ACID", 4, 10], ["methyltrityl", "SIMPLE_CHEMICAL", 59, 71], ["\u03b5-amino", "SIMPLE_CHEMICAL", 82, 89], ["TFA", "SIMPLE_CHEMICAL", 180, 183], ["dichloromethane", "SIMPLE_CHEMICAL", 187, 202], ["The lysine position", "TREATMENT", 0, 19], ["a methyltrityl protected \u03b5-amino group", "TREATMENT", 57, 95], ["the peptide synthesis", "TREATMENT", 150, 171], ["1% TFA in dichloromethane", "TREATMENT", 177, 202], ["lysine position", "OBSERVATION", 4, 19]]], ["The partly deprotected peptide was glycated in methanol using a ten-fold molar excess of 2,3-4,5-di-O-isopropylidene-aldehydo-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose and NaBH3CN for 18 h at 70\u00b0C. After cleavage the overall yields were in the range of 50 -70 % for the tested octapeptides.", [["methanol", "CHEMICAL", 47, 55], ["2,3-4,5-di-O-isopropylidene-aldehydo-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose", "CHEMICAL", 89, 162], ["NaBH3CN", "CHEMICAL", 167, 174], ["methanol", "CHEMICAL", 47, 55], ["2,3-4,5-di-O-isopropylidene-aldehydo-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose", "CHEMICAL", 89, 162], ["NaBH3CN", "CHEMICAL", 167, 174], ["methanol", "SIMPLE_CHEMICAL", 47, 55], ["2,3-4,5-di-O-isopropylidene-aldehydo-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose", "SIMPLE_CHEMICAL", 89, 162], ["NaBH3CN", "SIMPLE_CHEMICAL", 167, 174], ["octapeptides", "SIMPLE_CHEMICAL", 272, 284], ["The partly deprotected peptide", "TREATMENT", 0, 30], ["methanol", "TREATMENT", 47, 55], ["a ten-fold molar excess", "TREATMENT", 62, 85], ["NaBH3CN", "TREATMENT", 167, 174], ["the tested octapeptides", "TEST", 261, 284]]], ["All byproducts were well separated by RP-HPLC allowing a simple purification strategy even for medium-sized peptides.", [["All byproducts", "TREATMENT", 0, 14], ["a simple purification strategy", "TREATMENT", 55, 85], ["medium-sized peptides", "TREATMENT", 95, 116]]], ["Thus the general strategy presented here allows routine synthesis of Amadori peptides at reasonable yields and purities using standard protocols established in most laboratories synthesizing peptides.CSS-Albachem, Elvingston Science Centre, Nr. Gladsmuir, East Lothian, UK2-chlorotrityl chloride resins are recommended for the synthesis of C-terminal proline peptide acids to overcome diketopiperazine formation during chain assembly.", [["UK2-chlorotrityl chloride", "CHEMICAL", 270, 295], ["diketopiperazine", "CHEMICAL", 385, 401], ["UK2-chlorotrityl chloride", "CHEMICAL", 270, 295], ["C", "CHEMICAL", 340, 341], ["proline peptide acids", "CHEMICAL", 351, 372], ["diketopiperazine", "CHEMICAL", 385, 401], ["Amadori peptides", "SIMPLE_CHEMICAL", 69, 85], ["UK2-chlorotrityl chloride resins", "SIMPLE_CHEMICAL", 270, 302], ["C-terminal proline peptide acids", "SIMPLE_CHEMICAL", 340, 372], ["diketopiperazine", "SIMPLE_CHEMICAL", 385, 401], ["routine synthesis of Amadori peptides", "TREATMENT", 48, 85], ["standard protocols", "TREATMENT", 126, 144], ["UK2-chlorotrityl chloride resins", "TREATMENT", 270, 302], ["C-terminal proline peptide acids", "TREATMENT", 340, 372], ["diketopiperazine formation", "PROBLEM", 385, 411]]], ["However, we have found these (and similar) resins to be unsuitable for the synthesis of peptides greater than 20 residues.", [["the synthesis of peptides", "TREATMENT", 71, 96]]], ["For example, the chemokine guinea pig eotaxin, (73 residues C-terminal proline) assembles poorly if not at all on a 2-chlorotrityl resin.", [["2-chlorotrityl", "CHEMICAL", 116, 130], ["C-", "CHEMICAL", 60, 62], ["proline", "CHEMICAL", 71, 78], ["2-chlorotrityl", "CHEMICAL", 116, 130], ["guinea pig", "ORGANISM", 27, 37], ["eotaxin", "GENE_OR_GENE_PRODUCT", 38, 45], ["proline", "AMINO_ACID", 71, 78], ["2-chlorotrityl resin", "SIMPLE_CHEMICAL", 116, 136], ["chemokine guinea pig eotaxin", "PROTEIN", 17, 45], ["guinea pig", "SPECIES", 27, 37], ["guinea pig", "SPECIES", 27, 37], ["the chemokine guinea pig eotaxin", "TREATMENT", 13, 45], ["residues C-terminal proline)", "TREATMENT", 51, 79], ["a 2-chlorotrityl resin", "TREATMENT", 114, 136]]], ["We sought to circumvent these problems in the chemical synthesis of peptides and proteins, through the development of a resin-swap procedure.", [["these problems", "PROBLEM", 24, 38], ["a resin-swap procedure", "TREATMENT", 118, 140]]], ["Whereby the initial C-terminal protected tripeptide is assembled on a 2-chlorotrityl resin, liberated from the solid-support, then reattached to a resin that is suited for long chain peptide / protein synthesis.", [["2-chlorotrityl resin", "CHEMICAL", 70, 90], ["C", "CHEMICAL", 20, 21], ["tripeptide", "CHEMICAL", 41, 51], ["2-chlorotrityl", "CHEMICAL", 70, 84], ["2-chlorotrityl resin", "SIMPLE_CHEMICAL", 70, 90], ["a 2-chlorotrityl resin", "TREATMENT", 68, 90], ["the solid-support", "TREATMENT", 107, 124], ["a resin", "TREATMENT", 145, 152], ["long chain peptide / protein synthesis", "TREATMENT", 172, 210], ["protein synthesis", "OBSERVATION", 193, 210]]], ["Using this approach, the synthesis of guinea pig eotaxin is reported.CSS-Albachem, Elvingston Science Centre, Nr. Gladsmuir, East Lothian, UKThe tripeptide Fmoc-Thr(But)-Lys(Boc)-Pro-OH was assemble on 2-chlorotrityl resin, cleaved with 20% TFE in DCM and attached to Wang resin using standard protocols.", [["Fmoc-Thr", "CHEMICAL", 156, 164], ["2-chlorotrityl resin", "CHEMICAL", 202, 222], ["TFE", "CHEMICAL", 241, 244], ["DCM", "CHEMICAL", 248, 251], ["Fmoc-Thr(But)-Lys(Boc)-Pro-OH", "CHEMICAL", 156, 185], ["2-chlorotrityl", "CHEMICAL", 202, 216], ["TFE", "CHEMICAL", 241, 244], ["guinea", "ORGANISM", 38, 44], ["pig", "ORGANISM", 45, 48], ["eotaxin", "GENE_OR_GENE_PRODUCT", 49, 56], ["UKThe tripeptide Fmoc-Thr(But)-Lys(Boc)-Pro-OH", "SIMPLE_CHEMICAL", 139, 185], ["2-chlorotrityl resin", "SIMPLE_CHEMICAL", 202, 222], ["TFE", "SIMPLE_CHEMICAL", 241, 244], ["guinea pig eotaxin", "PROTEIN", 38, 56], ["guinea pig", "SPECIES", 38, 48], ["guinea pig", "SPECIES", 38, 48], ["this approach", "TREATMENT", 6, 19], ["the synthesis of guinea pig eotaxin", "TREATMENT", 21, 56], ["UKThe tripeptide Fmoc", "TREATMENT", 139, 160], ["2-chlorotrityl resin", "TREATMENT", 202, 222], ["20% TFE in DCM", "TREATMENT", 237, 251], ["Wang resin", "TREATMENT", 268, 278], ["standard protocols", "TREATMENT", 285, 303]]], ["Peptide assembly gave the gp eotaxin in 53% overall yield (as determined by UV monitoring).", [["eotaxin", "GENE_OR_GENE_PRODUCT", 29, 36], ["gp eotaxin", "PROTEIN", 26, 36], ["the gp eotaxin", "TREATMENT", 22, 36], ["UV monitoring", "TEST", 76, 89]]], ["Fmoc-On cleavage, purification and tag removal followed by folding gave the native chemokine in good yield.CSS-Albachem, Elvingston Science Centre, Nr. Gladsmuir, East Lothian, UKChoice of resin is one of the most critical factors in ensuring a successful peptide synthesis, we have shown the superiority of Wang resin over chlorotrityl resin in the synthesis of medium and long peptides and developed a method for the synthesis of C-terminal proline containing peptides which overcomes the problem of diketopiperazine formation.", [["Fmoc", "CHEMICAL", 0, 4], ["chlorotrityl resin", "CHEMICAL", 324, 342], ["C-terminal proline", "CHEMICAL", 432, 450], ["diketopiperazine", "CHEMICAL", 502, 518], ["Fmoc", "CHEMICAL", 0, 4], ["chlorotrityl resin", "CHEMICAL", 324, 342], ["C", "CHEMICAL", 432, 433], ["proline", "CHEMICAL", 443, 450], ["diketopiperazine", "CHEMICAL", 502, 518], ["chlorotrityl resin", "SIMPLE_CHEMICAL", 324, 342], ["C-terminal proline", "SIMPLE_CHEMICAL", 432, 450], ["diketopiperazine", "SIMPLE_CHEMICAL", 502, 518], ["native chemokine", "PROTEIN", 76, 92], ["Fmoc", "TREATMENT", 0, 4], ["cleavage", "TREATMENT", 8, 16], ["purification", "TREATMENT", 18, 30], ["tag removal", "TREATMENT", 35, 46], ["resin", "TREATMENT", 189, 194], ["a successful peptide synthesis", "TREATMENT", 243, 273], ["Wang resin over chlorotrityl resin", "TREATMENT", 308, 342], ["the synthesis of medium and long peptides", "TREATMENT", 346, 387], ["a method", "TREATMENT", 402, 410], ["C-terminal proline containing peptides", "TREATMENT", 432, 470], ["diketopiperazine formation", "PROBLEM", 502, 528], ["diketopiperazine formation", "OBSERVATION", 502, 528]]], ["The technique is being applied to the synthesis of other C-terminal proline peptides e.g. human eotaxin and IP10.Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, PolandDimerization of cell receptors, involved in antigen presentation, is an essential step in several cellular signal transduction processes, therefore substances that are able to modulate such a process are of potential therapeutic value.", [["cell", "ANATOMY", 341, 345], ["cellular", "ANATOMY", 423, 431], ["C", "CHEMICAL", 57, 58], ["proline", "CHEMICAL", 68, 75], ["human", "ORGANISM", 90, 95], ["eotaxin", "GENE_OR_GENE_PRODUCT", 96, 103], ["IP10", "GENE_OR_GENE_PRODUCT", 108, 112], ["cell", "CELL", 341, 345], ["cellular", "CELL", 423, 431], ["human eotaxin", "PROTEIN", 90, 103], ["IP10", "PROTEIN", 108, 112], ["cell receptors", "PROTEIN", 341, 355], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["The technique", "TREATMENT", 0, 13], ["other C-terminal proline peptides", "TREATMENT", 51, 84], ["human eotaxin", "TREATMENT", 90, 103], ["IP10", "TREATMENT", 108, 112], ["Experimental Therapy", "TREATMENT", 260, 280]]], ["Dimeric peptide ligands could represent useful tools to cause dimerization of such receptors.", [["Dimeric peptide ligands", "PROBLEM", 0, 23], ["dimerization of such receptors", "PROBLEM", 62, 92], ["peptide ligands", "OBSERVATION", 8, 23]]], ["A similar strategy applies dimerization of ligands, interacting with dimeric proteins or proteins with multiple binding sites, to design molecules with enhanced affinity.Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, PolandDimeric analogs of the immunosuppressory HLA class II fragments were synthesized using suitably modified, standard Fmoc solid-phase protocols and MBHA-resin.", [["MBHA", "CHEMICAL", 528, 532], ["Fmoc", "CHEMICAL", 497, 501], ["MBHA-resin", "SIMPLE_CHEMICAL", 528, 538], ["dimeric proteins", "PROTEIN", 69, 85], ["multiple binding sites", "PROTEIN", 103, 125], ["immunosuppressory HLA class II fragments", "DNA", 405, 445], ["dimeric proteins", "PROBLEM", 69, 85], ["multiple binding sites", "PROBLEM", 103, 125], ["enhanced affinity", "PROBLEM", 152, 169], ["Experimental Therapy", "TREATMENT", 317, 337], ["Wroc\u0142aw", "TREATMENT", 367, 374], ["the immunosuppressory HLA class II fragments", "TREATMENT", 401, 445], ["standard Fmoc solid-phase protocols", "TREATMENT", 488, 523], ["MBHA-resin", "TREATMENT", 528, 538]]], ["The dimerization was achieved by crosslinking N-terminal amino groups of the peptides with the commercially available mixture of poly(ethyleneglycol)biscarboxylic acid (average MW 600, length range 30-45\u00c5), activated by esterification with pentafluorophenol.", [["N-terminal amino", "CHEMICAL", 46, 62], ["poly(ethyleneglycol)biscarboxylic acid", "CHEMICAL", 129, 167], ["pentafluorophenol", "CHEMICAL", 240, 257], ["N", "CHEMICAL", 46, 47], ["amino", "CHEMICAL", 57, 62], ["poly(ethyleneglycol)biscarboxylic acid", "CHEMICAL", 129, 167], ["pentafluorophenol", "CHEMICAL", 240, 257], ["poly(ethyleneglycol)biscarboxylic acid", "SIMPLE_CHEMICAL", 129, 167], ["pentafluorophenol", "SIMPLE_CHEMICAL", 240, 257], ["The dimerization", "TREATMENT", 0, 16], ["crosslinking N-terminal amino groups of the peptides", "TREATMENT", 33, 85], ["poly(ethyleneglycol)biscarboxylic acid", "TREATMENT", 129, 167], ["length range", "TEST", 185, 197], ["pentafluorophenol", "TREATMENT", 240, 257]]], ["The same procedure was applied to synthesize a series of dimeric analogs of C-terminal fragments of plexin-B, consisting of two undecapeptides, linked by the polyethyleneglycol spacers.", [["plexin-B", "CHEMICAL", 100, 108], ["C", "CHEMICAL", 76, 77], ["undecapeptides", "CHEMICAL", 128, 142], ["polyethyleneglycol", "CHEMICAL", 158, 176], ["plexin-B", "GENE_OR_GENE_PRODUCT", 100, 108], ["undecapeptides", "SIMPLE_CHEMICAL", 128, 142], ["polyethyleneglycol", "SIMPLE_CHEMICAL", 158, 176], ["C-terminal fragments", "PROTEIN", 76, 96], ["plexin-B", "PROTEIN", 100, 108], ["undecapeptides", "PROTEIN", 128, 142], ["The same procedure", "TREATMENT", 0, 18], ["C-terminal fragments of plexin-B", "PROBLEM", 76, 108], ["the polyethyleneglycol spacers", "TREATMENT", 154, 184], ["terminal", "ANATOMY_MODIFIER", 78, 86], ["fragments", "OBSERVATION", 87, 96], ["polyethyleneglycol spacers", "OBSERVATION", 158, 184]]], ["Other biand polyvalent linkers were also investigated.Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, PolandOur results demonstrated that the amino-terminal dimerizations of the tested HLA-fragments resulted in enhanced immunosuppressive activities, whereas interaction of PDZ dimer with the plexin fragments led to about 20-fold increase in affinity, as compared to their monomeric counterparts.Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, Poland[Background and aims] Elucidation of Alzheimer's disease (AD)-related A\u00df1-42 dynamic events is a difficult issue due to uncontrolled polymerization.Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, Poland[Methods] Based on the \"O-acyl isopeptide method\" (Chem.", [["amino-terminal", "CHEMICAL", 300, 314], ["Alzheimer's disease", "DISEASE", 803, 822], ["AD", "DISEASE", 824, 826], ["A\u00df1-42", "CHEMICAL", 836, 842], ["amino", "CHEMICAL", 300, 305], ["O-acyl", "CHEMICAL", 1150, 1156], ["amino", "AMINO_ACID", 300, 305], ["PDZ", "GENE_OR_GENE_PRODUCT", 431, 434], ["plexin", "GENE_OR_GENE_PRODUCT", 450, 456], ["O-acyl isopeptide", "SIMPLE_CHEMICAL", 1150, 1167], ["HLA-fragments", "DNA", 343, 356], ["PDZ dimer", "PROTEIN", 431, 440], ["plexin fragments", "DNA", 450, 466], ["Other biand polyvalent linkers", "TREATMENT", 0, 30], ["Experimental Therapy", "TREATMENT", 201, 221], ["the amino-terminal dimerizations", "TREATMENT", 296, 328], ["the tested HLA-fragments", "PROBLEM", 332, 356], ["enhanced immunosuppressive activities", "TREATMENT", 369, 406], ["PDZ dimer", "PROBLEM", 431, 440], ["the plexin fragments", "PROBLEM", 446, 466], ["Experimental Therapy", "TREATMENT", 701, 721], ["Alzheimer's disease", "PROBLEM", 803, 822], ["dynamic events", "PROBLEM", 843, 857], ["uncontrolled polymerization", "PROBLEM", 886, 913], ["polyvalent linkers", "OBSERVATION", 12, 30], ["immunosuppressive activities", "OBSERVATION", 378, 406], ["plexin fragments", "OBSERVATION", 450, 466]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["2006, 128, 696), we have developed a novel photo-triggered \"click peptide\" of A\u00df1-42 (1), e.g., \"26-N-Nvoc-26-AIA\u00df42 (2)\", in which a 6-nitroveratryloxycarbonyl (Nvoc) group was introduced at Ser26 in 26-O-acyl isoA\u00df1-42 (26-AIA\u00df42, 3).Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, Poland[Results] i) The click peptide 2 did not exhibit the self-assembling nature under physiological conditions due to one single modified ester; ii) photo-irradiation of the click peptide 2 and subsequent O-N intramolecular acyl migration afforded the intact A\u00df1-42 (1) with a quick and one-way conversion (so-called \"click\"); and iii) no additional fibril inhibitory auxiliaries were released during conversion to A\u00df1-42 (1).Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, Poland[Conclusions] This method provides a novel system useful for investigating the dynamic biological functions of A\u00df1-42, such as the self-assembly and aggregation processes in AD.", [["A\u00df1-42", "CHEMICAL", 78, 84], ["6-nitroveratryloxycarbonyl", "CHEMICAL", 134, 160], ["Nvoc", "CHEMICAL", 162, 166], ["Ser26", "CHEMICAL", 192, 197], ["26-O-acyl isoA\u00df1-42", "CHEMICAL", 201, 220], ["O-N", "CHEMICAL", 649, 652], ["acyl", "CHEMICAL", 668, 672], ["A\u00df1-42", "CHEMICAL", 703, 709], ["A\u00df1-42", "CHEMICAL", 859, 865], ["A\u00df1-42", "CHEMICAL", 1193, 1199], ["AD", "DISEASE", 1256, 1258], ["A\u00df1-42", "CHEMICAL", 78, 84], ["26-N-Nvoc-26-AIA\u00df42", "CHEMICAL", 97, 116], ["6-nitroveratryloxycarbonyl", "CHEMICAL", 134, 160], ["Nvoc", "CHEMICAL", 162, 166], ["Ser26", "CHEMICAL", 192, 197], ["26-O-acyl isoA\u00df1-42", "CHEMICAL", 201, 220], ["ester", "CHEMICAL", 582, 587], ["O-N", "CHEMICAL", 649, 652], ["acyl", "CHEMICAL", 668, 672], ["A\u00df1-42", "CHEMICAL", 703, 709], ["A\u00df1-42", "CHEMICAL", 859, 865], ["A\u00df1-42 (1)", "SIMPLE_CHEMICAL", 78, 88], ["26-N-Nvoc-26-AIA\u00df42 (2)", "SIMPLE_CHEMICAL", 97, 120], ["6-nitroveratryloxycarbonyl", "SIMPLE_CHEMICAL", 134, 160], ["Nvoc", "SIMPLE_CHEMICAL", 162, 166], ["Ser26", "SIMPLE_CHEMICAL", 192, 197], ["26-O-acyl isoA\u00df1-42", "SIMPLE_CHEMICAL", 201, 220], ["ester", "SIMPLE_CHEMICAL", 582, 587], ["O-N intramolecular acyl", "SIMPLE_CHEMICAL", 649, 672], ["A\u00df1-42", "GENE_OR_GENE_PRODUCT", 859, 865], ["A\u00df1-42", "GENE_OR_GENE_PRODUCT", 1193, 1199], ["A\u00df1", "PROTEIN", 1193, 1196], ["a novel photo", "TEST", 35, 48], ["A\u00df1", "TEST", 78, 81], ["Nvoc", "TEST", 102, 106], ["AIA", "TEST", 110, 113], ["acyl isoA\u00df1", "TEST", 206, 217], ["The click peptide", "TEST", 461, 478], ["the click peptide", "TEST", 614, 631], ["intramolecular acyl migration", "PROBLEM", 653, 682], ["additional fibril inhibitory auxiliaries", "PROBLEM", 783, 823], ["A\u00df1", "TEST", 859, 862], ["acyl migration", "OBSERVATION", 668, 682]]], ["Several insulin analogues have recently been introduced clinically for improved treatment of diabetes.", [["diabetes", "DISEASE", 93, 101], ["insulin", "GENE_OR_GENE_PRODUCT", 8, 15], ["Several insulin analogues", "TREATMENT", 0, 25], ["diabetes", "PROBLEM", 93, 101], ["diabetes", "OBSERVATION", 93, 101]]], ["Industrial productions of such insulins are based on microbial expression systems, which are highly efficient, but generally limited to the 20 proteogenic amino acids.", [["amino acids", "CHEMICAL", 155, 166], ["amino acids", "CHEMICAL", 155, 166], ["insulins", "GENE_OR_GENE_PRODUCT", 31, 39], ["amino acids", "AMINO_ACID", 155, 166], ["such insulins", "TREATMENT", 26, 39], ["microbial expression systems", "PROBLEM", 53, 81], ["the 20 proteogenic amino acids", "TREATMENT", 136, 166]]], ["Also, some sequences form inclusion bodies or fail to express.", [["some sequences form inclusion bodies", "PROBLEM", 6, 42]]], ["The total chemical synthesis of insulin in research scale was a landmark achievement in peptide science.", [["insulin", "GENE_OR_GENE_PRODUCT", 32, 39], ["insulin", "PROTEIN", 32, 39], ["The total chemical synthesis of insulin", "TREATMENT", 0, 39], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["However, the most commonly used method relies on recombination of A-and B-chains under \"random\" folding and pairing of the three disulfide bridges.", [["disulfide", "CHEMICAL", 129, 138], ["B-chains", "GENE_OR_GENE_PRODUCT", 72, 80], ["A-and B-chains", "PROTEIN", 66, 80], ["disulfide bridges", "PROTEIN", 129, 146], ["A-and B-chains under \"random\" folding", "TREATMENT", 66, 103], ["the three disulfide bridges", "TREATMENT", 119, 146]]], ["This folding/oxidation step is difficult and low yielding.", [["This folding/oxidation step", "PROBLEM", 0, 27]]], ["A general approach using a removable auxiliary which can direct correct formation of disulfide bridges is highly desirable.Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, PolandIn the pancreas as well as in microbial expression systems, insulins are prepared and folded as single chain precursors, with a C-peptide connecting the A and Bchains.", [["pancreas", "ANATOMY", 342, 350], ["disulfide", "CHEMICAL", 85, 94], ["pancreas", "ORGAN", 342, 350], ["insulins", "GENE_OR_GENE_PRODUCT", 395, 403], ["Bchains", "PROTEIN", 494, 501], ["A general approach", "TREATMENT", 0, 18], ["a removable auxiliary", "TREATMENT", 25, 46], ["disulfide bridges", "PROBLEM", 85, 102], ["Experimental Therapy", "TREATMENT", 270, 290], ["insulins", "TREATMENT", 395, 403], ["a C-peptide", "TREATMENT", 461, 472], ["disulfide bridges", "OBSERVATION", 85, 102], ["pancreas", "ANATOMY", 342, 350]]], ["The C-peptide helps direct the orientation of A and B-chains in obtaining the correct disulfide pairing and overall peptide folding.", [["disulfide", "CHEMICAL", 86, 95], ["C-peptide", "SIMPLE_CHEMICAL", 4, 13], ["A", "GENE_OR_GENE_PRODUCT", 46, 47], ["A and B-chains", "PROTEIN", 46, 60], ["The C-peptide", "TREATMENT", 0, 13], ["A and B-chains", "TREATMENT", 46, 60], ["the correct disulfide pairing", "TREATMENT", 74, 103], ["overall peptide folding", "PROBLEM", 108, 131], ["peptide folding", "OBSERVATION", 116, 131]]], ["Upon folding, the C-peptide is removed enzymatically.", [["C-peptide", "SIMPLE_CHEMICAL", 18, 27], ["the C-peptide", "TREATMENT", 14, 27]]], ["We report here a new method for total chemical synthesis of insulin by use of Fmoc-based step-wise solid-phase synthesis of single-chain precursors followed by Cpeptide directed folding and cleavage of C-peptide, thereby allowing total chemical synthesis of novel insulins with unnatural substitutions.", [["Fmoc", "CHEMICAL", 78, 82], ["Cpeptide", "CHEMICAL", 160, 168], ["Fmoc", "CHEMICAL", 78, 82], ["insulin", "GENE_OR_GENE_PRODUCT", 60, 67], ["Cpeptide", "SIMPLE_CHEMICAL", 160, 168], ["C-peptide", "SIMPLE_CHEMICAL", 202, 211], ["insulins", "GENE_OR_GENE_PRODUCT", 264, 272], ["insulin", "PROTEIN", 60, 67], ["total chemical synthesis of insulin", "TREATMENT", 32, 67], ["Fmoc", "TEST", 78, 82], ["single-chain precursors", "TREATMENT", 124, 147], ["Cpeptide directed folding", "TREATMENT", 160, 185], ["C-peptide", "TREATMENT", 202, 211], ["total chemical synthesis of novel insulins", "TREATMENT", 230, 272], ["unnatural substitutions", "PROBLEM", 278, 301]]], ["2-Chloro-4-methoxy-1,3,5-triazines 1a-c anchored on cellulose, silica or Wang resin were prepared by the treatment of 2,4-dichloro-6-methoxy-1,3,5-triazine with appropriate solid support in the presence of a base.", [["2-Chloro-4-methoxy-1,3,5-triazines 1a-c", "CHEMICAL", 0, 39], ["silica", "CHEMICAL", 63, 69], ["2,4-dichloro-6-methoxy-1,3,5-triazine", "CHEMICAL", 118, 155], ["2-Chloro-4-methoxy-1,3,5-triazines", "CHEMICAL", 0, 34], ["silica", "CHEMICAL", 63, 69], ["2,4-dichloro-6-methoxy-1,3,5-triazine", "CHEMICAL", 118, 155], ["2-Chloro-4-methoxy-1,3,5-triazines 1a-c", "SIMPLE_CHEMICAL", 0, 39], ["cellulose", "SIMPLE_CHEMICAL", 52, 61], ["silica", "SIMPLE_CHEMICAL", 63, 69], ["Wang resin", "SIMPLE_CHEMICAL", 73, 83], ["2,4-dichloro-6-methoxy-1,3,5-triazine", "SIMPLE_CHEMICAL", 118, 155], ["Chloro", "TREATMENT", 2, 8], ["methoxy", "TREATMENT", 11, 18], ["triazines", "TREATMENT", 25, 34], ["cellulose, silica", "TREATMENT", 52, 69], ["Wang resin", "TREATMENT", 73, 83], ["dichloro", "TREATMENT", 122, 130], ["methoxy", "TREATMENT", 133, 140], ["triazine", "TREATMENT", 147, 155], ["appropriate solid support", "TREATMENT", 161, 186], ["base", "ANATOMY_MODIFIER", 208, 212]]], ["Immobilized, environmentally friendly triazine coupling reagents 3a-c were obtained by treatment of 1a-c with N-methylmorpholinium p-toluenesulfonates 2 in the presence of HCl acceptor.", [["triazine", "CHEMICAL", 38, 46], ["1a-c", "CHEMICAL", 100, 104], ["N-methylmorpholinium p-toluenesulfonates", "CHEMICAL", 110, 150], ["HCl", "CHEMICAL", 172, 175], ["triazine", "CHEMICAL", 38, 46], ["N-methylmorpholinium p-toluenesulfonates", "CHEMICAL", 110, 150], ["HCl", "CHEMICAL", 172, 175], ["triazine", "SIMPLE_CHEMICAL", 38, 46], ["3a-c", "SIMPLE_CHEMICAL", 65, 69], ["1a-c", "SIMPLE_CHEMICAL", 100, 104], ["N-methylmorpholinium p-toluenesulfonates 2", "SIMPLE_CHEMICAL", 110, 152], ["HCl acceptor", "SIMPLE_CHEMICAL", 172, 184], ["N-methylmorpholinium p-toluenesulfonates", "TREATMENT", 110, 150], ["HCl acceptor", "TREATMENT", 172, 184]]], ["The loading of the solid carriers were calculated from N, S contents, determined by microanalysis.Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, PolandAll prepared immobilized N-triazynylammonium toluenosulfonates 3a-c have been found stable at room temperatures.", [["N-triazynylammonium toluenosulfonates 3a-c", "CHEMICAL", 335, 377], ["N-triazynylammonium toluenosulfonates", "CHEMICAL", 335, 372], ["N-triazynylammonium toluenosulfonates 3a-c", "SIMPLE_CHEMICAL", 335, 377], ["the solid carriers", "PROBLEM", 15, 33], ["Experimental Therapy", "TREATMENT", 245, 265], ["triazynylammonium toluenosulfonates", "TREATMENT", 337, 372], ["loading", "OBSERVATION_MODIFIER", 4, 11], ["stable", "OBSERVATION_MODIFIER", 394, 400]]], ["Activation of carboxylic components afforded triazine activate esters 4a-c connected to the support.", [["triazine", "CHEMICAL", 45, 53], ["esters 4a-c", "CHEMICAL", 63, 74], ["triazine", "CHEMICAL", 45, 53], ["esters", "CHEMICAL", 63, 69], ["triazine", "SIMPLE_CHEMICAL", 45, 53], ["esters 4a-c", "SIMPLE_CHEMICAL", 63, 74], ["Activation of carboxylic components", "TREATMENT", 0, 35], ["triazine activate esters", "TREATMENT", 45, 69], ["the support", "TREATMENT", 88, 99]]], ["Treatment of 4a-c with appropriate amino components gave amides or peptides.", [["amino", "CHEMICAL", 35, 40], ["amides", "CHEMICAL", 57, 63], ["4a-c", "SIMPLE_CHEMICAL", 13, 17], ["amino", "AMINO_ACID", 35, 40], ["amides", "SIMPLE_CHEMICAL", 57, 63], ["appropriate amino components", "TREATMENT", 23, 51], ["amides or peptides", "TREATMENT", 57, 75]]], ["The final products, chromatographically homogenous amides and peptides, were isolated by filtration or extraction from the solid support.", [["amides", "CHEMICAL", 51, 57], ["extraction", "TREATMENT", 103, 113], ["the solid support", "TREATMENT", 119, 136], ["solid support", "OBSERVATION", 123, 136]]], ["Mutter's pseudoproline dipeptides and Sheppard's Hmb derivatives are powerful tools for enhancing synthetic efficiency in Fmoc SPPS.", [["Fmoc SPPS", "CHEMICAL", 122, 131], ["pseudoproline", "CHEMICAL", 9, 22], ["Fmoc", "CHEMICAL", 122, 126], ["pseudoproline dipeptides", "SIMPLE_CHEMICAL", 9, 33], ["Hmb derivatives", "SIMPLE_CHEMICAL", 49, 64], ["Mutter's pseudoproline dipeptides", "TREATMENT", 0, 33], ["Sheppard's Hmb derivatives", "TREATMENT", 38, 64], ["enhancing synthetic efficiency", "PROBLEM", 88, 118], ["Fmoc SPPS", "TREATMENT", 122, 131]]], ["They work by exploiting the natural propensity of N-alkyl amino acids to disrupt the formation of the secondary structures during peptide assembly.", [["N-alkyl amino acids", "CHEMICAL", 50, 69], ["N-alkyl amino acids", "CHEMICAL", 50, 69], ["N-alkyl amino acids", "SIMPLE_CHEMICAL", 50, 69], ["N-alkyl amino acids", "TREATMENT", 50, 69]]], ["Their use results in better and more predictable acylation and deprotection kinetics, enhanced reaction rates, and improved yields of crude products.", [["predictable acylation and deprotection kinetics", "TREATMENT", 37, 84], ["enhanced reaction rates", "TEST", 86, 109], ["crude products", "TREATMENT", 134, 148]]], ["However, these approaches have certain limitations: pseudoproline dipeptides can only be used for sequences containing serine or threonine, and the coupling of the amino acid following the Hmb residue can be extremely difficult.", [["pseudoproline", "CHEMICAL", 52, 65], ["threonine", "CHEMICAL", 129, 138], ["amino acid", "CHEMICAL", 164, 174], ["pseudoproline dipeptides", "CHEMICAL", 52, 76], ["serine", "CHEMICAL", 119, 125], ["threonine", "CHEMICAL", 129, 138], ["amino acid", "CHEMICAL", 164, 174], ["pseudoproline dipeptides", "SIMPLE_CHEMICAL", 52, 76], ["serine", "AMINO_ACID", 119, 125], ["threonine", "AMINO_ACID", 129, 138], ["amino acid", "AMINO_ACID", 164, 174], ["pseudoproline dipeptides", "TREATMENT", 52, 76], ["threonine", "TREATMENT", 129, 138], ["the amino acid", "TREATMENT", 160, 174], ["the Hmb residue", "PROBLEM", 185, 200]]], ["To alleviate some of these shortcomings, we have prepared Fmoc-Ala-(Dmb)Gly-OH and Fmoc-Gly-(Dmb)Gly-OH.", [["Fmoc-Ala", "CHEMICAL", 58, 66], ["Gly-OH", "CHEMICAL", 72, 78], ["Fmoc-Gly", "CHEMICAL", 83, 91], ["Gly-OH", "CHEMICAL", 97, 103], ["Fmoc-Ala-(Dmb)Gly-OH", "CHEMICAL", 58, 78], ["Fmoc-Gly-(Dmb)Gly-OH", "CHEMICAL", 83, 103], ["Fmoc-Ala-(Dmb)Gly-OH", "SIMPLE_CHEMICAL", 58, 78], ["Fmoc-Gly-(Dmb)Gly-OH", "SIMPLE_CHEMICAL", 83, 103], ["Gly", "TEST", 72, 75], ["Fmoc-Gly", "TEST", 83, 91]]], ["These Dmb-dipeptides can be incorporated into peptides in place of Ala-Gly and Gly-Gly, resulting in peptides containing structure breaking (Dmb)Gly residues.", [["Dmb-dipeptides", "CHEMICAL", 6, 20], ["Ala-Gly", "CHEMICAL", 67, 74], ["Gly-Gly", "CHEMICAL", 79, 86], ["Dmb-dipeptides", "CHEMICAL", 6, 20], ["Ala-Gly", "CHEMICAL", 67, 74], ["Gly-Gly", "CHEMICAL", 79, 86], ["Gly", "CHEMICAL", 145, 148], ["Dmb-dipeptides", "SIMPLE_CHEMICAL", 6, 20], ["Ala-Gly", "SIMPLE_CHEMICAL", 67, 74], ["Gly-Gly", "AMINO_ACID", 79, 86], ["These Dmb-dipeptides", "TREATMENT", 0, 20], ["Ala-Gly and Gly-Gly", "TREATMENT", 67, 86]]], ["By introducing the (Dmb)Gly residue as part of a dipeptide unit, the need to acylate the highly hindered secondary amino group of (Dmb)Gly is avoided.", [["(Dmb)Gly", "CHEMICAL", 19, 27], ["dipeptide", "CHEMICAL", 49, 58], ["amino", "CHEMICAL", 115, 120], ["(Dmb)Gly", "CHEMICAL", 130, 138], ["the (Dmb)Gly residue", "TREATMENT", 15, 35], ["a dipeptide unit", "TREATMENT", 47, 63], ["acylate", "TREATMENT", 77, 84], ["secondary amino group of (Dmb)Gly", "TREATMENT", 105, 138]]], ["On treatment with TFA the Dmb group is cleaved regenerating Gly.Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, PolandTo test the efficacy of our new derivatives in expediting the synthesis of hydrophobic peptides, we undertook the preparation of the challenging neurotoxic prion peptide 106-126 1; this peptide reportedly can not be made using Fmoc SPPS methods.", [["TFA", "CHEMICAL", 18, 21], ["neurotoxic", "DISEASE", 421, 431], ["peptide 106-126", "CHEMICAL", 438, 453], ["TFA", "CHEMICAL", 18, 21], ["Gly", "CHEMICAL", 60, 63], ["Fmoc", "CHEMICAL", 503, 507], ["TFA", "SIMPLE_CHEMICAL", 18, 21], ["Dmb", "SIMPLE_CHEMICAL", 26, 29], ["Gly", "AMINO_ACID", 60, 63], ["treatment", "TREATMENT", 3, 12], ["TFA", "TREATMENT", 18, 21], ["Experimental Therapy", "TREATMENT", 211, 231], ["our new derivatives", "TREATMENT", 300, 319], ["the synthesis of hydrophobic peptides", "TREATMENT", 334, 371], ["the challenging neurotoxic prion peptide", "TEST", 405, 445], ["Fmoc SPPS methods", "TREATMENT", 503, 520]]], ["The dipeptides marked in bold were systematically substituted with the appropriate Dmb peptides.", [["dipeptides", "CHEMICAL", 4, 14], ["Dmb", "GENE_OR_GENE_PRODUCT", 83, 86], ["The dipeptides", "TREATMENT", 0, 14], ["the appropriate Dmb peptides", "TREATMENT", 67, 95], ["marked", "OBSERVATION_MODIFIER", 15, 21]]], ["The effects of the substitution were evaluated using conductivity monitoring and LC-MS analysis of the crude peptides.Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, PolandH-Lys-Thr-Asn-Met-Lys-His-Met-Ala-Gly-Ala-Ala-Ala-Ala-Gly-Ala-Val-Val-Gly-Gly-Leu-Gly-OH 1 Th120 EFFICIENT DIPEPTIDE PRODUCTION FORM UNPROTECTED L-AMINO ACIDS WITH THE NOVEL ENZYME L-AMINO ACID \u03b1-LIGASE.Faculty Of Chemistry, University Of Wroc\u0142Aw 2 Institute of Biochemistry and Molecular Biology, University of Wroclaw 3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc\u0142aw, PolandK.", [["the substitution", "TREATMENT", 15, 31], ["conductivity monitoring", "TEST", 53, 76], ["LC-MS analysis", "TEST", 81, 95], ["the crude peptides", "TEST", 99, 117], ["Experimental Therapy", "TREATMENT", 265, 285], ["Wroc\u0142aw", "TEST", 315, 322], ["L-AMINO ACIDS", "TREATMENT", 475, 488], ["THE NOVEL ENZYME L-AMINO ACID \u03b1-LIGASE", "TEST", 494, 532], ["Experimental Therapy", "TREATMENT", 680, 700]]], ["Tabata 2 , H. Ikeda 1 , M. Yagasaki 1 , S. Hashimoto 1Technical Research Laboratories 2 BioFrontier Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Tokyo, JapanBackground and aims: Application of \u03b1-dipeptides has been limited due to the lack of cost-effective manufacturing methods.", [["\u03b1-dipeptides", "CHEMICAL", 200, 212], ["\u03b1-dipeptides", "CHEMICAL", 200, 212], ["\u03b1-dipeptides", "SIMPLE_CHEMICAL", 200, 212], ["\u03b1-dipeptides", "TREATMENT", 200, 212], ["cost-effective manufacturing methods", "TREATMENT", 249, 285]]], ["The known methods require the protection of amino acid(s) to fix the order of the amino acids ( Fig. 1) .", [["amino acid", "CHEMICAL", 44, 54], ["amino acids", "CHEMICAL", 82, 93], ["amino acid", "CHEMICAL", 44, 54], ["amino acids", "CHEMICAL", 82, 93], ["amino acid", "AMINO_ACID", 44, 54], ["amino acids", "AMINO_ACID", 82, 93], ["amino acid", "TREATMENT", 44, 54], ["the amino acids ( Fig", "TREATMENT", 78, 99]]], ["To establish the costeffective manufacturing method, a novel activity which synthesizes \u03b1-dipeptides from two unprotected L-amino acids was screened.", [["\u03b1-dipeptides", "CHEMICAL", 88, 100], ["L-amino acids", "CHEMICAL", 122, 135], ["\u03b1-dipeptides", "CHEMICAL", 88, 100], ["L-amino acids", "CHEMICAL", 122, 135], ["\u03b1-dipeptides", "SIMPLE_CHEMICAL", 88, 100], ["L-amino acids", "SIMPLE_CHEMICAL", 122, 135], ["the costeffective manufacturing method", "TREATMENT", 13, 51]]], ["Methods and Results: A gene was found in the genome of Bacillus subtilis by in silico screening based on a putative reaction mechanism.", [["A", "GENE_OR_GENE_PRODUCT", 21, 22], ["Bacillus subtilis", "ORGANISM", 55, 72], ["Bacillus subtilis", "SPECIES", 55, 72], ["Bacillus subtilis", "SPECIES", 55, 72], ["silico screening", "TEST", 79, 95], ["a putative reaction mechanism", "TREATMENT", 105, 134]]], ["The purified protein coded on the gene, i) catalyses \u03b1-dipeptide formation from unmodified L-amino acids with a specific order in an ATP-dependent manner, ii) never forms tri-or longer peptides, and iii) takes a wide variety of L-amino acids but no D-amino acids.", [["\u03b1-dipeptide", "CHEMICAL", 53, 64], ["L-amino acids", "CHEMICAL", 91, 104], ["ATP", "CHEMICAL", 133, 136], ["L-amino acids", "CHEMICAL", 228, 241], ["D-amino acids", "CHEMICAL", 249, 262], ["\u03b1-dipeptide", "CHEMICAL", 53, 64], ["L-amino acids", "CHEMICAL", 91, 104], ["ATP", "CHEMICAL", 133, 136], ["L-amino acids", "CHEMICAL", 228, 241], ["D-amino acids", "CHEMICAL", 249, 262], ["\u03b1-dipeptide", "SIMPLE_CHEMICAL", 53, 64], ["L-amino acids", "SIMPLE_CHEMICAL", 91, 104], ["ATP", "SIMPLE_CHEMICAL", 133, 136], ["L-amino acids", "SIMPLE_CHEMICAL", 228, 241], ["D-", "SIMPLE_CHEMICAL", 249, 251], ["amino acids", "AMINO_ACID", 251, 262], ["dipeptide formation", "TREATMENT", 55, 74], ["unmodified L-amino acids", "TREATMENT", 80, 104], ["L-amino acids", "TREATMENT", 228, 241], ["D-amino acids", "TREATMENT", 249, 262]]], ["The enzyme was tentatively named L-amino acid \u03b1-ligase (Lal).", [["L-amino acid", "CHEMICAL", 33, 45], ["L-amino acid", "CHEMICAL", 33, 45], ["L-amino acid \u03b1-ligase", "SIMPLE_CHEMICAL", 33, 54], ["L-amino acid \u03b1-ligase", "PROTEIN", 33, 54], ["The enzyme", "TEST", 0, 10], ["L-amino acid \u03b1-ligase", "TEST", 33, 54]]], ["The whole cell reaction of a recombinant E. coli strain expressing Lal and polyphosphate kinase (Ppk) with two L-amino acids and polyphosphate (polyP) enable the efficient production of many dipeptides with a certain order of the constituent amino acids through the coupling reaction of Lal and Ppk (Fig. 2) .", [["cell", "ANATOMY", 10, 14], ["polyphosphate", "CHEMICAL", 75, 88], ["L-amino acids", "CHEMICAL", 111, 124], ["polyphosphate", "CHEMICAL", 129, 142], ["polyP", "CHEMICAL", 144, 149], ["amino acids", "CHEMICAL", 242, 253], ["polyphosphate", "CHEMICAL", 75, 88], ["L-amino acids", "CHEMICAL", 111, 124], ["polyphosphate", "CHEMICAL", 129, 142], ["polyP", "CHEMICAL", 144, 149], ["dipeptides", "CHEMICAL", 191, 201], ["amino acids", "CHEMICAL", 242, 253], ["cell", "CELL", 10, 14], ["E. coli", "ORGANISM", 41, 48], ["strain", "ORGANISM", 49, 55], ["Lal", "GENE_OR_GENE_PRODUCT", 67, 70], ["polyphosphate kinase", "GENE_OR_GENE_PRODUCT", 75, 95], ["L-amino acids", "SIMPLE_CHEMICAL", 111, 124], ["polyphosphate", "SIMPLE_CHEMICAL", 129, 142], ["polyP", "SIMPLE_CHEMICAL", 144, 149], ["amino acids", "AMINO_ACID", 242, 253], ["Lal", "GENE_OR_GENE_PRODUCT", 287, 290], ["Lal", "PROTEIN", 67, 70], ["polyphosphate kinase", "PROTEIN", 75, 95], ["Ppk", "PROTEIN", 97, 100], ["E. coli", "SPECIES", 41, 48], ["E. coli", "SPECIES", 41, 48], ["The whole cell reaction", "PROBLEM", 0, 23], ["a recombinant E. coli strain", "TREATMENT", 27, 55], ["Lal and polyphosphate kinase", "TREATMENT", 67, 95], ["two L-amino acids", "TREATMENT", 107, 124], ["polyphosphate (polyP", "TREATMENT", 129, 149], ["many dipeptides", "TREATMENT", 186, 201], ["the constituent amino acids", "TREATMENT", 226, 253], ["the coupling reaction of Lal", "TREATMENT", 262, 290], ["whole cell reaction", "OBSERVATION", 4, 23]]], ["Conclusion: A novel enzyme, Lal, enables to synthesize dipeptides cost-effectively directly from unmodified L-amino acids.M121 THE FIRST TOTAL SYNTHESIS OF LL-15G256GAMMAT.", [["L-amino acids", "CHEMICAL", 108, 121], ["dipeptides", "CHEMICAL", 55, 65], ["L-amino acids", "CHEMICAL", 108, 121], ["Lal", "GENE_OR_GENE_PRODUCT", 28, 31], ["L-amino acids", "SIMPLE_CHEMICAL", 108, 121], ["A novel enzyme", "TEST", 12, 26], ["unmodified L-amino acids", "TREATMENT", 97, 121], ["LL", "TEST", 156, 158], ["L-amino acids", "OBSERVATION", 108, 121]]], ["Ye 1 Marine organisms continue to provide rich sources of structurally unique and pharmaceutically active compounds.", [["structurally unique and pharmaceutically active compounds", "PROBLEM", 58, 115], ["pharmaceutically", "OBSERVATION_MODIFIER", 82, 98], ["active compounds", "OBSERVATION", 99, 115]]], ["Due to the difficulties in the isolation of significant quantities of these natural products, synthetic chemistry serves an important role in their structural assignment and biological evaluation.", [["the difficulties", "PROBLEM", 7, 23], ["these natural products", "TREATMENT", 70, 92], ["biological evaluation", "TEST", 174, 195]]], ["Antifungal agents have received considerable attention recently since the spread of HIV has left many people open to fungal infections, and there is a rapidly growing number of drug resistant strains of fungus emerging.", [["HIV", "DISEASE", 84, 87], ["fungal infections", "DISEASE", 117, 134], ["HIV", "ORGANISM", 84, 87], ["people", "ORGANISM", 102, 108], ["HIV", "SPECIES", 84, 87], ["people", "SPECIES", 102, 108], ["HIV", "SPECIES", 84, 87], ["Antifungal agents", "TREATMENT", 0, 17], ["HIV", "PROBLEM", 84, 87], ["fungal infections", "PROBLEM", 117, 134], ["drug resistant strains of fungus", "PROBLEM", 177, 209], ["fungal", "OBSERVATION_MODIFIER", 117, 123], ["infections", "OBSERVATION", 124, 134], ["rapidly", "OBSERVATION_MODIFIER", 151, 158], ["growing", "OBSERVATION_MODIFIER", 159, 166], ["number", "OBSERVATION_MODIFIER", 167, 173], ["drug resistant strains", "OBSERVATION", 177, 199], ["fungus", "OBSERVATION", 203, 209]]], ["LL-15G256gamma is a cyclodepsipeptide isolated from the marine fungus Hypoxylon oceanicum and structurally assigned in 1998 by Schlingmann.", [["LL-15G256gamma", "CHEMICAL", 0, 14], ["cyclodepsipeptide", "CHEMICAL", 20, 37], ["cyclodepsipeptide", "CHEMICAL", 20, 37], ["LL-15G256gamma", "GENE_OR_GENE_PRODUCT", 0, 14], ["cyclodepsipeptide", "SIMPLE_CHEMICAL", 20, 37], ["Hypoxylon oceanicum", "ORGANISM", 70, 89], ["15G256gamma", "PROTEIN", 3, 14], ["Hypoxylon oceanicum", "SPECIES", 70, 89], ["Hypoxylon oceanicum", "SPECIES", 70, 89], ["LL", "TEST", 0, 2], ["a cyclodepsipeptide", "TREATMENT", 18, 37]]], ["The structure of LL-15G256gamma was determined by a combination of chemical degradation, chiral chromatography and spectroscopic analysis.", [["LL-15G256", "CHEMICAL", 17, 26], ["LL-15G256gamma", "GENE_OR_GENE_PRODUCT", 17, 31], ["LL-15G256gamma", "PROTEIN", 17, 31], ["chemical degradation", "PROBLEM", 67, 87], ["chiral chromatography", "TEST", 89, 110], ["spectroscopic analysis", "TEST", 115, 137], ["LL", "OBSERVATION_MODIFIER", 17, 19]]], ["LL-15G256gamma uniquely combines a beta-ketotryptophan and a polyketide portion within a macrolactone ring.", [["LL-15G256", "CHEMICAL", 0, 9], ["beta-ketotryptophan", "CHEMICAL", 35, 54], ["polyketide", "CHEMICAL", 61, 71], ["macrolactone", "CHEMICAL", 89, 101], ["beta-ketotryptophan", "CHEMICAL", 35, 54], ["polyketide", "CHEMICAL", 61, 71], ["macrolactone", "CHEMICAL", 89, 101], ["LL-15G256gamma", "GENE_OR_GENE_PRODUCT", 0, 14], ["beta-ketotryptophan", "GENE_OR_GENE_PRODUCT", 35, 54], ["macrolactone ring", "SIMPLE_CHEMICAL", 89, 106], ["15G256gamma", "PROTEIN", 3, 14], ["LL", "TEST", 0, 2], ["a beta-ketotryptophan", "TREATMENT", 33, 54], ["a polyketide portion", "TREATMENT", 59, 79], ["a macrolactone ring", "TREATMENT", 87, 106]]], ["LL-15G256gamma has exhibited potent activity against fungal strains and as such, is an attractive compound to develop as a future therapeutic agent.", [["LL-15G256gamma", "CHEMICAL", 0, 14], ["LL-15G256gamma", "GENE_OR_GENE_PRODUCT", 0, 14], ["15G256gamma", "PROTEIN", 3, 14], ["LL", "TEST", 0, 2], ["fungal strains", "PROBLEM", 53, 67], ["a future therapeutic agent", "TREATMENT", 121, 147], ["potent activity", "OBSERVATION_MODIFIER", 29, 44]]], ["To date, there have been no reported studies towards the synthesis of LL-15G256gamma.", [["LL-15G256gamma", "CHEMICAL", 70, 84], ["LL-15G256gamma", "CHEMICAL", 70, 84], ["LL-15G256gamma", "GENE_OR_GENE_PRODUCT", 70, 84]]], ["We have completed the total synthesis of LL-15G256gamma by employing the macrolactamization followed by a C-H oxidation as the key step.", [["LL-15G256", "CHEMICAL", 41, 50], ["C-H", "CHEMICAL", 106, 109], ["C-H", "CHEMICAL", 106, 109], ["LL-15G256gamma", "GENE_OR_GENE_PRODUCT", 41, 55], ["C-H", "SIMPLE_CHEMICAL", 106, 109], ["15G256gamma", "PROTEIN", 44, 55], ["the total synthesis of LL-15G256gamma", "TREATMENT", 18, 55], ["the macrolactamization", "TREATMENT", 69, 91], ["a C-H oxidation", "TREATMENT", 104, 119]]], ["Aspartimide (aminosuccinimide, Asu) formation is the first step in the degradation of Asp/Asn containing peptides and proteins.", [["Aspartimide", "CHEMICAL", 0, 11], ["aminosuccinimide", "CHEMICAL", 13, 29], ["Asu", "CHEMICAL", 31, 34], ["Asp/Asn", "CHEMICAL", 86, 93], ["Aspartimide", "CHEMICAL", 0, 11], ["aminosuccinimide", "CHEMICAL", 13, 29], ["Asu", "CHEMICAL", 31, 34], ["Asp", "CHEMICAL", 86, 89], ["Asn", "CHEMICAL", 90, 93], ["Aspartimide", "SIMPLE_CHEMICAL", 0, 11], ["aminosuccinimide", "SIMPLE_CHEMICAL", 13, 29], ["Asu", "SIMPLE_CHEMICAL", 31, 34], ["Asp", "AMINO_ACID", 86, 89], ["Asn", "AMINO_ACID", 90, 93], ["Aspartimide (aminosuccinimide, Asu)", "TREATMENT", 0, 35], ["Asp/Asn containing peptides", "TREATMENT", 86, 113]]], ["The reaction is especially prevalent at Asx-Gly sites and results in a variety of rearranged and racemized products.", [["Asx-Gly", "CHEMICAL", 40, 47], ["Asx-Gly", "CHEMICAL", 40, 47], ["Asx-Gly", "SIMPLE_CHEMICAL", 40, 47], ["The reaction", "PROBLEM", 0, 12], ["rearranged and racemized products", "TREATMENT", 82, 115]]], ["The bases used in Fmoc-tert-based SPPS promote the formation of Asu and related products.", [["Fmoc", "CHEMICAL", 18, 22], ["SPPS", "CHEMICAL", 34, 38], ["Asu", "CHEMICAL", 64, 67], ["Fmoc", "CHEMICAL", 18, 22], ["Fmoc-tert-based SPPS", "SIMPLE_CHEMICAL", 18, 38], ["Asu", "SIMPLE_CHEMICAL", 64, 67], ["The bases", "TREATMENT", 0, 9], ["Fmoc", "TREATMENT", 18, 22], ["tert-based SPPS", "TREATMENT", 23, 38], ["Asu and related products", "TREATMENT", 64, 88], ["bases", "ANATOMY_MODIFIER", 4, 9]]], ["We recently found that the Dmb backbone protection efficiently prevents secondary structure formation at GG sites and is orthogonal with respect to standard Fmoc SPPS.", [["Fmoc", "CHEMICAL", 157, 161], ["Dmb", "GENE_OR_GENE_PRODUCT", 27, 30], ["the Dmb backbone protection", "TREATMENT", 23, 50], ["secondary structure formation at GG sites", "PROBLEM", 72, 113], ["standard Fmoc SPPS", "TREATMENT", 148, 166], ["secondary structure", "OBSERVATION", 72, 91]]], ["Here we explore the use of Dmb, Tmb and Nbzl groups (Z) for the synthesis of \"difficult\"/Asu-prone peptides, in three different schemes: A) Fmoc-Asx-(Z)Gly-OH dipeptide building blocks; B) Fmoc-(Z)Gly-OH monomer building blocks, and C) two steps \"submonomeric\" approach for synthesis of substituted N-benzyl glycines on the resin.", [["Fmoc", "CHEMICAL", 140, 144], ["Fmoc", "CHEMICAL", 189, 193], ["N-benzyl", "CHEMICAL", 299, 307], ["Tmb", "CHEMICAL", 32, 35], ["Nbzl", "CHEMICAL", 40, 44], ["Fmoc-Asx-(Z)Gly-OH dipeptide", "CHEMICAL", 140, 168], ["Fmoc-(Z)Gly-OH", "CHEMICAL", 189, 203], ["N-benzyl glycines", "CHEMICAL", 299, 316], ["Dmb", "SIMPLE_CHEMICAL", 27, 30], ["Tmb", "SIMPLE_CHEMICAL", 32, 35], ["Asx-(Z)Gly-OH dipeptide", "SIMPLE_CHEMICAL", 145, 168], ["B) Fmoc-(Z)Gly-OH", "SIMPLE_CHEMICAL", 186, 203], ["substituted N-benzyl glycines", "SIMPLE_CHEMICAL", 287, 316], ["Dmb", "PROTEIN", 27, 30], ["Tmb", "PROTEIN", 32, 35], ["Nbzl groups", "PROTEIN", 40, 51], ["Dmb", "TREATMENT", 27, 30], ["Fmoc", "TEST", 140, 144], ["Asx", "TEST", 145, 148], ["Z)Gly-OH dipeptide building blocks", "TREATMENT", 150, 184], ["Fmoc-(Z)Gly-OH monomer building blocks", "TREATMENT", 189, 227], ["submonomeric\" approach", "TREATMENT", 247, 269], ["synthesis of substituted N-benzyl glycines", "TREATMENT", 274, 316], ["the resin", "TREATMENT", 320, 329]]], ["We tested the new methods on two model peptides VKD/NGYI and HA21-20HIV-TAT48-57 (H-G1LFGAIAGFI ENGWEGMIDG20GRKKRRQRRR30-OH) fusion peptide.", [["HA21-20HIV-TAT48-57", "CHEMICAL", 61, 80], ["OH", "CHEMICAL", 121, 123], ["HA21-20HIV-TAT48-57", "SIMPLE_CHEMICAL", 61, 80], ["H-G1LFGAIAGFI ENGWEGMIDG20GRKKRRQRRR30-OH", "SIMPLE_CHEMICAL", 82, 123], ["NGYI", "TEST", 52, 56], ["HA21", "TEST", 61, 65], ["TAT48", "TEST", 72, 77], ["H-G1LFGAIAGFI ENGWEGMIDG20GRKKRRQRRR30-OH) fusion peptide", "TREATMENT", 82, 139], ["new", "OBSERVATION_MODIFIER", 14, 17]]], ["The yield and purity of the products reach and even exceed the level in control experiments obtained with Hmb protection and the peptides were found free of Asu/piperidides.", [["Asu", "CHEMICAL", 157, 160], ["piperidides", "CHEMICAL", 161, 172], ["Asu", "CHEMICAL", 157, 160], ["piperidides", "CHEMICAL", 161, 172], ["Hmb", "SIMPLE_CHEMICAL", 106, 109], ["Asu", "SIMPLE_CHEMICAL", 157, 160], ["piperidides", "SIMPLE_CHEMICAL", 161, 172], ["the products", "TREATMENT", 24, 36], ["Hmb protection", "TREATMENT", 106, 120], ["the peptides", "TEST", 125, 137], ["Asu/piperidides", "TREATMENT", 157, 172]]], ["The acid removal of the Dmb protection is ~30% faster than that of Hmb.", [["Dmb", "GENE_OR_GENE_PRODUCT", 24, 27], ["Hmb", "GENE_OR_GENE_PRODUCT", 67, 70], ["Hmb", "PROTEIN", 67, 70], ["The acid removal", "TREATMENT", 0, 16], ["the Dmb protection", "TREATMENT", 20, 38], ["acid removal", "OBSERVATION", 4, 16]]], ["The submonomeric route (Strategy C) is especially simple, efficient, cost effective and it allows the use of different amines for halogen-displacement.", [["amines", "CHEMICAL", 119, 125], ["amines", "CHEMICAL", 119, 125], ["halogen", "CHEMICAL", 130, 137], ["amines", "SIMPLE_CHEMICAL", 119, 125], ["different amines", "TREATMENT", 109, 125], ["halogen-displacement", "TREATMENT", 130, 150]]], ["The backbone protecting groups used were in many respects superior to the commercial reagents and applicable for synthesis of both peptide acids and peptide amides.", [["peptide amides", "CHEMICAL", 149, 163], ["amides", "CHEMICAL", 157, 163], ["peptide acids", "SIMPLE_CHEMICAL", 131, 144], ["peptide amides", "SIMPLE_CHEMICAL", 149, 163], ["The backbone protecting groups", "TREATMENT", 0, 30], ["the commercial reagents", "TREATMENT", 70, 93], ["synthesis of both peptide acids", "TREATMENT", 113, 144], ["peptide amides", "TREATMENT", 149, 163]]], ["The use of Nbzl-NH2 for halogen displacement represents a new method for preparation of backbone-caged peptides.", [["Nbzl-NH2", "CHEMICAL", 11, 19], ["Nbzl", "CHEMICAL", 11, 15], ["NH2", "CHEMICAL", 16, 19], ["halogen", "CHEMICAL", 24, 31], ["Nbzl-NH2", "SIMPLE_CHEMICAL", 11, 19], ["Nbzl", "PROTEIN", 11, 15], ["NH2", "PROTEIN", 16, 19], ["Nbzl-NH2", "TREATMENT", 11, 19], ["halogen displacement", "PROBLEM", 24, 44], ["a new method", "TREATMENT", 56, 68], ["backbone-caged peptides", "TREATMENT", 88, 111]]], ["Alkyl bonded silica gels historically have been the standard in reversed phase (RP) purification of biomolecules such as synthetic peptides, small proteins, and oligonucleotides.", [["Alkyl", "CHEMICAL", 0, 5], ["Alkyl", "CHEMICAL", 0, 5], ["silica", "CHEMICAL", 13, 19], ["Alkyl", "SIMPLE_CHEMICAL", 0, 5], ["Alkyl bonded silica gels", "TREATMENT", 0, 24], ["purification of biomolecules", "TREATMENT", 84, 112], ["synthetic peptides", "TEST", 121, 139], ["small proteins", "PROBLEM", 141, 155], ["oligonucleotides", "TREATMENT", 161, 177], ["bonded", "OBSERVATION_MODIFIER", 6, 12], ["silica gels", "OBSERVATION", 13, 24], ["small proteins", "OBSERVATION", 141, 155]]], ["Silica gels provided the resolving power needed for challenging separations and the mechanical stability required to be operated industrially under high pressure conditions.", [["Silica", "CHEMICAL", 0, 6], ["Silica", "CHEMICAL", 0, 6], ["Silica gels", "TREATMENT", 0, 11], ["challenging separations", "TREATMENT", 52, 75], ["the mechanical stability", "TREATMENT", 80, 104], ["high pressure conditions", "TREATMENT", 148, 172], ["mechanical stability", "OBSERVATION", 84, 104]]], ["The chief disadvantage of silica gels is poor chemical stability under alkaline conditions, which limits their capability to withstand rigorous clean and sanitization -in-place (CIP/SIP) protocols.", [["silica gels", "CHEMICAL", 26, 37], ["silica", "CHEMICAL", 26, 32], ["silica gels", "SIMPLE_CHEMICAL", 26, 37], ["The chief disadvantage of silica gels", "TREATMENT", 0, 37], ["poor chemical stability under alkaline conditions", "PROBLEM", 41, 90], ["rigorous clean", "TREATMENT", 135, 149], ["sanitization", "TREATMENT", 154, 166], ["CIP/SIP) protocols", "TREATMENT", 178, 196], ["alkaline conditions", "OBSERVATION_MODIFIER", 71, 90]]], ["As a result, polymeric media have gained recent market attention because of their excellent chemical stability, which enables full compatibility with modern CIP/SIP protocols.", [["polymeric media", "TREATMENT", 13, 28], ["modern CIP/SIP protocols", "TREATMENT", 150, 174], ["excellent", "OBSERVATION_MODIFIER", 82, 91], ["chemical stability", "OBSERVATION", 92, 110]]], ["However, first generation polymeric gels lacked both the resolving power and the mechanical stability to be compatible with industrial high pressure dynamic axial compression (DAC) hardware.M121 THE FIRST TOTAL SYNTHESIS OF LL-15G256GAMMARohm and Haas' Advanced Biosciences division recently introduced a new, monospheric, 10 micron, high performance polymeric RP material.", [["DAC", "CHEMICAL", 176, 179], ["first generation polymeric gels", "PROBLEM", 9, 40], ["industrial high pressure dynamic axial compression (DAC) hardware", "TREATMENT", 124, 189], ["LL", "TEST", 224, 226], ["a new, monospheric, 10 micron, high performance polymeric RP material", "TREATMENT", 303, 372], ["resolving", "OBSERVATION_MODIFIER", 57, 66], ["power", "OBSERVATION_MODIFIER", 67, 72], ["mechanical stability", "OBSERVATION", 81, 101], ["high pressure", "OBSERVATION", 135, 148], ["axial compression", "OBSERVATION", 157, 174], ["hardware", "OBSERVATION", 181, 189], ["RP material", "OBSERVATION", 361, 372]]], ["Unlike existing softer polymeric gels, this product has higher mechanical stability which enables it to be used effectively with industrial DAC / HPLC hardware.", [["DAC", "CHEMICAL", 140, 143], ["DAC", "CHEMICAL", 140, 143], ["DAC", "SIMPLE_CHEMICAL", 140, 143], ["existing softer polymeric gels", "TREATMENT", 7, 37], ["higher mechanical stability", "PROBLEM", 56, 83], ["industrial DAC / HPLC hardware", "TREATMENT", 129, 159], ["softer", "OBSERVATION_MODIFIER", 16, 22], ["polymeric gels", "OBSERVATION_MODIFIER", 23, 37], ["higher mechanical", "OBSERVATION_MODIFIER", 56, 73], ["stability", "OBSERVATION", 74, 83], ["HPLC hardware", "OBSERVATION", 146, 159]]], ["In addition, this material provides high resolving power for the most challenging industrial separations, because of its unique and selective pore structure, as well as its small monospheric particle size.", [["pore", "ANATOMY", 142, 146], ["most challenging", "OBSERVATION_MODIFIER", 65, 81], ["industrial separations", "OBSERVATION", 82, 104], ["selective", "OBSERVATION_MODIFIER", 132, 141], ["pore", "OBSERVATION_MODIFIER", 142, 146], ["structure", "OBSERVATION", 147, 156], ["small", "OBSERVATION_MODIFIER", 173, 178], ["monospheric", "OBSERVATION_MODIFIER", 179, 190], ["particle", "OBSERVATION_MODIFIER", 191, 199], ["size", "OBSERVATION_MODIFIER", 200, 204]]], ["Finally, because of its excellent chemical stability, the media is not limited in the range of pH that can be used.", [["excellent", "OBSERVATION_MODIFIER", 24, 33], ["chemical", "OBSERVATION_MODIFIER", 34, 42], ["stability", "OBSERVATION", 43, 52]]], ["The combination of mechanical stability for high throughput, chemical stability for long lifetime in use, and high resolution for high yield, together translate to an effective cost-in-use solution for industrial polishing processes.Department of Bioscience and Biotechnology, Okayama University, Okayama, JapanWe have developed new types of peptide nucleic acids with improved water solubility by introducing ether linkages and pyrrolidine rings in the main chain; pyrrolidine-based oxy-PNAs (POPNAs).", [["nucleic acids", "CHEMICAL", 350, 363], ["pyrrolidine", "CHEMICAL", 429, 440], ["pyrrolidine", "CHEMICAL", 466, 477], ["oxy-PNAs", "CHEMICAL", 484, 492], ["ether", "CHEMICAL", 410, 415], ["pyrrolidine", "CHEMICAL", 429, 440], ["pyrrolidine", "CHEMICAL", 466, 477], ["oxy-PNAs", "CHEMICAL", 484, 492], ["POPNAs", "CHEMICAL", 494, 500], ["peptide nucleic acids", "SIMPLE_CHEMICAL", 342, 363], ["water", "SIMPLE_CHEMICAL", 378, 383], ["ether linkages", "SIMPLE_CHEMICAL", 410, 424], ["pyrrolidine rings", "SIMPLE_CHEMICAL", 429, 446], ["pyrrolidine-based oxy-PNAs", "SIMPLE_CHEMICAL", 466, 492], ["POPNAs", "SIMPLE_CHEMICAL", 494, 500], ["mechanical stability", "PROBLEM", 19, 39], ["industrial polishing processes", "TREATMENT", 202, 232], ["peptide nucleic acids", "TREATMENT", 342, 363], ["improved water solubility", "TREATMENT", 369, 394], ["introducing ether linkages", "TREATMENT", 398, 424], ["pyrrolidine rings in the main chain", "TREATMENT", 429, 464], ["pyrrolidine", "TREATMENT", 466, 477], ["PNAs", "PROBLEM", 488, 492], ["mechanical stability", "OBSERVATION", 19, 39], ["high", "OBSERVATION_MODIFIER", 44, 48], ["pyrrolidine rings", "OBSERVATION", 429, 446], ["main chain", "ANATOMY", 454, 464], ["PNAs", "OBSERVATION", 488, 492]]], ["In this work, cellular uptake and endosomal release of the trans-L-POPNA oligomers, one of stereoisomes of the POPNA, were investigated.", [["cellular", "ANATOMY", 14, 22], ["endosomal", "ANATOMY", 34, 43], ["cellular", "CELL", 14, 22], ["endosomal", "CELLULAR_COMPONENT", 34, 43], ["POPNA", "GENE_OR_GENE_PRODUCT", 111, 116], ["POPNA", "PROTEIN", 111, 116], ["cellular uptake", "PROBLEM", 14, 29], ["the trans-L-POPNA oligomers", "TREATMENT", 55, 82], ["the POPNA", "PROBLEM", 107, 116], ["cellular uptake", "OBSERVATION", 14, 29], ["endosomal release", "OBSERVATION", 34, 51], ["POPNA", "ANATOMY", 111, 116]]], ["The cellular uptake was achieved by combining the POPNA oligomer with an N-terminal 23-mer peptide of an influenza virus hemagglutinin protein (HA2) that is labeled with a rhodamine fluorophore at the N-terminal and covalently linked with a hepta-arginine unit at the C-terminal (Rho-HA2-R7).", [["cellular", "ANATOMY", 4, 12], ["rhodamine", "CHEMICAL", 172, 181], ["hepta-arginine", "CHEMICAL", 241, 255], ["N", "CHEMICAL", 73, 74], ["rhodamine", "CHEMICAL", 172, 181], ["N", "CHEMICAL", 201, 202], ["hepta-arginine", "CHEMICAL", 241, 255], ["cellular", "CELL", 4, 12], ["influenza virus hemagglutinin", "ORGANISM", 105, 134], ["rhodamine fluorophore", "SIMPLE_CHEMICAL", 172, 193], ["Rho", "GENE_OR_GENE_PRODUCT", 280, 283], ["influenza virus hemagglutinin protein", "PROTEIN", 105, 142], ["HA2", "PROTEIN", 144, 147], ["N-terminal", "PROTEIN", 201, 211], ["hepta-arginine unit", "PROTEIN", 241, 260], ["C-terminal", "PROTEIN", 268, 278], ["Rho", "PROTEIN", 280, 283], ["HA2", "PROTEIN", 284, 287], ["R7", "PROTEIN", 288, 290], ["influenza virus hemagglutinin", "SPECIES", 105, 134], ["The cellular uptake", "TEST", 0, 19], ["the POPNA oligomer", "TEST", 46, 64], ["an N", "TEST", 70, 74], ["an influenza virus hemagglutinin protein", "PROBLEM", 102, 142], ["a rhodamine fluorophore", "TREATMENT", 170, 193], ["a hepta-arginine unit", "TREATMENT", 239, 260], ["cellular uptake", "OBSERVATION", 4, 19], ["influenza virus", "OBSERVATION", 105, 120]]], ["The fluorescence images of the CHO cells after incubation with FAM-PO(13) [FAM-O-CAG TTA GGG TTA G-Gly-NH2] in the absence and presence of Rho-HA2-R7 were observed with confocal laser-scanning microscopy.", [["CHO cells", "ANATOMY", 31, 40], ["FAM-PO", "CHEMICAL", 63, 69], ["FAM-O", "CHEMICAL", 75, 80], ["G-Gly-NH2", "CHEMICAL", 97, 106], ["FAM-PO(13)", "CHEMICAL", 63, 73], ["FAM-O-CAG TTA GGG TTA G-Gly-NH2", "CHEMICAL", 75, 106], ["CHO cells", "CELL", 31, 40], ["FAM-PO(13)", "SIMPLE_CHEMICAL", 63, 73], ["FAM-O-CAG", "SIMPLE_CHEMICAL", 75, 84], ["TTA G-Gly-NH2", "SIMPLE_CHEMICAL", 93, 106], ["Rho", "GENE_OR_GENE_PRODUCT", 139, 142], ["CHO cells", "CELL_LINE", 31, 40], ["NH2", "PROTEIN", 103, 106], ["Rho", "PROTEIN", 139, 142], ["HA2", "PROTEIN", 143, 146], ["R7", "PROTEIN", 147, 149], ["The fluorescence images", "TEST", 0, 23], ["incubation", "TEST", 47, 57], ["FAM", "TEST", 63, 66], ["FAM", "TEST", 75, 78], ["CAG TTA GGG", "TREATMENT", 81, 92], ["Rho", "TEST", 139, 142], ["confocal laser-scanning microscopy", "TEST", 169, 203], ["R7", "ANATOMY", 147, 149]]], ["Incubation with FAM-PO(13) alone, no internalization of the oligomer was observed.", [["FAM-PO", "CHEMICAL", 16, 22], ["FAM-PO(13)", "CHEMICAL", 16, 26], ["FAM-PO(13)", "SIMPLE_CHEMICAL", 16, 26], ["FAM-PO", "TREATMENT", 16, 22]]], ["In the presence of Rho-HA2-R7, however, FAM-PO(13) was successfully internalized into CHO cells and, more importantly, the fluorescence spread over the whole cell.Department of Bioscience and Biotechnology, Okayama University, Okayama, JapanThe fluorescence image indicates that the POPNA oligomer in combination with the HA2-R7 peptide was transferred into cytoplasm within 1 h.", [["CHO cells", "ANATOMY", 86, 95], ["cell", "ANATOMY", 158, 162], ["cytoplasm", "ANATOMY", 358, 367], ["FAM-PO", "CHEMICAL", 40, 46], ["POPNA", "CHEMICAL", 283, 288], ["HA2-R7", "CHEMICAL", 322, 328], ["FAM-PO(13)", "CHEMICAL", 40, 50], ["Rho", "GENE_OR_GENE_PRODUCT", 19, 22], ["FAM-PO(13)", "SIMPLE_CHEMICAL", 40, 50], ["CHO cells", "CELL", 86, 95], ["cell", "CELL", 158, 162], ["POPNA", "SIMPLE_CHEMICAL", 283, 288], ["cytoplasm", "ORGANISM_SUBSTANCE", 358, 367], ["Rho", "PROTEIN", 19, 22], ["HA2", "PROTEIN", 23, 26], ["R7", "PROTEIN", 27, 29], ["CHO cells", "CELL_LINE", 86, 95], ["HA2", "PROTEIN", 322, 325], ["Rho", "TEST", 19, 22], ["FAM", "TEST", 40, 43], ["The fluorescence image", "TEST", 241, 263], ["the POPNA oligomer", "TREATMENT", 279, 297], ["the HA2-R7 peptide", "TREATMENT", 318, 336], ["R7", "ANATOMY", 27, 29], ["whole cell", "OBSERVATION", 152, 162]]], ["Since both the red (Rho) and green (FAM) fluorescence spread over the cytoplasm, the POPNA oligomers that were taken up into endosomes together with the Rho-HA2-R7 were released into cytoplasm as the disruption of the endosomes by the HA2 peptide.Department of Bioscience and Biotechnology, Okayama University, Okayama, JapanIn summary, the POPNA oligomers were readily taken up into cytoplasm of CHO cells, when combined with a HA2-R7 peptide.Department of Medical and Bioengineering Science, Okayama University, Okayama, JapanMost of functional RNAs have post-transcriptional modifications, some of which are quite important for their structure and function.", [["cytoplasm", "ANATOMY", 70, 79], ["endosomes", "ANATOMY", 125, 134], ["cytoplasm", "ANATOMY", 183, 192], ["endosomes", "ANATOMY", 218, 227], ["cytoplasm", "ANATOMY", 384, 393], ["CHO cells", "ANATOMY", 397, 406], ["Rho", "GENE_OR_GENE_PRODUCT", 20, 23], ["cytoplasm", "ORGANISM_SUBSTANCE", 70, 79], ["POPNA", "GENE_OR_GENE_PRODUCT", 85, 90], ["endosomes", "CELLULAR_COMPONENT", 125, 134], ["Rho-HA2-R7", "GENE_OR_GENE_PRODUCT", 153, 163], ["cytoplasm", "ORGANISM_SUBSTANCE", 183, 192], ["endosomes", "CELLULAR_COMPONENT", 218, 227], ["cytoplasm", "ORGANISM_SUBSTANCE", 384, 393], ["CHO cells", "CELL", 397, 406], ["Rho", "PROTEIN", 20, 23], ["POPNA oligomers", "PROTEIN", 85, 100], ["Rho-HA2", "PROTEIN", 153, 160], ["R7", "PROTEIN", 161, 163], ["CHO cells", "CELL_LINE", 397, 406], ["HA2", "PROTEIN", 429, 432], ["green (FAM) fluorescence spread", "PROBLEM", 29, 60], ["the POPNA oligomers", "TREATMENT", 81, 100], ["the HA2 peptide", "TREATMENT", 231, 246], ["the POPNA oligomers", "PROBLEM", 337, 356], ["a HA2-R7 peptide", "TREATMENT", 427, 443], ["post-transcriptional modifications", "TREATMENT", 557, 591], ["red", "OBSERVATION", 15, 18], ["functional RNAs", "OBSERVATION", 536, 551], ["post-transcriptional modifications", "OBSERVATION", 557, 591]]], ["Thus, for studying such RNAs, it is necessary to use purified raw RNAs obtained from living organisms.", [["purified raw RNAs", "PROBLEM", 53, 70]]], ["Isolation of native RNA is necessary also in the case of analyzing the sequence and modifications of mature RNA, which may be different from simple transcript of its gene.", [["native RNA", "RNA", 13, 23], ["mature RNA", "RNA", 101, 111], ["Isolation of native RNA", "TREATMENT", 0, 23], ["analyzing the sequence", "TEST", 57, 79], ["mature RNA", "PROBLEM", 101, 111], ["native RNA", "OBSERVATION", 13, 23], ["mature RNA", "OBSERVATION", 101, 111]]], ["Therefore, RNA isolation method is required.", [["RNA isolation method", "TREATMENT", 11, 31]]], ["Many previous reports demonstrated isolation of RNAs, especially tRNAs.", [["RNAs", "RNA", 48, 52], ["tRNAs", "RNA", 65, 70], ["isolation of RNAs", "PROBLEM", 35, 52]]], ["Most common and traditional purification methods are based on successive column chromatographies.", [["traditional purification methods", "TREATMENT", 16, 48], ["successive column chromatographies", "TREATMENT", 62, 96]]], ["It seems difficult to apply such method to every tRNA because effective combination of columns varies among individual tRNAs.", [["such method", "TREATMENT", 28, 39], ["tRNA", "TREATMENT", 49, 53]]], ["To overcome the difficulty, a sequence-specific selection method using a solid-phase DNA has been devised.", [["DNA", "CELLULAR_COMPONENT", 85, 88], ["solid-phase DNA", "DNA", 73, 88], ["a sequence", "TEST", 28, 38], ["a solid-phase DNA", "TREATMENT", 71, 88]]], ["In this method, a tRNA can be purified from RNA mixture by a single step.", [["a tRNA", "TREATMENT", 16, 22], ["RNA mixture", "TREATMENT", 44, 55]]], ["However, this method needs high temperature treatment, which might assist hydrolysis of RNA strand and might impair heat labile modifications.", [["RNA strand", "RNA", 88, 98], ["high temperature treatment", "TREATMENT", 27, 53], ["RNA strand", "TREATMENT", 88, 98], ["impair heat labile modifications", "PROBLEM", 109, 141], ["high temperature", "OBSERVATION_MODIFIER", 27, 43]]], ["PNA-RNA hybrid has been known to be much more stable than DNA-RNA hybrid.", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["PNA", "PROBLEM", 0, 3], ["RNA hybrid", "PROBLEM", 4, 14], ["RNA hybrid", "PROBLEM", 62, 72], ["RNA hybrid", "OBSERVATION", 4, 14], ["RNA hybrid", "OBSERVATION", 62, 72]]], ["Thus PNA-based RNA purification method seems to be possible for wider variety of RNAs in lower temperature, in comparison with DNA-based method.", [["PNA", "SIMPLE_CHEMICAL", 5, 8], ["DNA", "CELLULAR_COMPONENT", 127, 130], ["RNAs", "RNA", 81, 85], ["PNA", "PROBLEM", 5, 8], ["based RNA purification method", "PROBLEM", 9, 38], ["wider variety of RNAs in lower temperature", "PROBLEM", 64, 106], ["PNA", "OBSERVATION", 5, 8], ["seems to be possible", "UNCERTAINTY", 39, 59], ["RNAs", "OBSERVATION", 81, 85], ["lower temperature", "OBSERVATION_MODIFIER", 89, 106]]], ["In this study, we attempted to purify a single RNA, such as a tRNA and a noncoding RNA, from RNA mixture by using immobilized PNA.PEPTIDE SYNTHESIS OF TROJAN HORSES FOR PLASMID TRANSFER AND TOPICAL ACTIVATIONR.", [["PNA", "SIMPLE_CHEMICAL", 126, 129], ["single RNA", "RNA", 40, 50], ["tRNA", "RNA", 62, 66], ["noncoding RNA", "RNA", 73, 86], ["this study", "TEST", 3, 13], ["a single RNA", "PROBLEM", 38, 50], ["a tRNA", "TREATMENT", 60, 66], ["a noncoding RNA", "PROBLEM", 71, 86], ["RNA mixture", "TREATMENT", 93, 104], ["immobilized PNA", "PROBLEM", 114, 129], ["PLASMID TRANSFER", "TREATMENT", 169, 185], ["TOPICAL ACTIVATIONR", "TREATMENT", 190, 209], ["PNA", "OBSERVATION", 126, 129], ["TROJAN HORSES", "OBSERVATION", 151, 164]]], ["Pipkorn 1 , W. Waldeck 2 , H. Spring 3 , J. Jenne 4 , K. Braun 5Central Peptide Synthesis Unit,German Cancer Research Center 2 German Cancer Research Center 3 Biomedical Structure Analysis Group 4 Clinical Cooperation Unit Radiation Oncology 5 Division of Molecular Toxicology,German Cancer Research Center, Heidelberg, GermanyBackground and aims: Safe drug delivery technologies are pivotal for genetic interventions, but viral vectors baer the risk of inflammatory reaction.", [["Cancer", "DISEASE", 102, 108], ["Cancer", "DISEASE", 134, 140], ["Cancer", "DISEASE", 284, 290], ["Pipkorn", "TREATMENT", 0, 7], ["Braun 5Central Peptide Synthesis Unit", "TREATMENT", 57, 94], ["Safe drug delivery technologies", "TREATMENT", 348, 379], ["genetic interventions", "TREATMENT", 396, 417], ["viral vectors", "TREATMENT", 423, 436], ["inflammatory reaction", "PROBLEM", 454, 475], ["Cancer", "OBSERVATION", 102, 108], ["German Cancer", "OBSERVATION", 277, 290], ["inflammatory reaction", "OBSERVATION", 454, 475]]], ["Questions concerning the efficacy of delivery of the genetic substances, the desired topical gene activation and targeting must be answered.", [["the genetic substances", "TREATMENT", 49, 71]]], ["Therefore we attempted to develop a membrane non-perturbing delivery system for transport of inactive functional genes into cells and tissues.", [["membrane", "ANATOMY", 36, 44], ["cells", "ANATOMY", 124, 129], ["tissues", "ANATOMY", 134, 141], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["cells", "CELL", 124, 129], ["tissues", "TISSUE", 134, 141], ["inactive functional genes", "DNA", 93, 118], ["a membrane non-perturbing delivery system", "TREATMENT", 34, 75]]], ["Our concept bases on the use of peptide-nucleic-acids (PNAs) resistant against proteases and nucleases, oligonucleotide derivatives, in which the phosphate-backbone has been replaced with ethylen-amin connected alpha-amino-ethylglycine-units.", [["peptide-nucleic-acids", "CHEMICAL", 32, 53], ["PNAs", "CHEMICAL", 55, 59], ["phosphate", "CHEMICAL", 146, 155], ["ethylen-amin", "CHEMICAL", 188, 200], ["alpha-amino-ethylglycine", "CHEMICAL", 211, 235], ["phosphate", "CHEMICAL", 146, 155], ["ethylen-amin", "CHEMICAL", 188, 200], ["alpha-amino-ethylglycine", "CHEMICAL", 211, 235], ["peptide-nucleic-acids", "SIMPLE_CHEMICAL", 32, 53], ["PNAs", "SIMPLE_CHEMICAL", 55, 59], ["phosphate", "SIMPLE_CHEMICAL", 146, 155], ["ethylen-amin connected alpha-amino-ethylglycine", "SIMPLE_CHEMICAL", 188, 235], ["proteases", "PROTEIN", 79, 88], ["nucleases", "PROTEIN", 93, 102], ["peptide-nucleic-acids (PNAs", "TREATMENT", 32, 59], ["proteases and nucleases", "TREATMENT", 79, 102], ["oligonucleotide derivatives", "TREATMENT", 104, 131], ["the phosphate-backbone", "TREATMENT", 142, 164], ["ethylen", "TREATMENT", 188, 195], ["alpha-amino", "TREATMENT", 211, 222], ["ethylglycine", "TREATMENT", 223, 235], ["bases", "ANATOMY_MODIFIER", 12, 17]]], ["Methods: Peptides conjugates were composed and synthesized according to the solid phase synthesis and protecting group chemistry strategies.", [["Peptides conjugates", "TREATMENT", 9, 28], ["the solid phase synthesis", "TREATMENT", 72, 97], ["protecting group chemistry strategies", "TREATMENT", 102, 139]]], ["PNA sequences were conjugated covalently, non cleavable, with a capronic acid spacer to the NLS, PKKKRKV.Leibniz-Institute of Molecular Pharmacology, Berlin, GermanyPNAs have gained broad attention in antisense/antigene experiments and as diagnostic tools.", [["capronic acid", "CHEMICAL", 64, 77], ["capronic acid", "CHEMICAL", 64, 77], ["PNA", "SIMPLE_CHEMICAL", 0, 3], ["capronic acid", "SIMPLE_CHEMICAL", 64, 77], ["NLS", "GENE_OR_GENE_PRODUCT", 92, 95], ["capronic acid spacer", "PROTEIN", 64, 84], ["NLS", "PROTEIN", 92, 95], ["PKKKRKV", "PROTEIN", 97, 104], ["PNA sequences", "TEST", 0, 13], ["a capronic acid spacer", "TREATMENT", 62, 84], ["antisense/antigene experiments", "TREATMENT", 201, 231]]], ["In principal, they can be synthesised with several activating reagents known from peptide synthesis.", [["several activating reagents", "TREATMENT", 43, 70], ["peptide synthesis", "TREATMENT", 82, 99]]], ["Namely, HATU or PyBOP are often used.", [["HATU", "CHEMICAL", 8, 12], ["PyBOP", "CHEMICAL", 16, 21], ["HATU", "CHEMICAL", 8, 12], ["PyBOP", "CHEMICAL", 16, 21], ["HATU", "SIMPLE_CHEMICAL", 8, 12], ["PyBOP", "SIMPLE_CHEMICAL", 16, 21], ["PyBOP", "TREATMENT", 16, 21]]], ["Synthesis with HATU is more laborious, because preactivation is needed in order to avoid guadinylation of the N-terminus of the growing PNA-chain.", [["HATU", "CHEMICAL", 15, 19], ["N", "CHEMICAL", 110, 111], ["HATU", "SIMPLE_CHEMICAL", 15, 19], ["N-terminus", "PROTEIN", 110, 120], ["growing PNA-chain", "PROTEIN", 128, 145], ["Synthesis with HATU", "TREATMENT", 0, 19], ["growing", "OBSERVATION_MODIFIER", 128, 135], ["PNA", "OBSERVATION", 136, 139], ["chain", "OBSERVATION_MODIFIER", 140, 145]]], ["We wanted to use PyBOP, because preactivation should not be needed in this case, which is especially useful in automated synthesis.", [["PyBOP", "CHEMICAL", 17, 22], ["PyBOP", "CHEMICAL", 17, 22], ["PyBOP", "SIMPLE_CHEMICAL", 17, 22], ["PyBOP", "TREATMENT", 17, 22]]], ["Surprisingly, in the PyBOP-mediated syntheses of 18mer PNAs we obtained products showing molecular masses approx.", [["PyBOP", "CHEMICAL", 21, 26], ["PyBOP", "SIMPLE_CHEMICAL", 21, 26], ["18mer PNAs", "SIMPLE_CHEMICAL", 49, 59], ["PNAs", "PROBLEM", 55, 59], ["molecular masses", "PROBLEM", 89, 105], ["molecular", "OBSERVATION_MODIFIER", 89, 98], ["masses", "OBSERVATION", 99, 105]]], ["Detailed analysis revealed, that the modification occurred at the only guanine residue in the sequence.", [["guanine", "CHEMICAL", 71, 78], ["guanine", "CHEMICAL", 71, 78], ["Detailed analysis", "TEST", 0, 17], ["the modification", "PROBLEM", 33, 49], ["guanine residue", "OBSERVATION", 71, 86]]], ["In order to further characterise the side reaction, a short PNA fragment was synthesised using HATU and PyBOP activation, respectively, and cleaved from the resin with and without the N-terminal Fmoc-group.", [["HATU", "CHEMICAL", 95, 99], ["PyBOP", "CHEMICAL", 104, 109], ["HATU", "CHEMICAL", 95, 99], ["PyBOP", "CHEMICAL", 104, 109], ["HATU", "SIMPLE_CHEMICAL", 95, 99], ["PyBOP", "SIMPLE_CHEMICAL", 104, 109], ["N-terminal Fmoc-group", "PROTEIN", 184, 205], ["the side reaction", "PROBLEM", 33, 50], ["a short PNA fragment", "PROBLEM", 52, 72], ["HATU and PyBOP activation", "TREATMENT", 95, 120], ["short", "OBSERVATION_MODIFIER", 54, 59]]], ["While synthesis with HATU gave the desired products, PyBOP partly activates the aromatic carboxy group of the guanine residue, which is substituted by piperidine during subsequent Fmoc cleavage.", [["HATU", "CHEMICAL", 21, 25], ["PyBOP", "CHEMICAL", 53, 58], ["guanine", "CHEMICAL", 110, 117], ["piperidine", "CHEMICAL", 151, 161], ["Fmoc", "CHEMICAL", 180, 184], ["HATU", "CHEMICAL", 21, 25], ["PyBOP", "CHEMICAL", 53, 58], ["carboxy", "CHEMICAL", 89, 96], ["guanine", "CHEMICAL", 110, 117], ["piperidine", "CHEMICAL", 151, 161], ["Fmoc", "CHEMICAL", 180, 184], ["HATU", "SIMPLE_CHEMICAL", 21, 25], ["PyBOP", "SIMPLE_CHEMICAL", 53, 58], ["guanine", "SIMPLE_CHEMICAL", 110, 117], ["piperidine", "SIMPLE_CHEMICAL", 151, 161], ["HATU", "PROTEIN", 21, 25], ["HATU", "TREATMENT", 21, 25], ["the desired products", "TREATMENT", 31, 51], ["PyBOP", "TREATMENT", 53, 58], ["the guanine residue", "PROBLEM", 106, 125], ["piperidine", "TREATMENT", 151, 161], ["subsequent Fmoc cleavage", "TREATMENT", 169, 193], ["guanine residue", "OBSERVATION", 110, 125]]], ["The modified sequences could be further characterised by MS/MS-fragmentation.Leibniz-Institute of Molecular Pharmacology, Berlin, GermanyOur results show that care must be taken when synthesising PNAs with PyBOP activation.", [["PyBOP", "SIMPLE_CHEMICAL", 206, 211], ["PyBOP", "PROTEIN", 206, 211], ["The modified sequences", "TEST", 0, 22], ["fragmentation", "PROBLEM", 63, 76], ["synthesising PNAs", "PROBLEM", 183, 200], ["PyBOP activation", "PROBLEM", 206, 222], ["fragmentation", "OBSERVATION", 63, 76], ["PNAs", "OBSERVATION", 196, 200]]], ["On the other hand, this reaction possibly opens an opportunity to synthesise guanine derivatives.", [["guanine", "CHEMICAL", 77, 84], ["guanine", "CHEMICAL", 77, 84], ["guanine derivatives", "SIMPLE_CHEMICAL", 77, 96], ["this reaction", "PROBLEM", 19, 32], ["synthesise guanine derivatives", "TREATMENT", 66, 96]]], ["The opioid receptor system in the central nervous system (CNS) controls a number of physiological processes including pain, reward, gastrointestinal and cardiovascular functions.", [["central nervous system", "ANATOMY", 34, 56], ["CNS", "ANATOMY", 58, 61], ["gastrointestinal", "ANATOMY", 132, 148], ["cardiovascular", "ANATOMY", 153, 167], ["pain", "DISEASE", 118, 122], ["opioid receptor", "GENE_OR_GENE_PRODUCT", 4, 19], ["central nervous system", "ANATOMICAL_SYSTEM", 34, 56], ["CNS", "ANATOMICAL_SYSTEM", 58, 61], ["gastrointestinal", "ORGANISM_SUBDIVISION", 132, 148], ["cardiovascular", "ANATOMICAL_SYSTEM", 153, 167], ["The opioid receptor system", "TREATMENT", 0, 26], ["pain", "PROBLEM", 118, 122], ["central", "ANATOMY_MODIFIER", 34, 41], ["nervous system", "ANATOMY", 42, 56], ["gastrointestinal", "ANATOMY", 132, 148], ["cardiovascular", "ANATOMY", 153, 167]]], ["As a consequence, most pain modulating compounds currently available cause a variety of side-effects.", [["pain", "DISEASE", 23, 27], ["most pain modulating compounds", "PROBLEM", 18, 48]]], ["The endogenous ligands for the opioid receptors are a series of peptides that includes Endomorphin-1.", [["Endomorphin-1", "GENE_OR_GENE_PRODUCT", 87, 100], ["opioid receptors", "PROTEIN", 31, 47], ["Endomorphin-1", "PROTEIN", 87, 100], ["the opioid receptors", "TREATMENT", 27, 47], ["Endomorphin", "TREATMENT", 87, 98], ["endogenous ligands", "OBSERVATION", 4, 22]]], ["Endomorphin-1 has been shown to elicit potent anti-nociception through the highly selective activation of \u00b5-opioid receptors.", [["Endomorphin-1", "CHEMICAL", 0, 13], ["Endomorphin-1", "GENE_OR_GENE_PRODUCT", 0, 13], ["\u00b5-opioid receptors", "GENE_OR_GENE_PRODUCT", 106, 124], ["Endomorphin-1", "PROTEIN", 0, 13], ["\u00b5-opioid receptors", "PROTEIN", 106, 124], ["Endomorphin", "TREATMENT", 0, 11], ["\u00b5-opioid receptors", "TREATMENT", 106, 124]]], ["It is this receptor that mediates supraspinal analgesia and thus, selectivity for this receptor results in analgesia without affecting other processes.", [["supraspinal", "ANATOMY", 34, 45], ["supraspinal analgesia", "TREATMENT", 34, 55], ["this receptor", "TREATMENT", 82, 95], ["analgesia", "TREATMENT", 107, 116]]], ["Therefore, endomorphin-1 is considered a promising lead compound for the development of a new, safer pain medication.Leibniz-Institute of Molecular Pharmacology, Berlin, GermanyWe have synthesized a large number of lipid-and carbohydrate-modified endomorphin-1 analogues and screened these compounds for their binding and activation of \u00b5-and \u03b4-opioid receptors in SH-SY5Y cells as well as Caco-2 cell monolayer permeability and plasma stability.", [["SH-SY5Y cells", "ANATOMY", 364, 377], ["Caco-2 cell monolayer", "ANATOMY", 389, 410], ["plasma", "ANATOMY", 428, 434], ["endomorphin-1", "CHEMICAL", 11, 24], ["pain", "DISEASE", 101, 105], ["carbohydrate", "CHEMICAL", 225, 237], ["endomorphin-1", "GENE_OR_GENE_PRODUCT", 11, 24], ["lipid", "SIMPLE_CHEMICAL", 215, 220], ["carbohydrate", "SIMPLE_CHEMICAL", 225, 237], ["endomorphin-1 analogues", "SIMPLE_CHEMICAL", 247, 270], ["SH-SY5Y cells", "CELL", 364, 377], ["Caco-2 cell monolayer", "CELL", 389, 410], ["plasma", "ORGANISM_SUBSTANCE", 428, 434], ["\u00b5-and \u03b4-opioid receptors", "PROTEIN", 336, 360], ["SH-SY5Y cells", "CELL_LINE", 364, 377], ["Caco-2 cell monolayer", "CELL_LINE", 389, 410], ["safer pain medication", "TREATMENT", 95, 116], ["carbohydrate", "TREATMENT", 225, 237], ["modified endomorphin", "TREATMENT", 238, 258], ["their binding", "PROBLEM", 304, 317], ["\u00b5-and \u03b4-opioid receptors", "TREATMENT", 336, 360], ["Caco", "TEST", 389, 393], ["plasma stability", "TEST", 428, 444], ["new", "OBSERVATION_MODIFIER", 90, 93], ["large", "OBSERVATION_MODIFIER", 199, 204]]], ["Compounds conjugated with either a lipoamino acid or sugar moiety on the C-terminus lost binding affinity by several orders of magnitude, whilst N-terminal conjugations resulted in minimal loss of binding affinity.", [["lipoamino acid", "CHEMICAL", 35, 49], ["lipoamino acid", "CHEMICAL", 35, 49], ["sugar", "CHEMICAL", 53, 58], ["C", "CHEMICAL", 73, 74], ["N", "CHEMICAL", 145, 146], ["lipoamino acid", "SIMPLE_CHEMICAL", 35, 49], ["sugar moiety", "SIMPLE_CHEMICAL", 53, 65], ["C-terminus", "PROTEIN", 73, 83], ["N-terminal conjugations", "PROTEIN", 145, 168], ["a lipoamino acid or sugar moiety", "PROBLEM", 33, 65], ["minimal loss of binding affinity", "PROBLEM", 181, 213], ["minimal", "OBSERVATION_MODIFIER", 181, 188], ["loss", "OBSERVATION", 189, 193], ["binding affinity", "OBSERVATION", 197, 213]]], ["A number of analogues showed pM binding affinity and high apparent permeability, and of these compounds, one has been selected for assessment in nociceptive and neuropathic pain models.", [["neuropathic pain", "DISEASE", 161, 177], ["pM binding affinity", "PROBLEM", 29, 48], ["high apparent permeability", "PROBLEM", 53, 79], ["assessment", "TEST", 131, 141], ["nociceptive and neuropathic pain models", "PROBLEM", 145, 184], ["high apparent permeability", "OBSERVATION_MODIFIER", 53, 79]]], ["In addition to these pre-clinical studies, internalization and tolerance formation of these compounds has also been measured in an effort to synthesise a non-tolerant opioid agonist.", [["these pre-clinical studies", "TEST", 15, 41], ["internalization", "TREATMENT", 43, 58], ["a non-tolerant opioid agonist", "TREATMENT", 152, 181]]], ["Endomorphin-1 analogues with a high degree of amphiphilicity cause increased receptor internalization and subsequently less tolerance formation.OXYTOCIN AND VASOPRESSIN ANALOGUES MODIFIED WITH GLYCOAMINO ACIDSA.", [["Endomorphin-1", "CHEMICAL", 0, 13], ["Endomorphin-1", "GENE_OR_GENE_PRODUCT", 0, 13], ["Endomorphin", "TREATMENT", 0, 11], ["a high degree of amphiphilicity", "PROBLEM", 29, 60], ["increased receptor internalization", "PROBLEM", 67, 101], ["OXYTOCIN", "TREATMENT", 144, 152], ["VASOPRESSIN ANALOGUES", "TREATMENT", 157, 178], ["GLYCOAMINO ACIDSA", "TREATMENT", 193, 210], ["high degree", "OBSERVATION_MODIFIER", 31, 42], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["receptor internalization", "OBSERVATION", 77, 101], ["less tolerance", "OBSERVATION_MODIFIER", 119, 133]]], ["Marcinkowska 1 , L. Borovi\u010dkova 2 , J. Slaninow\u00e1 2 , Z. Grzonka 1Faculty of Chemistry, University of Gda\u0144Sk, Poland 2 Institute of Organic Chemistry and Biochemistry, Academy of Sciences of The Czech Republic, Prague, Czech RepublicCarbohydrate moieties of glycopeptides and glycoproteins play different decisive roles in various biological phenomena.", [["Marcinkowska", "TREATMENT", 0, 12], ["Organic Chemistry", "TEST", 131, 148], ["Czech RepublicCarbohydrate moieties of glycopeptides", "TREATMENT", 218, 270], ["glycoproteins", "TREATMENT", 275, 288], ["biological phenomena", "OBSERVATION", 330, 350]]], ["Conformation and solubility of proteins are influenced by the oligosaccharide chains, which can also inhibit the proteolytic degradation.", [["the proteolytic degradation", "PROBLEM", 109, 136]]], ["As a result, the synthesis of glycopeptides is an attractive field that contributes to understanding of mutual interactions between both moieties and for their biological interest.", [["the synthesis of glycopeptides", "TREATMENT", 13, 43]]], ["The synthesis of glycopeptides requires a combination of synthetic methods from both carbohydrate and peptide chemistry.", [["carbohydrate", "CHEMICAL", 85, 97], ["carbohydrate", "SIMPLE_CHEMICAL", 85, 97], ["The synthesis of glycopeptides", "TREATMENT", 0, 30], ["synthetic methods", "TREATMENT", 57, 74], ["peptide chemistry", "TEST", 102, 119], ["glycopeptides", "OBSERVATION", 17, 30]]], ["Moreover, this synthesis needs stereoselective formation of the glycosyl bond between a carbohydrate and a peptide (amino acid) part, and also an appropriate protecting group methodology that allows selective deblocking of only one functional group in these polyfunctional molecules.Faculty of Chemistry, University of Gda\u0144Sk, Poland 2 Institute of Organic Chemistry and Biochemistry, Academy of Sciences of The Czech Republic, Prague, Czech RepublicIn the present work we modified the oxytocin and vasopressin structure with glycoamino acids.", [["amino acid", "CHEMICAL", 116, 126], ["oxytocin", "CHEMICAL", 486, 494], ["vasopressin", "CHEMICAL", 499, 510], ["glycoamino acids", "CHEMICAL", 526, 542], ["glycosyl", "CHEMICAL", 64, 72], ["carbohydrate", "CHEMICAL", 88, 100], ["amino acid", "CHEMICAL", 116, 126], ["oxytocin", "CHEMICAL", 486, 494], ["vasopressin", "CHEMICAL", 499, 510], ["glycoamino acids", "CHEMICAL", 526, 542], ["carbohydrate", "SIMPLE_CHEMICAL", 88, 100], ["amino acid", "AMINO_ACID", 116, 126], ["oxytocin", "SIMPLE_CHEMICAL", 486, 494], ["vasopressin", "SIMPLE_CHEMICAL", 499, 510], ["glycoamino acids", "SIMPLE_CHEMICAL", 526, 542], ["this synthesis", "PROBLEM", 10, 24], ["the glycosyl bond", "TREATMENT", 60, 77], ["a carbohydrate", "TREATMENT", 86, 100], ["a peptide (amino acid)", "TREATMENT", 105, 127], ["selective deblocking", "TREATMENT", 199, 219], ["Organic Chemistry", "TEST", 349, 366], ["the oxytocin", "TREATMENT", 482, 494], ["vasopressin structure", "TREATMENT", 499, 520], ["glycoamino acids", "TREATMENT", 526, 542], ["polyfunctional molecules", "OBSERVATION", 258, 282]]], ["Transformations of Fmoc-protected serine and threonine derivatives into appropriate O-glycosylated precursors suitable for solid phase peptide synthesis were worked out.", [["Fmoc-", "CHEMICAL", 19, 24], ["serine", "CHEMICAL", 34, 40], ["threonine", "CHEMICAL", 45, 54], ["Fmoc-", "CHEMICAL", 19, 24], ["serine", "CHEMICAL", 34, 40], ["threonine", "CHEMICAL", 45, 54], ["O", "CHEMICAL", 84, 85], ["Fmoc-protected", "SIMPLE_CHEMICAL", 19, 33], ["serine", "AMINO_ACID", 34, 40], ["threonine derivatives", "SIMPLE_CHEMICAL", 45, 66], ["O-glycosylated", "SIMPLE_CHEMICAL", 84, 98], ["O-glycosylated precursors", "CELL_LINE", 84, 109], ["Fmoc-protected serine", "TREATMENT", 19, 40], ["threonine derivatives", "TREATMENT", 45, 66], ["appropriate O-glycosylated precursors", "TREATMENT", 72, 109], ["solid phase peptide synthesis", "TREATMENT", 123, 152]]], ["The -and -O-glycosides were synthesized from Fmocserine and Fmoc-threonine allyl esters and appropriate glycosyl bromide using Hanessian's modification of the Koenigs -Knorr reaction.", [["Fmocserine", "CHEMICAL", 45, 55], ["Fmoc-threonine allyl esters", "CHEMICAL", 60, 87], ["glycosyl bromide", "CHEMICAL", 104, 120], ["Hanessian", "CHEMICAL", 127, 136], ["O-glycosides", "CHEMICAL", 10, 22], ["Fmocserine", "CHEMICAL", 45, 55], ["Fmoc-threonine allyl esters", "CHEMICAL", 60, 87], ["glycosyl bromide", "CHEMICAL", 104, 120], ["-O-glycosides", "SIMPLE_CHEMICAL", 9, 22], ["Fmocserine", "SIMPLE_CHEMICAL", 45, 55], ["Fmoc-threonine allyl esters", "SIMPLE_CHEMICAL", 60, 87], ["glycosyl bromide", "SIMPLE_CHEMICAL", 104, 120], ["Hanessian", "SIMPLE_CHEMICAL", 127, 136], ["Koenigs", "SIMPLE_CHEMICAL", 159, 166], ["glycosides", "TREATMENT", 12, 22], ["Fmocserine", "TREATMENT", 45, 55], ["Fmoc", "TREATMENT", 60, 64], ["threonine allyl esters", "TREATMENT", 65, 87], ["appropriate glycosyl bromide", "TREATMENT", 92, 120], ["Hanessian", "TREATMENT", 127, 136], ["the Koenigs", "TREATMENT", 155, 166], ["Knorr reaction", "PROBLEM", 168, 182]]], ["These N--Fmoc-protected glycosides were used in synthesis of glycopeptides.", [["N--Fmoc-", "CHEMICAL", 6, 14], ["N--Fmoc-protected glycosides", "CHEMICAL", 6, 34], ["N--Fmoc-protected glycosides", "SIMPLE_CHEMICAL", 6, 34], ["Fmoc-protected glycosides", "TREATMENT", 9, 34], ["synthesis of glycopeptides", "TREATMENT", 48, 74]]], ["Eight analogues of oxytocin modified in position 4 were obtained.Faculty of Chemistry, University of Gda\u0144Sk, Poland 2 Institute of Organic Chemistry and Biochemistry, Academy of Sciences of The Czech Republic, Prague, Czech RepublicWe have also prepared two types of lysin-vasopressin analogues modified with glycoamino acid, in which the glucuronic acid was attached to the \u03c9-amino group of lysine in position 8 through the amide bond.", [["oxytocin", "CHEMICAL", 19, 27], ["vasopressin", "CHEMICAL", 273, 284], ["glycoamino acid", "CHEMICAL", 309, 324], ["glucuronic acid", "CHEMICAL", 339, 354], ["\u03c9-amino", "CHEMICAL", 375, 382], ["lysine", "CHEMICAL", 392, 398], ["oxytocin", "CHEMICAL", 19, 27], ["vasopressin", "CHEMICAL", 273, 284], ["glycoamino acid", "CHEMICAL", 309, 324], ["glucuronic acid", "CHEMICAL", 339, 354], ["\u03c9-amino", "CHEMICAL", 375, 382], ["lysine", "CHEMICAL", 392, 398], ["amide", "CHEMICAL", 425, 430], ["oxytocin", "SIMPLE_CHEMICAL", 19, 27], ["lysin-vasopressin analogues", "SIMPLE_CHEMICAL", 267, 294], ["glycoamino acid", "SIMPLE_CHEMICAL", 309, 324], ["glucuronic acid", "SIMPLE_CHEMICAL", 339, 354], ["lysine", "AMINO_ACID", 392, 398], ["Eight analogues of oxytocin", "TREATMENT", 0, 27], ["Organic Chemistry", "TEST", 131, 148], ["lysin", "TREATMENT", 267, 272], ["vasopressin analogues", "TREATMENT", 273, 294], ["glycoamino acid", "TREATMENT", 309, 324], ["the glucuronic acid", "TREATMENT", 335, 354], ["the \u03c9-amino group of lysine", "TREATMENT", 371, 398]]], ["Glycosylated analogues of oxytocin and vasopressin display an increased stability towards enzymatic degradation, and retain some hormonal activities.", [["oxytocin", "CHEMICAL", 26, 34], ["vasopressin", "CHEMICAL", 39, 50], ["oxytocin", "CHEMICAL", 26, 34], ["vasopressin", "CHEMICAL", 39, 50], ["oxytocin", "SIMPLE_CHEMICAL", 26, 34], ["vasopressin", "SIMPLE_CHEMICAL", 39, 50], ["Glycosylated analogues", "TREATMENT", 0, 22], ["oxytocin", "TREATMENT", 26, 34], ["vasopressin", "TREATMENT", 39, 50], ["an increased stability", "PROBLEM", 59, 81], ["enzymatic degradation", "PROBLEM", 90, 111], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["stability", "OBSERVATION_MODIFIER", 72, 81]]], ["Supported by grants: DS/8350-5-0131-6 (ZG) and Z40550506 (JS)Faculty of Chemistry, University of Wroc\u0142Aw, PolandAccording to many authors the formation of Amadori products is a key stage in the glycation process.", [["Z40550506", "CHEMICAL", 47, 56], ["Z40550506", "CHEMICAL", 47, 56], ["PolandAccording", "TREATMENT", 106, 121], ["Amadori products", "TREATMENT", 155, 171], ["Amadori products", "OBSERVATION", 155, 171], ["glycation process", "OBSERVATION", 194, 211]]], ["Glycated proteins may show allergenic properties and potentially initiate autoimmunological processes.", [["Glycated proteins", "GENE_OR_GENE_PRODUCT", 0, 17], ["Glycated proteins", "PROTEIN", 0, 17], ["Glycated proteins", "TEST", 0, 17], ["allergenic properties", "PROBLEM", 27, 48], ["autoimmunological processes", "PROBLEM", 74, 101], ["allergenic properties", "OBSERVATION", 27, 48]]], ["They may also serve as the markers of diabetes.", [["diabetes", "DISEASE", 38, 46], ["diabetes", "PROBLEM", 38, 46], ["diabetes", "OBSERVATION", 38, 46]]], ["To our best knowledge, all procedures concerning the synthesis of peptide-derived Amadori products reported in literature are based on \"in solution\" approach which makes them tedious and time consuming.Faculty of Chemistry, University of Wroc\u0142Aw, PolandA modified method of the solid phase synthesis of peptide-derived Amadori products based on direct alkylation of the deprotected \u03b5-amino groups with 2,3:4,5-di-Oisopropylidene-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose in the presence of sodium cyanoborohydride was proposed.", [["\u03b5-amino", "CHEMICAL", 382, 389], ["2,3:4,5-di-Oisopropylidene-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose", "CHEMICAL", 402, 465], ["sodium cyanoborohydride", "CHEMICAL", 485, 508], ["\u03b5-amino", "CHEMICAL", 382, 389], ["2,3:4,5-di-Oisopropylidene-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose", "CHEMICAL", 402, 465], ["sodium cyanoborohydride", "CHEMICAL", 485, 508], ["Amadori products", "SIMPLE_CHEMICAL", 319, 335], ["\u03b5-amino groups", "SIMPLE_CHEMICAL", 382, 396], ["2,3:4,5-di-Oisopropylidene-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose", "SIMPLE_CHEMICAL", 402, 465], ["sodium cyanoborohydride", "SIMPLE_CHEMICAL", 485, 508], ["Amadori products", "PROTEIN", 82, 98], ["all procedures", "TREATMENT", 23, 37], ["the synthesis of peptide", "TREATMENT", 49, 73], ["Amadori products", "TREATMENT", 82, 98], ["the solid phase synthesis of peptide", "TREATMENT", 274, 310], ["Amadori products", "TREATMENT", 319, 335], ["direct alkylation", "TREATMENT", 345, 362], ["the deprotected \u03b5-amino groups", "TREATMENT", 366, 396], ["di-Oisopropylidene-\u03b2-D-arabino", "TREATMENT", 410, 440], ["pyranose", "TREATMENT", 457, 465], ["sodium cyanoborohydride", "TREATMENT", 485, 508]]], ["Isopropylidene groups, protecting the sugar moiety in the obtained conjugate, were removed with trifluoroacetic acid containing 5% water.", [["Isopropylidene", "CHEMICAL", 0, 14], ["trifluoroacetic acid", "CHEMICAL", 96, 116], ["Isopropylidene", "CHEMICAL", 0, 14], ["sugar", "CHEMICAL", 38, 43], ["trifluoroacetic acid", "CHEMICAL", 96, 116], ["Isopropylidene", "SIMPLE_CHEMICAL", 0, 14], ["sugar moiety", "SIMPLE_CHEMICAL", 38, 50], ["trifluoroacetic acid", "SIMPLE_CHEMICAL", 96, 116], ["water", "SIMPLE_CHEMICAL", 131, 136], ["Isopropylidene groups", "TREATMENT", 0, 21], ["the sugar moiety", "TREATMENT", 34, 50], ["trifluoroacetic acid", "TREATMENT", 96, 116]]], ["Studies on optimization of the reaction performed on the model peptide attached to a Wang resin, Fmoc-Lys-Leu-Leu-Phe-(RESIN), showed that the best yield of the product is attained with a two-fold excess of 2,3:4,5-di-Oisopropylidene-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose and a five-fold excess of sodium cyanoborohydride.", [["Fmoc-", "CHEMICAL", 97, 102], ["Lys-Leu-Leu-Phe", "CHEMICAL", 102, 117], ["2,3:4,5-di-Oisopropylidene-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose", "CHEMICAL", 207, 270], ["sodium cyanoborohydride", "CHEMICAL", 297, 320], ["Fmoc-Lys-Leu-Leu-Phe", "CHEMICAL", 97, 117], ["2,3:4,5-di-Oisopropylidene-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose", "CHEMICAL", 207, 270], ["sodium cyanoborohydride", "CHEMICAL", 297, 320], ["Fmoc-Lys-Leu-Leu-Phe", "SIMPLE_CHEMICAL", 97, 117], ["2,3:4,5-di-Oisopropylidene-\u03b2-D-arabino-hexos-2-ulo-2,6-pyranose", "SIMPLE_CHEMICAL", 207, 270], ["sodium cyanoborohydride", "SIMPLE_CHEMICAL", 297, 320], ["the reaction", "PROBLEM", 27, 39], ["a Wang resin", "TREATMENT", 83, 95], ["Fmoc-Lys", "TEST", 97, 105], ["di-Oisopropylidene-\u03b2-D-arabino", "TREATMENT", 215, 245], ["pyranose", "TREATMENT", 262, 270], ["sodium cyanoborohydride", "TREATMENT", 297, 320]]], ["The identity of the product was confirmed by high resolution MS. The several side products were isolated and their structures will be discussed.Faculty of Chemistry, University of Wroc\u0142Aw, PolandOur results prove that the synthesis of glycated peptides in the solid phase is feasible.", [["glycated peptides", "GENE_OR_GENE_PRODUCT", 235, 252], ["The several side products", "TREATMENT", 65, 90], ["the synthesis of glycated peptides", "TREATMENT", 218, 252], ["several", "OBSERVATION_MODIFIER", 69, 76]]], ["The lack of homogeneous glycoproteins in sufficient quantities is an ongoing challenge in glycobiology.", [["homogeneous glycoproteins", "PROBLEM", 12, 37], ["homogeneous", "OBSERVATION_MODIFIER", 12, 23], ["glycoproteins", "OBSERVATION", 24, 37], ["sufficient quantities", "OBSERVATION_MODIFIER", 41, 62]]], ["In order to solve this problem researchers have turned to a variety of approaches ranging from mutant eukaryotic strains to the highly demanding total synthesis of glycoproteins.", [["glycoproteins", "PROTEIN", 164, 177], ["mutant eukaryotic strains", "PROBLEM", 95, 120], ["total synthesis of glycoproteins", "TREATMENT", 145, 177]]], ["[1] Using RNase B as a model Nglycoprotein [2] we have searched a path to assemble this enzyme employing a combination of chemical and recombinant methods.", [["RNase B", "GENE_OR_GENE_PRODUCT", 10, 17], ["RNase B", "PROTEIN", 10, 17], ["enzyme", "PROTEIN", 88, 94], ["RNase B", "TREATMENT", 10, 17], ["a model Nglycoprotein", "TREATMENT", 21, 42], ["this enzyme", "TREATMENT", 83, 94], ["chemical and recombinant methods", "TREATMENT", 122, 154]]], ["Native chemical ligation [3] allows the coupling of protein segments of unrestricted size in a chemoselective manner.", [["protein segments", "PROTEIN", 52, 68], ["Native chemical ligation", "TREATMENT", 0, 24], ["chemical", "OBSERVATION_MODIFIER", 7, 15], ["ligation", "OBSERVATION", 16, 24], ["size", "OBSERVATION_MODIFIER", 85, 89]]], ["We have developed solid phase methods to produce the required thioester building blocks 1-25-SR (A) and glycopeptide thioester 26-39-SR (B) containing an N-glycan at Asn34 on a dual linker PEGA resin.", [["1-25-SR", "CHEMICAL", 88, 95], ["glycopeptide thioester 26-39-SR", "CHEMICAL", 104, 135], ["thioester", "CHEMICAL", 62, 71], ["1-25-SR", "CHEMICAL", 88, 95], ["thioester 26-39-SR", "CHEMICAL", 117, 135], ["N", "CHEMICAL", 154, 155], ["1-25-SR", "SIMPLE_CHEMICAL", 88, 95], ["A", "SIMPLE_CHEMICAL", 97, 98], ["glycopeptide thioester 26-39-SR", "SIMPLE_CHEMICAL", 104, 135], ["B", "SIMPLE_CHEMICAL", 137, 138], ["N-glycan", "SIMPLE_CHEMICAL", 154, 162], ["Asn34", "SIMPLE_CHEMICAL", 166, 171], ["Asn34", "PROTEIN", 166, 171], ["solid phase methods", "PROBLEM", 18, 37], ["thioester building blocks", "TREATMENT", 62, 87], ["glycopeptide thioester", "TREATMENT", 104, 126], ["an N-glycan", "TREATMENT", 151, 162], ["a dual linker PEGA resin", "TREATMENT", 175, 199], ["solid phase", "OBSERVATION_MODIFIER", 18, 29]]], ["[4] The remaining segment 40-124 (C) was expressed in E. coli as a fusion protein and released by intein mediated protein cleavage.", [["40-124", "CHEMICAL", 26, 32], ["C", "GENE_OR_GENE_PRODUCT", 34, 35], ["E. coli", "ORGANISM", 54, 61], ["fusion protein", "PROTEIN", 67, 81], ["E. coli", "SPECIES", 54, 61], ["E. coli", "SPECIES", 54, 61], ["E. coli", "PROBLEM", 54, 61], ["a fusion protein", "TREATMENT", 65, 81], ["intein mediated protein cleavage", "TREATMENT", 98, 130], ["segment", "ANATOMY_MODIFIER", 18, 25], ["E. coli", "OBSERVATION", 54, 61]]], ["[5] Sequential coupling of the three RNase segments requires the use of a protective group at the N-terminus of segment B compatible with the oligosaccharide part.", [["N", "CHEMICAL", 98, 99], ["RNase", "GENE_OR_GENE_PRODUCT", 37, 42], ["RNase segments", "PROTEIN", 37, 51], ["N-terminus", "PROTEIN", 98, 108], ["segment B", "PROTEIN", 112, 121], ["Sequential coupling of the three RNase segments", "TREATMENT", 4, 51], ["a protective group", "TREATMENT", 72, 90], ["segment B", "ANATOMY_MODIFIER", 112, 121], ["compatible with", "UNCERTAINTY", 122, 137], ["oligosaccharide part", "OBSERVATION", 142, 162]]], ["Dysfunctional mutations of antitrypsin can result in a loss of elastase inhibitory activity or allow self-aggregation to occur and cause emphysema and cirrhosis, respectively.", [["emphysema", "DISEASE", 137, 146], ["cirrhosis", "DISEASE", 151, 160], ["antitrypsin", "GENE_OR_GENE_PRODUCT", 27, 38], ["elastase", "GENE_OR_GENE_PRODUCT", 63, 71], ["emphysema", "PATHOLOGICAL_FORMATION", 137, 146], ["antitrypsin", "PROTEIN", 27, 38], ["elastase", "PROTEIN", 63, 71], ["Dysfunctional mutations of antitrypsin", "PROBLEM", 0, 38], ["a loss of elastase inhibitory activity", "PROBLEM", 53, 91], ["self-aggregation", "PROBLEM", 101, 117], ["emphysema", "PROBLEM", 137, 146], ["cirrhosis", "PROBLEM", 151, 160], ["emphysema", "OBSERVATION", 137, 146], ["cirrhosis", "OBSERVATION", 151, 160]]], ["Insights of the mechanism of disease provide strategy to cope with the aberrant protein aggregation and may bring potential therapeutic agents.", [["disease", "PROBLEM", 29, 36], ["the aberrant protein aggregation", "PROBLEM", 67, 99], ["therapeutic agents", "TREATMENT", 124, 142]]], ["In the present work, we describe our effort to identify effective anti-protein polymerization ligands by the employment of combinatorial technology.", [["effective anti-protein polymerization ligands", "TREATMENT", 56, 101], ["combinatorial technology", "TREATMENT", 123, 147]]], ["Antitrypsin from human plasma was purified by glutathione Sepharose and Mono Q-Sepharose column chromatography.", [["plasma", "ANATOMY", 23, 29], ["Antitrypsin", "CHEMICAL", 0, 11], ["glutathione", "CHEMICAL", 46, 57], ["glutathione", "CHEMICAL", 46, 57], ["Mono Q", "CHEMICAL", 72, 78], ["Antitrypsin", "GENE_OR_GENE_PRODUCT", 0, 11], ["human", "ORGANISM", 17, 22], ["plasma", "ORGANISM_SUBSTANCE", 23, 29], ["glutathione", "SIMPLE_CHEMICAL", 46, 57], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["Antitrypsin from human plasma", "TEST", 0, 29], ["glutathione Sepharose", "TEST", 46, 67], ["Mono Q-Sepharose column chromatography", "TREATMENT", 72, 110]]], ["Both Ala-scanning and peptide shortening were carried out systematically to explore the structural requirements necessary for binding.", [["Ala-scanning and peptide shortening", "TREATMENT", 5, 40], ["peptide shortening", "OBSERVATION", 22, 40]]], ["Combinatorial chemistry was then employed to conduct the library screening experiments.", [["Combinatorial chemistry", "TEST", 0, 23], ["the library screening experiments", "TEST", 53, 86]]], ["Assessment of peptide binding was achieved through an unique gel electrophoresis assay.", [["Assessment of peptide binding", "PROBLEM", 0, 29], ["an unique gel electrophoresis assay", "TEST", 51, 86]]], ["The structural requirements and the minimal peptide length required for binding were revealed by our systematic approach.", [["the minimal peptide length", "TREATMENT", 32, 58]]], ["This information was critical for the design of combinatorial library and the discovery of antitrypsin binding peptides with much improved affinity and specificity.", [["antitrypsin", "GENE_OR_GENE_PRODUCT", 91, 102], ["combinatorial library", "TREATMENT", 48, 69], ["antitrypsin binding peptides", "TREATMENT", 91, 119]]], ["There is currently no effective cure for Z antitrypsin related cirrhosis and emphysema.", [["cirrhosis", "DISEASE", 63, 72], ["emphysema", "DISEASE", 77, 86], ["Z antitrypsin", "GENE_OR_GENE_PRODUCT", 41, 54], ["emphysema", "PATHOLOGICAL_FORMATION", 77, 86], ["Z antitrypsin", "PROTEIN", 41, 54], ["Z antitrypsin related cirrhosis", "PROBLEM", 41, 72], ["emphysema", "PROBLEM", 77, 86], ["no", "UNCERTAINTY", 19, 21], ["effective", "OBSERVATION_MODIFIER", 22, 31], ["cirrhosis", "OBSERVATION", 63, 72], ["emphysema", "OBSERVATION", 77, 86]]], ["The synthesis and screening of combinatorial libraries offer avenues to increase throughput and ultimately lead to the discovery of inhibitory peptides to the polymerization of pathogenic antitrypsin.", [["antitrypsin", "GENE_OR_GENE_PRODUCT", 188, 199], ["pathogenic antitrypsin", "PROTEIN", 177, 199], ["The synthesis", "TREATMENT", 0, 13], ["combinatorial libraries", "TREATMENT", 31, 54], ["inhibitory peptides", "TREATMENT", 132, 151], ["pathogenic antitrypsin", "PROBLEM", 177, 199], ["pathogenic antitrypsin", "OBSERVATION", 177, 199]]], ["With the rapidly increasing number of biopharmaceuticals in the industrial pipeline the need for efficient and expedient purification procedures is growing ever greater.", [["biopharmaceuticals", "TREATMENT", 38, 56], ["expedient purification procedures", "TREATMENT", 111, 144], ["rapidly", "OBSERVATION_MODIFIER", 9, 16], ["increasing", "OBSERVATION_MODIFIER", 17, 27], ["number", "OBSERVATION_MODIFIER", 28, 34], ["biopharmaceuticals", "OBSERVATION", 38, 56], ["greater", "OBSERVATION_MODIFIER", 161, 168]]], ["Affinity chromatography is one of the most promising technologies in this regard, as it offers very high selectivity and can often replace lengthy and expensive traditional chromatographic procedures.", [["Affinity chromatography", "TEST", 0, 23], ["expensive traditional chromatographic procedures", "TREATMENT", 151, 199]]], ["The use of combinatorial split-and-mix libraries is a powerful tool for discovering new affinity ligands but the technique has been limited by the laborious spectroscopic and chemical analysis needed to identify the binding ligand.", [["combinatorial split", "TREATMENT", 11, 30], ["new affinity ligands", "PROBLEM", 84, 104], ["the laborious spectroscopic", "TEST", 143, 170], ["chemical analysis", "TEST", 175, 192]]], ["We have previously introduced a novel bead encoding technology based on a 3-dimensional image recognition of patterns made by fluorescent particles randomly distributed inside larger beads.", [["fluorescent particles", "PROBLEM", 126, 147], ["larger", "OBSERVATION_MODIFIER", 176, 182], ["beads", "OBSERVATION_MODIFIER", 183, 188]]], ["[1] The beads are read prior to each chemical transformation by an instrument featuring three fluorescence microscopes at a rate of 5,000 beads per hour.", [["beads", "ANATOMY", 8, 13], ["The beads", "TREATMENT", 4, 13]]], ["We here present the development of small peptidomimetic affinity ligands for the human growth hormone (hGH) by the use of this technology.", [["human", "ORGANISM", 81, 86], ["growth hormone", "GENE_OR_GENE_PRODUCT", 87, 101], ["hGH", "GENE_OR_GENE_PRODUCT", 103, 106], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["small peptidomimetic affinity ligands", "TREATMENT", 35, 72], ["this technology", "TREATMENT", 122, 137], ["small", "OBSERVATION_MODIFIER", 35, 40], ["peptidomimetic affinity", "OBSERVATION", 41, 64]]], ["The library was sought enriched prior to synthesis by in silico screening of a virtual combinatorial library using a large number of diverse building blocks.", [["synthesis", "TREATMENT", 41, 50], ["diverse building blocks", "TREATMENT", 133, 156], ["large", "OBSERVATION_MODIFIER", 117, 122], ["diverse", "OBSERVATION_MODIFIER", 133, 140], ["building blocks", "OBSERVATION", 141, 156]]], ["Binding ligands were identified by incubation with fluorescence tagged hGH.", [["hGH", "GENE_OR_GENE_PRODUCT", 71, 74], ["fluorescence tagged hGH", "TEST", 51, 74]]], ["[ The cinnamic acids and their derivatives have been found to possess a variety of biological effects, including antiviral, Antimicrobial, antitumor and antioxidant activity.", [["antitumor", "ANATOMY", 139, 148], ["cinnamic acids", "CHEMICAL", 6, 20], ["cinnamic acids", "CHEMICAL", 6, 20], ["cinnamic acids", "SIMPLE_CHEMICAL", 6, 20], ["antitumor", "CANCER", 139, 148], ["The cinnamic acids", "TREATMENT", 2, 20], ["antiviral", "TREATMENT", 113, 122], ["Antimicrobial", "TREATMENT", 124, 137], ["antitumor", "TREATMENT", 139, 148], ["antioxidant activity", "TREATMENT", 153, 173], ["cinnamic acids", "OBSERVATION", 6, 20]]], ["For example, several hydroxycinnamic acid conjugates with amino acids, isolated from plant sources showed enhanced antioxidant activity.", [["hydroxycinnamic acid", "CHEMICAL", 21, 41], ["amino acids", "CHEMICAL", 58, 69], ["hydroxycinnamic acid", "CHEMICAL", 21, 41], ["amino acids", "CHEMICAL", 58, 69], ["hydroxycinnamic acid", "SIMPLE_CHEMICAL", 21, 41], ["amino acids", "AMINO_ACID", 58, 69], ["several hydroxycinnamic acid conjugates", "TEST", 13, 52], ["amino acids", "TEST", 58, 69], ["enhanced antioxidant activity", "PROBLEM", 106, 135], ["antioxidant activity", "OBSERVATION", 115, 135]]], ["The synthesis of cinnamic acid amides and their opioid activity was also cited in the literature.", [["cinnamic acid amides", "CHEMICAL", 17, 37], ["cinnamic acid amides", "CHEMICAL", 17, 37], ["cinnamic acid amides", "SIMPLE_CHEMICAL", 17, 37], ["opioid", "SIMPLE_CHEMICAL", 48, 54], ["cinnamic acid amides", "TREATMENT", 17, 37], ["opioid activity", "OBSERVATION", 48, 63]]], ["However the synthesis and pharmacological properties of sinapoyl-peptide amides continues to be virtually unexplored.Faculty of Chemistry, University of Wroc\u0142Aw, PolandOn the other hand, the synthesis and opioid activity of analogs of Tyr-MIF-1 has been well documented by us.", [["sinapoyl-peptide amides", "CHEMICAL", 56, 79], ["Tyr", "CHEMICAL", 235, 238], ["sinapoyl-peptide amides", "CHEMICAL", 56, 79], ["Tyr", "CHEMICAL", 235, 238], ["sinapoyl-peptide amides", "SIMPLE_CHEMICAL", 56, 79], ["Tyr-MIF-1", "GENE_OR_GENE_PRODUCT", 235, 244], ["MIF", "PROTEIN", 239, 242], ["the synthesis", "TREATMENT", 8, 21], ["sinapoyl-peptide amides", "TREATMENT", 56, 79], ["the synthesis", "TREATMENT", 187, 200], ["Tyr-MIF", "TEST", 235, 242]]], ["Herein we present a synthesis of a series of sinapoyl -peptide amides where sinapic acid were attached consecutively to both C-and N-end of the Tyr-MIF-1 peptide chain: SA-Pro-Xaa-Gly-NH2; SA-Tyr-Pro-Xaa-Gly-NH2;Faculty of Chemistry, University of Wroc\u0142Aw, PolandPro-Leu-Gly-NH(CH2)nNH-SA SA=sinapic acid; Xaa=Leu, unusual aminoacid; n=2,3Faculty of Chemistry, University of Wroc\u0142Aw, PolandTo obtain the sinapoyl-peptide-amides, both Fmoc-and Boc-based SPPS approach were used.", [["sinapoyl -peptide amides", "CHEMICAL", 45, 69], ["sinapic acid", "CHEMICAL", 76, 88], ["Tyr", "CHEMICAL", 144, 147], ["SA-Pro-Xaa-Gly-NH2", "CHEMICAL", 169, 187], ["SA-Tyr-Pro-Xaa-Gly-NH2", "CHEMICAL", 189, 211], ["Xaa=Leu", "CHEMICAL", 306, 313], ["aminoacid", "CHEMICAL", 323, 332], ["sinapoyl-peptide-amides", "CHEMICAL", 404, 427], ["sinapoyl -peptide amides", "CHEMICAL", 45, 69], ["sinapic acid", "CHEMICAL", 76, 88], ["C", "CHEMICAL", 125, 126], ["Tyr", "CHEMICAL", 144, 147], ["SA-Pro-Xaa-Gly-NH2", "CHEMICAL", 169, 187], ["SA-Tyr-Pro-Xaa-Gly-NH2", "CHEMICAL", 189, 211], ["PolandPro-Leu-Gly-NH(CH2)nNH-SA", "CHEMICAL", 257, 288], ["sinapic acid", "CHEMICAL", 292, 304], ["Xaa=Leu", "CHEMICAL", 306, 313], ["aminoacid", "CHEMICAL", 323, 332], ["sinapoyl-peptide-amides", "CHEMICAL", 404, 427], ["Fmoc", "CHEMICAL", 434, 438], ["sinapoyl -peptide amides", "SIMPLE_CHEMICAL", 45, 69], ["sinapic acid", "SIMPLE_CHEMICAL", 76, 88], ["C", "SIMPLE_CHEMICAL", 125, 126], ["SA-Pro-Xaa-Gly-NH2", "SIMPLE_CHEMICAL", 169, 187], ["SA-Tyr-Pro-Xaa-Gly-NH2", "SIMPLE_CHEMICAL", 189, 211], ["Wroc\u0142Aw", "SIMPLE_CHEMICAL", 248, 255], ["PolandPro-Leu-Gly-NH(CH2)nNH-SA SA=sinapic acid", "SIMPLE_CHEMICAL", 257, 304], ["Xaa=Leu", "SIMPLE_CHEMICAL", 306, 313], ["sinapoyl-peptide-amides", "SIMPLE_CHEMICAL", 404, 427], ["Fmoc", "SIMPLE_CHEMICAL", 434, 438], ["C-and N-end", "PROTEIN", 125, 136], ["MIF", "PROTEIN", 148, 151], ["sinapoyl -peptide amides", "TREATMENT", 45, 69], ["sinapic acid", "TEST", 76, 88], ["C", "TEST", 125, 126], ["the Tyr-MIF", "TEST", 140, 151], ["SA", "TEST", 169, 171], ["Xaa", "TEST", 176, 179], ["SA", "TEST", 189, 191], ["Wroc\u0142Aw", "TEST", 248, 255], ["PolandPro", "TEST", 257, 266], ["nNH", "TEST", 282, 285], ["SA SA", "TEST", 286, 291], ["sinapic acid", "TEST", 292, 304], ["Xaa", "TEST", 306, 309], ["unusual aminoacid", "TEST", 315, 332], ["the sinapoyl-peptide", "TREATMENT", 400, 420], ["both Fmoc", "TREATMENT", 429, 438], ["Boc-based SPPS approach", "TREATMENT", 443, 466]]], ["Analgesic activity was determined by the Randall-Sellitto paw-pressure test.", [["Analgesic activity", "TREATMENT", 0, 18], ["pressure test", "TEST", 62, 75]]], ["The antioxidant effects were examined by DPPH test as well.", [["DPPH", "CHEMICAL", 41, 45], ["DPPH", "CHEMICAL", 41, 45], ["DPPH", "SIMPLE_CHEMICAL", 41, 45], ["DPPH test", "TEST", 41, 50]]], ["Studies to establish the importance of introducing the sinapoyl moiety in the Tyr-MIF-1 molecule for the antioxidant and opioid activities are underway.", [["Tyr", "CHEMICAL", 78, 81], ["sinapoyl", "CHEMICAL", 55, 63], ["Tyr", "CHEMICAL", 78, 81], ["Tyr-MIF-1", "GENE_OR_GENE_PRODUCT", 78, 87], ["opioid", "SIMPLE_CHEMICAL", 121, 127], ["Tyr-MIF-1 molecule", "PROTEIN", 78, 96], ["the sinapoyl moiety", "TREATMENT", 51, 70], ["the Tyr-MIF", "TEST", 74, 85], ["the antioxidant", "TREATMENT", 101, 116], ["opioid activities", "TREATMENT", 121, 138]]], ["Several proteins are involved in the transcription of DNA to mRNA, among which the basic leucine zipper (bZIP) proteins.", [["leucine", "CHEMICAL", 89, 96], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["basic leucine zipper", "GENE_OR_GENE_PRODUCT", 83, 103], ["bZIP", "GENE_OR_GENE_PRODUCT", 105, 109], ["mRNA", "RNA", 61, 65], ["basic leucine zipper (bZIP) proteins", "PROTEIN", 83, 119], ["the basic leucine zipper (bZIP) proteins", "TREATMENT", 79, 119], ["proteins", "OBSERVATION", 8, 16]]], ["These transcription factors bind specific DNA sequences by dimerization and inserting short alpha-helices into the DNA major groove.", [["DNA", "CELLULAR_COMPONENT", 42, 45], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["transcription factors", "PROTEIN", 6, 27], ["DNA sequences", "DNA", 42, 55], ["alpha-helices", "PROTEIN", 92, 105], ["DNA major groove", "PROTEIN", 115, 131], ["specific DNA sequences", "TEST", 33, 55], ["inserting short alpha-helices into the DNA major groove", "TREATMENT", 76, 131], ["groove", "ANATOMY_MODIFIER", 125, 131]]], ["Because the dimerization domain is only required to obtain the correct geometrical positioning of the alpha-helices, we will replace it by a dipodal steroid scaffold with defined stereochemistry.", [["steroid", "CHEMICAL", 149, 156], ["steroid", "CHEMICAL", 149, 156], ["dimerization domain", "PROTEIN", 12, 31], ["alpha-helices", "PROTEIN", 102, 115], ["the dimerization domain", "PROBLEM", 8, 31], ["a dipodal steroid scaffold", "TREATMENT", 139, 165]]], ["Due to orthogonal protecting groups, a unique feature of this scaffold is the possibility to design not only homodimers, but also heterodimers.", [["homodimers", "PROTEIN", 109, 119], ["heterodimers", "PROTEIN", 130, 142], ["this scaffold", "PROBLEM", 57, 70], ["homodimers", "TREATMENT", 109, 119]]], ["Native chemical ligation and Staudinger ligation are both suitable for the construction of these peptide dimers.", [["Native chemical ligation", "TREATMENT", 0, 24], ["Staudinger ligation", "TREATMENT", 29, 48], ["these peptide dimers", "TREATMENT", 91, 111], ["chemical ligation", "OBSERVATION", 7, 24]]], ["Moreover, a combination of solution-and solid-phase chemistry allows for the generation of combinatorial libraries.", [["a combination of solution", "TREATMENT", 10, 35], ["solid-phase chemistry", "TREATMENT", 40, 61], ["combinatorial libraries", "TREATMENT", 91, 114]]], ["The increasing number of antibiotic-resistant bacteria is a global health problem.", [["antibiotic", "TREATMENT", 25, 35], ["resistant bacteria", "PROBLEM", 36, 54], ["a global health problem", "PROBLEM", 58, 81], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["number", "OBSERVATION_MODIFIER", 15, 21], ["antibiotic", "OBSERVATION_MODIFIER", 25, 35], ["resistant", "OBSERVATION_MODIFIER", 36, 45], ["bacteria", "OBSERVATION", 46, 54], ["global", "OBSERVATION_MODIFIER", 60, 66], ["health problem", "OBSERVATION", 67, 81]]], ["Therefore the development of new highly efficient drugs is one of the major tasks of this century.Faculty of Chemistry, University of Wroc\u0142Aw, PolandAs an example of peptides, which inhibit the growth of E. coli, we demonstrate an easy and rapid method for finding peptides with optimized antimicrobial properties.Faculty of Chemistry, University of Wroc\u0142Aw, PolandAs a first step we built a modular construct.", [["E. coli", "ORGANISM", 204, 211], ["E. coli", "SPECIES", 204, 211], ["E. coli", "SPECIES", 204, 211], ["peptides", "PROBLEM", 166, 174], ["E. coli", "PROBLEM", 204, 211], ["optimized antimicrobial properties", "TREATMENT", 279, 313], ["new", "OBSERVATION_MODIFIER", 29, 32], ["highly", "OBSERVATION_MODIFIER", 33, 39], ["efficient", "OBSERVATION_MODIFIER", 40, 49], ["drugs", "OBSERVATION", 50, 55], ["modular construct", "OBSERVATION", 392, 409]]], ["This construct consists of a constant cationic and a variable module.", [["a constant cationic", "PROBLEM", 27, 46], ["a variable module", "PROBLEM", 51, 68], ["constant", "OBSERVATION_MODIFIER", 29, 37], ["cationic", "OBSERVATION_MODIFIER", 38, 46], ["variable", "OBSERVATION_MODIFIER", 53, 61], ["module", "OBSERVATION", 62, 68]]], ["The cationic module was choosen to achieve cellpenetrating properties.", [["The cationic module", "TREATMENT", 0, 19], ["cationic module", "OBSERVATION", 4, 19]]], ["The variable module was expected to act as the virtual active part of the peptide.", [["variable", "OBSERVATION_MODIFIER", 4, 12], ["module", "OBSERVATION", 13, 19]]], ["To increase the proteolytic stability of the peptide we synthesized them in cyclic form.Faculty of Chemistry, University of Wroc\u0142Aw, PolandIn the first step we used the combinatorial approach to screen approximately 64.000.000 peptide sequences in the variable region in order to find highly active peptides against E. coli.Faculty of Chemistry, University of Wroc\u0142Aw, PolandTo optimize the identified sequence, we substituted all amino acids of the sequence with other amino acids and building blocks.", [["amino acids", "CHEMICAL", 431, 442], ["amino acids", "CHEMICAL", 470, 481], ["amino acids", "CHEMICAL", 431, 442], ["amino acids", "CHEMICAL", 470, 481], ["E. coli", "ORGANISM", 316, 323], ["amino acids", "AMINO_ACID", 431, 442], ["amino acids", "AMINO_ACID", 470, 481], ["E. coli", "SPECIES", 316, 323], ["E. coli", "SPECIES", 316, 323], ["the proteolytic stability of the peptide", "TREATMENT", 12, 52], ["the combinatorial approach", "TREATMENT", 165, 191], ["E. coli", "PROBLEM", 316, 323], ["all amino acids", "TREATMENT", 427, 442], ["other amino acids", "TREATMENT", 464, 481], ["building blocks", "TREATMENT", 486, 501], ["coli", "OBSERVATION", 319, 323]]], ["Additionally, in order to increase stability we modified the bridging.", [["stability", "OBSERVATION_MODIFIER", 35, 44], ["bridging", "OBSERVATION_MODIFIER", 61, 69]]], ["In this way we were able to uncover peptides with high antimicrobial activity as well as proteolytic stability and reasonable solubility.Faculty of Chemistry, University of Wroc\u0142Aw, PolandA series of melanocortin active core tetrapeptide HFRW nonpeptide imitations has been prepared using a combination of solution and solid phase synthesis.Faculty of Chemistry, University of Wroc\u0142Aw, PolandMost of them included residue of 3-(1-imidazolyl) propylamine or histamine as substitutes of histidine.", [["3-(1-imidazolyl) propylamine", "CHEMICAL", 425, 453], ["histamine", "CHEMICAL", 457, 466], ["histidine", "CHEMICAL", 485, 494], ["3-(1-imidazolyl) propylamine", "CHEMICAL", 425, 453], ["histamine", "CHEMICAL", 457, 466], ["histidine", "CHEMICAL", 485, 494], ["melanocortin", "GENE_OR_GENE_PRODUCT", 200, 212], ["3-(1-imidazolyl) propylamine", "SIMPLE_CHEMICAL", 425, 453], ["histamine", "SIMPLE_CHEMICAL", 457, 466], ["histidine", "AMINO_ACID", 485, 494], ["high antimicrobial activity", "TREATMENT", 50, 77], ["proteolytic stability", "TREATMENT", 89, 110], ["melanocortin active core tetrapeptide HFRW nonpeptide imitations", "TREATMENT", 200, 264], ["a combination of solution and solid phase synthesis", "TREATMENT", 289, 340], ["imidazolyl", "TREATMENT", 430, 440], ["propylamine", "TREATMENT", 442, 453], ["histamine", "TREATMENT", 457, 466], ["histidine", "TREATMENT", 485, 494]]], ["Phenylalanine residue, which is included in melanocortins was replaced by residues of derivatives of 4, 4'-disubstituted isopropylidenedicyclohexane, 4, 4'-disubstituted bicyclohexane, 1,4-disubstituted cyclohexane, 1,5-disubstituted cyclooctane, and 1,2-, 1,3-or 1,4disubstituted benzenes.", [["Phenylalanine", "CHEMICAL", 0, 13], ["4, 4'-disubstituted isopropylidenedicyclohexane", "CHEMICAL", 101, 148], ["4, 4'-disubstituted bicyclohexane", "CHEMICAL", 150, 183], ["1,4-disubstituted cyclohexane", "CHEMICAL", 185, 214], ["1,5-disubstituted cyclooctane", "CHEMICAL", 216, 245], ["1,2-, 1,3-or 1,4disubstituted benzenes", "CHEMICAL", 251, 289], ["Phenylalanine", "CHEMICAL", 0, 13], ["melanocortins", "CHEMICAL", 44, 57], ["4, 4'-disubstituted isopropylidenedicyclohexane", "CHEMICAL", 101, 148], ["4, 4'-disubstituted bicyclohexane", "CHEMICAL", 150, 183], ["1,4-disubstituted cyclohexane", "CHEMICAL", 185, 214], ["1,5-disubstituted cyclooctane", "CHEMICAL", 216, 245], ["1,2-, 1,3-or 1,4disubstituted benzenes", "CHEMICAL", 251, 289], ["Phenylalanine", "AMINO_ACID", 0, 13], ["melanocortins", "SIMPLE_CHEMICAL", 44, 57], ["4, 4'-disubstituted isopropylidenedicyclohexane, 4, 4'-disubstituted bicyclohexane", "SIMPLE_CHEMICAL", 101, 183], ["1,4-disubstituted cyclohexane", "SIMPLE_CHEMICAL", 185, 214], ["1,5-disubstituted cyclooctane", "SIMPLE_CHEMICAL", 216, 245], ["1,2-, 1,3-or 1,4disubstituted benzenes", "SIMPLE_CHEMICAL", 251, 289], ["Phenylalanine residue", "TREATMENT", 0, 21], ["melanocortins", "TREATMENT", 44, 57], ["derivatives", "TREATMENT", 86, 97], ["disubstituted isopropylidenedicyclohexane", "TREATMENT", 107, 148], ["disubstituted cyclohexane", "TREATMENT", 189, 214]]], ["Instead of arginine, residues of oligomethylene diamines, 2-butyl-2-ethyl-1,5-pentanediamine, 4,4'-methylene-bis(cyclohexylamine), and 4,4'-diaminodiphenylmethane were introduced.", [["arginine", "CHEMICAL", 11, 19], ["oligomethylene diamines", "CHEMICAL", 33, 56], ["2-butyl-2-ethyl-1,5-pentanediamine", "CHEMICAL", 58, 92], ["4,4'-methylene-bis", "CHEMICAL", 94, 112], ["cyclohexylamine", "CHEMICAL", 113, 128], ["4,4'-diaminodiphenylmethane", "CHEMICAL", 135, 162], ["arginine", "CHEMICAL", 11, 19], ["oligomethylene diamines", "CHEMICAL", 33, 56], ["2-butyl-2-ethyl-1,5-pentanediamine", "CHEMICAL", 58, 92], ["4,4'-methylene-bis(cyclohexylamine)", "CHEMICAL", 94, 129], ["4,4'-diaminodiphenylmethane", "CHEMICAL", 135, 162], ["arginine", "AMINO_ACID", 11, 19], ["oligomethylene diamines", "SIMPLE_CHEMICAL", 33, 56], ["2-butyl-2-ethyl-1,5-pentanediamine", "SIMPLE_CHEMICAL", 58, 92], ["4,4'-methylene-bis(cyclohexylamine)", "SIMPLE_CHEMICAL", 94, 129], ["4,4'-diaminodiphenylmethane", "SIMPLE_CHEMICAL", 135, 162], ["arginine", "TREATMENT", 11, 19], ["oligomethylene diamines", "TREATMENT", 33, 56], ["ethyl", "TREATMENT", 68, 73], ["pentanediamine", "TREATMENT", 78, 92], ["methylene-bis(cyclohexylamine)", "TREATMENT", 99, 129], ["diaminodiphenylmethane", "TREATMENT", 140, 162]]], ["2-Naphtyloxyacetyl-, (4-1H-indol-3-yl)-butyryl-, 2-phenyl-ethanesulfonyl-and naphthalene-2-sulfonyl-groups served as replacement of tryptophan residue.Faculty of Chemistry, University of Wroc\u0142Aw, PolandTested on binding assay on melanocortin receptors, active core imitations exhibited a micromolar affinity to them.", [["2-Naphtyloxyacetyl-, (4-1H-indol-3-yl)-butyryl-, 2-phenyl-ethanesulfonyl-and naphthalene-2-sulfonyl", "CHEMICAL", 0, 99], ["tryptophan", "CHEMICAL", 132, 142], ["2-Naphtyloxyacetyl-, (4-1H-indol-3-yl)-butyryl-, 2-phenyl-ethanesulfonyl-and naphthalene-2-sulfonyl", "CHEMICAL", 0, 99], ["tryptophan", "CHEMICAL", 132, 142], ["2-Naphtyloxyacetyl-, (4-1H-indol-3-yl)-butyryl-, 2-phenyl-ethanesulfonyl-and naphthalene-2-sulfonyl-groups", "SIMPLE_CHEMICAL", 0, 106], ["tryptophan", "AMINO_ACID", 132, 142], ["melanocortin receptors", "GENE_OR_GENE_PRODUCT", 229, 251], ["melanocortin receptors", "PROTEIN", 229, 251], ["Naphtyloxyacetyl-", "TREATMENT", 2, 19], ["indol", "TREATMENT", 27, 32], ["butyryl", "TREATMENT", 39, 46], ["phenyl", "TREATMENT", 51, 57], ["ethanesulfonyl", "TREATMENT", 58, 72], ["naphthalene", "TREATMENT", 77, 88], ["sulfonyl-groups", "TREATMENT", 91, 106], ["replacement of tryptophan residue", "TREATMENT", 117, 150], ["melanocortin receptors", "TREATMENT", 229, 251], ["active core imitations", "PROBLEM", 253, 275]]], ["Isopropylidenedicyclohexane and bicyclohexane derivatives showed about 10 fold higher affinity compared with corresponding derivatives of cyclohexane, cyclooctane or disubstituted benzene.", [["Isopropylidenedicyclohexane", "CHEMICAL", 0, 27], ["bicyclohexane", "CHEMICAL", 32, 45], ["cyclohexane", "CHEMICAL", 138, 149], ["cyclooctane", "CHEMICAL", 151, 162], ["disubstituted benzene", "CHEMICAL", 166, 187], ["Isopropylidenedicyclohexane", "CHEMICAL", 0, 27], ["bicyclohexane", "CHEMICAL", 32, 45], ["cyclohexane", "CHEMICAL", 138, 149], ["cyclooctane", "CHEMICAL", 151, 162], ["benzene", "CHEMICAL", 180, 187], ["Isopropylidenedicyclohexane", "SIMPLE_CHEMICAL", 0, 27], ["bicyclohexane derivatives", "SIMPLE_CHEMICAL", 32, 57], ["cyclohexane", "SIMPLE_CHEMICAL", 138, 149], ["cyclooctane", "SIMPLE_CHEMICAL", 151, 162], ["disubstituted benzene", "SIMPLE_CHEMICAL", 166, 187], ["Isopropylidenedicyclohexane", "TREATMENT", 0, 27], ["bicyclohexane derivatives", "TREATMENT", 32, 57], ["10 fold higher affinity", "PROBLEM", 71, 94], ["cyclohexane", "TREATMENT", 138, 149], ["cyclooctane", "TREATMENT", 151, 162], ["disubstituted benzene", "PROBLEM", 166, 187], ["disubstituted benzene", "OBSERVATION", 166, 187]]], ["Obestatin is a novel endogenous ghrelin-associate peptide, which is involved in the regulation of food intake and weight gain.", [["Obestatin", "CHEMICAL", 0, 9], ["weight gain", "DISEASE", 114, 125], ["Obestatin", "CHEMICAL", 0, 9], ["Obestatin", "SIMPLE_CHEMICAL", 0, 9], ["ghrelin", "GENE_OR_GENE_PRODUCT", 32, 39], ["Obestatin", "TREATMENT", 0, 9], ["weight gain", "PROBLEM", 114, 125]]], ["It was shown to be anorexigenic, able to decrease food intake, gastric emptying and jejunal motility.", [["gastric", "ANATOMY", 63, 70], ["jejunal", "ANATOMY", 84, 91], ["gastric", "ORGANISM_SUBDIVISION", 63, 70], ["jejunal", "MULTI-TISSUE_STRUCTURE", 84, 91], ["anorexigenic", "PROBLEM", 19, 31], ["gastric emptying", "TREATMENT", 63, 79], ["anorexigenic", "OBSERVATION", 19, 31], ["gastric", "ANATOMY", 63, 70], ["emptying", "OBSERVATION", 71, 79], ["jejunal motility", "OBSERVATION", 84, 100]]], ["Although obestatin and ghrelin originate from a common prepropeptide of 117 residues, they are reported to exert opposing physiological roles, by binding distinct receptors belonging to the subgroup of type A GPCRs [1] .", [["obestatin", "CHEMICAL", 9, 18], ["obestatin", "GENE_OR_GENE_PRODUCT", 9, 18], ["ghrelin", "GENE_OR_GENE_PRODUCT", 23, 30], ["type A GPCRs", "GENE_OR_GENE_PRODUCT", 202, 214], ["type A GPCRs", "PROTEIN", 202, 214], ["obestatin", "PROBLEM", 9, 18]]], ["Obestatin was found to be the natural ligand of the orphan GPR39 receptor, a GPCR, expressed in jejunum, duodenum, stomach, pituitary, ileum, liver and hypothalamus.", [["jejunum", "ANATOMY", 96, 103], ["duodenum", "ANATOMY", 105, 113], ["stomach", "ANATOMY", 115, 122], ["pituitary", "ANATOMY", 124, 133], ["ileum", "ANATOMY", 135, 140], ["liver", "ANATOMY", 142, 147], ["hypothalamus", "ANATOMY", 152, 164], ["Obestatin", "CHEMICAL", 0, 9], ["Obestatin", "CHEMICAL", 0, 9], ["Obestatin", "SIMPLE_CHEMICAL", 0, 9], ["GPR39 receptor", "GENE_OR_GENE_PRODUCT", 59, 73], ["GPCR", "GENE_OR_GENE_PRODUCT", 77, 81], ["jejunum", "MULTI-TISSUE_STRUCTURE", 96, 103], ["duodenum", "MULTI-TISSUE_STRUCTURE", 105, 113], ["stomach", "ORGAN", 115, 122], ["pituitary", "MULTI-TISSUE_STRUCTURE", 124, 133], ["ileum", "MULTI-TISSUE_STRUCTURE", 135, 140], ["liver", "ORGAN", 142, 147], ["hypothalamus", "ORGAN", 152, 164], ["orphan GPR39 receptor", "PROTEIN", 52, 73], ["GPCR", "PROTEIN", 77, 81], ["Obestatin", "TREATMENT", 0, 9], ["a GPCR", "TEST", 75, 81], ["expressed in jejunum, duodenum, stomach, pituitary, ileum, liver and hypothalamus", "PROBLEM", 83, 164], ["jejunum", "ANATOMY", 96, 103], ["duodenum", "ANATOMY", 105, 113], ["stomach", "ANATOMY", 115, 122], ["pituitary", "ANATOMY", 124, 133], ["ileum", "ANATOMY", 135, 140], ["liver", "ANATOMY", 142, 147], ["hypothalamus", "ANATOMY", 152, 164]]], ["As many other peptides involved in the obesity process, it is a new and interesting drug target for the discovery of new anti-obesity molecules.", [["obesity", "DISEASE", 39, 46], ["the obesity process", "PROBLEM", 35, 54], ["new anti-obesity molecules", "PROBLEM", 117, 143], ["obesity", "OBSERVATION", 39, 46], ["new", "OBSERVATION_MODIFIER", 117, 120], ["anti-obesity molecules", "OBSERVATION", 121, 143]]], ["In particular, the first step for the design of new molecules with potential improved anti-obesity activity, is the elucidation of the obestatin conformational features.", [["obestatin", "GENE_OR_GENE_PRODUCT", 135, 144], ["the obestatin conformational features", "PROBLEM", 131, 168], ["improved", "OBSERVATION_MODIFIER", 77, 85], ["anti-obesity activity", "OBSERVATION", 86, 107]]], ["Here, we present the synthesis and the conformational analysis by NMR and CD spectroscopies of obestatin and its related 13-mer C-terminal sub-fragment, in aqueous solution and in membrane mimicking environment.", [["membrane", "ANATOMY", 180, 188], ["obestatin", "CHEMICAL", 95, 104], ["C", "CHEMICAL", 128, 129], ["obestatin", "GENE_OR_GENE_PRODUCT", 95, 104], ["membrane", "CELLULAR_COMPONENT", 180, 188], ["13-mer C-terminal sub-fragment", "DNA", 121, 151], ["the conformational analysis", "TEST", 35, 62], ["NMR", "TEST", 66, 69], ["CD spectroscopies", "TEST", 74, 91], ["obestatin", "TREATMENT", 95, 104], ["terminal sub-fragment", "PROBLEM", 130, 151], ["aqueous solution", "TREATMENT", 156, 172], ["terminal", "OBSERVATION_MODIFIER", 130, 138], ["sub", "OBSERVATION_MODIFIER", 139, 142], ["fragment", "OBSERVATION", 143, 151]]], ["The data outline the obestatin C-terminal portion as the region characterized by significant conformational features potentially opened to interesting future developments.M151[ A total of 50 isolates of Rhizobium were collected from root nodules of Medicago sativa and Melilotus officialis plants in different regions of isfahan province .all of isolates on TY medium formed white ,slimy colonies with smooth margins and their inoculation on to roots of young alfalfa plants produced spindly nodules . the nodules developed with some of the isolates were big and pinkish ,although the rest of isolates produced small and white nodules .the speed of nodulation for all the isolates was almost similar and the related nodules were appeared within two weeks . the production of brown pigments on aged colonies of some isolates on TY or TY supplemented with L_tyrosine and copper sulfate revealed that these isolates of S. meliloti are melanin-producing rhizobia.based on the motility and sensitivity to antibiotics tests ,all of the isolates formed a reasonably homogenous group .however a few of them were able to produce an anti-microbial compound which was found to inhibit a number of isolates of S. meliloti .the compound did not suppress the growth of other bacteria . partial purification and spectrophotometery of the compound suggested that it likely belong to the antimicrobial polypeptides .considering on their physiological and biochemical properties ,none of the isolates were selected as a superior and competitive strain ,although based on nodulation efficiency , melanin and antimicrobial compounds production capability the isolate S. meliloti SM2 and SA23 were nominated to investigate in details.", [["root nodules", "ANATOMY", 233, 245], ["colonies", "ANATOMY", 388, 396], ["roots", "ANATOMY", 445, 450], ["nodules", "ANATOMY", 492, 499], ["nodules", "ANATOMY", 506, 513], ["white nodules", "ANATOMY", 621, 634], ["nodules", "ANATOMY", 716, 723], ["colonies", "ANATOMY", 798, 806], ["TY", "CHEMICAL", 827, 829], ["L_tyrosine", "CHEMICAL", 854, 864], ["copper", "CHEMICAL", 869, 875], ["melanin", "CHEMICAL", 932, 939], ["melanin", "CHEMICAL", 1577, 1584], ["C", "CHEMICAL", 31, 32], ["L_tyrosine", "CHEMICAL", 854, 864], ["copper sulfate", "CHEMICAL", 869, 883], ["obestatin", "GENE_OR_GENE_PRODUCT", 21, 30], ["root nodules", "MULTI-TISSUE_STRUCTURE", 233, 245], ["Medicago sativa", "ORGANISM", 249, 264], ["Melilotus officialis plants", "ORGANISM", 269, 296], ["smooth margins", "MULTI-TISSUE_STRUCTURE", 402, 416], ["roots", "ORGAN", 445, 450], ["spindly nodules", "CANCER", 484, 499], ["nodules", "CANCER", 506, 513], ["nodules", "PATHOLOGICAL_FORMATION", 627, 634], ["nodules", "CANCER", 716, 723], ["L_tyrosine", "SIMPLE_CHEMICAL", 854, 864], ["copper sulfate", "SIMPLE_CHEMICAL", 869, 883], ["S. meliloti", "ORGANISM", 916, 927], ["melanin", "SIMPLE_CHEMICAL", 932, 939], ["S. meliloti", "ORGANISM", 1198, 1209], ["melanin", "SIMPLE_CHEMICAL", 1577, 1584], ["S. meliloti SM2", "ORGANISM", 1647, 1662], ["obestatin C-terminal portion", "PROTEIN", 21, 49], ["Medicago sativa", "SPECIES", 249, 264], ["Melilotus officialis", "SPECIES", 269, 289], ["S. meliloti", "SPECIES", 916, 927], ["S. meliloti", "SPECIES", 1198, 1209], ["S. meliloti", "SPECIES", 1647, 1658], ["Medicago sativa", "SPECIES", 249, 264], ["Melilotus officialis", "SPECIES", 269, 289], ["alfalfa", "SPECIES", 460, 467], ["S. meliloti", "SPECIES", 916, 927], ["S. meliloti", "SPECIES", 1198, 1209], ["S. meliloti", "SPECIES", 1647, 1658], ["The data", "TEST", 0, 8], ["significant conformational features", "PROBLEM", 81, 116], ["Rhizobium", "PROBLEM", 203, 212], ["root nodules", "PROBLEM", 233, 245], ["Medicago sativa", "TREATMENT", 249, 264], ["Melilotus officialis plants", "TREATMENT", 269, 296], ["TY medium formed white ,slimy colonies", "PROBLEM", 358, 396], ["smooth margins", "PROBLEM", 402, 416], ["their inoculation", "PROBLEM", 421, 438], ["spindly nodules", "PROBLEM", 484, 499], ["the nodules", "PROBLEM", 502, 513], ["the isolates", "PROBLEM", 537, 549], ["small and white nodules", "PROBLEM", 611, 634], ["all the isolates", "PROBLEM", 664, 680], ["the related nodules", "PROBLEM", 704, 723], ["brown pigments", "PROBLEM", 775, 789], ["some isolates", "PROBLEM", 810, 823], ["L_tyrosine", "TREATMENT", 854, 864], ["copper sulfate", "TREATMENT", 869, 883], ["S. meliloti", "PROBLEM", 916, 927], ["rhizobia", "PROBLEM", 950, 958], ["antibiotics tests", "TEST", 1000, 1017], ["the isolates", "TEST", 1026, 1038], ["an anti-microbial compound", "PROBLEM", 1120, 1146], ["S. meliloti", "PROBLEM", 1198, 1209], ["other bacteria", "PROBLEM", 1255, 1269], ["partial purification", "TEST", 1272, 1292], ["the antimicrobial polypeptides", "TREATMENT", 1367, 1397], ["the isolates", "TEST", 1470, 1482], ["a superior and competitive strain", "PROBLEM", 1500, 1533], ["nodulation efficiency", "PROBLEM", 1553, 1574], ["melanin", "PROBLEM", 1577, 1584], ["antimicrobial compounds", "TREATMENT", 1589, 1612], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["root", "ANATOMY", 233, 237], ["nodules", "OBSERVATION", 238, 245], ["Medicago sativa", "OBSERVATION", 249, 264], ["smooth", "OBSERVATION_MODIFIER", 402, 408], ["margins", "OBSERVATION_MODIFIER", 409, 416], ["inoculation", "OBSERVATION_MODIFIER", 427, 438], ["spindly", "OBSERVATION_MODIFIER", 484, 491], ["nodules", "OBSERVATION", 492, 499], ["nodules", "OBSERVATION", 506, 513], ["big", "OBSERVATION_MODIFIER", 555, 558], ["pinkish", "OBSERVATION_MODIFIER", 563, 570], ["small", "OBSERVATION_MODIFIER", 611, 616], ["white", "OBSERVATION_MODIFIER", 621, 626], ["nodules", "OBSERVATION", 627, 634], ["nodulation", "OBSERVATION", 649, 659], ["nodules", "OBSERVATION", 716, 723], ["brown pigments", "OBSERVATION", 775, 789], ["rhizobia", "OBSERVATION", 950, 958], ["bacteria", "OBSERVATION", 1261, 1269], ["nodulation efficiency", "OBSERVATION", 1553, 1574]]], ["Cyclotides are a fascinating family of plant-derived peptides characterized by their head-to-tail cyclized backbone and knotted arrangement of three disulfide bonds.", [["head", "ANATOMY", 85, 89], ["Cyclotides", "CHEMICAL", 0, 10], ["Cyclotides", "CHEMICAL", 0, 10], ["disulfide", "CHEMICAL", 149, 158], ["Cyclotides", "SIMPLE_CHEMICAL", 0, 10], ["Cyclotides", "TREATMENT", 0, 10], ["disulfide bonds", "OBSERVATION", 149, 164]]], ["This conserved structural architecture, termed the cyclic cystine knot, is responsible for their exceptional resistance to thermal, chemical and enzymatic degradation.", [["cystine", "CHEMICAL", 58, 65], ["cyclic cystine", "CHEMICAL", 51, 65], ["the cyclic cystine knot", "PROBLEM", 47, 70], ["structural architecture", "OBSERVATION", 15, 38], ["cyclic cystine knot", "OBSERVATION", 51, 70], ["responsible for", "UNCERTAINTY", 75, 90], ["exceptional", "OBSERVATION_MODIFIER", 97, 108], ["resistance", "OBSERVATION", 109, 119], ["enzymatic degradation", "OBSERVATION", 145, 166]]], ["Cyclotides have a variety of biological activities but their insecticidal activities suggest that their primary function is in plant defense.", [["Cyclotides", "CHEMICAL", 0, 10], ["Cyclotides", "CHEMICAL", 0, 10], ["Cyclotides", "SIMPLE_CHEMICAL", 0, 10], ["Cyclotides", "TREATMENT", 0, 10]]], ["In this study we determined the cyclotide content of the sweet violet Viola odorata, a member of the Violaceae family.", [["cyclotide", "CHEMICAL", 32, 41], ["cyclotide", "CHEMICAL", 32, 41], ["cyclotide", "SIMPLE_CHEMICAL", 32, 41], ["Viola odorata", "ORGANISM", 70, 83], ["Violaceae", "GENE_OR_GENE_PRODUCT", 101, 110], ["Viola odorata", "SPECIES", 70, 83], ["sweet violet Viola odorata", "SPECIES", 57, 83], ["this study", "TEST", 3, 13], ["sweet violet", "OBSERVATION", 57, 69]]], ["We identified 30 cyclotides from the aerial parts and roots of this plant, 13 of which are novel sequences.", [["aerial parts", "ANATOMY", 37, 49], ["roots", "ANATOMY", 54, 59], ["cyclotides", "CHEMICAL", 17, 27], ["cyclotides", "CHEMICAL", 17, 27], ["cyclotides", "GENE_OR_GENE_PRODUCT", 17, 27], ["aerial parts", "MULTI-TISSUE_STRUCTURE", 37, 49], ["roots", "ORGAN", 54, 59], ["30 cyclotides", "TREATMENT", 14, 27], ["30 cyclotides", "OBSERVATION_MODIFIER", 14, 27], ["aerial", "ANATOMY_MODIFIER", 37, 43], ["parts", "ANATOMY_MODIFIER", 44, 49], ["roots", "ANATOMY_MODIFIER", 54, 59]]], ["The new sequences provide information about the natural diversity of cyclotides and the role of particular residues in defining structure and function.", [["cyclotides", "CHEMICAL", 69, 79], ["cyclotides", "SIMPLE_CHEMICAL", 69, 79], ["cyclotides", "TREATMENT", 69, 79]]], ["As many of the biological activities of cyclotides appear to be associated with membrane interactions, we used hemolytic activity as a marker of bioactivity for a selection of the new cyclotides.", [["membrane", "ANATOMY", 80, 88], ["cyclotides", "CHEMICAL", 40, 50], ["hemolytic", "DISEASE", 111, 120], ["cyclotides", "CHEMICAL", 40, 50], ["cyclotides", "CHEMICAL", 184, 194], ["cyclotides", "SIMPLE_CHEMICAL", 40, 50], ["membrane", "CELLULAR_COMPONENT", 80, 88], ["cyclotides", "SIMPLE_CHEMICAL", 184, 194], ["cyclotides", "TREATMENT", 40, 50], ["membrane interactions", "PROBLEM", 80, 101], ["hemolytic activity", "TREATMENT", 111, 129], ["a marker of bioactivity", "TREATMENT", 133, 156], ["the new cyclotides", "TREATMENT", 176, 194]]], ["The new cyclotides were tested for their ability to resist proteolysis by a range of enzymes and, in common with other cyclotides, were completely resistant to trypsin, pepsin and thermolysin.", [["cyclotides", "CHEMICAL", 8, 18], ["cyclotides", "CHEMICAL", 8, 18], ["cyclotides", "CHEMICAL", 119, 129], ["cyclotides", "SIMPLE_CHEMICAL", 8, 18], ["cyclotides", "SIMPLE_CHEMICAL", 119, 129], ["trypsin", "GENE_OR_GENE_PRODUCT", 160, 167], ["pepsin", "GENE_OR_GENE_PRODUCT", 169, 175], ["thermolysin", "GENE_OR_GENE_PRODUCT", 180, 191], ["enzymes", "PROTEIN", 85, 92], ["trypsin", "PROTEIN", 160, 167], ["pepsin", "PROTEIN", 169, 175], ["thermolysin", "PROTEIN", 180, 191], ["The new cyclotides", "TREATMENT", 0, 18], ["a range of enzymes", "TEST", 74, 92], ["other cyclotides", "TREATMENT", 113, 129], ["trypsin", "TREATMENT", 160, 167], ["pepsin", "TREATMENT", 169, 175], ["thermolysin", "TREATMENT", 180, 191], ["new", "OBSERVATION_MODIFIER", 4, 7], ["cyclotides", "OBSERVATION", 8, 18]]], ["The results show that while biological activity varies with the sequence the proteolytic stability of the framework does not, and appears to be an inherent feature of the cyclotide framework.", [["cyclotide", "CHEMICAL", 171, 180], ["cyclotide", "SIMPLE_CHEMICAL", 171, 180]]], ["The structure of one of the new cyclotides, cycloviolacin O14, was determined and shown to contain the cyclic cystine knot motif.", [["cyclotides", "CHEMICAL", 32, 42], ["cycloviolacin O14", "CHEMICAL", 44, 61], ["cystine", "CHEMICAL", 110, 117], ["cyclotides", "CHEMICAL", 32, 42], ["cycloviolacin O14", "CHEMICAL", 44, 61], ["cyclic cystine", "CHEMICAL", 103, 117], ["cyclotides", "SIMPLE_CHEMICAL", 32, 42], ["cycloviolacin O14", "SIMPLE_CHEMICAL", 44, 61], ["cyclic cystine knot motif", "PROTEIN", 103, 128], ["the new cyclotides", "TREATMENT", 24, 42], ["cycloviolacin O14", "TREATMENT", 44, 61], ["the cyclic cystine knot motif", "TREATMENT", 99, 128], ["new", "OBSERVATION_MODIFIER", 28, 31], ["cyclotides", "OBSERVATION", 32, 42], ["cyclic cystine knot", "OBSERVATION", 103, 122]]], ["This study confirms that cyclotides may be regarded as a natural combinatorial template that displays a variety of peptide epitopes most likely targeted to a range of plant pests and pathogens.", [["cyclotides", "CHEMICAL", 25, 35], ["cyclotides", "CHEMICAL", 25, 35], ["cyclotides", "SIMPLE_CHEMICAL", 25, 35], ["This study", "TEST", 0, 10], ["cyclotides", "TREATMENT", 25, 35], ["a natural combinatorial template", "TREATMENT", 55, 87], ["a variety of peptide epitopes", "PROBLEM", 102, 131], ["pathogens", "PROBLEM", 183, 192]]], ["Furthermore, the inherent stability of the framework makes it an excellent scaffold for protein engineering applications.", [["protein engineering applications", "TREATMENT", 88, 120], ["stability", "OBSERVATION_MODIFIER", 26, 35]]], ["Warfarin is the most widely prescribed anticoagulant drug for the prevention and treatment of arterial and venous thromboembolic disorders.Because of large interpatient variability in the dose-anticoagulant effect relationship and a narrow therapeutic index careful dosage adjustment based on INR is essential.", [["arterial", "ANATOMY", 94, 102], ["venous", "ANATOMY", 107, 113], ["Warfarin", "CHEMICAL", 0, 8], ["arterial and venous thromboembolic disorders", "DISEASE", 94, 138], ["Warfarin", "CHEMICAL", 0, 8], ["Warfarin", "SIMPLE_CHEMICAL", 0, 8], ["arterial", "MULTI-TISSUE_STRUCTURE", 94, 102], ["venous", "MULTI-TISSUE_STRUCTURE", 107, 113], ["INR", "PROTEIN", 293, 296], ["Warfarin", "TREATMENT", 0, 8], ["anticoagulant drug", "TREATMENT", 39, 57], ["arterial and venous thromboembolic disorders", "PROBLEM", 94, 138], ["large interpatient variability", "PROBLEM", 150, 180], ["a narrow therapeutic index careful dosage adjustment", "TREATMENT", 231, 283], ["INR", "TEST", 293, 296], ["most widely", "OBSERVATION_MODIFIER", 16, 27], ["arterial", "ANATOMY", 94, 102], ["venous", "ANATOMY", 107, 113], ["thromboembolic", "OBSERVATION", 114, 128], ["large", "OBSERVATION_MODIFIER", 150, 155], ["interpatient", "OBSERVATION_MODIFIER", 156, 168], ["variability", "OBSERVATION_MODIFIER", 169, 180]]], ["Warfarin is available as a racemic mixture of two enantiomers,(S)-and (R)-warfarin.", [["Warfarin", "CHEMICAL", 0, 8], ["warfarin", "CHEMICAL", 74, 82], ["Warfarin", "CHEMICAL", 0, 8], ["(S)-and (R)-warfarin", "CHEMICAL", 62, 82], ["Warfarin", "SIMPLE_CHEMICAL", 0, 8], ["(S)", "SIMPLE_CHEMICAL", 62, 65], ["(R)-warfarin", "SIMPLE_CHEMICAL", 70, 82], ["Warfarin", "TREATMENT", 0, 8], ["warfarin", "TREATMENT", 74, 82]]], ["In contrast to (R)-warfarin, which is metabolized by multiple cytochrome P450s(CYPs), Including CYP1A2 and CYP3A4,(S)-warfarin, is predominantly metabolized to 7-hydroxywarfarin by polymorphic CYP2C9.", [["warfarin", "CHEMICAL", 19, 27], ["warfarin", "CHEMICAL", 118, 126], ["7-hydroxywarfarin", "CHEMICAL", 160, 177], ["(R)-warfarin", "CHEMICAL", 15, 27], ["(S)-warfarin", "CHEMICAL", 114, 126], ["7-hydroxywarfarin", "CHEMICAL", 160, 177], ["(R)-warfarin", "SIMPLE_CHEMICAL", 15, 27], ["cytochrome P450s", "GENE_OR_GENE_PRODUCT", 62, 78], ["CYPs", "GENE_OR_GENE_PRODUCT", 79, 83], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 96, 102], ["CYP3A4", "SIMPLE_CHEMICAL", 107, 113], ["(S)-warfarin", "SIMPLE_CHEMICAL", 114, 126], ["7-hydroxywarfarin", "SIMPLE_CHEMICAL", 160, 177], ["CYP2C9", "GENE_OR_GENE_PRODUCT", 193, 199], ["cytochrome P450s", "PROTEIN", 62, 78], ["CYPs", "PROTEIN", 79, 83], ["polymorphic CYP2C9", "PROTEIN", 181, 199], ["warfarin", "TREATMENT", 19, 27], ["multiple cytochrome P450s(CYPs)", "PROBLEM", 53, 84], ["CYP1A2", "TEST", 96, 102], ["CYP3A4", "TEST", 107, 113], ["warfarin", "TREATMENT", 118, 126], ["hydroxywarfarin", "TREATMENT", 162, 177], ["polymorphic CYP2C9", "PROBLEM", 181, 199], ["multiple", "OBSERVATION_MODIFIER", 53, 61], ["cytochrome P450s", "OBSERVATION", 62, 78]]], ["Since the potency of (S)-warfarin is much higher than that of (R)-warfarin, about 3-to 5-fold,any change in the activity of CYP2C9 gene is likely to have a significant influence on the anticoagulant response.", [["warfarin", "CHEMICAL", 25, 33], ["warfarin", "CHEMICAL", 66, 74], ["(S)-warfarin", "CHEMICAL", 21, 33], ["(R)-warfarin", "CHEMICAL", 62, 74], ["(S)-warfarin", "SIMPLE_CHEMICAL", 21, 33], ["(R)-warfarin", "SIMPLE_CHEMICAL", 62, 74], ["CYP2C9", "GENE_OR_GENE_PRODUCT", 124, 130], ["CYP2C9 gene", "DNA", 124, 135], ["warfarin", "TREATMENT", 25, 33], ["warfarin", "TREATMENT", 66, 74], ["any change", "PROBLEM", 94, 104], ["significant", "OBSERVATION_MODIFIER", 156, 167]]], ["Previous in vitro findings revealed that certain variants in the CYP2C9 gene are associated with large interindividual differences in the pharmacokinetic and pharmacodynamic outcomes of warfarin therapy.", [["warfarin", "CHEMICAL", 186, 194], ["warfarin", "CHEMICAL", 186, 194], ["CYP2C9", "GENE_OR_GENE_PRODUCT", 65, 71], ["warfarin", "SIMPLE_CHEMICAL", 186, 194], ["CYP2C9 gene", "DNA", 65, 76], ["Previous in vitro findings", "TEST", 0, 26], ["certain variants", "PROBLEM", 41, 57], ["large interindividual differences", "PROBLEM", 97, 130], ["warfarin therapy", "TREATMENT", 186, 202], ["certain variants", "OBSERVATION", 41, 57], ["large", "OBSERVATION_MODIFIER", 97, 102], ["interindividual", "OBSERVATION_MODIFIER", 103, 118], ["differences", "OBSERVATION", 119, 130]]], ["Three major alleles have been found to date in humans:Arg144/Ile359, and Cys144/Ile359 and Arg144/leu359, and Arg144/Leu359, which have been designated CYP2C92, and CYP2C92, and CYP2C90501/DQB10501/DQB1*0301 (DQ7) are highly correlated to autoimmune diseases as Sjogren Syndrome (SS) and Systemic Lupus Erythematosus (SLE).", [["autoimmune diseases", "DISEASE", 239, 258], ["Sjogren Syndrome", "DISEASE", 262, 278], ["SS", "DISEASE", 280, 282], ["Systemic Lupus Erythematosus", "DISEASE", 288, 316], ["SLE", "DISEASE", 318, 321], ["humans", "ORGANISM", 47, 53], ["Arg144", "GENE_OR_GENE_PRODUCT", 54, 60], ["Ile359", "GENE_OR_GENE_PRODUCT", 61, 67], ["Cys144", "GENE_OR_GENE_PRODUCT", 73, 79], ["Ile359", "GENE_OR_GENE_PRODUCT", 80, 86], ["Arg144", "GENE_OR_GENE_PRODUCT", 91, 97], ["leu359", "GENE_OR_GENE_PRODUCT", 98, 104], ["Arg144", "GENE_OR_GENE_PRODUCT", 110, 116], ["Leu359", "GENE_OR_GENE_PRODUCT", 117, 123], ["CYP2C92", "GENE_OR_GENE_PRODUCT", 152, 159], ["CYP2C92", "GENE_OR_GENE_PRODUCT", 165, 172], ["CYP2C90501", "GENE_OR_GENE_PRODUCT", 178, 188], ["DQB1*0301", "GENE_OR_GENE_PRODUCT", 198, 207], ["CYP2C92", "DNA", 152, 159], ["CYP2C92", "DNA", 165, 172], ["CYP2C90501", "DNA", 178, 188], ["DQB10501", "DNA", 189, 197], ["DQ7", "DNA", 209, 212], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["CYP2C92", "TEST", 165, 172], ["CYP2C90501", "TEST", 178, 188], ["autoimmune diseases", "PROBLEM", 239, 258], ["Sjogren Syndrome", "PROBLEM", 262, 278], ["Systemic Lupus Erythematosus (SLE)", "PROBLEM", 288, 322], ["autoimmune", "OBSERVATION", 239, 249], ["Sjogren Syndrome", "OBSERVATION", 262, 278], ["Systemic", "ANATOMY", 288, 296], ["Lupus Erythematosus", "OBSERVATION", 297, 316]]], ["The non polymorphic \u03b2 regions of the modelled HLA-DQ7, which are exposed to the solvent and may disrupt the interaction of DQ7 with CD4+ T lymphocytes were determinated using the GETAREA program.", [["T lymphocytes", "ANATOMY", 137, 150], ["HLA-DQ7", "GENE_OR_GENE_PRODUCT", 46, 53], ["DQ7", "GENE_OR_GENE_PRODUCT", 123, 126], ["CD4", "GENE_OR_GENE_PRODUCT", 132, 135], ["T lymphocytes", "CELL", 137, 150], ["polymorphic \u03b2 regions", "DNA", 8, 29], ["HLA-DQ7", "DNA", 46, 53], ["DQ7", "PROTEIN", 123, 126], ["CD4", "PROTEIN", 132, 135], ["T lymphocytes", "CELL_TYPE", 137, 150], ["the modelled HLA", "TEST", 33, 49], ["the GETAREA program", "TREATMENT", 175, 194], ["non polymorphic", "OBSERVATION_MODIFIER", 4, 19], ["lymphocytes", "OBSERVATION", 139, 150]]], ["It was found that the regions 133-140 (Arg-Asn-Asp-Gln-Glu-Glu-Thr-Thr) and 59-66 (Glu-Tyr-Trp-Asn-Ser-Gln-Lys-Glu) display the highest solvent accessibility.", [["133-140", "CHEMICAL", 30, 37], ["Arg-Asn-Asp-Gln-Glu-Glu-Thr-Thr", "CHEMICAL", 39, 70], ["Glu-Tyr-Trp-Asn-Ser-Gln-Lys-Glu", "CHEMICAL", 83, 114], ["Arg-Asn-Asp-Gln-Glu-Glu-Thr-Thr", "CHEMICAL", 39, 70], ["Glu-Tyr-Trp-Asn-Ser-Gln-Lys-Glu", "CHEMICAL", 83, 114], ["Arg-Asn-", "SIMPLE_CHEMICAL", 39, 47], ["Asp", "AMINO_ACID", 47, 50], ["Thr-Thr", "AMINO_ACID", 63, 70], ["59-66", "AMINO_ACID", 76, 81], ["Glu-Tyr-Trp-Asn-Ser-Gln-Lys-Glu", "AMINO_ACID", 83, 114], ["the regions", "TEST", 18, 29], ["Arg", "TEST", 39, 42], ["Asn", "TEST", 43, 46], ["Asp", "TEST", 47, 50], ["Gln", "TEST", 51, 54], ["Glu", "TEST", 55, 58], ["Glu", "TEST", 59, 62], ["Thr", "TEST", 63, 66], ["Glu", "TEST", 83, 86], ["Tyr-", "TEST", 87, 91], ["Trp", "TEST", 91, 94], ["Asn-", "TEST", 95, 99], ["Ser", "TEST", 99, 102], ["Gln", "TEST", 103, 106], ["Lys", "TEST", 107, 110], ["solvent accessibility", "OBSERVATION", 136, 157]]], ["Peptide analogs of these regions were synthesized, by the Fmoc/OtBu solid phase strategy, purified by RP-HPLC and characterized by mass spectrometry ESI-MS.", [["Fmoc", "CHEMICAL", 58, 62], ["OtBu", "CHEMICAL", 63, 67], ["Fmoc", "CHEMICAL", 58, 62], ["OtBu", "CHEMICAL", 63, 67], ["OtBu", "SIMPLE_CHEMICAL", 63, 67], ["the Fmoc/OtBu solid phase strategy", "TREATMENT", 54, 88], ["mass", "OBSERVATION", 131, 135]]], ["The dimeric analogs of the peptides, designed to mimic the superdimeric nature of the immunosuppressory fragments of HLA class II molecules were also synthesized and investigated.MHC-DERIVED PEPTIDES AS IMMUNOMODULATORS IN AUTOIMMUNE DISEASESConformational studies were performed with CD spectroscopy and biological experiments are in progress.Department of Medical Chemistry Institute of Pharmaceutical Chemistry, University of Szeged 3 Institute of Biophysics, Biological Research Center 4 Department of Inorganic and Analytical Chemistry, University of Szeged, HungaryBackground and aims: Aggregates of \u03b2-amyloid peptide (A\u03b2) play central role in the etiopathology of Alzheimer's disease (AD).", [["\u03b2-amyloid peptide", "CHEMICAL", 606, 623], ["Alzheimer's disease", "DISEASE", 671, 690], ["AD", "DISEASE", 692, 694], ["\u03b2-amyloid peptide", "GENE_OR_GENE_PRODUCT", 606, 623], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 625, 627], ["Alzheimer's disease", "CANCER", 671, 690], ["immunosuppressory fragments", "PROTEIN", 86, 113], ["HLA class II molecules", "PROTEIN", 117, 139], ["MHC", "PROTEIN", 179, 182], ["the immunosuppressory fragments", "PROBLEM", 82, 113], ["AUTOIMMUNE DISEASESConformational studies", "TEST", 223, 264], ["CD spectroscopy", "TEST", 285, 300], ["\u03b2-amyloid peptide", "TREATMENT", 606, 623], ["Alzheimer's disease", "PROBLEM", 671, 690], ["central", "OBSERVATION_MODIFIER", 634, 641], ["Alzheimer", "OBSERVATION", 671, 680]]], ["Short peptides like C. Soto's pentapeptide LPFFD and LPYFD-amide synthesized in our laboratory are neuroprotective agents against A\u03b2 assemblies both in vitro and in vivo.", [["LPFFD", "CHEMICAL", 43, 48], ["LPYFD-amide", "CHEMICAL", 53, 64], ["LPFFD", "CHEMICAL", 43, 48], ["LPYFD-amide", "CHEMICAL", 53, 64], ["pentapeptide LPFFD", "SIMPLE_CHEMICAL", 30, 48], ["LPYFD-amide", "SIMPLE_CHEMICAL", 53, 64], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 130, 132], ["Short peptides", "PROBLEM", 0, 14], ["C. Soto's pentapeptide LPFFD", "TREATMENT", 20, 48], ["LPYFD", "TREATMENT", 53, 58], ["neuroprotective agents", "TREATMENT", 99, 121]]], ["Methods: transmission electron microscopy (TEM), CD, FT-IR, diffusion ordered NMR spectroscopy, dynamic light scattering, and radioligand binding assays were used.", [["FT", "TEST", 53, 55], ["NMR spectroscopy", "TEST", 78, 94], ["dynamic light scattering", "TEST", 96, 120], ["radioligand binding assays", "TEST", 126, 152]]], ["Results: all the methods applied showed that the pentapeptides mentioned above do not break the fibrillar structure of A\u03b2, that is these molecules are not real \u03b2-sheet breakers (BSB).", [["pentapeptides", "SIMPLE_CHEMICAL", 49, 62], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 119, 121], ["fibrillar structure", "PROTEIN", 96, 115], ["A\u03b2", "PROTEIN", 119, 121], ["all the methods", "TEST", 9, 24], ["the pentapeptides", "TREATMENT", 45, 62], ["fibrillar structure", "OBSERVATION", 96, 115]]], ["The pentapeptides bind to A\u03b2 fibrils and cause small structural changes by intercalating into the A\u03b2 assemblies.", [["A\u03b2 fibrils", "ANATOMY", 26, 36], ["pentapeptides", "SIMPLE_CHEMICAL", 4, 17], ["A\u03b2 fibrils", "GENE_OR_GENE_PRODUCT", 26, 36], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 98, 100], ["A\u03b2 fibrils", "PROTEIN", 26, 36], ["A\u03b2 assemblies", "PROTEIN", 98, 111], ["The pentapeptides bind", "TREATMENT", 0, 22], ["A\u03b2 fibrils", "TREATMENT", 26, 36], ["small structural changes", "PROBLEM", 47, 71], ["small", "OBSERVATION_MODIFIER", 47, 52], ["structural changes", "OBSERVATION", 53, 71]]], ["Fibrils of A\u03b2 survive one week treatment with the pentapeptides using them in 2 to 5-time molar excess.", [["pentapeptides", "CHEMICAL", 50, 63], ["A\u03b2", "SIMPLE_CHEMICAL", 11, 13], ["pentapeptides", "SIMPLE_CHEMICAL", 50, 63], ["A\u03b2", "PROTEIN", 11, 13], ["the pentapeptides", "TREATMENT", 46, 63]]], ["Conclusion: All the results in our laboratory show that the short peptides have long-term interaction on A\u03b2-assemblies.", [["A\u03b2", "SIMPLE_CHEMICAL", 105, 107], ["A\u03b2", "PROTEIN", 105, 107], ["the short peptides", "PROBLEM", 56, 74]]], ["In the first step they bind tightly to the A\u03b2 surface and prevent further interaction of A\u03b2 fibrils with the neuronal membranes.", [["A\u03b2 surface", "ANATOMY", 43, 53], ["neuronal membranes", "ANATOMY", 109, 127], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 43, 45], ["A\u03b2 fibrils", "GENE_OR_GENE_PRODUCT", 89, 99], ["neuronal membranes", "CELLULAR_COMPONENT", 109, 127], ["A\u03b2 fibrils", "PROTEIN", 89, 99], ["A\u03b2 fibrils", "PROBLEM", 89, 99], ["neuronal membranes", "OBSERVATION", 109, 127]]], ["After this step the short peptides can be built into the structure of A\u03b2-assemblies with intercalation causing a less ordered \u03b2-conformation.", [["A\u03b2", "SIMPLE_CHEMICAL", 70, 72], ["A\u03b2", "PROTEIN", 70, 72], ["this step the short peptides", "TREATMENT", 6, 34], ["intercalation", "TREATMENT", 89, 102], ["a less ordered \u03b2-conformation", "PROBLEM", 111, 140]]], ["Proteolytic enzymes (neprilisin, IDE) could cleave and hydrolyze A\u03b2 peptides after this structural change, therefore the short peptides are good drug candidates for the treatment of AD.Medicinal Chemistry, Leibniz Institute for Molecular Pharmacology and Institute for Chemistry and Biochemistry, Free University Berlin, GermanyCellular processes in normal and pathogenic cell states are regulated by external stimuli via complex networks of catalytic and non-catalytic protein-protein interactions.Medicinal Chemistry, Leibniz Institute for Molecular Pharmacology and Institute for Chemistry and Biochemistry, Free University Berlin, GermanyWe have developed methodology for the synthetic variation of peptides and peptidomimetics using polymer reagents including linker reagents enabling polymer-supported Cacylations.", [["cell", "ANATOMY", 372, 376], ["AD", "DISEASE", 182, 184], ["neprilisin", "GENE_OR_GENE_PRODUCT", 21, 31], ["IDE", "GENE_OR_GENE_PRODUCT", 33, 36], ["A\u03b2 peptides", "GENE_OR_GENE_PRODUCT", 65, 76], ["cell", "CELL", 372, 376], ["Proteolytic enzymes", "PROTEIN", 0, 19], ["neprilisin", "PROTEIN", 21, 31], ["IDE", "PROTEIN", 33, 36], ["catalytic and non-catalytic protein", "PROTEIN", 442, 477], ["Proteolytic enzymes", "TEST", 0, 19], ["neprilisin, IDE)", "TREATMENT", 21, 37], ["A\u03b2 peptides", "TREATMENT", 65, 76], ["this structural change", "PROBLEM", 83, 105], ["the short peptides", "PROBLEM", 117, 135], ["AD", "PROBLEM", 182, 184], ["Chemistry", "TEST", 269, 278], ["pathogenic cell states", "PROBLEM", 361, 383], ["external stimuli", "TEST", 401, 417], ["catalytic and non-catalytic protein-protein interactions", "TREATMENT", 442, 498], ["the synthetic variation of peptides", "TREATMENT", 676, 711], ["peptidomimetics", "TREATMENT", 716, 731], ["polymer reagents", "TREATMENT", 738, 754], ["linker reagents", "TREATMENT", 765, 780], ["polymer-supported Cacylations", "TREATMENT", 790, 819], ["normal", "OBSERVATION", 350, 356], ["pathogenic cell", "OBSERVATION", 361, 376]]], ["[1] In combination with the virtual screening of protein subsites, we have demonstrated the application of the novel synthetic methods to inhibitor optimization for various proteases including plasmepsin II, HIV protease, and SARS coronavirus main protease.", [["plasmepsin II", "GENE_OR_GENE_PRODUCT", 193, 206], ["HIV protease", "GENE_OR_GENE_PRODUCT", 208, 220], ["SARS coronavirus", "ORGANISM", 226, 242], ["protein subsites", "PROTEIN", 49, 65], ["proteases", "PROTEIN", 173, 182], ["plasmepsin II", "PROTEIN", 193, 206], ["HIV protease", "PROTEIN", 208, 220], ["SARS coronavirus main protease", "PROTEIN", 226, 256], ["HIV", "SPECIES", 208, 211], ["SARS coronavirus", "SPECIES", 226, 242], ["the virtual screening", "TEST", 24, 45], ["protein subsites", "PROBLEM", 49, 65], ["the novel synthetic methods", "TREATMENT", 107, 134], ["inhibitor optimization", "TREATMENT", 138, 160], ["various proteases", "TREATMENT", 165, 182], ["plasmepsin II", "TREATMENT", 193, 206], ["HIV protease", "TREATMENT", 208, 220], ["SARS coronavirus main protease", "TREATMENT", 226, 256]]], ["[2, 3] Moreover, multivalent peptide polymers have been developed for the intracellular targeting of proteins.", [["intracellular", "ANATOMY", 74, 87], ["multivalent peptide polymers", "SIMPLE_CHEMICAL", 17, 45], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 87], ["multivalent peptide polymers", "PROBLEM", 17, 45]]], ["[4] This methodology was now extended to the inhibition of PEPTIDE-PROTEIN INTERACTIONS by small molecules.", [["PEPTIDE-PROTEIN INTERACTIONS", "TREATMENT", 59, 87], ["small molecules", "PROBLEM", 91, 106], ["small molecules", "OBSERVATION", 91, 106]]], ["For this purpose, we have composed a library of 20,000 small molecules by algorithmic searching of a database of bioactive molecules with virtually designed substructures (fragments).", [["fragments", "ANATOMY", 172, 181], ["bioactive molecules", "PROBLEM", 113, 132], ["bioactive molecules", "OBSERVATION", 113, 132], ["fragments", "OBSERVATION_MODIFIER", 172, 181]]], ["High throughput assays were developed on the basis of fluorescence and fluorescence polarization detection.", [["High throughput assays", "PROBLEM", 0, 22], ["fluorescence polarization detection", "TEST", 71, 106]]], ["Despite the scepticism regarding the inhibition of protein-protein interactions with small molecules, efficient hit molecules have been developed for several intracellular targets and were subjected to synthetic variation and cellular follow-up assays.", [["intracellular", "ANATOMY", 158, 171], ["cellular", "ANATOMY", 226, 234], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 158, 171], ["cellular", "CELL", 226, 234], ["hit molecules", "PROTEIN", 112, 125], ["protein-protein interactions", "TREATMENT", 51, 79], ["small molecules", "PROBLEM", 85, 100], ["efficient hit molecules", "PROBLEM", 102, 125], ["synthetic variation", "TEST", 202, 221], ["cellular follow-up assays", "TEST", 226, 251]]], ["The essential event in platelet adhesion to the blood vessel wall after injury or in thrombosis is the binding to sub-endothelial collagen of plasma von Willebrand factor (VWF), a protein which interacts transiently with platelet glycoprotein (GP) IbAlpha , slowing circulating platelets to facilitate their firm adhesion through other collagen receptors, e.g. integrin Alpha2beta1 and GPVI.", [["platelet", "ANATOMY", 23, 31], ["blood vessel wall", "ANATOMY", 48, 65], ["platelets", "ANATOMY", 278, 287], ["thrombosis", "DISEASE", 85, 95], ["platelet", "CELL", 23, 31], ["blood vessel wall", "MULTI-TISSUE_STRUCTURE", 48, 65], ["sub-endothelial collagen", "GENE_OR_GENE_PRODUCT", 114, 138], ["plasma", "ORGANISM_SUBSTANCE", 142, 148], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 149, 170], ["VWF", "GENE_OR_GENE_PRODUCT", 172, 175], ["platelet glycoprotein (GP) IbAlpha", "GENE_OR_GENE_PRODUCT", 221, 255], ["platelets", "CELL", 278, 287], ["collagen", "GENE_OR_GENE_PRODUCT", 336, 344], ["integrin Alpha2beta1", "GENE_OR_GENE_PRODUCT", 361, 381], ["GPVI", "GENE_OR_GENE_PRODUCT", 386, 390], ["sub-endothelial collagen", "PROTEIN", 114, 138], ["plasma von Willebrand factor", "PROTEIN", 142, 170], ["VWF", "PROTEIN", 172, 175], ["platelet glycoprotein (GP) IbAlpha", "PROTEIN", 221, 255], ["circulating platelets", "CELL_TYPE", 266, 287], ["collagen receptors", "PROTEIN", 336, 354], ["integrin", "PROTEIN", 361, 369], ["Alpha2beta1", "PROTEIN", 370, 381], ["GPVI", "PROTEIN", 386, 390], ["platelet adhesion", "PROBLEM", 23, 40], ["injury", "PROBLEM", 72, 78], ["thrombosis", "PROBLEM", 85, 95], ["the binding", "PROBLEM", 99, 110], ["a protein", "PROBLEM", 178, 187], ["platelet glycoprotein", "TEST", 221, 242], ["IbAlpha", "TEST", 248, 255], ["slowing circulating platelets", "PROBLEM", 258, 287], ["their firm adhesion", "TREATMENT", 302, 321], ["other collagen receptors", "TREATMENT", 330, 354], ["integrin Alpha2beta1", "TREATMENT", 361, 381], ["GPVI", "PROBLEM", 386, 390], ["essential", "OBSERVATION_MODIFIER", 4, 13], ["platelet adhesion", "OBSERVATION", 23, 40], ["blood vessel", "ANATOMY", 48, 60], ["wall", "ANATOMY_MODIFIER", 61, 65], ["injury", "OBSERVATION", 72, 78], ["thrombosis", "OBSERVATION", 85, 95], ["firm adhesion", "OBSERVATION", 308, 321], ["GPVI", "OBSERVATION", 386, 390]]], ["To locate theVWF-binding site in collagen III; we synthesized 57 overlapping triple-helical peptides which comprise the whole native sequence of collagen III .", [["theVWF", "GENE_OR_GENE_PRODUCT", 10, 16], ["collagen III", "GENE_OR_GENE_PRODUCT", 33, 45], ["collagen III", "GENE_OR_GENE_PRODUCT", 145, 157], ["theVWF-binding site", "DNA", 10, 29], ["collagen III", "PROTEIN", 33, 45], ["collagen III", "PROTEIN", 145, 157], ["triple-helical peptides", "TREATMENT", 77, 100]]], ["Peptide #23 (GPOGPSGPRGQOGVMGFOGPKGND (O is hydroxyproline)) alone bound VWF, with an affinity comparable to that of native collagen III.", [["hydroxyproline", "CHEMICAL", 44, 58], ["hydroxyproline", "CHEMICAL", 44, 58], ["hydroxyproline", "SIMPLE_CHEMICAL", 44, 58], ["VWF", "GENE_OR_GENE_PRODUCT", 73, 76], ["collagen III", "GENE_OR_GENE_PRODUCT", 124, 136], ["VWF", "PROTEIN", 73, 76], ["collagen III", "PROTEIN", 124, 136], ["hydroxyproline)", "TREATMENT", 44, 59], ["alone bound VWF", "PROBLEM", 61, 76], ["an affinity", "PROBLEM", 83, 94]]], ["Immobilized peptide #23 supported platelet adhesion under static and flow conditions, processes blocked by an antibody which prevents the VWF A3 domain from binding full-length collagen.", [["platelet", "ANATOMY", 34, 42], ["platelet", "CELL", 34, 42], ["VWF A3", "GENE_OR_GENE_PRODUCT", 138, 144], ["collagen", "GENE_OR_GENE_PRODUCT", 177, 185], ["VWF A3 domain", "PROTEIN", 138, 151], ["collagen", "PROTEIN", 177, 185], ["Immobilized peptide", "TREATMENT", 0, 19], ["platelet adhesion", "TREATMENT", 34, 51], ["static and flow conditions", "TREATMENT", 58, 84], ["an antibody", "TEST", 107, 118], ["the VWF A3 domain", "PROBLEM", 134, 151], ["platelet adhesion", "OBSERVATION", 34, 51]]], ["Truncated and alaninesubstituted triple-helical peptides derived from #23 either strongly interacted with both VWF and platelets, or lacked both VWF and platelet binding.", [["platelets", "ANATOMY", 119, 128], ["platelet", "ANATOMY", 153, 161], ["VWF", "GENE_OR_GENE_PRODUCT", 111, 114], ["platelets", "CELL", 119, 128], ["VWF", "GENE_OR_GENE_PRODUCT", 145, 148], ["platelet", "CELL", 153, 161], ["VWF", "PROTEIN", 111, 114], ["platelets", "CELL_TYPE", 119, 128], ["VWF", "PROTEIN", 145, 148], ["platelets", "TEST", 119, 128], ["platelet binding", "PROBLEM", 153, 169], ["VWF", "OBSERVATION", 145, 148], ["platelet binding", "OBSERVATION", 153, 169]]], ["Thus, we identified the sequence RGQOGVMGF as the minimal VWF-binding sequence in collagen III.", [["RGQOGVMGF", "GENE_OR_GENE_PRODUCT", 33, 42], ["VWF", "GENE_OR_GENE_PRODUCT", 58, 61], ["collagen III", "GENE_OR_GENE_PRODUCT", 82, 94], ["RGQOGVMGF", "DNA", 33, 42], ["minimal VWF-binding sequence", "DNA", 50, 78], ["collagen III", "PROTEIN", 82, 94], ["the sequence RGQOGVMGF", "TEST", 20, 42], ["minimal", "OBSERVATION_MODIFIER", 50, 57], ["VWF", "OBSERVATION", 58, 61]]], ["The present work completes our understanding of the collagen-VWF interaction, providing information on crucial sequences in collagen that perfectly complements our existing knowledge of the collagen-binding site in VWF and may assist in targeting the collagen-VWF interaction for therapeutic purposes Solid phase assay systems such as enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), and overlay gels are used to study processes of protein-protein and protein-peptide interactions.", [["collagen", "GENE_OR_GENE_PRODUCT", 52, 60], ["VWF", "GENE_OR_GENE_PRODUCT", 61, 64], ["collagen", "GENE_OR_GENE_PRODUCT", 124, 132], ["collagen", "GENE_OR_GENE_PRODUCT", 190, 198], ["VWF", "GENE_OR_GENE_PRODUCT", 215, 218], ["collagen", "GENE_OR_GENE_PRODUCT", 251, 259], ["VWF", "GENE_OR_GENE_PRODUCT", 260, 263], ["collagen", "PROTEIN", 52, 60], ["VWF", "PROTEIN", 61, 64], ["collagen", "PROTEIN", 124, 132], ["collagen-binding site", "DNA", 190, 211], ["VWF", "PROTEIN", 215, 218], ["collagen", "PROTEIN", 251, 259], ["VWF", "PROTEIN", 260, 263], ["protein-protein", "PROTEIN", 459, 474], ["the collagen-binding site", "PROBLEM", 186, 211], ["Solid phase assay systems", "TEST", 301, 326], ["enzyme", "TEST", 335, 341], ["immunosorbent assay", "TEST", 349, 368], ["ELISA", "TEST", 370, 375], ["surface plasmon resonance", "TEST", 378, 403], ["overlay gels", "TREATMENT", 415, 427], ["protein", "TEST", 459, 466], ["protein", "TEST", 479, 486]]], ["The common principle of all these methods is that they monitor the binding between soluble and surfaceimmobilized molecules.", [["surfaceimmobilized molecules", "PROTEIN", 95, 123], ["common", "OBSERVATION_MODIFIER", 4, 10]]], ["Following the use of bovine serum albumin (BSA)-peptide conjugates or isolated synthetic peptides and the above-mentioned solid phase assay systems, we were able to demonstrate that positively charged peptides, which would be expected to repulse each other, can interact with each other.", [["serum", "ANATOMY", 28, 33], ["bovine", "ORGANISM", 21, 27], ["serum", "ORGANISM_SUBSTANCE", 28, 33], ["albumin", "SIMPLE_CHEMICAL", 34, 41], ["BSA)-peptide conjugates", "SIMPLE_CHEMICAL", 43, 66], ["bovine", "SPECIES", 21, 27], ["bovine", "SPECIES", 21, 27], ["bovine serum albumin (BSA)", "TEST", 21, 47], ["peptide conjugates", "TREATMENT", 48, 66], ["isolated synthetic peptides", "PROBLEM", 70, 97], ["solid phase assay systems", "TEST", 122, 147]]], ["Both the ELISA and SPR methods showed that the binding process reached saturation with Kd values ranging between 1 and 14 nM.", [["the ELISA", "TEST", 5, 14], ["SPR methods", "TEST", 19, 30], ["the binding process", "PROBLEM", 43, 62], ["Kd values", "TEST", 87, 96]]], ["No interaction was observed between BSA conjugates bearing positively charged peptides and conjugates bearing negatively charged peptides or with pure BSA molecules, strengthening the view that interaction occurs only between positively charged peptides.", [["BSA", "CHEMICAL", 36, 39], ["BSA conjugates", "SIMPLE_CHEMICAL", 36, 50], ["BSA molecules", "SIMPLE_CHEMICAL", 151, 164], ["pure BSA molecules", "TREATMENT", 146, 164], ["interaction", "OBSERVATION", 3, 14]]], ["However, interactions between the same peptides were not observed in solution when was monitored by nuclear magnetic resonance (NMR) or by native gel electrophoresis.Medicinal Chemistry, Leibniz Institute for Molecular Pharmacology and Institute for Chemistry and Biochemistry, Free University Berlin, GermanyThus, it appears that for positively charged molecules to interact one of the binding partners must be immobilized to a surface, a process that may lead to the exposure of otherwise masked groups or atoms.", [["surface", "ANATOMY", 429, 436], ["surface", "CELLULAR_COMPONENT", 429, 436], ["native gel electrophoresis", "TEST", 139, 165]]], ["The relevance of our findings for the use of solid phase assay systems to study interactions between biomolecules will be discussed.", [["solid phase assay systems", "TEST", 45, 70]]], ["The hematopoietic progenitor kinase 1 (HPK1), a mammalian hematopoiesis-specific Ste20 kinase, contains a cluster of four proline-rich sequences called P1, P2, P3 and P4 located after the kinase domain.", [["hematopoietic progenitor", "ANATOMY", 4, 28], ["proline", "CHEMICAL", 122, 129], ["proline", "CHEMICAL", 122, 129], ["hematopoietic progenitor kinase 1", "GENE_OR_GENE_PRODUCT", 4, 37], ["HPK1", "GENE_OR_GENE_PRODUCT", 39, 43], ["Ste20", "GENE_OR_GENE_PRODUCT", 81, 86], ["P2", "GENE_OR_GENE_PRODUCT", 156, 158], ["P3", "GENE_OR_GENE_PRODUCT", 160, 162], ["hematopoietic progenitor kinase 1", "PROTEIN", 4, 37], ["HPK1", "PROTEIN", 39, 43], ["Ste20 kinase", "PROTEIN", 81, 93], ["proline-rich sequences", "PROTEIN", 122, 144], ["P1", "DNA", 152, 154], ["P2", "DNA", 156, 158], ["P3", "DNA", 160, 162], ["P4", "DNA", 167, 169], ["kinase domain", "PROTEIN", 188, 201], ["The hematopoietic progenitor kinase", "TEST", 0, 35], ["HPK1", "TEST", 39, 43], ["a mammalian hematopoiesis", "PROBLEM", 46, 71], ["the kinase domain", "TEST", 184, 201], ["hematopoietic progenitor kinase", "OBSERVATION", 4, 35], ["mammalian hematopoiesis", "OBSERVATION", 48, 71]]], ["These Pro-rich regions play an important role in the interactions of this kinase with different adapter proteins.", [["Pro-rich regions", "PROTEIN", 6, 22], ["kinase", "PROTEIN", 74, 80], ["adapter proteins", "PROTEIN", 96, 112], ["different adapter proteins", "TREATMENT", 86, 112]]], ["Previous studies showed that P1, which contains the canonical PxxPxR motif, and P2 and P4 with the canonical PxxPxK motif interact with the C-terminal SH3 domain of hematopoietic lineage cell-specific protein 1 (HS1) even if with different affinity.", [["hematopoietic lineage cell", "ANATOMY", 165, 191], ["P1", "GENE_OR_GENE_PRODUCT", 29, 31], ["PxxPxR", "GENE_OR_GENE_PRODUCT", 62, 68], ["P4", "GENE_OR_GENE_PRODUCT", 87, 89], ["PxxPxK", "GENE_OR_GENE_PRODUCT", 109, 115], ["hematopoietic lineage cell-specific protein 1", "GENE_OR_GENE_PRODUCT", 165, 210], ["HS1", "GENE_OR_GENE_PRODUCT", 212, 215], ["P1", "DNA", 29, 31], ["canonical PxxPxR motif", "DNA", 52, 74], ["P2", "DNA", 80, 82], ["P4", "DNA", 87, 89], ["PxxPxK motif", "DNA", 109, 121], ["C-terminal SH3 domain", "PROTEIN", 140, 161], ["hematopoietic lineage cell-specific protein 1", "PROTEIN", 165, 210], ["HS1", "PROTEIN", 212, 215], ["Previous studies", "TEST", 0, 16], ["P1", "PROBLEM", 29, 31], ["the canonical PxxPxR motif", "TEST", 48, 74], ["P2 and P4", "TREATMENT", 80, 89], ["the canonical PxxPxK motif", "TREATMENT", 95, 121], ["the C-terminal SH3 domain", "TREATMENT", 136, 161], ["hematopoietic lineage cell", "PROBLEM", 165, 191], ["different affinity", "PROBLEM", 230, 248], ["hematopoietic lineage cell", "OBSERVATION", 165, 191]]], ["HS1 protein shares a high amino acid sequence and structural similarity to cortactin although their functions differ considerably.", [["amino acid", "CHEMICAL", 26, 36], ["amino acid", "CHEMICAL", 26, 36], ["HS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["amino acid", "AMINO_ACID", 26, 36], ["cortactin", "GENE_OR_GENE_PRODUCT", 75, 84], ["HS1 protein", "PROTEIN", 0, 11], ["cortactin", "PROTEIN", 75, 84], ["HS1 protein", "TEST", 0, 11], ["a high amino acid sequence", "PROBLEM", 19, 45]]], ["Here we report the results of our investigation on the interaction between the C-terminal SH3 domain of cortactin and the four proline-rich motifs of HPK1.", [["proline", "CHEMICAL", 127, 134], ["C", "CHEMICAL", 79, 80], ["proline", "CHEMICAL", 127, 134], ["cortactin", "GENE_OR_GENE_PRODUCT", 104, 113], ["HPK1", "GENE_OR_GENE_PRODUCT", 150, 154], ["C-terminal SH3 domain", "PROTEIN", 79, 100], ["cortactin", "PROTEIN", 104, 113], ["proline-rich motifs", "PROTEIN", 127, 146], ["HPK1", "PROTEIN", 150, 154], ["our investigation", "TEST", 30, 47], ["the C-terminal SH3 domain of cortactin", "TREATMENT", 75, 113], ["the four proline-rich motifs of HPK1", "TREATMENT", 118, 154]]], ["Upon peptide addition, the binding was monitored by the CD changes of the Trp side-chains of the conjugate GST-SH3cort.", [["Trp", "CHEMICAL", 74, 77], ["Trp", "CHEMICAL", 74, 77], ["GST", "GENE_OR_GENE_PRODUCT", 107, 110], ["Trp side-chains", "PROTEIN", 74, 89], ["GST", "PROTEIN", 107, 110], ["SH3cort", "PROTEIN", 111, 118]]], ["The dissociation constants Kd were determined analyzing the CD data at 294 nm using a nonlinear regression method.", [["The dissociation constants", "PROBLEM", 0, 26], ["a nonlinear regression method", "TREATMENT", 84, 113], ["dissociation constants", "OBSERVATION", 4, 26]]], ["The results demonstrate that GST-SH3cort displays an affinity binding higher than that found with the corresponding HS1 domain and that the four HPK1 Pro-rich regions are not equivalent.", [["GST", "GENE_OR_GENE_PRODUCT", 29, 32], ["HS1", "GENE_OR_GENE_PRODUCT", 116, 119], ["HPK1", "GENE_OR_GENE_PRODUCT", 145, 149], ["GST", "PROTEIN", 29, 32], ["SH3cort", "PROTEIN", 33, 40], ["HS1 domain", "PROTEIN", 116, 126], ["HPK1", "PROTEIN", 145, 149], ["GST", "TEST", 29, 32], ["an affinity binding", "PROBLEM", 50, 69], ["the corresponding HS1 domain", "PROBLEM", 98, 126], ["not", "UNCERTAINTY", 171, 174], ["equivalent", "OBSERVATION_MODIFIER", 175, 185]]], ["P2 appears to bind with the highest affinity (Kd=0.5 \u00b5M), followed by P1 (Kd=10 \u00b5M) and P4 (Kd=33 \u00b5M), whilst P3 does not interact at all.", [["P2", "DNA", 0, 2], ["P2", "PROBLEM", 0, 2], ["Kd", "TEST", 46, 48], ["Kd", "TEST", 74, 76], ["P4", "TEST", 88, 90], ["Kd", "TEST", 92, 94]]], ["The generation of a fibrin clot is mediated by the regulated activation of a series of serine proteases and their cofactors.", [["fibrin clot", "ANATOMY", 20, 31], ["serine", "CHEMICAL", 87, 93], ["fibrin", "GENE_OR_GENE_PRODUCT", 20, 26], ["serine proteases", "PROTEIN", 87, 103], ["a fibrin clot", "PROBLEM", 18, 31], ["serine proteases", "TREATMENT", 87, 103], ["fibrin", "OBSERVATION_MODIFIER", 20, 26], ["clot", "OBSERVATION", 27, 31]]], ["Factor VIII in its activated form, FVIIIa, acts as a cofactor to the serine protease FIXa, in the conversion of the zymogen FX to the active enzyme FXa.", [["serine", "CHEMICAL", 69, 75], ["Factor VIII", "GENE_OR_GENE_PRODUCT", 0, 11], ["FVIIIa", "GENE_OR_GENE_PRODUCT", 35, 41], ["FIXa", "GENE_OR_GENE_PRODUCT", 85, 89], ["zymogen", "GENE_OR_GENE_PRODUCT", 116, 123], ["FX", "GENE_OR_GENE_PRODUCT", 124, 126], ["FXa", "GENE_OR_GENE_PRODUCT", 148, 151], ["Factor VIII", "PROTEIN", 0, 11], ["FVIIIa", "PROTEIN", 35, 41], ["serine protease FIXa", "PROTEIN", 69, 89], ["zymogen FX", "PROTEIN", 116, 126], ["active enzyme", "PROTEIN", 134, 147], ["FXa", "PROTEIN", 148, 151], ["Factor VIII", "TEST", 0, 11], ["the serine protease FIXa", "TREATMENT", 65, 89], ["the zymogen FX", "PROBLEM", 112, 126], ["FXa", "OBSERVATION", 148, 151]]], ["Both FVIII and FIX are essential for normal coagulation, deficiencies of either are associated with the bleeding diatheses hemophilia A and B, respectively.", [["bleeding", "DISEASE", 104, 112], ["hemophilia", "DISEASE", 123, 133], ["FVIII", "GENE_OR_GENE_PRODUCT", 5, 10], ["FIX", "GENE_OR_GENE_PRODUCT", 15, 18], ["B", "CANCER", 140, 141], ["FVIII", "PROTEIN", 5, 10], ["FIX", "PROTEIN", 15, 18], ["Both FVIII and FIX", "TREATMENT", 0, 18], ["the bleeding diatheses hemophilia", "PROBLEM", 100, 133], ["FVIII", "OBSERVATION", 5, 10], ["coagulation", "OBSERVATION", 44, 55], ["bleeding", "OBSERVATION", 104, 112]]], ["The role of FVIIIa is to bind factor IXa, generating the phospholipid-dependent intrinsic factor Xase complex.", [["FVIIIa", "GENE_OR_GENE_PRODUCT", 12, 18], ["IXa", "GENE_OR_GENE_PRODUCT", 37, 40], ["phospholipid", "SIMPLE_CHEMICAL", 57, 69], ["Xase", "GENE_OR_GENE_PRODUCT", 97, 101], ["FVIIIa", "PROTEIN", 12, 18], ["factor IXa", "PROTEIN", 30, 40], ["phospholipid-dependent intrinsic factor Xase complex", "PROTEIN", 57, 109], ["the phospholipid", "TEST", 53, 69]]], ["At least two interactive sites have been identified for the enzyme-cofactor interaction.", [["enzyme", "PROTEIN", 60, 66], ["the enzyme", "TEST", 56, 66], ["two", "OBSERVATION_MODIFIER", 9, 12], ["interactive", "OBSERVATION", 13, 24], ["cofactor interaction", "OBSERVATION", 67, 87]]], ["The Ser558-Gln565 region within the A2 subunit has been shown to be crucial for VIIIa-IXa interaction.Medicinal Chemistry, Leibniz Institute for Molecular Pharmacology and Institute for Chemistry and Biochemistry, Free University Berlin, GermanyIn an attempt to study this interaction, we synthesized a series of peptides of 558-565 loop of the A2 subunit.", [["Ser558", "GENE_OR_GENE_PRODUCT", 4, 10], ["Gln565", "GENE_OR_GENE_PRODUCT", 11, 17], ["A2", "GENE_OR_GENE_PRODUCT", 36, 38], ["VIIIa-IXa", "GENE_OR_GENE_PRODUCT", 80, 89], ["A2", "GENE_OR_GENE_PRODUCT", 345, 347], ["Ser558-Gln565 region", "DNA", 4, 24], ["A2 subunit", "PROTEIN", 36, 46], ["VIIIa", "PROTEIN", 80, 85], ["IXa", "PROTEIN", 86, 89], ["A2 subunit", "PROTEIN", 345, 355]]], ["The syntheses of these peptides were carried out by using SPPS and Fmoc/But methodology.", [["Fmoc", "CHEMICAL", 67, 71], ["these peptides", "TEST", 17, 31]]], ["The synthesized compounds were purified by RP-HPLC and lyophilized to give fluffy solid, identified by FT-IR, NMR and ES-MS spectra.", [["RP-HPLC", "CHEMICAL", 43, 50], ["RP-HPLC", "TEST", 43, 50], ["fluffy solid", "PROBLEM", 75, 87], ["FT", "TEST", 103, 105], ["NMR", "TEST", 110, 113]]], ["These compounds were tested for inhibitory activity on human platelet aggregation in vitro, by adding common aggregation reagents to citrated platelet rich plasma (PRP).", [["platelet", "ANATOMY", 61, 69], ["platelet rich plasma", "ANATOMY", 142, 162], ["platelet aggregation", "DISEASE", 61, 81], ["human", "ORGANISM", 55, 60], ["platelet", "CELL", 61, 69], ["citrated platelet rich", "GENE_OR_GENE_PRODUCT", 133, 155], ["plasma", "ORGANISM_SUBSTANCE", 156, 162], ["PRP", "SIMPLE_CHEMICAL", 164, 167], ["citrated platelet", "CELL_TYPE", 133, 150], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["inhibitory activity", "PROBLEM", 32, 51], ["human platelet aggregation", "TREATMENT", 55, 81], ["common aggregation reagents", "TREATMENT", 102, 129], ["citrated platelet rich plasma (PRP)", "TREATMENT", 133, 168]]], ["The aggregation was determined using a dual channel electronic aggregometer by recording the light transmission. and 120 Ci/mmol, respectively.", [["a dual channel electronic aggregometer", "TREATMENT", 37, 75]]], ["Both tritiated A\u03b2 peptides were used in cat brain( in vivo) experiments and it was found that the peptide aggregates enter the neurons within 30 min (electronmicroscopic autoradiography).", [["brain", "ANATOMY", 44, 49], ["neurons", "ANATOMY", 127, 134], ["A\u03b2 peptides", "GENE_OR_GENE_PRODUCT", 15, 26], ["cat", "ORGANISM", 40, 43], ["brain", "ORGAN", 44, 49], ["neurons", "CELL", 127, 134], ["Both tritiated A\u03b2 peptides", "TREATMENT", 0, 26], ["the peptide aggregates", "PROBLEM", 94, 116], ["electronmicroscopic autoradiography", "TEST", 150, 185]]], ["This transport is most probably an endocytotic pathway.", [["most probably", "UNCERTAINTY", 18, 31], ["endocytotic pathway", "OBSERVATION", 35, 54]]], ["A\u03b2 aggregates could interact also with cytoplasmic proteins such as 3-phosphoglyceraldehyde dehydrogenase etc. We suppose that A\u03b2 assemblies can interact both with membrane receptors (NMDA, AMPA, ACh) and with cytoplasmic proteins triggering neuronal dysfunction and death.GBF -German Research Centre for Biotechnology, Braunschweig, GermanyBackground and Aims: WW domains are the shortest known protein domains and contain a stable three-stranded b-sheet, which presents the binding site for prolinerich ligands.", [["cytoplasmic", "ANATOMY", 39, 50], ["membrane", "ANATOMY", 164, 172], ["cytoplasmic", "ANATOMY", 210, 221], ["neuronal", "ANATOMY", 242, 250], ["3-phosphoglyceraldehyde", "CHEMICAL", 68, 91], ["NMDA", "CHEMICAL", 184, 188], ["AMPA", "CHEMICAL", 190, 194], ["ACh", "CHEMICAL", 196, 199], ["neuronal dysfunction", "DISEASE", 242, 262], ["death", "DISEASE", 267, 272], ["3-phosphoglyceraldehyde", "CHEMICAL", 68, 91], ["NMDA", "CHEMICAL", 184, 188], ["AMPA", "CHEMICAL", 190, 194], ["ACh", "CHEMICAL", 196, 199], ["prolinerich", "CHEMICAL", 493, 504], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 0, 2], ["cytoplasmic", "ORGANISM_SUBSTANCE", 39, 50], ["3-phosphoglyceraldehyde dehydrogenase", "GENE_OR_GENE_PRODUCT", 68, 105], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 127, 129], ["membrane", "CELLULAR_COMPONENT", 164, 172], ["NMDA", "SIMPLE_CHEMICAL", 184, 188], ["AMPA", "SIMPLE_CHEMICAL", 190, 194], ["ACh", "SIMPLE_CHEMICAL", 196, 199], ["cytoplasmic", "ORGANISM_SUBSTANCE", 210, 221], ["neuronal", "CELL", 242, 250], ["prolinerich ligands", "SIMPLE_CHEMICAL", 493, 512], ["cytoplasmic proteins", "PROTEIN", 39, 59], ["3-phosphoglyceraldehyde dehydrogenase", "PROTEIN", 68, 105], ["A\u03b2", "PROTEIN", 127, 129], ["membrane receptors", "PROTEIN", 164, 182], ["cytoplasmic proteins", "PROTEIN", 210, 230], ["WW domains", "PROTEIN", 362, 372], ["protein domains", "PROTEIN", 396, 411], ["prolinerich ligands", "PROTEIN", 493, 512], ["cytoplasmic proteins", "TEST", 39, 59], ["cytoplasmic proteins", "PROBLEM", 210, 230], ["neuronal dysfunction", "PROBLEM", 242, 262], ["death", "PROBLEM", 267, 272], ["the shortest known protein domains", "PROBLEM", 377, 411], ["prolinerich ligands", "TREATMENT", 493, 512], ["neuronal dysfunction", "OBSERVATION", 242, 262], ["stable", "OBSERVATION_MODIFIER", 426, 432]]], ["This interaction is mediated by hydrophobic interactions between aromatic and hydrophobic residues of the domain, and the polyproline core of the ligand.", [["polyproline core", "PROTEIN", 122, 138], ["the polyproline core of the ligand", "TREATMENT", 118, 152], ["hydrophobic residues", "OBSERVATION", 78, 98], ["ligand", "ANATOMY", 146, 152]]], ["As part of our ongoing efforts aimed at synthetically mimicking conformationally defined protein binding sites (1), we have designed and synthesized linear and cyclic peptides covering the binding site of the WW domain of human Yes-associated protein (hYAP-WW), whose structure in complex with a proline-rich ligand had been solved by NMR spectroscopy (2) .GBF -German Research Centre for Biotechnology, Braunschweig, GermanyMethods: Peptides were synthesized by SPPS, purified by HPLC, and characterized by 2D-NMR spectroscopy, as well as by molecular dynamics calculations.", [["proline", "CHEMICAL", 296, 303], ["proline", "CHEMICAL", 296, 303], ["human", "ORGANISM", 222, 227], ["Yes-associated protein", "GENE_OR_GENE_PRODUCT", 228, 250], ["hYAP-WW", "GENE_OR_GENE_PRODUCT", 252, 259], ["SPPS", "SIMPLE_CHEMICAL", 463, 467], ["protein binding sites", "PROTEIN", 89, 110], ["WW domain", "PROTEIN", 209, 218], ["human Yes-associated protein", "PROTEIN", 222, 250], ["hYAP", "PROTEIN", 252, 256], ["WW", "PROTEIN", 257, 259], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 222, 227], ["synthesized linear and cyclic peptides", "TREATMENT", 137, 175], ["a proline-rich ligand", "TREATMENT", 294, 315], ["NMR spectroscopy", "TEST", 335, 351], ["2D-NMR spectroscopy", "TEST", 508, 527]]], ["Affinities of the peptides to a hYAP-WW ligand were determined in direct and competitive binding assays.GBF -German Research Centre for Biotechnology, Braunschweig, GermanyResults and Conclusions: A cyclic peptide covering the sequence stretch of hYAP-WW that contains its primary contact residues for proline-rich ligands, was found to compete with the domain for binding to a hYAP-WW ligand.", [["proline", "CHEMICAL", 302, 309], ["proline", "CHEMICAL", 302, 309], ["hYAP-WW ligand", "GENE_OR_GENE_PRODUCT", 32, 46], ["hYAP-WW", "GENE_OR_GENE_PRODUCT", 247, 254], ["proline", "AMINO_ACID", 302, 309], ["hYAP-WW ligand", "GENE_OR_GENE_PRODUCT", 378, 392], ["hYAP", "PROTEIN", 32, 36], ["WW ligand", "PROTEIN", 37, 46], ["hYAP", "PROTEIN", 247, 251], ["WW", "PROTEIN", 252, 254], ["hYAP-WW ligand", "PROTEIN", 378, 392], ["A cyclic peptide", "TREATMENT", 197, 213]]], ["Long-ranging NOEs identified in the NMR spectra of this peptide indicate a conformation, in which sequentially distant residues are brought into spatial proximity, likely through formation of a beta-sheet.", [["beta-sheet", "PROTEIN", 194, 204], ["Long-ranging NOEs", "PROBLEM", 0, 17]]], ["These result demonstrate the feasibility of functional, as well as structural, mimicry of conformationally defined protein binding sites through synthetic peptides.C.G. UnsonThe Rockefeller University, New York, NY, USA Integrins constitute a family of transmembrane cell surface receptors.", [["transmembrane cell surface", "ANATOMY", 253, 279], ["USA Integrins", "GENE_OR_GENE_PRODUCT", 216, 229], ["transmembrane", "CELLULAR_COMPONENT", 253, 266], ["cell surface receptors", "GENE_OR_GENE_PRODUCT", 267, 289], ["protein binding sites", "PROTEIN", 115, 136], ["transmembrane cell surface receptors", "PROTEIN", 253, 289], ["conformationally defined protein binding sites", "PROBLEM", 90, 136], ["synthetic peptides", "TREATMENT", 145, 163], ["transmembrane cell surface receptors", "TREATMENT", 253, 289]]], ["They are involved in cell-cell and cell-extracellular matrix interactions.", [["cell", "ANATOMY", 21, 25], ["cell", "ANATOMY", 26, 30], ["cell", "ANATOMY", 35, 39], ["extracellular matrix", "ANATOMY", 40, 60], ["cell", "CELL", 21, 25], ["cell", "CELL", 26, 30], ["cell", "CELL", 35, 39], ["extracellular matrix", "CELLULAR_COMPONENT", 40, 60], ["cell-extracellular matrix interactions", "TREATMENT", 35, 73], ["extracellular matrix", "OBSERVATION", 40, 60]]], ["Thus, they participate in many physiological and pathophysiological processes and are of crucial importance for the living organism.", [["many physiological and pathophysiological processes", "PROBLEM", 26, 77], ["the living organism", "PROBLEM", 112, 131]]], ["Integrins possess two non-covalently bound subunits, \u03b1 and \u03b2, that jointly participate in ligand binding.", [["Integrins", "GENE_OR_GENE_PRODUCT", 0, 9], ["\u03b1", "GENE_OR_GENE_PRODUCT", 53, 54], ["\u03b2", "GENE_OR_GENE_PRODUCT", 59, 60], ["Integrins", "PROTEIN", 0, 9], ["non-covalently bound subunits", "PROTEIN", 22, 51], ["\u03b1", "PROTEIN", 53, 54], ["\u03b2", "PROTEIN", 59, 60]]], ["These dimeric proteins show very high specificity in recognition of natural ligands.", [["dimeric proteins", "PROTEIN", 6, 22], ["These dimeric proteins", "TEST", 0, 22], ["very", "OBSERVATION_MODIFIER", 28, 32], ["high", "OBSERVATION_MODIFIER", 33, 37], ["natural ligands", "OBSERVATION", 68, 83]]], ["For example, \u03b14\u03b21 integrin recognizes VCAM-1 (vascular cell adhesion molecule 1) and fibronectin through binding amino acid motifs TQIDSPLN and LDV, respectively.", [["amino acid", "CHEMICAL", 113, 123], ["amino acid", "CHEMICAL", 113, 123], ["\u03b14\u03b21 integrin", "GENE_OR_GENE_PRODUCT", 13, 26], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 38, 44], ["vascular cell adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 46, 79], ["fibronectin", "GENE_OR_GENE_PRODUCT", 85, 96], ["amino acid", "AMINO_ACID", 113, 123], ["\u03b14\u03b21 integrin", "PROTEIN", 13, 26], ["VCAM-1", "PROTEIN", 38, 44], ["vascular cell adhesion molecule 1", "PROTEIN", 46, 79], ["fibronectin", "PROTEIN", 85, 96], ["binding amino acid motifs", "PROTEIN", 105, 130], ["VCAM", "TEST", 38, 42], ["vascular cell adhesion molecule", "TREATMENT", 46, 77], ["fibronectin through binding amino acid motifs TQIDSPLN", "TEST", 85, 139], ["vascular", "ANATOMY", 46, 54]]], ["On the other hand, fibronectin is a classical ligand for \u03b15\u03b21 integrin with the recognition motif RGD.", [["fibronectin", "GENE_OR_GENE_PRODUCT", 19, 30], ["\u03b15\u03b21 integrin", "GENE_OR_GENE_PRODUCT", 57, 70], ["fibronectin", "PROTEIN", 19, 30], ["\u03b15\u03b21 integrin", "PROTEIN", 57, 70]]], ["As shown, identification of the integrin ligands occurs through small recognition amino acid sequences (mostly tripeptides).", [["amino acid", "CHEMICAL", 82, 92], ["amino acid", "CHEMICAL", 82, 92], ["integrin", "GENE_OR_GENE_PRODUCT", 32, 40], ["amino acid", "AMINO_ACID", 82, 92], ["integrin ligands", "PROTEIN", 32, 48], ["the integrin ligands", "PROBLEM", 28, 48], ["small recognition amino acid sequences", "TREATMENT", 64, 102]]], ["Thus, small cyclic peptides possessing a recognition motif in the appropriate three-dimensional conformation are able to interfere with the integrin-ligand interactions and act as inhibitors.Despite insights from receptor mutagenesis and structural function studies of peptide ligands the interaction of peptide hormones with family B G proteincoupled receptors (GPCRs) is not fully understood.", [["integrin", "GENE_OR_GENE_PRODUCT", 140, 148], ["family B G proteincoupled receptors", "GENE_OR_GENE_PRODUCT", 326, 361], ["recognition motif", "PROTEIN", 41, 58], ["integrin", "PROTEIN", 140, 148], ["family B G proteincoupled receptors", "PROTEIN", 326, 361], ["GPCRs", "PROTEIN", 363, 368], ["small cyclic peptides", "PROBLEM", 6, 27], ["a recognition motif", "PROBLEM", 39, 58], ["the integrin-ligand interactions", "TREATMENT", 136, 168], ["receptor mutagenesis", "TREATMENT", 213, 233], ["structural function studies", "TEST", 238, 265], ["peptide ligands", "PROBLEM", 269, 284], ["peptide hormones", "TREATMENT", 304, 320], ["family B G proteincoupled receptors", "TREATMENT", 326, 361], ["small", "OBSERVATION_MODIFIER", 6, 11], ["cyclic peptides", "OBSERVATION", 12, 27]]], ["In family B GPCRs an intact disulfide-bonded amino-terminal domain and extracellular loops linking the seven-helical bundle are believed to contain the peptide binding site.", [["extracellular loops", "ANATOMY", 71, 90], ["amino-terminal", "CHEMICAL", 45, 59], ["disulfide", "CHEMICAL", 28, 37], ["amino", "CHEMICAL", 45, 50], ["family B GPCRs", "GENE_OR_GENE_PRODUCT", 3, 17], ["extracellular loops", "CELLULAR_COMPONENT", 71, 90], ["family B GPCRs", "PROTEIN", 3, 17], ["disulfide-bonded amino-terminal domain", "PROTEIN", 28, 66], ["extracellular loops", "PROTEIN", 71, 90], ["seven-helical bundle", "PROTEIN", 103, 123], ["peptide binding site", "PROTEIN", 152, 172], ["an intact disulfide-bonded amino-terminal domain", "TREATMENT", 18, 66], ["extracellular loops", "TREATMENT", 71, 90], ["the peptide binding site", "PROBLEM", 148, 172], ["intact disulfide", "OBSERVATION", 21, 37], ["extracellular loops", "OBSERVATION", 71, 90], ["peptide binding", "OBSERVATION", 152, 167]]], ["The lack of high-resolution, three-dimensional information is an important factor thatThe aim of this investigation is the characterisation of small cyclic peptides containing the RGD motif and the determination of the selectivity and specificity of these inhibitors.", [["this investigation", "TEST", 97, 115], ["small cyclic peptides", "PROBLEM", 143, 164], ["the RGD motif", "TEST", 176, 189], ["these inhibitors", "TREATMENT", 250, 266], ["high", "OBSERVATION_MODIFIER", 12, 16], ["small", "OBSERVATION_MODIFIER", 143, 148], ["cyclic peptides", "OBSERVATION", 149, 164]]], ["Two new pentapeptides with 3-amino-cyclopropane-1,2-dicarboxylic acid monomethyl ester ((+/-)ACC) were synthesized and tested.", [["pentapeptides", "CHEMICAL", 8, 21], ["3-amino-cyclopropane-1,2-dicarboxylic acid monomethyl ester", "CHEMICAL", 27, 86], ["pentapeptides", "CHEMICAL", 8, 21], ["3-amino-cyclopropane-1,2-dicarboxylic acid monomethyl ester", "CHEMICAL", 27, 86], ["(+/-)ACC", "CHEMICAL", 88, 96], ["pentapeptides", "SIMPLE_CHEMICAL", 8, 21], ["3-amino-cyclopropane-1,2-dicarboxylic acid monomethyl ester", "SIMPLE_CHEMICAL", 27, 86], ["(+/-)ACC", "SIMPLE_CHEMICAL", 88, 96], ["Two new pentapeptides", "TREATMENT", 0, 21], ["amino-cyclopropane", "TREATMENT", 29, 47], ["dicarboxylic acid monomethyl ester", "TREATMENT", 52, 86]]], ["Peptides were characterized in biological assays with living cells (K562 and WM115) and in surface plasmon resonance binding studies.", [["cells", "ANATOMY", 61, 66], ["K562", "ANATOMY", 68, 72], ["WM115", "ANATOMY", 77, 82], ["cells", "CELL", 61, 66], ["K562", "CELL", 68, 72], ["WM115", "CELL", 77, 82], ["K562", "CELL_LINE", 68, 72], ["WM115", "CELL_LINE", 77, 82], ["Peptides", "TEST", 0, 8], ["K562", "TEST", 68, 72], ["surface plasmon resonance binding studies", "TEST", 91, 132]]], ["Experiments have shown that cyclic peptide cyclo-(Arg-Gly-Asp-(+)ACC-Val) is a very potent inhibitor (IC50-value in nM range) of interaction between vitronectin and \u03b1v\u03b23 or \u03b1v\u03b25 integrins.", [["cyclo-(Arg-Gly-Asp", "CHEMICAL", 43, 61], ["Val", "CHEMICAL", 69, 72], ["cyclo-(Arg-Gly-Asp-(+)ACC-Val", "CHEMICAL", 43, 72], ["cyclo-(Arg-Gly-Asp-(+)ACC-Val", "SIMPLE_CHEMICAL", 43, 72], ["vitronectin", "GENE_OR_GENE_PRODUCT", 149, 160], ["\u03b1v\u03b23", "GENE_OR_GENE_PRODUCT", 165, 169], ["\u03b1v\u03b25 integrins", "GENE_OR_GENE_PRODUCT", 173, 187], ["vitronectin", "PROTEIN", 149, 160], ["\u03b1v\u03b23", "PROTEIN", 165, 169], ["\u03b1v\u03b25 integrins", "PROTEIN", 173, 187], ["cyclic peptide cyclo", "TEST", 28, 48], ["Arg", "TEST", 50, 53], ["Gly", "TEST", 54, 57], ["Asp", "TEST", 58, 61], ["a very potent inhibitor", "TREATMENT", 77, 100], ["IC50", "TEST", 102, 106], ["vitronectin", "TREATMENT", 149, 160], ["\u03b1v\u03b23", "TREATMENT", 165, 169], ["\u03b1v\u03b25 integrins", "TREATMENT", 173, 187]]], ["When preparing biotin-labelled peptides as ligands for avidin-based assays, it is chemically most expedient to locate the biotin label on the N-terminal group of the peptide.", [["biotin", "CHEMICAL", 15, 21], ["biotin", "CHEMICAL", 122, 128], ["biotin", "CHEMICAL", 15, 21], ["biotin", "CHEMICAL", 122, 128], ["N", "CHEMICAL", 142, 143], ["biotin", "SIMPLE_CHEMICAL", 15, 21], ["avidin", "SIMPLE_CHEMICAL", 55, 61], ["biotin", "SIMPLE_CHEMICAL", 122, 128], ["avidin", "PROTEIN", 55, 61], ["N-terminal group", "PROTEIN", 142, 158], ["biotin-labelled peptides", "TREATMENT", 15, 39], ["avidin-based assays", "TEST", 55, 74]]], ["This is done without any regard to how this may affect peptide-target interactions, biotin-avidin binding, and the solubility properties of the resultant peptide.", [["biotin-avidin", "CHEMICAL", 84, 97], ["biotin", "CHEMICAL", 84, 90], ["biotin", "SIMPLE_CHEMICAL", 84, 90], ["avidin", "SIMPLE_CHEMICAL", 91, 97], ["biotin-avidin binding", "TREATMENT", 84, 105], ["the resultant peptide", "TREATMENT", 140, 161]]], ["In many instances, the products are poorly soluble, have little biological activity, and poor affinity for avidin.", [["avidin", "GENE_OR_GENE_PRODUCT", 107, 113], ["avidin", "PROTEIN", 107, 113]]], ["Problems can also arise during the synthesis of such Nterminally biotinylated peptides due to the poor solubility and reactivity of many of the reagents used for biotin introduction.Despite insights from receptor mutagenesis and structural function studies of peptide ligands the interaction of peptide hormones with family B G proteincoupled receptors (GPCRs) is not fully understood.", [["biotin", "CHEMICAL", 162, 168], ["biotin", "CHEMICAL", 162, 168], ["biotin", "SIMPLE_CHEMICAL", 162, 168], ["family B G proteincoupled receptors", "GENE_OR_GENE_PRODUCT", 317, 352], ["family B G proteincoupled receptors", "PROTEIN", 317, 352], ["GPCRs", "PROTEIN", 354, 359], ["such Nterminally biotinylated peptides", "TREATMENT", 48, 86], ["the poor solubility", "PROBLEM", 94, 113], ["the reagents", "TREATMENT", 140, 152], ["biotin introduction", "TREATMENT", 162, 181], ["receptor mutagenesis", "TREATMENT", 204, 224], ["structural function studies", "TEST", 229, 256], ["peptide ligands", "PROBLEM", 260, 275], ["peptide hormones", "TREATMENT", 295, 311], ["family B G proteincoupled receptors", "TREATMENT", 317, 352], ["poor solubility", "OBSERVATION_MODIFIER", 98, 113]]], ["In family B GPCRs an intact disulfide-bonded amino-terminal domain and extracellular loops linking the seven-helical bundle are believed to contain the peptide binding site.", [["extracellular loops", "ANATOMY", 71, 90], ["amino-terminal", "CHEMICAL", 45, 59], ["disulfide", "CHEMICAL", 28, 37], ["amino", "CHEMICAL", 45, 50], ["family B GPCRs", "GENE_OR_GENE_PRODUCT", 3, 17], ["extracellular loops", "CELLULAR_COMPONENT", 71, 90], ["family B GPCRs", "PROTEIN", 3, 17], ["disulfide-bonded amino-terminal domain", "PROTEIN", 28, 66], ["extracellular loops", "PROTEIN", 71, 90], ["seven-helical bundle", "PROTEIN", 103, 123], ["peptide binding site", "PROTEIN", 152, 172], ["an intact disulfide-bonded amino-terminal domain", "TREATMENT", 18, 66], ["extracellular loops", "TREATMENT", 71, 90], ["the peptide binding site", "PROBLEM", 148, 172], ["intact disulfide", "OBSERVATION", 21, 37], ["extracellular loops", "OBSERVATION", 71, 90], ["peptide binding", "OBSERVATION", 152, 167]]], ["The lack of high-resolution, three-dimensional information is an important factor thatTo overcome these limitations, we have developed an extremely simple method for synthesising peptides C-terminally with biotin.", [["biotin", "CHEMICAL", 206, 212], ["C", "CHEMICAL", 188, 189], ["biotin", "CHEMICAL", 206, 212], ["biotin", "SIMPLE_CHEMICAL", 206, 212], ["synthesising peptides C", "PROBLEM", 166, 189], ["biotin", "TREATMENT", 206, 212], ["high", "OBSERVATION_MODIFIER", 12, 16]]], ["Peptides can now be easily prepared by standard solid phase techniques either N-or C-terminally labelled, and screened to determine the optimum presentation for the biotin.", [["biotin", "CHEMICAL", 165, 171], ["C", "CHEMICAL", 83, 84], ["biotin", "CHEMICAL", 165, 171], ["biotin", "SIMPLE_CHEMICAL", 165, 171], ["standard solid phase techniques", "TREATMENT", 39, 70], ["the biotin", "TREATMENT", 161, 171]]], ["In cases studies using protein-protein interaction and kinase assays, peptides C-terminally labelled with biotin gave better sensitivity.SYNTHESIS OF CYCLIC PEPTIDES AS INHIBITORS OF INVASIN WITH INTEGRIN ALPHA3 BETA1Y.", [["biotin", "CHEMICAL", 106, 112], ["C", "CHEMICAL", 79, 80], ["biotin", "CHEMICAL", 106, 112], ["biotin", "SIMPLE_CHEMICAL", 106, 112], ["protein-protein interaction", "TEST", 23, 50], ["kinase assays", "TEST", 55, 68], ["peptides C", "TEST", 70, 80], ["biotin", "TREATMENT", 106, 112], ["CYCLIC PEPTIDES", "TREATMENT", 150, 165], ["INVASIN WITH INTEGRIN ALPHA3 BETA1Y", "TREATMENT", 183, 218]]], ["Yang 1 , J. Eble 2 , N. Sewald 1Department of Chemistry, Bielefeld University, Bielefeld 2 Institute of Physiological Chemistry and Pathological Biochemistry, University of Muenster, Muenster, GermanyMany bacterial pathogens bind and enter eukaryotic cells to establish infection.", [["cells", "ANATOMY", 251, 256], ["infection", "DISEASE", 270, 279], ["eukaryotic cells", "CELL", 240, 256], ["eukaryotic cells", "CELL_TYPE", 240, 256], ["Physiological Chemistry", "TEST", 104, 127], ["GermanyMany bacterial pathogens bind", "PROBLEM", 193, 229], ["infection", "PROBLEM", 270, 279], ["eukaryotic cells", "OBSERVATION", 240, 256], ["infection", "OBSERVATION", 270, 279]]], ["Invasin is an outer membrane protein required for efficient uptake of Yersinia into M cells.", [["outer membrane", "ANATOMY", 14, 28], ["M cells", "ANATOMY", 84, 91], ["Invasin", "GENE_OR_GENE_PRODUCT", 0, 7], ["outer membrane", "CELLULAR_COMPONENT", 14, 28], ["M cells", "CELL", 84, 91], ["Invasin", "PROTEIN", 0, 7], ["outer membrane protein", "PROTEIN", 14, 36], ["M cells", "CELL_LINE", 84, 91], ["Invasin", "TREATMENT", 0, 7], ["an outer membrane protein", "TREATMENT", 11, 36], ["Yersinia into M cells", "PROBLEM", 70, 91], ["Yersinia", "OBSERVATION", 70, 78]]], ["Invasin mediates its entry into eukaryotic cells by binding to members of \u03b21 integrin family that lack insertion domains (I domains), such as \u03b13\u03b21,\u03b14\u03b21,\u03b15\u03b21,\u03b16\u03b21, and \u03b1v\u03b21.", [["cells", "ANATOMY", 43, 48], ["Invasin", "CHEMICAL", 0, 7], ["Invasin", "GENE_OR_GENE_PRODUCT", 0, 7], ["cells", "CELL", 43, 48], ["\u03b21 integrin", "GENE_OR_GENE_PRODUCT", 74, 85], ["\u03b13\u03b21", "GENE_OR_GENE_PRODUCT", 142, 146], ["\u03b14\u03b21", "GENE_OR_GENE_PRODUCT", 147, 151], ["\u03b15\u03b21", "GENE_OR_GENE_PRODUCT", 152, 156], ["\u03b16\u03b21", "GENE_OR_GENE_PRODUCT", 157, 161], ["\u03b1v\u03b21", "GENE_OR_GENE_PRODUCT", 167, 171], ["Invasin", "PROTEIN", 0, 7], ["eukaryotic cells", "CELL_TYPE", 32, 48], ["\u03b21 integrin family", "PROTEIN", 74, 92], ["insertion domains", "PROTEIN", 103, 120], ["I domains", "PROTEIN", 122, 131], ["\u03b13\u03b21", "PROTEIN", 142, 146], ["\u03b14\u03b21", "PROTEIN", 147, 151], ["\u03b15\u03b21", "PROTEIN", 152, 156], ["\u03b16\u03b21", "PROTEIN", 157, 161], ["\u03b1v\u03b21", "DNA", 167, 171], ["lack insertion domains (I domains)", "PROBLEM", 98, 132], ["eukaryotic cells", "OBSERVATION", 32, 48]]], ["This type of peptide-protein interaction is an ideal subject for the rational design of inhibitors.Department of Chemistry, Bielefeld University, Bielefeld 2 Institute of Physiological Chemistry and Pathological Biochemistry, University of Muenster, Muenster, GermanyThe integrin binding motif consists of one loop region with a conservative Asp911 residue and two synergistic regions.", [["Asp", "CHEMICAL", 342, 345], ["integrin", "GENE_OR_GENE_PRODUCT", 271, 279], ["integrin binding motif", "PROTEIN", 271, 293], ["protein interaction", "PROBLEM", 21, 40], ["the rational design of inhibitors", "TREATMENT", 65, 98], ["Physiological Chemistry", "TEST", 171, 194], ["The integrin binding motif", "TREATMENT", 267, 293], ["synergistic", "OBSERVATION_MODIFIER", 365, 376]]], ["The aim of this project is to synthesize cyclic peptides based on the invasin binding epitope SDMS.", [["invasin binding epitope SDMS", "PROTEIN", 70, 98], ["synthesize cyclic peptides", "TREATMENT", 30, 56]]], ["This sequence has to be positioned in a \u03b2-turn with Asp in i+1 position for optimal activity of the peptide.", [["Asp", "CHEMICAL", 52, 55], ["Asp", "CHEMICAL", 52, 55], ["Asp", "TEST", 52, 55], ["the peptide", "TREATMENT", 96, 107]]], ["Also the Arg883 and Asp811 residue, which are about 27.29\u00c5 and 31.54\u00c5 respectively away from the Asp911 residue of the SDMS loop in invasin, should be investigated.", [["Arg883", "CHEMICAL", 9, 15], ["Asp811", "CHEMICAL", 20, 26], ["Arg883", "GENE_OR_GENE_PRODUCT", 9, 15], ["Asp811", "AMINO_ACID", 20, 26], ["invasin", "GENE_OR_GENE_PRODUCT", 132, 139], ["Asp911 residue", "PROTEIN", 97, 111], ["SDMS loop", "PROTEIN", 119, 128], ["invasin", "PROTEIN", 132, 139], ["the SDMS loop in invasin", "TREATMENT", 115, 139], ["SDMS loop", "OBSERVATION", 119, 128]]], ["Peptides that mimic these recognition sites have been synthesized and tested as ligands for the integrinDepartment of Organic Chemistry, Laboratory for Organic and Biomimetic Chemistry, University of Ghent, BelgiumPeptide-DNA cross-linking is a very powerful tool for studying peptide-DNA complexes.", [["DNA", "CELLULAR_COMPONENT", 222, 225], ["DNA", "CELLULAR_COMPONENT", 285, 288], ["peptide-DNA complexes", "PROTEIN", 277, 298], ["Organic Chemistry", "TEST", 118, 135], ["BelgiumPeptide", "TEST", 207, 221], ["studying peptide", "TEST", 268, 284]]], ["It transforms non-covalent complexes into covalent complexes, which renders characterization of the adduct by classical techniques (mass spectroscopy, NMR,\u2026) much easier.", [["covalent complexes", "PROTEIN", 42, 60], ["mass spectroscopy", "TEST", 132, 149], ["NMR", "TEST", 151, 154], ["non-covalent complexes", "OBSERVATION", 14, 36], ["covalent complexes", "OBSERVATION", 42, 60], ["adduct", "OBSERVATION", 100, 106]]], ["The aim of our research is to develop a new method for peptide-DNA cross-linking involving the incorporation of a furan moiety.", [["furan", "CHEMICAL", 114, 119], ["furan", "CHEMICAL", 114, 119], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["furan moiety", "SIMPLE_CHEMICAL", 114, 126], ["a new method for peptide", "TREATMENT", 38, 62], ["a furan moiety", "TREATMENT", 112, 126]]], ["The strategy is inspired by the naturally occurring process of oxidative furan ring opening by Cytochrome P450.", [["furan", "CHEMICAL", 73, 78], ["Cytochrome P450", "GENE_OR_GENE_PRODUCT", 95, 110], ["Cytochrome P450", "PROTEIN", 95, 110], ["oxidative furan ring", "TREATMENT", 63, 83], ["oxidative", "OBSERVATION", 63, 72], ["furan ring", "OBSERVATION", 73, 83]]], ["The resulting cis-butene-1,4-dial has been shown to react with amino-and sulfhydryl groups of macromolecules such as proteins and DNA.", [["cis-butene-1,4-dial", "CHEMICAL", 14, 33], ["sulfhydryl", "CHEMICAL", 73, 83], ["cis-butene-1,4-dial", "CHEMICAL", 14, 33], ["amino", "CHEMICAL", 63, 68], ["sulfhydryl", "CHEMICAL", 73, 83], ["cis-butene-1,4-dial", "SIMPLE_CHEMICAL", 14, 33], ["sulfhydryl", "SIMPLE_CHEMICAL", 73, 83], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["The resulting cis-butene", "TEST", 0, 24], ["amino-and sulfhydryl groups of macromolecules", "TREATMENT", 63, 108], ["DNA", "PROBLEM", 130, 133]]], ["In our research, DNA binding peptides are modified with a furan moiety and then chemically oxidized into a reactive enal.", [["furan", "CHEMICAL", 58, 63], ["furan", "CHEMICAL", 58, 63], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["furan moiety", "SIMPLE_CHEMICAL", 58, 70], ["DNA binding peptides", "PROBLEM", 17, 37], ["a furan moiety", "TREATMENT", 56, 70], ["reactive enal", "OBSERVATION", 107, 120]]], ["This enal can react with DNA to form a covalent peptide-DNA complex.", [["enal", "CHEMICAL", 5, 9], ["DNA", "CELLULAR_COMPONENT", 25, 28], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["covalent peptide-DNA complex", "PROTEIN", 39, 67], ["a covalent peptide", "TEST", 37, 55], ["DNA complex", "PROBLEM", 56, 67]]], ["Previous attempts to selectively oxidize furan modified minor groove binding peptides consisting of N-methylpyrrole building blocks failed.", [["furan", "CHEMICAL", 41, 46], ["N-methylpyrrole", "CHEMICAL", 100, 115], ["furan", "CHEMICAL", 41, 46], ["N-methylpyrrole", "CHEMICAL", 100, 115], ["furan", "SIMPLE_CHEMICAL", 41, 46], ["N-methylpyrrole", "SIMPLE_CHEMICAL", 100, 115], ["furan modified minor groove binding peptides", "TREATMENT", 41, 85], ["N-methylpyrrole building blocks", "TREATMENT", 100, 131]]], ["We are now applying the same strategy on major groove binding peptides consisting of natural amino acids.", [["amino acids", "CHEMICAL", 93, 104], ["amino acids", "CHEMICAL", 93, 104], ["amino acids", "AMINO_ACID", 93, 104], ["major groove binding peptides", "TREATMENT", 41, 70], ["natural amino acids", "TREATMENT", 85, 104]]], ["Currently the oxidation conditions are being optimized so that the furan moiety undergoes selective oxidation.", [["furan", "CHEMICAL", 67, 72], ["furan", "CHEMICAL", 67, 72], ["furan moiety", "SIMPLE_CHEMICAL", 67, 79], ["the oxidation conditions", "TREATMENT", 10, 34], ["the furan moiety", "TREATMENT", 63, 79], ["selective oxidation", "TREATMENT", 90, 109], ["selective oxidation", "OBSERVATION", 90, 109]]], ["These optimized conditions will be applied to known DNA binding peptides, in order to obtain a peptide-DNA cross-link.", [["DNA", "CELLULAR_COMPONENT", 52, 55], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["known DNA binding peptides", "PROBLEM", 46, 72], ["a peptide-DNA cross-link", "TREATMENT", 93, 117]]], ["We coupled octanoyl or palmitoyl group to the N-terminus of an analogue of SV40 nuclear localization signal (NLS) peptide, SV126-133(Ser128) to investigate the effect of fatty acid chain length on the conformation of the lipopeptide-antisense oligodeoxynucleotide (ODN) complexes and to establish the optimal peptide/ODN molar ratio (rM) for the effective delivery of ODN into the cells.", [["nuclear", "ANATOMY", 80, 87], ["cells", "ANATOMY", 381, 386], ["octanoyl", "CHEMICAL", 11, 19], ["palmitoyl", "CHEMICAL", 23, 32], ["SV126-133", "CHEMICAL", 123, 132], ["fatty acid", "CHEMICAL", 170, 180], ["oligodeoxynucleotide", "CHEMICAL", 243, 263], ["ODN", "CHEMICAL", 265, 268], ["ODN", "CHEMICAL", 317, 320], ["ODN", "CHEMICAL", 368, 371], ["octanoyl", "CHEMICAL", 11, 19], ["palmitoyl", "CHEMICAL", 23, 32], ["N", "CHEMICAL", 46, 47], ["Ser", "CHEMICAL", 133, 136], ["fatty acid", "CHEMICAL", 170, 180], ["octanoyl", "SIMPLE_CHEMICAL", 11, 19], ["palmitoyl", "SIMPLE_CHEMICAL", 23, 32], ["SV40", "ORGANISM", 75, 79], ["Ser128", "AMINO_ACID", 133, 139], ["fatty acid", "SIMPLE_CHEMICAL", 170, 180], ["ODN", "SIMPLE_CHEMICAL", 265, 268], ["ODN", "SIMPLE_CHEMICAL", 317, 320], ["ODN", "SIMPLE_CHEMICAL", 368, 371], ["cells", "CELL", 381, 386], ["N-terminus", "PROTEIN", 46, 56], ["NLS", "PROTEIN", 109, 112], ["lipopeptide-antisense oligodeoxynucleotide (ODN) complexes", "PROTEIN", 221, 279], ["palmitoyl group", "TREATMENT", 23, 38], ["SV126", "TEST", 123, 128], ["fatty acid chain length", "PROBLEM", 170, 193], ["the lipopeptide-antisense oligodeoxynucleotide (ODN) complexes", "TREATMENT", 217, 279], ["the optimal peptide/ODN molar ratio", "TREATMENT", 297, 332], ["the effective delivery of ODN into the cells", "TREATMENT", 342, 386]]], ["The ODNs used in this study were targeted towards either the green fluorescent protein (GFP) mRNA and the junction sequence between EWS and Fli1 genes.", [["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 61, 86], ["GFP", "GENE_OR_GENE_PRODUCT", 88, 91], ["EWS", "GENE_OR_GENE_PRODUCT", 132, 135], ["Fli1", "GENE_OR_GENE_PRODUCT", 140, 144], ["green fluorescent protein (GFP) mRNA", "RNA", 61, 97], ["EWS and Fli1 genes", "DNA", 132, 150], ["The ODNs", "TREATMENT", 0, 8], ["this study", "TEST", 17, 27], ["the junction sequence", "TEST", 102, 123], ["Fli1 genes", "OBSERVATION", 140, 150]]], ["The conformational change of ODN at different rM values was followed by circular dichroism (CD), attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy and atomic force microscopy (AFM).", [["ODN", "CHEMICAL", 29, 32], ["ODN", "SIMPLE_CHEMICAL", 29, 32], ["rM", "PROTEIN", 46, 48], ["The conformational change of ODN", "PROBLEM", 0, 32], ["circular dichroism", "TEST", 72, 90], ["Fourier transform", "TEST", 125, 142], ["atomic force microscopy", "TEST", 180, 203]]], ["The SV40 peptide-mediated ODN transfer into NIH/3T3 cells was studied by epifluorescence microscopy.", [["NIH/3T3 cells", "ANATOMY", 44, 57], ["ODN", "CHEMICAL", 26, 29], ["SV40", "ORGANISM", 4, 8], ["ODN", "SIMPLE_CHEMICAL", 26, 29], ["NIH/3T3 cells", "CELL", 44, 57], ["NIH/3T3 cells", "CELL_LINE", 44, 57], ["The SV40 peptide-mediated ODN transfer into NIH/3T3 cells", "TREATMENT", 0, 57], ["epifluorescence microscopy", "TEST", 73, 99]]], ["The interaction between the HIV-1 regulatory protein Rev and Rev responsive element (RRE) of HIV-1 mRNA has emerged in the last decade as an important target in antiviral therapy.", [["HIV-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["Rev", "GENE_OR_GENE_PRODUCT", 53, 56], ["Rev", "GENE_OR_GENE_PRODUCT", 61, 64], ["HIV-1", "ORGANISM", 93, 98], ["HIV-1 regulatory protein Rev and Rev responsive element", "DNA", 28, 83], ["RRE", "DNA", 85, 88], ["HIV-1 mRNA", "RNA", 93, 103], ["HIV-1", "SPECIES", 28, 33], ["HIV-1", "SPECIES", 93, 98], ["HIV-1", "SPECIES", 28, 33], ["HIV-1", "SPECIES", 93, 98], ["the HIV", "TEST", 24, 31], ["HIV", "PROBLEM", 93, 96], ["antiviral therapy", "TREATMENT", 161, 178], ["antiviral therapy", "OBSERVATION", 161, 178]]], ["The Rev-RRE interaction is essential for the replication of HIV.", [["Rev-", "GENE_OR_GENE_PRODUCT", 4, 8], ["HIV", "ORGANISM", 60, 63], ["HIV", "SPECIES", 60, 63], ["HIV", "PROBLEM", 60, 63]]], ["The Rev protein binds to the RRE site located in the env coding region of the full length viral mRNA and facilities the export of the RNA from the nucleus, while protecting it from the cell's splicing machinery.", [["nucleus", "ANATOMY", 147, 154], ["cell", "ANATOMY", 185, 189], ["Rev", "GENE_OR_GENE_PRODUCT", 4, 7], ["nucleus", "CELLULAR_COMPONENT", 147, 154], ["cell", "CELL", 185, 189], ["Rev protein", "PROTEIN", 4, 15], ["RRE site", "DNA", 29, 37], ["env coding region", "DNA", 53, 70], ["full length viral mRNA", "RNA", 78, 100], ["The Rev protein binds", "TREATMENT", 0, 21], ["the RRE site", "PROBLEM", 25, 37], ["Rev protein binds", "OBSERVATION", 4, 21], ["RRE site", "OBSERVATION", 29, 37], ["env", "OBSERVATION", 53, 56], ["nucleus", "ANATOMY", 147, 154]]], ["In the published NMR structure of the RRE/Rev-derived peptide complex, an -helical segment of Rev binding domain recognises a specific region of RRE.", [["RRE", "GENE_OR_GENE_PRODUCT", 38, 41], ["RRE", "GENE_OR_GENE_PRODUCT", 145, 148], ["RRE", "DNA", 38, 41], ["Rev-derived peptide complex", "PROTEIN", 42, 69], ["-helical segment", "PROTEIN", 74, 90], ["Rev binding domain", "PROTEIN", 94, 112], ["RRE", "DNA", 145, 148], ["Rev-derived peptide complex", "PROBLEM", 42, 69], ["Rev binding domain", "PROBLEM", 94, 112], ["Rev binding", "OBSERVATION", 94, 105], ["RRE", "OBSERVATION", 145, 148]]], ["An approach is described to design a new class of -hairpin peptidomimetic ligands for HIV-1 Rev protein, which inhibit its binding to the RRE RNA.", [["HIV-1", "ORGANISM", 86, 91], ["Rev", "GENE_OR_GENE_PRODUCT", 92, 95], ["HIV-1 Rev protein", "PROTEIN", 86, 103], ["RRE RNA", "RNA", 138, 145], ["HIV-1", "SPECIES", 86, 91], ["HIV-1", "SPECIES", 86, 91], ["-hairpin peptidomimetic ligands", "TREATMENT", 50, 81], ["HIV", "PROBLEM", 86, 89], ["RRE RNA", "OBSERVATION", 138, 145]]], ["A model -hairpin peptide served as a scaffold to pre-organise side chains into a geometry similar to that seen in a helical peptide.", [["A model -hairpin peptide", "TREATMENT", 0, 24], ["a scaffold to pre-organise side chains", "TREATMENT", 35, 73], ["a helical peptide", "TREATMENT", 114, 131]]], ["A library of peptidomimetics was prepared by grafting sequences related to the RNA recognition element in Rev onto a hairpin-inducing D-Pro-L-Pro template.", [["D-Pro", "CHEMICAL", 134, 139], ["D-Pro-L-Pro", "CHEMICAL", 134, 145], ["Rev", "GENE_OR_GENE_PRODUCT", 106, 109], ["RNA recognition element", "DNA", 79, 102], ["Rev", "PROTEIN", 106, 109], ["hairpin-inducing D-Pro-L-Pro template", "DNA", 117, 154], ["A library of peptidomimetics", "TREATMENT", 0, 28], ["a hairpin", "TREATMENT", 115, 124], ["L-Pro template", "TREATMENT", 140, 154]]], ["The electrophoretic mobility shift assay (EMSA) revealed that all of the designed peptidomimetics bind to RRE and the best examples show affinities (Kd) in a nanomolar range.", [["RRE", "GENE_OR_GENE_PRODUCT", 106, 109], ["RRE", "DNA", 106, 109], ["The electrophoretic mobility shift assay", "TEST", 0, 40], ["the designed peptidomimetics bind to RRE", "PROBLEM", 69, 109]]], ["These new ligands show a novel approach to designing Rev peptidomimetics, represent interesting leads for the development of more potent HIV RRE/Rev inhibitors and permit more detailed studies of the mechanism of binding to RNA.CAPILLARY ELECTROPHORESIS ANALYSIS OF INTERACTION OF NUCLEOBASE-CONTAINING TAT PEPTIDES WITH TAR RNA HIV-1A.", [["HIV", "ORGANISM", 137, 140], ["Rev", "GENE_OR_GENE_PRODUCT", 145, 148], ["HIV-1A", "ORGANISM", 329, 335], ["RNA", "RNA", 224, 227], ["HIV", "SPECIES", 137, 140], ["HIV-1A", "SPECIES", 329, 335], ["Rev peptidomimetics", "TREATMENT", 53, 72], ["potent HIV RRE", "TREATMENT", 130, 144], ["Rev inhibitors", "TREATMENT", 145, 159]]], ["Napiorkowska, A. Sawula, M. Olkowicz, P. Mucha, P. RekowskiFaculty of Chemistry, University of Gdansk, PolandTat (trans-activator of transcription) is the protein which controls the early phase of HIV-1 replication cycle.", [["trans-activator", "GENE_OR_GENE_PRODUCT", 114, 129], ["HIV-1", "ORGANISM", 197, 202], ["Tat", "PROTEIN", 109, 112], ["trans-activator of transcription", "PROTEIN", 114, 146], ["HIV-1", "SPECIES", 197, 202], ["HIV-1", "SPECIES", 197, 202]]], ["It is a potent viral trans-activator containing from 86 to 101 amino acid residues which binds to TAR RNA.", [["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 63, 73], ["amino acid", "AMINO_ACID", 63, 73], ["viral trans-activator", "PROTEIN", 15, 36], ["TAR RNA", "RNA", 98, 105], ["a potent viral trans-activator", "TREATMENT", 6, 36], ["amino acid residues", "TREATMENT", 63, 82], ["TAR RNA", "OBSERVATION", 98, 105]]], ["The fundamental role of Tat is promoting effective elongation of viral mRNA (vmRNA).", [["Tat", "GENE_OR_GENE_PRODUCT", 24, 27], ["vmRNA", "GENE_OR_GENE_PRODUCT", 77, 82], ["Tat", "PROTEIN", 24, 27], ["viral mRNA", "RNA", 65, 75], ["vmRNA", "PROTEIN", 77, 82], ["viral mRNA (vmRNA)", "PROBLEM", 65, 83], ["Tat", "OBSERVATION", 24, 27], ["effective", "OBSERVATION_MODIFIER", 41, 50], ["elongation", "OBSERVATION_MODIFIER", 51, 61], ["viral mRNA", "OBSERVATION", 65, 75]]], ["Binding of Tat to TAR is mediated by a 9-amino-acid, highly basic Arg49-Lys-Lys-Arg52-Arg-Gln-Arg-Arg-Arg57 sequence of the ARM (arginine rich motif); the key role in these interactions is played by Arg52.", [["9-amino-acid", "CHEMICAL", 39, 51], ["arginine", "CHEMICAL", 129, 137], ["9-amino-acid", "CHEMICAL", 39, 51], ["Arg49-Lys-Lys-Arg52-Arg-Gln-Arg-Arg-Arg57", "CHEMICAL", 66, 107], ["arginine", "CHEMICAL", 129, 137], ["Arg52", "CHEMICAL", 199, 204], ["Tat", "GENE_OR_GENE_PRODUCT", 11, 14], ["TAR", "GENE_OR_GENE_PRODUCT", 18, 21], ["Arg49", "GENE_OR_GENE_PRODUCT", 66, 71], ["ARM", "AMINO_ACID", 124, 127], ["arginine", "AMINO_ACID", 129, 137], ["Arg52", "GENE_OR_GENE_PRODUCT", 199, 204], ["Tat", "PROTEIN", 11, 14], ["TAR", "DNA", 18, 21], ["Arg52", "PROTEIN", 80, 85], ["Arg-Gln-Arg-Arg-Arg57 sequence", "PROTEIN", 86, 116], ["ARM", "PROTEIN", 124, 127], ["arginine rich motif", "PROTEIN", 129, 148], ["Arg52", "PROTEIN", 199, 204], ["Lys", "TEST", 72, 75], ["Lys", "TEST", 76, 79], ["Arg52", "TEST", 80, 85], ["Arg", "TEST", 98, 101], ["the ARM (arginine rich motif", "TREATMENT", 120, 148], ["ARM", "ANATOMY", 124, 127]]], ["The goal of our research was to investigate the interaction of 27-nucleotide TAR RNA with synthesized Tat peptide analogues using capillary electrophoresis (CE), a powerful analytical technique of biochemical studies.", [["27-nucleotide", "CHEMICAL", 63, 76], ["capillary", "TISSUE", 130, 139], ["27-nucleotide TAR RNA", "RNA", 63, 84], ["nucleotide TAR RNA", "TREATMENT", 66, 84], ["synthesized Tat peptide analogues", "TREATMENT", 90, 123], ["capillary electrophoresis", "TEST", 130, 155], ["biochemical studies", "TEST", 197, 216]]], ["Changes in electrophoretic mobility of the TAR peak are employed for monitoring TAR-Tat complex formation.", [["TAR-Tat complex", "GENE_OR_GENE_PRODUCT", 80, 95], ["TAR", "DNA", 43, 46], ["TAR", "DNA", 80, 83], ["Tat complex", "PROTEIN", 84, 95], ["Changes in electrophoretic mobility", "PROBLEM", 0, 35], ["electrophoretic", "OBSERVATION_MODIFIER", 11, 26], ["mobility", "OBSERVATION_MODIFIER", 27, 35]]], ["CE experiments were performed using LPA-coated capillary and a physical gel containing buffer.", [["capillary", "ANATOMY", 47, 56], ["LPA", "CHEMICAL", 36, 39], ["LPA", "CHEMICAL", 36, 39], ["LPA", "SIMPLE_CHEMICAL", 36, 39], ["capillary", "TISSUE", 47, 56], ["CE experiments", "TEST", 0, 14], ["LPA", "TEST", 36, 39], ["a physical gel containing buffer", "TREATMENT", 61, 93]]], ["Native ARM fragment Tat(49-57)NH2, its analogues Ac-Tat(49-57)NH2 and Ac-[Lys52]Tat(49-57)NH2 and analogues substituted in position 52 with alanine-, homoalanine and lysine-derived amino acids containing nucleobases (adenine, guanine, cytosine, uracil, thymine) and nucleosides (adenosine, guanosine, uridine and cytidine) in the side chain were studied.", [["49-57)NH2", "CHEMICAL", 24, 33], ["49-57)NH2", "CHEMICAL", 56, 65], ["49-57)NH2", "CHEMICAL", 84, 93], ["alanine", "CHEMICAL", 140, 147], ["homoalanine", "CHEMICAL", 150, 161], ["lysine", "CHEMICAL", 166, 172], ["amino acids", "CHEMICAL", 181, 192], ["nucleobases", "CHEMICAL", 204, 215], ["adenine", "CHEMICAL", 217, 224], ["guanine", "CHEMICAL", 226, 233], ["cytosine", "CHEMICAL", 235, 243], ["uracil", "CHEMICAL", 245, 251], ["thymine", "CHEMICAL", 253, 260], ["nucleosides", "CHEMICAL", 266, 277], ["adenosine", "CHEMICAL", 279, 288], ["guanosine", "CHEMICAL", 290, 299], ["uridine", "CHEMICAL", 301, 308], ["cytidine", "CHEMICAL", 313, 321], ["NH2", "CHEMICAL", 30, 33], ["NH2", "CHEMICAL", 62, 65], ["Ac-[Lys52]Tat", "CHEMICAL", 70, 83], ["NH2", "CHEMICAL", 90, 93], ["alanine", "CHEMICAL", 140, 147], ["homoalanine", "CHEMICAL", 150, 161], ["lysine", "CHEMICAL", 166, 172], ["amino acids", "CHEMICAL", 181, 192], ["nucleobases", "CHEMICAL", 204, 215], ["adenine", "CHEMICAL", 217, 224], ["guanine", "CHEMICAL", 226, 233], ["cytosine", "CHEMICAL", 235, 243], ["uracil", "CHEMICAL", 245, 251], ["thymine", "CHEMICAL", 253, 260], ["nucleosides", "CHEMICAL", 266, 277], ["adenosine", "CHEMICAL", 279, 288], ["guanosine", "CHEMICAL", 290, 299], ["uridine", "CHEMICAL", 301, 308], ["cytidine", "CHEMICAL", 313, 321], ["Ac-Tat", "SIMPLE_CHEMICAL", 49, 55], ["49-57)NH2", "SIMPLE_CHEMICAL", 56, 65], ["Ac-[Lys52]Tat", "SIMPLE_CHEMICAL", 70, 83], ["49-57)NH2", "SIMPLE_CHEMICAL", 84, 93], ["alanine", "AMINO_ACID", 140, 147], ["homoalanine", "SIMPLE_CHEMICAL", 150, 161], ["lysine-derived", "SIMPLE_CHEMICAL", 166, 180], ["amino acids", "AMINO_ACID", 181, 192], ["adenine", "SIMPLE_CHEMICAL", 217, 224], ["guanine", "SIMPLE_CHEMICAL", 226, 233], ["cytosine", "SIMPLE_CHEMICAL", 235, 243], ["uracil", "SIMPLE_CHEMICAL", 245, 251], ["thymine", "SIMPLE_CHEMICAL", 253, 260], ["nucleosides", "SIMPLE_CHEMICAL", 266, 277], ["adenosine", "SIMPLE_CHEMICAL", 279, 288], ["guanosine", "SIMPLE_CHEMICAL", 290, 299], ["uridine", "SIMPLE_CHEMICAL", 301, 308], ["cytidine", "SIMPLE_CHEMICAL", 313, 321], ["ARM fragment Tat", "PROTEIN", 7, 23], ["NH2", "PROTEIN", 30, 33], ["Tat", "PROTEIN", 52, 55], ["NH2", "PROTEIN", 62, 65], ["NH2", "PROTEIN", 90, 93], ["Native ARM fragment Tat", "TEST", 0, 23], ["its analogues Ac", "TEST", 35, 51], ["Tat", "TEST", 52, 55], ["NH2", "TEST", 62, 65], ["Ac", "TEST", 70, 72], ["Tat", "TEST", 80, 83], ["NH2", "TEST", 90, 93], ["analogues", "TEST", 98, 107], ["alanine", "TEST", 140, 147], ["homoalanine", "TREATMENT", 150, 161], ["lysine", "TREATMENT", 166, 172], ["amino acids", "TREATMENT", 181, 192], ["nucleobases (adenine", "TREATMENT", 204, 224], ["guanine", "TREATMENT", 226, 233], ["cytosine", "TREATMENT", 235, 243], ["uracil, thymine", "TREATMENT", 245, 260], ["nucleosides", "TREATMENT", 266, 277], ["adenosine", "TREATMENT", 279, 288], ["guanosine", "TREATMENT", 290, 299], ["uridine and cytidine", "TREATMENT", 301, 321], ["ARM", "ANATOMY", 7, 10], ["fragment", "OBSERVATION", 11, 19]]], ["Specific interactions and complex formation were observed for both the native ARM peptide fragment and selected Tat analogues.", [["native ARM peptide fragment", "PROTEIN", 71, 98], ["Tat", "PROTEIN", 112, 115], ["the native ARM peptide fragment", "TREATMENT", 67, 98], ["selected Tat analogues", "TREATMENT", 103, 125], ["ARM peptide", "ANATOMY", 78, 89], ["fragment", "OBSERVATION", 90, 98]]], ["The research is aimed at improving our understanding of the molecular mechanism of peptide-nucleic acid interaction, as well as evaluating the usefulness of selected nucleobase-containing amino acids as point probes for investigating peptide-RNA interactions.Department of Chemistry 2 Department of Physics 3 Department of Biology, Bielefeld University, Bielefeld, GermanyInteractions between proteins and DNA are important to all living organisms.", [["nucleic acid", "CHEMICAL", 91, 103], ["nucleobase", "CHEMICAL", 166, 176], ["amino acids", "CHEMICAL", 188, 199], ["nucleobase", "CHEMICAL", 166, 176], ["amino acids", "CHEMICAL", 188, 199], ["nucleic acid", "SIMPLE_CHEMICAL", 91, 103], ["amino acids", "AMINO_ACID", 188, 199], ["DNA", "CELLULAR_COMPONENT", 406, 409], ["nucleic acid interaction", "PROBLEM", 91, 115], ["selected nucleobase", "TREATMENT", 157, 176], ["amino acids", "TREATMENT", 188, 199], ["GermanyInteractions between proteins", "TREATMENT", 365, 401], ["DNA", "PROBLEM", 406, 409]]], ["The goal is to investigate the molecular recognition between DNA and the transcription factor PhoB of E. coli on the single molecule level and to identify amino acids required for DNA binding.Department of Chemistry 2 Department of Physics 3 Department of Biology, Bielefeld University, Bielefeld, GermanyPhoB is composed of a transactivation domain (amino acids 1-127) and a DNA binding domain (amino acids 123-229) that binds to specific DNA sequences (pho boxes) containing a TGTCA sequence.", [["amino acids", "CHEMICAL", 155, 166], ["amino acids 1-127", "CHEMICAL", 351, 368], ["amino acids 123-229", "CHEMICAL", 396, 415], ["amino acids", "CHEMICAL", 155, 166], ["amino acids", "CHEMICAL", 351, 362], ["amino acids", "CHEMICAL", 396, 407], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["PhoB", "GENE_OR_GENE_PRODUCT", 94, 98], ["E. coli", "ORGANISM", 102, 109], ["amino acids", "AMINO_ACID", 155, 166], ["DNA", "CELLULAR_COMPONENT", 180, 183], ["amino acids", "AMINO_ACID", 351, 362], ["DNA", "CELLULAR_COMPONENT", 376, 379], ["amino acids 123-229", "AMINO_ACID", 396, 415], ["DNA", "CELLULAR_COMPONENT", 440, 443], ["transcription factor", "PROTEIN", 73, 93], ["PhoB", "PROTEIN", 94, 98], ["transactivation domain", "PROTEIN", 327, 349], ["amino acids 1-127", "PROTEIN", 351, 368], ["DNA binding domain", "PROTEIN", 376, 394], ["amino acids 123-229", "PROTEIN", 396, 415], ["DNA sequences", "DNA", 440, 453], ["pho boxes", "DNA", 455, 464], ["TGTCA sequence", "DNA", 479, 493], ["E. coli", "SPECIES", 102, 109], ["E. coli", "SPECIES", 102, 109], ["E. coli", "PROBLEM", 102, 109], ["the single molecule level", "TEST", 113, 138], ["amino acids", "TEST", 155, 166], ["DNA binding", "PROBLEM", 180, 191], ["a transactivation domain", "TEST", 325, 349], ["amino acids", "TEST", 351, 362], ["a DNA binding domain", "TEST", 374, 394], ["amino acids", "TEST", 396, 407], ["specific DNA sequences", "TEST", 431, 453], ["a TGTCA sequence", "TEST", 477, 493]]], ["[1] Chemical synthesis of peptide epitopes present in the DNA binding domain of PhoB and isolation of the whole DNA binding domain of PhoB was performed.", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["PhoB", "GENE_OR_GENE_PRODUCT", 80, 84], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["PhoB", "GENE_OR_GENE_PRODUCT", 134, 138], ["DNA binding domain", "PROTEIN", 58, 76], ["PhoB", "PROTEIN", 80, 84], ["whole DNA binding domain", "PROTEIN", 106, 130], ["PhoB", "PROTEIN", 134, 138], ["Chemical synthesis of peptide epitopes", "TREATMENT", 4, 42], ["PhoB", "TREATMENT", 80, 84], ["isolation", "TREATMENT", 89, 98], ["the whole DNA binding domain of PhoB", "TEST", 102, 138]]], ["The protein was purified using intein mediated protein purification.", [["intein mediated protein purification", "TREATMENT", 31, 67]]], ["An additional cysteine residue was ligated to the protein using intein mediated ligation reactions and will be used for immobilization and labeling.Department of Chemistry 2 Department of Physics 3 Department of Biology, Bielefeld University, Bielefeld, GermanyIn single molecule force spectroscopy (AFM) experiments it has been shown that both a peptide with a native PhoB-sequence and the recombinant protein bind to DNA.", [["cysteine", "CHEMICAL", 14, 22], ["cysteine", "AMINO_ACID", 14, 22], ["PhoB", "GENE_OR_GENE_PRODUCT", 369, 373], ["DNA", "CELLULAR_COMPONENT", 419, 422], ["PhoB", "PROTEIN", 369, 373], ["recombinant protein", "PROTEIN", 391, 410], ["An additional cysteine residue", "TREATMENT", 0, 30], ["intein mediated ligation reactions", "TREATMENT", 64, 98], ["immobilization", "TREATMENT", 120, 134], ["the recombinant protein bind to DNA", "PROBLEM", 387, 422], ["cysteine residue", "OBSERVATION", 14, 30], ["ligation", "OBSERVATION", 80, 88]]], ["Competition experiments were performed to prove specific DNA binding.", [["DNA", "CELLULAR_COMPONENT", 57, 60], ["Competition experiments", "TEST", 0, 23], ["specific DNA binding", "PROBLEM", 48, 68]]], ["[2] Mutated peptides and proteins where strategic amino acids were replaced by alanine have also been examined to reveal the contributions of single residues to molecular recognition.Department of Chemistry 2 Department of Physics 3 Department of Biology, Bielefeld University, Bielefeld, GermanyThe binding contribution of the proteins is determined by surface plasmon resonance, electrophoretic mobility shift assays and fluorescence correlation spectroscopy.Department of Chemistry 2 Department of Biology, University of Ferrara, ItalyWe investigated the biophysical characteristics and the pore formation dynamics of naturally occurring and synthetic peptides forming membrane-spanning channels by using isolated rod outer segments (OS) of reptilia and amphibia recorded in the whole-cell configuration.", [["pore", "ANATOMY", 594, 598], ["membrane", "ANATOMY", 672, 680], ["rod outer segments", "ANATOMY", 717, 735], ["reptilia", "ANATOMY", 744, 752], ["amphibia", "ANATOMY", 757, 765], ["whole-cell", "ANATOMY", 782, 792], ["amino acids", "CHEMICAL", 50, 61], ["alanine", "CHEMICAL", 79, 86], ["amino acids", "CHEMICAL", 50, 61], ["alanine", "CHEMICAL", 79, 86], ["amino acids", "AMINO_ACID", 50, 61], ["alanine", "AMINO_ACID", 79, 86], ["membrane", "CELLULAR_COMPONENT", 672, 680], ["outer segments", "MULTI-TISSUE_STRUCTURE", 721, 735], ["cell", "CELL", 788, 792], ["membrane-spanning channels", "PROTEIN", 672, 698], ["Mutated peptides and proteins", "PROBLEM", 4, 33], ["strategic amino acids", "TREATMENT", 40, 61], ["single residues to molecular recognition", "PROBLEM", 142, 182], ["the proteins", "PROBLEM", 324, 336], ["surface plasmon resonance", "TEST", 354, 379], ["electrophoretic mobility shift assays", "TEST", 381, 418], ["fluorescence correlation spectroscopy", "TEST", 423, 460], ["isolated rod outer segments", "TREATMENT", 708, 735], ["reptilia", "TEST", 744, 752], ["amphibia", "PROBLEM", 757, 765], ["rod", "OBSERVATION_MODIFIER", 717, 720], ["outer", "OBSERVATION_MODIFIER", 721, 726], ["segments", "OBSERVATION_MODIFIER", 727, 735], ["reptilia", "ANATOMY_MODIFIER", 744, 752], ["cell configuration", "OBSERVATION", 788, 806]]], ["Once blocked the two OS endogenous conductances (the cGMP channels by light and the retinal exchanger by removing one of the transported ion species from both sides of the membrane, i.e. K+, Na+ or Ca2+), the OS membrane resistance (Rm) could be >5 G\u038f.", [["retinal", "ANATOMY", 84, 91], ["membrane", "ANATOMY", 172, 180], ["membrane", "ANATOMY", 212, 220], ["cGMP", "CHEMICAL", 53, 57], ["K", "CHEMICAL", 187, 188], ["Na", "CHEMICAL", 191, 193], ["Ca2", "CHEMICAL", 198, 201], ["cGMP", "CHEMICAL", 53, 57], ["K+", "CHEMICAL", 187, 189], ["Na+", "CHEMICAL", 191, 194], ["Ca2+", "CHEMICAL", 198, 202], ["cGMP", "SIMPLE_CHEMICAL", 53, 57], ["retinal", "MULTI-TISSUE_STRUCTURE", 84, 91], ["membrane", "CELLULAR_COMPONENT", 172, 180], ["K+", "SIMPLE_CHEMICAL", 187, 189], ["Na+", "SIMPLE_CHEMICAL", 191, 194], ["Ca2+", "SIMPLE_CHEMICAL", 198, 202], ["cGMP channels", "PROTEIN", 53, 66], ["retinal exchanger", "PROTEIN", 84, 101], ["the cGMP channels", "TREATMENT", 49, 66], ["the retinal exchanger", "TREATMENT", 80, 101], ["K", "TEST", 187, 188], ["Na", "TEST", 191, 193], ["Ca2", "TEST", 198, 201], ["the OS membrane resistance", "TEST", 205, 231], ["endogenous conductances", "OBSERVATION", 24, 47], ["retinal", "ANATOMY", 84, 91], ["membrane resistance", "OBSERVATION", 212, 231]]], ["Macroscopic currents of amplitude of ~300 pA were recorded in symmetric K+ or Na+ (>100 mM) and Ca2+ (1 mM) from the commercially available alamethicin mixture, the synthetic alamethicin F50/5 (a major component of the natural mixture), and selected analogues applied at 1 \u00b5M concentration at -20 mV.", [["K", "CHEMICAL", 72, 73], ["Na", "CHEMICAL", 78, 80], ["Ca2", "CHEMICAL", 96, 99], ["alamethicin", "CHEMICAL", 140, 151], ["alamethicin", "CHEMICAL", 175, 186], ["F50/5", "CHEMICAL", 187, 192], ["K+", "CHEMICAL", 72, 74], ["Na+", "CHEMICAL", 78, 81], ["Ca2+", "CHEMICAL", 96, 100], ["alamethicin", "CHEMICAL", 140, 151], ["alamethicin F50/5", "CHEMICAL", 175, 192], ["K+", "SIMPLE_CHEMICAL", 72, 74], ["Na+", "SIMPLE_CHEMICAL", 78, 81], ["Ca2+", "SIMPLE_CHEMICAL", 96, 100], ["alamethicin", "SIMPLE_CHEMICAL", 140, 151], ["alamethicin F50/5", "SIMPLE_CHEMICAL", 175, 192], ["Macroscopic currents", "TEST", 0, 20], ["amplitude", "TEST", 24, 33], ["symmetric K", "TEST", 62, 73], ["Na", "TEST", 78, 80], ["Ca2", "TEST", 96, 99], ["alamethicin mixture", "TREATMENT", 140, 159], ["the synthetic alamethicin F50", "TREATMENT", 161, 190]]], ["Once applied and removed the peptide, the current activates and deactivates with a time constant of about 160 ms.", [["the peptide", "TREATMENT", 25, 36]]], ["The synthetic analogues [Glu(OMe)7,18,19] and [Glu(OMe)18,19] produce a current of about 100 pA at 1 \u00b5M concentration, and they show a strong activation by hyperpolarization as alamethicin F50/5 itself.", [["Glu", "CHEMICAL", 25, 28], ["Glu", "CHEMICAL", 47, 50], ["alamethicin", "CHEMICAL", 177, 188], ["[Glu(OMe)7,18,19] and [Glu(OMe)18,19]", "CHEMICAL", 24, 61], ["alamethicin", "CHEMICAL", 177, 188], ["[Glu(OMe)7,18,19]", "SIMPLE_CHEMICAL", 24, 41], ["[Glu(OMe)18,19]", "SIMPLE_CHEMICAL", 46, 61], ["The synthetic analogues", "TEST", 0, 23], ["Glu(OMe)", "TEST", 25, 33], ["Glu(OMe)", "TEST", 47, 55], ["alamethicin F50", "TREATMENT", 177, 192]]], ["Clear single channel events were observed when the concentration of all of the alamethicin peptides is reduced to <250 nM.", [["alamethicin", "CHEMICAL", 79, 90], ["Clear single channel events", "PROBLEM", 0, 27], ["the alamethicin peptides", "TREATMENT", 75, 99], ["single channel", "OBSERVATION_MODIFIER", 6, 20]]], ["These results indicate that the three Gln residues at positions 7, 18 and 19 of alamethicin F50/5 are not a key factor for pore formation and its conduction properties.", [["pore", "ANATOMY", 123, 127], ["Gln", "CHEMICAL", 38, 41], ["alamethicin", "CHEMICAL", 80, 91], ["Gln", "CHEMICAL", 38, 41], ["alamethicin", "CHEMICAL", 80, 91], ["alamethicin F50/5", "SIMPLE_CHEMICAL", 80, 97], ["pore", "CELLULAR_COMPONENT", 123, 127], ["alamethicin F50/5", "TREATMENT", 80, 97], ["pore formation", "PROBLEM", 123, 137], ["Gln residues", "OBSERVATION", 38, 50]]], ["In general, the pore assembly and disassembly are very fast and cooperative events.", [["pore", "ANATOMY", 16, 20], ["pore", "CELLULAR_COMPONENT", 16, 20], ["very fast and cooperative events", "PROBLEM", 50, 82]]], ["The translocation mechanism of penetratin (RQIKIWFQNRRMKWKK) is not clear, but the involvement of cell membrane was supposed.", [["cell membrane", "ANATOMY", 98, 111], ["penetratin", "CHEMICAL", 31, 41], ["penetratin", "CHEMICAL", 31, 41], ["RQIKIWFQNRRMKWKK", "CHEMICAL", 43, 59], ["penetratin", "SIMPLE_CHEMICAL", 31, 41], ["cell membrane", "CELLULAR_COMPONENT", 98, 111], ["cell membrane", "PROBLEM", 98, 111], ["penetratin", "OBSERVATION_MODIFIER", 31, 41], ["not", "UNCERTAINTY", 64, 67], ["clear", "OBSERVATION", 68, 73], ["cell membrane", "OBSERVATION", 98, 111]]], ["Recent studies with phospholipid model membranes have shown that penetratin interacts only with negatively charged liposomes.", [["membranes", "ANATOMY", 39, 48], ["penetratin", "CHEMICAL", 65, 75], ["penetratin", "CHEMICAL", 65, 75], ["phospholipid", "SIMPLE_CHEMICAL", 20, 32], ["membranes", "CELLULAR_COMPONENT", 39, 48], ["penetratin", "SIMPLE_CHEMICAL", 65, 75], ["liposomes", "SIMPLE_CHEMICAL", 115, 124], ["Recent studies", "TEST", 0, 14], ["phospholipid model membranes", "TREATMENT", 20, 48], ["penetratin interacts", "PROBLEM", 65, 85]]], ["We aimed to analyse the effect of penetratin on liposomes composed of different phospholipids (DPPC/DPPG 2:8-8:2) by fluorescence spectroscopy.", [["penetratin", "CHEMICAL", 34, 44], ["DPPC", "CHEMICAL", 95, 99], ["DPPG 2:8-8:2", "CHEMICAL", 100, 112], ["penetratin", "CHEMICAL", 34, 44], ["DPPC", "CHEMICAL", 95, 99], ["DPPG 2:8-8:2", "CHEMICAL", 100, 112], ["penetratin", "SIMPLE_CHEMICAL", 34, 44], ["liposomes", "SIMPLE_CHEMICAL", 48, 57], ["phospholipids", "SIMPLE_CHEMICAL", 80, 93], ["DPPC", "SIMPLE_CHEMICAL", 95, 99], ["DPPG 2:8-8:2", "SIMPLE_CHEMICAL", 100, 112], ["penetratin on liposomes", "TREATMENT", 34, 57], ["different phospholipids (DPPC/DPPG", "TREATMENT", 70, 104], ["fluorescence spectroscopy", "TEST", 117, 142]]], ["In the first set of experiments, liposomes labelled with fluorescent markers (DPH, ANS and TMA-DPH) were incubated with penetratin and the fluorescence polarisation was determined as a function of the temperature.", [["DPH", "CHEMICAL", 78, 81], ["penetratin", "CHEMICAL", 120, 130], ["DPH", "CHEMICAL", 78, 81], ["TMA", "CHEMICAL", 91, 94], ["DPH", "CHEMICAL", 95, 98], ["penetratin", "CHEMICAL", 120, 130], ["liposomes", "SIMPLE_CHEMICAL", 33, 42], ["DPH", "SIMPLE_CHEMICAL", 78, 81], ["ANS", "SIMPLE_CHEMICAL", 83, 86], ["TMA-DPH", "SIMPLE_CHEMICAL", 91, 98], ["penetratin", "SIMPLE_CHEMICAL", 120, 130], ["fluorescent markers", "TEST", 57, 76], ["DPH", "TEST", 78, 81], ["ANS and TMA-DPH", "TREATMENT", 83, 98], ["penetratin", "TREATMENT", 120, 130], ["the fluorescence polarisation", "TEST", 135, 164]]], ["In the range of 15-200 mol/mol phospholipid/penetratin ratio, no change in the transition temperature was observed indicating that penetratin has no influence on the membrane structure.", [["membrane", "ANATOMY", 166, 174], ["penetratin", "CHEMICAL", 44, 54], ["penetratin", "CHEMICAL", 131, 141], ["penetratin", "CHEMICAL", 44, 54], ["penetratin", "CHEMICAL", 131, 141], ["phospholipid", "SIMPLE_CHEMICAL", 31, 43], ["penetratin", "SIMPLE_CHEMICAL", 44, 54], ["penetratin", "SIMPLE_CHEMICAL", 131, 141], ["membrane", "CELLULAR_COMPONENT", 166, 174], ["mol phospholipid/penetratin ratio", "TREATMENT", 27, 60], ["the transition temperature", "PROBLEM", 75, 101], ["influence on the membrane structure", "PROBLEM", 149, 184], ["no", "UNCERTAINTY", 62, 64], ["change", "OBSERVATION_MODIFIER", 65, 71], ["penetratin", "OBSERVATION", 131, 141]]], ["Next, we have analysed the interactions between phospholipids and penetratin through changes in the intrinsic fluorescence of the peptide due to the presence of two W residues in its sequence.", [["phospholipids", "CHEMICAL", 48, 61], ["penetratin", "CHEMICAL", 66, 76], ["penetratin", "CHEMICAL", 66, 76], ["phospholipids", "SIMPLE_CHEMICAL", 48, 61], ["penetratin", "SIMPLE_CHEMICAL", 66, 76], ["phospholipids", "TREATMENT", 48, 61], ["penetratin through changes", "TREATMENT", 66, 92], ["two W residues in its sequence", "PROBLEM", 161, 191]]], ["Comparing the emission spectra corresponding to penetratin in aqueous media or in presence of vesicles one can clearly appreciate a blue shift.", [["vesicles", "ANATOMY", 94, 102], ["penetratin", "CHEMICAL", 48, 58], ["penetratin", "CHEMICAL", 48, 58], ["penetratin", "SIMPLE_CHEMICAL", 48, 58], ["penetratin in aqueous media", "TREATMENT", 48, 75], ["a blue shift", "PROBLEM", 130, 142], ["blue shift", "OBSERVATION", 132, 142]]], ["This indicates that that tryptophan residues are mainly exposed to a hydrophobic environment.", [["tryptophan", "CHEMICAL", 25, 35], ["tryptophan", "CHEMICAL", 25, 35], ["tryptophan", "SIMPLE_CHEMICAL", 25, 35], ["tryptophan residues", "PROBLEM", 25, 44], ["tryptophan residues", "OBSERVATION", 25, 44], ["hydrophobic environment", "OBSERVATION", 69, 92]]], ["Analysis of the main band shows low values of polarization suggesting a free motion of the peptide chain.", [["Analysis of the main band", "TEST", 0, 25], ["low values of polarization", "PROBLEM", 32, 58], ["a free motion of the peptide chain", "PROBLEM", 70, 104], ["main", "OBSERVATION_MODIFIER", 16, 20], ["low values", "OBSERVATION", 32, 42], ["free motion", "OBSERVATION", 72, 83], ["peptide chain", "OBSERVATION", 91, 104]]], ["On the contrary polarization measured for penetratin mixed with liposomes results in higher values.", [["penetratin", "CHEMICAL", 42, 52], ["penetratin", "CHEMICAL", 42, 52], ["penetratin", "SIMPLE_CHEMICAL", 42, 52], ["liposomes", "SIMPLE_CHEMICAL", 64, 73], ["penetratin mixed with liposomes", "TREATMENT", 42, 73]]], ["This indicates that hydrophobic residues, like Trp, are inserted into the bilayer and their motion is restricted.", [["Trp", "CHEMICAL", 47, 50], ["Trp", "CHEMICAL", 47, 50], ["Trp", "AMINO_ACID", 47, 50], ["bilayer", "CELLULAR_COMPONENT", 74, 81], ["hydrophobic residues", "PROBLEM", 20, 40], ["hydrophobic residues", "OBSERVATION", 20, 40], ["bilayer", "OBSERVATION_MODIFIER", 74, 81], ["motion", "OBSERVATION_MODIFIER", 92, 98]]], ["These data suggest the presence of interation sensed strongly by Trp properties.", [["Trp", "CHEMICAL", 65, 68], ["Trp", "CHEMICAL", 65, 68], ["Trp", "GENE_OR_GENE_PRODUCT", 65, 68], ["These data", "TEST", 0, 10]]], ["Cyclopeptide antibiotic gramicidin S (GS) has antimicrobial activity against Gram-positive and Gram-negative bacteria and some fungi.", [["Cyclopeptide", "CHEMICAL", 0, 12], ["gramicidin S", "CHEMICAL", 24, 36], ["GS", "CHEMICAL", 38, 40], ["Cyclopeptide", "CHEMICAL", 0, 12], ["Cyclopeptide antibiotic", "SIMPLE_CHEMICAL", 0, 23], ["gramicidin S", "SIMPLE_CHEMICAL", 24, 36], ["GS", "SIMPLE_CHEMICAL", 38, 40], ["Gram-", "GENE_OR_GENE_PRODUCT", 77, 82], ["Gram-", "GENE_OR_GENE_PRODUCT", 95, 100], ["Cyclopeptide antibiotic gramicidin S", "TREATMENT", 0, 36], ["antimicrobial activity", "TEST", 46, 68], ["Gram-positive and Gram-negative bacteria", "PROBLEM", 77, 117], ["some fungi", "PROBLEM", 122, 132], ["negative bacteria", "OBSERVATION", 100, 117], ["fungi", "OBSERVATION", 127, 132]]], ["But non-specific action of GS and its high lytic potential limits therapeutic application of GS.", [["non-specific action of GS", "PROBLEM", 4, 29], ["non-specific", "OBSERVATION_MODIFIER", 4, 16]]], ["We attempted to elucidate in which way GS molecule could be modified to lose its haemolytic side effects.", [["GS molecule", "GENE_OR_GENE_PRODUCT", 39, 50], ["its haemolytic side effects", "PROBLEM", 77, 104]]], ["GS molecule interacts directly with membrane phospholipids due to electrostatic and hydrophobic interaction.", [["membrane phospholipids", "ANATOMY", 36, 58], ["GS molecule", "GENE_OR_GENE_PRODUCT", 0, 11], ["membrane phospholipids", "CELLULAR_COMPONENT", 36, 58], ["GS molecule", "PROTEIN", 0, 11], ["membrane phospholipids", "TREATMENT", 36, 58], ["electrostatic and hydrophobic interaction", "PROBLEM", 66, 107], ["hydrophobic interaction", "OBSERVATION", 84, 107]]], ["Naturally, changes in the state of a lipid bilayer cause changes in the GS molecule binding to a bilayer.", [["lipid bilayer", "ANATOMY", 37, 50], ["GS molecule", "GENE_OR_GENE_PRODUCT", 72, 83], ["GS molecule", "PROTEIN", 72, 83], ["the GS molecule binding", "PROBLEM", 68, 91]]], ["We studied the effect of GS on human blood platelets and the effect of platelet membrane state on the GS-induced disaggregation of cells with the help of turbidimetric and microscopy techniques.", [["blood platelets", "ANATOMY", 37, 52], ["platelet membrane", "ANATOMY", 71, 88], ["cells", "ANATOMY", 131, 136], ["GS", "SIMPLE_CHEMICAL", 25, 27], ["human", "ORGANISM", 31, 36], ["blood platelets", "CELL", 37, 52], ["platelet", "CELL", 71, 79], ["GS", "SIMPLE_CHEMICAL", 102, 104], ["cells", "CELL", 131, 136], ["human blood platelets", "CELL_TYPE", 31, 52], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["human blood platelets", "TREATMENT", 31, 52], ["platelet membrane state", "PROBLEM", 71, 94], ["the GS", "TEST", 98, 104], ["induced disaggregation of cells", "PROBLEM", 105, 136], ["turbidimetric", "TEST", 154, 167], ["microscopy techniques", "TEST", 172, 193], ["platelet membrane", "OBSERVATION", 71, 88]]], ["We modified the membrane state by temperature, osmotic stress, ionizing irradiation, lipid oxidation.", [["membrane", "ANATOMY", 16, 24], ["membrane", "CELLULAR_COMPONENT", 16, 24], ["lipid", "SIMPLE_CHEMICAL", 85, 90], ["osmotic stress", "PROBLEM", 47, 61], ["ionizing irradiation", "TREATMENT", 63, 83], ["lipid oxidation", "TREATMENT", 85, 100], ["ionizing irradiation", "OBSERVATION", 63, 83], ["lipid oxidation", "OBSERVATION", 85, 100]]], ["Depending on concentration GS causes platelet shape change and activation.", [["platelet", "ANATOMY", 37, 45], ["GS", "SIMPLE_CHEMICAL", 27, 29], ["platelet", "CELL", 37, 45], ["concentration GS", "TEST", 13, 29], ["platelet shape change", "PROBLEM", 37, 58], ["platelet shape", "OBSERVATION", 37, 51]]], ["When added to preliminary aggregated (in response to physiological agonists -thrombin, epinephrine, ADP) platelets, GS causes crumble of cells aggregates.", [["platelets", "ANATOMY", 105, 114], ["cells", "ANATOMY", 137, 142], ["epinephrine", "CHEMICAL", 87, 98], ["ADP", "CHEMICAL", 100, 103], ["epinephrine", "CHEMICAL", 87, 98], ["ADP", "CHEMICAL", 100, 103], ["thrombin", "GENE_OR_GENE_PRODUCT", 77, 85], ["epinephrine", "SIMPLE_CHEMICAL", 87, 98], ["ADP", "SIMPLE_CHEMICAL", 100, 103], ["platelets", "CELL", 105, 114], ["GS", "SIMPLE_CHEMICAL", 116, 118], ["cells", "CELL", 137, 142], ["thrombin", "PROTEIN", 77, 85], ["platelets", "CELL_TYPE", 105, 114], ["physiological agonists", "TREATMENT", 53, 75], ["thrombin", "TREATMENT", 77, 85], ["epinephrine", "TREATMENT", 87, 98], ["ADP) platelets", "TREATMENT", 100, 114], ["GS", "TEST", 116, 118], ["crumble of cells aggregates", "PROBLEM", 126, 153], ["cells aggregates", "OBSERVATION", 137, 153]]], ["The rate and extent of platelet disaggregation under the effect of GS non monotonously depends on temperature (range of 5-40\u00b0C) and irradiation dose (up to 200 Gy).", [["platelet", "ANATOMY", 23, 31], ["platelet", "CELL", 23, 31], ["platelet", "CELL_TYPE", 23, 31], ["The rate", "TEST", 0, 8], ["platelet disaggregation", "PROBLEM", 23, 46], ["GS", "TEST", 67, 69], ["temperature", "TEST", 98, 109], ["irradiation dose", "TREATMENT", 132, 148], ["extent", "OBSERVATION_MODIFIER", 13, 19], ["platelet disaggregation", "OBSERVATION", 23, 46]]], ["Parameters of the GS interaction with membranes are determined by the mobility of membrane lipids.", [["membranes", "ANATOMY", 38, 47], ["membrane", "ANATOMY", 82, 90], ["membranes", "CELLULAR_COMPONENT", 38, 47], ["membrane lipids", "CELLULAR_COMPONENT", 82, 97], ["membranes", "TREATMENT", 38, 47], ["membrane lipids", "TREATMENT", 82, 97]]], ["Factors modifying the lipid bilayer change the degree and the speed of the GS interaction with platelet membranes.", [["lipid bilayer", "ANATOMY", 22, 35], ["platelet membranes", "ANATOMY", 95, 113], ["lipid bilayer", "CELLULAR_COMPONENT", 22, 35], ["platelet membranes", "CELLULAR_COMPONENT", 95, 113], ["the lipid bilayer change", "TREATMENT", 18, 42], ["platelet membranes", "TREATMENT", 95, 113], ["lipid bilayer", "OBSERVATION", 22, 35], ["platelet membranes", "OBSERVATION", 95, 113]]], ["Results obtained permit to use GS for testing the state of membrane lipids and on the other hand allow to suppose ways of GS molecule modifications to achieve its tolerance to blood cells.INSIGHTS ON THE INTERACTIONS BETWEEN TWO CECROPIN-MELITTIN PEPTIDES AND MODEL MEMBRANES: CALORIMETRIC AND SPECTROSCOPIC RESULTSG.", [["membrane", "ANATOMY", 59, 67], ["blood cells", "ANATOMY", 176, 187], ["membrane lipids", "CELLULAR_COMPONENT", 59, 74], ["GS molecule", "GENE_OR_GENE_PRODUCT", 122, 133], ["blood cells", "CELL", 176, 187], ["blood cells", "CELL_TYPE", 176, 187], ["GS", "TEST", 31, 33], ["testing", "TEST", 38, 45], ["membrane lipids", "TREATMENT", 59, 74], ["GS molecule modifications", "TREATMENT", 122, 147], ["blood cells", "TEST", 176, 187]]], ["Bai 1 , P. Gomes 1 , R. Seixas 1 , M. Hicks 2 , M. Prieto 3 , M. Bastos 1CIQ (UP), Department of Chemistry of Faculty of Sciences of The University of Porto, Portugal 2 Department of Chemistry, University of Warwick, Coventry, UK 3 Centro de Qu\u00edmica-F\u00edsica Molecular do Instituto Superior T\u00e9cnico -UTL, Lisbon, PortugalEukaryotic antibiotic peptides (EAPs) have been widely studied for the past years as an alternative to conventional antibiotics due to emergence of multi-resistant microbial strains, and significant efforts targeting increasingly potent and specific antimicrobial peptides are being made.", [["PortugalEukaryotic antibiotic peptides", "TREATMENT", 311, 349], ["conventional antibiotics", "TREATMENT", 422, 446], ["multi-resistant microbial strains", "PROBLEM", 467, 500], ["specific antimicrobial peptides", "TREATMENT", 560, 591], ["potent", "OBSERVATION_MODIFIER", 549, 555]]], ["One interesting approach in peptide antibiotics is based on hybrid sequences derived from natural EAPs, with CA ( Resistance to conventional antibiotics has stimulated a search for alternative therapeutics for microbial infections, a possible source that has gained much interest in recent years are antimicrobial peptides.", [["microbial infections", "DISEASE", 210, 230], ["EAPs", "SIMPLE_CHEMICAL", 98, 102], ["CA", "GENE_OR_GENE_PRODUCT", 109, 111], ["peptide antibiotics", "TREATMENT", 28, 47], ["hybrid sequences", "TEST", 60, 76], ["CA", "PROBLEM", 109, 111], ["conventional antibiotics", "TREATMENT", 128, 152], ["alternative therapeutics", "TREATMENT", 181, 205], ["microbial infections", "PROBLEM", 210, 230], ["antimicrobial peptides", "TREATMENT", 300, 322]]], ["Antimicrobial peptides target the cell membrane directly, which is a key feature as evolution has shown bacteria have had difficulty in altering their membrane composition and organization to mount a suitable defence against these peptides.", [["cell membrane", "ANATOMY", 34, 47], ["membrane", "ANATOMY", 151, 159], ["cell membrane", "CELLULAR_COMPONENT", 34, 47], ["membrane", "CELLULAR_COMPONENT", 151, 159], ["Antimicrobial peptides", "TREATMENT", 0, 22], ["bacteria", "PROBLEM", 104, 112], ["cell membrane", "OBSERVATION", 34, 47], ["membrane composition", "OBSERVATION_MODIFIER", 151, 171]]], ["A common theory is that peptides that bind strongly exhibit high biological activity, but our real-time quantitative binding studies via surface plasmon resonance (SPR) have shown that this correlation does not always hold.", [["high biological activity", "PROBLEM", 60, 84], ["surface plasmon resonance", "TEST", 137, 162]]], ["As more information on the molecular details of membrane disruption is required, we have used Atomic Force Microscopy (AFM) to visualise peptide insertion and changes in membrane morphology by a range of antimicrobial peptides in situ.", [["membrane", "ANATOMY", 48, 56], ["membrane", "ANATOMY", 170, 178], ["membrane", "CELLULAR_COMPONENT", 48, 56], ["membrane", "CELLULAR_COMPONENT", 170, 178], ["membrane disruption", "PROBLEM", 48, 67], ["Atomic Force Microscopy", "TEST", 94, 117], ["visualise peptide insertion", "TREATMENT", 127, 154], ["changes in membrane morphology", "PROBLEM", 159, 189], ["antimicrobial peptides", "TREATMENT", 204, 226], ["membrane morphology", "OBSERVATION", 170, 189]]], ["Interaction studies were performed with a series of phospholipid mixtures that mimic either mammalian cells (high in phosphatidylcholine and cholesterol) or microbial cells (high in phosphatidylethanolamine and phosphatidylglycerol).", [["cells", "ANATOMY", 102, 107], ["cells", "ANATOMY", 167, 172], ["phosphatidylcholine", "CHEMICAL", 117, 136], ["cholesterol", "CHEMICAL", 141, 152], ["phosphatidylethanolamine", "CHEMICAL", 182, 206], ["phosphatidylglycerol", "CHEMICAL", 211, 231], ["phosphatidylcholine", "CHEMICAL", 117, 136], ["cholesterol", "CHEMICAL", 141, 152], ["phosphatidylethanolamine", "CHEMICAL", 182, 206], ["phosphatidylglycerol", "CHEMICAL", 211, 231], ["phospholipid", "SIMPLE_CHEMICAL", 52, 64], ["cells", "CELL", 102, 107], ["phosphatidylcholine", "SIMPLE_CHEMICAL", 117, 136], ["cholesterol", "SIMPLE_CHEMICAL", 141, 152], ["microbial cells", "CELL", 157, 172], ["phosphatidylethanolamine", "SIMPLE_CHEMICAL", 182, 206], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 211, 231], ["mammalian cells", "CELL_TYPE", 92, 107], ["microbial cells", "CELL_TYPE", 157, 172], ["Interaction studies", "TEST", 0, 19], ["phospholipid mixtures", "TREATMENT", 52, 73], ["mammalian cells", "PROBLEM", 92, 107], ["microbial cells", "PROBLEM", 157, 172], ["phosphatidylethanolamine and phosphatidylglycerol", "TREATMENT", 182, 231], ["mammalian cells", "OBSERVATION", 92, 107], ["microbial cells", "OBSERVATION", 157, 172]]], ["The present study may assist in the design of new specific antimicrobial peptides with high antimicrobial activity and low host toxicity.The interaction of the dodecapeptide antimicrobial peptide Omiganan pentahydrochloride (ILRWPWWPWRRK-NH.5Cl) with bacterial and mammalian model membranes was characterized by means of UV-Vis absorption and fluorescence emission spectroscopy using large unilamellar vesicles of differentproportions of POPC and POPG as models.", [["membranes", "ANATOMY", 281, 290], ["unilamellar vesicles", "ANATOMY", 390, 410], ["toxicity", "DISEASE", 128, 136], ["Omiganan pentahydrochloride", "CHEMICAL", 196, 223], ["ILRWPWWPWRRK-NH.5Cl", "CHEMICAL", 225, 244], ["POPC", "CHEMICAL", 438, 442], ["Omiganan pentahydrochloride", "CHEMICAL", 196, 223], ["ILRWPWWPWRRK-NH.5Cl", "CHEMICAL", 225, 244], ["POPC", "CHEMICAL", 438, 442], ["POPG", "CHEMICAL", 447, 451], ["dodecapeptide", "SIMPLE_CHEMICAL", 160, 173], ["Omiganan pentahydrochloride", "SIMPLE_CHEMICAL", 196, 223], ["ILRWPWWPWRRK-NH.5Cl", "SIMPLE_CHEMICAL", 225, 244], ["membranes", "CELLULAR_COMPONENT", 281, 290], ["POPC", "SIMPLE_CHEMICAL", 438, 442], ["POPG", "SIMPLE_CHEMICAL", 447, 451], ["The present study", "TEST", 0, 17], ["new specific antimicrobial peptides", "PROBLEM", 46, 81], ["high antimicrobial activity", "TREATMENT", 87, 114], ["low host toxicity", "PROBLEM", 119, 136], ["the dodecapeptide antimicrobial peptide Omiganan pentahydrochloride", "TREATMENT", 156, 223], ["bacterial and mammalian model membranes", "PROBLEM", 251, 290], ["fluorescence emission spectroscopy", "TEST", 343, 377], ["large unilamellar vesicles of differentproportions of POPC", "TREATMENT", 384, 442], ["low host toxicity", "OBSERVATION", 119, 136], ["mammalian model membranes", "OBSERVATION", 265, 290]]], ["Very high molar ratio partition constants ((18.9+-1.3)x10^3 and (43.5+-8.7)x10^3) were obtained for the bacterial models (POPG:POPC 4:1 and 2:1, respectively), these being about one order of magnitude greater than the partition constants obtained for the less anionic mammalian model systems ((3.7+-0.4)x10^3 for the 100% POPC system).", [["POPC", "CHEMICAL", 127, 131], ["POPC", "CHEMICAL", 322, 326], ["POPG", "SIMPLE_CHEMICAL", 122, 126], ["Very high molar ratio partition constants", "PROBLEM", 0, 41], ["the bacterial models", "TEST", 100, 120], ["POPC", "TEST", 127, 131], ["high", "OBSERVATION_MODIFIER", 5, 9], ["molar", "OBSERVATION", 10, 15]]], ["At low lipid:peptide ratios there were significant deviations from the usual hyperbolic-like partition behavior of peptide vesicle titration curves, especially in the case of the most anionic systems.", [["vesicle", "ANATOMY", 123, 130], ["lipid", "SIMPLE_CHEMICAL", 7, 12], ["significant deviations", "PROBLEM", 39, 61], ["peptide vesicle titration curves", "TREATMENT", 115, 147], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["deviations", "OBSERVATION", 51, 61]]], ["Membrane saturation was shown to be related to such observations and mathematical models were derived to further characterize the peptide-lipid interaction under these conditions.", [["Membrane", "ANATOMY", 0, 8], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["lipid", "SIMPLE_CHEMICAL", 138, 143], ["Membrane saturation", "TEST", 0, 19], ["mathematical models", "TEST", 69, 88]]], ["The calculated peptide-to-lipid saturation proportions, together with the determined partition constants, suggest that the Minimal Inhibitory Concentrations of Omiganan pentahydrochloride could represent the conditions required for bacterial membrane saturation to occur.", [["membrane", "ANATOMY", 242, 250], ["Omiganan pentahydrochloride", "CHEMICAL", 160, 187], ["Omiganan pentahydrochloride", "CHEMICAL", 160, 187], ["lipid", "SIMPLE_CHEMICAL", 26, 31], ["Omiganan pentahydrochloride", "SIMPLE_CHEMICAL", 160, 187], ["membrane", "CELLULAR_COMPONENT", 242, 250], ["The calculated peptide", "TEST", 0, 22], ["Omiganan pentahydrochloride", "TREATMENT", 160, 187], ["the conditions", "PROBLEM", 204, 218], ["bacterial membrane saturation", "PROBLEM", 232, 261]]], ["The hemolytic pore-forming toxin sticholysin II (StII) produced by the sea anemone Stichodactyla heliantus belongs to the actinoporin protein family.", [["sticholysin II", "CHEMICAL", 33, 47], ["StII", "CHEMICAL", 49, 53], ["hemolytic pore-forming toxin sticholysin II", "GENE_OR_GENE_PRODUCT", 4, 47], ["StII", "GENE_OR_GENE_PRODUCT", 49, 53], ["sea anemone", "ORGANISM", 71, 82], ["Stichodactyla heliantus", "ORGANISM", 83, 106], ["actinoporin", "GENE_OR_GENE_PRODUCT", 122, 133], ["hemolytic pore-forming toxin", "PROTEIN", 4, 32], ["sticholysin II", "PROTEIN", 33, 47], ["StII", "PROTEIN", 49, 53], ["actinoporin protein family", "PROTEIN", 122, 148], ["anemone", "SPECIES", 75, 82], ["Stichodactyla heliantus", "SPECIES", 83, 106], ["Stichodactyla heliantus", "SPECIES", 83, 106], ["The hemolytic pore", "TREATMENT", 0, 18], ["the sea anemone", "TREATMENT", 67, 82], ["hemolytic", "OBSERVATION_MODIFIER", 4, 13]]], ["The N-terminal domain of these proteins is required for interaction with membranes.", [["membranes", "ANATOMY", 73, 82], ["N", "CHEMICAL", 4, 5], ["membranes", "CELLULAR_COMPONENT", 73, 82], ["N-terminal domain", "PROTEIN", 4, 21], ["The N-terminal domain of these proteins", "TREATMENT", 0, 39], ["membranes", "TREATMENT", 73, 82]]], ["To investigate the role of StII\u00b4s N-terminal domain in membrane binding and in the molecular mechanism of hemolysis, peptides corresponding to residues 1 to 35, or shorter fragments from this region, were synthesized.", [["membrane", "ANATOMY", 55, 63], ["hemolysis", "DISEASE", 106, 115], ["StII", "CHEMICAL", 27, 31], ["N", "CHEMICAL", 34, 35], ["StII", "GENE_OR_GENE_PRODUCT", 27, 31], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["StII", "PROTEIN", 27, 31], ["N-terminal domain", "PROTEIN", 34, 51], ["terminal domain in membrane binding", "PROBLEM", 36, 71], ["hemolysis", "PROBLEM", 106, 115], ["shorter fragments from this region", "PROBLEM", 164, 198], ["membrane binding", "OBSERVATION", 55, 71], ["hemolysis", "OBSERVATION", 106, 115]]], ["In some peptides Leu was replaced by Trp.", [["Leu", "CHEMICAL", 17, 20], ["Trp", "CHEMICAL", 37, 40], ["Leu", "CHEMICAL", 17, 20], ["Trp", "CHEMICAL", 37, 40], ["Leu", "AMINO_ACID", 17, 20], ["Trp", "AMINO_ACID", 37, 40], ["peptides Leu", "OBSERVATION", 8, 20]]], ["All peptides exhibited hemolytic activity, albeit to a lesser extent than the whole protein.", [["hemolytic", "DISEASE", 23, 32], ["hemolytic activity", "PROBLEM", 23, 41], ["hemolytic activity", "OBSERVATION", 23, 41]]], ["Moreover, peptides lacking the 1-14 hydrophobic stretch were less active.", [["peptides", "TEST", 10, 18], ["less", "OBSERVATION_MODIFIER", 61, 65], ["active", "OBSERVATION_MODIFIER", 66, 72]]], ["The longer peptides were also able to permeabilize phospholipid vesicles.", [["phospholipid vesicles", "ANATOMY", 51, 72], ["phospholipid vesicles", "CELLULAR_COMPONENT", 51, 72], ["The longer peptides", "PROBLEM", 0, 19]]], ["Conformational studies were performed in aqueous solution and in membranemimicking environments.", [["Conformational studies", "TEST", 0, 22]]], ["CD spectra showed that, while the shorter, more hydrophilic peptides, displayed a random conformation, the longer peptides underwent aggregation with increasing concentration, pH, and ionic strength.", [["CD spectra", "TEST", 0, 10], ["increasing concentration", "TREATMENT", 150, 174], ["pH", "TEST", 176, 178], ["ionic strength", "OBSERVATION", 184, 198]]], ["In the presence of trifluoroethanol and upon binding to detergent micelles and phospholipid bilayers, the peptides showed a propensity to acquire -helical conformation, as expected for the sequence comprising residues 14 to 26.", [["trifluoroethanol", "CHEMICAL", 19, 35], ["trifluoroethanol", "CHEMICAL", 19, 35], ["trifluoroethanol", "SIMPLE_CHEMICAL", 19, 35], ["detergent micelles", "SIMPLE_CHEMICAL", 56, 74], ["phospholipid bilayers", "SIMPLE_CHEMICAL", 79, 100], ["residues 14 to 26", "PROTEIN", 209, 226], ["trifluoroethanol", "TREATMENT", 19, 35], ["detergent micelles", "TREATMENT", 56, 74], ["phospholipid bilayers", "TEST", 79, 100], ["the peptides", "TEST", 102, 114], ["the sequence comprising residues", "TEST", 185, 217]]], ["Fluorescence spectra demonstrated that the first residues of StII\u00b4s N-terminus penetrate more deeply into the bilayer, whereas residues 14-26 are located more superficially.", [["StII", "CHEMICAL", 61, 65], ["N", "CHEMICAL", 68, 69], ["StII", "GENE_OR_GENE_PRODUCT", 61, 65], ["StII", "PROTEIN", 61, 65], ["N-terminus", "PROTEIN", 68, 78], ["Fluorescence spectra", "TEST", 0, 20], ["StII\u00b4s N-terminus penetrate", "TREATMENT", 61, 88], ["bilayer", "ANATOMY_MODIFIER", 110, 117]]], ["This is in agreement with the predicted amphipathic nature of the helix formed by these residues and corroborates the existing hypotheses for the role of the N-terminal domain in the process of membrane insertion and pore formation.", [["membrane", "ANATOMY", 194, 202], ["pore", "ANATOMY", 217, 221], ["N", "CHEMICAL", 158, 159], ["membrane", "CELLULAR_COMPONENT", 194, 202], ["pore", "CELLULAR_COMPONENT", 217, 221], ["N-terminal domain", "PROTEIN", 158, 175], ["these residues", "PROBLEM", 82, 96], ["membrane insertion and pore formation", "TREATMENT", 194, 231], ["membrane insertion", "OBSERVATION", 194, 212], ["pore formation", "OBSERVATION", 217, 231]]], ["Among a great number of antibacterial peptides a group of Trp-rich peptides is of special interest.", [["Trp", "CHEMICAL", 58, 61], ["Trp", "CHEMICAL", 58, 61], ["Trp", "SIMPLE_CHEMICAL", 58, 61], ["antibacterial peptides", "TREATMENT", 24, 46], ["Trp-rich peptides", "TREATMENT", 58, 75], ["great", "OBSERVATION_MODIFIER", 8, 13]]], ["Taking into consideration, that in most of proteins tryptophan is not frequently occurring amino acid, the biological meaning of a high content of tryptophan in structure of these antimicrobial peptides is particularly interesting.", [["tryptophan", "CHEMICAL", 52, 62], ["amino acid", "CHEMICAL", 91, 101], ["tryptophan", "CHEMICAL", 147, 157], ["tryptophan", "CHEMICAL", 52, 62], ["amino acid", "CHEMICAL", 91, 101], ["tryptophan", "CHEMICAL", 147, 157], ["tryptophan", "AMINO_ACID", 52, 62], ["amino acid", "AMINO_ACID", 91, 101], ["tryptophan", "SIMPLE_CHEMICAL", 147, 157], ["proteins tryptophan", "PROBLEM", 43, 62], ["amino acid", "PROBLEM", 91, 101], ["these antimicrobial peptides", "TREATMENT", 174, 202], ["antimicrobial peptides", "OBSERVATION", 180, 202]]], ["In the present study we carried out the investigation of antimicrobial and hemolytic activities of selected Trp-rich peptides and their action on microbial membrane:MODEL PEPTIDES MIMIC THE STRUCTURE AND FUNCTION OF THE N-TERMINUS OF THE PORE-FORMING TOXIN STICHOLYSIN IIILPWKWPWWPWRR-NH2 - indolicidin (I) PITWPWKWWKGG-NH2 - 3B3 (II) PLSWFFPRTWGKR-NH2 - GSP-1a (III) FPVTWRWWKWWKG-NH2 - puroindoline (IV) VRRFPWWWPFLRR-NH2 - tritrypticin (V).Department of Bioorganic Chemistry, Faculty of Chemistry, University of Gda\u0144Sk, PolandSunflower trypsin inhibitor SFTI-1 is the smallest and the most potent known peptidic trypsin inhibitor from the Bowman-Birk class of proteins [1] .", [["membrane", "ANATOMY", 156, 164], ["hemolytic", "DISEASE", 75, 84], ["Trp", "CHEMICAL", 108, 111], ["indolicidin", "CHEMICAL", 291, 302], ["FPVTWRWWKWWKG-NH2 - puroindoline", "CHEMICAL", 368, 400], ["VRRFPWWWPFLRR-NH2 - tritrypticin", "CHEMICAL", 406, 438], ["SFTI-1", "CHEMICAL", 557, 563], ["Trp", "CHEMICAL", 108, 111], ["IIILPWKWPWWPWRR-NH2 - indolicidin (I) PITWPWKWWKGG-NH2 - 3B3 (II) PLSWFFPRTWGKR-NH2 - GSP-1a (III) FPVTWRWWKWWKG-NH2 - puroindoline (IV) VRRFPWWWPFLRR-NH2 - tritrypticin (V)", "CHEMICAL", 269, 442], ["Trp", "SIMPLE_CHEMICAL", 108, 111], ["microbial membrane", "CELLULAR_COMPONENT", 146, 164], ["NH2 - indolicidin (I) PITWPWKWWKGG-NH2 - 3B3 (II) PLSWFFPRTWGKR-NH2 - GSP-1a (III) FPVTWRWWKWWKG-NH2 - puroindoline (IV) VRRFPWWWPFLRR-NH2 - tritrypticin", "SIMPLE_CHEMICAL", 285, 438], ["SFTI-1", "GENE_OR_GENE_PRODUCT", 557, 563], ["trypsin", "GENE_OR_GENE_PRODUCT", 615, 622], ["NH2", "PROTEIN", 285, 288], ["NH2", "PROTEIN", 320, 323], ["NH2", "PROTEIN", 349, 352], ["NH2", "PROTEIN", 382, 385], ["NH2", "PROTEIN", 420, 423], ["antimicrobial and hemolytic activities", "TREATMENT", 57, 95], ["Trp-rich peptides", "TREATMENT", 108, 125], ["TOXIN", "TEST", 251, 256], ["STICHOLYSIN", "TEST", 257, 268], ["IIILPWKWPWWPWRR", "TEST", 269, 284], ["PITWPWKWWKGG", "TEST", 307, 319], ["NH2", "TEST", 320, 323], ["PLSWFFPRTWGKR", "TEST", 335, 348], ["NH2", "TEST", 349, 352], ["GSP", "TEST", 355, 358], ["FPVTWRWWKWWKG", "TEST", 368, 381], ["NH2", "TEST", 382, 385], ["puroindoline (IV)", "TREATMENT", 388, 405], ["VRRFPWWWPFLRR", "TEST", 406, 419], ["Gda\u0144Sk", "TEST", 515, 521], ["PolandSunflower trypsin inhibitor SFTI", "TEST", 523, 561], ["peptidic trypsin inhibitor", "TREATMENT", 606, 632]]], ["This head-to-tailcyclized 14-amino-acid peptide contains one disulfide bridge and a lysine residue (Lys5) present in the P1 position, which is responsible for inhibitor specificity.As was reported by us and other groups, SFTI-1 analogues with one cycle only retain trypsin inhibitory activity.", [["head", "ANATOMY", 5, 9], ["14-amino-acid", "CHEMICAL", 26, 39], ["lysine", "CHEMICAL", 84, 90], ["SFTI-1 analogues", "CHEMICAL", 221, 237], ["14-amino-acid", "CHEMICAL", 26, 39], ["disulfide", "CHEMICAL", 61, 70], ["lysine", "CHEMICAL", 84, 90], ["SFTI-1", "CHEMICAL", 221, 227], ["head", "ORGANISM_SUBDIVISION", 5, 9], ["14-amino-acid", "SIMPLE_CHEMICAL", 26, 39], ["Lys5", "AMINO_ACID", 100, 104], ["SFTI-1 analogues", "SIMPLE_CHEMICAL", 221, 237], ["trypsin", "GENE_OR_GENE_PRODUCT", 265, 272], ["disulfide bridge", "PROTEIN", 61, 77], ["P1 position", "PROTEIN", 121, 132], ["trypsin", "PROTEIN", 265, 272], ["This head", "TEST", 0, 9], ["amino-acid peptide", "TREATMENT", 29, 47], ["one disulfide bridge", "TREATMENT", 57, 77], ["a lysine residue (Lys5)", "TREATMENT", 82, 105], ["inhibitor specificity", "TEST", 159, 180], ["SFTI", "TEST", 221, 225], ["lysine residue", "OBSERVATION", 84, 98]]], ["Very recently we have shown [2] that introduction of Nsubstituted glycine residues mimicking Lys and Phe (denoted as Nlys and Nphe) in the P1 position of monocyclic SFTI-1 with disulfide bridge yielded potent trypsin and chymotrypsin inhibitors, respectively.", [["Nsubstituted glycine", "CHEMICAL", 53, 73], ["Lys", "CHEMICAL", 93, 96], ["Phe", "CHEMICAL", 101, 104], ["glycine", "CHEMICAL", 66, 73], ["Lys", "CHEMICAL", 93, 96], ["Phe", "CHEMICAL", 101, 104], ["Nlys", "CHEMICAL", 117, 121], ["Nphe", "CHEMICAL", 126, 130], ["monocyclic SFTI-1", "CHEMICAL", 154, 171], ["disulfide", "CHEMICAL", 177, 186], ["Nsubstituted glycine residues", "SIMPLE_CHEMICAL", 53, 82], ["Lys", "AMINO_ACID", 93, 96], ["Phe", "AMINO_ACID", 101, 104], ["Nlys", "GENE_OR_GENE_PRODUCT", 117, 121], ["SFTI-1", "GENE_OR_GENE_PRODUCT", 165, 171], ["disulfide bridge", "SIMPLE_CHEMICAL", 177, 193], ["trypsin", "GENE_OR_GENE_PRODUCT", 209, 216], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 221, 233], ["Nlys", "PROTEIN", 117, 121], ["Nphe", "PROTEIN", 126, 130], ["trypsin", "PROTEIN", 209, 216], ["Nsubstituted glycine residues", "TREATMENT", 53, 82], ["Phe", "TEST", 101, 104], ["Nlys", "TEST", 117, 121], ["monocyclic SFTI", "TEST", 154, 169], ["disulfide bridge", "TREATMENT", 177, 193], ["potent trypsin and chymotrypsin inhibitors", "TREATMENT", 202, 244]]], ["In this novel class of proteinase inhibitors contains completely proteolytic resistant P1-P1' reactive site.Department of Bioorganic Chemistry, Faculty of Chemistry, University of Gda\u0144Sk, PolandIn the present communication we report chemical synthesis and determination of trypsin and chymotrypsin inhibitory activity of a series of ten SFTI-1 analogues modified in the P1 position by these peptoid monomers (Nlys and Nphe).", [["SFTI-1", "CHEMICAL", 337, 343], ["trypsin", "GENE_OR_GENE_PRODUCT", 273, 280], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 285, 297], ["SFTI-1 analogues", "SIMPLE_CHEMICAL", 337, 353], ["peptoid monomers", "SIMPLE_CHEMICAL", 391, 407], ["Nlys", "SIMPLE_CHEMICAL", 409, 413], ["Nphe", "SIMPLE_CHEMICAL", 418, 422], ["P1-P1' reactive site", "DNA", 87, 107], ["trypsin", "PROTEIN", 273, 280], ["chymotrypsin", "PROTEIN", 285, 297], ["peptoid monomers", "PROTEIN", 391, 407], ["Nlys", "PROTEIN", 409, 413], ["Nphe", "PROTEIN", 418, 422], ["proteinase inhibitors", "TREATMENT", 23, 44], ["completely proteolytic resistant P1", "PROBLEM", 54, 89], ["chemical synthesis", "TREATMENT", 233, 251], ["trypsin", "TREATMENT", 273, 280], ["chymotrypsin inhibitory activity", "TREATMENT", 285, 317], ["ten SFTI-1 analogues", "TREATMENT", 333, 353], ["these peptoid monomers", "TREATMENT", 385, 407], ["reactive", "OBSERVATION_MODIFIER", 94, 102]]], ["Each of the synthesized peptomeric (peptide-peptoid hybrid polymer) SFTI-1 analogues contains one of the following cycles: head-to-tail, disulfide bridge formed by Cys, by Pen and by Cys/Pen residues.", [["SFTI-1 analogues", "CHEMICAL", 68, 84], ["Cys", "CHEMICAL", 164, 167], ["disulfide", "CHEMICAL", 137, 146], ["Cys", "CHEMICAL", 164, 167], ["Cys", "CHEMICAL", 183, 186], ["peptomeric", "SIMPLE_CHEMICAL", 24, 34], ["SFTI-1 analogues", "SIMPLE_CHEMICAL", 68, 84], ["Cys", "AMINO_ACID", 164, 167], ["head-to-tail", "PROTEIN", 123, 135], ["disulfide bridge", "PROTEIN", 137, 153], ["the synthesized peptomeric (peptide-peptoid hybrid polymer", "TREATMENT", 8, 66], ["SFTI", "TEST", 68, 72], ["disulfide bridge", "TREATMENT", 137, 153], ["head", "ANATOMY", 123, 127], ["tail", "ANATOMY", 131, 135]]], ["The impact of the different cycles introduced into SFTI-1 structure on proteinase inhibitory activity will be discussed.Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) is the causative agent for the recent outbreak of SARS infection.", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 127, 165], ["SARS-CoV)", "DISEASE", 167, 176], ["SARS infection", "DISEASE", 227, 241], ["SFTI-1", "GENE_OR_GENE_PRODUCT", 51, 57], ["proteinase", "GENE_OR_GENE_PRODUCT", 71, 81], ["SARS-CoV", "ORGANISM", 167, 175], ["SFTI", "PROTEIN", 51, 55], ["proteinase", "PROTEIN", 71, 81], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV", "SPECIES", 120, 175], ["the different cycles", "TREATMENT", 14, 34], ["proteinase inhibitory activity", "TREATMENT", 71, 101], ["Severe Acute Respiratory Syndrome", "PROBLEM", 120, 153], ["Coronavirus (SARS-CoV", "PROBLEM", 154, 175], ["SARS infection", "PROBLEM", 227, 241], ["Acute", "OBSERVATION_MODIFIER", 127, 132], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 133, 165], ["SARS", "OBSERVATION_MODIFIER", 227, 231], ["infection", "OBSERVATION", 232, 241]]], ["SARS-CoV spike glycoprotein (S) is considered as one of the prime targets for SARS therapeutics and intervention.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 78, 82], ["SARS-CoV spike glycoprotein (S)", "GENE_OR_GENE_PRODUCT", 0, 31], ["SARS-CoV spike glycoprotein", "PROTEIN", 0, 27], ["S", "PROTEIN", 29, 30], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["SARS therapeutics", "TREATMENT", 78, 95], ["intervention", "TREATMENT", 100, 112]]], ["Consistent with type I viral fusion protein, the SARS-CoVS-protein contains a proteolytic processing site and two interacting heptad repeat regions denoted as HR-N and HR-C.", [["type I viral fusion protein", "GENE_OR_GENE_PRODUCT", 16, 43], ["type I viral fusion protein", "PROTEIN", 16, 43], ["SARS-CoVS-protein", "PROTEIN", 49, 66], ["proteolytic processing site", "PROTEIN", 78, 105], ["heptad repeat regions", "PROTEIN", 126, 147], ["HR", "PROTEIN", 159, 161], ["type I viral fusion protein", "PROBLEM", 16, 43], ["the SARS", "TEST", 45, 53], ["a proteolytic processing site", "PROBLEM", 76, 105], ["two interacting heptad repeat regions", "PROBLEM", 110, 147], ["HR", "TEST", 159, 161], ["HR", "TEST", 168, 170], ["viral fusion", "OBSERVATION", 23, 35]]], ["Following processing of S-protein mediated by host cellular protease/s, the C-terminal S2-fragment fuse with host cell membranes via its HR-N and HR-C domains that form coiled coil 6-helix bundle (trimeric of dimers)-crucial for its receptor-mediated viral fusion.", [["cellular", "ANATOMY", 51, 59], ["cell membranes", "ANATOMY", 114, 128], ["S-protein", "GENE_OR_GENE_PRODUCT", 24, 33], ["cellular", "CELL", 51, 59], ["cell membranes", "CELLULAR_COMPONENT", 114, 128], ["S-protein", "PROTEIN", 24, 33], ["host cellular protease", "PROTEIN", 46, 68], ["C-terminal S2-fragment", "PROTEIN", 76, 98], ["HR", "PROTEIN", 137, 139], ["N", "PROTEIN", 140, 141], ["HR", "PROTEIN", 146, 148], ["C domains", "PROTEIN", 149, 158], ["coiled coil 6-helix bundle", "PROTEIN", 169, 195], ["trimeric of dimers", "PROTEIN", 197, 215], ["S-protein", "TREATMENT", 24, 33], ["host cellular protease", "TREATMENT", 46, 68], ["the C-terminal S2-fragment fuse", "PROBLEM", 72, 103], ["host cell membranes", "TREATMENT", 109, 128], ["its HR", "TEST", 133, 139], ["HR", "TEST", 146, 148], ["C domains", "PROBLEM", 149, 158], ["coiled coil", "TREATMENT", 169, 180], ["its receptor-mediated viral fusion", "TREATMENT", 229, 263], ["S2", "ANATOMY", 87, 89], ["host cell membranes", "OBSERVATION", 109, 128], ["viral fusion", "OBSERVATION", 251, 263]]], ["Our objective in this work is to study the proteolytic site using model peptides and also to examine the interaction of HR-N and HR-C domains using fluorescence microscopy and other techniques.", [["proteolytic site", "PROTEIN", 43, 59], ["HR", "PROTEIN", 120, 122], ["N", "PROTEIN", 123, 124], ["HR", "PROTEIN", 129, 131], ["C domains", "PROTEIN", 132, 141], ["model peptides", "TREATMENT", 66, 80], ["HR", "TEST", 120, 122], ["fluorescence microscopy", "TEST", 148, 171], ["other techniques", "TEST", 176, 192]]], ["Thus we synthesized an intramolecularly quenched fluorogenic peptide containing the proposed cleavage site [Abz-EQDRNTR761 EVFATyx, Abz=2-amino benzoic acid and Tyx=3-nitro tyrosine] and showed by kinetic measurements that this cleavage is mediated most efficiently by furin, followed PC5 and PC7.", [["Abz=2-amino benzoic acid", "CHEMICAL", 132, 156], ["Tyx=3-nitro tyrosine", "CHEMICAL", 161, 181], ["Abz-EQDRNTR761", "CHEMICAL", 108, 122], ["Abz", "CHEMICAL", 132, 135], ["2-amino benzoic acid", "CHEMICAL", 136, 156], ["Tyx", "CHEMICAL", 161, 164], ["3-nitro tyrosine", "CHEMICAL", 165, 181], ["Abz=2-amino benzoic acid", "SIMPLE_CHEMICAL", 132, 156], ["Tyx=3-nitro tyrosine", "SIMPLE_CHEMICAL", 161, 181], ["furin", "GENE_OR_GENE_PRODUCT", 269, 274], ["PC5", "SIMPLE_CHEMICAL", 285, 288], ["furin", "PROTEIN", 269, 274], ["PC5", "PROTEIN", 285, 288], ["PC7", "PROTEIN", 293, 296], ["an intramolecularly quenched fluorogenic peptide", "TREATMENT", 20, 68], ["the proposed cleavage site", "TREATMENT", 80, 106], ["EVFATyx", "TEST", 123, 130], ["Abz", "TEST", 132, 135], ["amino benzoic acid", "TEST", 138, 156], ["Tyx", "TEST", 161, 164], ["nitro tyrosine", "TREATMENT", 167, 181], ["this cleavage", "PROBLEM", 223, 236], ["PC7", "TREATMENT", 293, 296]]], ["Above cleavage can be blocked by specific-PC-inhibitors in a dose-dependent manner.", [["Above cleavage", "TREATMENT", 0, 14], ["PC-inhibitors", "TREATMENT", 42, 55]]], ["In addition using fluorescent-labeled peptides derived from HR-N and HR-C domains, circular dichroism spectra and surface assisted laser desorption mass spectralSubtilisin Kexin Isozyme-1 (SKI-1)/Site1 Protease (S1P) is a Ca+2-dependent membrane bound mammalian subtilase of pyrolysin subtype.", [["membrane", "ANATOMY", 237, 245], ["Ca+2", "CHEMICAL", 222, 226], ["Ca+2", "CHEMICAL", 222, 226], ["Subtilisin Kexin Isozyme-1", "GENE_OR_GENE_PRODUCT", 161, 187], ["SKI-1", "GENE_OR_GENE_PRODUCT", 189, 194], ["Site1 Protease", "GENE_OR_GENE_PRODUCT", 196, 210], ["S1P", "GENE_OR_GENE_PRODUCT", 212, 215], ["Ca+2", "SIMPLE_CHEMICAL", 222, 226], ["membrane", "CELLULAR_COMPONENT", 237, 245], ["pyrolysin", "GENE_OR_GENE_PRODUCT", 275, 284], ["Subtilisin Kexin Isozyme-1 (SKI-1", "PROTEIN", 161, 194], ["Site1 Protease", "PROTEIN", 196, 210], ["S1P", "PROTEIN", 212, 215], ["Ca+2-dependent membrane bound mammalian subtilase", "PROTEIN", 222, 271], ["pyrolysin subtype", "PROTEIN", 275, 292], ["fluorescent", "TEST", 18, 29], ["HR", "TEST", 60, 62], ["HR", "TEST", 69, 71], ["C domains", "PROBLEM", 72, 81], ["circular dichroism spectra", "TREATMENT", 83, 109], ["surface assisted laser desorption mass", "TREATMENT", 114, 152], ["Subtilisin Kexin Isozyme", "TREATMENT", 161, 185], ["a Ca+2-dependent membrane", "TREATMENT", 220, 245], ["pyrolysin subtype", "PROBLEM", 275, 292], ["mass", "OBSERVATION", 148, 152]]], ["It cleaves peptide bonds at motif Arg-X-Leu/Ile/Val-Leu/Thr/Gly/Lys where X=any amino acid other than Cys.", [["Val-Leu", "CHEMICAL", 48, 55], ["amino acid", "CHEMICAL", 80, 90], ["Arg-X-Leu", "CHEMICAL", 34, 43], ["Ile", "CHEMICAL", 44, 47], ["Val", "CHEMICAL", 48, 51], ["Leu", "CHEMICAL", 52, 55], ["Thr", "CHEMICAL", 56, 59], ["Gly", "CHEMICAL", 60, 63], ["Lys", "CHEMICAL", 64, 67], ["amino acid", "CHEMICAL", 80, 90], ["Cys", "CHEMICAL", 102, 105], ["Ile", "AMINO_ACID", 44, 47], ["Val-Leu", "AMINO_ACID", 48, 55], ["Thr/", "AMINO_ACID", 56, 60], ["Gly/Lys", "AMINO_ACID", 60, 67], ["amino acid", "AMINO_ACID", 80, 90], ["Cys", "AMINO_ACID", 102, 105], ["motif Arg", "TEST", 28, 37], ["Leu/Ile", "TEST", 40, 47], ["Val", "TEST", 48, 51], ["Leu/Thr/Gly/Lys", "TREATMENT", 52, 67], ["any amino acid", "TEST", 76, 90]]], ["SKI-1, a Golgi enzyme is clinically linked to lipid metabolism, cholesterol homeostasis and infections caused by hemorrhagic fever viruses such as Lassa and others.Interest has grown to develop specific and potent inhibitors of this enzyme.", [["Golgi", "ANATOMY", 9, 14], ["cholesterol", "CHEMICAL", 64, 75], ["infections", "DISEASE", 92, 102], ["hemorrhagic fever", "DISEASE", 113, 130], ["cholesterol", "CHEMICAL", 64, 75], ["SKI-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Golgi", "CELLULAR_COMPONENT", 9, 14], ["lipid", "SIMPLE_CHEMICAL", 46, 51], ["cholesterol", "SIMPLE_CHEMICAL", 64, 75], ["Lassa", "ORGANISM", 147, 152], ["SKI-1", "PROTEIN", 0, 5], ["Golgi enzyme", "PROTEIN", 9, 21], ["enzyme", "PROTEIN", 233, 239], ["a Golgi enzyme", "TEST", 7, 21], ["lipid metabolism", "PROBLEM", 46, 62], ["cholesterol homeostasis", "PROBLEM", 64, 87], ["infections", "PROBLEM", 92, 102], ["hemorrhagic fever viruses", "PROBLEM", 113, 138], ["Lassa", "PROBLEM", 147, 152], ["this enzyme", "TEST", 228, 239], ["infections", "OBSERVATION", 92, 102], ["hemorrhagic", "OBSERVATION_MODIFIER", 113, 124], ["fever", "OBSERVATION", 125, 130]]], ["Our objectives in this study are to generate soluble recombinant human (h)SKI-1 enzyme, design potent inhibitors and study its 3Dmodel structure.", [["human", "ORGANISM", 65, 70], ["SKI-1", "GENE_OR_GENE_PRODUCT", 74, 79], ["recombinant human (h)SKI-1 enzyme", "PROTEIN", 53, 86], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["this study", "TEST", 18, 28], ["SKI", "TEST", 74, 77], ["enzyme", "TEST", 80, 86], ["design potent inhibitors", "TREATMENT", 88, 112]]], ["We have successfully expressed hSKI-1 enzyme lacking its transmembrane domain in HEK-293 cells and purified the enzyme via chromatography.", [["transmembrane", "ANATOMY", 57, 70], ["HEK-293 cells", "ANATOMY", 81, 94], ["hSKI-1", "GENE_OR_GENE_PRODUCT", 31, 37], ["transmembrane", "CELLULAR_COMPONENT", 57, 70], ["HEK-293 cells", "CELL", 81, 94], ["hSKI-1 enzyme", "PROTEIN", 31, 44], ["transmembrane domain", "PROTEIN", 57, 77], ["HEK-293 cells", "CELL_LINE", 81, 94], ["HEK-293", "SPECIES", 81, 88], ["hSKI", "TEST", 31, 35], ["the enzyme via chromatography", "TEST", 108, 137]]], ["In addition we developed SKI-1 inhibitors by using pseudo-and multi-branch peptide approaches.", [["SKI-1", "GENE_OR_GENE_PRODUCT", 25, 30], ["SKI-1 inhibitors", "TREATMENT", 25, 41], ["pseudo", "TEST", 51, 57], ["multi-branch peptide approaches", "TREATMENT", 62, 93]]], ["In first approach we inserted dipeptide isosteres amino oxy acetic acid (Aoaa) or 8-amino 3, 6 dioxa octanoic acid (Adoa) at scissile P1-P1' position ((R175 L) of hSKI-1.", [["amino oxy acetic acid", "CHEMICAL", 50, 71], ["Aoaa", "CHEMICAL", 73, 77], ["8-amino 3, 6 dioxa octanoic acid", "CHEMICAL", 82, 114], ["dipeptide", "CHEMICAL", 30, 39], ["amino oxy acetic acid", "CHEMICAL", 50, 71], ["Aoaa", "CHEMICAL", 73, 77], ["8-amino 3, 6 dioxa octanoic acid", "CHEMICAL", 82, 114], ["Adoa", "CHEMICAL", 116, 120], ["dipeptide isosteres amino oxy acetic acid", "SIMPLE_CHEMICAL", 30, 71], ["Aoaa", "SIMPLE_CHEMICAL", 73, 77], ["8-amino 3, 6 dioxa octanoic acid", "SIMPLE_CHEMICAL", 82, 114], ["Adoa", "SIMPLE_CHEMICAL", 116, 120], ["hSKI-1", "GENE_OR_GENE_PRODUCT", 163, 169], ["hSKI", "PROTEIN", 163, 167], ["dipeptide isosteres amino oxy acetic acid (Aoaa)", "TREATMENT", 30, 78], ["hSKI", "TEST", 163, 167]]], ["A typical example is 167GRYSSRRL(Adoa)AIP179.", [["167GRYSSRRL(Adoa)AIP179", "DNA", 21, 44]]], ["Other dipeptide isosters were also incorporated at the cleavage site of either SKI-1 prodomain or Lassa virus glycoprotein.", [["dipeptide", "CHEMICAL", 6, 15], ["dipeptide isosters", "SIMPLE_CHEMICAL", 6, 24], ["SKI-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["Lassa virus", "ORGANISM", 98, 109], ["cleavage site", "PROTEIN", 55, 68], ["SKI-1 prodomain", "PROTEIN", 79, 94], ["Lassa virus glycoprotein", "PROTEIN", 98, 122], ["Lassa virus", "SPECIES", 98, 109], ["Lassa virus", "SPECIES", 98, 109], ["Other dipeptide isosters", "PROBLEM", 0, 24], ["Lassa virus glycoprotein", "PROBLEM", 98, 122], ["SKI", "ANATOMY", 79, 82]]], ["In second approach we prepared 2 and 4-branch peptides containing hSKI-1128-137 segment.", [["hSKI-1128-137", "CHEMICAL", 66, 79], ["hSKI-1128-137 segment", "DNA", 66, 87]]], ["These peptides inhibit SKI-1 in competitive manners with varying degrees ranging from low M to high nM IC50.", [["SKI-1", "GENE_OR_GENE_PRODUCT", 23, 28], ["SKI-1", "PROTEIN", 23, 28]]], ["Circular dichroism spectra indicated strong interactions of inhibitors with SKI-1 consistent with observed inhibition profile.", [["SKI-1", "GENE_OR_GENE_PRODUCT", 76, 81], ["SKI", "PROTEIN", 76, 79], ["Circular dichroism spectra", "TEST", 0, 26], ["SKI", "TEST", 76, 79], ["observed inhibition profile", "PROBLEM", 98, 125], ["strong", "OBSERVATION_MODIFIER", 37, 43]]], ["A 3D-model structure of catalytic domain of SKI-1 indicated a broad catalytic pocket Cysteine proteases are of great importance in biochemical processes and these enzymes are used in biotechnology, food industry and agriculture.", [["Cysteine", "CHEMICAL", 85, 93], ["SKI-1", "GENE_OR_GENE_PRODUCT", 44, 49], ["Cysteine proteases", "GENE_OR_GENE_PRODUCT", 85, 103], ["catalytic domain", "PROTEIN", 24, 40], ["SKI-1", "PROTEIN", 44, 49], ["enzymes", "PROTEIN", 163, 170], ["SKI", "TEST", 44, 47], ["a broad catalytic pocket Cysteine proteases", "TREATMENT", 60, 103], ["these enzymes", "TEST", 157, 170], ["pocket Cysteine", "OBSERVATION", 78, 93]]], ["In this connection synthesis of high selectivity and high specificity substrates for cysteine proteases is of importance.", [["cysteine", "CHEMICAL", 85, 93], ["cysteine", "CHEMICAL", 85, 93], ["cysteine", "AMINO_ACID", 85, 93], ["cysteine proteases", "PROTEIN", 85, 103], ["high selectivity", "PROBLEM", 32, 48], ["cysteine proteases", "TREATMENT", 85, 103], ["high selectivity", "OBSERVATION_MODIFIER", 32, 48]]], ["Enzymatic synthesis of peptides is a good tool for obtaining different biologically active peptides.", [["Enzymatic synthesis of peptides", "PROBLEM", 0, 31]]], ["Immobilized serine proteases, subtilisin Carlsberg and \u03b1-chymotrypsin immobilized on poly(vinyl alcohol) cryogel (PVAcryogel), proved to be a convenient biocatalyst for such kind of syntheses.", [["\u03b1-chymotrypsin", "CHEMICAL", 55, 69], ["poly(vinyl alcohol", "CHEMICAL", 85, 103], ["cryogel", "CHEMICAL", 105, 112], ["PVAcryogel", "CHEMICAL", 114, 124], ["serine", "CHEMICAL", 12, 18], ["poly(vinyl alcohol)", "CHEMICAL", 85, 104], ["PVAcryogel", "CHEMICAL", 114, 124], ["serine", "AMINO_ACID", 12, 18], ["subtilisin Carlsberg", "SIMPLE_CHEMICAL", 30, 50], ["\u03b1-chymotrypsin", "SIMPLE_CHEMICAL", 55, 69], ["poly(vinyl alcohol) cryogel", "SIMPLE_CHEMICAL", 85, 112], ["PVAcryogel", "SIMPLE_CHEMICAL", 114, 124], ["serine proteases", "PROTEIN", 12, 28], ["\u03b1-chymotrypsin", "PROTEIN", 55, 69], ["Immobilized serine proteases", "TREATMENT", 0, 28], ["subtilisin Carlsberg and \u03b1-chymotrypsin immobilized", "TREATMENT", 30, 81], ["poly(vinyl alcohol) cryogel (PVAcryogel)", "TREATMENT", 85, 125], ["a convenient biocatalyst", "TREATMENT", 140, 164], ["syntheses", "PROBLEM", 182, 191]]], ["The high specific chromogenic substrate for cysteine proteases assay Glp-Phe-Ala-pNA was obtained with high product yields (up to 88% in 24 h) using subtilisin and chymotrypsin immobilized on PVA-cryogel.", [["cysteine", "CHEMICAL", 44, 52], ["Glp-Phe-Ala-pNA", "CHEMICAL", 69, 84], ["PVA-cryogel", "CHEMICAL", 192, 203], ["cysteine", "CHEMICAL", 44, 52], ["Glp-Phe-Ala-pNA", "CHEMICAL", 69, 84], ["PVA", "CHEMICAL", 192, 195], ["cysteine", "AMINO_ACID", 44, 52], ["Glp-Phe-Ala-pNA", "SIMPLE_CHEMICAL", 69, 84], ["subtilisin", "GENE_OR_GENE_PRODUCT", 149, 159], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 164, 176], ["PVA-cryogel", "SIMPLE_CHEMICAL", 192, 203], ["cysteine proteases", "PROTEIN", 44, 62], ["subtilisin", "PROTEIN", 149, 159], ["chymotrypsin", "PROTEIN", 164, 176], ["cysteine proteases", "TEST", 44, 62], ["Glp", "TEST", 69, 72], ["Phe", "TEST", 73, 76], ["pNA", "PROBLEM", 81, 84], ["subtilisin and chymotrypsin immobilized", "TREATMENT", 149, 188], ["PVA", "TREATMENT", 192, 195], ["cryogel", "TREATMENT", 196, 203], ["Ala", "ANATOMY", 77, 80], ["pNA", "OBSERVATION", 81, 84]]], ["The reaction was carried out according to the following scheme:Subtilisin Kexin Isozyme-1 (SKI-1)/Site1 Protease (S1P) is a Ca+2-dependent membrane bound mammalian subtilase of pyrolysin subtype.", [["membrane", "ANATOMY", 139, 147], ["S1P", "CHEMICAL", 114, 117], ["Ca+2", "CHEMICAL", 124, 128], ["Ca+2", "CHEMICAL", 124, 128], ["Subtilisin Kexin Isozyme-1", "GENE_OR_GENE_PRODUCT", 63, 89], ["SKI-1", "GENE_OR_GENE_PRODUCT", 91, 96], ["Site1 Protease", "GENE_OR_GENE_PRODUCT", 98, 112], ["S1P", "GENE_OR_GENE_PRODUCT", 114, 117], ["Ca+2", "SIMPLE_CHEMICAL", 124, 128], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["pyrolysin", "GENE_OR_GENE_PRODUCT", 177, 186], ["Subtilisin Kexin Isozyme-1 (SKI-1", "PROTEIN", 63, 96], ["Site1 Protease", "PROTEIN", 98, 112], ["S1P", "PROTEIN", 114, 117], ["Ca+2-dependent membrane bound mammalian subtilase", "PROTEIN", 124, 173], ["pyrolysin subtype", "PROTEIN", 177, 194], ["The reaction", "PROBLEM", 0, 12], ["Subtilisin Kexin Isozyme", "TREATMENT", 63, 87], ["a Ca+2-dependent membrane", "TREATMENT", 122, 147], ["pyrolysin subtype", "PROBLEM", 177, 194]]], ["It cleaves peptide bonds at motif Arg-X-Leu/Ile/Val-Leu/Thr/Gly/Lys where X=any amino acid other than Cys.", [["Val-Leu", "CHEMICAL", 48, 55], ["amino acid", "CHEMICAL", 80, 90], ["Arg-X-Leu", "CHEMICAL", 34, 43], ["Ile", "CHEMICAL", 44, 47], ["Val", "CHEMICAL", 48, 51], ["Leu", "CHEMICAL", 52, 55], ["Thr", "CHEMICAL", 56, 59], ["Gly", "CHEMICAL", 60, 63], ["Lys", "CHEMICAL", 64, 67], ["amino acid", "CHEMICAL", 80, 90], ["Cys", "CHEMICAL", 102, 105], ["Ile", "AMINO_ACID", 44, 47], ["Val-Leu", "AMINO_ACID", 48, 55], ["Thr/", "AMINO_ACID", 56, 60], ["Gly/Lys", "AMINO_ACID", 60, 67], ["amino acid", "AMINO_ACID", 80, 90], ["Cys", "AMINO_ACID", 102, 105], ["motif Arg", "TEST", 28, 37], ["Leu/Ile", "TEST", 40, 47], ["Val", "TEST", 48, 51], ["Leu/Thr/Gly/Lys", "TREATMENT", 52, 67], ["any amino acid", "TEST", 76, 90]]], ["SKI-1, a Golgi enzyme is clinically linked to lipid metabolism, cholesterol homeostasis and infections caused by hemorrhagic fever viruses such as Lassa and others.Glp -the residue of pyroglutamic acid, pNA -p-nitroanilide.", [["Golgi", "ANATOMY", 9, 14], ["cholesterol", "CHEMICAL", 64, 75], ["infections", "DISEASE", 92, 102], ["hemorrhagic fever", "DISEASE", 113, 130], ["Glp", "CHEMICAL", 164, 167], ["pyroglutamic acid", "CHEMICAL", 184, 201], ["pNA -p-nitroanilide", "CHEMICAL", 203, 222], ["cholesterol", "CHEMICAL", 64, 75], ["pyroglutamic acid", "CHEMICAL", 184, 201], ["pNA -p-nitroanilide", "CHEMICAL", 203, 222], ["SKI-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Golgi", "CELLULAR_COMPONENT", 9, 14], ["lipid", "SIMPLE_CHEMICAL", 46, 51], ["cholesterol", "SIMPLE_CHEMICAL", 64, 75], ["Lassa", "ORGANISM", 147, 152], ["Glp", "SIMPLE_CHEMICAL", 164, 167], ["pyroglutamic acid", "SIMPLE_CHEMICAL", 184, 201], ["pNA -p-nitroanilide", "SIMPLE_CHEMICAL", 203, 222], ["SKI-1", "PROTEIN", 0, 5], ["Golgi enzyme", "PROTEIN", 9, 21], ["Glp", "PROTEIN", 164, 167], ["a Golgi enzyme", "TEST", 7, 21], ["lipid metabolism", "PROBLEM", 46, 62], ["cholesterol homeostasis", "PROBLEM", 64, 87], ["infections", "PROBLEM", 92, 102], ["hemorrhagic fever viruses", "PROBLEM", 113, 138], ["Lassa", "PROBLEM", 147, 152], ["Glp", "TEST", 164, 167], ["pyroglutamic acid", "TREATMENT", 184, 201], ["pNA", "PROBLEM", 203, 206], ["nitroanilide", "TREATMENT", 210, 222], ["infections", "OBSERVATION", 92, 102], ["hemorrhagic", "OBSERVATION_MODIFIER", 113, 124], ["fever", "OBSERVATION", 125, 130], ["pNA", "OBSERVATION", 203, 206]]], ["The influence of initial concentrations of components, the reaction mixture composition, the biocatalyst content and time on product yield was studied.", [["initial concentrations of components", "TREATMENT", 17, 53], ["the reaction mixture composition", "TREATMENT", 55, 87]]], ["It was shown that the optimal conditions are: dimethylformamide-acetonitrile mixture 20:80 (v/v), initial concentrations -85 mM, and enzyme-to-substrate ratio -1:3900.", [["dimethylformamide-acetonitrile", "CHEMICAL", 46, 76], ["dimethylformamide", "CHEMICAL", 46, 63], ["acetonitrile", "CHEMICAL", 64, 76], ["dimethylformamide", "SIMPLE_CHEMICAL", 46, 63], ["dimethylformamide-acetonitrile mixture", "TREATMENT", 46, 84], ["initial concentrations", "TEST", 98, 120], ["enzyme", "TEST", 133, 139], ["substrate ratio", "TEST", 143, 158]]], ["This approach was used in order to synthesize analogous substrates, containing different fluorogenic and chromogenic groups as well as other amino acids in P1position.", [["amino acids", "CHEMICAL", 141, 152], ["amino acids", "CHEMICAL", 141, 152], ["amino acids", "AMINO_ACID", 141, 152], ["This approach", "TREATMENT", 0, 13], ["analogous substrates", "TREATMENT", 46, 66], ["different fluorogenic and chromogenic groups", "TREATMENT", 79, 123], ["other amino acids in P1position", "TREATMENT", 135, 166]]], ["The obtained substrates were tested for the papain assay.", [["papain", "GENE_OR_GENE_PRODUCT", 44, 50], ["the papain assay", "TEST", 40, 56]]], ["Peptidyl-a-ketoaldehydes 3 represent attractive lead compounds and intermediates in the development of potent protease inhibitors due to their structural similarity with peptide aldehydes, previously known to be excellent inhibitors of serine-and cysteine protease.", [["Peptidyl-a-ketoaldehydes", "CHEMICAL", 0, 24], ["peptide aldehydes", "CHEMICAL", 170, 187], ["Peptidyl-a-ketoaldehydes", "CHEMICAL", 0, 24], ["aldehydes", "CHEMICAL", 178, 187], ["serine", "CHEMICAL", 236, 242], ["cysteine", "CHEMICAL", 247, 255], ["Peptidyl-a-ketoaldehydes 3", "SIMPLE_CHEMICAL", 0, 26], ["peptide aldehydes", "SIMPLE_CHEMICAL", 170, 187], ["serine", "AMINO_ACID", 236, 242], ["cysteine", "AMINO_ACID", 247, 255], ["cysteine protease", "PROTEIN", 247, 264], ["Peptidyl-a-ketoaldehydes", "TREATMENT", 0, 24], ["attractive lead compounds", "PROBLEM", 37, 62], ["potent protease inhibitors", "TREATMENT", 103, 129], ["peptide aldehydes", "PROBLEM", 170, 187], ["cysteine protease", "TREATMENT", 247, 264], ["attractive", "OBSERVATION_MODIFIER", 37, 47], ["lead compounds", "OBSERVATION", 48, 62]]], ["Recently, we demonstrated the application of polymer cyano methylene-and carboxylato methylene phosphoranes in the assembly of a-hydroxy-b-amino esters (norstatines), a,b-diketoesters, and a,b-unsaturated ketones.", [["polymer cyano methylene", "CHEMICAL", 45, 68], ["carboxylato methylene", "CHEMICAL", 73, 94], ["a-hydroxy-b-amino esters", "CHEMICAL", 127, 151], ["norstatines", "CHEMICAL", 153, 164], ["a,b-unsaturated ketones", "CHEMICAL", 189, 212], ["cyano methylene-and carboxylato methylene phosphoranes", "CHEMICAL", 53, 107], ["a-hydroxy-b-amino esters", "CHEMICAL", 127, 151], ["norstatines", "CHEMICAL", 153, 164], [",b-diketoesters", "CHEMICAL", 168, 183], ["a,b-unsaturated ketones", "CHEMICAL", 189, 212], ["polymer cyano methylene", "SIMPLE_CHEMICAL", 45, 68], ["carboxylato methylene phosphoranes", "SIMPLE_CHEMICAL", 73, 107], ["a-hydroxy-b-amino esters", "SIMPLE_CHEMICAL", 127, 151], ["norstatines", "SIMPLE_CHEMICAL", 153, 164], [",b-diketoesters", "SIMPLE_CHEMICAL", 168, 183], ["a,b-unsaturated ketones", "SIMPLE_CHEMICAL", 189, 212], ["polymer cyano methylene", "TREATMENT", 45, 68], ["carboxylato methylene phosphoranes", "TREATMENT", 73, 107], ["a-hydroxy", "TEST", 127, 136], ["b-amino esters", "TEST", 137, 151], ["a,b-diketoesters", "TEST", 167, 183], ["a,b-unsaturated ketones", "TEST", 189, 212]]], ["[1, 2, 3] We now present a further development of our reagent linker 2 approach employing peptidyl-a-ketoaldehydes 3 and diamino propanoles 4.", [["peptidyl-a-ketoaldehydes 3 and diamino propanoles", "CHEMICAL", 90, 139], ["peptidyl-a-ketoaldehydes", "CHEMICAL", 90, 114], ["diamino propanoles", "CHEMICAL", 121, 139], ["peptidyl-a-ketoaldehydes 3", "SIMPLE_CHEMICAL", 90, 116], ["diamino propanoles 4", "SIMPLE_CHEMICAL", 121, 141], ["our reagent linker 2 approach", "TREATMENT", 50, 79], ["peptidyl-a-ketoaldehydes", "TREATMENT", 90, 114], ["diamino propanoles", "TREATMENT", 121, 139]]], ["Carboxylato methylen phosphoranes 1 derived from bromo acetic esters which are readly acylated without racemization, play the key role in our synthetic concept.", [["Carboxylato methylen phosphoranes", "CHEMICAL", 0, 33], ["bromo acetic esters", "CHEMICAL", 49, 68], ["Carboxylato methylen phosphoranes", "CHEMICAL", 0, 33], ["bromo acetic esters", "CHEMICAL", 49, 68], ["Carboxylato methylen phosphoranes 1", "SIMPLE_CHEMICAL", 0, 35], ["bromo acetic esters", "SIMPLE_CHEMICAL", 49, 68], ["Carboxylato methylen phosphoranes", "TREATMENT", 0, 33], ["bromo acetic esters", "TREATMENT", 49, 68]]], ["Herein we show the oxidative cleavage to peptidyl-a-ketoaldehydes 3 using dimethyldioxirane (DMD) in acetone as oxidant, after saponification and decarboxylation on the solid support.", [["peptidyl-a-ketoaldehydes", "CHEMICAL", 41, 65], ["dimethyldioxirane", "CHEMICAL", 74, 91], ["DMD", "CHEMICAL", 93, 96], ["acetone", "CHEMICAL", 101, 108], ["peptidyl-a-ketoaldehydes", "CHEMICAL", 41, 65], ["dimethyldioxirane", "CHEMICAL", 74, 91], ["DMD", "CHEMICAL", 93, 96], ["acetone", "CHEMICAL", 101, 108], ["peptidyl-a-ketoaldehydes 3", "SIMPLE_CHEMICAL", 41, 67], ["dimethyldioxirane", "SIMPLE_CHEMICAL", 74, 91], ["DMD", "SIMPLE_CHEMICAL", 93, 96], ["acetone", "SIMPLE_CHEMICAL", 101, 108], ["the oxidative cleavage", "PROBLEM", 15, 37], ["peptidyl-a-ketoaldehydes", "TREATMENT", 41, 65], ["dimethyldioxirane (DMD", "TREATMENT", 74, 96], ["saponification", "TREATMENT", 127, 141], ["decarboxylation", "TREATMENT", 146, 161], ["the solid support", "TREATMENT", 165, 182]]], ["Diamino propanoles 4 were furnished via the reductive amination of resin-bound peptides.", [["Diamino propanoles 4", "CHEMICAL", 0, 20], ["Diamino propanoles", "CHEMICAL", 0, 18], ["Diamino propanoles 4", "SIMPLE_CHEMICAL", 0, 20], ["Diamino propanoles", "TREATMENT", 0, 18], ["the reductive amination of resin-bound peptides", "TREATMENT", 40, 87]]], ["Over the past few years Nuclear Magnetic Resonance has emerged as a powerful means for lead molecular identification and optimization.On the other hand, the 19F NMR has been used succesfully in several structural studies, protein folding studies and for the identification of active compounds, using a very similar methodology that the one used in the present work.", [["19F", "CHEMICAL", 157, 160], ["lead molecular identification", "TEST", 87, 116], ["the 19F NMR", "TEST", 153, 164], ["protein folding studies", "TEST", 222, 245], ["active compounds", "PROBLEM", 276, 292], ["active", "OBSERVATION_MODIFIER", 276, 282], ["compounds", "OBSERVATION", 283, 292]]], ["The methodology required the labeling of the substrate with a CF3 moiety.", [["CF3", "CHEMICAL", 62, 65], ["CF3", "CHEMICAL", 62, 65], ["CF3 moiety", "SIMPLE_CHEMICAL", 62, 72], ["a CF3 moiety", "TREATMENT", 60, 72]]], ["The enzymatic reaction is performed with the CF3 substrate and quenched, using an enzyme inhibitor.", [["CF3", "CHEMICAL", 45, 48], ["The enzymatic reaction", "PROBLEM", 0, 22], ["the CF3 substrate", "TEST", 41, 58], ["an enzyme inhibitor", "TREATMENT", 79, 98], ["enzymatic reaction", "OBSERVATION", 4, 22]]], ["19F NMR is then used to monitor the evolution of both substrate and product.", [["19F NMR", "TEST", 0, 7]]], ["Only two peaks are observed, the starting substrate and the cleaved substrate.", [["the cleaved substrate", "PROBLEM", 56, 77], ["two", "OBSERVATION_MODIFIER", 5, 8], ["peaks", "OBSERVATION", 9, 14]]], ["This NMR method has some advantages: Fluorine NMR is very sensitive, 0,83 times that of the proton.", [["Fluorine", "CHEMICAL", 37, 45], ["Fluorine", "CHEMICAL", 37, 45], ["Fluorine", "SIMPLE_CHEMICAL", 37, 45], ["Fluorine NMR", "TEST", 37, 49]]], ["There are no spectral interference from protonated solvents, buffers or detergents typically present in the enzymatic reactions.The 19F isotropic chemical shift is extremely sensitive to small structural perturbations resulting in different chemical shift for the signals of the substrate and product.", [["spectral interference", "PROBLEM", 13, 34], ["protonated solvents", "TREATMENT", 40, 59], ["detergents", "TREATMENT", 72, 82], ["the enzymatic reactions", "PROBLEM", 104, 127], ["small structural perturbations", "PROBLEM", 187, 217], ["no", "UNCERTAINTY", 10, 12], ["spectral interference", "OBSERVATION", 13, 34], ["protonated solvents", "OBSERVATION", 40, 59], ["chemical shift", "OBSERVATION", 146, 160], ["structural perturbations", "OBSERVATION", 193, 217], ["chemical shift", "OBSERVATION", 241, 255]]], ["As a model, Caspase-8, which play a critical role in the initiation of apoptosis process5 and HIV-1 protease were chosen.", [["Caspase-8", "GENE_OR_GENE_PRODUCT", 12, 21], ["process5", "GENE_OR_GENE_PRODUCT", 81, 89], ["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 94, 108], ["Caspase-8", "PROTEIN", 12, 21], ["apoptosis process5", "PROTEIN", 71, 89], ["HIV-1 protease", "PROTEIN", 94, 108], ["HIV-1", "SPECIES", 94, 99], ["HIV-1", "SPECIES", 94, 99], ["apoptosis process5", "TREATMENT", 71, 89], ["HIV-1 protease", "TREATMENT", 94, 108]]], ["Two different kind of libraries were screened: One based on natural products from plant and animal extracts used in tradicional Chinese medicine and a second one corresponding of a synthetic library with two sublibraries of 160 and 144 compounds.With this methodology it has been possible to identify some compounds with very promising inhibitory properties.", [["extracts", "ANATOMY", 99, 107], ["extracts", "ORGANISM_SUBSTANCE", 99, 107], ["natural products", "TREATMENT", 60, 76], ["animal extracts", "TREATMENT", 92, 107], ["this methodology", "TREATMENT", 251, 267], ["libraries", "OBSERVATION", 22, 31]]], ["Background and aims: Human kallikrein 2 (hK2), a prostate specific serine protease, regulates the activity of several factors that may participate in proteolytic cascades promoting tumor growth and metastasis.", [["prostate", "ANATOMY", 49, 57], ["tumor", "ANATOMY", 181, 186], ["tumor", "DISEASE", 181, 186], ["serine", "CHEMICAL", 67, 73], ["Human", "ORGANISM", 21, 26], ["kallikrein 2", "GENE_OR_GENE_PRODUCT", 27, 39], ["hK2", "GENE_OR_GENE_PRODUCT", 41, 44], ["prostate", "CANCER", 49, 57], ["tumor", "CANCER", 181, 186], ["Human kallikrein 2", "PROTEIN", 21, 39], ["hK2", "PROTEIN", 41, 44], ["prostate specific serine protease", "PROTEIN", 49, 82], ["Human", "SPECIES", 21, 26], ["Human kallikrein", "TREATMENT", 21, 37], ["a prostate specific serine protease", "TREATMENT", 47, 82], ["proteolytic cascades", "PROBLEM", 150, 170], ["tumor growth", "PROBLEM", 181, 193], ["metastasis", "PROBLEM", 198, 208], ["prostate", "ANATOMY", 49, 57], ["tumor", "OBSERVATION", 181, 186], ["metastasis", "OBSERVATION", 198, 208]]], ["Thus, inhibition of its enzymatic activity is a potential way of preventing growth and metastasis of prostate cancer.", [["prostate cancer", "ANATOMY", 101, 116], ["prostate cancer", "DISEASE", 101, 116], ["prostate cancer", "CANCER", 101, 116], ["metastasis", "PROBLEM", 87, 97], ["prostate cancer", "PROBLEM", 101, 116], ["growth", "OBSERVATION_MODIFIER", 76, 82], ["metastasis", "OBSERVATION", 87, 97], ["prostate", "ANATOMY", 101, 109], ["cancer", "OBSERVATION", 110, 116]]], ["Moreover, specific ligands for hK2 have potential use for targeting and in vivo imaging of prostate cancer and for development of novel assays.", [["prostate cancer", "ANATOMY", 91, 106], ["prostate cancer", "DISEASE", 91, 106], ["hK2", "GENE_OR_GENE_PRODUCT", 31, 34], ["prostate cancer", "CANCER", 91, 106], ["hK2", "PROTEIN", 31, 34], ["vivo imaging", "TEST", 75, 87], ["prostate cancer", "PROBLEM", 91, 106], ["novel assays", "PROBLEM", 130, 142], ["prostate", "ANATOMY", 91, 99], ["cancer", "OBSERVATION", 100, 106]]], ["Methods: To find peptide ligands we panned several phage display peptide libraries against active recombinant hK2 captured by a monoclonal antibody exposing the active site of the enzyme.", [["hK2", "GENE_OR_GENE_PRODUCT", 110, 113], ["hK2", "PROTEIN", 110, 113], ["monoclonal antibody", "PROTEIN", 128, 147], ["enzyme", "PROTEIN", 180, 186], ["peptide ligands", "TREATMENT", 17, 32], ["several phage", "TREATMENT", 43, 56], ["peptide libraries", "TREATMENT", 65, 82], ["active recombinant hK2", "PROBLEM", 91, 113], ["a monoclonal antibody", "TREATMENT", 126, 147], ["the enzyme", "TEST", 176, 186], ["active", "OBSERVATION_MODIFIER", 161, 167]]], ["Alanine scanning and amino acid deletion analyses were performed to elucidate the motifs required for hK2 inhibition.", [["Alanine", "CHEMICAL", 0, 7], ["amino acid", "CHEMICAL", 21, 31], ["Alanine", "CHEMICAL", 0, 7], ["amino acid", "CHEMICAL", 21, 31], ["Alanine", "AMINO_ACID", 0, 7], ["amino acid", "AMINO_ACID", 21, 31], ["hK2", "GENE_OR_GENE_PRODUCT", 102, 105], ["hK2", "PROTEIN", 102, 105], ["Alanine scanning", "TEST", 0, 16], ["amino acid deletion analyses", "TEST", 21, 49], ["hK2 inhibition", "TREATMENT", 102, 116]]], ["Results: From libraries expressing 10 and 11 amino acid long linear peptides we isolated six different hK2-binding peptides.", [["amino acid", "CHEMICAL", 45, 55], ["amino acid", "CHEMICAL", 45, 55], ["amino acid", "AMINO_ACID", 45, 55], ["hK2", "GENE_OR_GENE_PRODUCT", 103, 106], ["hK2", "PROTEIN", 103, 106], ["11 amino acid long linear peptides", "TREATMENT", 42, 76], ["binding peptides", "OBSERVATION", 107, 123]]], ["Three of these peptides are specific inhibitors of the enzymatic activity of hK2.", [["hK2", "GENE_OR_GENE_PRODUCT", 77, 80], ["hK2", "PROTEIN", 77, 80], ["these peptides", "TREATMENT", 9, 23]]], ["Amino acid substitution and deletion studies indicated that motifs of 6 amino acids are necessary for the inhibitory activity.", [["Amino acid", "CHEMICAL", 0, 10], ["amino acids", "CHEMICAL", 72, 83], ["Amino acid", "CHEMICAL", 0, 10], ["amino acids", "CHEMICAL", 72, 83], ["Amino acid", "AMINO_ACID", 0, 10], ["amino acids", "AMINO_ACID", 72, 83], ["Amino acid substitution", "TREATMENT", 0, 23], ["deletion studies", "TEST", 28, 44], ["motifs of 6 amino acids", "TREATMENT", 60, 83], ["acid substitution", "OBSERVATION", 6, 23]]], ["Conclusions: We have developed specific hK2 inhibitors by phage display technology.", [["hK2", "GENE_OR_GENE_PRODUCT", 40, 43], ["specific hK2 inhibitors", "TREATMENT", 31, 54]]], ["These novel hK2 specific peptides are potentially useful for treatment and targeting of prostate cancer.", [["prostate cancer", "ANATOMY", 88, 103], ["prostate cancer", "DISEASE", 88, 103], ["hK2", "GENE_OR_GENE_PRODUCT", 12, 15], ["prostate cancer", "CANCER", 88, 103], ["These novel hK2 specific peptides", "PROBLEM", 0, 33], ["treatment", "TREATMENT", 61, 70], ["prostate cancer", "PROBLEM", 88, 103], ["prostate", "ANATOMY", 88, 96], ["cancer", "OBSERVATION", 97, 103]]], ["Peptidylarginine deiminase IV (PADIV) catalyzes the citrullination of Arg residues in various peptides and proteins, such as histone, resulting in the production of citrullinated proteins in granulocytes [1, 2] .", [["granulocytes", "ANATOMY", 191, 203], ["Peptidylarginine", "CHEMICAL", 0, 16], ["Peptidylarginine", "CHEMICAL", 0, 16], ["Arg", "CHEMICAL", 70, 73], ["Peptidylarginine deiminase IV", "GENE_OR_GENE_PRODUCT", 0, 29], ["PADIV", "GENE_OR_GENE_PRODUCT", 31, 36], ["Arg", "AMINO_ACID", 70, 73], ["histone", "GENE_OR_GENE_PRODUCT", 125, 132], ["granulocytes", "CELL", 191, 203], ["Peptidylarginine deiminase IV", "PROTEIN", 0, 29], ["PADIV", "PROTEIN", 31, 36], ["histone", "PROTEIN", 125, 132], ["citrullinated proteins", "PROTEIN", 165, 187], ["granulocytes", "CELL_TYPE", 191, 203], ["Peptidylarginine deiminase IV (PADIV)", "TREATMENT", 0, 37], ["Arg residues in various peptides", "PROBLEM", 70, 102], ["citrullinated proteins in granulocytes", "PROBLEM", 165, 203], ["citrullinated proteins", "OBSERVATION", 165, 187]]], ["The citrullination mechanism of histone subunits and its functional effects in cells are not well known yet in detail.M238Recently, it has been reported that the protein deimination/citrullination by PAD IV plays a role in rheumatoid arthritis [3] .", [["cells", "ANATOMY", 79, 84], ["rheumatoid arthritis", "DISEASE", 223, 243], ["histone subunits", "GENE_OR_GENE_PRODUCT", 32, 48], ["cells", "CELL", 79, 84], ["PAD IV", "GENE_OR_GENE_PRODUCT", 200, 206], ["histone subunits", "PROTEIN", 32, 48], ["M238Recently", "PROTEIN", 118, 130], ["PAD IV", "PROTEIN", 200, 206], ["The citrullination mechanism of histone subunits", "TREATMENT", 0, 48], ["the protein deimination", "PROBLEM", 158, 181], ["citrullination", "PROBLEM", 182, 196], ["PAD IV", "TREATMENT", 200, 206], ["rheumatoid arthritis", "PROBLEM", 223, 243], ["rheumatoid arthritis", "OBSERVATION", 223, 243]]], ["This implicates that the citrullination of histone may be related to rheumatoid arthritis.", [["rheumatoid arthritis", "DISEASE", 69, 89], ["histone", "GENE_OR_GENE_PRODUCT", 43, 50], ["histone", "PROTEIN", 43, 50], ["the citrullination of histone", "PROBLEM", 21, 50], ["rheumatoid arthritis", "PROBLEM", 69, 89], ["may be related to", "UNCERTAINTY", 51, 68], ["rheumatoid", "OBSERVATION_MODIFIER", 69, 79], ["arthritis", "OBSERVATION", 80, 89]]], ["In order to further study the citrullination mechanism of histone, we explored the citrullination sites of histone H2A and H3 by PAD IV using a series of synthetic peptides.M238Recently, Hagiwara et. al. reported that PAD IV only citrullinates the Arg3 of histone H2A as well as the Arg3 in histone H4 [4, 5] .", [["histone", "GENE_OR_GENE_PRODUCT", 58, 65], ["histone H2A", "GENE_OR_GENE_PRODUCT", 107, 118], ["H3", "GENE_OR_GENE_PRODUCT", 123, 125], ["PAD IV", "GENE_OR_GENE_PRODUCT", 129, 135], ["PAD IV", "GENE_OR_GENE_PRODUCT", 218, 224], ["Arg3", "GENE_OR_GENE_PRODUCT", 248, 252], ["histone H2A", "GENE_OR_GENE_PRODUCT", 256, 267], ["Arg3", "GENE_OR_GENE_PRODUCT", 283, 287], ["histone H4", "GENE_OR_GENE_PRODUCT", 291, 301], ["histone", "PROTEIN", 58, 65], ["citrullination sites", "PROTEIN", 83, 103], ["histone H2A", "PROTEIN", 107, 118], ["H3", "PROTEIN", 123, 125], ["PAD IV", "PROTEIN", 129, 135], ["PAD IV", "PROTEIN", 218, 224], ["Arg3", "PROTEIN", 248, 252], ["histone H2A", "PROTEIN", 256, 267], ["Arg3", "PROTEIN", 283, 287], ["histone H4", "PROTEIN", 291, 301], ["the citrullination sites", "TREATMENT", 79, 103], ["histone H2A", "TREATMENT", 107, 118], ["H3", "TREATMENT", 123, 125], ["PAD IV", "TREATMENT", 129, 135], ["a series of synthetic peptides", "TREATMENT", 142, 172], ["PAD IV", "TREATMENT", 218, 224], ["histone H2A", "TREATMENT", 256, 267], ["histone H2A", "OBSERVATION", 107, 118], ["histone H2A", "OBSERVATION", 256, 267]]], ["In order to investigate the citrullination mechanism, the N-terminal peptides of histone H2A and H3 were chemically synthesized and examined the citullination by PAD IV.", [["histone H2A", "GENE_OR_GENE_PRODUCT", 81, 92], ["H3", "GENE_OR_GENE_PRODUCT", 97, 99], ["histone H2A", "PROTEIN", 81, 92], ["H3", "PROTEIN", 97, 99], ["PAD IV", "PROTEIN", 162, 168], ["the citrullination mechanism", "PROBLEM", 24, 52], ["the N-terminal peptides of histone H2A", "TREATMENT", 54, 92], ["H3", "PROBLEM", 97, 99], ["PAD IV", "TREATMENT", 162, 168]]], ["The N-terminal acetylation effect of the N-terminal synthetic peptide was also estimated on the citrullination by PADIV.", [["N", "CHEMICAL", 4, 5], ["N", "CHEMICAL", 41, 42], ["PADIV", "SIMPLE_CHEMICAL", 114, 119], ["PADIV", "PROTEIN", 114, 119], ["The N-terminal acetylation effect", "TREATMENT", 0, 33], ["the N-terminal synthetic peptide", "TREATMENT", 37, 69], ["-terminal", "OBSERVATION_MODIFIER", 5, 14], ["acetylation effect", "OBSERVATION", 15, 33]]], ["The velocity of each Arg residues in the N-terminal peptides were estimated in vitro.", [["Arg", "CHEMICAL", 21, 24], ["Arg", "CHEMICAL", 21, 24], ["N", "CHEMICAL", 41, 42], ["each Arg residues", "PROBLEM", 16, 33], ["the N-terminal peptides", "TREATMENT", 37, 60], ["velocity", "OBSERVATION_MODIFIER", 4, 12], ["each", "OBSERVATION_MODIFIER", 16, 20], ["Arg residues", "OBSERVATION", 21, 33]]], ["The results indicated that PADIV recognizes the specific Arg residues in the synthetic peptide, and that the N-terminal acetylation of the histone peptides dramatically affects on the substrate recognition of PADIV.", [["PADIV", "CHEMICAL", 27, 32], ["Arg", "CHEMICAL", 57, 60], ["Arg", "CHEMICAL", 57, 60], ["N", "CHEMICAL", 109, 110], ["PADIV", "SIMPLE_CHEMICAL", 27, 32], ["Arg", "AMINO_ACID", 57, 60], ["histone peptides", "GENE_OR_GENE_PRODUCT", 139, 155], ["PADIV", "GENE_OR_GENE_PRODUCT", 209, 214], ["PADIV", "PROTEIN", 27, 32], ["PADIV", "PROTEIN", 209, 214], ["Arg residues in the synthetic peptide", "PROBLEM", 57, 94], ["the N-terminal acetylation of the histone peptides", "TREATMENT", 105, 155], ["terminal", "OBSERVATION_MODIFIER", 111, 119], ["acetylation", "OBSERVATION_MODIFIER", 120, 131], ["dramatically", "OBSERVATION_MODIFIER", 156, 168]]], ["In addition, the CD spectra of the N-terminal peptides were measured to elucidate the structural specificity for the recognition of PAD IV.", [["N", "CHEMICAL", 35, 36], ["PAD IV", "GENE_OR_GENE_PRODUCT", 132, 138], ["PAD IV", "PROTEIN", 132, 138], ["the CD spectra", "TEST", 13, 27], ["PAD IV", "TREATMENT", 132, 138]]], ["Prolyl oligopeptidase (POP) is a serine peptidase that cleaves oligopeptides after prolyl residues.", [["Prolyl", "CHEMICAL", 0, 6], ["Prolyl", "CHEMICAL", 0, 6], ["serine", "CHEMICAL", 33, 39], ["prolyl", "CHEMICAL", 83, 89], ["Prolyl oligopeptidase", "GENE_OR_GENE_PRODUCT", 0, 21], ["POP", "GENE_OR_GENE_PRODUCT", 23, 26], ["serine", "AMINO_ACID", 33, 39], ["Prolyl oligopeptidase", "PROTEIN", 0, 21], ["POP", "PROTEIN", 23, 26], ["serine peptidase", "PROTEIN", 33, 49], ["Prolyl oligopeptidase (POP)", "TREATMENT", 0, 27], ["a serine peptidase", "TREATMENT", 31, 49], ["prolyl residues", "TREATMENT", 83, 98]]], ["It has been associated with cognitive disorders.", [["cognitive disorders", "DISEASE", 28, 47], ["cognitive disorders", "PROBLEM", 28, 47], ["associated with", "UNCERTAINTY", 12, 27], ["cognitive disorders", "OBSERVATION", 28, 47]]], ["POP inhibitors have been shown to enhance cognition in monkeys (1) and to improve performance in verbal memory tests in humans (2) .", [["POP", "GENE_OR_GENE_PRODUCT", 0, 3], ["humans", "ORGANISM", 120, 126], ["humans", "SPECIES", 120, 126], ["humans", "SPECIES", 120, 126], ["POP inhibitors", "TREATMENT", 0, 14], ["verbal memory tests", "TEST", 97, 116]]], ["In the present study, the P2 L-prolyl residue of POP inhibitors was replaced by two L-proline mimetics, the 5-t-butyl-L-prolyl group and the (R)-cyclopent-2-enecarbonyl group.", [["L-proline", "CHEMICAL", 84, 93], ["5-t-butyl-L-prolyl", "CHEMICAL", 108, 126], ["cyclopent-2-enecarbonyl", "CHEMICAL", 145, 168], ["-prolyl", "CHEMICAL", 30, 37], ["L-proline", "CHEMICAL", 84, 93], ["5-t-butyl-L-prolyl", "CHEMICAL", 108, 126], ["(R)-cyclopent-2-enecarbonyl", "CHEMICAL", 141, 168], ["L-proline", "SIMPLE_CHEMICAL", 84, 93], ["5-t-butyl-L-prolyl group", "SIMPLE_CHEMICAL", 108, 132], ["(R)-cyclopent-2-enecarbonyl", "SIMPLE_CHEMICAL", 141, 168], ["the present study", "TEST", 3, 20], ["the P2 L-prolyl residue", "TREATMENT", 22, 45], ["POP inhibitors", "TREATMENT", 49, 63], ["two L-proline mimetics", "TREATMENT", 80, 102], ["cyclopent", "TEST", 145, 154]]], ["The effect of the mimetics on in vitro potency, lipophilicity and binding kinetics were studied.M238Methods.", [["the mimetics", "TREATMENT", 14, 26]]], ["The L-proline mimetics were synthesized according to the published procedures (3, 4) with minor modifications.", [["L-proline", "CHEMICAL", 4, 13], ["L-proline", "CHEMICAL", 4, 13], ["L-proline", "SIMPLE_CHEMICAL", 4, 13], ["The L-proline mimetics", "TREATMENT", 0, 22], ["minor modifications", "TREATMENT", 90, 109]]], ["The IC50 and Ki values and the binding kinetics were determined for porcine POP.", [["porcine", "ORGANISM", 68, 75], ["porcine", "SPECIES", 68, 75], ["The IC50", "TEST", 0, 8], ["Ki values", "TEST", 13, 22], ["the binding kinetics", "TEST", 27, 47], ["porcine POP", "TREATMENT", 68, 79]]], ["The log P values were determined with the shake-flask method.M238Results.", [["M238Results", "PROTEIN", 61, 72], ["The log P values", "TEST", 0, 16]]], ["The replacement of the P2 L-prolyl residue by the L-proline mimetics gave compounds which were equipotent with their parent structures.", [["-prolyl", "CHEMICAL", 27, 34], ["-proline", "CHEMICAL", 51, 59], ["L-proline", "SIMPLE_CHEMICAL", 50, 59], ["The replacement", "TREATMENT", 0, 15], ["the P2 L-prolyl residue", "TREATMENT", 19, 42], ["the L-proline mimetics", "TREATMENT", 46, 68], ["replacement", "OBSERVATION", 4, 15]]], ["Both L-proline mimetics increased lipophilicity but the effect of the 5-t-butyl-L-prolyl group was more pronounced.", [["-proline", "CHEMICAL", 6, 14], ["5-t-butyl-L-prolyl", "CHEMICAL", 70, 88], ["L-proline", "CHEMICAL", 5, 14], ["5-t-butyl-L-prolyl", "CHEMICAL", 70, 88], ["L-proline", "SIMPLE_CHEMICAL", 5, 14], ["5-t-butyl-L-prolyl", "SIMPLE_CHEMICAL", 70, 88], ["Both L-proline mimetics increased lipophilicity", "TREATMENT", 0, 47], ["L", "ANATOMY_MODIFIER", 5, 6], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["lipophilicity", "OBSERVATION", 34, 47], ["more pronounced", "OBSERVATION_MODIFIER", 99, 114]]], ["While the 5-t-butyl-L-prolyl group increased the dissociation half-life of the enzymeinhibitor complex, the (R)-cyclopent-2-enecarbonyl group decreased it.M238Conclusions.", [["5-t-butyl-L-prolyl", "CHEMICAL", 10, 28], ["cyclopent-2-enecarbonyl", "CHEMICAL", 112, 135], ["5-t-butyl-L-prolyl", "CHEMICAL", 10, 28], ["(R)-cyclopent-2-enecarbonyl", "CHEMICAL", 108, 135], ["5-t-butyl-L-prolyl", "SIMPLE_CHEMICAL", 10, 28], ["enzymeinhibitor", "SIMPLE_CHEMICAL", 79, 94], ["(R)-cyclopent-2-enecarbonyl", "SIMPLE_CHEMICAL", 108, 135], ["enzymeinhibitor complex", "PROTEIN", 79, 102], ["cyclopent", "TEST", 112, 121], ["2-enecarbonyl group", "TREATMENT", 122, 141]]], ["Both L-proline mimetics perfectly mimicked L-proline at the P2 position of POP inhibitors.", [["-proline", "CHEMICAL", 6, 14], ["L-proline", "CHEMICAL", 43, 52], ["L-proline", "CHEMICAL", 5, 14], ["L-proline", "CHEMICAL", 43, 52], ["L-proline", "SIMPLE_CHEMICAL", 5, 14], ["L-proline", "SIMPLE_CHEMICAL", 43, 52], ["POP", "GENE_OR_GENE_PRODUCT", 75, 78], ["Both L-proline mimetics", "TREATMENT", 0, 23], ["L-proline", "TREATMENT", 43, 52], ["POP inhibitors", "TREATMENT", 75, 89], ["L", "ANATOMY_MODIFIER", 5, 6]]], ["These mimetics can be used to modify the lipophilicity and the binding kinetics of POP inhibitors.Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, TX, USAThe proteasome is an essential multicatalytic protease of the ubiquitin proteasome pathway.", [["POP", "GENE_OR_GENE_PRODUCT", 83, 86], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 287, 296], ["proteasome", "PROTEIN", 229, 239], ["multicatalytic protease", "PROTEIN", 256, 279], ["ubiquitin proteasome", "PROTEIN", 287, 307], ["These mimetics", "TREATMENT", 0, 14], ["the lipophilicity", "TREATMENT", 37, 54], ["POP inhibitors", "TREATMENT", 83, 97], ["USAThe proteasome", "TREATMENT", 222, 239], ["the ubiquitin proteasome pathway", "TREATMENT", 283, 315]]], ["As a prime executor of regulated proteolysis, the proteasome controls almost all aspects of cell metabolism from signal transduction to cell cycle and differentiation.", [["cell", "ANATOMY", 92, 96], ["cell", "ANATOMY", 136, 140], ["cell", "CELL", 92, 96], ["cell", "CELL", 136, 140], ["proteasome", "PROTEIN", 50, 60], ["regulated proteolysis", "PROBLEM", 23, 44], ["the proteasome controls", "TREATMENT", 46, 69], ["cell metabolism", "PROBLEM", 92, 107], ["proteolysis", "OBSERVATION", 33, 44], ["cell metabolism", "OBSERVATION", 92, 107]]], ["Pharmacological intervention into proteasome activity leads to cell apoptosis.", [["cell", "ANATOMY", 63, 67], ["cell", "CELL", 63, 67], ["proteasome", "PROTEIN", 34, 44], ["Pharmacological intervention", "TREATMENT", 0, 28], ["cell apoptosis", "PROBLEM", 63, 77], ["cell apoptosis", "OBSERVATION", 63, 77]]], ["This observation was applied to successfully treat multiple myeloma, since the cancer cells exhibit substantially higher sensitivity to competitive inhibition of proteasome than normal cells.", [["myeloma", "ANATOMY", 60, 67], ["cancer cells", "ANATOMY", 79, 91], ["cells", "ANATOMY", 185, 190], ["multiple myeloma", "DISEASE", 51, 67], ["cancer", "DISEASE", 79, 85], ["myeloma", "CANCER", 60, 67], ["cancer cells", "CELL", 79, 91], ["cells", "CELL", 185, 190], ["cancer cells", "CELL_TYPE", 79, 91], ["proteasome", "PROTEIN", 162, 172], ["normal cells", "CELL_TYPE", 178, 190], ["This observation", "TEST", 0, 16], ["multiple myeloma", "PROBLEM", 51, 67], ["the cancer cells", "PROBLEM", 75, 91], ["substantially higher sensitivity", "PROBLEM", 100, 132], ["multiple", "OBSERVATION_MODIFIER", 51, 59], ["myeloma", "OBSERVATION", 60, 67]]], ["However, the complete shutting down of the proteasome catalyzed proteolysis leads to serious side effects resulting from the disruption of proteolytic homeostasis even in noncancerous cells.", [["noncancerous cells", "ANATOMY", 171, 189], ["noncancerous cells", "CELL", 171, 189], ["proteasome", "PROTEIN", 43, 53], ["noncancerous cells", "CELL_TYPE", 171, 189], ["the proteasome catalyzed proteolysis", "TREATMENT", 39, 75], ["serious side effects", "PROBLEM", 85, 105], ["proteolytic homeostasis", "PROBLEM", 139, 162], ["noncancerous cells", "PROBLEM", 171, 189], ["noncancerous cells", "OBSERVATION", 171, 189]]], ["Here, we show an alternative approach to control the proteasome activity using peptide based noncompetitive regulators.", [["proteasome", "PROTEIN", 53, 63], ["an alternative approach", "TREATMENT", 14, 37], ["the proteasome activity", "TREATMENT", 49, 72], ["peptide based noncompetitive regulators", "TREATMENT", 79, 118]]], ["The cathelicidins derived peptides rich in proline and arginine (PR) residues have been found to affect activity of all the proteasome complexes both in vivo and in vitro, likely by binding to the face of the enzyme.", [["proline", "CHEMICAL", 43, 50], ["arginine", "CHEMICAL", 55, 63], ["proline", "CHEMICAL", 43, 50], ["arginine", "CHEMICAL", 55, 63], ["proline", "AMINO_ACID", 43, 50], ["arginine", "AMINO_ACID", 55, 63], ["PR", "PROTEIN", 65, 67], ["proteasome complexes", "PROTEIN", 124, 144], ["enzyme", "PROTEIN", 209, 215], ["The cathelicidins derived peptides", "TREATMENT", 0, 34], ["proline and arginine (PR) residues", "TREATMENT", 43, 77], ["the enzyme", "TEST", 205, 215]]], ["Mechanism and structural constrains of the PR peptides dictating their influence on the proteasome remain elusive.", [["PR peptides", "GENE_OR_GENE_PRODUCT", 43, 54], ["PR", "PROTEIN", 43, 45], ["proteasome", "PROTEIN", 88, 98], ["structural constrains of the PR peptides", "PROBLEM", 14, 54], ["the proteasome", "TREATMENT", 84, 98], ["structural constrains", "OBSERVATION", 14, 35]]], ["Our results indicate that there are three sequence related properties of the PR peptides controlling their effectiveness as proteasome regulators: length of the peptide, distribution of a set of positive charges at the peptide N-terminus, and positioning of proline residues.", [["proline", "CHEMICAL", 258, 265], ["N", "CHEMICAL", 227, 228], ["proline", "CHEMICAL", 258, 265], ["PR peptides", "GENE_OR_GENE_PRODUCT", 77, 88], ["proline", "AMINO_ACID", 258, 265], ["PR", "PROTEIN", 77, 79], ["proteasome regulators", "PROTEIN", 124, 145], ["peptide N-terminus", "PROTEIN", 219, 237], ["the PR peptides", "TREATMENT", 73, 88], ["positive charges", "PROBLEM", 195, 211], ["positioning of proline residues", "TREATMENT", 243, 274], ["positive charges", "OBSERVATION", 195, 211], ["proline residues", "OBSERVATION", 258, 274]]], ["Far UV CD spectroscopy demonstrates that these properties also correlate with the structure of PR peptides.", [["PR peptides", "GENE_OR_GENE_PRODUCT", 95, 106], ["PR", "PROTEIN", 95, 97], ["Far UV CD spectroscopy", "TEST", 0, 22], ["PR peptides", "TREATMENT", 95, 106]]], ["In particular, it seems that structural propensity of the PR peptides to form beta-turns are required to bind to proteasome as regulatory competent molecules.Faculty of Chemistry, University of Gda\u0144Sk, PolandOur work is focused on the search of selective, low-molecular cathepsin B peptide inhibitors acylated with the (E)-3-(benzylsulphonyl)acroyl group (Bsa).", [["(E)-3-(benzylsulphonyl)acroyl", "CHEMICAL", 319, 348], ["Bsa", "CHEMICAL", 356, 359], ["PR peptides", "GENE_OR_GENE_PRODUCT", 58, 69], ["cathepsin B peptide", "SIMPLE_CHEMICAL", 270, 289], ["(E)-3-(benzylsulphonyl)acroyl group", "SIMPLE_CHEMICAL", 319, 354], ["Bsa", "SIMPLE_CHEMICAL", 356, 359], ["PR", "PROTEIN", 58, 60], ["beta", "PROTEIN", 78, 82], ["proteasome", "PROTEIN", 113, 123], ["regulatory competent molecules", "PROTEIN", 127, 157], ["the PR peptides", "TREATMENT", 54, 69], ["beta-turns", "TREATMENT", 78, 88], ["low-molecular cathepsin B peptide inhibitors", "TREATMENT", 256, 300]]], ["The double bond, embedded in the Bsa moiety is activated by two electron-withdrawing groups and may be a good target for the Michael-type addition of the catalytically active -SH group.", [["Bsa", "CHEMICAL", 33, 36], ["Bsa", "CHEMICAL", 33, 36], ["SH", "CHEMICAL", 176, 178], ["Bsa moiety", "SIMPLE_CHEMICAL", 33, 43], ["double bond", "OBSERVATION", 4, 15]]], ["Three series of peptide derivatives possessing general structures: Bsa-Phe-Asn(R)-OH, Bsa-Ile-X(OH)-N(CH3)2 and Bsa-X-Pro-OH were synthesized in solution and characterized by enzyme kinetic studies against papain, cathepsins B and K. It should be noted that all the investigated compounds were competitive and reversible inhibitors of the enzymes examined.", [["Bsa-Phe-Asn", "CHEMICAL", 67, 78], ["Bsa-Ile", "CHEMICAL", 86, 93], ["OH", "CHEMICAL", 96, 98], ["Bsa-X-Pro-OH", "CHEMICAL", 112, 124], ["Bsa-Phe-Asn(R)-OH", "CHEMICAL", 67, 84], ["Bsa-Ile-X(OH)-N(CH3)2", "CHEMICAL", 86, 107], ["Bsa-X-Pro-OH", "CHEMICAL", 112, 124], ["peptide derivatives", "SIMPLE_CHEMICAL", 16, 35], ["Bsa-Phe-Asn(R)-OH", "SIMPLE_CHEMICAL", 67, 84], ["Bsa-Ile-X(OH)-N(CH3)2", "SIMPLE_CHEMICAL", 86, 107], ["Bsa-X-Pro-OH", "SIMPLE_CHEMICAL", 112, 124], ["papain", "GENE_OR_GENE_PRODUCT", 206, 212], ["cathepsins B", "GENE_OR_GENE_PRODUCT", 214, 226], ["K", "GENE_OR_GENE_PRODUCT", 231, 232], ["papain", "PROTEIN", 206, 212], ["cathepsins B and K", "PROTEIN", 214, 232], ["enzymes", "PROTEIN", 339, 346], ["peptide derivatives", "TREATMENT", 16, 35], ["Bsa", "TEST", 67, 70], ["Phe", "TEST", 71, 74], ["Asn", "TEST", 75, 78], ["OH", "TEST", 82, 84], ["Bsa", "TEST", 86, 89], ["Bsa-X", "TEST", 112, 117], ["enzyme kinetic studies", "TEST", 175, 197], ["papain", "TREATMENT", 206, 212], ["the enzymes", "TEST", 335, 346]]], ["Using 2D 1H NMR (TOCSY, COSY, ROESY) and 13C NMR spectroscopy along with theoretical calculations (ANALYSE program) we determined the conformational properties of two most potent and selective cathepsin B inhibitors.", [["1H", "CHEMICAL", 9, 11], ["13C", "CHEMICAL", 41, 44], ["13C", "SIMPLE_CHEMICAL", 41, 44], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 193, 204], ["cathepsin B", "PROTEIN", 193, 204], ["13C NMR spectroscopy", "TEST", 41, 61], ["theoretical calculations", "TEST", 73, 97], ["selective cathepsin B inhibitors", "TREATMENT", 183, 215]]], ["Background and aims: We have developed peptides inhibiting human kallikrein-2 (hK2) activity.", [["human", "ORGANISM", 59, 64], ["kallikrein-2", "GENE_OR_GENE_PRODUCT", 65, 77], ["hK2", "GENE_OR_GENE_PRODUCT", 79, 82], ["human kallikrein-2", "PROTEIN", 59, 77], ["hK2", "PROTEIN", 79, 82], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["peptides inhibiting human kallikrein", "PROBLEM", 39, 75]]], ["As hK2 is overexpressed in prostate cancer tissue, these peptides are potentially useful for treatment and diagnosis of prostate cancer.", [["prostate cancer tissue", "ANATOMY", 27, 49], ["prostate cancer", "ANATOMY", 120, 135], ["prostate cancer", "DISEASE", 27, 42], ["prostate cancer", "DISEASE", 120, 135], ["hK2", "GENE_OR_GENE_PRODUCT", 3, 6], ["prostate cancer tissue", "TISSUE", 27, 49], ["prostate cancer", "CANCER", 120, 135], ["hK2", "PROTEIN", 3, 6], ["prostate cancer tissue", "PROBLEM", 27, 49], ["treatment", "TREATMENT", 93, 102], ["prostate cancer", "PROBLEM", 120, 135], ["prostate", "ANATOMY", 27, 35], ["cancer", "OBSERVATION", 36, 42], ["prostate", "ANATOMY", 120, 128], ["cancer", "OBSERVATION", 129, 135]]], ["Two of the potential physiological substrates for hK2 are proform of prostate specific antigen (proPSA) and insulin-like growth factor-binding protein-3 (IGFBP-3).", [["prostate", "ANATOMY", 69, 77], ["hK2", "GENE_OR_GENE_PRODUCT", 50, 53], ["prostate specific antigen", "GENE_OR_GENE_PRODUCT", 69, 94], ["proPSA", "GENE_OR_GENE_PRODUCT", 96, 102], ["insulin-like growth factor-binding protein-3", "GENE_OR_GENE_PRODUCT", 108, 152], ["IGFBP-3", "GENE_OR_GENE_PRODUCT", 154, 161], ["hK2", "PROTEIN", 50, 53], ["prostate specific antigen", "PROTEIN", 69, 94], ["proPSA", "PROTEIN", 96, 102], ["insulin-like growth factor-binding protein-3", "PROTEIN", 108, 152], ["IGFBP", "PROTEIN", 154, 159], ["hK2", "TEST", 50, 53], ["prostate specific antigen", "TEST", 69, 94], ["proPSA", "TEST", 96, 102], ["insulin", "TEST", 108, 115], ["growth factor", "TEST", 121, 134], ["binding protein", "TEST", 135, 150], ["IGFBP", "TEST", 154, 159], ["prostate", "ANATOMY", 69, 77]]], ["Both of these might participate in the regulation of prostate cancer growth: IGFBP-3 by inhibiting IGF-dependent tumor growth and PSA by degrading extracellular matrix.", [["prostate cancer", "ANATOMY", 53, 68], ["tumor", "ANATOMY", 113, 118], ["extracellular matrix", "ANATOMY", 147, 167], ["prostate cancer", "DISEASE", 53, 68], ["tumor", "DISEASE", 113, 118], ["prostate cancer", "CANCER", 53, 68], ["IGFBP-3", "GENE_OR_GENE_PRODUCT", 77, 84], ["IGF", "GENE_OR_GENE_PRODUCT", 99, 102], ["tumor", "CANCER", 113, 118], ["PSA", "GENE_OR_GENE_PRODUCT", 130, 133], ["extracellular matrix", "CELLULAR_COMPONENT", 147, 167], ["IGFBP-3", "PROTEIN", 77, 84], ["IGF", "PROTEIN", 99, 102], ["PSA", "PROTEIN", 130, 133], ["prostate cancer growth", "PROBLEM", 53, 75], ["IGFBP", "TEST", 77, 82], ["IGF", "TEST", 99, 102], ["dependent tumor growth", "PROBLEM", 103, 125], ["PSA", "TEST", 130, 133], ["prostate", "ANATOMY", 53, 61], ["cancer", "OBSERVATION", 62, 68], ["dependent", "OBSERVATION_MODIFIER", 103, 112], ["tumor", "OBSERVATION", 113, 118], ["growth", "OBSERVATION_MODIFIER", 119, 125], ["extracellular matrix", "OBSERVATION", 147, 167]]], ["We aimed to study whether our hK2-inhibiting peptides inhibit also hK2 activity towards natural protein substrates, i.e. activation of proPSA and degradation of IGFBP-3.Faculty of Chemistry, University of Gda\u0144Sk, PolandMethods: The effect of the peptides on the activation of proPSA by hK2 was studied by preincubating the peptides with hK2, followed by addition of PSA and specific PSA substrate.", [["hK2", "GENE_OR_GENE_PRODUCT", 30, 33], ["hK2", "GENE_OR_GENE_PRODUCT", 67, 70], ["proPSA", "GENE_OR_GENE_PRODUCT", 135, 141], ["IGFBP-3", "GENE_OR_GENE_PRODUCT", 161, 168], ["proPSA", "GENE_OR_GENE_PRODUCT", 276, 282], ["hK2", "GENE_OR_GENE_PRODUCT", 286, 289], ["hK2", "GENE_OR_GENE_PRODUCT", 337, 340], ["PSA", "GENE_OR_GENE_PRODUCT", 366, 369], ["PSA", "GENE_OR_GENE_PRODUCT", 383, 386], ["hK2", "PROTEIN", 30, 33], ["hK2", "PROTEIN", 67, 70], ["proPSA", "PROTEIN", 135, 141], ["IGFBP-3", "PROTEIN", 161, 168], ["proPSA", "PROTEIN", 276, 282], ["hK2", "PROTEIN", 286, 289], ["hK2", "PROTEIN", 337, 340], ["PSA", "PROTEIN", 366, 369], ["PSA", "PROTEIN", 383, 386], ["our hK2", "TEST", 26, 33], ["inhibiting peptides", "PROBLEM", 34, 53], ["hK2 activity", "PROBLEM", 67, 79], ["natural protein substrates", "TREATMENT", 88, 114], ["proPSA", "PROBLEM", 135, 141], ["IGFBP", "TEST", 161, 166], ["the peptides", "PROBLEM", 242, 254], ["PSA", "TEST", 366, 369], ["specific PSA substrate", "TEST", 374, 396]]], ["IGFBP-3 degradation was studied by two specific immunoassays, one detecting only native IGFBP-3, while the other one also detected proteolytically cleaved forms of the protein.Faculty of Chemistry, University of Gda\u0144Sk, PolandResults: hK2-inhibiting peptides were found to inhibit proPSA activation and IGFBP-3 degradation by hK2 in a dose dependent fashion.", [["IGFBP-3", "GENE_OR_GENE_PRODUCT", 0, 7], ["IGFBP-3", "GENE_OR_GENE_PRODUCT", 88, 95], ["hK2", "GENE_OR_GENE_PRODUCT", 235, 238], ["proPSA", "GENE_OR_GENE_PRODUCT", 281, 287], ["IGFBP-3", "GENE_OR_GENE_PRODUCT", 303, 310], ["hK2", "GENE_OR_GENE_PRODUCT", 326, 329], ["IGFBP-3", "PROTEIN", 0, 7], ["IGFBP-3", "PROTEIN", 88, 95], ["proPSA", "PROTEIN", 281, 287], ["IGFBP-3", "PROTEIN", 303, 310], ["hK2", "PROTEIN", 326, 329], ["IGFBP", "TEST", 0, 5], ["specific immunoassays", "TEST", 39, 60], ["hK2", "TEST", 235, 238], ["inhibiting peptides", "PROBLEM", 239, 258], ["IGFBP", "TEST", 303, 308], ["IGFBP", "OBSERVATION", 88, 93]]], ["Conclusions: We have developed new peptides inhibiting hK2 activity towards natural substrates, like proPSA and IGFBP-3.", [["hK2", "GENE_OR_GENE_PRODUCT", 55, 58], ["proPSA", "SIMPLE_CHEMICAL", 101, 107], ["IGFBP-3", "GENE_OR_GENE_PRODUCT", 112, 119], ["hK2", "PROTEIN", 55, 58], ["proPSA", "PROTEIN", 101, 107], ["IGFBP", "PROTEIN", 112, 117], ["new peptides inhibiting hK2 activity", "PROBLEM", 31, 67], ["natural substrates", "PROBLEM", 76, 94], ["IGFBP", "TEST", 112, 117]]], ["The peptides might be useful for treatment of prostate cancer and other diseases associated with increased hK2 activity.", [["prostate cancer", "ANATOMY", 46, 61], ["prostate cancer", "DISEASE", 46, 61], ["prostate cancer", "CANCER", 46, 61], ["hK2", "GENE_OR_GENE_PRODUCT", 107, 110], ["hK2", "PROTEIN", 107, 110], ["The peptides", "TREATMENT", 0, 12], ["treatment", "TREATMENT", 33, 42], ["prostate cancer", "PROBLEM", 46, 61], ["other diseases", "PROBLEM", 66, 80], ["increased hK2 activity", "PROBLEM", 97, 119], ["prostate", "ANATOMY", 46, 54], ["cancer", "OBSERVATION", 55, 61], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["hK2 activity", "OBSERVATION", 107, 119]]], ["From the seeds of garden four-o'clock and spinach we isolated two serine proteinase inhibitors (MJTI I -Mirabilis jalapa trypsin inhibitor and SOTI I -Spinacia oleracea trypsin inhibitor), which are probably representatives of a new family of inhibitors.", [["SOTI I -Spinacia oleracea", "CHEMICAL", 143, 168], ["serine", "CHEMICAL", 66, 72], ["spinach", "ORGANISM_SUBDIVISION", 42, 49], ["trypsin", "GENE_OR_GENE_PRODUCT", 121, 128], ["SOTI I -Spinacia oleracea trypsin", "GENE_OR_GENE_PRODUCT", 143, 176], ["Spinacia oleracea", "SPECIES", 151, 168], ["Spinacia oleracea", "SPECIES", 151, 168], ["spinach", "TREATMENT", 42, 49], ["two serine proteinase inhibitors", "TREATMENT", 62, 94], ["MJTI I -Mirabilis jalapa trypsin inhibitor", "TREATMENT", 96, 138], ["SOTI I -Spinacia oleracea trypsin inhibitor", "TREATMENT", 143, 186], ["seeds", "OBSERVATION_MODIFIER", 9, 14]]], ["The purification procedures of these inhibitors included affinity chromatography on immobilized methylchymotrypsin in a presence of 5 M NaCl, ion exchange chromatography and/or preparative electrophoresis and finally RP-HPLC on C18 column.", [["methylchymotrypsin", "CHEMICAL", 96, 114], ["NaCl", "CHEMICAL", 136, 140], ["methylchymotrypsin", "CHEMICAL", 96, 114], ["NaCl", "CHEMICAL", 136, 140], ["methylchymotrypsin", "SIMPLE_CHEMICAL", 96, 114], ["The purification procedures", "TREATMENT", 0, 27], ["these inhibitors", "TREATMENT", 31, 47], ["affinity chromatography", "TEST", 57, 80], ["immobilized methylchymotrypsin", "TREATMENT", 84, 114], ["5 M NaCl", "TREATMENT", 132, 140], ["ion exchange chromatography", "TREATMENT", 142, 169], ["preparative electrophoresis", "TREATMENT", 177, 204], ["RP-HPLC on C18 column", "TREATMENT", 217, 238]]], ["Their primary structures (Fig. 1 ) differ from those of known trypsin inhibitors, but showed significant similarity to one another, as well as to the antimicrobial peptides isolated from the seeds of Mirabilis jalapa (MJ-AMP1, MJ-AMP2), Mesembryanthemum crystallinum (AMP1) and Phytolacca americana (AMP-2 and PAFS-S) and from hemolymph of Acrocinus longimanus (Alo-1, 2 and 3).", [["seeds", "ANATOMY", 191, 196], ["hemolymph", "ANATOMY", 327, 336], ["AMP-2 and PAFS-S", "CHEMICAL", 300, 316], ["trypsin", "GENE_OR_GENE_PRODUCT", 62, 69], ["Mirabilis jalapa", "ORGANISM", 200, 216], ["MJ-AMP1", "ORGANISM", 218, 225], ["MJ-AMP2", "ORGANISM", 227, 234], ["Mesembryanthemum crystallinum", "ORGANISM", 237, 266], ["AMP1", "ORGANISM", 268, 272], ["Phytolacca americana", "ORGANISM", 278, 298], ["AMP-2", "CELL", 300, 305], ["PAFS-S", "CELL", 310, 316], ["hemolymph", "ORGANISM_SUBSTANCE", 327, 336], ["Acrocinus longimanus", "ORGANISM", 340, 360], ["Alo-1", "ORGANISM", 362, 367], ["Mirabilis jalapa", "SPECIES", 200, 216], ["Mesembryanthemum crystallinum", "SPECIES", 237, 266], ["Phytolacca americana", "SPECIES", 278, 298], ["Acrocinus longimanus", "SPECIES", 340, 360], ["Mirabilis jalapa", "SPECIES", 200, 216], ["Mesembryanthemum crystallinum", "SPECIES", 237, 266], ["Phytolacca americana", "SPECIES", 278, 298], ["Acrocinus longimanus", "SPECIES", 340, 360], ["known trypsin inhibitors", "TREATMENT", 56, 80], ["the antimicrobial peptides", "PROBLEM", 146, 172], ["Mirabilis jalapa", "PROBLEM", 200, 216], ["MJ", "TEST", 218, 220], ["Phytolacca americana", "TEST", 278, 298], ["AMP", "TEST", 300, 303], ["PAFS", "TEST", 310, 314], ["hemolymph", "TEST", 327, 336], ["Acrocinus", "TEST", 340, 349], ["hemolymph", "ANATOMY", 327, 336]]], ["The equilibrium association constants (Ka) of MJTI I and SOTI I with bovine -trypsin were found to be about 107-109 M-1.", [["MJTI I", "GENE_OR_GENE_PRODUCT", 46, 52], ["SOTI I", "GENE_OR_GENE_PRODUCT", 57, 63], ["bovine", "ORGANISM", 69, 75], ["trypsin", "GENE_OR_GENE_PRODUCT", 77, 84], ["MJTI I", "PROTEIN", 46, 52], ["SOTI I", "PROTEIN", 57, 63], ["trypsin", "PROTEIN", 77, 84], ["bovine", "SPECIES", 69, 75], ["bovine -trypsin", "TEST", 69, 84]]], ["MJTI I and SOTI I have been synthesized using solid-phase method.", [["SOTI I", "CHEMICAL", 11, 17], ["SOTI I", "GENE_OR_GENE_PRODUCT", 11, 17], ["MJTI I", "PROTEIN", 0, 6], ["SOTI I", "PROTEIN", 11, 17], ["solid-phase method", "TREATMENT", 46, 64]]], ["The synthesized inhibitors and inhibitors isolated from plants have similar properties.", [["The synthesized inhibitors", "TREATMENT", 0, 26], ["inhibitors", "TREATMENT", 31, 41]]], ["The disulfide bridge pattern in both inhibitors was established after digestion with thermolysine, followed by the MALDI-TOF: Cys1-Cys-4, Cys2-Cys5 and Cys3-Cys6.NMR STUDIES OF THE INHIBITION OF PEPSIN BY PEPTIDE GLYOXAL INHIBITORSS.", [["thermolysine", "CHEMICAL", 85, 97], ["disulfide", "CHEMICAL", 4, 13], ["thermolysine", "CHEMICAL", 85, 97], ["Cys", "CHEMICAL", 131, 134], ["Cys2", "CHEMICAL", 138, 142], ["Cys3-Cys6", "CHEMICAL", 152, 161], ["thermolysine", "SIMPLE_CHEMICAL", 85, 97], ["Cys1-Cys-4", "SIMPLE_CHEMICAL", 126, 136], ["Cys2-Cys5", "SIMPLE_CHEMICAL", 138, 147], ["Cys3-Cys6", "GENE_OR_GENE_PRODUCT", 152, 161], ["Cys2", "PROTEIN", 138, 142], ["Cys5", "PROTEIN", 143, 147], ["Cys3", "PROTEIN", 152, 156], ["Cys6", "PROTEIN", 157, 161], ["The disulfide bridge pattern in both inhibitors", "TREATMENT", 0, 47], ["thermolysine", "TREATMENT", 85, 97], ["Cys1", "TEST", 126, 130], ["Cys", "TEST", 131, 134], ["Cys2", "TEST", 138, 142], ["NMR STUDIES", "TEST", 162, 173], ["disulfide bridge", "OBSERVATION", 4, 20]]], ["Cosgrove, L. Rogers, C. Hewage, J.P. MalthouseCentre for Synthesis and Chemical Biology, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, IrelandAspartyl proteases are required for the multiplication of the AIDS virus and for producing the amyloid protein which causes Alzheimer's disease.", [["AIDS", "DISEASE", 250, 254], ["Alzheimer's disease", "DISEASE", 312, 331], ["AIDS virus", "ORGANISM", 250, 260], ["amyloid protein", "PROTEIN", 283, 298], ["AIDS virus", "SPECIES", 250, 260], ["IrelandAspartyl proteases", "TREATMENT", 181, 206], ["the AIDS virus", "PROBLEM", 246, 260], ["the amyloid protein", "PROBLEM", 279, 298], ["Alzheimer's disease", "PROBLEM", 312, 331], ["Alzheimer's disease", "OBSERVATION", 312, 331]]], ["HIV protease inhibitors have been highly effective in treating Aids patients and it is hoped that potent inhibitors of the beta secretases will also prove effective in treating Alzheimer's disease.", [["Alzheimer's disease", "DISEASE", 177, 196], ["patients", "ORGANISM", 68, 76], ["beta secretases", "GENE_OR_GENE_PRODUCT", 123, 138], ["beta secretases", "PROTEIN", 123, 138], ["HIV", "SPECIES", 0, 3], ["patients", "SPECIES", 68, 76], ["HIV", "SPECIES", 0, 3], ["HIV protease inhibitors", "TREATMENT", 0, 23], ["potent inhibitors", "TREATMENT", 98, 115], ["the beta secretases", "TREATMENT", 119, 138], ["Alzheimer's disease", "PROBLEM", 177, 196]]], ["Therefore inhibitors of the aspartyl proteases have great therapeutic potential.", [["aspartyl proteases", "PROTEIN", 28, 46], ["inhibitors", "TREATMENT", 10, 20], ["the aspartyl proteases", "TREATMENT", 24, 46]]], ["We have shown that the peptide glyoxals are potent inhibitors of the thiol protease papain and of the serine proteases subtilisin and chymotrypsin.", [["glyoxals", "CHEMICAL", 31, 39], ["thiol", "CHEMICAL", 69, 74], ["glyoxals", "CHEMICAL", 31, 39], ["thiol", "CHEMICAL", 69, 74], ["serine", "CHEMICAL", 102, 108], ["glyoxals", "SIMPLE_CHEMICAL", 31, 39], ["papain", "GENE_OR_GENE_PRODUCT", 84, 90], ["subtilisin", "GENE_OR_GENE_PRODUCT", 119, 129], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 134, 146], ["thiol protease papain", "PROTEIN", 69, 90], ["serine proteases", "PROTEIN", 102, 118], ["subtilisin", "PROTEIN", 119, 129], ["chymotrypsin", "PROTEIN", 134, 146], ["the peptide glyoxals", "TREATMENT", 19, 39], ["potent inhibitors", "TREATMENT", 44, 61], ["the thiol protease papain", "TREATMENT", 65, 90], ["the serine proteases subtilisin", "TREATMENT", 98, 129], ["chymotrypsin", "PROBLEM", 134, 146]]], ["Using 13C-NMR we have been able to show that glyoxal inhibitors react reversibly with an active site nucleophile in these enzymes to form a tetrahedral adduct which is tightly bound by the enzyme.Centre for Synthesis and Chemical Biology, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, IrelandIn the present work we synthesise 13C-enriched peptide glyoxals, we assess their inhibitor potency, and use 13C-NMR to examine how the inhibitors interact with the aspartyl protease pepsin.", [["glyoxal", "CHEMICAL", 45, 52], ["13C", "CHEMICAL", 6, 9], ["glyoxal", "CHEMICAL", 45, 52], ["13C", "CHEMICAL", 372, 375], ["glyoxals", "CHEMICAL", 393, 401], ["13C", "CHEMICAL", 446, 449], ["13C", "SIMPLE_CHEMICAL", 6, 9], ["glyoxal inhibitors", "SIMPLE_CHEMICAL", 45, 63], ["13C", "SIMPLE_CHEMICAL", 372, 375], ["glyoxals", "SIMPLE_CHEMICAL", 393, 401], ["13C", "SIMPLE_CHEMICAL", 446, 449], ["pepsin", "GENE_OR_GENE_PRODUCT", 520, 526], ["enzymes", "PROTEIN", 122, 129], ["enzyme", "PROTEIN", 189, 195], ["aspartyl protease", "PROTEIN", 502, 519], ["pepsin", "PROTEIN", 520, 526], ["glyoxal inhibitors", "TREATMENT", 45, 63], ["an active site nucleophile", "PROBLEM", 86, 112], ["these enzymes", "TEST", 116, 129], ["a tetrahedral adduct", "PROBLEM", 138, 158], ["the enzyme", "TEST", 185, 195], ["enriched peptide glyoxals", "TREATMENT", 376, 401], ["the inhibitors", "TREATMENT", 469, 483], ["the aspartyl protease pepsin", "TREATMENT", 498, 526], ["active", "OBSERVATION", 89, 95], ["tetrahedral adduct", "OBSERVATION", 140, 158]]], ["Z-Ala-Ala-[2-13C]Phe-glyoxal was synthesised from [1-13C]Phenylalanine which was converted to its methyl ester.", [["Z-Ala-Ala-[2-13C", "CHEMICAL", 0, 16], ["Phe-glyoxal", "CHEMICAL", 17, 28], ["[1-13C]", "CHEMICAL", 50, 57], ["Phenylalanine", "CHEMICAL", 57, 70], ["methyl ester", "CHEMICAL", 98, 110], ["Z-Ala-Ala-[2-13C]Phe-glyoxal", "CHEMICAL", 0, 28], ["Phenylalanine", "CHEMICAL", 57, 70], ["methyl ester", "CHEMICAL", 98, 110], ["Z-Ala-Ala-[2-13C]Phe-glyoxal", "SIMPLE_CHEMICAL", 0, 28], ["[1-13C]", "SIMPLE_CHEMICAL", 50, 57], ["Phenylalanine", "SIMPLE_CHEMICAL", 57, 70], ["methyl ester", "SIMPLE_CHEMICAL", 98, 110], ["Z", "TEST", 0, 1], ["Ala", "TEST", 6, 9], ["Phenylalanine", "TREATMENT", 57, 70], ["its methyl ester", "TREATMENT", 94, 110]]], ["This was then coupled with Z-Ala-Ala to give Z-Ala-Ala-[2-13C]Phe-OMe which was hydrolysed to the free acid.", [["Z-Ala-Ala", "CHEMICAL", 27, 36], ["Z-Ala-Ala-[2-13C]", "CHEMICAL", 45, 62], ["Phe-OMe", "CHEMICAL", 62, 69], ["Z-Ala-Ala", "CHEMICAL", 27, 36], ["Z-Ala-Ala-[2-13C]", "CHEMICAL", 45, 62], ["Phe", "CHEMICAL", 62, 65], ["Z-Ala-Ala", "SIMPLE_CHEMICAL", 27, 36], ["Z-Ala-Ala-[2-13C]", "SIMPLE_CHEMICAL", 45, 62], ["Phe-OMe", "SIMPLE_CHEMICAL", 62, 69], ["free acid", "SIMPLE_CHEMICAL", 98, 107], ["Z", "TEST", 27, 28], ["OMe", "PROBLEM", 66, 69]]], ["This was converted to the diazoketone and transformed into Z-Ala-Ala-[2-13C]Phe-glyoxal using dimethyldioxirane.", [["diazoketone", "CHEMICAL", 26, 37], ["Z-Ala-Ala-[2-13C]", "CHEMICAL", 59, 76], ["Phe-glyoxal", "CHEMICAL", 76, 87], ["dimethyldioxirane", "CHEMICAL", 94, 111], ["diazoketone", "CHEMICAL", 26, 37], ["Z-Ala-Ala-[2-13C]", "CHEMICAL", 59, 76], ["Phe-glyoxal", "CHEMICAL", 76, 87], ["dimethyldioxirane", "CHEMICAL", 94, 111], ["diazoketone", "SIMPLE_CHEMICAL", 26, 37], ["Z-Ala-Ala-[2-13C]", "SIMPLE_CHEMICAL", 59, 76], ["Phe-glyoxal", "SIMPLE_CHEMICAL", 76, 87], ["dimethyldioxirane", "SIMPLE_CHEMICAL", 94, 111], ["the diazoketone", "TREATMENT", 22, 37], ["Phe-glyoxal", "TREATMENT", 76, 87], ["dimethyldioxirane", "TREATMENT", 94, 111]]], ["NMR spectra at 11.75 T were recorded with a Bruker Avance DRX 500 standard-bore spectrometer.Centre for Synthesis and Chemical Biology, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, IrelandWe show that peptide glyoxal inhibitors can be potent inhibitors of pepsin and that pepsin only binds one of the four glyoxal forms (one non-hydrated, one fully hydrated and two partially hydrated forms).", [["glyoxal", "CHEMICAL", 256, 263], ["glyoxal", "CHEMICAL", 353, 360], ["glyoxal", "CHEMICAL", 256, 263], ["glyoxal", "CHEMICAL", 353, 360], ["glyoxal inhibitors", "SIMPLE_CHEMICAL", 256, 274], ["pepsin", "GENE_OR_GENE_PRODUCT", 303, 309], ["pepsin", "GENE_OR_GENE_PRODUCT", 319, 325], ["glyoxal", "SIMPLE_CHEMICAL", 353, 360], ["NMR spectra", "TEST", 0, 11], ["a Bruker Avance DRX", "TREATMENT", 42, 61], ["peptide glyoxal inhibitors", "TREATMENT", 248, 274], ["potent inhibitors of pepsin", "TREATMENT", 282, 309]]], ["Alzheimers) includes MIF-1, Tyr-MIF-1, Tyr-W-MIF-1 and Tyr-K-MIF-1, which have been isolated from bovine hypothalamus and human brain cortex.", [["hypothalamus", "ANATOMY", 105, 117], ["brain cortex", "ANATOMY", 128, 140], ["MIF-1", "GENE_OR_GENE_PRODUCT", 21, 26], ["Tyr-MIF-1", "GENE_OR_GENE_PRODUCT", 28, 37], ["Tyr-W-MIF-1", "GENE_OR_GENE_PRODUCT", 39, 50], ["Tyr-K-MIF-1", "GENE_OR_GENE_PRODUCT", 55, 66], ["bovine", "ORGANISM", 98, 104], ["hypothalamus", "MULTI-TISSUE_STRUCTURE", 105, 117], ["human", "ORGANISM", 122, 127], ["brain cortex", "CANCER", 128, 140], ["MIF", "PROTEIN", 21, 24], ["MIF", "PROTEIN", 32, 35], ["Tyr-W", "PROTEIN", 39, 44], ["MIF", "PROTEIN", 45, 48], ["Tyr-K", "PROTEIN", 55, 60], ["MIF", "PROTEIN", 61, 64], ["bovine", "SPECIES", 98, 104], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 122, 127], ["Alzheimers", "PROBLEM", 0, 10], ["MIF", "TEST", 21, 24], ["Tyr-MIF", "TEST", 28, 35], ["Tyr-W-MIF", "TEST", 39, 48], ["Tyr-K-MIF", "TEST", 55, 64], ["bovine hypothalamus", "OBSERVATION", 98, 117], ["human", "ANATOMY_MODIFIER", 122, 127], ["brain", "ANATOMY", 128, 133], ["cortex", "ANATOMY_MODIFIER", 134, 140]]], ["All these peptides interact with opioid receptors and in addition bind to non-opiate sites specific for each of the peptides.", [["opioid receptors", "GENE_OR_GENE_PRODUCT", 33, 49], ["opioid receptors", "PROTEIN", 33, 49], ["non-opiate sites", "DNA", 74, 90], ["opioid receptors", "TREATMENT", 33, 49], ["non-opiate sites", "TREATMENT", 74, 90]]], ["Data in the literature suggest that Tyr-MIF-1`s have antiopioid and opioid -like effects.", [["Tyr-MIF-1", "GENE_OR_GENE_PRODUCT", 36, 45], ["antiopioid", "SIMPLE_CHEMICAL", 53, 63], ["opioid", "SIMPLE_CHEMICAL", 68, 74], ["MIF", "PROTEIN", 40, 43], ["Tyr-MIF", "TEST", 36, 43], ["antiopioid", "TREATMENT", 53, 63], ["opioid", "TREATMENT", 68, 74]]], ["We used Wistar rats to study distribution and density of the tyrozine hydroxylase (TH) imunoreactive fibres and NADPH-d reactive neurons in the rat ventral and dorsal striatum.", [["neurons", "ANATOMY", 129, 136], ["ventral", "ANATOMY", 148, 155], ["dorsal striatum", "ANATOMY", 160, 175], ["tyrozine", "CHEMICAL", 61, 69], ["NADPH", "CHEMICAL", 112, 117], ["tyrozine", "CHEMICAL", 61, 69], ["NADPH", "CHEMICAL", 112, 117], ["Wistar rats", "ORGANISM", 8, 19], ["tyrozine hydroxylase", "GENE_OR_GENE_PRODUCT", 61, 81], ["TH", "GENE_OR_GENE_PRODUCT", 83, 85], ["NADPH-d", "GENE_OR_GENE_PRODUCT", 112, 119], ["rat", "ORGANISM", 144, 147], ["ventral", "MULTI-TISSUE_STRUCTURE", 148, 155], ["dorsal striatum", "MULTI-TISSUE_STRUCTURE", 160, 175], ["tyrozine hydroxylase (TH) imunoreactive fibres", "PROTEIN", 61, 107], ["rats", "SPECIES", 15, 19], ["rat", "SPECIES", 144, 147], ["the tyrozine hydroxylase", "TEST", 57, 81], ["NADPH-d reactive neurons in the rat ventral and dorsal striatum", "PROBLEM", 112, 175], ["reactive neurons", "OBSERVATION", 120, 136], ["rat", "ANATOMY_MODIFIER", 144, 147], ["ventral", "ANATOMY_MODIFIER", 148, 155], ["dorsal", "ANATOMY_MODIFIER", 160, 166], ["striatum", "ANATOMY", 167, 175]]], ["Our results showed that neuropeptides MIF-1 and Tyr-MIF-1 may affect them.", [["Tyr", "CHEMICAL", 48, 51], ["MIF-1", "GENE_OR_GENE_PRODUCT", 38, 43], ["Tyr-MIF-1", "GENE_OR_GENE_PRODUCT", 48, 57], ["MIF", "PROTEIN", 38, 41], ["MIF", "PROTEIN", 52, 55], ["neuropeptides MIF", "TEST", 24, 41], ["Tyr-MIF", "TEST", 48, 55]]], ["Opioid peptides have been recognized as modulators of reactive oxygen species (ROS) in mouse macrophages and human neutrophils.", [["macrophages", "ANATOMY", 93, 104], ["neutrophils", "ANATOMY", 115, 126], ["ROS", "CHEMICAL", 79, 82], ["oxygen", "CHEMICAL", 63, 69], ["Opioid peptides", "GENE_OR_GENE_PRODUCT", 0, 15], ["reactive oxygen species", "SIMPLE_CHEMICAL", 54, 77], ["ROS", "SIMPLE_CHEMICAL", 79, 82], ["mouse", "ORGANISM", 87, 92], ["macrophages", "CELL", 93, 104], ["human", "ORGANISM", 109, 114], ["neutrophils", "CELL", 115, 126], ["mouse macrophages", "CELL_TYPE", 87, 104], ["human neutrophils", "CELL_TYPE", 109, 126], ["mouse", "SPECIES", 87, 92], ["human", "SPECIES", 109, 114], ["mouse", "SPECIES", 87, 92], ["human", "SPECIES", 109, 114], ["Opioid peptides", "TREATMENT", 0, 15], ["reactive oxygen species", "PROBLEM", 54, 77], ["human neutrophils", "TEST", 109, 126], ["reactive", "OBSERVATION_MODIFIER", 54, 62], ["oxygen species", "OBSERVATION", 63, 77]]], ["Data in the literature suggest that peptides of the Tyr-MIF-1 family -MIF-1 and Tyr-MIF-1 have antiopioid and opioid -like effects.", [["Tyr", "CHEMICAL", 52, 55], ["Tyr", "CHEMICAL", 80, 83], ["Tyr-MIF-1", "GENE_OR_GENE_PRODUCT", 52, 61], ["MIF-1", "GENE_OR_GENE_PRODUCT", 70, 75], ["Tyr-MIF-1", "GENE_OR_GENE_PRODUCT", 80, 89], ["antiopioid", "SIMPLE_CHEMICAL", 95, 105], ["opioid", "SIMPLE_CHEMICAL", 110, 116], ["Tyr-MIF-1 family", "PROTEIN", 52, 68], ["MIF", "PROTEIN", 70, 73], ["Tyr", "PROTEIN", 80, 83], ["MIF", "PROTEIN", 84, 87], ["MIF", "TEST", 70, 73], ["Tyr-MIF", "TEST", 80, 87], ["antiopioid", "TREATMENT", 95, 105], ["opioid", "TREATMENT", 110, 116]]], ["These neuropeptides are isolated from bovine hypothalamus and human brain cortex.", [["hypothalamus", "ANATOMY", 45, 57], ["brain cortex", "ANATOMY", 68, 80], ["bovine", "ORGANISM", 38, 44], ["hypothalamus", "MULTI-TISSUE_STRUCTURE", 45, 57], ["human", "ORGANISM", 62, 67], ["brain cortex", "MULTI-TISSUE_STRUCTURE", 68, 80], ["bovine", "SPECIES", 38, 44], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["bovine hypothalamus and human brain cortex", "PROBLEM", 38, 80], ["bovine hypothalamus", "OBSERVATION", 38, 57], ["human", "ANATOMY_MODIFIER", 62, 67], ["brain", "ANATOMY", 68, 73], ["cortex", "ANATOMY_MODIFIER", 74, 80]]], ["So far no data about direct scavenger properties of Tyr-MIFs peptides were available.", [["Tyr", "CHEMICAL", 52, 55], ["Tyr", "CHEMICAL", 52, 55], ["Tyr-MIFs peptides", "SIMPLE_CHEMICAL", 52, 69], ["Tyr-MIFs peptides", "TEST", 52, 69]]], ["In this study we tested the hypothesis that they may scavenge ROS in vitro.", [["ROS", "CHEMICAL", 62, 65], ["ROS", "SIMPLE_CHEMICAL", 62, 65], ["this study", "TEST", 3, 13]]], ["The antioxidant activity of these two substances was studied in the concentration range of 10-6 -10-4 mol/l.", [["antioxidant", "OBSERVATION_MODIFIER", 4, 15], ["activity", "OBSERVATION_MODIFIER", 16, 24]]], ["We investigated the luminol-dependent chemiluminescence to test their ability to scavenge the biologically relevant oxygen-derived species: hydroxyl radical, superoxide radical, hypochlorous acid in vitro.", [["luminol", "CHEMICAL", 20, 27], ["oxygen", "CHEMICAL", 116, 122], ["hydroxyl", "CHEMICAL", 140, 148], ["superoxide", "CHEMICAL", 158, 168], ["hypochlorous acid", "CHEMICAL", 178, 195], ["luminol", "CHEMICAL", 20, 27], ["oxygen", "CHEMICAL", 116, 122], ["hydroxyl", "CHEMICAL", 140, 148], ["superoxide", "CHEMICAL", 158, 168], ["hypochlorous acid", "CHEMICAL", 178, 195], ["luminol", "SIMPLE_CHEMICAL", 20, 27], ["oxygen", "SIMPLE_CHEMICAL", 116, 122], ["hydroxyl radical", "SIMPLE_CHEMICAL", 140, 156], ["superoxide radical", "SIMPLE_CHEMICAL", 158, 176], ["hypochlorous acid", "SIMPLE_CHEMICAL", 178, 195], ["the luminol-dependent chemiluminescence", "PROBLEM", 16, 55], ["hydroxyl radical", "TREATMENT", 140, 156], ["superoxide radical", "TREATMENT", 158, 176], ["hypochlorous acid in vitro", "TREATMENT", 178, 204], ["hypochlorous acid", "OBSERVATION", 178, 195]]], ["We found that Tyr-MIF-1 was a powerful scavenger in all tested systems.", [["Tyr", "CHEMICAL", 14, 17], ["Tyr", "CHEMICAL", 14, 17], ["Tyr-MIF-1", "GENE_OR_GENE_PRODUCT", 14, 23], ["MIF", "PROTEIN", 18, 21], ["Tyr-MIF", "TEST", 14, 21]]], ["The effects were higher for hypochlorous anion and weaker for superoxide radical.", [["hypochlorous anion", "CHEMICAL", 28, 46], ["superoxide", "CHEMICAL", 62, 72], ["superoxide", "CHEMICAL", 62, 72], ["hypochlorous anion", "SIMPLE_CHEMICAL", 28, 46], ["superoxide radical", "SIMPLE_CHEMICAL", 62, 80], ["hypochlorous anion", "PROBLEM", 28, 46], ["superoxide radical", "TREATMENT", 62, 80]]], ["MIF-1 had no scavenge activity against the hydroxyl and superoxide radicals and showed a moderate scavenger effect on hypochlorous anion.", [["hydroxyl", "CHEMICAL", 43, 51], ["superoxide", "CHEMICAL", 56, 66], ["hypochlorous anion", "CHEMICAL", 118, 136], ["hydroxyl", "CHEMICAL", 43, 51], ["superoxide", "CHEMICAL", 56, 66], ["hypochlorous", "CHEMICAL", 118, 130], ["MIF-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["hydroxyl", "SIMPLE_CHEMICAL", 43, 51], ["superoxide radicals", "SIMPLE_CHEMICAL", 56, 75], ["hypochlorous anion", "SIMPLE_CHEMICAL", 118, 136], ["MIF", "PROTEIN", 0, 3], ["MIF", "TEST", 0, 3], ["scavenge activity", "PROBLEM", 13, 30], ["the hydroxyl", "TREATMENT", 39, 51], ["superoxide radicals", "TEST", 56, 75], ["a moderate scavenger effect on hypochlorous anion", "PROBLEM", 87, 136], ["moderate", "OBSERVATION_MODIFIER", 89, 97], ["scavenger effect", "OBSERVATION", 98, 114], ["hypochlorous anion", "OBSERVATION", 118, 136]]], ["We have compared different strategies to increase the immunogenicity of an antigenic HIV peptide as a vaccine candidate.", [["HIV", "SPECIES", 85, 88], ["an antigenic HIV peptide", "TREATMENT", 72, 96]]], ["Our selected B-cell epitope comprises 15 amino acids (317-331) of the V3 region of HIV-1, JY1 isolate (subtype D), and is in tandem with a T-helper epitope corresponding to the 830-844 region of tetanus toxoid.", [["B-cell", "ANATOMY", 13, 19], ["amino acids", "CHEMICAL", 41, 52], ["tetanus toxoid", "DISEASE", 195, 209], ["amino acids", "CHEMICAL", 41, 52], ["B-cell", "CELL", 13, 19], ["amino acids", "AMINO_ACID", 41, 52], ["HIV-1", "ORGANISM", 83, 88], ["JY1 isolate", "ORGANISM", 90, 101], ["tetanus toxoid", "ORGANISM", 195, 209], ["B-cell epitope", "PROTEIN", 13, 27], ["V3 region", "PROTEIN", 70, 79], ["T-helper epitope", "PROTEIN", 139, 155], ["830-844 region", "DNA", 177, 191], ["HIV-1", "SPECIES", 83, 88], ["HIV-1", "SPECIES", 83, 88], ["Our selected B-cell epitope", "TEST", 0, 27], ["amino acids", "TEST", 41, 52], ["HIV", "TEST", 83, 86], ["a T-helper epitope", "TREATMENT", 137, 155], ["tetanus toxoid", "TREATMENT", 195, 209]]], ["Several presentations, including oligomerization, MAP dendrimer, conjugation to dextran beads or to other macromolecular carriers, have been synthesized and evaluated.", [["dextran", "CHEMICAL", 80, 87], ["MAP dendrimer", "SIMPLE_CHEMICAL", 50, 63], ["dextran beads", "SIMPLE_CHEMICAL", 80, 93], ["oligomerization", "PROBLEM", 33, 48], ["MAP dendrimer", "TREATMENT", 50, 63], ["conjugation to dextran beads", "TREATMENT", 65, 93], ["other macromolecular carriers", "PROBLEM", 100, 129]]], ["Murine sera from the different presentations of the V3 epitope have been compared with regard to antibody titers and cross-reactivity with heterologous HIV subtypes.", [["sera", "ANATOMY", 7, 11], ["Murine", "ORGANISM", 0, 6], ["sera", "ORGANISM_SUBSTANCE", 7, 11], ["HIV", "ORGANISM", 152, 155], ["V3 epitope", "PROTEIN", 52, 62], ["Murine", "SPECIES", 0, 6], ["HIV", "SPECIES", 152, 155], ["Murine", "SPECIES", 0, 6], ["HIV", "SPECIES", 152, 155], ["Murine sera", "TEST", 0, 11], ["the V3 epitope", "PROBLEM", 48, 62], ["antibody titers", "TEST", 97, 112], ["heterologous HIV subtypes", "PROBLEM", 139, 164]]], ["The MAP dendrimer version of the peptide, conjugated to recombinant hepatitis B surface antigen protein, was a better immunogen than the dendrimer alone, and showed higher immunogenicity than other multimeric presentations, or than the peptide alone conjugated to dextran beads.", [["hepatitis B surface antigen", "CHEMICAL", 68, 95], ["dextran", "CHEMICAL", 264, 271], ["MAP dendrimer", "SIMPLE_CHEMICAL", 4, 17], ["hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 68, 95], ["dendrimer", "SIMPLE_CHEMICAL", 137, 146], ["dextran beads", "SIMPLE_CHEMICAL", 264, 277], ["recombinant hepatitis B surface antigen protein", "PROTEIN", 56, 103], ["The MAP dendrimer version", "TREATMENT", 0, 25], ["the peptide", "TREATMENT", 29, 40], ["recombinant hepatitis B surface antigen protein", "TEST", 56, 103], ["dextran beads", "TREATMENT", 264, 277], ["dextran beads", "OBSERVATION", 264, 277]]], ["The MAP dendrimer version, either alone or conjugated to HBsAg, enhanced cross-reactivity towards heterologous V3 sequences relative to monomeric peptide.", [["HBsAg", "CHEMICAL", 57, 62], ["MAP dendrimer", "SIMPLE_CHEMICAL", 4, 17], ["HBsAg", "GENE_OR_GENE_PRODUCT", 57, 62], ["HBsAg", "PROTEIN", 57, 62], ["heterologous V3 sequences", "DNA", 98, 123], ["The MAP dendrimer version", "TEST", 0, 25], ["HBsAg", "TEST", 57, 62], ["heterologous V3 sequences", "TEST", 98, 123]]], ["Group A Streptococcus (GAS) responsible for critical diseases (eg. acute rheumatic fever and rheumatic heart disease) are classified over 100 serotypes according to their surface virulence M proteins.", [["heart", "ANATOMY", 103, 108], ["surface", "ANATOMY", 171, 178], ["acute rheumatic fever", "DISEASE", 67, 88], ["rheumatic heart disease", "DISEASE", 93, 116], ["Group A Streptococcus", "ORGANISM", 0, 21], ["GAS", "ORGANISM", 23, 26], ["heart", "ORGAN", 103, 108], ["surface virulence M proteins", "PROTEIN", 171, 199], ["Group A Streptococcus (GAS)", "TEST", 0, 27], ["critical diseases", "PROBLEM", 44, 61], ["acute rheumatic fever", "PROBLEM", 67, 88], ["rheumatic heart disease", "PROBLEM", 93, 116], ["Streptococcus", "OBSERVATION", 8, 21], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["rheumatic", "OBSERVATION_MODIFIER", 73, 82], ["rheumatic", "OBSERVATION_MODIFIER", 93, 102], ["heart", "ANATOMY", 103, 108], ["disease", "OBSERVATION", 109, 116]]], ["Development of vaccine to prevent infection with GAS is hampered by the widespread diversity of circulating GAS strains and M protein serotypes, and multivalent vaccine strategy would contribute to prevention against various GAS infections and provide better protective immunity.", [["infection", "DISEASE", 34, 43], ["infections", "DISEASE", 229, 239], ["GAS strains", "ORGANISM", 108, 119], ["M protein", "GENE_OR_GENE_PRODUCT", 124, 133], ["GAS", "SPECIES", 225, 228], ["vaccine", "TREATMENT", 15, 22], ["infection", "PROBLEM", 34, 43], ["GAS", "PROBLEM", 49, 52], ["circulating GAS strains", "PROBLEM", 96, 119], ["M protein serotypes", "PROBLEM", 124, 143], ["multivalent vaccine strategy", "TREATMENT", 149, 177], ["various GAS infections", "PROBLEM", 217, 239], ["infection", "OBSERVATION", 34, 43], ["widespread", "OBSERVATION_MODIFIER", 72, 82], ["diversity", "OBSERVATION_MODIFIER", 83, 92], ["GAS strains", "OBSERVATION", 108, 119]]], ["We have studied the efficacy of incorporating four different epitopes derived from GAS M protein into a single synthetic lipid core peptide (LCP) construct, in inducing broadly protective immune responses against GAS following parenteral delivery to mice.", [["GAS M", "GENE_OR_GENE_PRODUCT", 83, 88], ["GAS", "ORGANISM", 213, 216], ["parenteral", "IMMATERIAL_ANATOMICAL_ENTITY", 227, 237], ["mice", "ORGANISM", 250, 254], ["epitopes", "PROTEIN", 61, 69], ["GAS M protein", "PROTEIN", 83, 96], ["GAS", "DNA", 213, 216], ["mice", "SPECIES", 250, 254], ["mice", "SPECIES", 250, 254], ["GAS M protein", "TREATMENT", 83, 96], ["a single synthetic lipid core peptide (LCP) construct", "TREATMENT", 102, 155], ["parenteral delivery", "TREATMENT", 227, 246]]], ["Peptide vaccine was synthesized on MBHA resin by manual SPPS in situ neutralization/HBTU activation in Boc-chemistry.", [["SPPS", "CHEMICAL", 56, 60], ["HBTU", "CHEMICAL", 84, 88], ["MBHA resin", "SIMPLE_CHEMICAL", 35, 45], ["HBTU", "SIMPLE_CHEMICAL", 84, 88], ["Peptide vaccine", "TREATMENT", 0, 15], ["MBHA resin", "TREATMENT", 35, 45], ["manual SPPS", "TREATMENT", 49, 60]]], ["Immunisation with the mono-or multi-epitopic LCP vaccine led to high titers of antigen-specific systemic IgG responses, and the production of broad protective immune responses as demonstrated by the ability of immune sera to opsonise multiple GAS strains.", [["sera", "ANATOMY", 217, 221], ["antigen", "GENE_OR_GENE_PRODUCT", 79, 86], ["IgG", "GENE_OR_GENE_PRODUCT", 105, 108], ["sera", "ORGANISM_SUBSTANCE", 217, 221], ["IgG", "PROTEIN", 105, 108], ["Immunisation", "TREATMENT", 0, 12], ["the mono", "TREATMENT", 18, 26], ["multi-epitopic LCP vaccine", "TREATMENT", 30, 56], ["immune sera", "TREATMENT", 210, 221], ["multiple GAS strains", "PROBLEM", 234, 254], ["GAS strains", "OBSERVATION", 243, 254]]], ["Systemic challenge of mice after primary vaccination showed that mice were significantly protected against GAS infection in comparison with control mice demonstrating that vaccination stimulated long-lasting protective immunity.", [["GAS infection", "DISEASE", 107, 120], ["mice", "ORGANISM", 22, 26], ["mice", "ORGANISM", 65, 69], ["GAS", "ORGANISM", 107, 110], ["mice", "ORGANISM", 148, 152], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 148, 152], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 148, 152], ["primary vaccination", "TREATMENT", 33, 52], ["GAS infection", "PROBLEM", 107, 120]]], ["These data support to the usefulness of LCP system in the development of synthetic multiepitope vaccine to prevent GAS infection.MULTI-EPITOPIC LIPID CORE PEPTIDE VACCINE WITH BROAD PROTECTIVE IMMUNE RESPONSES AGAINST GROUP A STREPTOCOCCUSGlycoprotein D represents a major immunogenic component of the virion envelope of herpes simplex virus and able to induce high titres of neutralizing antibodies.", [["infection", "DISEASE", 119, 128], ["herpes simplex", "DISEASE", 321, 335], ["STREPTOCOCCUSGlycoprotein D", "GENE_OR_GENE_PRODUCT", 226, 253], ["herpes simplex virus", "ORGANISM", 321, 341], ["neutralizing antibodies", "PROTEIN", 376, 399], ["herpes simplex virus", "SPECIES", 321, 341], ["GAS", "SPECIES", 115, 118], ["herpes simplex virus", "SPECIES", 321, 341], ["LCP system", "TREATMENT", 40, 50], ["synthetic multiepitope vaccine", "TREATMENT", 73, 103], ["GAS infection", "PROBLEM", 115, 128], ["MULTI-EPITOPIC LIPID CORE PEPTIDE VACCINE", "TREATMENT", 129, 170], ["A STREPTOCOCCUSGlycoprotein D", "PROBLEM", 224, 253], ["a major immunogenic component", "PROBLEM", 265, 294], ["herpes simplex virus", "PROBLEM", 321, 341], ["high titres of neutralizing antibodies", "PROBLEM", 361, 399], ["GAS infection", "OBSERVATION", 115, 128], ["virion envelope", "OBSERVATION", 302, 317]]], ["One of its optimal epitopes is the 9-22 region (9LKMADPNRFRGKDL22).", [["9-22 region", "DNA", 35, 46], ["optimal", "OBSERVATION_MODIFIER", 11, 18], ["epitopes", "OBSERVATION", 19, 27]]], ["Several cyclic peptides possessing thioether bond and different ring size have been already prepared and some of them were conjugated with tetratuftsin derivative (Ac-[TKPKG]4-NH2) by thioether bond formation using selectively removable Cys protecting groups.", [["thioether", "CHEMICAL", 35, 44], ["tetratuftsin", "CHEMICAL", 139, 151], ["Ac-[TKPKG]4-NH2", "CHEMICAL", 164, 179], ["thioether", "CHEMICAL", 184, 193], ["Cys", "CHEMICAL", 237, 240], ["thioether", "CHEMICAL", 35, 44], ["tetratuftsin", "CHEMICAL", 139, 151], ["Ac-[TKPKG]4-NH2", "CHEMICAL", 164, 179], ["thioether", "CHEMICAL", 184, 193], ["Cys", "CHEMICAL", 237, 240], ["tetratuftsin derivative", "SIMPLE_CHEMICAL", 139, 162], ["Ac-[TKPKG]4-NH2", "SIMPLE_CHEMICAL", 164, 179], ["thioether bond", "SIMPLE_CHEMICAL", 184, 198], ["Several cyclic peptides", "PROBLEM", 0, 23], ["thioether bond and different ring size", "TREATMENT", 35, 73], ["tetratuftsin derivative (Ac-[TKPKG]4-NH2)", "TREATMENT", 139, 180], ["thioether bond formation", "TREATMENT", 184, 208], ["selectively removable Cys protecting groups", "TREATMENT", 215, 258], ["cyclic peptides", "OBSERVATION", 8, 23], ["thioether bond", "OBSERVATION", 35, 49], ["different", "OBSERVATION_MODIFIER", 54, 63], ["ring", "OBSERVATION_MODIFIER", 64, 68], ["size", "OBSERVATION_MODIFIER", 69, 73]]], ["Antibody recognition results suggested that the size of the cycle has considerable influence on antibody recognition, however, the replacement of Met in position 11 by Nle is permitted.", [["Met", "CHEMICAL", 146, 149], ["Met", "CHEMICAL", 146, 149], ["Met", "GENE_OR_GENE_PRODUCT", 146, 149], ["Met", "PROTEIN", 146, 149], ["Nle", "PROTEIN", 168, 171], ["Antibody recognition", "TEST", 0, 20], ["antibody recognition", "TEST", 96, 116], ["the replacement of Met in position", "TREATMENT", 127, 161], ["size", "OBSERVATION_MODIFIER", 48, 52]]], ["Conjugation of cyclic peptide might increase the antibody recognition, but the binding depends on the structure and/or conjugation site of the cyclic peptide.", [["cyclic peptide", "CHEMICAL", 15, 29], ["cyclic peptide", "SIMPLE_CHEMICAL", 15, 29], ["cyclic peptide", "SIMPLE_CHEMICAL", 143, 157], ["cyclic peptide", "PROBLEM", 15, 29], ["the antibody recognition", "TEST", 45, 69], ["the binding", "PROBLEM", 75, 86], ["the cyclic peptide", "PROBLEM", 139, 157]]], ["Conjugate with the best binding capacity (7.2 pmol/100uL) as well as the conjugate containing the linear (9-22C) epitope (0.7 pmol/100uL) were selected for immunization.", [["epitope", "TREATMENT", 113, 120], ["immunization", "TREATMENT", 156, 168]]], ["In order to increase the production of antibodies a new group of conjugates was prepared.", [["antibodies", "PROTEIN", 39, 49], ["a new group of conjugates", "TREATMENT", 50, 75]]], ["In these constructs promiscouos T cell epitope peptide derived from tetanus toxoid (YSYFPSV) was attached to both amino groups of lysine residue coupled to the N-terminus of the carrier (Ac-YSYFPSV-K(Ac-YSYFPSV)-[TKPK(ClAc)G]4-NH2).", [["tetanus toxoid", "CHEMICAL", 68, 82], ["lysine", "CHEMICAL", 130, 136], ["amino", "CHEMICAL", 114, 119], ["lysine", "CHEMICAL", 130, 136], ["N", "CHEMICAL", 160, 161], ["Ac-YSYFPSV-K(Ac-YSYFPSV)-[TKPK(ClAc)G]4-NH2", "CHEMICAL", 187, 230], ["promiscouos T cell", "CELL", 20, 38], ["tetanus toxoid", "ORGANISM", 68, 82], ["YSYFPSV", "GENE_OR_GENE_PRODUCT", 84, 91], ["lysine residue", "AMINO_ACID", 130, 144], ["N-terminus", "PROTEIN", 160, 170], ["Ac", "PROTEIN", 187, 189], ["YSYFPSV", "PROTEIN", 190, 197], ["K", "PROTEIN", 198, 199], ["Ac", "PROTEIN", 200, 202], ["YSYFPSV", "PROTEIN", 203, 210], ["NH2", "PROTEIN", 227, 230], ["tetanus toxoid", "SPECIES", 68, 82], ["T cell epitope peptide", "TREATMENT", 32, 54], ["tetanus toxoid (YSYFPSV)", "TREATMENT", 68, 92], ["lysine residue", "PROBLEM", 130, 144], ["the carrier", "TEST", 174, 185], ["Ac", "TEST", 187, 189], ["YSYFPSV", "TEST", 190, 197], ["Ac", "TEST", 200, 202], ["YSYFPSV", "TEST", 203, 210], ["TKPK", "TEST", 213, 217], ["lysine residue", "OBSERVATION", 130, 144]]], ["The Cys containing linear and cyclic epitope peptides were conjugated to the carrier in solution (0.1M Tris buffer, pH 8).", [["Cys", "CHEMICAL", 4, 7], ["Cys", "CHEMICAL", 4, 7], ["The Cys", "TREATMENT", 0, 7], ["linear and cyclic epitope peptides", "TREATMENT", 19, 53], ["the carrier in solution (0.1M Tris buffer", "TREATMENT", 73, 114], ["Cys", "OBSERVATION", 4, 7], ["linear", "OBSERVATION_MODIFIER", 19, 25], ["cyclic", "OBSERVATION_MODIFIER", 30, 36], ["epitope peptides", "OBSERVATION", 37, 53]]], ["Primary hyperparathyroidism (PHT) is characterized with increased parathyroid hormone (PTH) secretion and in 70% of PHT patients with hypertension.", [["Primary hyperparathyroidism", "DISEASE", 0, 27], ["PHT", "DISEASE", 29, 32], ["PHT", "DISEASE", 116, 119], ["hypertension", "DISEASE", 134, 146], ["parathyroid hormone", "GENE_OR_GENE_PRODUCT", 66, 85], ["PTH", "GENE_OR_GENE_PRODUCT", 87, 90], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["Primary hyperparathyroidism (PHT)", "PROBLEM", 0, 33], ["increased parathyroid hormone (PTH) secretion", "PROBLEM", 56, 101], ["hypertension", "PROBLEM", 134, 146], ["hyperparathyroidism", "OBSERVATION", 8, 27], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["parathyroid hormone", "ANATOMY", 66, 85], ["hypertension", "OBSERVATION", 134, 146]]], ["It was previously shown that pro-analogue of PTH with a reversed sequence (which include strong alkali sequence -Arg-Lys-Lys-) induced significant hypertensive response at dose 10-10M/kg b.w.", [["PTH", "CHEMICAL", 45, 48], ["Arg-Lys-Lys", "CHEMICAL", 113, 124], ["hypertensive", "DISEASE", 147, 159], ["Lys", "CHEMICAL", 117, 120], ["Lys", "CHEMICAL", 121, 124], ["PTH", "SIMPLE_CHEMICAL", 45, 48], ["PTH", "TEST", 45, 48], ["a reversed sequence", "PROBLEM", 54, 73], ["strong alkali sequence", "TEST", 89, 111], ["Arg", "TEST", 113, 116], ["Lys", "TEST", 117, 120], ["Lys", "TEST", 121, 124], ["significant hypertensive response", "PROBLEM", 135, 168], ["significant", "OBSERVATION_MODIFIER", 135, 146], ["hypertensive", "OBSERVATION", 147, 159]]], ["One of the hypothesis attributed hypertension in PHT patients to the presence of fragments of degraded PTH possessing -Arg-Lys-Lys-sequence.", [["fragments", "ANATOMY", 81, 90], ["hypertension", "DISEASE", 33, 45], ["PHT", "DISEASE", 49, 52], ["PTH", "CHEMICAL", 103, 106], ["Arg-Lys-Lys", "CHEMICAL", 119, 130], ["Arg", "CHEMICAL", 119, 122], ["Lys", "CHEMICAL", 123, 126], ["Lys", "CHEMICAL", 127, 130], ["patients", "ORGANISM", 53, 61], ["PTH", "SIMPLE_CHEMICAL", 103, 106], ["patients", "SPECIES", 53, 61], ["hypertension", "PROBLEM", 33, 45], ["fragments of degraded PTH", "PROBLEM", 81, 106], ["hypertension", "OBSERVATION", 33, 45], ["fragments", "OBSERVATION", 81, 90]]], ["To compare influence on mean arterial blood pressure (MAP) of analogue of 25-34 PTH fragment (amide) and 25-34 fragment of PTH, with -Arg-Lys-Lys-sequence and also responsible for binding to PTH receptor.", [["arterial blood", "ANATOMY", 29, 43], ["25-34 PTH", "CHEMICAL", 74, 83], ["Arg-Lys-Lys", "CHEMICAL", 134, 145], ["amide", "CHEMICAL", 94, 99], ["Arg", "CHEMICAL", 134, 137], ["Lys", "CHEMICAL", 138, 141], ["Lys", "CHEMICAL", 142, 145], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 29, 43], ["amide", "SIMPLE_CHEMICAL", 94, 99], ["PTH", "SIMPLE_CHEMICAL", 123, 126], ["PTH receptor", "GENE_OR_GENE_PRODUCT", 191, 203], ["PTH receptor", "PROTEIN", 191, 203], ["mean arterial blood pressure", "TEST", 24, 52], ["MAP", "TEST", 54, 57], ["analogue", "TEST", 62, 70], ["PTH fragment (amide)", "PROBLEM", 80, 100], ["PTH", "TEST", 123, 126], ["Arg", "TEST", 134, 137], ["PTH receptor", "TEST", 191, 203]]], ["Chosen peptides were synthesized manually by a solid phase peptide synthesis method.", [["Chosen peptides", "TREATMENT", 0, 15], ["a solid phase peptide synthesis method", "TREATMENT", 45, 83]]], ["The synthesized peptides showed the right molecular mass.", [["The synthesized peptides", "TEST", 0, 24], ["the right molecular mass", "PROBLEM", 32, 56], ["right", "ANATOMY_MODIFIER", 36, 41], ["molecular", "ANATOMY", 42, 51], ["mass", "OBSERVATION", 52, 56]]], ["The influence on MAP of synthesized peptides was tested in Wistar rats.", [["Wistar rats", "ORGANISM", 59, 70], ["rats", "SPECIES", 66, 70], ["MAP of synthesized peptides", "TREATMENT", 17, 44]]], ["Sequential increasing boluses of each peptide: 10-10, 10-9 and 10-8M/kg.b.w. in the same animal were given i.v.", [["Sequential increasing boluses of each peptide", "TREATMENT", 0, 45], ["increasing", "OBSERVATION_MODIFIER", 11, 21]]], ["Blood pressure was measured continuously in carotid artery.", [["Blood", "ANATOMY", 0, 5], ["carotid artery", "ANATOMY", 44, 58], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 44, 58], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14], ["carotid artery", "ANATOMY", 44, 58]]], ["Injection of synthesized analogue of 25-34 fragment of PTH does not show influence on MAP vs. control group.", [["PTH", "SIMPLE_CHEMICAL", 55, 58], ["Injection of synthesized analogue", "TREATMENT", 0, 33], ["PTH", "TEST", 55, 58], ["MAP", "TEST", 86, 89]]], ["Synthesized 25-34 fragment of PTH increased MAP in 92min. of experiment for 12mmHg \u00b1 3mmHg vs. time of administration of first dose and for 17mmHg vs. control group.", [["PTH", "CHEMICAL", 30, 33], ["PTH", "SIMPLE_CHEMICAL", 30, 33], ["PTH increased MAP", "TREATMENT", 30, 47]]], ["It seems to be possible, that in case of alternate degradation of PTH, accumulation of 25-34 fragment of PTH may partially play role in the mechanism inducing hypertension in PHT patients.MULTI-EPITOPIC LIPID CORE PEPTIDE VACCINE WITH BROAD PROTECTIVE IMMUNE RESPONSES AGAINST GROUP A STREPTOCOCCUSBiologically active domains of a high affinity receptor for Ig \u0415 (Fc\u03b5RI) were determined, the fragments 111-114 and 111-117 of the receptor.", [["PTH", "CHEMICAL", 66, 69], ["hypertension", "DISEASE", 159, 171], ["PHT", "DISEASE", 175, 178], ["PTH", "GENE_OR_GENE_PRODUCT", 66, 69], ["PTH", "GENE_OR_GENE_PRODUCT", 105, 108], ["patients", "ORGANISM", 179, 187], ["Ig \u0415", "GENE_OR_GENE_PRODUCT", 358, 362], ["Fc\u03b5RI", "GENE_OR_GENE_PRODUCT", 364, 369], ["high affinity receptor", "PROTEIN", 331, 353], ["Ig \u0415", "PROTEIN", 358, 362], ["Fc\u03b5RI", "PROTEIN", 364, 369], ["patients", "SPECIES", 179, 187], ["alternate degradation of PTH", "PROBLEM", 41, 69], ["accumulation of 25-34 fragment of PTH", "PROBLEM", 71, 108], ["hypertension in PHT patients", "PROBLEM", 159, 187], ["MULTI-EPITOPIC LIPID CORE PEPTIDE VACCINE", "TREATMENT", 188, 229], ["a high affinity receptor", "TREATMENT", 329, 353], ["Ig \u0415 (Fc\u03b5RI", "TREATMENT", 358, 369], ["the fragments", "TEST", 388, 401], ["seems to be possible", "UNCERTAINTY", 3, 23], ["hypertension", "OBSERVATION", 159, 171]]], ["The program of research of biological properties of synthesized tetrapeptide RNWD and heptapeptide RNWDVYK included the study of their binding with IgE, which was contained in standard solutions and in patients' blood serum.", [["blood serum", "ANATOMY", 212, 223], ["RNWD", "CHEMICAL", 77, 81], ["RNWDVYK", "CHEMICAL", 99, 106], ["tetrapeptide", "CHEMICAL", 64, 76], ["tetrapeptide RNWD", "SIMPLE_CHEMICAL", 64, 81], ["heptapeptide RNWDVYK", "SIMPLE_CHEMICAL", 86, 106], ["IgE", "GENE_OR_GENE_PRODUCT", 148, 151], ["patients", "ORGANISM", 202, 210], ["blood serum", "ORGANISM_SUBSTANCE", 212, 223], ["IgE", "PROTEIN", 148, 151], ["patients", "SPECIES", 202, 210], ["synthesized tetrapeptide RNWD", "TREATMENT", 52, 81], ["heptapeptide RNWDVYK", "TREATMENT", 86, 106], ["the study", "TEST", 116, 125], ["patients' blood serum", "TEST", 202, 223]]], ["The binding of peptides with IgE was explored by the IFA method using IgE antibodies labeled with horse-radish peroxidase (HRPO).", [["IgE", "GENE_OR_GENE_PRODUCT", 29, 32], ["radish peroxidase", "SIMPLE_CHEMICAL", 104, 121], ["HRPO", "SIMPLE_CHEMICAL", 123, 127], ["IgE", "PROTEIN", 29, 32], ["IgE antibodies", "PROTEIN", 70, 84], ["horse-radish peroxidase", "PROTEIN", 98, 121], ["HRPO", "PROTEIN", 123, 127], ["horse", "SPECIES", 98, 103], ["radish", "SPECIES", 104, 110], ["radish", "SPECIES", 104, 110], ["IgE", "PROBLEM", 29, 32], ["IgE antibodies", "TEST", 70, 84]]], ["Peptides in the concentration of 100 mkg/ml were used for sorption on immunological plotting boards.", [["Peptides", "TREATMENT", 0, 8]]], ["Higher correlation between the IgE concentration and the optical density of the solution after introducing monoclonal antibodies labeled with HRPO and substrate chromogenic mixture (r=0.99) was found in the diagnostic system with sorption RNWDVYK-peptide than in the diagnostic system with sorption RNWD-peptide (r=0.94).", [["IgE", "GENE_OR_GENE_PRODUCT", 31, 34], ["HRPO", "SIMPLE_CHEMICAL", 142, 146], ["RNWD-peptide", "SIMPLE_CHEMICAL", 299, 311], ["IgE", "PROTEIN", 31, 34], ["monoclonal antibodies", "PROTEIN", 107, 128], ["HRPO", "PROTEIN", 142, 146], ["the IgE concentration", "TREATMENT", 27, 48], ["the solution", "TREATMENT", 76, 88], ["introducing monoclonal antibodies", "TEST", 95, 128], ["substrate chromogenic mixture", "TEST", 151, 180], ["sorption RNWD", "TEST", 290, 303]]], ["Similar investigations were conducted with the diagnostic systems with sorption RNWD and RNWDVYK peptides, but RWND peptides conjugated with HRPO were used as antibodies against immunoglobulin E, instead of HRPO-labeled monoclonal antibodies.", [["HRPO", "CHEMICAL", 141, 145], ["HRPO", "CHEMICAL", 207, 211], ["RNWD", "SIMPLE_CHEMICAL", 80, 84], ["HRPO", "SIMPLE_CHEMICAL", 141, 145], ["immunoglobulin E", "SIMPLE_CHEMICAL", 178, 194], ["HRPO", "SIMPLE_CHEMICAL", 207, 211], ["HRPO", "PROTEIN", 141, 145], ["antibodies", "PROTEIN", 159, 169], ["immunoglobulin E", "PROTEIN", 178, 194], ["HRPO", "PROTEIN", 207, 211], ["labeled monoclonal antibodies", "PROTEIN", 212, 241], ["Similar investigations", "TEST", 0, 22], ["the diagnostic systems", "TEST", 43, 65], ["sorption RNWD", "TEST", 71, 84], ["RNWDVYK peptides", "TREATMENT", 89, 105], ["HRPO", "TREATMENT", 141, 145], ["antibodies", "TEST", 159, 169], ["immunoglobulin E", "TEST", 178, 194], ["HRPO", "TEST", 207, 211], ["monoclonal antibodies", "OBSERVATION", 220, 241]]], ["Almost equal correlation was found between the concentration of IgE in standard serum and serum of allergy patients with the known concentration of IgE and the optical density of the solutions after introducing the RNWD peptide, conjugated with HRPO.", [["serum", "ANATOMY", 80, 85], ["serum", "ANATOMY", 90, 95], ["allergy", "DISEASE", 99, 106], ["HRPO", "CHEMICAL", 245, 249], ["IgE", "GENE_OR_GENE_PRODUCT", 64, 67], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["patients", "ORGANISM", 107, 115], ["IgE", "GENE_OR_GENE_PRODUCT", 148, 151], ["RNWD peptide", "SIMPLE_CHEMICAL", 215, 227], ["HRPO", "SIMPLE_CHEMICAL", 245, 249], ["IgE", "PROTEIN", 64, 67], ["IgE", "PROTEIN", 148, 151], ["HRPO", "PROTEIN", 245, 249], ["patients", "SPECIES", 107, 115], ["the RNWD peptide", "TREATMENT", 211, 227], ["HRPO", "TREATMENT", 245, 249]]], ["After introducing allergy patients' blood serum in the holes on the plotting board, the heptapeptide bound 23.79% more IgE than the tetrapeptide.", [["blood serum", "ANATOMY", 36, 47], ["allergy", "DISEASE", 18, 25], ["tetrapeptide", "CHEMICAL", 132, 144], ["patients", "ORGANISM", 26, 34], ["blood serum", "ORGANISM_SUBSTANCE", 36, 47], ["IgE", "GENE_OR_GENE_PRODUCT", 119, 122], ["IgE", "PROTEIN", 119, 122], ["patients", "SPECIES", 26, 34], ["blood serum", "TEST", 36, 47], ["the heptapeptide bound", "TREATMENT", 84, 106], ["the tetrapeptide", "TREATMENT", 128, 144]]], ["Our experiments demonstrated a high IgE binding activity of synthetic RNWD-and RNWDVYK-peptides.", [["IgE", "GENE_OR_GENE_PRODUCT", 36, 39], ["RNWD", "SIMPLE_CHEMICAL", 70, 74], ["RNWDVYK-peptides", "GENE_OR_GENE_PRODUCT", 79, 95], ["IgE", "PROTEIN", 36, 39], ["Our experiments", "TEST", 0, 15], ["a high IgE binding activity", "PROBLEM", 29, 56], ["synthetic RNWD", "TEST", 60, 74], ["RNWDVYK-peptides", "TREATMENT", 79, 95]]], ["In this study, the Information Spectrum Method (ISM) of the HA1 subunit of the H5 hemagglutinin protein of the Influenza Virus, H5N1, of different reference isolates was performed in order to identify possible antigenic determinants resistant to virus mutations.", [["Influenza Virus", "DISEASE", 111, 126], ["Influenza Virus", "ORGANISM", 111, 126], ["H5N1", "ORGANISM", 128, 132], ["HA1 subunit", "PROTEIN", 60, 71], ["H5 hemagglutinin protein", "PROTEIN", 79, 103], ["Influenza Virus", "SPECIES", 111, 126], ["Influenza Virus", "SPECIES", 111, 126], ["this study", "TEST", 3, 13], ["the HA1 subunit", "TREATMENT", 56, 71], ["the H5 hemagglutinin protein", "TREATMENT", 75, 103], ["the Influenza Virus", "PROBLEM", 107, 126], ["H5N1", "PROBLEM", 128, 132], ["different reference isolates", "TEST", 137, 165], ["antigenic determinants resistant to virus mutations", "PROBLEM", 210, 261]]], ["Results of this analysis demonstrated that the primary structures of HA1 subunit of H5 hemagglutinins encode a common information corresponding to one characteristic frequency in their ISs, which is probably important for the biological function of these proteins, including their possible recognition by the immune proteins targeting this molecule.", [["HA1 subunit", "GENE_OR_GENE_PRODUCT", 69, 80], ["H5 hemagglutinins", "ORGANISM", 84, 101], ["HA1 subunit", "PROTEIN", 69, 80], ["H5 hemagglutinins", "PROTEIN", 84, 101], ["immune proteins", "PROTEIN", 309, 324], ["this analysis", "TEST", 11, 24], ["H5 hemagglutinins", "TREATMENT", 84, 101], ["probably important", "UNCERTAINTY", 199, 217]]], ["Besides, comparison of the ISs of HA1 proteins of H1 \"Spanish flu\" and H5N1 isolates demonstrated an informational similarity between them.", [["HA1 proteins", "GENE_OR_GENE_PRODUCT", 34, 46], ["H1", "GENE_OR_GENE_PRODUCT", 50, 52], ["H5N1", "ORGANISM", 71, 75], ["HA1 proteins", "PROTEIN", 34, 46], ["H5N1 isolates", "TREATMENT", 71, 84]]], ["Based on these results, a segment of the N-terminus of HA1 H5N1 was identified to play a crucial role in the inhibitory and immunological properties of all possible H5N1 variants.", [["HA1 H5N1", "ORGANISM", 55, 63], ["H5N1", "ORGANISM", 165, 169], ["N-terminus", "PROTEIN", 41, 51], ["HA1 H5N1", "SPECIES", 55, 63], ["HA1 H5N1", "PROBLEM", 55, 63], ["H5N1 variants", "PROBLEM", 165, 178], ["possible", "UNCERTAINTY", 156, 164], ["H5N1 variants", "OBSERVATION", 165, 178]]], ["The identified core segment, being highly conserved in all H5 strains, was selected as an antigenic determinant and coupled to the Sequential Oligopeptide Carrier (SOCn), (Lys-Aib-Gly)n, to the Lys-N\u03b5H2 groups, in order to develop a diagnostic immunoassay and formulate a vaccine candidate for the highly pathogenic H5N1 influenza virus.", [["H5N1 influenza virus", "DISEASE", 316, 336], ["Gly", "CHEMICAL", 180, 183], ["Lys", "CHEMICAL", 194, 197], ["SOCn", "SIMPLE_CHEMICAL", 164, 168], ["Lys-Aib-Gly", "SIMPLE_CHEMICAL", 172, 183], ["H5N1 influenza virus", "ORGANISM", 316, 336], ["H5N1 influenza virus", "SPECIES", 316, 336], ["H5N1 influenza virus", "SPECIES", 316, 336], ["all H5 strains", "PROBLEM", 55, 69], ["a diagnostic immunoassay", "TEST", 231, 255], ["a vaccine", "TREATMENT", 270, 279], ["the highly pathogenic H5N1 influenza virus", "PROBLEM", 294, 336], ["core", "ANATOMY_MODIFIER", 15, 19], ["segment", "ANATOMY_MODIFIER", 20, 27], ["H5 strains", "OBSERVATION", 59, 69]]], ["Background and aims: Thrombin plays a key role in various disorders such as arterial thrombosis, atherosclerosis, restenosis, inflammation and myocardial infarction.", [["arterial", "ANATOMY", 76, 84], ["myocardial", "ANATOMY", 143, 153], ["arterial thrombosis", "DISEASE", 76, 95], ["atherosclerosis", "DISEASE", 97, 112], ["restenosis", "DISEASE", 114, 124], ["inflammation", "DISEASE", 126, 138], ["myocardial infarction", "DISEASE", 143, 164], ["Thrombin", "GENE_OR_GENE_PRODUCT", 21, 29], ["arterial", "MULTI-TISSUE_STRUCTURE", 76, 84], ["myocardial", "MULTI-TISSUE_STRUCTURE", 143, 153], ["Thrombin", "PROTEIN", 21, 29], ["Thrombin", "TREATMENT", 21, 29], ["various disorders", "PROBLEM", 50, 67], ["arterial thrombosis", "PROBLEM", 76, 95], ["atherosclerosis", "PROBLEM", 97, 112], ["restenosis", "PROBLEM", 114, 124], ["inflammation", "PROBLEM", 126, 138], ["myocardial infarction", "PROBLEM", 143, 164], ["Thrombin", "OBSERVATION", 21, 29], ["arterial", "ANATOMY", 76, 84], ["thrombosis", "OBSERVATION", 85, 95], ["atherosclerosis", "OBSERVATION", 97, 112], ["restenosis", "OBSERVATION", 114, 124], ["inflammation", "OBSERVATION", 126, 138], ["myocardial", "ANATOMY", 143, 153], ["infarction", "OBSERVATION", 154, 164]]], ["Insights into the way in which thrombin interacts with its many substrates and cofactors have been clarified by crystal structure and site-directed mutagenesis analyses, but until recently there has been little consideration of how its non-proteolytic functions are performed.", [["thrombin", "GENE_OR_GENE_PRODUCT", 31, 39], ["thrombin", "PROTEIN", 31, 39], ["directed mutagenesis analyses", "TEST", 139, 168]]], ["We investigated cardiovascular effects of seven modified proline-and RGD-containing peptides designed from three surface-exposed sites of prothrombin, corresponding to residues 218-223, 332-347, and 445-454.", [["cardiovascular", "ANATOMY", 16, 30], ["surface", "ANATOMY", 113, 120], ["proline", "CHEMICAL", 57, 64], ["RGD", "CHEMICAL", 69, 72], ["proline", "CHEMICAL", 57, 64], ["cardiovascular", "ANATOMICAL_SYSTEM", 16, 30], ["proline", "SIMPLE_CHEMICAL", 57, 64], ["prothrombin", "GENE_OR_GENE_PRODUCT", 138, 149], ["prothrombin", "PROTEIN", 138, 149], ["seven modified proline", "TREATMENT", 42, 64], ["RGD-containing peptides", "TREATMENT", 69, 92], ["prothrombin", "PROBLEM", 138, 149], ["prothrombin", "OBSERVATION", 138, 149]]], ["Methods: Cardioprotective effects of synthetic peptides were tested on the two rat models of heart failure produced by coronary artery occlusion (10-or 45-min) and reperfusion (30-or 240-min).", [["heart", "ANATOMY", 93, 98], ["coronary artery", "ANATOMY", 119, 134], ["heart failure", "DISEASE", 93, 106], ["rat", "ORGANISM", 79, 82], ["heart", "ORGAN", 93, 98], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 119, 134], ["rat", "SPECIES", 79, 82], ["synthetic peptides", "TREATMENT", 37, 55], ["heart failure", "PROBLEM", 93, 106], ["coronary artery occlusion", "TREATMENT", 119, 144], ["reperfusion", "TEST", 164, 175], ["heart", "ANATOMY", 93, 98], ["failure", "OBSERVATION", 99, 106], ["coronary artery", "ANATOMY", 119, 134], ["occlusion", "OBSERVATION", 135, 144]]], ["Arterial blood pressures from left carotid artery, heart rate and ECG II standard lead were measured throughout experiment.", [["Arterial", "ANATOMY", 0, 8], ["blood", "ANATOMY", 9, 14], ["left carotid artery", "ANATOMY", 30, 49], ["heart", "ANATOMY", 51, 56], ["Arterial blood", "MULTI-TISSUE_STRUCTURE", 0, 14], ["left carotid artery", "MULTI-TISSUE_STRUCTURE", 30, 49], ["heart", "ORGAN", 51, 56], ["Arterial blood pressures", "TEST", 0, 24], ["heart rate", "TEST", 51, 61], ["pressures", "OBSERVATION_MODIFIER", 15, 24], ["left carotid artery", "ANATOMY", 30, 49], ["heart", "ANATOMY", 51, 56]]], ["At the end of second experiment hearts were morphologically investigated by light microscopy and electron microscopy methods.", [["hearts", "ANATOMY", 32, 38], ["hearts", "ORGAN", 32, 38], ["light microscopy", "TEST", 76, 92], ["electron microscopy methods", "TEST", 97, 124]]], ["Results: On animal model with short-term ischemia investigated peptides did not protected from myocardium ischemia during occlusion, however, TP-L13, BK-mc and TP-H7 protected rat hearts from ventricular fibrillation, contributed more significant functional recovery during reperfusion and raising survival rate.", [["myocardium", "ANATOMY", 95, 105], ["hearts", "ANATOMY", 180, 186], ["ventricular", "ANATOMY", 192, 203], ["ischemia", "DISEASE", 41, 49], ["myocardium ischemia", "DISEASE", 95, 114], ["TP-H7", "CHEMICAL", 160, 165], ["ventricular fibrillation", "DISEASE", 192, 216], ["myocardium", "ORGAN", 95, 105], ["TP-L13", "GENE_OR_GENE_PRODUCT", 142, 148], ["BK-mc", "GENE_OR_GENE_PRODUCT", 150, 155], ["TP-H7", "GENE_OR_GENE_PRODUCT", 160, 165], ["rat", "ORGANISM", 176, 179], ["hearts", "ORGAN", 180, 186], ["ventricular", "MULTI-TISSUE_STRUCTURE", 192, 203], ["rat", "SPECIES", 176, 179], ["rat", "SPECIES", 176, 179], ["short-term ischemia", "PROBLEM", 30, 49], ["myocardium ischemia", "PROBLEM", 95, 114], ["occlusion", "PROBLEM", 122, 131], ["TP", "TEST", 142, 144], ["BK", "TEST", 150, 152], ["TP", "TEST", 160, 162], ["H7", "PROBLEM", 163, 165], ["ventricular fibrillation", "PROBLEM", 192, 216], ["survival rate", "TEST", 298, 311], ["myocardium", "ANATOMY", 95, 105], ["ischemia", "OBSERVATION", 106, 114], ["occlusion", "OBSERVATION", 122, 131], ["ventricular", "ANATOMY", 192, 203], ["fibrillation", "OBSERVATION", 204, 216], ["significant", "OBSERVATION_MODIFIER", 235, 246], ["functional recovery", "OBSERVATION", 247, 266]]], ["On the model with prolong ischemia, acceptable cardioprotective effect revealed TP-H7 and BK-mc.", [["BK-mc", "ANATOMY", 90, 95], ["ischemia", "DISEASE", 26, 34], ["TP-H7", "GENE_OR_GENE_PRODUCT", 80, 85], ["BK-mc", "GENE_OR_GENE_PRODUCT", 90, 95], ["TP", "PROTEIN", 80, 82], ["H7", "PROTEIN", 83, 85], ["prolong ischemia", "PROBLEM", 18, 34], ["TP", "TEST", 80, 82], ["BK", "TEST", 90, 92]]], ["These peptides significantly diminished necrotic zone of left ventricle, protected hearts from ischemia-reperfusion induced functional and morphological changes.", [["necrotic zone", "ANATOMY", 40, 53], ["left ventricle", "ANATOMY", 57, 71], ["hearts", "ANATOMY", 83, 89], ["necrotic", "DISEASE", 40, 48], ["necrotic zone", "TISSUE", 40, 53], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 57, 71], ["hearts", "ORGAN", 83, 89], ["significantly diminished necrotic zone of left ventricle", "PROBLEM", 15, 71], ["ischemia-reperfusion induced functional and morphological changes", "PROBLEM", 95, 160], ["significantly", "OBSERVATION_MODIFIER", 15, 28], ["diminished", "OBSERVATION_MODIFIER", 29, 39], ["necrotic", "OBSERVATION", 40, 48], ["zone", "ANATOMY_MODIFIER", 49, 53], ["left ventricle", "ANATOMY", 57, 71], ["hearts", "ANATOMY", 83, 89], ["ischemia-reperfusion induced", "OBSERVATION", 95, 123], ["functional", "OBSERVATION_MODIFIER", 124, 134]]], ["Conclusions: Investigated proline-containing peptides revealed activity on cardiovascular system -decreasing of blood pressure, cardioprotective properties and improved recovery from ischemia.PEPTIDE BASED RADIOPHARMACEUTICALS FOR IMAGING OF TWO DIFFERENT RECEPTORSR.", [["cardiovascular", "ANATOMY", 75, 89], ["blood", "ANATOMY", 112, 117], ["proline", "CHEMICAL", 26, 33], ["ischemia", "DISEASE", 183, 191], ["proline", "CHEMICAL", 26, 33], ["cardiovascular", "ANATOMICAL_SYSTEM", 75, 89], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["Investigated proline-containing peptides", "TREATMENT", 13, 53], ["activity on cardiovascular system", "PROBLEM", 63, 96], ["blood pressure", "TEST", 112, 126], ["cardioprotective properties", "TREATMENT", 128, 155], ["ischemia", "PROBLEM", 183, 191], ["IMAGING", "TEST", 231, 238], ["decreasing", "OBSERVATION_MODIFIER", 98, 108], ["blood pressure", "OBSERVATION", 112, 126], ["ischemia", "OBSERVATION", 183, 191], ["RADIOPHARMACEUTICALS", "OBSERVATION", 206, 226]]], ["Mansi, D. Tesauro, C. Pedone, E. Benedetti, G. MorelliDepartment of Biological Sciences & CIRPeB, University of Napoli \"Federico II\", Naples, ItalyThe widespread use of compounds containing the gamma-emitting radionuclide 99mTc in nuclear medicine for the scintigraphic imaging, as well as the recent introduction of the beta-emitting radionuclides 188Re and 186Re in radiotherapy, have led to a rapid development of their chemistries, in order to produce novel radiopharmaceuticals.Department of Biological Sciences & CIRPeB, University of Napoli \"Federico II\", Naples, ItalyWe have developed new peptide based radiopharmaceuticals based on a scaffold in which the radioactive metal ion is complexed by two different peptides that are able to bind two target receptors (see figure) .", [["nuclear", "ANATOMY", 231, 238], ["99mTc", "CHEMICAL", 222, 227], ["99mTc", "SIMPLE_CHEMICAL", 222, 227], ["target receptors", "PROTEIN", 753, 769], ["compounds", "TREATMENT", 169, 178], ["the scintigraphic imaging", "TEST", 252, 277], ["the beta-emitting radionuclides 188Re", "TREATMENT", 317, 354], ["radiotherapy", "TREATMENT", 368, 380], ["their chemistries", "TEST", 417, 434], ["novel radiopharmaceuticals", "TREATMENT", 456, 482], ["new peptide based radiopharmaceuticals", "PROBLEM", 594, 632], ["a scaffold", "TREATMENT", 642, 652], ["the radioactive metal ion", "TREATMENT", 662, 687], ["widespread", "OBSERVATION_MODIFIER", 151, 161], ["new", "OBSERVATION_MODIFIER", 594, 597], ["radiopharmaceuticals", "OBSERVATION", 612, 632]]], ["The 3+1 mixed-ligand approach has been used for the preparation of neutral oxotechnetium(V) and oxorhenium(V) peptide complexes.", [["oxotechnetium", "CHEMICAL", 75, 88], ["oxorhenium", "CHEMICAL", 96, 106], ["oxotechnetium(V)", "CHEMICAL", 75, 91], ["oxorhenium(V) peptide", "CHEMICAL", 96, 117], ["oxotechnetium(V)", "SIMPLE_CHEMICAL", 75, 91], ["oxorhenium(V) peptide", "SIMPLE_CHEMICAL", 96, 117], ["The 3+1 mixed-ligand approach", "TREATMENT", 0, 29], ["neutral oxotechnetium(V", "TREATMENT", 67, 90], ["oxorhenium(V) peptide complexes", "TREATMENT", 96, 127]]], ["The complex preparation requires the simultaneous action of a dianionic tridentate ligand and a monoanionic monodentate thiolato on a suitable metal precursor.", [["thiolato", "CHEMICAL", 120, 128], ["thiolato", "CHEMICAL", 120, 128], ["monoanionic monodentate thiolato", "SIMPLE_CHEMICAL", 96, 128], ["metal precursor", "SIMPLE_CHEMICAL", 143, 158], ["a dianionic tridentate ligand", "TREATMENT", 60, 89], ["a monoanionic monodentate thiolato", "TREATMENT", 94, 128], ["complex", "OBSERVATION_MODIFIER", 4, 11]]], ["The dianionic tridentate ligand is based on the SNN donor set able to stabilize the metal complex.", [["SNN", "CHEMICAL", 48, 51], ["SNN", "SIMPLE_CHEMICAL", 48, 51], ["metal complex", "PROTEIN", 84, 97], ["The dianionic tridentate ligand", "TREATMENT", 0, 31]]], ["The chelating agent (HSC(CH3)2CONHCH2CH(CO-R)NH2) was coupled step by step to a bioactive peptide synthesized on solid phase.", [["HSC(CH3)2CONHCH2CH(CO-R)NH2", "CHEMICAL", 21, 48], ["HSC(CH3)2CONHCH2CH(CO-R)NH2", "SIMPLE_CHEMICAL", 21, 48], ["The chelating agent", "TREATMENT", 0, 19], ["HSC(CH3)2CONHCH2CH(CO-R)NH2", "TREATMENT", 21, 48], ["HSC", "ANATOMY", 21, 24]]], ["The second ligand, based on monodentate thiolato moiety, was coupled on N-terminus of the second peptide.Department of Biological Sciences & CIRPeB, University of Napoli \"Federico II\", Naples, ItalyLabelling procedures and biological tests on tumour cells overexpressing receptors are described for 99mTc(O) complexed by CCK8 and octreotide peptide derivatives.", [["tumour cells", "ANATOMY", 243, 255], ["tumour", "DISEASE", 243, 249], ["CCK8", "CHEMICAL", 321, 325], ["octreotide", "CHEMICAL", 330, 340], ["thiolato", "CHEMICAL", 40, 48], ["N", "CHEMICAL", 72, 73], ["99mTc", "CHEMICAL", 299, 304], ["CCK8", "CHEMICAL", 321, 325], ["octreotide", "CHEMICAL", 330, 340], ["monodentate thiolato moiety", "SIMPLE_CHEMICAL", 28, 55], ["tumour cells", "CELL", 243, 255], ["99mTc(O)", "SIMPLE_CHEMICAL", 299, 307], ["CCK8", "SIMPLE_CHEMICAL", 321, 325], ["octreotide peptide derivatives", "SIMPLE_CHEMICAL", 330, 360], ["N-terminus", "PROTEIN", 72, 82], ["tumour cells", "CELL_TYPE", 243, 255], ["monodentate thiolato moiety", "TREATMENT", 28, 55], ["ItalyLabelling procedures", "TREATMENT", 193, 218], ["biological tests", "TEST", 223, 239], ["tumour cells overexpressing receptors", "TREATMENT", 243, 280], ["CCK8", "TEST", 321, 325], ["octreotide peptide derivatives", "TREATMENT", 330, 360]]], ["Background: Endostatin inhibits the proliferation of endothelial cells and induces their apoptosis.", [["endothelial cells", "ANATOMY", 53, 70], ["Endostatin", "CHEMICAL", 12, 22], ["Endostatin", "CHEMICAL", 12, 22], ["Endostatin", "GENE_OR_GENE_PRODUCT", 12, 22], ["endothelial cells", "CELL", 53, 70], ["Endostatin", "PROTEIN", 12, 22], ["endothelial cells", "CELL_TYPE", 53, 70], ["Endostatin", "TREATMENT", 12, 22], ["the proliferation of endothelial cells", "PROBLEM", 32, 70], ["their apoptosis", "PROBLEM", 83, 98], ["Endostatin", "OBSERVATION", 12, 22], ["endothelial cells", "OBSERVATION", 53, 70], ["apoptosis", "OBSERVATION_MODIFIER", 89, 98]]], ["The measurement of serum endostatin can predict tumor vascularity.", [["serum", "ANATOMY", 19, 24], ["tumor", "ANATOMY", 48, 53], ["tumor", "DISEASE", 48, 53], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["endostatin", "GENE_OR_GENE_PRODUCT", 25, 35], ["tumor", "CANCER", 48, 53], ["serum endostatin", "PROTEIN", 19, 35], ["serum endostatin", "TREATMENT", 19, 35], ["tumor vascularity", "PROBLEM", 48, 65]]], ["Tumor angiogenesis is a strong prognostic factor in patients with hepatocellular carcinoma(HCC).", [["Tumor", "ANATOMY", 0, 5], ["hepatocellular carcinoma", "ANATOMY", 66, 90], ["HCC", "ANATOMY", 91, 94], ["hepatocellular carcinoma", "DISEASE", 66, 90], ["HCC", "DISEASE", 91, 94], ["Tumor", "CANCER", 0, 5], ["patients", "ORGANISM", 52, 60], ["hepatocellular carcinoma", "CANCER", 66, 90], ["HCC", "CANCER", 91, 94], ["patients", "SPECIES", 52, 60], ["Tumor angiogenesis", "PROBLEM", 0, 18], ["a strong prognostic factor", "PROBLEM", 22, 48], ["hepatocellular carcinoma", "PROBLEM", 66, 90], ["HCC", "PROBLEM", 91, 94], ["hepatocellular", "ANATOMY", 66, 80], ["carcinoma", "OBSERVATION", 81, 90], ["HCC", "OBSERVATION", 91, 94]]], ["Significantly high levels of endostatin were noted in patients with trabecular-type tumors , and with hepatitis infection.", [["trabecular-type tumors", "ANATOMY", 68, 90], ["trabecular-type tumors", "DISEASE", 68, 90], ["hepatitis infection", "DISEASE", 102, 121], ["endostatin", "GENE_OR_GENE_PRODUCT", 29, 39], ["patients", "ORGANISM", 54, 62], ["trabecular-type tumors", "CANCER", 68, 90], ["endostatin", "PROTEIN", 29, 39], ["patients", "SPECIES", 54, 62], ["Significantly high levels of endostatin", "PROBLEM", 0, 39], ["trabecular-type tumors", "PROBLEM", 68, 90], ["hepatitis infection", "PROBLEM", 102, 121], ["high", "OBSERVATION_MODIFIER", 14, 18], ["endostatin", "OBSERVATION", 29, 39], ["trabecular", "ANATOMY", 68, 78], ["type tumors", "OBSERVATION", 79, 90], ["hepatitis", "OBSERVATION_MODIFIER", 102, 111], ["infection", "OBSERVATION", 112, 121]]], ["Methods : 20 patients with HCC, 16 patients with GIT malignancies, 8 patients with liver metastasis and 8 without metastasis, and 10 normal persons .", [["HCC", "ANATOMY", 27, 30], ["GIT malignancies", "ANATOMY", 49, 65], ["liver", "ANATOMY", 83, 88], ["HCC", "DISEASE", 27, 30], ["GIT malignancies", "DISEASE", 49, 65], ["liver metastasis", "DISEASE", 83, 99], ["patients", "ORGANISM", 13, 21], ["HCC", "CANCER", 27, 30], ["patients", "ORGANISM", 35, 43], ["GIT malignancies", "CANCER", 49, 65], ["patients", "ORGANISM", 69, 77], ["liver", "ORGAN", 83, 88], ["persons", "ORGANISM", 140, 147], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 69, 77], ["persons", "SPECIES", 140, 147], ["HCC", "PROBLEM", 27, 30], ["GIT malignancies", "PROBLEM", 49, 65], ["liver metastasis", "PROBLEM", 83, 99], ["metastasis", "PROBLEM", 114, 124], ["GIT", "ANATOMY", 49, 52], ["malignancies", "OBSERVATION", 53, 65], ["liver", "ANATOMY", 83, 88], ["metastasis", "OBSERVATION", 89, 99], ["without", "UNCERTAINTY", 106, 113], ["metastasis", "OBSERVATION", 114, 124]]], ["All subjects were tested for alfa-feto protein (AFP) , CA19.9 , Carcinoemberyonic antigen (CEA), and Endostatin by ELISA Results : Endostatin in normal control persons was 47.5 \u00b1 14.22 ng/ml with a significant elevation (p< 0.001) between the HCC group and all the other tested groups .AFP was 1.9 \u00b1 0.98 ng/ml in normal persons with a significant elevation between HCC and all the other tested groups ( p< 0.01).", [["HCC", "ANATOMY", 243, 246], ["HCC", "ANATOMY", 366, 369], ["Endostatin", "CHEMICAL", 131, 141], ["HCC", "DISEASE", 243, 246], ["HCC", "DISEASE", 366, 369], ["alfa-feto protein", "GENE_OR_GENE_PRODUCT", 29, 46], ["AFP", "GENE_OR_GENE_PRODUCT", 48, 51], ["CA19.9", "GENE_OR_GENE_PRODUCT", 55, 61], ["Carcinoemberyonic antigen", "GENE_OR_GENE_PRODUCT", 64, 89], ["CEA", "GENE_OR_GENE_PRODUCT", 91, 94], ["Endostatin", "SIMPLE_CHEMICAL", 101, 111], ["Endostatin", "GENE_OR_GENE_PRODUCT", 131, 141], ["persons", "ORGANISM", 160, 167], ["HCC", "CANCER", 243, 246], ["AFP", "GENE_OR_GENE_PRODUCT", 286, 289], ["persons", "ORGANISM", 321, 328], ["HCC", "CANCER", 366, 369], ["alfa-feto protein", "PROTEIN", 29, 46], ["AFP", "PROTEIN", 48, 51], ["CA19.9", "PROTEIN", 55, 61], ["Carcinoemberyonic antigen", "PROTEIN", 64, 89], ["CEA", "PROTEIN", 91, 94], ["AFP", "PROTEIN", 286, 289], ["persons", "SPECIES", 160, 167], ["persons", "SPECIES", 321, 328], ["All subjects", "TEST", 0, 12], ["alfa-feto protein", "TEST", 29, 46], ["AFP", "TEST", 48, 51], ["CA", "TEST", 55, 57], ["Carcinoemberyonic antigen", "TEST", 64, 89], ["CEA", "TEST", 91, 94], ["Endostatin", "TEST", 131, 141], ["a significant elevation", "PROBLEM", 196, 219], ["AFP", "TEST", 286, 289], ["a significant elevation between HCC", "PROBLEM", 334, 369], ["significant", "OBSERVATION_MODIFIER", 198, 209], ["elevation", "OBSERVATION", 210, 219], ["HCC", "OBSERVATION", 243, 246], ["significant", "OBSERVATION_MODIFIER", 336, 347], ["elevation", "OBSERVATION", 348, 357], ["HCC", "OBSERVATION", 366, 369]]], ["CA19.9 was 8.14 \u00b1 1.89 U/ml in normal persons with a significance elevation ( p< 0.01) relative to HCC., and a significance of ( p< 0.001 ) relative to GIT cancers with metastases.", [["HCC", "ANATOMY", 99, 102], ["GIT cancers", "ANATOMY", 152, 163], ["metastases", "ANATOMY", 169, 179], ["HCC", "DISEASE", 99, 102], ["cancers", "DISEASE", 156, 163], ["metastases", "DISEASE", 169, 179], ["persons", "ORGANISM", 38, 45], ["HCC", "CANCER", 99, 102], ["GIT cancers", "CANCER", 152, 163], ["persons", "SPECIES", 38, 45], ["CA19.9", "TEST", 0, 6], ["U/ml", "TEST", 23, 27], ["a significance elevation", "PROBLEM", 51, 75], ["HCC", "PROBLEM", 99, 102], ["GIT cancers", "PROBLEM", 152, 163], ["metastases", "PROBLEM", 169, 179], ["elevation", "OBSERVATION_MODIFIER", 66, 75], ["HCC", "OBSERVATION", 99, 102], ["GIT", "ANATOMY", 152, 155], ["cancers", "OBSERVATION", 156, 163], ["metastases", "OBSERVATION", 169, 179]]], ["CEA was tested to be 1.12 \u00b1 0.71 \u00b5g/l in normal persons , and had a significance of ( p< 0.001) relative to GIT metastases.", [["GIT metastases", "ANATOMY", 108, 122], ["metastases", "DISEASE", 112, 122], ["CEA", "GENE_OR_GENE_PRODUCT", 0, 3], ["persons", "ORGANISM", 48, 55], ["GIT", "ORGAN", 108, 111], ["CEA", "PROTEIN", 0, 3], ["persons", "SPECIES", 48, 55], ["CEA", "TEST", 0, 3], ["GIT metastases", "PROBLEM", 108, 122], ["normal", "OBSERVATION", 41, 47], ["GIT", "ANATOMY", 108, 111], ["metastases", "OBSERVATION", 112, 122]]], ["Endostatin was elevated in 2 of 8 patients with GIT cancers not proved to have metastasis.", [["GIT cancers", "ANATOMY", 48, 59], ["Endostatin", "CHEMICAL", 0, 10], ["GIT cancers", "DISEASE", 48, 59], ["Endostatin", "CHEMICAL", 0, 10], ["Endostatin", "GENE_OR_GENE_PRODUCT", 0, 10], ["patients", "ORGANISM", 34, 42], ["GIT cancers", "CANCER", 48, 59], ["patients", "SPECIES", 34, 42], ["Endostatin", "TEST", 0, 10], ["elevated", "PROBLEM", 15, 23], ["GIT cancers", "PROBLEM", 48, 59], ["metastasis", "PROBLEM", 79, 89], ["elevated", "OBSERVATION_MODIFIER", 15, 23], ["GIT", "ANATOMY", 48, 51], ["cancers", "OBSERVATION", 52, 59], ["metastasis", "OBSERVATION", 79, 89]]], ["Conclusion : Endostatin can be used to denote metaplasia and can also detect possibilities of metastasis or liver cell affection even before the frank development of metaplasia Affibody\u00ae molecules are a novel class of affinity proteins which are generated by combinatorial engineering of the 58 aa three-helix bundle scaffold, originating from the B domain of staphylococcal protein A. We have used Fmoc/tBu chemistry for total chemical synthesis of the Affibody ZHER2:342, binding with picomolar affinity to the cell surface receptor HER2.", [["metaplasia", "ANATOMY", 46, 56], ["liver cell", "ANATOMY", 108, 118], ["metaplasia", "ANATOMY", 166, 176], ["cell surface", "ANATOMY", 513, 525], ["Endostatin", "CHEMICAL", 13, 23], ["liver cell affection", "DISEASE", 108, 128], ["Fmoc", "CHEMICAL", 399, 403], ["Fmoc", "CHEMICAL", 399, 403], ["Endostatin", "GENE_OR_GENE_PRODUCT", 13, 23], ["metaplasia", "CANCER", 46, 56], ["liver cell", "CELL", 108, 118], ["metaplasia", "CANCER", 166, 176], ["cell", "CELL", 513, 517], ["HER2", "GENE_OR_GENE_PRODUCT", 535, 539], ["Endostatin", "PROTEIN", 13, 23], ["affinity proteins", "PROTEIN", 218, 235], ["58 aa three-helix bundle scaffold", "PROTEIN", 292, 325], ["B domain", "PROTEIN", 348, 356], ["staphylococcal protein A.", "PROTEIN", 360, 385], ["cell surface receptor", "PROTEIN", 513, 534], ["HER2", "PROTEIN", 535, 539], ["Endostatin", "TREATMENT", 13, 23], ["metaplasia", "PROBLEM", 46, 56], ["metastasis", "PROBLEM", 94, 104], ["liver cell affection", "PROBLEM", 108, 128], ["metaplasia Affibody\u00ae molecules", "PROBLEM", 166, 196], ["affinity proteins", "PROBLEM", 218, 235], ["staphylococcal protein A.", "TREATMENT", 360, 385], ["Fmoc/tBu chemistry", "TREATMENT", 399, 417], ["total chemical synthesis", "TREATMENT", 422, 446], ["picomolar affinity", "TREATMENT", 487, 505], ["metaplasia", "OBSERVATION", 46, 56], ["metastasis", "OBSERVATION", 94, 104], ["liver", "ANATOMY", 108, 113], ["cell", "OBSERVATION", 114, 118], ["metaplasia", "OBSERVATION", 166, 176]]], ["The synthetic protein was investigated for molecular imaging of HER2-overexpressing tumours.", [["HER2-overexpressing tumours", "ANATOMY", 64, 91], ["HER2", "GENE_OR_GENE_PRODUCT", 64, 68], ["tumours", "CANCER", 84, 91], ["HER2", "PROTEIN", 64, 68], ["The synthetic protein", "TEST", 0, 21], ["molecular imaging", "TEST", 43, 60], ["HER2", "TEST", 64, 68], ["overexpressing tumours", "PROBLEM", 69, 91], ["overexpressing tumours", "OBSERVATION", 69, 91]]], ["In vivo detection of HER2 in malignant tumours provides important diagnostic information which may influence patient management.", [["malignant tumours", "ANATOMY", 29, 46], ["malignant tumours", "DISEASE", 29, 46], ["HER2", "GENE_OR_GENE_PRODUCT", 21, 25], ["malignant tumours", "CANCER", 29, 46], ["patient", "ORGANISM", 109, 116], ["HER2", "PROTEIN", 21, 25], ["patient", "SPECIES", 109, 116], ["HER2 in malignant tumours", "PROBLEM", 21, 46], ["patient management", "TREATMENT", 109, 127]]], ["To enable gamma camera imaging of the tumours, a panel of potential 99mTc-chelating sequences was designed and introduced into the Affibody.", [["tumours", "ANATOMY", 38, 45], ["99mTc-chelating", "CHEMICAL", 68, 83], ["99mTc", "CHEMICAL", 68, 73], ["tumours", "CANCER", 38, 45], ["99mTc", "SIMPLE_CHEMICAL", 68, 73], ["gamma camera imaging", "TEST", 10, 30], ["a panel", "TEST", 47, 54], ["potential 99mTc-chelating sequences", "TEST", 58, 93]]], ["The well-studied Tc-chelating sequence mercaptoacetyltriglycyl (MAG3) was compared to serine-containing sequences with increased hydrophilicity, such as mercaptoacetyltriserinyl (MAS3).Department of Biological Sciences & CIRPeB, University of Napoli \"Federico II\", Naples, ItalyThe total synthetic yield was 14-16 % and the HER2-binding affinity of the Affibody conjugates were all in the range 200-400 pM.", [["Tc", "CHEMICAL", 17, 19], ["mercaptoacetyltriglycyl", "CHEMICAL", 39, 62], ["MAG3", "CHEMICAL", 64, 68], ["mercaptoacetyltriserinyl", "CHEMICAL", 153, 177], ["Affibody", "CHEMICAL", 353, 361], ["Tc", "CHEMICAL", 17, 19], ["mercaptoacetyltriglycyl", "CHEMICAL", 39, 62], ["MAG3", "CHEMICAL", 64, 68], ["serine", "CHEMICAL", 86, 92], ["mercaptoacetyltriserinyl", "CHEMICAL", 153, 177], ["MAS3", "CHEMICAL", 179, 183], ["Tc-chelating sequence", "SIMPLE_CHEMICAL", 17, 38], ["mercaptoacetyltriglycyl", "SIMPLE_CHEMICAL", 39, 62], ["MAG3", "SIMPLE_CHEMICAL", 64, 68], ["serine", "AMINO_ACID", 86, 92], ["mercaptoacetyltriserinyl", "SIMPLE_CHEMICAL", 153, 177], ["MAS3", "SIMPLE_CHEMICAL", 179, 183], ["HER2", "GENE_OR_GENE_PRODUCT", 324, 328], ["Affibody conjugates", "SIMPLE_CHEMICAL", 353, 372], ["HER2", "PROTEIN", 324, 328], ["MAG3", "TEST", 64, 68], ["increased hydrophilicity", "PROBLEM", 119, 143], ["mercaptoacetyltriserinyl (MAS3)", "TREATMENT", 153, 184], ["The total synthetic yield", "TEST", 278, 303], ["the HER2", "TEST", 320, 328], ["the Affibody conjugates", "TEST", 349, 372], ["increased hydrophilicity", "OBSERVATION", 119, 143]]], ["Binding specificity of Tc-labelled Affibody molecules was determined on HER2-expressing SKOV-3 ovarian carcinoma cells.", [["SKOV-3 ovarian carcinoma cells", "ANATOMY", 88, 118], ["Tc", "CHEMICAL", 23, 25], ["ovarian carcinoma", "DISEASE", 95, 112], ["Tc", "SIMPLE_CHEMICAL", 23, 25], ["HER2", "GENE_OR_GENE_PRODUCT", 72, 76], ["SKOV-3 ovarian carcinoma cells", "CELL", 88, 118], ["Tc-labelled Affibody molecules", "PROTEIN", 23, 53], ["HER2", "PROTEIN", 72, 76], ["SKOV-3 ovarian carcinoma cells", "CELL_LINE", 88, 118], ["Binding specificity", "TEST", 0, 19], ["Tc", "TEST", 23, 25], ["HER2", "TEST", 72, 76], ["3 ovarian carcinoma cells", "PROBLEM", 93, 118], ["ovarian", "ANATOMY", 95, 102], ["carcinoma cells", "OBSERVATION", 103, 118]]], ["All variants showed receptor-specific binding.", [["receptor-specific binding", "PROBLEM", 20, 45]]], ["The tumour-targeting properties were studied in SKOV-3 tumour-bearing nude mice.", [["tumour", "ANATOMY", 4, 10], ["SKOV-3 tumour", "ANATOMY", 48, 61], ["tumour", "DISEASE", 4, 10], ["tumour", "CANCER", 4, 10], ["SKOV-3 tumour", "CANCER", 48, 61], ["nude mice", "ORGANISM", 70, 79], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["SKOV", "TEST", 48, 52], ["tumour", "OBSERVATION", 4, 10]]], ["All conjugates demonstrated high tumour uptake, quick blood clearance and low uptake in most other organs.", [["tumour", "ANATOMY", 33, 39], ["blood", "ANATOMY", 54, 59], ["organs", "ANATOMY", 99, 105], ["tumour", "DISEASE", 33, 39], ["tumour", "CANCER", 33, 39], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["organs", "ORGAN", 99, 105], ["All conjugates", "TEST", 0, 14], ["high tumour uptake", "PROBLEM", 28, 46], ["quick blood clearance", "TEST", 48, 69], ["low uptake in most other organs", "PROBLEM", 74, 105], ["high", "OBSERVATION_MODIFIER", 28, 32], ["tumour uptake", "OBSERVATION", 33, 46], ["low uptake", "OBSERVATION", 74, 84]]], ["The biodistribution results further showed that the more hydrophilic, serine-containing chelators resulted in a reduced hepatobiliary excretion, which significantly decrease the background in the abdomen area and provide for more sensitive detection.", [["hepatobiliary", "ANATOMY", 120, 133], ["abdomen area", "ANATOMY", 196, 208], ["serine", "CHEMICAL", 70, 76], ["serine", "CHEMICAL", 70, 76], ["serine-containing chelators", "SIMPLE_CHEMICAL", 70, 97], ["hepatobiliary", "ORGAN", 120, 133], ["abdomen", "ORGAN", 196, 203], ["the more hydrophilic, serine-containing chelators", "PROBLEM", 48, 97], ["a reduced hepatobiliary excretion", "PROBLEM", 110, 143], ["more", "OBSERVATION_MODIFIER", 52, 56], ["hydrophilic", "OBSERVATION_MODIFIER", 57, 68], ["reduced", "OBSERVATION_MODIFIER", 112, 119], ["hepatobiliary excretion", "OBSERVATION", 120, 143], ["decrease", "OBSERVATION_MODIFIER", 165, 173], ["abdomen", "ANATOMY", 196, 203]]], ["Gamma camera images of mice with grafted tumours showed clear visualization of HER2-expressing tumours using the 99mTclabelled MAS3-Affibody conjugate, suggesting a potential future application of this agent for diagnostic imaging.Department of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144Sk, PolandAntimicrobial peptides are molecules with a unique mechanism of action.", [["tumours", "ANATOMY", 41, 48], ["tumours", "ANATOMY", 95, 102], ["mice", "ORGANISM", 23, 27], ["tumours", "CANCER", 41, 48], ["HER2", "GENE_OR_GENE_PRODUCT", 79, 83], ["tumours", "CANCER", 95, 102], ["MAS3", "SIMPLE_CHEMICAL", 127, 131], ["HER2", "PROTEIN", 79, 83], ["MAS3", "PROTEIN", 127, 131], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["Gamma camera images", "TEST", 0, 19], ["HER2", "TEST", 79, 83], ["this agent", "TREATMENT", 197, 207], ["diagnostic imaging", "TEST", 212, 230], ["PolandAntimicrobial peptides", "TREATMENT", 317, 345]]], ["They are widespread in nature and play the role of an effective weapon of innate immune system against bacteria, fungi and viruses.", [["immune system", "ANATOMICAL_SYSTEM", 81, 94], ["innate immune system", "TREATMENT", 74, 94], ["bacteria", "PROBLEM", 103, 111], ["fungi", "PROBLEM", 113, 118], ["viruses", "PROBLEM", 123, 130], ["widespread", "OBSERVATION_MODIFIER", 9, 19], ["viruses", "OBSERVATION", 123, 130]]], ["The purpose of this study was to investigate the in vitro activity of natural antimicrobial peptides: citropin, piscidin, protegrin, temporin, uperin and the analogues of antimicrobial peptides: iseganan, pexiganan and omiganan.", [["citropin", "CHEMICAL", 102, 110], ["piscidin", "CHEMICAL", 112, 120], ["protegrin", "CHEMICAL", 122, 131], ["temporin", "CHEMICAL", 133, 141], ["uperin", "CHEMICAL", 143, 149], ["iseganan", "CHEMICAL", 195, 203], ["pexiganan", "CHEMICAL", 205, 214], ["omiganan", "CHEMICAL", 219, 227], ["citropin", "CHEMICAL", 102, 110], ["piscidin", "CHEMICAL", 112, 120], ["protegrin", "CHEMICAL", 122, 131], ["temporin", "CHEMICAL", 133, 141], ["uperin", "CHEMICAL", 143, 149], ["pexiganan", "CHEMICAL", 205, 214], ["citropin", "SIMPLE_CHEMICAL", 102, 110], ["piscidin", "SIMPLE_CHEMICAL", 112, 120], ["protegrin", "SIMPLE_CHEMICAL", 122, 131], ["temporin", "SIMPLE_CHEMICAL", 133, 141], ["uperin", "SIMPLE_CHEMICAL", 143, 149], ["iseganan", "SIMPLE_CHEMICAL", 195, 203], ["pexiganan", "SIMPLE_CHEMICAL", 205, 214], ["omiganan", "SIMPLE_CHEMICAL", 219, 227], ["this study", "TEST", 15, 25], ["natural antimicrobial peptides", "TREATMENT", 70, 100], ["citropin", "TREATMENT", 102, 110], ["piscidin", "TREATMENT", 112, 120], ["protegrin", "TREATMENT", 122, 131], ["temporin", "TREATMENT", 133, 141], ["uperin", "TREATMENT", 143, 149], ["antimicrobial peptides", "TREATMENT", 171, 193], ["iseganan", "TREATMENT", 195, 203], ["pexiganan", "TREATMENT", 205, 214], ["omiganan", "TREATMENT", 219, 227]]], ["The peptides were synthesized using the solid-phase method and purified by high-performance liquid chromatography.", [["The peptides", "TREATMENT", 0, 12], ["the solid-phase method", "TREATMENT", 36, 58]]], ["The peptides were subjected to microbiological tests [MIC (minimal inhibitory concentration) and MBC (minimal bactericidal concentration)] on reference strains of bacteria, according to the procedures outlined by the National Committee for Clinical Laboratory Standards (NCCLS).", [["MBC", "CHEMICAL", 97, 100], ["MBC", "SIMPLE_CHEMICAL", 97, 100], ["microbiological tests", "TEST", 31, 52], ["MIC (minimal inhibitory concentration", "TREATMENT", 54, 91], ["MBC", "TEST", 97, 100], ["minimal bactericidal concentration", "PROBLEM", 102, 136], ["bacteria", "PROBLEM", 163, 171]]], ["For comparison, conventional antibiotics (vancomycin, rifampycin, piperacillin, chloramphenicol) were included in this research.", [["vancomycin", "CHEMICAL", 42, 52], ["rifampycin", "CHEMICAL", 54, 64], ["piperacillin", "CHEMICAL", 66, 78], ["chloramphenicol", "CHEMICAL", 80, 95], ["vancomycin", "CHEMICAL", 42, 52], ["rifampycin", "CHEMICAL", 54, 64], ["piperacillin", "CHEMICAL", 66, 78], ["chloramphenicol", "CHEMICAL", 80, 95], ["vancomycin", "SIMPLE_CHEMICAL", 42, 52], ["rifampycin", "SIMPLE_CHEMICAL", 54, 64], ["piperacillin", "SIMPLE_CHEMICAL", 66, 78], ["chloramphenicol", "SIMPLE_CHEMICAL", 80, 95], ["conventional antibiotics", "TREATMENT", 16, 40], ["vancomycin", "TREATMENT", 42, 52], ["rifampycin", "TREATMENT", 54, 64], ["piperacillin", "TREATMENT", 66, 78], ["chloramphenicol", "TREATMENT", 80, 95]]], ["Both the natural antimicrobial peptides and the analogues inhibited the growth of bacteria, but at higher concentrations than did conventional antibiotics.", [["bacteria", "PROBLEM", 82, 90], ["conventional antibiotics", "TREATMENT", 130, 154], ["natural", "OBSERVATION_MODIFIER", 9, 16], ["antimicrobial peptides", "OBSERVATION", 17, 39], ["growth", "OBSERVATION_MODIFIER", 72, 78], ["bacteria", "OBSERVATION", 82, 90]]], ["Nevertheless, both natural origin of antimicrobial peptides and their low toxicity constitute a considerable advantage and this is an argument for considering the antimicrobial peptides as good candidates for medicines.", [["toxicity", "DISEASE", 74, 82], ["antimicrobial peptides", "TREATMENT", 37, 59], ["their low toxicity", "PROBLEM", 64, 82], ["the antimicrobial peptides", "TREATMENT", 159, 185], ["medicines", "TREATMENT", 209, 218], ["antimicrobial peptides", "OBSERVATION", 37, 59]]], ["The linear hexapeptide cypate-GRDSPK (compound 1; the cypate moiety is a near-infrared fluorescent label) whose RGD sequence was rearranged to GRD showed high uptake in the \u03b1v\u03b23 integrin-positive tumor tissues in vitro and in vivo.", [["\u03b1v\u03b23 integrin-positive tumor tissues", "ANATOMY", 173, 209], ["cypate", "CHEMICAL", 23, 29], ["GRDSPK", "CHEMICAL", 30, 36], ["tumor", "DISEASE", 196, 201], ["cypate", "CHEMICAL", 54, 60], ["cypate moiety", "SIMPLE_CHEMICAL", 54, 67], ["\u03b1v\u03b23 integrin", "GENE_OR_GENE_PRODUCT", 173, 186], ["tumor tissues", "TISSUE", 196, 209], ["GRD", "PROTEIN", 143, 146], ["\u03b1v\u03b23 integrin", "PROTEIN", 173, 186], ["The linear hexapeptide cypate", "TEST", 0, 29], ["the cypate moiety", "PROBLEM", 50, 67], ["RGD sequence", "TEST", 112, 124], ["GRD", "TEST", 143, 146], ["high uptake in the \u03b1v\u03b23 integrin", "PROBLEM", 154, 186], ["positive tumor tissues", "PROBLEM", 187, 209], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["hexapeptide cypate", "OBSERVATION", 11, 29], ["high uptake", "OBSERVATION", 154, 165], ["positive", "OBSERVATION_MODIFIER", 187, 195], ["tumor tissues", "OBSERVATION", 196, 209]]], ["Despite low affinity of 1 to the integrin in the binding assays, the uptake was inhibited by equimolar amounts of the cyclic peptide c(RGDfV), which possesses high affinity to \u03b1v\u03b23 integrin.", [["integrin", "GENE_OR_GENE_PRODUCT", 33, 41], ["RGDfV", "SIMPLE_CHEMICAL", 135, 140], ["\u03b1v\u03b23 integrin", "GENE_OR_GENE_PRODUCT", 176, 189], ["integrin", "PROTEIN", 33, 41], ["\u03b1v\u03b23 integrin", "PROTEIN", 176, 189], ["low affinity", "PROBLEM", 8, 20], ["the cyclic peptide c", "PROBLEM", 114, 134], ["\u03b1v\u03b23 integrin", "TREATMENT", 176, 189], ["low affinity", "OBSERVATION_MODIFIER", 8, 20], ["high affinity", "OBSERVATION", 159, 172]]], ["These observations led to hypothesis that cell internalization of compound 1 may be mediated mostly by only one of the integrin subunits, as the \u03b23 one.", [["cell", "ANATOMY", 42, 46], ["cell", "CELL", 42, 46], ["compound 1", "GENE_OR_GENE_PRODUCT", 66, 76], ["integrin", "GENE_OR_GENE_PRODUCT", 119, 127], ["\u03b23", "GENE_OR_GENE_PRODUCT", 145, 147], ["integrin subunits", "PROTEIN", 119, 136], ["\u03b23 one", "PROTEIN", 145, 151], ["the integrin subunits", "TREATMENT", 115, 136]]], ["Indeed, blocking of \u03b1v integrin by the specific antibody did not inhibit the internalization of 1 in tumor cells, which was in the contrast with successful blocking the cell internalization by the anti-\u03b23 integrin antibody.", [["tumor cells", "ANATOMY", 101, 112], ["cell", "ANATOMY", 169, 173], ["tumor", "DISEASE", 101, 106], ["\u03b1v integrin", "GENE_OR_GENE_PRODUCT", 20, 31], ["tumor cells", "CELL", 101, 112], ["cell", "CELL", 169, 173], ["anti-\u03b23 integrin antibody", "GENE_OR_GENE_PRODUCT", 197, 222], ["\u03b1v integrin", "PROTEIN", 20, 31], ["tumor cells", "CELL_TYPE", 101, 112], ["anti-\u03b23 integrin antibody", "PROTEIN", 197, 222], ["\u03b1v integrin", "TREATMENT", 20, 31], ["the specific antibody", "TEST", 35, 56], ["the internalization of 1 in tumor cells", "PROBLEM", 73, 112], ["successful blocking the cell internalization", "TREATMENT", 145, 189], ["the anti-\u03b23 integrin antibody", "TREATMENT", 193, 222], ["tumor cells", "OBSERVATION", 101, 112]]], ["Similar results were obtained in immunocytochemical assays employing the anti-\u03b1v and anti-\u03b23 integrin antibodies.", [["anti-\u03b1v", "GENE_OR_GENE_PRODUCT", 73, 80], ["anti-\u03b23 integrin antibodies", "GENE_OR_GENE_PRODUCT", 85, 112], ["anti-\u03b1v", "PROTEIN", 73, 80], ["anti-\u03b23 integrin antibodies", "PROTEIN", 85, 112], ["immunocytochemical assays", "TEST", 33, 58], ["the anti-\u03b1v and anti-\u03b23 integrin antibodies", "TREATMENT", 69, 112]]], ["Also, studies utilizing the \u03b23-knockout and wild-type mouse cell lines demonstrated that deletion of the \u03b23 subunit markedly decreased internalization of compound 1 in the \u03b23knockout cells.", [["cell lines", "ANATOMY", 60, 70], ["\u03b23knockout cells", "ANATOMY", 172, 188], ["\u03b23", "GENE_OR_GENE_PRODUCT", 28, 30], ["mouse", "ORGANISM", 54, 59], ["cell lines", "CELL", 60, 70], ["\u03b23", "GENE_OR_GENE_PRODUCT", 105, 107], ["compound 1", "GENE_OR_GENE_PRODUCT", 154, 164], ["\u03b23knockout cells", "CELL", 172, 188], ["\u03b23-knockout and wild-type mouse cell lines", "CELL_LINE", 28, 70], ["\u03b23 subunit", "PROTEIN", 105, 115], ["\u03b23knockout cells", "CELL_LINE", 172, 188], ["mouse", "SPECIES", 54, 59], ["mouse", "SPECIES", 54, 59], ["studies", "TEST", 6, 13], ["the \u03b23-knockout", "TREATMENT", 24, 39], ["wild-type mouse cell lines", "TREATMENT", 44, 70], ["cell lines", "OBSERVATION", 60, 70], ["markedly", "OBSERVATION_MODIFIER", 116, 124], ["decreased", "OBSERVATION_MODIFIER", 125, 134], ["internalization", "OBSERVATION_MODIFIER", 135, 150], ["compound", "OBSERVATION_MODIFIER", 154, 162]]], ["The preferential interaction of compound 1 with the \u03b23 subunit of integrins relative to the \u03b1v subunit was supported also by molecular modeling studies.", [["compound 1", "GENE_OR_GENE_PRODUCT", 32, 42], ["\u03b23", "GENE_OR_GENE_PRODUCT", 52, 54], ["integrins", "GENE_OR_GENE_PRODUCT", 66, 75], ["\u03b1v", "GENE_OR_GENE_PRODUCT", 92, 94], ["\u03b23 subunit", "PROTEIN", 52, 62], ["integrins", "PROTEIN", 66, 75], ["\u03b1v subunit", "PROTEIN", 92, 102], ["molecular modeling studies", "TEST", 125, 151]]], ["Summarizing, the bulk of our experimental and modeling data emphasizes interaction with the \u03b23 integrin as the primary mechanism of the uptake of cypate-GRDSPK by tumors.", [["tumors", "ANATOMY", 163, 169], ["tumors", "DISEASE", 163, 169], ["\u03b23 integrin", "GENE_OR_GENE_PRODUCT", 92, 103], ["cypate-GRDSPK", "SIMPLE_CHEMICAL", 146, 159], ["tumors", "CANCER", 163, 169], ["\u03b23 integrin", "PROTEIN", 92, 103], ["cypate", "PROTEIN", 146, 152], ["GRDSPK", "PROTEIN", 153, 159], ["the \u03b23 integrin", "TREATMENT", 88, 103], ["tumors", "PROBLEM", 163, 169], ["tumors", "OBSERVATION", 163, 169]]], ["Since this compound showed the superior biodistribution profile in vivo, our results may provide a strategy to image and monitor the functional status of the \u03b23 integrin in cells and live animals.Institute of Biophysics and Cell Engineering, National Academy of Sciences of Belarus, Minsk, BelarusBackground and aim: A growing tumor is accompanied by tumor intoxication development.", [["cells", "ANATOMY", 173, 178], ["Cell", "ANATOMY", 224, 228], ["tumor", "ANATOMY", 327, 332], ["tumor", "ANATOMY", 351, 356], ["tumor", "DISEASE", 327, 332], ["tumor", "DISEASE", 351, 356], ["\u03b23 integrin", "GENE_OR_GENE_PRODUCT", 158, 169], ["cells", "CELL", 173, 178], ["Cell", "CELL", 224, 228], ["tumor", "CANCER", 327, 332], ["tumor", "CANCER", 351, 356], ["\u03b23 integrin", "PROTEIN", 158, 169], ["image", "TEST", 111, 116], ["A growing tumor", "PROBLEM", 317, 332], ["tumor intoxication development", "PROBLEM", 351, 381], ["superior", "OBSERVATION_MODIFIER", 31, 39], ["biodistribution profile", "OBSERVATION", 40, 63], ["growing", "OBSERVATION_MODIFIER", 319, 326], ["tumor", "OBSERVATION", 327, 332], ["tumor", "OBSERVATION", 351, 356]]], ["Intoxication independs on tumor size and intensity of its break-up.", [["tumor", "ANATOMY", 26, 31], ["tumor", "DISEASE", 26, 31], ["tumor", "CANCER", 26, 31], ["Intoxication", "PROBLEM", 0, 12], ["tumor size", "PROBLEM", 26, 36], ["tumor", "OBSERVATION", 26, 31], ["size", "OBSERVATION_MODIFIER", 32, 36], ["intensity", "OBSERVATION_MODIFIER", 41, 50], ["break", "OBSERVATION_MODIFIER", 58, 63]]], ["Tumor intoxication is one of variant of endogenous intoxication.", [["Tumor", "ANATOMY", 0, 5], ["Tumor", "DISEASE", 0, 5], ["Tumor", "CANCER", 0, 5], ["Tumor intoxication", "PROBLEM", 0, 18], ["endogenous intoxication", "PROBLEM", 40, 63], ["one of variant", "OBSERVATION_MODIFIER", 22, 36], ["endogenous", "OBSERVATION_MODIFIER", 40, 50], ["intoxication", "OBSERVATION", 51, 63]]], ["Concentration of tyrosine-contained peptides (TCP) in blood plasma have been proposed as biochemical marker of endogenous intoxication at different organs cancers.", [["blood plasma", "ANATOMY", 54, 66], ["organs cancers", "ANATOMY", 148, 162], ["tyrosine", "CHEMICAL", 17, 25], ["cancers", "DISEASE", 155, 162], ["tyrosine", "CHEMICAL", 17, 25], ["tyrosine", "AMINO_ACID", 17, 25], ["TCP", "SIMPLE_CHEMICAL", 46, 49], ["blood plasma", "ORGANISM_SUBSTANCE", 54, 66], ["organs cancers", "CANCER", 148, 162], ["tyrosine", "TREATMENT", 17, 25], ["blood plasma", "TEST", 54, 66], ["endogenous intoxication", "PROBLEM", 111, 134], ["different organs cancers", "PROBLEM", 138, 162], ["endogenous intoxication", "OBSERVATION", 111, 134], ["organs", "ANATOMY", 148, 154], ["cancers", "OBSERVATION", 155, 162]]], ["Our aim was to determine the TCP concentration in blood plasma patients with ovary tumor and its association with the severity of tumor.", [["blood plasma", "ANATOMY", 50, 62], ["ovary tumor", "ANATOMY", 77, 88], ["tumor", "ANATOMY", 130, 135], ["TCP", "CHEMICAL", 29, 32], ["ovary tumor", "DISEASE", 77, 88], ["tumor", "DISEASE", 130, 135], ["TCP", "CHEMICAL", 29, 32], ["TCP", "SIMPLE_CHEMICAL", 29, 32], ["blood plasma", "ORGANISM_SUBSTANCE", 50, 62], ["patients", "ORGANISM", 63, 71], ["ovary tumor", "CANCER", 77, 88], ["tumor", "CANCER", 130, 135], ["patients", "SPECIES", 63, 71], ["blood plasma", "TEST", 50, 62], ["ovary tumor", "PROBLEM", 77, 88], ["tumor", "PROBLEM", 130, 135], ["ovary", "ANATOMY", 77, 82], ["tumor", "OBSERVATION", 83, 88], ["tumor", "OBSERVATION", 130, 135]]], ["Materials and methods: 178 patients with ovary tumor, mean age is 53 years, were studied.", [["ovary tumor", "ANATOMY", 41, 52], ["ovary tumor", "DISEASE", 41, 52], ["patients", "ORGANISM", 27, 35], ["ovary tumor", "CANCER", 41, 52], ["patients", "SPECIES", 27, 35], ["ovary tumor", "PROBLEM", 41, 52], ["ovary", "ANATOMY", 41, 46], ["tumor", "OBSERVATION", 47, 52]]], ["The control group consisted of 20 healthy women without tumor.", [["tumor", "ANATOMY", 56, 61], ["tumor", "DISEASE", 56, 61], ["women", "ORGANISM", 42, 47], ["tumor", "CANCER", 56, 61], ["women", "SPECIES", 42, 47], ["tumor", "PROBLEM", 56, 61], ["without", "UNCERTAINTY", 48, 55], ["tumor", "OBSERVATION", 56, 61]]], ["Patients were divided into 2 groups: people with non-malignant and people with malignant ovary tumor.", [["non-malignant", "ANATOMY", 49, 62], ["malignant ovary tumor", "ANATOMY", 79, 100], ["malignant ovary tumor", "DISEASE", 79, 100], ["Patients", "ORGANISM", 0, 8], ["people", "ORGANISM", 37, 43], ["non-malignant", "CANCER", 49, 62], ["people", "ORGANISM", 67, 73], ["malignant ovary tumor", "CANCER", 79, 100], ["Patients", "SPECIES", 0, 8], ["people", "SPECIES", 37, 43], ["people", "SPECIES", 67, 73], ["malignant ovary tumor", "PROBLEM", 79, 100], ["non-malignant", "OBSERVATION", 49, 62], ["malignant", "OBSERVATION_MODIFIER", 79, 88], ["ovary", "ANATOMY", 89, 94], ["tumor", "OBSERVATION", 95, 100]]], ["TCP content in blood plasma was estimated by our technique.", [["blood plasma", "ANATOMY", 15, 27], ["TCP", "CHEMICAL", 0, 3], ["TCP", "SIMPLE_CHEMICAL", 0, 3], ["blood plasma", "ORGANISM_SUBSTANCE", 15, 27], ["TCP content", "TEST", 0, 11], ["blood plasma", "TEST", 15, 27]]], ["Results: TCP concentration in the control group were 0,32\u00b10,13 mmol.", [["TCP", "CHEMICAL", 9, 12], ["TCP", "SIMPLE_CHEMICAL", 9, 12], ["TCP concentration", "TEST", 9, 26]]], ["The tested marker was present in increased concentration in blood plasma of the patients with ovary tumor.", [["blood plasma", "ANATOMY", 60, 72], ["ovary tumor", "ANATOMY", 94, 105], ["ovary tumor", "DISEASE", 94, 105], ["blood plasma", "ORGANISM_SUBSTANCE", 60, 72], ["patients", "ORGANISM", 80, 88], ["ovary tumor", "CANCER", 94, 105], ["patients", "SPECIES", 80, 88], ["increased concentration", "PROBLEM", 33, 56], ["blood plasma", "TEST", 60, 72], ["ovary tumor", "PROBLEM", 94, 105], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["concentration", "OBSERVATION_MODIFIER", 43, 56], ["blood plasma", "OBSERVATION", 60, 72], ["ovary", "ANATOMY", 94, 99], ["tumor", "OBSERVATION", 100, 105]]], ["The mean concentration TCP in patients with non-malignant tumor was 0,53\u00b10,16 mmol.", [["non-malignant tumor", "ANATOMY", 44, 63], ["TCP", "CHEMICAL", 23, 26], ["tumor", "DISEASE", 58, 63], ["patients", "ORGANISM", 30, 38], ["non-malignant tumor", "CANCER", 44, 63], ["patients", "SPECIES", 30, 38], ["The mean concentration TCP", "TREATMENT", 0, 26], ["non-malignant tumor", "PROBLEM", 44, 63], ["mean concentration", "OBSERVATION_MODIFIER", 4, 22], ["TCP", "OBSERVATION_MODIFIER", 23, 26], ["non-malignant", "OBSERVATION_MODIFIER", 44, 57], ["tumor", "OBSERVATION", 58, 63]]], ["The content of this marker in blood plasma of patients from second group was increased 1,32\u00b10,20 mmol compared with healthy control group.", [["blood plasma", "ANATOMY", 30, 42], ["blood plasma", "ORGANISM_SUBSTANCE", 30, 42], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54]]], ["After treatment a significant decrease in TCP content was observed.", [["TCP", "CHEMICAL", 42, 45], ["TCP", "SIMPLE_CHEMICAL", 42, 45], ["treatment", "TREATMENT", 6, 15], ["a significant decrease in TCP content", "PROBLEM", 16, 53], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["decrease", "OBSERVATION_MODIFIER", 30, 38], ["TCP content", "OBSERVATION", 42, 53]]], ["Conclusions: The result indicate that content TCP in blood plasma depends of the type of tumor.", [["blood plasma", "ANATOMY", 53, 65], ["tumor", "ANATOMY", 89, 94], ["TCP", "CHEMICAL", 46, 49], ["tumor", "DISEASE", 89, 94], ["TCP", "SIMPLE_CHEMICAL", 46, 49], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["tumor", "CANCER", 89, 94], ["content TCP", "PROBLEM", 38, 49], ["blood plasma", "TEST", 53, 65], ["tumor", "PROBLEM", 89, 94], ["tumor", "OBSERVATION", 89, 94]]], ["It could be suggested that determination of TCP concentration in blood plasma could be useful for improve the diagnostic of ovary tumor and monitoring of its progression.CARDIAC TROPONINS DERIVED CONJUGATES AS TOOLS FOR PRODUCING SPECIFIC ANTIBODIES: SYNTHESIS AND IMMUNE RESPONSEC.", [["blood plasma", "ANATOMY", 65, 77], ["ovary tumor", "ANATOMY", 124, 135], ["TCP", "CHEMICAL", 44, 47], ["ovary tumor", "DISEASE", 124, 135], ["TCP", "CHEMICAL", 44, 47], ["TCP", "SIMPLE_CHEMICAL", 44, 47], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["plasma", "ORGANISM_SUBSTANCE", 71, 77], ["ovary tumor", "CANCER", 124, 135], ["TCP concentration in blood plasma", "TEST", 44, 77], ["ovary tumor", "PROBLEM", 124, 135], ["CARDIAC TROPONINS", "TEST", 170, 187], ["ovary", "ANATOMY", 124, 129], ["tumor", "OBSERVATION", 130, 135], ["progression", "OBSERVATION_MODIFIER", 158, 169]]], ["Papadopoulos 1 , K. Naka 2 , L. Michalis 2 , K. Soteriadou 3 , V. Tsikaris 1Department of Chemistry 2 School of Medicine, University of Ioannina 3 Hellenic Pasteur Institute, Athens, GreeceTroponin is a structural protein complex, which is responsible for the regulation of skeletal and cardiac muscle contraction.", [["skeletal", "ANATOMY", 274, 282], ["cardiac muscle", "ANATOMY", 287, 301], ["GreeceTroponin", "CHEMICAL", 183, 197], ["GreeceTroponin", "SIMPLE_CHEMICAL", 183, 197], ["skeletal", "TISSUE", 274, 282], ["cardiac muscle", "TISSUE", 287, 301], ["structural protein complex", "PROTEIN", 203, 229], ["Papadopoulos", "TEST", 0, 12], ["a structural protein complex", "PROBLEM", 201, 229], ["protein complex", "OBSERVATION", 214, 229], ["skeletal", "ANATOMY", 274, 282], ["cardiac muscle", "ANATOMY", 287, 301]]], ["It consists of three components: troponin I (24kDa), troponin C (18kDa), and troponin T (37kDa), each of which carries out different functions in the striated muscles.", [["striated muscles", "ANATOMY", 150, 166], ["troponin I", "GENE_OR_GENE_PRODUCT", 33, 43], ["24kDa", "GENE_OR_GENE_PRODUCT", 45, 50], ["troponin C", "GENE_OR_GENE_PRODUCT", 53, 63], ["18kDa", "GENE_OR_GENE_PRODUCT", 65, 70], ["troponin T", "GENE_OR_GENE_PRODUCT", 77, 87], ["37kDa", "GENE_OR_GENE_PRODUCT", 89, 94], ["striated muscles", "ORGAN", 150, 166], ["troponin I", "PROTEIN", 33, 43], ["24kDa", "PROTEIN", 45, 50], ["troponin C", "PROTEIN", 53, 63], ["18kDa", "PROTEIN", 65, 70], ["troponin T", "PROTEIN", 77, 87], ["troponin I", "TEST", 33, 43], ["troponin C", "TEST", 53, 63], ["troponin T", "TEST", 77, 87], ["striated muscles", "ANATOMY", 150, 166]]], ["Cardiac troponins are released into the bloodstream of patients after the onset of a cardiovascular damage.", [["Cardiac", "ANATOMY", 0, 7], ["bloodstream", "ANATOMY", 40, 51], ["cardiovascular", "ANATOMY", 85, 99], ["cardiovascular damage", "DISEASE", 85, 106], ["Cardiac troponins", "GENE_OR_GENE_PRODUCT", 0, 17], ["patients", "ORGANISM", 55, 63], ["cardiovascular", "ANATOMICAL_SYSTEM", 85, 99], ["troponins", "PROTEIN", 8, 17], ["patients", "SPECIES", 55, 63], ["Cardiac troponins", "TEST", 0, 17], ["a cardiovascular damage", "PROBLEM", 83, 106], ["troponins", "OBSERVATION", 8, 17], ["bloodstream", "OBSERVATION_MODIFIER", 40, 51], ["cardiovascular", "ANATOMY", 85, 99], ["damage", "OBSERVATION", 100, 106]]], ["Even minimal elevations over the normal values, of serum troponin T and I are being used to diagnose acute myocardial infarction and also to rule out the patients' condition.", [["serum", "ANATOMY", 51, 56], ["myocardial", "ANATOMY", 107, 117], ["acute myocardial infarction", "DISEASE", 101, 128], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["troponin T", "GENE_OR_GENE_PRODUCT", 57, 67], ["myocardial", "MULTI-TISSUE_STRUCTURE", 107, 117], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["minimal elevations", "PROBLEM", 5, 23], ["serum troponin T", "TEST", 51, 67], ["acute myocardial infarction", "PROBLEM", 101, 128], ["the patients' condition", "PROBLEM", 150, 173], ["minimal", "OBSERVATION_MODIFIER", 5, 12], ["elevations", "OBSERVATION_MODIFIER", 13, 23], ["myocardial", "ANATOMY", 107, 117], ["infarction", "OBSERVATION", 118, 128]]], ["The development and commercialization of highly specific biological assays for the detection of cardiac troponins is based on the production of specific antibodies against the whole complex or individual subunits.", [["cardiac", "ANATOMY", 96, 103], ["cardiac troponins", "DISEASE", 96, 113], ["cardiac", "ORGAN", 96, 103], ["cardiac troponins", "PROTEIN", 96, 113], ["specific antibodies", "PROTEIN", 144, 163], ["cardiac troponins", "PROBLEM", 96, 113], ["specific antibodies", "PROBLEM", 144, 163]]], ["However, the specificity and sensitivity of these assays vary due to problems mainly originated from the fact that cardiac troponins have a high homology with the skeletal isoforms.", [["cardiac", "ANATOMY", 115, 122], ["skeletal", "ANATOMY", 163, 171], ["cardiac troponins", "GENE_OR_GENE_PRODUCT", 115, 132], ["skeletal", "ORGAN", 163, 171], ["cardiac troponins", "PROTEIN", 115, 132], ["skeletal isoforms", "PROTEIN", 163, 180], ["the specificity", "TEST", 9, 24], ["these assays", "TEST", 44, 56], ["problems", "PROBLEM", 69, 77], ["cardiac troponins", "TEST", 115, 132], ["skeletal", "ANATOMY", 163, 171]]], ["The aim of this work is to select and synthesize appropriate regions of the cardiac isoforms of troponin I, C and T, suitable for the production of more sensitive and specific cardiac troponin detecting reagents.", [["cardiac", "ANATOMY", 76, 83], ["cardiac", "ANATOMY", 176, 183], ["cardiac", "ORGAN", 76, 83], ["troponin I", "GENE_OR_GENE_PRODUCT", 96, 106], ["C", "SIMPLE_CHEMICAL", 108, 109], ["troponin", "GENE_OR_GENE_PRODUCT", 184, 192], ["cardiac isoforms", "PROTEIN", 76, 92], ["troponin I, C and T", "PROTEIN", 96, 115], ["troponin", "PROTEIN", 184, 192], ["troponin I", "TEST", 96, 106], ["cardiac", "ANATOMY", 76, 83]]], ["In order to construct the immunogenic complexes, the selected sequences were conjugated to the tetrameric Sequential Oligopeptide Carrier (SOC4), either by the classic solid phase step-by-step methodology or by chemoselective ligation reactions.", [["SOC4", "SIMPLE_CHEMICAL", 139, 143], ["immunogenic complexes", "PROTEIN", 26, 47], ["SOC4", "PROTEIN", 139, 143], ["the selected sequences", "TEST", 49, 71], ["chemoselective ligation reactions", "TREATMENT", 211, 244], ["ligation", "OBSERVATION", 226, 234]]], ["Using the carrier conjugated troponin sequences, anti cardiac troponin complex specific antibodies in high titers were produced.Organic and Biomimetic Chemistry, Ghent University, Ghent, BelgiumThe increasing problems with the reproductive systems of man and animals are recently linked to the presence of polluting chemicals with endocrine activity, the so called Endocrine Disrupting Chemicals or EDC's .", [["cardiac", "ANATOMY", 54, 61], ["endocrine", "ANATOMY", 331, 340], ["EDC", "CHEMICAL", 399, 402], ["EDC", "CHEMICAL", 399, 402], ["troponin", "GENE_OR_GENE_PRODUCT", 29, 37], ["cardiac troponin", "GENE_OR_GENE_PRODUCT", 54, 70], ["man", "ORGANISM", 251, 254], ["endocrine", "ANATOMICAL_SYSTEM", 331, 340], ["EDC", "SIMPLE_CHEMICAL", 399, 402], ["carrier conjugated troponin sequences", "DNA", 10, 47], ["anti cardiac troponin complex specific antibodies", "PROTEIN", 49, 98], ["man", "SPECIES", 251, 254], ["the carrier conjugated troponin sequences", "TEST", 6, 47], ["anti cardiac troponin complex specific antibodies", "TEST", 49, 98], ["The increasing problems", "PROBLEM", 194, 217], ["high titers", "OBSERVATION", 102, 113], ["increasing", "OBSERVATION_MODIFIER", 198, 208], ["problems", "OBSERVATION", 209, 217]]], ["The family of EDC's is a heterogeneous one and consists of natural and synthetic hormones (like estradiol, ethynylestradiol and diethylstilbesterol), phyto-estrogens (like genistein and coumestrol) and industrial chemicals (like bisfenol-A, ftalates and various pesticides).", [["EDC", "CHEMICAL", 14, 17], ["estradiol", "CHEMICAL", 96, 105], ["ethynylestradiol", "CHEMICAL", 107, 123], ["diethylstilbesterol", "CHEMICAL", 128, 147], ["phyto-estrogens", "CHEMICAL", 150, 165], ["genistein", "CHEMICAL", 172, 181], ["coumestrol", "CHEMICAL", 186, 196], ["bisfenol-A, ftalates", "CHEMICAL", 229, 249], ["EDC", "CHEMICAL", 14, 17], ["estradiol", "CHEMICAL", 96, 105], ["ethynylestradiol", "CHEMICAL", 107, 123], ["diethylstilbesterol", "CHEMICAL", 128, 147], ["phyto-estrogens", "CHEMICAL", 150, 165], ["genistein", "CHEMICAL", 172, 181], ["coumestrol", "CHEMICAL", 186, 196], ["bisfenol-A", "CHEMICAL", 229, 239], ["ftalates", "CHEMICAL", 241, 249], ["estradiol", "SIMPLE_CHEMICAL", 96, 105], ["ethynylestradiol", "SIMPLE_CHEMICAL", 107, 123], ["diethylstilbesterol", "SIMPLE_CHEMICAL", 128, 147], ["phyto-estrogens", "SIMPLE_CHEMICAL", 150, 165], ["genistein", "SIMPLE_CHEMICAL", 172, 181], ["coumestrol", "SIMPLE_CHEMICAL", 186, 196], ["bisfenol-A", "SIMPLE_CHEMICAL", 229, 239], ["ftalates", "SIMPLE_CHEMICAL", 241, 249], ["natural and synthetic hormones", "TREATMENT", 59, 89], ["estradiol", "TREATMENT", 96, 105], ["ethynylestradiol", "TREATMENT", 107, 123], ["diethylstilbesterol)", "TREATMENT", 128, 148], ["phyto-estrogens", "TREATMENT", 150, 165], ["coumestrol", "TREATMENT", 186, 196], ["industrial chemicals", "TEST", 202, 222]]], ["Because of the complexity of the environmental matrices and the low physiologically active concentrations of the EDC's there is still a need for an efficient routine analysis protocol.Organic and Biomimetic Chemistry, Ghent University, Ghent, BelgiumWe want to develop a solid-phase bound receptor that possesses a high selectivity for EDC's and thus can be used in a simple solid-phase extraction protocol.", [["EDC", "CHEMICAL", 336, 339], ["EDC", "SIMPLE_CHEMICAL", 113, 116], ["EDC", "SIMPLE_CHEMICAL", 336, 339], ["solid-phase bound receptor", "PROTEIN", 271, 297], ["the environmental matrices", "PROBLEM", 29, 55], ["an efficient routine analysis protocol", "TEST", 145, 183], ["EDC's", "TREATMENT", 336, 341], ["a simple solid-phase extraction protocol", "TREATMENT", 366, 406], ["environmental matrices", "OBSERVATION", 33, 55], ["high selectivity", "OBSERVATION_MODIFIER", 315, 331]]], ["This receptor must have the right functional groups that bind the EDC's with a strong affinity and must be able to create a cavity in which the EDC's can fit.", [["EDC", "SIMPLE_CHEMICAL", 66, 69], ["EDC", "SIMPLE_CHEMICAL", 144, 147], ["right", "ANATOMY_MODIFIER", 28, 33], ["cavity", "OBSERVATION", 124, 130]]], ["By looking at nature's own estrogenic receptor for humans we have found the different amino acids responsible for the specific interactions .Organic and Biomimetic Chemistry, Ghent University, Ghent, BelgiumIn order to create the cavity which mimics the behaviour of the hormone-binding domain of the human estrogenic receptor we have made a tripodal scaffold.", [["amino acids", "CHEMICAL", 86, 97], ["amino acids", "CHEMICAL", 86, 97], ["humans", "ORGANISM", 51, 57], ["amino acids", "AMINO_ACID", 86, 97], ["human", "ORGANISM", 301, 306], ["estrogenic receptor", "PROTEIN", 27, 46], ["hormone-binding domain", "PROTEIN", 271, 293], ["human estrogenic receptor", "PROTEIN", 301, 326], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 301, 306], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 301, 306], ["the different amino acids", "TREATMENT", 72, 97], ["the human estrogenic receptor", "TREATMENT", 297, 326], ["a tripodal scaffold", "TREATMENT", 340, 359], ["cavity", "OBSERVATION", 230, 236], ["tripodal scaffold", "OBSERVATION", 342, 359]]], ["This tripodal scaffold has three orthogonal protected amino groups that will allow the generation of three independent peptide chains.Department of Biochemistry, Institute of Biology, University of Warmia and Mazury, Olsztyn, PolandMilk proteins are a source of opioid peptides.", [["amino", "CHEMICAL", 54, 59], ["amino", "CHEMICAL", 54, 59], ["opioid peptides", "GENE_OR_GENE_PRODUCT", 262, 277], ["This tripodal scaffold", "TREATMENT", 0, 22], ["orthogonal protected amino groups", "TREATMENT", 33, 66], ["Warmia", "TREATMENT", 198, 204], ["Mazury", "TREATMENT", 209, 215], ["Olsztyn", "TREATMENT", 217, 224], ["PolandMilk proteins", "TREATMENT", 226, 245], ["opioid peptides", "TREATMENT", 262, 277]]], ["These peptides are liberated from milk proteins during enzymatic hydrolysis.", [["milk", "ANATOMY", 34, 38], ["milk", "ORGANISM_SUBSTANCE", 34, 38], ["milk proteins", "PROTEIN", 34, 47], ["enzymatic hydrolysis", "TREATMENT", 55, 75], ["enzymatic hydrolysis", "OBSERVATION", 55, 75]]], ["Some of these peptides are characterized with agonistic (\u03b2-Casomorphins) and some with antagonistic (Casoxins) properties.", [["\u03b2-Casomorphins", "SIMPLE_CHEMICAL", 57, 71], ["Casoxins", "SIMPLE_CHEMICAL", 101, 109], ["agonistic (\u03b2-Casomorphins)", "TREATMENT", 46, 72], ["antagonistic (Casoxins) properties", "TREATMENT", 87, 121], ["peptides", "OBSERVATION", 14, 22]]], ["The aim of the investigations was to determine the presence of opioid peptides with antagonistic properties in milk products.", [["milk", "ANATOMY", 111, 115], ["milk", "ORGANISM", 111, 115], ["the investigations", "TEST", 11, 29], ["opioid peptides", "TREATMENT", 63, 78], ["antagonistic properties in milk products", "TREATMENT", 84, 124]]], ["The experimental material included cheeses, yogurts and kefirs.", [["yogurts", "ANATOMY", 44, 51]]], ["Peptides were extracted with a methanol-chloroform mixture (2:1 v/v).", [["methanol-chloroform", "CHEMICAL", 31, 50], ["methanol", "CHEMICAL", 31, 39], ["chloroform", "CHEMICAL", 40, 50], ["methanol", "SIMPLE_CHEMICAL", 31, 39], ["a methanol-chloroform mixture", "TREATMENT", 29, 58]]], ["The peptide extracts were purified by SPE method on C18 or StrataX columns and characterized by SDS-PAGE electrophoresis.", [["extracts", "ANATOMY", 12, 20], ["extracts", "ORGANISM_SUBSTANCE", 12, 20], ["C18", "SIMPLE_CHEMICAL", 52, 55], ["The peptide extracts", "TEST", 0, 20], ["SPE method", "TEST", 38, 48], ["StrataX columns", "TEST", 59, 74], ["SDS", "TEST", 96, 99], ["PAGE electrophoresis", "TEST", 100, 120]]], ["The agonist opioid peptides (Casoxins) were identified by HPLC using standard agonist peptides.", [["Casoxins", "SIMPLE_CHEMICAL", 29, 37], ["The agonist opioid peptides (Casoxins", "TREATMENT", 0, 37], ["standard agonist peptides", "TREATMENT", 69, 94]]], ["The opioid activity was measured by examining the effects of peptide extracts on the motor activity of isolated rabbit intestine.", [["extracts", "ANATOMY", 69, 77], ["intestine", "ANATOMY", 119, 128], ["extracts", "ORGANISM_SUBSTANCE", 69, 77], ["rabbit", "ORGANISM", 112, 118], ["intestine", "ORGAN", 119, 128], ["rabbit", "SPECIES", 112, 118], ["rabbit", "SPECIES", 112, 118], ["The opioid activity", "PROBLEM", 0, 19], ["peptide extracts", "TREATMENT", 61, 77], ["isolated rabbit intestine", "PROBLEM", 103, 128], ["opioid activity", "OBSERVATION", 4, 19], ["rabbit intestine", "OBSERVATION", 112, 128]]], ["The results of SDS-PAGE electrophoresis indicated the presence of 5 to 9 fractions in peptide extract derived from cheeses and yogurts and 17 to 20 ones from kefirs.", [["extract", "ANATOMY", 94, 101], ["peptide extract", "CHEMICAL", 86, 101], ["SDS", "TEST", 15, 18], ["PAGE electrophoresis", "TEST", 19, 39], ["peptide extract", "TEST", 86, 101]]], ["The presence of casoxin A (0.22-0.68 \u00b5g/mg of extract) was proved in all examined the milk products.", [["extract", "ANATOMY", 46, 53], ["milk", "ANATOMY", 86, 90], ["casoxin A", "CHEMICAL", 16, 25], ["casoxin A", "CHEMICAL", 16, 25], ["casoxin A", "SIMPLE_CHEMICAL", 16, 25], ["milk", "ORGANISM", 86, 90], ["casoxin A", "TREATMENT", 16, 25]]], ["Lactoferroxin A (0.31-1.88 \u00b5g/mg of extract) was identified only in kefirs and yogurts.", [["extract", "ANATOMY", 36, 43], ["kefirs", "ANATOMY", 68, 74], ["yogurts", "ANATOMY", 79, 86], ["Lactoferroxin A", "CHEMICAL", 0, 15], ["Lactoferroxin A", "CHEMICAL", 0, 15], ["Lactoferroxin A", "SIMPLE_CHEMICAL", 0, 15], ["kefirs", "SIMPLE_CHEMICAL", 68, 74], ["Lactoferroxin A", "TREATMENT", 0, 15]]], ["Those products were also found to contain trace amounts of casoxin C. All peptide extracts showed the antagonistic activity in the relation to motor activity of isolated rabbit intestine.", [["extracts", "ANATOMY", 82, 90], ["intestine", "ANATOMY", 177, 186], ["casoxin", "CHEMICAL", 59, 66], ["extracts", "ORGANISM_SUBSTANCE", 82, 90], ["rabbit", "ORGANISM", 170, 176], ["intestine", "ORGAN", 177, 186], ["rabbit", "SPECIES", 170, 176], ["rabbit", "SPECIES", 170, 176], ["casoxin C.", "TREATMENT", 59, 69], ["All peptide extracts", "TEST", 70, 90], ["the antagonistic activity", "PROBLEM", 98, 123], ["isolated rabbit intestine", "PROBLEM", 161, 186], ["trace", "OBSERVATION_MODIFIER", 42, 47], ["amounts", "OBSERVATION_MODIFIER", 48, 55], ["antagonistic activity", "OBSERVATION", 102, 123], ["motor activity", "OBSERVATION", 143, 157], ["rabbit intestine", "OBSERVATION", 170, 186]]], ["The highest antagonistic activity was reported of peptide extract from kefirs (3.62-17 .20%) and Gouda cheese (15.68-16.36%), as compared to morphine.", [["peptide extract", "CHEMICAL", 50, 65], ["kefirs", "CHEMICAL", 71, 77], ["morphine", "CHEMICAL", 141, 149], ["morphine", "CHEMICAL", 141, 149], ["kefirs", "SIMPLE_CHEMICAL", 71, 77], ["morphine", "SIMPLE_CHEMICAL", 141, 149], ["peptide extract", "PROBLEM", 50, 65], ["kefirs", "TEST", 71, 77], ["Gouda cheese", "TEST", 97, 109], ["morphine", "TREATMENT", 141, 149]]], ["The physiological and nutritional function of these antagonist peptides requires elucidation.HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC ENANTIOSEPARATION OF \u03b2-AMINO ACIDSA.", [["these antagonist peptides", "TREATMENT", 46, 71]]], ["P\u00e9ter 1 , R. Berkecz 1 , F. F\u00fcl\u00f6p 2Department of Inorganic and Analytical Chemistry 2 Institute of Pharmaceutical Chemistry, University of Szeged, HungaryThe past decade has seen a growing interest in \u03b2-amino acids, which are important intermediates for the synthesis of compounds of pharmaceutical interest and can be used as building blocks for peptidomimetics.", [["\u03b2-amino acids", "CHEMICAL", 201, 214], ["\u03b2-amino acids", "CHEMICAL", 201, 214], ["\u03b2-amino acids", "SIMPLE_CHEMICAL", 201, 214], ["\u03b2-amino acids", "TREATMENT", 201, 214], ["peptidomimetics", "TREATMENT", 347, 362]]], ["Oligomers of \u03b2-amino acids (\u03b2-peptides) fold into compact helices in solution.", [["\u03b2-amino acids", "CHEMICAL", 13, 26], ["\u03b2-amino acids", "CHEMICAL", 13, 26], ["\u03b2-amino acids", "SIMPLE_CHEMICAL", 13, 26], ["\u03b2-amino acids (\u03b2-peptides", "TREATMENT", 13, 38], ["compact helices in solution", "TREATMENT", 50, 77]]], ["Recently, a novel class of \u03b2-peptide analogues adopting predictable and reproducible folding patterns (foldamers) was evaluated as a potential source of new drugs and catalysts.", [["\u03b2-peptide", "CHEMICAL", 27, 36], ["\u03b2-peptide analogues", "SIMPLE_CHEMICAL", 27, 46], ["foldamers", "SIMPLE_CHEMICAL", 103, 112], ["\u03b2-peptide analogues", "TREATMENT", 27, 46], ["reproducible folding patterns (foldamers)", "PROBLEM", 72, 113], ["new drugs and catalysts", "TREATMENT", 153, 176], ["reproducible folding", "OBSERVATION", 72, 92]]], ["Studies on synthetic \u03b2-amino acids can be facilitated by versatile and robust methods for determining the enantiomeric purity of starting materials and products.", [["\u03b2-amino acids", "CHEMICAL", 21, 34], ["\u03b2-amino acids", "CHEMICAL", 21, 34], ["synthetic \u03b2-amino acids", "SIMPLE_CHEMICAL", 11, 34], ["synthetic \u03b2-amino acids", "TEST", 11, 34]]], ["Highperformance liquid chromatography (HPLC) is one of the most useful techniques for the recognition and/or separation of stereoisomers including enantiomers.", [["Highperformance liquid chromatography", "TEST", 0, 37]]], ["The aim of the present work was to evaluate HPLC methods for the separation of enantiomers of eighteen 3-amino-3-aryl-substituted propanoic acids (\u03b2-amino acids).", [["3-amino-3-aryl-substituted propanoic acids", "CHEMICAL", 103, 145], ["\u03b2-amino acids", "CHEMICAL", 147, 160], ["3-amino-3-aryl-substituted propanoic acids", "CHEMICAL", 103, 145], ["\u03b2-amino acids", "CHEMICAL", 147, 160], ["3-amino-3-aryl-substituted propanoic acids", "SIMPLE_CHEMICAL", 103, 145], ["\u03b2-amino acids", "SIMPLE_CHEMICAL", 147, 160], ["HPLC methods", "TEST", 44, 56], ["amino", "TEST", 105, 110], ["substituted propanoic acids (\u03b2-amino acids", "TREATMENT", 118, 160]]], ["Direct separations were carried out on different macrocyclic glycopeptide based stationary phases, such as ristocetin A containing Chirobiotic R, teicoplanin containing Chirobiotic T, teicoplanin aglycon containing Chirobiotic Tag, vancomycin containing Chirobiotic V columns and on a chiral crown ether based column.", [["Chirobiotic R", "CHEMICAL", 131, 144], ["teicoplanin", "CHEMICAL", 146, 157], ["Chirobiotic T", "CHEMICAL", 169, 182], ["teicoplanin", "CHEMICAL", 184, 195], ["vancomycin", "CHEMICAL", 232, 242], ["teicoplanin", "CHEMICAL", 146, 157], ["Chirobiotic T", "CHEMICAL", 169, 182], ["teicoplanin aglycon", "CHEMICAL", 184, 203], ["Chirobiotic Tag", "CHEMICAL", 215, 230], ["vancomycin", "CHEMICAL", 232, 242], ["crown ether", "CHEMICAL", 292, 303], ["ristocetin A", "SIMPLE_CHEMICAL", 107, 119], ["Chirobiotic R", "SIMPLE_CHEMICAL", 131, 144], ["teicoplanin", "SIMPLE_CHEMICAL", 146, 157], ["Chirobiotic T", "SIMPLE_CHEMICAL", 169, 182], ["teicoplanin aglycon", "SIMPLE_CHEMICAL", 184, 203], ["Chirobiotic Tag", "SIMPLE_CHEMICAL", 215, 230], ["vancomycin", "SIMPLE_CHEMICAL", 232, 242], ["Direct separations", "TEST", 0, 18], ["different macrocyclic glycopeptide", "TREATMENT", 39, 73], ["ristocetin A", "TREATMENT", 107, 119], ["Chirobiotic R, teicoplanin", "TREATMENT", 131, 157], ["Chirobiotic T, teicoplanin aglycon", "TREATMENT", 169, 203], ["Chirobiotic Tag", "TREATMENT", 215, 230], ["vancomycin", "TREATMENT", 232, 242], ["Chirobiotic V columns", "TREATMENT", 254, 275], ["a chiral crown ether based column", "TREATMENT", 283, 316]]], ["The effects of different parameters on selectivity, such as the nature of the organic modifier, the mobile phase composition, the flow rate and the structure of the analytes are examined and discussed.", [["the organic modifier", "TREATMENT", 74, 94], ["the flow rate", "TEST", 126, 139]]], ["The separation of the stereoisomers was optimized by variation of the chromatographic parameters.", [["the chromatographic parameters", "TEST", 66, 96], ["separation", "OBSERVATION_MODIFIER", 4, 14], ["stereoisomers", "OBSERVATION", 22, 35]]], ["The efficiency of the different methods and the role of molecular structure in the enantioseparation were noted.", [["the different methods", "TREATMENT", 18, 39], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["different", "OBSERVATION_MODIFIER", 22, 31], ["molecular structure", "OBSERVATION", 56, 75]]], ["The elution sequence of the enantiomers was determined in most cases.M520A RATIONAL APPROACH TO EVALUATING PEPTIDE PURITY A. Swietlow 1 , R. Lax 2 1 Amgen, Inc., Pharmaceutics, Thousand Oaks, CA 2 PolyPeptide Laboratories, Inc., Torrance, CA, USA Recent years have seen an enormous increase in interest in peptide therapeutics.", [["peptide therapeutics", "TREATMENT", 306, 326], ["enormous", "OBSERVATION_MODIFIER", 273, 281], ["increase", "OBSERVATION_MODIFIER", 282, 290]]], ["New peptide leads are often chosen by screening procedures using microgram to milligram quantities of peptides, frequently provided by specialized manufacturers utilizing automatic synthesizers to maximize output.", [["New peptide leads", "TREATMENT", 0, 17], ["screening procedures", "TEST", 38, 58], ["automatic synthesizers", "TREATMENT", 171, 193], ["peptide leads", "OBSERVATION", 4, 17]]], ["The purity of the resulting compounds is often not very high.", [["compounds", "OBSERVATION", 28, 37]]], ["The use of SPPS synthetic procedures predetermines that most impurities are closely related and difficult to resolve by reversephase purification.", [["SPPS synthetic procedures", "TREATMENT", 11, 36]]], ["These factors, combined with the use of generic analytical methods not specifically optimized for the peptide in question (e.g. the ubiquitous 0.1% TFA/water/acetonitrile system), lead to erroneous results that frequently severely overestimate the purity of the peptide.", [["acetonitrile", "CHEMICAL", 158, 170], ["TFA", "CHEMICAL", 148, 151], ["acetonitrile", "CHEMICAL", 158, 170], ["TFA", "SIMPLE_CHEMICAL", 148, 151], ["water", "SIMPLE_CHEMICAL", 152, 157], ["generic analytical methods", "TREATMENT", 40, 66], ["TFA/water/acetonitrile system", "TREATMENT", 148, 177]]], ["The use of poorly characterized materials in pharmaceutical development leads to significant risks of obtaining false negative or false positive results that may cause potential leads to be overlooked or misinterpretation of their pharmacological profiles.M520We describe a rapid, systematic and reliable HPLC procedure for evaluation of peptide purity.", [["false positive results", "PROBLEM", 130, 152], ["reliable HPLC procedure", "TREATMENT", 296, 319], ["evaluation", "TEST", 324, 334], ["peptide purity", "PROBLEM", 338, 352], ["poorly characterized", "OBSERVATION_MODIFIER", 11, 31]]], ["Utilizing the increased separation efficiency by increasing the column temperature and adjusting the gradient in two steps in reverse-phase buffers containing TFA, NaClO4, or ion-exchange buffers containing KCl, we demonstrate that methods -suitable for preclinical research -can be developed rapidly.", [["TFA", "CHEMICAL", 159, 162], ["NaClO4", "CHEMICAL", 164, 170], ["KCl", "CHEMICAL", 207, 210], ["TFA", "CHEMICAL", 159, 162], ["NaClO4", "CHEMICAL", 164, 170], ["KCl", "CHEMICAL", 207, 210], ["TFA", "SIMPLE_CHEMICAL", 159, 162], ["NaClO4", "SIMPLE_CHEMICAL", 164, 170], ["KCl", "SIMPLE_CHEMICAL", 207, 210], ["the increased separation efficiency", "PROBLEM", 10, 45], ["increasing the column temperature", "PROBLEM", 49, 82], ["the gradient", "TEST", 97, 109], ["reverse-phase buffers", "TREATMENT", 126, 147], ["TFA", "TREATMENT", 159, 162], ["NaClO4", "TREATMENT", 164, 170], ["ion-exchange buffers", "TREATMENT", 175, 195], ["KCl", "TREATMENT", 207, 210], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["separation efficiency", "OBSERVATION", 24, 45], ["column temperature", "OBSERVATION_MODIFIER", 64, 82]]], ["The proposed approach will be illustrated with examples of peptides ranging between 9 and 28 amino acids and a model peptide VYPNGA.", [["amino acids", "CHEMICAL", 93, 104], ["amino acids", "CHEMICAL", 93, 104], ["amino acids", "AMINO_ACID", 93, 104], ["peptides", "TEST", 59, 67], ["amino acids", "TEST", 93, 104], ["a model peptide VYPNGA", "TREATMENT", 109, 131]]], ["It will be demonstrated that peptides showing an HPLC purity close to 100% are often 10 -25% less pure.", [["peptides", "TEST", 29, 37], ["an HPLC purity", "TEST", 46, 60], ["HPLC purity", "OBSERVATION", 49, 60]]], ["To approach a high-throughput cell assay format using peptides, we attempt to design and construct a peptide microarray for examination of cell activities of peptides including apoptotic cell death.", [["cell", "ANATOMY", 30, 34], ["cell", "ANATOMY", 139, 143], ["cell", "ANATOMY", 187, 191], ["death", "DISEASE", 192, 197], ["cell", "CELL", 30, 34], ["cell", "CELL", 139, 143], ["cell", "CELL", 187, 191], ["peptides", "TREATMENT", 54, 62], ["a peptide microarray", "TEST", 99, 119], ["examination of cell activities", "TEST", 124, 154], ["apoptotic cell death", "PROBLEM", 177, 197], ["apoptotic cell death", "OBSERVATION", 177, 197]]], ["Peptides were immobilized onto solid surfaces via a novel multi-functional linker.", [["a novel multi-functional linker", "TREATMENT", 50, 81], ["multi-functional linker", "OBSERVATION", 58, 81]]], ["The linker enable us to examine various types of peptide cell assays in an array format.", [["cell", "ANATOMY", 57, 61], ["cell", "CELL", 57, 61], ["peptide cell assays", "TEST", 49, 68], ["peptide cell", "OBSERVATION", 49, 61]]], ["We also designed and synthesized peptidyl capture agents on the basis of the cell-active sequences suitable for the peptide microarray.RIHS, University of Wolverhampton, UKThe utility of targeted nanoparticles as fluorescent probes for tissue imaging has recently been subject to widespread interest.", [["cell", "ANATOMY", 77, 81], ["tissue", "ANATOMY", 236, 242], ["peptidyl capture agents", "SIMPLE_CHEMICAL", 33, 56], ["cell", "CELL", 77, 81], ["tissue", "TISSUE", 236, 242], ["synthesized peptidyl capture agents", "TREATMENT", 21, 56], ["the peptide microarray", "TEST", 112, 134], ["targeted nanoparticles", "TREATMENT", 187, 209], ["fluorescent probes", "TEST", 213, 231], ["tissue imaging", "TEST", 236, 250]]], ["One exciting prospect is the further development of nanoparticles conjugated to both targeting peptides and cytotoxic cargoes.", [["nanoparticles", "TREATMENT", 52, 65], ["cytotoxic cargoes", "PROBLEM", 108, 125], ["cytotoxic cargoes", "OBSERVATION", 108, 125]]], ["These nanodevices could preferentially bind to specific cells and/or tissues to provide effective tools for drug delivery.", [["cells", "ANATOMY", 56, 61], ["tissues", "ANATOMY", 69, 76], ["cells", "CELL", 56, 61], ["tissues", "TISSUE", 69, 76], ["These nanodevices", "TREATMENT", 0, 17], ["drug delivery", "TREATMENT", 108, 121]]], ["Hence, such multifunctional nanoparticles could provide both diagnostic and therapeutic functions by acting as fluorescent probes that offer targeted delivery of therapeutic agents.", [["such multifunctional nanoparticles", "TREATMENT", 7, 41], ["fluorescent probes", "TEST", 111, 129], ["targeted delivery of therapeutic agents", "TREATMENT", 141, 180]]], ["We have coated the surface of quantum dots (Qdots) with cell-penetrating peptides (CPP) to target and label U251M cells for fluorescence imaging.", [["surface", "ANATOMY", 19, 26], ["cell", "ANATOMY", 56, 60], ["U251M cells", "ANATOMY", 108, 119], ["Qdots", "SIMPLE_CHEMICAL", 44, 49], ["cell", "CELL", 56, 60], ["CPP", "SIMPLE_CHEMICAL", 83, 86], ["U251M cells", "CELL", 108, 119], ["U251M cells", "CELL_LINE", 108, 119], ["cell-penetrating peptides", "TREATMENT", 56, 81], ["CPP", "TEST", 83, 86], ["fluorescence imaging", "TEST", 124, 144], ["surface", "OBSERVATION_MODIFIER", 19, 26]]], ["Qdots were initially coupled to polyethylene glycol linkers via carboxyl functionalities on their surface.", [["surface", "ANATOMY", 98, 105], ["polyethylene glycol", "CHEMICAL", 32, 51], ["polyethylene glycol", "CHEMICAL", 32, 51], ["carboxyl", "CHEMICAL", 64, 72], ["Qdots", "SIMPLE_CHEMICAL", 0, 5], ["polyethylene glycol linkers", "SIMPLE_CHEMICAL", 32, 59], ["surface", "CELLULAR_COMPONENT", 98, 105], ["Qdots", "TREATMENT", 0, 5], ["polyethylene glycol linkers via carboxyl functionalities", "TREATMENT", 32, 88]]], ["A heterogeneous mixture of poly-arginine peptides of varying lengths (Arg(6)-Arg(10)) were covalently coupled via amide bonds to the polyethylene glycol linkers, conferring a cell penetrating capacity to the modified Qdots.", [["cell", "ANATOMY", 175, 179], ["poly-arginine", "CHEMICAL", 27, 40], ["Arg(6)-Arg", "CHEMICAL", 70, 80], ["polyethylene glycol", "CHEMICAL", 133, 152], ["poly-arginine", "CHEMICAL", 27, 40], ["Arg(6)-Arg(10)", "CHEMICAL", 70, 84], ["amide", "CHEMICAL", 114, 119], ["polyethylene glycol", "CHEMICAL", 133, 152], ["poly-arginine peptides", "SIMPLE_CHEMICAL", 27, 49], ["Arg(6)-Arg(10)", "SIMPLE_CHEMICAL", 70, 84], ["polyethylene glycol linkers", "SIMPLE_CHEMICAL", 133, 160], ["cell", "CELL", 175, 179], ["Qdots", "GENE_OR_GENE_PRODUCT", 217, 222], ["A heterogeneous mixture of poly-arginine peptides", "PROBLEM", 0, 49], ["Arg", "TEST", 70, 73], ["the polyethylene glycol linkers", "TREATMENT", 129, 160], ["a cell penetrating capacity", "TREATMENT", 173, 200], ["heterogeneous", "OBSERVATION_MODIFIER", 2, 15], ["mixture", "OBSERVATION_MODIFIER", 16, 23], ["varying", "OBSERVATION_MODIFIER", 53, 60], ["lengths", "OBSERVATION_MODIFIER", 61, 68], ["polyethylene glycol linkers", "OBSERVATION", 133, 160]]], ["Fluorescence imaging of U251M cells, after incubation with the conjugated Qdots at concentrations of 20nM, gave clear signals indicating cell binding and internalisation of the modified Qdots across the plasma membrane.", [["U251M cells", "ANATOMY", 24, 35], ["cell", "ANATOMY", 137, 141], ["plasma membrane", "ANATOMY", 203, 218], ["U251M cells", "CELL", 24, 35], ["Qdots", "SIMPLE_CHEMICAL", 74, 79], ["cell", "CELL", 137, 141], ["Qdots", "GENE_OR_GENE_PRODUCT", 186, 191], ["plasma membrane", "CELLULAR_COMPONENT", 203, 218], ["U251M cells", "CELL_LINE", 24, 35], ["Qdots", "PROTEIN", 186, 191], ["Fluorescence imaging", "TEST", 0, 20], ["incubation", "TREATMENT", 43, 53], ["the conjugated Qdots", "TREATMENT", 59, 79], ["cell binding", "PROBLEM", 137, 149], ["cell binding", "OBSERVATION", 137, 149], ["plasma membrane", "ANATOMY", 203, 218]]], ["We aim to further expand this work by employing racemic mixtures of CPP and cytotoxic agents to engineer conjugates that will facilitate both imaging and the therapeutic delivery of cytotoxic moieties.", [["CPP", "CHEMICAL", 68, 71], ["CPP", "SIMPLE_CHEMICAL", 68, 71], ["racemic mixtures of CPP", "TREATMENT", 48, 71], ["cytotoxic agents", "TREATMENT", 76, 92], ["both imaging", "TEST", 137, 149], ["the therapeutic delivery of cytotoxic moieties", "TREATMENT", 154, 200], ["cytotoxic moieties", "OBSERVATION", 182, 200]]], ["The ability of cell penetrating peptides (CPP) to deliver biologically active cargoes into different cell types has been successfully applied in several experimental systems.", [["cell", "ANATOMY", 15, 19], ["cell", "ANATOMY", 101, 105], ["cell", "CELL", 15, 19], ["cell", "CELL", 101, 105], ["cell penetrating peptides (CPP)", "TREATMENT", 15, 46], ["biologically active cargoes", "TREATMENT", 58, 85], ["different cell types", "TREATMENT", 91, 111], ["different cell types", "OBSERVATION", 91, 111]]], ["Despite the progress and growing number of described CPPs, reports about the internalization mechanisms and the intracellular routes of CPPs still remain controversial.", [["intracellular", "ANATOMY", 112, 125], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["the internalization mechanisms", "PROBLEM", 73, 103], ["the intracellular routes of CPPs", "TREATMENT", 108, 140]]], ["We have characterized the membrane interaction and cellular localization of proteins delivered into HeLa cells by cell penetrating peptide transportan (TP) and its shorter analogue TP10 on ultrastructural level.", [["membrane", "ANATOMY", 26, 34], ["cellular", "ANATOMY", 51, 59], ["HeLa cells", "ANATOMY", 100, 110], ["cell", "ANATOMY", 114, 118], ["membrane", "CELLULAR_COMPONENT", 26, 34], ["cellular", "CELL", 51, 59], ["HeLa cells", "CELL", 100, 110], ["cell", "CELL", 114, 118], ["transportan", "GENE_OR_GENE_PRODUCT", 139, 150], ["TP", "GENE_OR_GENE_PRODUCT", 152, 154], ["TP10", "SIMPLE_CHEMICAL", 181, 185], ["HeLa cells", "CELL_LINE", 100, 110], ["TP10", "PROTEIN", 181, 185], ["the membrane interaction", "PROBLEM", 22, 46], ["HeLa cells", "TREATMENT", 100, 110], ["cell penetrating peptide transportan (TP)", "TREATMENT", 114, 155], ["membrane interaction", "OBSERVATION", 26, 46]]], ["Our previous results obtained by transmission electron microscopy showed that complexes of transportans with gold-labeled streptavidin translocated into cells inducing large invagination of plasmamembrane, suggesting the uptake by macropinocytosis.", [["cells", "ANATOMY", 153, 158], ["plasmamembrane", "ANATOMY", 190, 204], ["gold", "CHEMICAL", 109, 113], ["transportans", "SIMPLE_CHEMICAL", 91, 103], ["gold", "SIMPLE_CHEMICAL", 109, 113], ["streptavidin", "GENE_OR_GENE_PRODUCT", 122, 134], ["cells", "CELL", 153, 158], ["plasmamembrane", "GENE_OR_GENE_PRODUCT", 190, 204], ["gold-labeled streptavidin", "PROTEIN", 109, 134], ["transmission electron microscopy", "TEST", 33, 65], ["complexes of transportans", "PROBLEM", 78, 103], ["gold-labeled streptavidin", "TREATMENT", 109, 134], ["large invagination of plasmamembrane", "PROBLEM", 168, 204], ["macropinocytosis", "PROBLEM", 231, 247], ["large", "OBSERVATION_MODIFIER", 168, 173], ["invagination", "OBSERVATION_MODIFIER", 174, 186], ["plasmamembrane", "ANATOMY", 190, 204], ["macropinocytosis", "OBSERVATION", 231, 247]]], ["The complexes of transportan with gold-labeled neutravidin, in contrary, were taken into cells mostly via caveosomes and clathrin-coated vesicles.", [["cells", "ANATOMY", 89, 94], ["vesicles", "ANATOMY", 137, 145], ["gold", "CHEMICAL", 34, 38], ["neutravidin", "CHEMICAL", 47, 58], ["neutravidin", "CHEMICAL", 47, 58], ["transportan", "SIMPLE_CHEMICAL", 17, 28], ["gold", "SIMPLE_CHEMICAL", 34, 38], ["neutravidin", "SIMPLE_CHEMICAL", 47, 58], ["cells", "CELL", 89, 94], ["clathrin", "GENE_OR_GENE_PRODUCT", 121, 129], ["vesicles", "CELLULAR_COMPONENT", 137, 145], ["caveosomes", "PROTEIN", 106, 116], ["clathrin", "PROTEIN", 121, 129], ["gold-labeled neutravidin", "TREATMENT", 34, 58], ["coated vesicles", "OBSERVATION", 130, 145]]], ["The cell-transduced transportanprotein complexes localized mainly in the vesicular structures of different size and morphology.", [["cell", "ANATOMY", 4, 8], ["vesicular structures", "ANATOMY", 73, 93], ["cell", "CELL", 4, 8], ["transportanprotein", "GENE_OR_GENE_PRODUCT", 20, 38], ["vesicular structures", "MULTI-TISSUE_STRUCTURE", 73, 93], ["transportanprotein complexes", "PROTEIN", 20, 48], ["transduced transportanprotein complexes", "TREATMENT", 9, 48], ["transduced transportanprotein complexes", "OBSERVATION", 9, 48], ["vesicular", "ANATOMY_MODIFIER", 73, 82], ["different", "OBSERVATION_MODIFIER", 97, 106], ["size", "OBSERVATION_MODIFIER", 107, 111], ["morphology", "OBSERVATION_MODIFIER", 116, 126]]], ["Most of the complexes-containing vesicles in the perinuclear area contained also Lamp2 protein, marker of late endosomes and lysosomes.", [["vesicles", "ANATOMY", 33, 41], ["perinuclear area", "ANATOMY", 49, 65], ["late endosomes", "ANATOMY", 106, 120], ["lysosomes", "ANATOMY", 125, 134], ["vesicles", "CELLULAR_COMPONENT", 33, 41], ["perinuclear area", "CELLULAR_COMPONENT", 49, 65], ["Lamp2", "GENE_OR_GENE_PRODUCT", 81, 86], ["late endosomes", "CELLULAR_COMPONENT", 106, 120], ["lysosomes", "CELLULAR_COMPONENT", 125, 134], ["Lamp2 protein", "PROTEIN", 81, 94], ["vesicles in the perinuclear area", "PROBLEM", 33, 65], ["Lamp2 protein", "TEST", 81, 94], ["vesicles", "OBSERVATION", 33, 41], ["perinuclear", "ANATOMY_MODIFIER", 49, 60], ["area", "ANATOMY_MODIFIER", 61, 65], ["Lamp2 protein", "OBSERVATION", 81, 94], ["late endosomes", "OBSERVATION", 106, 120], ["lysosomes", "OBSERVATION_MODIFIER", 125, 134]]], ["Still, the transportan-protein complexes were not confined in the membrane-surrounded vesicles, but spread in the cytosol suggesting the escape of transportan-protein complexes from endosomes.", [["membrane", "ANATOMY", 66, 74], ["vesicles", "ANATOMY", 86, 94], ["cytosol", "ANATOMY", 114, 121], ["endosomes", "ANATOMY", 182, 191], ["transportan", "GENE_OR_GENE_PRODUCT", 11, 22], ["membrane-", "CELLULAR_COMPONENT", 66, 75], ["surrounded vesicles", "CELLULAR_COMPONENT", 75, 94], ["cytosol", "CELLULAR_COMPONENT", 114, 121], ["transportan-protein complexes", "GENE_OR_GENE_PRODUCT", 147, 176], ["endosomes", "CELLULAR_COMPONENT", 182, 191], ["transportan-protein complexes", "PROTEIN", 11, 40], ["transportan-protein complexes", "PROTEIN", 147, 176], ["the transportan-protein complexes", "TEST", 7, 40], ["escape", "OBSERVATION_MODIFIER", 137, 143], ["protein complexes", "OBSERVATION", 159, 176]]], ["Our findings show the involvement of different endocytic pathways in the transportan-mediated uptake process of proteins.", [["transportan", "GENE_OR_GENE_PRODUCT", 73, 84], ["different", "OBSERVATION_MODIFIER", 37, 46], ["endocytic pathways", "OBSERVATION", 47, 65], ["uptake process", "OBSERVATION", 94, 108]]], ["The concentration of a CPP and the properties of cargo protein seem to determine the pathway for the cellular uptake of a particular construct.RIHS, University of Wolverhampton, UKRGD peptides (R = arginine; G = glycine; D = aspartic acid) have been found to promote cell adhesion upon interaction with alphaV-beta3 receptors, which are strongly overexpressed during neoangiogenesis by solid tumor associated cells compared to healthy cells.", [["cellular", "ANATOMY", 101, 109], ["cell", "ANATOMY", 267, 271], ["solid tumor", "ANATOMY", 386, 397], ["cells", "ANATOMY", 409, 414], ["cells", "ANATOMY", 435, 440], ["RIHS", "DISEASE", 143, 147], ["R = arginine", "CHEMICAL", 194, 206], ["glycine", "CHEMICAL", 212, 219], ["D = aspartic acid", "CHEMICAL", 221, 238], ["tumor", "DISEASE", 392, 397], ["arginine", "CHEMICAL", 198, 206], ["glycine", "CHEMICAL", 212, 219], ["aspartic acid", "CHEMICAL", 225, 238], ["cellular", "CELL", 101, 109], ["R = arginine", "SIMPLE_CHEMICAL", 194, 206], ["G = glycine", "SIMPLE_CHEMICAL", 208, 219], ["D = aspartic acid", "SIMPLE_CHEMICAL", 221, 238], ["cell", "CELL", 267, 271], ["alphaV-beta3", "GENE_OR_GENE_PRODUCT", 303, 315], ["solid tumor associated cells", "CELL", 386, 414], ["cells", "CELL", 435, 440], ["cargo protein", "PROTEIN", 49, 62], ["alphaV", "PROTEIN", 303, 309], ["beta3 receptors", "PROTEIN", 310, 325], ["solid tumor associated cells", "CELL_TYPE", 386, 414], ["healthy cells", "CELL_TYPE", 427, 440], ["a CPP", "TEST", 21, 26], ["cargo protein", "TEST", 49, 62], ["Wolverhampton", "TEST", 163, 176], ["UKRGD peptides", "TEST", 178, 192], ["arginine", "TEST", 198, 206], ["D = aspartic acid", "TREATMENT", 221, 238], ["alphaV-beta3 receptors", "TREATMENT", 303, 325], ["solid tumor associated cells", "PROBLEM", 386, 414], ["cellular uptake", "OBSERVATION", 101, 116], ["promote cell adhesion", "OBSERVATION", 259, 280], ["solid", "OBSERVATION_MODIFIER", 386, 391], ["tumor", "OBSERVATION", 392, 397]]], ["In this study we designed new targeting motifs aimed to deliver various antitumoral drugs specifically to cells involved in tumor vascularization.", [["antitumoral", "ANATOMY", 72, 83], ["cells", "ANATOMY", 106, 111], ["tumor", "ANATOMY", 124, 129], ["tumor", "DISEASE", 124, 129], ["antitumoral", "CANCER", 72, 83], ["cells", "CELL", 106, 111], ["tumor", "CANCER", 124, 129], ["this study", "TEST", 3, 13], ["new targeting motifs", "TREATMENT", 26, 46], ["various antitumoral drugs", "TREATMENT", 64, 89], ["tumor vascularization", "PROBLEM", 124, 145], ["tumor vascularization", "OBSERVATION", 124, 145]]], ["We inserted this short RGD sequence in tetracyclopeptides closed with various means.", [["tetracyclopeptides", "SIMPLE_CHEMICAL", 39, 57], ["short RGD sequence", "DNA", 17, 35], ["this short RGD sequence in tetracyclopeptides", "TREATMENT", 12, 57]]], ["We expect these new cyclotetrapeptides to be more specific for the targeted receptor.", [["cyclotetrapeptides", "CHEMICAL", 20, 38], ["cyclotetrapeptides", "SIMPLE_CHEMICAL", 20, 38], ["targeted receptor", "PROTEIN", 67, 84], ["these new cyclotetrapeptides", "TREATMENT", 10, 38]]], ["Moreover, these new type of cyclic peptides were multimerized on different scaffold to further improve the receptor avidity.", [["cyclic peptides", "PROBLEM", 28, 43], ["different scaffold", "TREATMENT", 65, 83], ["the receptor avidity", "PROBLEM", 103, 123], ["new", "OBSERVATION_MODIFIER", 16, 19], ["cyclic peptides", "OBSERVATION", 28, 43]]], ["Our purpose is first to scrutinize and to quantify the efficient cellular uptake of these molecules and second, to address the specific cell targeting of a fluorescent cargo by differents tools such as Fluorescence Activated Cells Sorting (FACS) analysis or fluorescence microscopy.", [["cellular", "ANATOMY", 65, 73], ["cell", "ANATOMY", 136, 140], ["Cells", "ANATOMY", 225, 230], ["cellular", "CELL", 65, 73], ["cell", "CELL", 136, 140], ["Cells", "CELL", 225, 230], ["fluorescence microscopy", "TEST", 258, 281]]], ["These new targeting units were evaluated on two different cell lines: Human Umbilical Vein Endothelial Cells (HUVEC) with an over expression of the alphaV-beta3 integrin receptor and A549 cells expressing a much lower level of this receptor.", [["cell lines", "ANATOMY", 58, 68], ["Umbilical Vein Endothelial Cells", "ANATOMY", 76, 108], ["HUVEC", "ANATOMY", 110, 115], ["A549 cells", "ANATOMY", 183, 193], ["cell lines", "CELL", 58, 68], ["Human", "ORGANISM", 70, 75], ["Umbilical Vein Endothelial Cells", "CELL", 76, 108], ["HUVEC", "CELL", 110, 115], ["alphaV-beta3 integrin receptor", "GENE_OR_GENE_PRODUCT", 148, 178], ["A549 cells", "CELL", 183, 193], ["cell lines", "CELL_LINE", 58, 68], ["Human Umbilical Vein Endothelial Cells", "CELL_LINE", 70, 108], ["HUVEC", "CELL_LINE", 110, 115], ["alphaV", "PROTEIN", 148, 154], ["beta3 integrin receptor", "PROTEIN", 155, 178], ["A549 cells", "CELL_LINE", 183, 193], ["Human", "SPECIES", 70, 75], ["Human", "SPECIES", 70, 75], ["Human Umbilical Vein Endothelial Cells (HUVEC", "TREATMENT", 70, 115], ["the alphaV", "TEST", 144, 154], ["beta3 integrin receptor", "TREATMENT", 155, 178], ["A549 cells", "TREATMENT", 183, 193], ["this receptor", "TREATMENT", 227, 240], ["new", "OBSERVATION_MODIFIER", 6, 9], ["cell lines", "OBSERVATION", 58, 68], ["Umbilical Vein", "ANATOMY", 76, 90], ["Endothelial Cells", "OBSERVATION", 91, 108], ["A549 cells", "OBSERVATION", 183, 193]]], ["Preliminary results about the selectivity and the efficacy of these new targeting units will be presented.Department of Bioengineering, Yildiz Technical University, Istanbul, TurkeyWe have recently developed new approaches for obtaining highly immunogenic peptide conjugates: synthetic polyelectrolytes (PE) were used for the conjugation with peptide molecules in which PE carry out the carrier and adjuvant roles simultaneously.", [["PE", "CHEMICAL", 304, 306], ["polyelectrolytes", "SIMPLE_CHEMICAL", 286, 302], ["PE", "SIMPLE_CHEMICAL", 304, 306], ["PE", "SIMPLE_CHEMICAL", 370, 372], ["these new targeting units", "TREATMENT", 62, 87], ["highly immunogenic peptide conjugates", "TREATMENT", 237, 274], ["synthetic polyelectrolytes (PE)", "TREATMENT", 276, 307], ["the conjugation with peptide molecules", "TREATMENT", 322, 360], ["new", "OBSERVATION_MODIFIER", 68, 71], ["new", "OBSERVATION_MODIFIER", 208, 211], ["PE", "OBSERVATION", 304, 306], ["PE", "OBSERVATION", 370, 372]]], ["In this study, 4 epitopes of antigenic parts of surface antigen of Hepatitis B virus (2-16, 22-35, 95-109 and 115-129 of the s gene.) had been synthesized.The synthesis of peptides was performed by Explorer PLS \u00ae Automated Microwave Synthesis Workstation (CEM).", [["surface", "ANATOMY", 48, 55], ["Hepatitis B", "DISEASE", 67, 78], ["Hepatitis B virus", "ORGANISM", 67, 84], ["surface antigen", "PROTEIN", 48, 63], ["Hepatitis B virus", "SPECIES", 67, 84], ["Hepatitis B virus", "SPECIES", 67, 84], ["this study", "TEST", 3, 13], ["surface antigen", "TEST", 48, 63], ["Hepatitis B virus", "PROBLEM", 67, 84], ["Hepatitis", "OBSERVATION", 67, 76]]], ["Peptide conjugates of synthetic anionic polyelectrolytes (copolymers of acrylic asid and N-vinylpyrrolidone) were synthesized by carbodiimide condensation following the modification procedures described early.", [["acrylic asid", "CHEMICAL", 72, 84], ["N-vinylpyrrolidone", "CHEMICAL", 89, 107], ["carbodiimide", "CHEMICAL", 129, 141], ["acrylic asid", "CHEMICAL", 72, 84], ["N-vinylpyrrolidone", "CHEMICAL", 89, 107], ["carbodiimide", "CHEMICAL", 129, 141], ["synthetic anionic polyelectrolytes", "SIMPLE_CHEMICAL", 22, 56], ["acrylic asid", "SIMPLE_CHEMICAL", 72, 84], ["N-vinylpyrrolidone", "SIMPLE_CHEMICAL", 89, 107], ["carbodiimide", "SIMPLE_CHEMICAL", 129, 141], ["synthetic anionic polyelectrolytes", "TREATMENT", 22, 56], ["copolymers of acrylic asid", "TREATMENT", 58, 84], ["N-vinylpyrrolidone", "TREATMENT", 89, 107], ["the modification procedures", "TREATMENT", 165, 192]]], ["Composition and structure of bioconjugates were characterized by HPLC (Shimadzu), NanoSPR-3, Zetasizer Nano ZS, Steady State Fluorescence Spectrometer QM-4 and Viscotek TDA 302 size exclusion chromatography.", [["HPLC", "TEST", 65, 69], ["NanoSPR", "TREATMENT", 82, 89], ["Zetasizer", "TREATMENT", 93, 102], ["Viscotek TDA", "TREATMENT", 160, 172]]], ["It was obtained that a single immunization of mice with PE-peptide conjugates without classical adjuvant increased the primary and secondary peptide-specific immune response to HBsAg.", [["PE-peptide", "CHEMICAL", 56, 66], ["HBsAg.", "CHEMICAL", 177, 183], ["mice", "ORGANISM", 46, 50], ["PE-peptide conjugates", "SIMPLE_CHEMICAL", 56, 77], ["HBs", "ORGANISM", 177, 180], ["HBs", "PROTEIN", 177, 180], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["a single immunization of mice", "TREATMENT", 21, 50], ["PE-peptide conjugates", "TREATMENT", 56, 77], ["classical adjuvant", "TREATMENT", 86, 104], ["secondary peptide", "PROBLEM", 131, 148], ["HBsAg.", "TEST", 177, 183], ["PE", "OBSERVATION", 56, 58]]], ["Moreover, these conjugates possess own selectivity for recognizing the antibody in blood sera of hepatitis virus injected people.", [["blood sera", "ANATOMY", 83, 93], ["hepatitis virus", "DISEASE", 97, 112], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["sera", "ORGANISM_SUBSTANCE", 89, 93], ["hepatitis virus", "ORGANISM", 97, 112], ["people", "ORGANISM", 122, 128], ["people", "SPECIES", 122, 128], ["hepatitis virus", "SPECIES", 97, 112], ["the antibody", "TEST", 67, 79], ["blood sera", "TEST", 83, 93], ["hepatitis virus", "PROBLEM", 97, 112]]], ["Tissue engineering requires delivery of transplanted cells to organ sites needing repair/regeneration.", [["Tissue", "ANATOMY", 0, 6], ["cells", "ANATOMY", 53, 58], ["organ sites", "ANATOMY", 62, 73], ["Tissue", "TISSUE", 0, 6], ["cells", "CELL", 53, 58], ["organ sites", "MULTI-TISSUE_STRUCTURE", 62, 73], ["transplanted cells", "CELL_TYPE", 40, 58], ["Tissue engineering", "TREATMENT", 0, 18], ["delivery of transplanted cells", "TREATMENT", 28, 58], ["organ sites", "TREATMENT", 62, 73], ["repair/regeneration", "TREATMENT", 82, 101], ["transplanted cells", "OBSERVATION", 40, 58], ["repair", "OBSERVATION", 82, 88], ["regeneration", "OBSERVATION_MODIFIER", 89, 101]]], ["We have demonstrated that several active laminin peptide-conjugated chitosan membranes enhanced the biological activity and promoted cell adhesion in a cell-type specific manner.", [["membranes", "ANATOMY", 77, 86], ["cell", "ANATOMY", 133, 137], ["cell", "ANATOMY", 152, 156], ["chitosan", "CHEMICAL", 68, 76], ["laminin", "GENE_OR_GENE_PRODUCT", 41, 48], ["cell", "CELL", 133, 137], ["cell", "CELL", 152, 156], ["several active laminin peptide", "TEST", 26, 56], ["conjugated chitosan membranes", "TREATMENT", 57, 86], ["promoted cell adhesion", "TREATMENT", 124, 146], ["several", "OBSERVATION_MODIFIER", 26, 33], ["active", "OBSERVATION_MODIFIER", 34, 40], ["laminin", "OBSERVATION_MODIFIER", 41, 48], ["chitosan membranes", "OBSERVATION", 68, 86], ["biological activity", "OBSERVATION_MODIFIER", 100, 119], ["promoted cell adhesion", "OBSERVATION", 124, 146]]], ["The most active laminin peptide (AG73: RKRLQVQLSIRT)-conjugated chitosan membrane could deliver keratinocytes to a wound bed.", [["membrane", "ANATOMY", 73, 81], ["keratinocytes", "ANATOMY", 96, 109], ["wound bed", "ANATOMY", 115, 124], ["chitosan", "CHEMICAL", 64, 72], ["laminin", "GENE_OR_GENE_PRODUCT", 16, 23], ["AG73", "SIMPLE_CHEMICAL", 33, 37], ["keratinocytes", "CELL", 96, 109], ["wound bed", "PATHOLOGICAL_FORMATION", 115, 124], ["keratinocytes", "CELL_TYPE", 96, 109], ["The most active laminin peptide", "TREATMENT", 0, 31], ["RKRLQVQLSIRT)-conjugated chitosan membrane", "TREATMENT", 39, 81], ["a wound bed", "TREATMENT", 113, 124], ["wound", "ANATOMY", 115, 120]]], ["When human keratinocytes were seeded onto the AG73-chitosan membranes under serum-free condition, more than 70% of the cells attached within 2 hrs.", [["keratinocytes", "ANATOMY", 11, 24], ["AG73-chitosan membranes", "ANATOMY", 46, 69], ["serum", "ANATOMY", 76, 81], ["cells", "ANATOMY", 119, 124], ["AG73-chitosan", "CHEMICAL", 46, 59], ["human", "ORGANISM", 5, 10], ["keratinocytes", "CELL", 11, 24], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["cells", "CELL", 119, 124], ["human keratinocytes", "CELL_TYPE", 5, 24], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["human keratinocytes", "PROBLEM", 5, 24], ["the AG73-chitosan membranes", "TREATMENT", 42, 69]]], ["The membranes carrying keratinocytes were stable enough for handling with forceps and were inverted onto the muscle fascia exposed on the trunk of nude mice.", [["membranes", "ANATOMY", 4, 13], ["keratinocytes", "ANATOMY", 23, 36], ["forceps", "ANATOMY", 74, 81], ["muscle fascia", "ANATOMY", 109, 122], ["trunk", "ANATOMY", 138, 143], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["keratinocytes", "CELL", 23, 36], ["muscle fascia", "TISSUE", 109, 122], ["trunk", "ORGANISM_SUBDIVISION", 138, 143], ["nude mice", "ORGANISM", 147, 156], ["keratinocytes", "CELL_TYPE", 23, 36], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 152, 156], ["forceps", "TREATMENT", 74, 81], ["stable", "OBSERVATION_MODIFIER", 42, 48], ["muscle fascia", "ANATOMY", 109, 122], ["trunk", "ANATOMY", 138, 143]]], ["Keratinocyte sheets were observed after 3 days and colonies appeared after 7 days on the fascia of host mice.", [["Keratinocyte sheets", "ANATOMY", 0, 19], ["colonies", "ANATOMY", 51, 59], ["fascia", "ANATOMY", 89, 95], ["Keratinocyte sheets", "CELL", 0, 19], ["fascia", "TISSUE", 89, 95], ["mice", "ORGANISM", 104, 108], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108], ["Keratinocyte sheets", "TREATMENT", 0, 19], ["fascia", "ANATOMY", 89, 95], ["host mice", "OBSERVATION", 99, 108]]], ["These cells were multilayered on day-3 and expressed various keratinocyte markers, including cytokeratin-1, involculin, and laminin ?2-chain.", [["cells", "ANATOMY", 6, 11], ["keratinocyte", "ANATOMY", 61, 73], ["cells", "CELL", 6, 11], ["keratinocyte", "CELL", 61, 73], ["cytokeratin-1", "GENE_OR_GENE_PRODUCT", 93, 106], ["involculin", "GENE_OR_GENE_PRODUCT", 108, 118], ["laminin", "GENE_OR_GENE_PRODUCT", 124, 131], ["keratinocyte markers", "PROTEIN", 61, 81], ["cytokeratin-1", "PROTEIN", 93, 106], ["involculin", "PROTEIN", 108, 118], ["laminin ?2-chain", "PROTEIN", 124, 140], ["These cells", "PROBLEM", 0, 11], ["various keratinocyte markers", "TEST", 53, 81], ["cytokeratin", "TEST", 93, 104], ["keratinocyte markers", "OBSERVATION", 61, 81]]], ["These results suggest that the AG73-conjugated chitosan membrane is useful as a therapeutic formulation and is applicable as a cell delivery system, such as delivering keratinocytes to the wound bed.", [["membrane", "ANATOMY", 56, 64], ["cell", "ANATOMY", 127, 131], ["keratinocytes", "ANATOMY", 168, 181], ["wound bed", "ANATOMY", 189, 198], ["AG73", "CHEMICAL", 31, 35], ["chitosan", "CHEMICAL", 47, 55], ["AG73", "CHEMICAL", 31, 35], ["AG73", "SIMPLE_CHEMICAL", 31, 35], ["chitosan", "SIMPLE_CHEMICAL", 47, 55], ["cell", "CELL", 127, 131], ["keratinocytes", "CELL", 168, 181], ["wound bed", "PATHOLOGICAL_FORMATION", 189, 198], ["AG73", "PROTEIN", 31, 35], ["keratinocytes", "CELL_TYPE", 168, 181], ["the AG73-conjugated chitosan membrane", "TREATMENT", 27, 64], ["a therapeutic formulation", "TREATMENT", 78, 103], ["a cell delivery system", "TREATMENT", 125, 147], ["keratinocytes to the wound bed", "TREATMENT", 168, 198], ["wound", "ANATOMY", 189, 194]]], ["The peptide-chitosan approach may be a powerful cell transplantation tool for various tissues and organs.", [["cell", "ANATOMY", 48, 52], ["tissues", "ANATOMY", 86, 93], ["organs", "ANATOMY", 98, 104], ["peptide-chitosan", "CHEMICAL", 4, 20], ["chitosan", "SIMPLE_CHEMICAL", 12, 20], ["cell", "CELL", 48, 52], ["tissues", "TISSUE", 86, 93], ["organs", "ORGAN", 98, 104], ["The peptide-chitosan approach", "TREATMENT", 0, 29], ["a powerful cell transplantation", "TREATMENT", 37, 68], ["powerful cell transplantation", "OBSERVATION", 39, 68], ["organs", "ANATOMY", 98, 104]]], ["The fluorescent semi-conductive (CdSe/ZnS) nanocristals possess very attractive optical properties that could be used for tracking individually biological receptors in vivo.", [["CdSe", "CHEMICAL", 33, 37], ["ZnS", "CHEMICAL", 38, 41], ["fluorescent semi-conductive (CdSe/ZnS) nanocristals", "CELL_LINE", 4, 55], ["The fluorescent semi-conductive (CdSe/ZnS) nanocristals", "TREATMENT", 0, 55]]], ["Our aim is to design functionalized water-soluble semi-conductive nanocristals (or quantum dots) that interact selectively with lipidic or biological membranes.", [["membranes", "ANATOMY", 150, 159], ["nanocristals", "SIMPLE_CHEMICAL", 66, 78], ["membranes", "CELLULAR_COMPONENT", 150, 159], ["design functionalized water-soluble semi-conductive nanocristals (or quantum dots", "TREATMENT", 14, 95], ["biological membranes", "OBSERVATION", 139, 159]]], ["To valid our approach, the interaction between the decorated QD and giant vesicles were observed by optical fluorescent and dark field microscopies.", [["giant vesicles", "ANATOMY", 68, 82], ["QD", "CHEMICAL", 61, 63], ["QD", "SIMPLE_CHEMICAL", 61, 63], ["giant vesicles", "PROBLEM", 68, 82], ["optical fluorescent", "TEST", 100, 119], ["dark field microscopies", "TEST", 124, 147], ["giant vesicles", "OBSERVATION", 68, 82]]], ["In view to solubilize and selectively bind fluorescent nanocristals to a lipid membrane, heterobifunctionalized peptidic ligands (LiIPe) that presented an adhesion domain for the nanocristal surface, an hydrophilic spacer and a terminal recognition function, were synthetized.", [["lipid membrane", "ANATOMY", 73, 87], ["nanocristal surface", "ANATOMY", 179, 198], ["LiIPe", "CHEMICAL", 130, 135], ["lipid membrane", "CELLULAR_COMPONENT", 73, 87], ["LiIPe", "SIMPLE_CHEMICAL", 130, 135], ["adhesion domain", "PROTEIN", 155, 170], ["a lipid membrane", "TREATMENT", 71, 87], ["heterobifunctionalized peptidic ligands", "PROBLEM", 89, 128], ["an adhesion domain", "PROBLEM", 152, 170], ["the nanocristal surface", "TREATMENT", 175, 198], ["an hydrophilic spacer", "TREATMENT", 200, 221], ["peptidic ligands", "OBSERVATION", 112, 128], ["adhesion", "OBSERVATION", 155, 163], ["hydrophilic spacer", "OBSERVATION", 203, 221], ["terminal", "OBSERVATION_MODIFIER", 228, 236]]], ["The collo\u00efdal stability of the water-soluble nanocristals (NC-LiPe) was checked by dynamic light scattering, optical and electron microscopies The interaction of grafted nanocristals (NC-LiPe) with positive or neutral giant vesicles was observed by optical fluorescence and dark field microscopies.", [["collo\u00efdal", "ANATOMY", 4, 13], ["giant vesicles", "ANATOMY", 218, 232], ["NC-LiPe", "CHEMICAL", 59, 66], ["NC-LiPe", "CHEMICAL", 184, 191], ["water", "SIMPLE_CHEMICAL", 31, 36], ["nanocristals", "SIMPLE_CHEMICAL", 45, 57], ["NC-LiPe", "SIMPLE_CHEMICAL", 59, 66], ["nanocristals", "SIMPLE_CHEMICAL", 170, 182], ["NC-LiPe", "SIMPLE_CHEMICAL", 184, 191], ["LiPe", "PROTEIN", 62, 66], ["LiPe", "PROTEIN", 187, 191], ["the water-soluble nanocristals", "TREATMENT", 27, 57], ["NC-LiPe", "TREATMENT", 59, 66], ["electron microscopies", "TEST", 121, 142], ["grafted nanocristals", "TREATMENT", 162, 182], ["positive or neutral giant vesicles", "PROBLEM", 198, 232], ["optical fluorescence", "TEST", 249, 269], ["dark field microscopies", "TEST", 274, 297], ["collo\u00efdal", "OBSERVATION_MODIFIER", 4, 13], ["stability", "OBSERVATION_MODIFIER", 14, 23], ["giant vesicles", "OBSERVATION", 218, 232]]], ["As shown in figure, negatively charged nanocristals (NC-LiPe) selectively adsorbed onto the surface of positively charged giant vesicles without altering the morphology of the vesicle.", [["surface", "ANATOMY", 92, 99], ["giant vesicles", "ANATOMY", 122, 136], ["vesicle", "ANATOMY", 176, 183], ["NC-LiPe", "CHEMICAL", 53, 60], ["nanocristals", "SIMPLE_CHEMICAL", 39, 51], ["NC-LiPe", "SIMPLE_CHEMICAL", 53, 60], ["surface", "CELLULAR_COMPONENT", 92, 99], ["giant vesicles", "CELLULAR_COMPONENT", 122, 136], ["vesicle", "CELLULAR_COMPONENT", 176, 183], ["LiPe", "PROTEIN", 56, 60], ["NC-LiPe)", "TREATMENT", 53, 61], ["giant vesicles", "OBSERVATION", 122, 136], ["vesicle", "ANATOMY", 176, 183]]], ["The nanocristals appeared as fluorescent patches growing on the surface of the vesicle until completely recovering.", [["nanocristals", "ANATOMY", 4, 16], ["surface", "ANATOMY", 64, 71], ["vesicle", "ANATOMY", 79, 86], ["nanocristals", "SIMPLE_CHEMICAL", 4, 16], ["surface", "CELLULAR_COMPONENT", 64, 71], ["vesicle", "CELLULAR_COMPONENT", 79, 86], ["fluorescent patches", "PROBLEM", 29, 48], ["fluorescent patches", "OBSERVATION", 29, 48], ["surface", "ANATOMY_MODIFIER", 64, 71], ["vesicle", "ANATOMY", 79, 86]]], ["Therefore these ligands (LiPe) permitted to chemically functionalize the nanocristals by keeping their collo\u00efdal stability and their fluorescence in water.", [["LiPe", "CHEMICAL", 25, 29], ["LiPe", "SIMPLE_CHEMICAL", 25, 29], ["nanocristals", "SIMPLE_CHEMICAL", 73, 85], ["water", "SIMPLE_CHEMICAL", 149, 154]]], ["Furthermore it was possible to selectively label vesicle membrane.", [["vesicle membrane", "ANATOMY", 49, 65], ["vesicle membrane", "CELLULAR_COMPONENT", 49, 65], ["vesicle membrane", "OBSERVATION", 49, 65]]]], "995ac7bbbf6d9548b3aeac502600ca99db919894": [["The global Internet can spread incorrect or incomplete information faster than the spread of the virus.", [["the virus", "PROBLEM", 93, 102]]], ["This results in a difficult tension between wanting to disseminate scientific information as quickly as possible while wanting it to be vetted (i.e., peer-reviewed) as well.IntroductionTo allow scientists, clinicians, and policy makers to avail themselves of the knowledge contained within this new information landscape, the White House requested that the Allen Institute for Artificial Intelligence and their collaborators aggregate a structured dataset of coronavirus research for the global research community [8] .", [["coronavirus", "DISEASE", 459, 470], ["coronavirus", "ORGANISM", 459, 470], ["coronavirus research", "TREATMENT", 459, 479]]], ["This COVID-19 Open Research Dataset, or CORD-19, contains scholarly articles about COVID-19 and the coronavirus family of viruses.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 83, 91], ["coronavirus", "ORGANISM", 100, 111], ["This COVID", "TEST", 0, 10], ["Open Research Dataset", "TEST", 14, 35], ["CORD", "TEST", 40, 44], ["COVID", "TEST", 83, 88], ["CORD", "ANATOMY", 40, 44], ["viruses", "OBSERVATION", 122, 129]]], ["The articles are drawn from peer-reviewed literature in PubMed Central 1 as well as from archival sites such as medRxiv 2 and bioRxiv.", [["bioRxiv", "DNA", 126, 133], ["medRxiv", "TREATMENT", 112, 119], ["bioRxiv", "TREATMENT", 126, 133], ["med", "ANATOMY", 112, 115]]], ["3 Importantly, CORD-19 is not a static document collection, but is regularly updated with new versions released once a week.", [["a static document collection", "PROBLEM", 30, 58], ["CORD", "ANATOMY", 15, 19], ["collection", "OBSERVATION", 48, 58]]], ["The different versions of CORD-19 capture the growth and change in the COVID-19 literature over time.IntroductionThe availability of CORD-19 provides the opportunity to create a test collection that captures the information needs of biomedical researchers using the scientific literature during a pandemic, and the TREC-COVID evaluation aims to do precisely that.", [["CORD-19", "DNA", 26, 33], ["CORD", "TEST", 26, 30], ["the growth", "PROBLEM", 42, 52], ["the COVID", "TEST", 67, 76], ["a test collection", "TEST", 176, 193], ["the TREC", "TEST", 311, 319], ["COVID evaluation", "TEST", 320, 336], ["CORD", "ANATOMY", 26, 30], ["growth", "OBSERVATION_MODIFIER", 46, 52], ["CORD", "ANATOMY", 133, 137]]], ["The twin goals of TREC-COVID are \u2022 to evaluate search algorithms and systems for helping scientists, clinicians, policy makers, and others manage the existing and rapidly growing corpus of scientific literature related to , andIntroduction\u2022 to discover methods that will assist with managing scientific information in future global biomedical crises.IntroductionBased on the TREC 4 framework, TREC-COVID is building a pandemic test collection through a series of rounds.", [["global biomedical crises", "PROBLEM", 325, 349], ["TREC", "TEST", 393, 397], ["a pandemic test collection", "PROBLEM", 416, 442]]], ["But as discussed in this article, TREC-COVID must also extend the evaluation procedures of these tracks to realize the goal of capturing the pandemic information environment.", [["the evaluation procedures", "TEST", 62, 87]]], ["These extensions include multi-round evaluation, mid-evaluation updates to the topic and document sets, and tight deadlines for both participation and assessment.IntroductionAs of this writing, the first round of TREC-COVID has just completed and the second round has begun.", [["multi-round evaluation", "TEST", 25, 47], ["assessment", "TEST", 151, 161], ["TREC-COVID", "TREATMENT", 213, 223]]], ["This paper provides a snapshot of TREC-COVID's process and results at this point in time.Structure of TREC-COVIDEach round of TREC-COVID is structured as an independent community evaluation challenge much like a typical TREC track.", [["TREC", "TEST", 102, 106], ["TREC", "TEST", 126, 130], ["an independent community evaluation challenge", "TEST", 154, 199]]], ["The systems' task is a classic ad hoc search task using CORD-19 as the document set and a set of biomedical questions as the topics (i.e., statements of information need).", [["CORD", "ANATOMY", 56, 60]]], ["The set of submitted runs are used to define a much smaller set of documents for human assessors to judge for relevance.", [["human", "ORGANISM", 81, 86], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["human assessors", "TEST", 81, 96]]], ["The documents, topics, and relevance judgments together form a test collection that can be used to evaluate the relative effectiveness of competing retrieval approaches.Structure of TREC-COVIDTREC-COVID differs from a typical TREC track in two important ways.", [["TREC-COVIDTREC", "PROTEIN", 182, 196], ["COVID", "DNA", 197, 202], ["a test collection", "TEST", 61, 78], ["competing retrieval approaches", "TREATMENT", 138, 168], ["a typical TREC track", "TREATMENT", 216, 236]]], ["The most obvious difference is the compressed time schedule.", [["most", "OBSERVATION_MODIFIER", 4, 8], ["obvious", "OBSERVATION_MODIFIER", 9, 16], ["difference", "OBSERVATION", 17, 27]]], ["Because we want to foster research on systems that are able to pivot quickly, deadlines are very short: roughly one week between when the test topics become available and the run submission deadline, followed by ten days for relevance assessing before the next round begins.Structure of TREC-COVIDThe second difference is that while each round is treated as an independent evaluation, the document and topic sets in each round are supersets of previous rounds' sets.", [["TREC-COVID", "PROTEIN", 287, 297], ["the test topics", "TEST", 134, 149], ["an independent evaluation", "TEST", 358, 383], ["second", "OBSERVATION_MODIFIER", 301, 307], ["difference", "OBSERVATION_MODIFIER", 308, 318]]], ["Relevance judgments from earlier rounds provide training data for later rounds (and also mean residual collection scoring must be done in later rounds as described below).", [["training data", "TEST", 48, 61], ["mean residual collection scoring", "PROBLEM", 89, 121]]], ["The cumulative document, topic, and relevance judgment sets will reflect the changes observed in real use of search systems during the current pandemic.Structure of TREC-COVIDThe remainder of this section describes the three components of the test collection in more detail.DocumentsTREC-COVID uses the document set provided by CORD-19 [8] .", [["TREC-COVID", "PROTEIN", 165, 175], ["DocumentsTREC", "DNA", 274, 287], ["COVID", "DNA", 288, 293], ["the changes", "PROBLEM", 73, 84], ["search systems", "TREATMENT", 109, 123], ["the test collection", "TEST", 239, 258], ["remainder", "OBSERVATION_MODIFIER", 179, 188], ["CORD", "ANATOMY", 328, 332]]], ["CORD-19 consists of new publications and preprints on the subject of COVID-19, as well as relevant historical research on coronaviruses, including SARS and MERS.", [["SARS", "DISEASE", 147, 151], ["coronaviruses", "ORGANISM", 122, 135], ["CORD", "TEST", 0, 4], ["new publications", "PROBLEM", 20, 36], ["COVID", "TEST", 69, 74], ["coronaviruses", "PROBLEM", 122, 135], ["SARS", "PROBLEM", 147, 151], ["new", "OBSERVATION_MODIFIER", 20, 23], ["publications", "OBSERVATION", 24, 36]]], ["The April 10, 2020 release of CORD-19, which is used for the first round of TREC-COVID, includes 51K papers, with full text available for 39K.", [["39K", "PROTEIN", 138, 141], ["CORD", "TEST", 30, 34], ["TREC", "TEST", 76, 80], ["CORD", "ANATOMY", 30, 34]]], ["As of May 1, 2020, CORD-19 consists of 60K papers, of which full text is available for 48K.", [["CORD-19", "DNA", 19, 26], ["48K", "PROTEIN", 87, 90], ["CORD", "TEST", 19, 23], ["CORD", "ANATOMY", 19, 23]]], ["Due to the ongoing nature of the pandemic, the CORD-19 corpus is constantly evolving and updated regularly (approximately weekly) as more new or historical research becomes available.", [["the pandemic", "PROBLEM", 29, 41], ["pandemic", "OBSERVATION", 33, 41], ["CORD", "ANATOMY", 47, 51]]], ["Content in CORD-19 is derived from multiple sources, and harmonization logic is applied to identify and remove duplicate entries.", [["CORD-19", "DNA", 11, 18], ["harmonization logic", "TREATMENT", 57, 76], ["CORD", "ANATOMY", 11, 15]]], ["Each resulting entry in CORD-19 is given a unique identifier, the CORD UID, which corresponds to the notion of a paper.", [["CORD-19", "DNA", 24, 31], ["CORD UID", "DNA", 66, 74], ["entry", "OBSERVATION_MODIFIER", 15, 20], ["CORD", "ANATOMY", 24, 28], ["CORD", "ANATOMY", 66, 70]]], ["In TREC-COVID, provisions are made during assessment to adapt to this notion of a paper, by showing all associated documents to assessors at the time of judgement.DocumentsResearchers have also made significant use of preprints during this epidemic to rapidly disseminate contributions.", [["TREC", "CELL_TYPE", 3, 7]]], ["Due to all versions inherently being part of the same paper, the identifiers for these preprints persist across CORD-19 corpus releases.", [["corpus", "ANATOMY", 120, 126], ["corpus", "MULTI-TISSUE_STRUCTURE", 120, 126], ["CORD", "ANATOMY", 112, 116]]], ["In cases where changes occur in the documents associated with the same paper (identified by UID) between CORD-19 corpus releases, prior judgments on the original documents may no longer hold.", [["CORD", "ANATOMY", 105, 109]]], ["Further challenges and proposed solutions are detailed in Section 4.TopicsThe topics used in TREC-COVID have been written by its organizers with biomedical training, inspired by consumer questions submitted to the National Library of Medicine, discussions by medical influencers on social media, and suggestions solicited on Twitter via the #COVIDSearch tag in late March 2020.", [["proposed solutions", "TREATMENT", 23, 41], ["biomedical training", "TREATMENT", 145, 164]]], ["They are representative of the high-level concerns related to the pandemic.", [["the pandemic", "PROBLEM", 62, 74], ["pandemic", "OBSERVATION", 66, 74]]], ["So far, the topics have not included detailed biological questions (e.g., RNA mutation rates, structure of a certain protein), though in future rounds more of these topics may be added.TopicsEach topic is composed of three fields:Topics1. query: a short keyword query 2. question: a more precise natural language question 3. narrative: a longer description that further elaborates on the question, often providing specific types of information that would fall under the topic scoreTopicsNote that while the question is a superset of the information in the query, the narrative is not intended to be a superset of the information in the question.", [["RNA mutation rates", "PROBLEM", 74, 92]]], ["For three examples of topics from Round 1, see Figure 1 .TopicsThere was considerable discussion amongst the organizers prior to Round 1-and some discussion with participants after Round 1-relating to the terminology used to refer to the virus/disease.", [["participants", "SPECIES", 162, 174], ["the virus/disease", "PROBLEM", 234, 251]]], ["Early real-world queries referred to the virus in informal terms (e.g., \"Wuhan virus\", \"Chinese flu\"), then evolved to more formal terms such as \"2019-nCoV \" and informally simply \"coronavirus\", and finally the official use of \"SARS-CoV-2 \" to refer to the virus and \"COVID-19 \" to refer to the condition it causes.", [["Wuhan virus", "SPECIES", 73, 84], ["Chinese flu", "SPECIES", 88, 99], ["SARS-CoV", "SPECIES", 228, 236]]], ["This is a fundamental linguistic problem in dealing with an emerging situation like a pandemic.", [["a fundamental linguistic problem", "PROBLEM", 8, 40], ["a pandemic", "PROBLEM", 84, 94], ["fundamental", "OBSERVATION_MODIFIER", 10, 21], ["linguistic", "OBSERVATION", 22, 32], ["pandemic", "OBSERVATION", 86, 94]]], ["A specific problem is that \"coronavirus\" refers to a class of viruses, not just SARS-CoV-2.", [["SARS", "DISEASE", 80, 84], ["SARS-CoV-2", "ORGANISM", 80, 90], ["SARS-CoV", "SPECIES", 80, 88], ["A specific problem", "PROBLEM", 0, 18], ["coronavirus", "PROBLEM", 28, 39], ["viruses", "OBSERVATION", 62, 69]]], ["However, the user intent of the information need is clear: the user is focused on COVID-19/SARS-CoV-2.", [["COVID", "TEST", 82, 87]]], ["A hybrid solution was taken to this problem in topic construction.", [["A hybrid solution", "TREATMENT", 0, 17]]], ["The query field often uses less formal terms, such as \"coronavirus\", while the narrative field is more likely to use a formal term such as \"COVID-19 \" or \"SARS-CoV-2 \".", [["SARS", "DISEASE", 155, 159]]], ["At least one of the unambiguous terms is guaranteed to be used in at least one of the fields for the topic, ensuring that-to a human, at least-it is clear that the topic is about the current pandemic.", [["human", "ORGANISM", 127, 132], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132]]], ["Of course, some information about prior coronaviruses is still useful in the current pandemic (which is why articles on these are included in .", [["prior coronaviruses", "PROBLEM", 34, 53]]], ["The extent to which this background information is useful depends on the topic, how much context is needed, and to some extent the user's expectation about what may be available about a novel virus.", [["a novel virus", "PROBLEM", 184, 197]]], ["Understanding user intent, then, is left as a challenge to the participant systems.TopicsIn future rounds, new topics will be added (5 per round are planned).", [["left", "ANATOMY_MODIFIER", 36, 40]]], ["These new topics will capture some of the trends that emerge as the crisis unfolds (especially new information after Round 1).", [["the crisis unfolds", "PROBLEM", 64, 82]]], ["More detailed, scientifically challenging topics will also be added to test the range of capabilities of systems. number:Topicsserological tests for coronavirus question:Topicsare there serological tests that detect antibodies to coronavirus? narrative: Looking for assays that measure immune response to COVID-19 that will help determine past infection and subsequent possible immunity.Topicsnumber: 20 query:Topicscoronavirus and ACE inhibitors question:Topicsare patients taking Angiotensin-converting enzyme inhibitors (ACE) at increased risk for COVID-19? narrative: Looking for information on interactions between coronavirus and angiotensin converting enzyme 2 (ACE2) receptors, risk for patients taking these medications, and recommendations for these patients.Topicsnumber: 29 query:Topicscoronavirus drug repurposing question:Topicswhich SARS-CoV-2 proteins-human proteins interactions indicate potential for drug targets.", [["coronavirus", "DISEASE", 230, 241], ["infection", "DISEASE", 344, 353], ["Angiotensin", "CHEMICAL", 482, 493], ["angiotensin", "CHEMICAL", 636, 647], ["COVID-19", "CHEMICAL", 305, 313], ["COVID-19", "CHEMICAL", 551, 559], ["coronavirus", "ORGANISM", 230, 241], ["ACE", "GENE_OR_GENE_PRODUCT", 432, 435], ["patients", "ORGANISM", 466, 474], ["Angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 482, 511], ["coronavirus", "ORGANISM", 620, 631], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 636, 667], ["ACE2", "GENE_OR_GENE_PRODUCT", 669, 673], ["patients", "ORGANISM", 695, 703], ["patients", "ORGANISM", 760, 768], ["CoV-2", "GENE_OR_GENE_PRODUCT", 853, 858], ["human", "ORGANISM", 868, 873], ["antibodies", "PROTEIN", 216, 226], ["coronavirus and angiotensin converting enzyme 2 (ACE2) receptors", "PROTEIN", 620, 684], ["Topicswhich SARS-CoV-2 proteins", "PROTEIN", 836, 867], ["human proteins", "PROTEIN", 868, 882], ["patients", "SPECIES", 466, 474], ["patients", "SPECIES", 695, 703], ["patients", "SPECIES", 760, 768], ["human", "SPECIES", 868, 873], ["human", "SPECIES", 868, 873], ["Topicsserological tests", "TEST", 121, 144], ["coronavirus", "PROBLEM", 149, 160], ["serological tests", "TEST", 186, 203], ["antibodies", "PROBLEM", 216, 226], ["coronavirus", "PROBLEM", 230, 241], ["assays", "TEST", 266, 272], ["COVID", "TEST", 305, 310], ["past infection", "PROBLEM", 339, 353], ["Topicscoronavirus", "TREATMENT", 410, 427], ["ACE inhibitors", "TREATMENT", 432, 446], ["Topicsare", "TREATMENT", 456, 465], ["Angiotensin", "TREATMENT", 482, 493], ["converting enzyme inhibitors", "TREATMENT", 494, 522], ["ACE", "TREATMENT", 524, 527], ["COVID", "TEST", 551, 556], ["coronavirus", "TREATMENT", 620, 631], ["angiotensin converting enzyme", "TREATMENT", 636, 665], ["these medications", "TREATMENT", 711, 728], ["Topicswhich SARS", "PROBLEM", 836, 852], ["CoV", "TEST", 853, 856], ["infection", "OBSERVATION", 344, 353]]], ["Are there approved drugs that can be repurposed based on this information? narrative: Seeking information about protein-protein interactions for any of the SARS-CoV-2 structural proteins that represent a promising therapeutic target, and the drug molecules that may inhibit the virus and the host cell receptors at entry step.", [["cell", "ANATOMY", 297, 301], ["host cell", "CELL", 292, 301], ["SARS-CoV-2 structural proteins", "PROTEIN", 156, 186], ["host cell receptors", "PROTEIN", 292, 311], ["drugs", "TREATMENT", 19, 24], ["protein-protein interactions", "TREATMENT", 112, 140], ["the SARS", "PROBLEM", 152, 160], ["2 structural proteins", "PROBLEM", 165, 186], ["the drug molecules", "PROBLEM", 238, 256], ["the virus", "PROBLEM", 274, 283], ["host cell", "OBSERVATION", 292, 301]]], ["Figure 1 : Example topics from the Round 1 test set.Relevance JudgmentsAs with the other TREC biomedical tasks, the annotators making relevance assessments for TREC-COVID are individuals with clinical expertise.", [["relevance assessments", "TEST", 134, 155], ["TREC", "TEST", 160, 164]]], ["To date, we have been able to enlist the help of ten Oregon Health and Science University medical students whose clinical activities were displaced due to Covid-19 restrictions, as well as additional relevance assessment help from professional indexers from the National Library of Medicine.", [["relevance assessment", "TEST", 200, 220]]], ["The assessment system shows the assessor the topic and a list of documents to be judged.", [["The assessment system", "TEST", 0, 21]]], ["The document list on the left side of the screen also indicates whether the document has been judged.Relevance JudgmentsAs mentioned earlier, the compressed schedule of TREC-COVID means that the amount of time available for performing relevance assessments is very short.", [["the screen", "TEST", 38, 48], ["relevance assessments", "TEST", 235, 256], ["left", "ANATOMY_MODIFIER", 25, 29]]], ["Assessments performed during the week that starts immediately after the run submission deadline of Round X runs are called X judgments.", [["Assessments", "TEST", 0, 11]]], ["Assessments performed in the following week when participants are constructing their Round X+1 submissions are called X.5 judgments.", [["participants", "SPECIES", 49, 61], ["Assessments", "TEST", 0, 11]]], ["Both judgment sets X and X.5 are derived from Round X runs and use the version of CORD-19 that runs in Round X searched.", [["X.5", "DNA", 25, 28], ["CORD-19", "DNA", 82, 89], ["Round X", "DNA", 103, 110], ["the version of CORD", "TREATMENT", 67, 86], ["CORD", "ANATOMY", 82, 86]]], ["However, the relevance judgments used to evaluate Round X runs, and which are publicly released before Round X+1 begins, consist of judgment sets X-.5 and X. The standard format of a relevance judgments file (the socalled qrels file) is topic-id iteration doc-id judgment where the iteration field is traditionally zero.", [["Round X runs", "TEST", 50, 62]]], ["TREC-COVID qrels files record the judgment round when the judgment was made in this field.", [["TREC-COVID qrels", "DNA", 0, 16]]], ["Because assessors were available before the first submission deadline, TREC-COVID organizers produced three runs based on the Anserini 5 system and used depth-40 pools across these three runs using the Round 1 release of CORD-19 (April 10) to create the 0.5 set.", [["TREC-COVID organizers", "DNA", 71, 92], ["TREC", "TEST", 71, 75], ["the Round 1 release of CORD", "TREATMENT", 198, 225], ["CORD", "ANATOMY", 221, 225]]], ["To obtain this number of assessments, a topic may be judged by more than one assessor.", [["assessments", "TEST", 25, 36]]], ["While full trec eval output as produced by the current round's qrels file is reported for each run 6 , Round 1 summaries therefore focused on three measures: Bpref, NDCG@10, and P@5.", [["NDCG@10", "CHEMICAL", 165, 172], ["NDCG@10", "SIMPLE_CHEMICAL", 165, 172], ["full trec eval output", "TEST", 6, 27]]], ["Bpref was designed for collections with incomplete judgments and is computed over only the judged set.", [["Bpref", "DNA", 0, 5], ["collections", "PROBLEM", 23, 34]]], ["P@5 and NDCG@10 are each affected by only the most highly ranked documents, which are the documents most likely to be judged.", [["NDCG@10", "CHEMICAL", 8, 15], ["P@5", "SIMPLE_CHEMICAL", 0, 3], ["NDCG@10", "SIMPLE_CHEMICAL", 8, 15], ["most likely", "UNCERTAINTY", 100, 111]]], ["The computation of NDCG uses gain values of 1 for 'Partially Relevant' documents and 2 for 'Relevant' documents.", [["NDCG", "DNA", 19, 23]]], ["Measures that use binary judgments are computed using both types of relevant documents as the relevant set.Relevance JudgmentsThe Round X qrels file is posted to the TREC-COVID web site at the time the Round X+1 test set is released.", [["Round X qrels", "DNA", 130, 143], ["TREC-COVID web site", "DNA", 166, 185], ["Round X+1 test set", "DNA", 202, 220], ["Round", "OBSERVATION_MODIFIER", 130, 135]]], ["Participants are free to use judgments from earlier rounds to construct runs for later rounds.", [["Participants", "SPECIES", 0, 12]]], ["To properly account for the use of relevance feedback when scoring runs, each round after the first will use residual collection evaluation [4] .", [["residual collection evaluation", "TEST", 109, 139]]], ["In residual collection evaluation, any document that has already been judged for a topic (in any round) is removed from the collection before scoring.", [["residual collection evaluation", "TEST", 3, 33], ["residual", "OBSERVATION_MODIFIER", 3, 11], ["collection", "OBSERVATION", 12, 22]]], ["This is implemented by removing all documents that were judged for a topic in an earlier round from all submitted runs.Relevance JudgmentsWhile residual collection evaluation is methodologically valid, it means that each round's runs can only be evaluated using a single round's qrels, not the cumulative set of judgments for a topic.", [["residual collection evaluation", "TEST", 144, 174], ["a single round's qrels", "TREATMENT", 262, 284], ["residual", "OBSERVATION_MODIFIER", 144, 152], ["collection", "OBSERVATION", 153, 163]]], ["Thus each round will most likely continue to be affected by incomplete judgments issues.", [["incomplete judgments issues", "PROBLEM", 60, 87]]], ["Further, residual collection evaluation will make effectiveness scores appear to degrade from round to round since the set of relevant documents in the collection is reduced in each round.", [["residual collection evaluation", "TEST", 9, 39], ["effectiveness scores", "PROBLEM", 50, 70], ["residual", "OBSERVATION_MODIFIER", 9, 17], ["collection", "OBSERVATION", 18, 28], ["collection", "OBSERVATION", 152, 162], ["reduced", "OBSERVATION_MODIFIER", 166, 173], ["round", "OBSERVATION_MODIFIER", 182, 187]]], ["The final pandemic test collection that is the end product of TREC-COVID will contain the cumulative judgments from all rounds and can therefore be expected to be much more stable than the individual-round collections.", [["The final pandemic test collection", "TEST", 0, 34], ["final", "OBSERVATION_MODIFIER", 4, 9], ["pandemic", "OBSERVATION", 10, 18], ["stable", "OBSERVATION_MODIFIER", 173, 179], ["round", "OBSERVATION_MODIFIER", 200, 205], ["collections", "OBSERVATION", 206, 217]]], ["Figure 3 : Illustration of the process to create the Round X qrels.", [["Round", "OBSERVATION_MODIFIER", 53, 58]]], ["The Round X qrels file is the union of the set of judgments made the week following the Round X submission deadline and the set of judgments made in the preceding week.", [["Round X qrels", "DNA", 4, 17], ["Round", "OBSERVATION_MODIFIER", 4, 9]]], ["One hundred of the runs are automatic runs (a run in which the system is given the topic file and produces ranked output with no human involvement at all) and the remaining 43 runs are manual runs (everything else).Round 1 ResultsThe number and diversity of the submitted runs meant that staying within the judgment budget of 200 average documents per topic was challenging.", [["human", "ORGANISM", 129, 134], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["automatic runs", "PROBLEM", 28, 42], ["human involvement", "PROBLEM", 129, 146], ["number", "OBSERVATION_MODIFIER", 234, 240], ["diversity", "OBSERVATION_MODIFIER", 245, 254]]], ["Anticipating the possibility that we would not be able to judge all runs, participants were asked to assign a judging priority (1) (2) (3) to their runs at submission time.", [["participants", "SPECIES", 74, 86]]], ["Depth-7 pools 7 created from only the first priority run from each team amounted to almost 7000 documents to be judged across the 30 topics.", [["Depth", "TEST", 0, 5]]], ["Subtracting the 0.5 judgments from that set left a total of just over 6000 documents.", [["left", "ANATOMY_MODIFIER", 44, 48]]], ["The union of judgment sets 0.5 and 1.0, which constitute the Round 1 qrels, contains 8,691 judgments, a mean of 289.7 judgments per topic with a range between 180-373 per topic (see Table 1 ).Round 1 ResultsThe maximum size of depth-7 pools across 56 runs (one run per team) is 11,760 (56 \u00d7 30 \u00d7 7).", [["judgment sets", "TEST", 13, 26], ["depth", "TEST", 227, 232], ["maximum", "OBSERVATION_MODIFIER", 211, 218], ["size", "OBSERVATION_MODIFIER", 219, 223], ["depth", "OBSERVATION_MODIFIER", 227, 232]]], ["The 7000 size obtained in Round 1 pooling is greater than half of that maximum, which is a high percentage compared to typical TREC collections.", [["a high percentage", "PROBLEM", 89, 106], ["typical TREC collections", "PROBLEM", 119, 143], ["size", "OBSERVATION_MODIFIER", 9, 13], ["Round", "OBSERVATION_MODIFIER", 26, 31], ["greater", "OBSERVATION_MODIFIER", 45, 52], ["maximum", "OBSERVATION_MODIFIER", 71, 78], ["high percentage", "OBSERVATION_MODIFIER", 91, 106], ["TREC collections", "OBSERVATION", 127, 143]]], ["Figure 4 shows a box-and-whiskers plot of the number of judged documents in the top 50 ranks per topic for all submitted runs.", [["a box", "TEST", 15, 20]]], ["The runs are plotted on the x-axis and are ordered by decreasing median number of documents judged (the heavy black line).", [["heavy", "OBSERVATION_MODIFIER", 104, 109], ["black line", "OBSERVATION", 110, 120]]], ["The variance across topics is large for most runs, and there is a set of runs to the far right in the graph that retrieved practically no documents in common with other runs' top documents down to depth 50.", [["large", "OBSERVATION_MODIFIER", 30, 35], ["right", "ANATOMY_MODIFIER", 89, 94]]], ["Historically, runs with extremely low overlap with other runs tend to be runs created with errors where the assumption that unjudged documents are not relevant holds.", [["extremely low overlap", "PROBLEM", 24, 45]]], ["We cannot know this to be true for the runs on the far right of the graph without more judgments, however.", [["right", "ANATOMY_MODIFIER", 55, 60]]], ["Table 1 shows relevance counts for each topic.", [["relevance counts", "TEST", 14, 30]]], ["The total number relevant per topic ranges from 26-202.", [["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The percentage of judged that are relevant is of interest as an indicator of the stability (or reusability) of the collection.", [["percentage", "OBSERVATION_MODIFIER", 4, 14], ["collection", "OBSERVATION", 115, 125]]], ["Historically, when more than a third of the judged documents are relevant for a topic, it is highly likely that many more relevant documents that have not yet been identified remain in the collection [6] .", [["highly likely", "UNCERTAINTY", 93, 106]]], ["Having fewer than one third relevant is not a guarantee that the collection is stable, but more than a third is strong evidence that it is not.", [["collection", "OBSERVATION", 65, 75], ["stable", "OBSERVATION_MODIFIER", 79, 85]]], ["For the Round 1 qrels, more than a quarter of the topics (8/30) have relevant percentages greater than 0.33.", [["Round", "OBSERVATION_MODIFIER", 8, 13], ["percentages", "OBSERVATION_MODIFIER", 78, 89], ["greater", "OBSERVATION_MODIFIER", 90, 97]]], ["Figure 5 provides a view of how effective the participants' systems were as a group.", [["participants", "SPECIES", 46, 58]]], ["The figure contains a box-and-whiskers plot of the NDCG@10 scores across all 143 submitted runs for each topic.", [["a box", "TEST", 20, 25]]], ["The median NDCG@10 score for the topic is plotted as the black bar inside the box; the top and bottom of the box represent the third and first quartiles of the scores,respectively; the whiskers extend out another 1.5 times the interquartile range; and outliers are plotted as points.", [["top", "OBSERVATION_MODIFIER", 87, 90], ["bottom", "ANATOMY_MODIFIER", 95, 101]]], ["Eight topics have maximum NDCG@10 scores of 1.0, meaning at least one system retrieved ten fully relevant documents in the top 10 ranks.", [["maximum NDCG@10 scores", "TEST", 18, 40]]], ["Nonetheless, the spread of scores across runs is good for each topic suggesting that the test collection is not too easy and that it will be able to discriminate between systems.ChallengesThe rapid organization of TREC-COVID and the shifting nature of knowledge of the underlying COVID-19 disease create challenges for organizing a TREC-style evaluation.", [["the test collection", "TEST", 85, 104], ["TREC", "TEST", 214, 218], ["the underlying COVID-19 disease", "PROBLEM", 265, 296], ["a TREC", "TEST", 330, 336], ["style evaluation", "TEST", 337, 353], ["spread", "OBSERVATION_MODIFIER", 17, 23], ["rapid", "OBSERVATION_MODIFIER", 192, 197]]], ["In this section we list some of the limitations and cautions for using the TREC-COVID test collection.ChallengesThe short time available for relevance judgments has had two main effects.", [["the TREC-COVID test collection", "TEST", 71, 101]]], ["First, it puts a hard limit on the number of judgments that can be obtained, which when coupled with many participants results in quite shallow judgment pools.", [["participants", "SPECIES", 106, 118]]], ["Shallow pools in turn lead to incomplete judgment sets and relatively large uncertainty in systems' evaluation scores.", [["Shallow pools", "PROBLEM", 0, 13], ["incomplete judgment sets", "PROBLEM", 30, 54], ["evaluation scores", "TEST", 100, 117], ["large", "OBSERVATION_MODIFIER", 70, 75], ["uncertainty", "OBSERVATION", 76, 87]]], ["The measures for which the uncertainty is small, such as P@5, are not necessarily the best measures to understand the target user task.", [["small", "OBSERVATION_MODIFIER", 42, 47]]], ["This can damage the internal consistency of the judgments for a topic, since different assessors are likely to have different notions of relevance.ChallengesCapturing the dynamic nature of COVID-19 literature is a primary goal of TREC-COVID, and using a dynamic collection as the basis for a retrieval test collection presents its own challenges.", [["COVID", "TEST", 189, 194], ["a dynamic collection", "TREATMENT", 252, 272], ["a retrieval test collection", "TEST", 290, 317], ["internal", "OBSERVATION_MODIFIER", 20, 28], ["consistency", "OBSERVATION_MODIFIER", 29, 40]]], ["For example, of the 51K papers in the April 10 release of CORD-19 used in Round 1, 1041 papers had some change in the title, abstract, or full text by the May 1 release.", [["CORD-19", "DNA", 58, 65], ["CORD", "TEST", 58, 62], ["CORD", "ANATOMY", 58, 62], ["change", "OBSERVATION_MODIFIER", 104, 110]]], ["The vast majority of these changes were minor such as simple text edits.", [["vast", "OBSERVATION_MODIFIER", 4, 8], ["majority", "OBSERVATION_MODIFIER", 9, 17]]], ["The relevance judgments in the final test collection will therefore not be a single judgment per document per topic as is the norm, but rather a series of judgments where each entry in the series is tied to a particular CORD-19 release through the round number.ChallengesAn assessor's notion of what it means to be relevant may also change as the science around COVID-19 evolves.", [["COVID-19", "CHEMICAL", 362, 370], ["COVID", "TEST", 362, 367], ["CORD", "ANATOMY", 220, 224], ["round", "OBSERVATION_MODIFIER", 248, 253], ["number", "OBSERVATION_MODIFIER", 254, 260]]], ["The very public nature of the disease means that the assessment process cannot happen in a vacuum: assessors are aware of many of the latest medical developments, and that may alter their perception of relevance.", [["the disease", "PROBLEM", 26, 37], ["the assessment", "TEST", 49, 63], ["very", "OBSERVATION_MODIFIER", 4, 8], ["public", "OBSERVATION_MODIFIER", 9, 15], ["disease", "OBSERVATION", 30, 37]]], ["This sort of re-assessment of prior judgments is not done.", [["prior judgments", "TEST", 30, 45]]], ["The judgments need to be viewed as occurring in the time frame of its associated the CORD-19 release.FutureAt the time of writing, TREC-COVID is entering Round 2 with five new topics, an updated document collection and the original set of judges.", [["CORD", "ANATOMY", 85, 89]]], ["The immediate plans include three more evaluation rounds, which will bring us to Round 5 in July.", [["three more evaluation rounds", "TEST", 28, 56]]], ["By that time, we anticipate to better understand the trends in the growth of the document collection, retrieval of residual relevant documents, stability of the systems' ranking, and the interest of research community in continuing the evaluation.", [["continuing the evaluation", "TEST", 221, 246]]], ["These factors will inform the organizers if additional rounds will be needed to build a permanent COVID-19 pandemic collection and resolve any remaining pandemic response system-building and evaluation questions.", [["a permanent COVID-19 pandemic collection", "PROBLEM", 86, 126], ["evaluation", "TEST", 191, 201]]], ["The completion of the last round and the analysis of the results will accomplish the first goal of TREC-COVID -an evaluation of the systems and approaches that directly address information needs brought about by the COVID-19 pandemic.FutureThe final collection built over the entire set of the evaluation rounds will support the second goal of TREC-COVID: to discover approaches to managing scientific information and satisfy information needs of scientists during global outbreaks and similar health threats.", [["TREC", "TEST", 99, 103], ["an evaluation", "TEST", 111, 124], ["the evaluation", "TEST", 290, 304], ["final", "OBSERVATION_MODIFIER", 244, 249], ["collection", "OBSERVATION", 250, 260]]], ["The final collection will consist of the clearly marked versions of the data, topics and relevance judgments corresponding to each evaluation round.", [["each evaluation", "TEST", 126, 141], ["final", "OBSERVATION_MODIFIER", 4, 9], ["collection", "OBSERVATION", 10, 20]]], ["The cumulative relevance judgments in combination with the final document collection will allow researchers to develop approaches in a traditional post hoc use of TREC collections, probably with some caveats mentioned in section 4.", [["The cumulative relevance judgments", "TREATMENT", 0, 34], ["TREC collections", "PROBLEM", 163, 179], ["collections", "OBSERVATION", 168, 179]]], ["Whereas using the versions of the rounds as they evolve, the researchers can study approaches to addressing information needs as they evolve during pandemics.", [["pandemics", "PROBLEM", 148, 157]]]], "227c2c7faa410dfa6c8f92f15e89c8057766c76f": [["Initial Crime DataSeveral researchers have made initial examinations into how crime rates have fluctuated in the advent of COVID-19.", [["initial examinations", "TEST", 48, 68], ["crime rates", "TEST", 78, 89], ["COVID", "TEST", 123, 128], ["fluctuated", "OBSERVATION_MODIFIER", 95, 105]]], ["The results have been mixed, to say the least, especially when comparing broad categories of crime across different cities and with different methods and periods of study.", [["study", "TEST", 165, 170]]], ["However, these initial academic studies are intrinsically valuable and deserve to be mentioned here.Initial Crime DataOne of the earliest studies with perhaps the most striking results was by Shayegh and Malpede (2020) , which identified an overall drop in crime in San Francisco of 43% and Oakland of about 50% following city issuance of some of the most restrictive and early stay-at-home orders in the US, beginning March 16th , 2020 and the two weeks after.Initial Crime DataSurprisingly, significant results are also clearly seen when examining specific crimes against retailers in crime in Los Angeles.", [["these initial academic studies", "TEST", 9, 39], ["the earliest studies", "TEST", 125, 145], ["overall", "OBSERVATION_MODIFIER", 241, 248], ["drop", "OBSERVATION_MODIFIER", 249, 253]]], ["Pietrawska, Aurand, and Palmer (2020a) found a 64% increase in retail burglary, while city-wide burglary rates were down 10%.", [["wide burglary rates", "TEST", 91, 110], ["increase", "OBSERVATION_MODIFIER", 51, 59]]], ["Continuing their study of crime rates in the pandemic outside of a retail focus, Pietrawska, Aurand, and Palmer (2020c) compared crimes against persons and crimes against property in four cities for ten weeks, finding sharp variations from week to week and within different crime types.Initial Crime DataAnother early study by Ashby (2020a) of eight large US cities during the first few weeks of the crisis (January to March 23rd-before some states and areas implemented stay-at-home orders) found disparate impacts by crime type and location.", [["persons", "ORGANISM", 144, 151], ["persons", "SPECIES", 144, 151], ["their study", "TEST", 11, 22], ["crime rates", "TEST", 26, 37], ["sharp variations", "PROBLEM", 218, 234], ["the crisis", "PROBLEM", 396, 406], ["large", "OBSERVATION_MODIFIER", 350, 355]]], ["Conversely, serious assaults in public declined in Austin, Los Angeles, and Louisville, but not other cities.", [["serious", "OBSERVATION_MODIFIER", 12, 19], ["assaults", "OBSERVATION", 20, 28]]], ["Their findings indicated an overall 32% decline in burglary, with the most substantial change in the third period.", [["an overall 32% decline in burglary", "PROBLEM", 25, 59], ["overall", "OBSERVATION_MODIFIER", 28, 35], ["32%", "OBSERVATION_MODIFIER", 36, 39], ["decline", "OBSERVATION_MODIFIER", 40, 47], ["substantial", "OBSERVATION_MODIFIER", 75, 86], ["change", "OBSERVATION", 87, 93]]], ["However, the decline was more significant in block groups of higher residential parcels than in mix-use land areas.", [["the decline", "PROBLEM", 9, 20], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["higher", "OBSERVATION_MODIFIER", 61, 67]]], ["Campedelli et al. (2020) analyzed crime in Los Angeles in two time periods (the first ending March 16th and the second ending March 28th) using Bayesian structural timeseries models to estimate what crime would have been if the COVID-19 pandemic had not occurred.", [["the COVID", "TEST", 224, 233], ["pandemic", "PROBLEM", 237, 245]]], ["Comparing the actual crime data against the estimated 'sans-pandemic' data, the first model found an overall crime reduction of 5.6% during the pandemic.", [["overall", "OBSERVATION_MODIFIER", 101, 108], ["crime", "OBSERVATION_MODIFIER", 109, 114], ["reduction", "OBSERVATION_MODIFIER", 115, 124]]], ["Likewise, the second model (ending March 28th) showed a 15% reduction.", [["a 15% reduction", "TREATMENT", 54, 69]]], ["Specifically, researchers found that overall crime rates significantly decreased, particularly when referencing robbery (\u221224%), shoplifting (\u221214%), theft (\u221221%), and battery (\u221211%).", [["overall crime rates", "TEST", 37, 56], ["overall", "OBSERVATION_MODIFIER", 37, 44], ["crime", "OBSERVATION", 45, 50], ["significantly", "OBSERVATION_MODIFIER", 57, 70], ["decreased", "OBSERVATION_MODIFIER", 71, 80]]], ["However, burglary, domestic violence, stolen vehicles, and homicide remained statically unchanged.Initial Crime DataWhile not explicitly measuring crime rates, studies of calls for police service can function as an indirect measure of crime in a given area.", [["homicide", "DISEASE", 59, 67], ["domestic violence", "OBSERVATION", 19, 36], ["statically", "OBSERVATION_MODIFIER", 77, 87], ["unchanged", "OBSERVATION_MODIFIER", 88, 97]]], ["Lum, Maupin, and Stoltz (2020) found that 57% of 1000 agencies surveyed in the United States and Canada reported a reduction in calls for service in March of 2020.", [["Maupin", "TREATMENT", 5, 11]]], ["Ashby (2020b) , on the other hand, found no discernible difference in forecasted calls for service in 10 large US cities between the first identified cases of COVID-19 in the US throughout early March.", [["COVID", "TEST", 159, 164], ["no", "UNCERTAINTY", 41, 43]]], ["Specifically, the researchers found residential burglary fell by 23%, commercial burglary declined 12.7%, and instances of pick-pocketing were reduced by a staggering 61% -however, there was little change in robberies or narcotics crime.", [["commercial burglary", "TEST", 70, 89], ["pick-pocketing", "PROBLEM", 123, 137], ["little change in robberies", "PROBLEM", 191, 217], ["little", "OBSERVATION_MODIFIER", 191, 197], ["change", "OBSERVATION_MODIFIER", 198, 204]]], ["In Australia, Payne and Morgan (2020) studied crime in March, finding assaults, sexual violations, and domestic violence were not significantly different from what was predicted under 'normal' conditions at the lower end of the confidence interval.", [["sexual violations, and domestic violence", "DISEASE", 80, 120], ["significantly different", "OBSERVATION_MODIFIER", 130, 153]]], ["They cautioned against early conclusions based on this data as the government orders came only a few weeks into the study.Initial Crime DataThese initial reports indicate that crime rates have indeed changed, but unequally across different categories, types, places, and timeframes.", [["this data", "TEST", 50, 59], ["the study", "TEST", 112, 121], ["crime rates", "TEST", 176, 187]]], ["The data and opportunities before every criminologist will provide near-endless research opportunities at levels never before possible, and every effort should be made to capture data and promote the study of crime.", [["the study", "TEST", 196, 205]]], ["As people around the world returned from frantic and stress-filled trips to stock up on food and other essentials and closed the door to their residence behind them, their biological and physiological conditions changed very little, nor did the labels attributed to them by society, friends, or family.", [["people", "ORGANISM", 3, 9], ["people", "SPECIES", 3, 9]]], ["It is unlikely that self-control dramatically increased either.", [["unlikely", "UNCERTAINTY", 6, 14], ["dramatically", "OBSERVATION_MODIFIER", 33, 45], ["increased", "OBSERVATION_MODIFIER", 46, 55]]], ["There were, however, things that did change; society became more disorganized, and social influences and relationships were suddenly cut, diminished, or otherwise altered.", [["more disorganized", "PROBLEM", 60, 77], ["disorganized", "OBSERVATION_MODIFIER", 65, 77], ["diminished", "OBSERVATION_MODIFIER", 138, 148]]], ["Strain, stress, and anomie likely increased significantly as many became fearful for the future (both financially and physically) and estranged from family and friends whom they could not visit physically.", [["Strain", "PROBLEM", 0, 6], ["stress", "PROBLEM", 8, 14], ["anomie", "PROBLEM", 20, 26], ["increased", "OBSERVATION_MODIFIER", 34, 43]]], ["Further, punitive responses to crime (i.e., deterrence) were slowed or ceased altogether as courts closed, police were encouraged to reduce contact with the public, and thousands of prisoners were released early.Crime in Lock-Down: Theoretical ImplicationsWith crime declining at such a significant pace and many of the often-attributed circumstances impacting crime staying consistent or in some cases increasing or decreasing in a direction opposite of what many believe drives crime, many criminological theories appear to be struggling to explain the abrupt and sweeping change.", [["the abrupt and sweeping change", "PROBLEM", 551, 581], ["decreasing", "OBSERVATION_MODIFIER", 417, 427], ["abrupt", "OBSERVATION_MODIFIER", 555, 561], ["sweeping", "OBSERVATION", 566, 574]]], ["We believe the scope and nature of crime changes during the COVID-19 crisis will become a proving ground for the many theories that attempt to explain the etiology of criminal behavior.", [["the scope", "TEST", 11, 20], ["crime changes", "PROBLEM", 35, 48], ["the COVID", "TEST", 56, 65], ["criminal behavior", "PROBLEM", 167, 184], ["criminal", "OBSERVATION", 167, 175]]], ["In the end, this naturally occurring experiment will advance our knowledge of crime and human behavior as no other event has ever done during the era in which criminological data were widely available.Crime in Lock-Down: Theoretical ImplicationsAs such, we argue that the single most salient aspect of the steep fall in crime rates during the COVID-19 pandemic are the legal stay-at-home orders (i.e., lock-down, shelter-in-place) implemented to slow the spread of the virus by promoting social distancing.", [["human", "ORGANISM", 88, 93], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["the steep fall", "PROBLEM", 302, 316]]], ["Commonly, these activities included seeking health care, purchasing food and other necessary supplies, banking, and similar activities.", [["banking", "TREATMENT", 103, 110]]], ["In short, these orders disrupted the daily activities of entire populations and was the only variable that changed abruptly, just days before double-digit drops in crime around the world.", [["double-digit drops", "TREATMENT", 142, 160], ["short", "OBSERVATION_MODIFIER", 3, 8]]], ["Specifically, we advocate for researchers to consider crime in the context of temporal shifts, in a place-based context, to use emerging data sources, and to study crime with specificity.Crime SpecificityCriminologists tend to overgeneralize about crime while underestimating the enormous specificity in offender decision making (LeClerc, & Wortley, R. (Eds.)., 2013).", [["temporal shifts", "PROBLEM", 78, 93]]], ["For example, the changes in daily activities in the wake of the pandemic tend to decrease the population in nonresidential parts of the metropolis, while increasing the population in residential zones.Crime SpecificityFor example, the broad category of 'theft' appears to be down across many cities in the US (Ashby, 2020a) .", [["the changes in daily activities", "PROBLEM", 13, 44], ["population", "OBSERVATION_MODIFIER", 94, 104], ["population", "OBSERVATION_MODIFIER", 169, 179], ["zones", "ANATOMY_MODIFIER", 195, 200], ["broad", "OBSERVATION_MODIFIER", 235, 240]]], ["However, theft is likely not declining evenly across all categories.", [["likely not", "UNCERTAINTY", 18, 28]]], ["The retail sector has experienced an 85% decline in foot traffic after the stay-at-home orders were implemented (Jahshan, 2020); many stores are closed, and thus the opportunity for shoplifting and employee theft are curtailed.", [["an 85% decline in foot traffic", "PROBLEM", 34, 64], ["foot", "ANATOMY", 52, 56]]], ["Pietrawska et al. (2020a) , for example, identified a 24% decline in shoplifting in Los Angeles, compared to a city-wide decline of theft at only 5%.", [["shoplifting", "DISEASE", 69, 80], ["a 24% decline", "PROBLEM", 52, 65]]], ["These thefts may be the result of a change in offender behavior (i.e., shifting from targeting a specific store-now closed, to another that is open), due to panic buying (i.e., purchasing limits on essential products may result in theft), or impacted by reduced guardianship within the stores (e.g., short-staffed employees are more focused on service than crime prevention).Crime SpecificityOne of the most exciting illustrations of crime specificity has to do with pocketpicking the covert removal of a wallet from a pocket or purse in a crowded venue.", [["panic", "DISEASE", 157, 162], ["wallet", "ORGANISM_SUBDIVISION", 505, 511], ["a change in offender behavior", "PROBLEM", 34, 63], ["panic buying", "PROBLEM", 157, 169], ["the covert removal", "TREATMENT", 481, 499], ["a pocket", "PROBLEM", 517, 525], ["change", "OBSERVATION_MODIFIER", 36, 42]]], ["As noted earlier, Swedish researchers (Gerell et al., 2020) found that pocket-picking decreased by 61% in Stockholm during the COVID-affected period when crowd-reduction was especially emphasized.", [["crowd-reduction", "TREATMENT", 154, 169], ["pocket", "OBSERVATION_MODIFIER", 71, 77]]], ["These findings underscore the importance of linking specific changes in routines to specific types of crime.Crime SpecificityTheft may also be moving outside of the physical retail structure and developing in areas where officially reported came data is not readily available.", [["may also be", "UNCERTAINTY", 131, 142]]], ["For example, before COVID-19 package theft (e.g., packages delivered outside a residence and stolen before the owner can retrieve them) was a growing concern, and few, if any, police agencies kept data on the problem (Stickle, Hicks, Stickle, & Hutchinson, 2020) .", [["COVID", "TEST", 20, 25]]], ["While more person may be home, daily routine activities have also been interrupted, which impact guardianship.", [["person", "SPECIES", 11, 17]]], ["As a result, packages left unattended for extended periods or forgotten altogether (Stickle, 2020b) .Crime SpecificityThese are just a few examples of why examining specific crime types and situations is vital to criminology.", [["left", "ANATOMY_MODIFIER", 22, 26]]], ["There are, no doubt, many factors that are impacting pandemic crime rates, and only by examining them with specificity can researchers achieve an enhanced understanding of crime.Temporal ShiftTemporal understanding of crime is essential because the time of day, day of the week, months, seasons, and other time-related factors are commonly known to impact crime; in other words, crime is not evenly distributed across place or time (Brantingham & Brantingham, 1995) .", [["no doubt", "UNCERTAINTY", 11, 19]]], ["However, stay-at-home orders that have people living, working, eating, and finding entertainment at home as weekdays merge into weekends may cause time distinctions to blur when speaking of crime.", [["people", "ORGANISM", 39, 45], ["people", "SPECIES", 39, 45]]], ["The change in the population's routine behavior, even at home, is already being seen in online browsing habits and television use; behavior has shifted to higher viewing rates on Mondays than on the traditional Saturday (Comcast, 2020) .", [["The change", "PROBLEM", 0, 10], ["change", "OBSERVATION_MODIFIER", 4, 10]]], ["However, there must be more specificity than a pre and post examination of crime trends, and measurements at the state and even community level are needed to ensure accuracy.Temporal ShiftWe propose the following seven important periods for identification and comparison of crime rate changes related to the crisis (Table 1) .Temporal ShiftThese measures must be tailored to individual communities or states to coincide with routine activity trends and government orders.", [["a pre and post examination", "TEST", 45, 71], ["crime trends", "TEST", 75, 87], ["accuracy", "TEST", 165, 173], ["crime rate changes", "PROBLEM", 274, 292], ["the crisis", "PROBLEM", 304, 314], ["Temporal Shift", "PROBLEM", 326, 340]]], ["Period 1 should be of sufficient time to establish some base levels of crime rates.", [["crime rates", "TEST", 71, 82]]], ["Period 2 is where the beginning of voluntary behavior changes is likely to be observable, somewhere around mid-February, and extending until the government ordered quarantines for the general population.", [["voluntary behavior changes", "PROBLEM", 35, 61], ["likely to be", "UNCERTAINTY", 65, 77]]], ["During this time, as concern swept across the nation, many people chose to alter their lifestyles; schools closed, and other modifications in society likely began to impact crime slowly.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65]]], ["Dividing the length of stay-at-home orders by half (or more if the order is longer than six weeks) will capture the changes in routine activity as the stay-at-home orders continue.", [["length", "OBSERVATION_MODIFIER", 13, 19]]], ["Capturing this data in two or more periods is crucial as the longer the order continues, the more likely people will begin to violate the order, and crime rates may begin to change.", [["people", "ORGANISM", 105, 111], ["people", "SPECIES", 105, 111]]], ["For example, early reports in Sweden saw a slight decline in vandalism (\u22124%), followed by a sharp increase after five weeks into the restrictions.", [["vandalism", "DISEASE", 61, 70], ["a slight decline in vandalism", "PROBLEM", 41, 70], ["slight", "OBSERVATION_MODIFIER", 43, 49], ["decline", "OBSERVATION_MODIFIER", 50, 57], ["sharp", "OBSERVATION_MODIFIER", 92, 97], ["increase", "OBSERVATION_MODIFIER", 98, 106]]], ["While early reports have not identified the same trends in the US, news reports during the month of May (Koetsier, 2020) indicated that a large number of persons were emerging from homes before an official end to the stay-athome orders.", [["persons", "ORGANISM", 154, 161], ["persons", "SPECIES", 154, 161], ["large", "OBSERVATION_MODIFIER", 138, 143]]], ["A rise in crime may be detected because it is possible that the longer the orders continue, the less effective they become.", [["A rise in crime", "PROBLEM", 0, 15], ["rise", "OBSERVATION_MODIFIER", 2, 6]]], ["These periods may coincide with the phased re-opening plan followed by many governments (see CDC, 2020) or within a timeframe for several weeks each, which may result in the need to add continued periods of crime data.Temporal ShiftCriminologists do not have to rely on the assumption that people follow stay-athome orders.", [["people", "ORGANISM", 290, 296], ["people", "SPECIES", 290, 296]]], ["These reports offer aggregated movement data based on anonymized cell phone location history at the national, state, and county levels.", [["cell", "ANATOMY", 65, 69], ["cell", "CELL", 65, 69], ["aggregated movement data", "TEST", 20, 44]]], ["With this data, it is possible to compare societal behavior within these recommended periods and gain a more accurate picture of where people were and importantly when they were there.", [["people", "ORGANISM", 135, 141], ["people", "SPECIES", 135, 141]]], ["Combined with the ability to measure compliance with movement restrictions, criminologists have the data to examine the routine activities of whole populations at a level never before possible while overlaying crime rates for both a temporal a place-based evaluation.Place-BasedStudying crime based at a place is another critical part of understanding not only crime trends but also methods to disrupt crime (Eck & Weisburd, 2015) .", [["movement restrictions", "TREATMENT", 53, 74], ["the data", "TEST", 96, 104], ["based evaluation", "TEST", 250, 266]]], ["Under the current circumstances with people's daily routine disrupted, this is even more important as people shift to more time within the home, the opportunities and places for offenders and victims to meet become limited.", [["people", "ORGANISM", 37, 43], ["people", "ORGANISM", 102, 108], ["people", "SPECIES", 37, 43], ["people", "SPECIES", 102, 108]]], ["As a result, there is likely far less crime as people; both victims and offenders are not together in a place for the crime to occur.Place-BasedTo illustrate, consider workplace violence and crime.", [["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["likely", "UNCERTAINTY", 22, 28]]], ["With a significant number of persons at home, rather than work, there is a reduced opportunity for offenders to assault co-workers.", [["persons", "ORGANISM", 29, 36], ["persons", "SPECIES", 29, 36], ["significant", "OBSERVATION_MODIFIER", 7, 18], ["number", "OBSERVATION_MODIFIER", 19, 25]]], ["Similarly, there is less opportunity for a victim to have a phone stolen from the breakroom.", [["less", "OBSERVATION_MODIFIER", 20, 24]]], ["It is important to remember that during the COVID-19 crisis, variables commonly related to many other criminological theories (i.e., poverty, stress, self-control) have not changed to such a degree to explain the sharp reduction in crime.", [["the sharp reduction in crime", "PROBLEM", 209, 237], ["sharp", "OBSERVATION_MODIFIER", 213, 218], ["reduction", "OBSERVATION", 219, 228]]], ["Instead, the opportunity to be connected to a victim in time and place appears to be the most significant variable that has led to a marked reduction in the workplace and other place-based crimes.Place-BasedHowever, in some regards, this place-based shift may result in increased crime rates in other areas (Roberts, 2020) .", [["a marked reduction", "TREATMENT", 131, 149], ["increased crime rates", "PROBLEM", 270, 291], ["marked", "OBSERVATION_MODIFIER", 133, 139], ["reduction", "OBSERVATION_MODIFIER", 140, 149], ["increased", "OBSERVATION_MODIFIER", 270, 279], ["crime", "OBSERVATION", 280, 285]]], ["For example, while digital, the internet can be classified as a 'place' or medium for victimization to occur (Machimbarrena et al., 2018) .", [["victimization", "PROBLEM", 86, 99]]], ["Under the COVID-19 stay-at-home orders, people are spending significantly more time online.", [["people", "ORGANISM", 40, 46], ["people", "SPECIES", 40, 46]]], ["By late March, for example, cable internet usage, as reported by The Internet and Television Association (2020), surged more than 30% and continued to grow until mid-April, which appears to coincide with many of the stay-at-home orders.", [["mid-April", "TREATMENT", 162, 171]]], ["The increased time using the internet likely leads to more opportunities for cybercrimes to occur as the victim's virtual presence has shifted dramatically (e.g., away from place-based crime at work or school and to place-based crime online).", [["increased", "OBSERVATION_MODIFIER", 4, 13]]], ["There are emerging trends in the new COVID-19 crime data suggesting crime differences in certain places (Ashby, 2020a) .", [["the new COVID", "TEST", 29, 42]]], ["For example, public places such as stores, restaurants, and entertainment areas are experiencing sharp decreases in some types of crime (Pietrawska et al., 2020a) , while crime in the home may be remaining consistent (Campbdelli, 2020; Payne & Morgan, 2020; Shayegh & Malpede, 2020, and mix-land use may see relatively stable or slightly increasing crime rates (Felson et al., 2020) .", [["sharp decreases", "PROBLEM", 97, 112], ["sharp", "OBSERVATION_MODIFIER", 97, 102], ["decreases", "OBSERVATION_MODIFIER", 103, 112], ["some types", "OBSERVATION_MODIFIER", 116, 126]]], ["However, a reasoning offender (Cornish & Clarke, 2014 ) may choose to target areas with fewer people (i.e., guardians) such as closed malls, business parks, and other places that may see an increase in property crimes.", [["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100]]], ["Additionally, mixed land usage, especially in population-dense areas, may allow an offender to travel in areas unnoticed easily and, therefore, present opportunities for crime (Felson et al., 2020) .Place-BasedPlace, whether virtual or physical, is a crucial factor in crime.", [["mixed", "OBSERVATION_MODIFIER", 14, 19], ["land usage", "OBSERVATION", 20, 30], ["dense", "OBSERVATION_MODIFIER", 57, 62], ["areas", "OBSERVATION", 63, 68]]], ["The COVID-19 crisis has re-shaped the places that persons routinely visit, increasing some-home and online, while decreasing others-work, retail, school, and entertainment.", [["persons", "ORGANISM", 50, 57], ["persons", "SPECIES", 50, 57]]], ["Highlighting the role that place has played in crime rates during the pandemic should influence how criminologists study crime in a post-pandemic world and lead to further crime reduction through place-based prevention techniques.Data-DrivenWe have listed some initial findings on crime in the COVID-19 era and also described the need to study crime specifically, temporally, and place-based.", [["further crime reduction", "TREATMENT", 164, 187]]], ["However, in the current pandemic, these problems decrease dramatically, and criminologists should take advantage of the favorable conditions and abundant data.Data-DrivenFirst, as described in the introduction, few variables changed during the first several weeks of the pandemic.", [["the pandemic", "PROBLEM", 267, 279], ["decrease", "OBSERVATION_MODIFIER", 49, 57], ["dramatically", "OBSERVATION_MODIFIER", 58, 70]]], ["The most substantial change has been the stay-at-home orders, which impacted the routine activities of entire populations.", [["substantial", "OBSERVATION_MODIFIER", 9, 20], ["change", "OBSERVATION", 21, 27]]], ["With so few variables changed, it should be easier to identify and measure significant and substantial changes in crime.", [["substantial changes in crime", "PROBLEM", 91, 119], ["substantial", "OBSERVATION_MODIFIER", 91, 102], ["changes", "OBSERVATION", 103, 110]]], ["Second, the variation in crime rates has been drastic.", [["crime rates", "TEST", 25, 36], ["variation", "OBSERVATION_MODIFIER", 12, 21], ["drastic", "OBSERVATION_MODIFIER", 46, 53]]], ["These significant measurable changes allow researchers to see 'past' other variables that have little impact and focus on the significant variables impacting crime.", [["significant", "OBSERVATION_MODIFIER", 6, 17], ["measurable", "OBSERVATION_MODIFIER", 18, 28], ["little", "OBSERVATION_MODIFIER", 95, 101], ["impact", "OBSERVATION_MODIFIER", 102, 108], ["significant", "OBSERVATION_MODIFIER", 126, 137]]], ["The impacted population is closer to the entire population rather than a 'sample population,' which means it is possible to move beyond inferential statistics and measure the actual change in the whole population.Data-DrivenAnother challenge for criminologists is crime data.", [["a 'sample population", "TREATMENT", 71, 91], ["impacted", "OBSERVATION_MODIFIER", 4, 12], ["population", "OBSERVATION", 13, 23]]], ["We encourage the use of four broad categories of data, including official police reports, victim and other self-report surveys, private or anecdotal data, and public data.", [["anecdotal data", "TEST", 139, 153], ["public data", "TEST", 159, 170]]], ["However, with many agencies experiencing workforce-related issues during the pandemic and purposely reducing the person-to-person contact to reduce the risk of virus spread, the official police data may underreport crime more than usual.", [["person", "SPECIES", 113, 119], ["person", "SPECIES", 123, 129], ["virus spread", "PROBLEM", 160, 172]]], ["Further, with more persons staying inside and not venturing out to school and work, other crimes, such as intimate partner violence and abuse of children, may not be captured through traditional reporting means.", [["intimate partner violence", "DISEASE", 106, 131], ["children", "ORGANISM", 145, 153], ["persons", "SPECIES", 19, 26], ["children", "SPECIES", 145, 153]]], ["Therefore, it will be important that victim and self-report surveys continue to be used to help capture data that official reports do not (see Krohn, Thornberry, Gibson, & Baldwin, 2010) .Data-DrivenOther sources of direct crime data and ancillary sources are often overlooked.", [["direct crime data", "TEST", 216, 233]]], ["Ancillary sources of data can take the form of calls to abuse hotlines, reports on consumer spending, internet traffic, police call for service, hospital mandatory reporting on specific injuries, and the Bureau of Labor Statics (2020) data on injuries resulting from violence at the workplace.", [["injuries", "DISEASE", 186, 194], ["injuries", "DISEASE", 243, 251], ["violence", "DISEASE", 267, 275], ["injuries", "PROBLEM", 243, 251]]], ["For example, many retail organizations release data on crime within their stores, credit card companies release fraud statistics, and insurance organizations publish claims related to crime victimization.", [["crime victimization", "DISEASE", 184, 203]]], ["These sources may be particularly important as many areas where crime is occurring during the COVID-19 crisis are within private spaces, and obtaining non-police data is essential to understanding the crime shift.", [["the COVID", "TEST", 90, 99], ["may be particularly", "UNCERTAINTY", 14, 33]]], ["Lastly, other publicly available resources should be included in the analysis as well.", [["the analysis", "TEST", 65, 77]]], ["This data set, never before publicly provided, should be used to overlay with other data (see Mohler et al., 2020) .Data-DrivenMoving beyond the data to the methods, the circumstances of the COVID-19 crisis has led to a naturally occurring quasi-random control trial.", [["This data", "TEST", 0, 9], ["the COVID", "TEST", 187, 196], ["quasi-random control trial", "TREATMENT", 240, 266]]], ["The response to alcohol also creates a valuable point in data analysis.", [["alcohol", "CHEMICAL", 16, 23], ["alcohol", "CHEMICAL", 16, 23], ["alcohol", "SIMPLE_CHEMICAL", 16, 23], ["data analysis", "TEST", 57, 70]]], ["Examples abound of states that relaxed laws on alcohol sales, such as Kentucky, which allowed for the first-time home delivery of alcohol and service of alcohol with food take-out orders during the crisis (Minton, 2020) .", [["alcohol", "CHEMICAL", 47, 54], ["alcohol", "CHEMICAL", 130, 137], ["alcohol", "CHEMICAL", 153, 160], ["alcohol", "CHEMICAL", 47, 54], ["alcohol", "CHEMICAL", 130, 137], ["alcohol", "CHEMICAL", 153, 160], ["alcohol", "SIMPLE_CHEMICAL", 47, 54], ["alcohol", "SIMPLE_CHEMICAL", 153, 160]]], ["On the other end of the spectrum, some states deemed alcohol 'non-essential' but changed course after public backlash.", [["alcohol", "CHEMICAL", 53, 60], ["alcohol", "CHEMICAL", 53, 60], ["alcohol", "SIMPLE_CHEMICAL", 53, 60], ["public backlash", "PROBLEM", 102, 117], ["backlash", "OBSERVATION", 109, 117]]], ["For example, Pennsylvania initially closed liquor stores and created a cascade of persons traveling outside the state seeking alcohol (Thomas, 2020) .", [["alcohol", "CHEMICAL", 126, 133], ["alcohol", "CHEMICAL", 126, 133], ["persons", "ORGANISM", 82, 89], ["alcohol", "SIMPLE_CHEMICAL", 126, 133], ["persons", "SPECIES", 82, 89]]], ["Conditions such as these either between states or even within states are plentiful and provide essential data points that allow for an excellent comparison of crime and related factors.The Largest Criminological Experiment in HistoryThere is little doubt that the COVID-19 crisis will impact history on a scale not seen since WWII.", [["the COVID", "TEST", 260, 269], ["a scale", "TEST", 303, 310], ["Largest", "OBSERVATION_MODIFIER", 189, 196], ["Criminological Experiment", "OBSERVATION", 197, 222], ["little doubt", "UNCERTAINTY", 242, 254]]], ["Provisional insights indicate that a substantial drop in crime is occurring around the world and within the US.", [["a substantial drop in crime", "PROBLEM", 35, 62], ["substantial", "OBSERVATION_MODIFIER", 37, 48], ["drop", "OBSERVATION", 49, 53]]], ["Therefore, we encourage criminologists to study this crisis through the use of new and existing sources of crime data, with a specificity of crime types, in a temporal fashion, and placed based.The Largest Criminological Experiment in HistoryMoreover, the leading feature of these crime changes will be that the government ordered stay-at-home mandates, which impacted the routine activities of entire populations.", [["crime data", "TEST", 107, 117], ["Largest", "OBSERVATION_MODIFIER", 198, 205], ["Criminological", "OBSERVATION_MODIFIER", 206, 220], ["Experiment", "OBSERVATION", 221, 231]]], ["The variation in these orders by state and community regarding when the orders were implemented and rescinded and what restrictions were in place has provided a naturally occurring, quasi-randomized control experiment.", [["quasi-randomized control experiment", "TREATMENT", 182, 217], ["variation", "OBSERVATION_MODIFIER", 4, 13]]], ["For example, researchers can compare states and communities that released prisoners early, increased or reduced alcohol availability, began lock-downs early, crime in public places as opposed to residential and mixed land use, and operationalize many variables that were previously intangible or inarticulable.The Largest Criminological Experiment in HistoryThe findings emerging from the COVID-19 crisis will impact criminological theories for the next several decades.", [["alcohol", "CHEMICAL", 112, 119], ["alcohol", "CHEMICAL", 112, 119], ["alcohol", "SIMPLE_CHEMICAL", 112, 119], ["the COVID", "TEST", 385, 394], ["Largest", "OBSERVATION_MODIFIER", 314, 321], ["Criminological Experiment", "OBSERVATION", 322, 347]]], ["We encourage researchers to embark on in-depth explorations of the data made available from the pandemic and to search for not only why, where, when, and to what extent crime fell, but also how to use this knowledge for practical applications after the world returns to 'normal' and concludes this experiment in crime reduction and extraordinary test of human determination and resiliency.The Largest Criminological Experiment in HistoryFunding Information No funding was received for this research.Compliance with Ethical StandardsConflicts of Interest The authors report no conflicts of interest.", [["human", "ORGANISM", 354, 359], ["human", "SPECIES", 354, 359], ["human", "SPECIES", 354, 359], ["practical applications", "TREATMENT", 220, 242], ["Ethical Standards", "TREATMENT", 515, 532], ["Largest", "OBSERVATION_MODIFIER", 393, 400], ["Criminological Experiment", "OBSERVATION", 401, 426], ["funding", "OBSERVATION", 460, 467], ["no", "UNCERTAINTY", 573, 575]]]], "7dd48b99f18e8e898e85351d82304f7b685fb0e7": [["IntroductionEven before the Covid-19 pandemic, we were living in a period of profound socioeconomic and environmental systemic change.", [["profound socioeconomic and environmental systemic change", "PROBLEM", 77, 133], ["environmental systemic change", "OBSERVATION", 104, 133]]], ["As in similar periods in the past, there is bound to be considerable instability and uncertainty before the new society and economy take shape.", [["considerable instability", "PROBLEM", 56, 80], ["considerable", "OBSERVATION_MODIFIER", 56, 68], ["instability", "OBSERVATION", 69, 80], ["new", "OBSERVATION_MODIFIER", 108, 111]]], ["This in turn will require more realistic tools and techniques to design these policies than those that failed to anticipate previous crises or to help design sustainable solutions to them.IntroductionTo tackle planetary emergencies linked to the environment, the economy, and socio-political systems, we have to understand their systemic properties.", [["previous crises", "PROBLEM", 124, 139]]], ["System resilience is a term of rising popularity during the Covid-19 pandemic, but we must not neglect other system properties such as tipping points, non-linearity, asymmetry, and interconnectedness.", [["rising popularity", "PROBLEM", 31, 48], ["the Covid", "TEST", 56, 65], ["pandemic", "PROBLEM", 69, 77], ["asymmetry", "PROBLEM", 166, 175]]], ["The systems approach can promote cross-sectoral, multidisciplinary collaboration in the process of policy formulation by taking proper account of the crucial linkages between issues generally treated separately within different specializations and scientific and institutional \"silos.\"", [["policy formulation", "TREATMENT", 99, 117]]], ["In order to promote positive social and economic change, a range of policies has to be integrated, including educational, demographic, employment, well-being, and technology and innovation policies.", [["positive", "OBSERVATION_MODIFIER", 20, 28]]], ["Systems thinking provides a methodology to achieve a better understanding of the behavior of complex systems and to improve the assessment of the consequences of policy interventions.IntroductionGrowing complexity and interdependence have made various systems (economic, public health, cyber, etc.) susceptible to widespread, irreversible, and cascading failure.", [["the assessment", "TEST", 124, 138], ["policy interventions", "TREATMENT", 162, 182], ["cascading failure", "PROBLEM", 344, 361], ["widespread", "OBSERVATION_MODIFIER", 314, 324], ["irreversible", "OBSERVATION_MODIFIER", 326, 338], ["cascading failure", "OBSERVATION", 344, 361]]], ["Serious disease outbreaks such as Covid-19 are the result of systemic properties, and in this case, emergence in particular.", [["Serious disease outbreaks", "PROBLEM", 0, 25], ["Covid", "TEST", 34, 39], ["systemic properties", "OBSERVATION", 61, 80]]], ["A recent paper published by the UK Royal Society (Johnson et al. 2020) shows that emerging infectious diseases in humans are frequently caused by pathogens originating from animal hosts, and that virus transmission risk is highest from animal species that have increased in abundance and even expanded their range by adapting to human-dominated landscapes.", [["infectious diseases", "DISEASE", 91, 110], ["humans", "ORGANISM", 114, 120], ["human", "ORGANISM", 329, 334], ["humans", "SPECIES", 114, 120], ["human", "SPECIES", 329, 334], ["humans", "SPECIES", 114, 120], ["human", "SPECIES", 329, 334], ["emerging infectious diseases", "PROBLEM", 82, 110], ["pathogens", "PROBLEM", 146, 155], ["virus transmission risk", "PROBLEM", 196, 219], ["animal species", "PROBLEM", 236, 250], ["infectious", "OBSERVATION", 91, 101], ["increased", "OBSERVATION_MODIFIER", 261, 270], ["dominated", "OBSERVATION_MODIFIER", 335, 344], ["landscapes", "OBSERVATION", 345, 355]]], ["Among threatened wildlife species, those with population reductions because of exploitation and loss of habitat share more viruses with humans.", [["humans", "ORGANISM", 136, 142], ["humans", "SPECIES", 136, 142], ["humans", "SPECIES", 136, 142], ["population reductions", "TREATMENT", 46, 67], ["loss of habitat", "PROBLEM", 96, 111]]], ["In other words, impacts on ecosystems due to changes to socioeconomic systems, such as the introduction of intensive agriculture, play a role in creating or aggravating epidemic risk.", [["changes to socioeconomic systems", "PROBLEM", 45, 77], ["intensive agriculture", "TREATMENT", 107, 128]]], ["One study looking at the emergence of infectious diseases calculated that since 1940, intensive agriculture has been associated with more than 25% of all infectious diseases that emerged in humans and more than half of all infectious diseases that spilled over from animals to humans (Rohr et al. 2019) .IntroductionStriving for maximum efficiency and optimization, such systems have neglected resilience against disruptions (Marchese 2012 ) whose shocks may leave governments, the public, and the environment in a weakened state.", [["infectious diseases", "DISEASE", 38, 57], ["infectious diseases", "DISEASE", 154, 173], ["infectious diseases", "DISEASE", 223, 242], ["humans", "ORGANISM", 190, 196], ["humans", "ORGANISM", 277, 283], ["humans", "SPECIES", 190, 196], ["humans", "SPECIES", 277, 283], ["humans", "SPECIES", 190, 196], ["humans", "SPECIES", 277, 283], ["One study", "TEST", 0, 9], ["infectious diseases", "PROBLEM", 38, 57], ["all infectious diseases", "PROBLEM", 150, 173], ["all infectious diseases", "PROBLEM", 219, 242], ["maximum efficiency", "PROBLEM", 329, 347], ["infectious", "OBSERVATION", 38, 48], ["infectious", "OBSERVATION", 154, 164], ["infectious", "OBSERVATION", 223, 233]]], ["More specifically, the concentration of industrial capacities and economic activity into smaller and more efficient sectors, up to the international level, has produced highly lucrative yet fragile supply chains, and economic exchanges whose disruptions could have sweeping effects in unexpected areas.", [["industrial capacities", "PROBLEM", 40, 61], ["economic activity into smaller", "PROBLEM", 66, 96], ["fragile supply chains", "PROBLEM", 190, 211], ["economic exchanges whose disruptions", "PROBLEM", 217, 253], ["industrial capacities", "OBSERVATION", 40, 61], ["economic activity", "OBSERVATION", 66, 83], ["smaller", "OBSERVATION_MODIFIER", 89, 96], ["more", "OBSERVATION_MODIFIER", 101, 105], ["efficient", "OBSERVATION_MODIFIER", 106, 115], ["sectors", "OBSERVATION_MODIFIER", 116, 123], ["fragile", "OBSERVATION", 190, 197], ["supply chains", "OBSERVATION", 198, 211], ["sweeping", "OBSERVATION_MODIFIER", 265, 273]]], ["While this has provided considerable opportunities, it has also made the systems we rely on in our daily lives (e.g., international supply chains) vulnerable to sudden and unexpected disruption, as the result of either an external shock, the way the system has self-organised, or a combination of both (Juttner and Maklan 2011; OECD and FAO 2019) .", [["shock", "DISEASE", 231, 236], ["unexpected disruption", "PROBLEM", 172, 193], ["an external shock", "PROBLEM", 219, 236], ["external", "OBSERVATION_MODIFIER", 222, 230], ["shock", "OBSERVATION", 231, 236]]], ["The 2011 earthquake and tsunami in Japan, for example, exposed the limits of just-in-time supply chain organization, and highlighted the importance of flexibility, diversification, and adaptability (Fujimoto 2011; Golan et al. 2020) .IntroductionSuch notions have been thoroughly described by leading economists and scholars since the onset of the 2007-2009 financial crisis, yet primarily in an abstract context, although Andrew Haldane, the Bank of England's Chief Economist, did argue in 2009 that \"the spread of epidemics and the disintegration of the financial system -each is essentially a different branch of the same network family tree\" (Haldane 2009).", [["epidemics", "PROBLEM", 516, 525]]], ["A key question, therefore, is focused not upon whether systemic risk would cause substantial cascading losses to the international economy, but rather on what type of disruption would trigger such a chain of events in the first place.", [["substantial cascading losses", "PROBLEM", 81, 109], ["substantial", "OBSERVATION_MODIFIER", 81, 92], ["cascading", "OBSERVATION", 93, 102]]], ["The Covid-19 outbreak has led to a crisis with considerable cascading losses for health but also for much of the global economy, with concordant high social costs.", [["a crisis", "PROBLEM", 33, 41], ["cascading losses", "OBSERVATION", 60, 76], ["social costs", "OBSERVATION", 150, 162]]], ["At the moment, national governments are struggling to absorb the shock generated by the pandemic, but in time the international community will overcome the crisis and begin the recovery phase.IntroductionResilience, or the ability to recover from and adapt to unexpected threats, has been a focus of specific parts of our system, for instance military and public health authorities.", [["shock", "DISEASE", 65, 70], ["the crisis", "PROBLEM", 152, 162], ["IntroductionResilience", "TREATMENT", 192, 214]]], ["But the notions of viability and resilience can be in tension with short-term profitability and apparent efficiency (Aubin 2010) .", [["short-term profitability", "PROBLEM", 67, 91]]], ["The disastrous consequences of recent bush fires in Australia and extensive flooding in many parts of the world, both attributable to climate change, show that resilience must become a core philosophy within system management and operations to ensure we are able to continue to function in the midst of these disruptions, and particularly those aggravated by disruptions from Covid-19.IntroductionThe policy response should be twofold: address immediate concerns, and propose an approach to dealing with the longer-term issues the pandemic highlights.", [["system management", "TREATMENT", 208, 225], ["operations", "TREATMENT", 230, 240], ["Covid", "TEST", 376, 381], ["the longer-term issues", "PROBLEM", 504, 526], ["disastrous", "OBSERVATION", 4, 14], ["bush", "OBSERVATION_MODIFIER", 38, 42], ["fires", "OBSERVATION_MODIFIER", 43, 48], ["extensive", "OBSERVATION_MODIFIER", 66, 75], ["flooding", "OBSERVATION", 76, 84]]], ["In the short term, that means identifying the people and activities most affected, assessing how measures to help them will impact others, and underlining that difficult trade-offs between health, economic, social, and other goals are inevitable.", [["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["short term", "OBSERVATION_MODIFIER", 7, 17]]], ["In the longer term, an approach that reacts to the systemic origins and impacts of major shocks is needed if policies are to be effective.", [["an approach", "TREATMENT", 20, 31], ["major shocks", "TREATMENT", 83, 95], ["longer term", "OBSERVATION_MODIFIER", 7, 18], ["systemic", "OBSERVATION_MODIFIER", 51, 59], ["origins", "OBSERVATION_MODIFIER", 60, 67], ["major", "OBSERVATION_MODIFIER", 83, 88], ["shocks", "OBSERVATION", 89, 95]]], ["The Covid-19 crisis also shows how important it is to keep resources in reserve for times when unexpected upheavals in the system prevent it from functioning normally (and the argument can be made for not depleting natural resources).", [["The Covid", "TEST", 0, 9]]], ["Furthermore, given the interdependence of our economies and social systems, the pandemic also highlights the need for strengthened international cooperation (building on existing frameworks for emergency preparedness) based on evidence to tackle systemic threats and help avert systemic collapse.", [["emergency preparedness", "TREATMENT", 194, 216], ["systemic collapse", "PROBLEM", 278, 295], ["systemic", "OBSERVATION_MODIFIER", 278, 286], ["collapse", "OBSERVATION", 287, 295]]], ["1 Helbing (2012) and others have noted that the consequences of failing to appreciate and manage the characteristics of complex global systems and problems can be immense.Economic and social impact of COVID-19Declared a pandemic by the World Health Organization (WHO) on March 11, 2020, Covid-19 quickly spread globally.", [["COVID-19Declared", "CHEMICAL", 201, 217], ["COVID", "TREATMENT", 201, 206], ["Covid", "TEST", 287, 292]]], ["The elderly disproportionality experience more negative health outcomes, but the effects on them result from more than just the medical conditions common to other at-risk groups, such as obesity, smoking, heart disease, and diabetes.", [["heart", "ANATOMY", 205, 210], ["obesity", "DISEASE", 187, 194], ["heart disease", "DISEASE", 205, 218], ["diabetes", "DISEASE", 224, 232], ["heart", "ORGAN", 205, 210], ["obesity", "PROBLEM", 187, 194], ["heart disease", "PROBLEM", 205, 218], ["diabetes", "PROBLEM", 224, 232], ["obesity", "OBSERVATION", 187, 194], ["heart", "ANATOMY", 205, 210], ["disease", "OBSERVATION", 211, 218], ["diabetes", "OBSERVATION", 224, 232]]], ["The elderly are exceptionally exposed to death from the disease, but also risks arising from isolation and weak social ties, compounded by the fragmentation of health and social care services.", [["death", "DISEASE", 41, 46], ["the disease", "PROBLEM", 52, 63], ["disease", "OBSERVATION", 56, 63]]], ["School closures are the main impact on children and young people, but the capacity to compensate for the projected loss in learning varies according to socioeconomic status, with those from low-income and/or single-parent families likely to be the most affected by the closure of schools and childcare facilities.", [["children", "ORGANISM", 39, 47], ["people", "ORGANISM", 58, 64], ["children", "SPECIES", 39, 47], ["people", "SPECIES", 58, 64], ["the projected loss", "PROBLEM", 101, 119]]], ["The PISA 2015 surveys (OECD 2016) reveal that nearly a quarter of 15-year-olds of low socioeconomic status do not have an office or a quiet place to study; just over 1 in 5 teenagers in the same families have no access to a computer for school work or an internet connection.", [["low socioeconomic status", "PROBLEM", 82, 106]]], ["The poorest children are also suffering by being deprived of school meals and other support measures provided by or at schools.Economic and social impact of COVID-19The differing social impacts are one result of a number of economic trends that have already been shaping well-being for many years before the Covid-19 pandemic, notably the impacts of austerity, growing inequality, weakened social protection, and increased precariousness in labor markets (OECD 2011 (OECD , 2018 .", [["COVID-19", "CHEMICAL", 157, 165], ["COVID-19", "CHEMICAL", 157, 165], ["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20], ["COVID", "TEST", 157, 162], ["increased precariousness in labor markets", "PROBLEM", 413, 454], ["differing", "OBSERVATION_MODIFIER", 169, 178], ["social", "OBSERVATION_MODIFIER", 179, 185], ["weakened", "OBSERVATION_MODIFIER", 381, 389], ["social protection", "OBSERVATION", 390, 407], ["increased", "OBSERVATION_MODIFIER", 413, 422]]], ["The OECD Interim Economic Outlook, released on March 2, 2020, shows how restrictions on the movement of people, goods, and services, in combination with containment measures such as business closures, have cut manufacturing and domestic demand sharply in China, while also affecting the rest of the world through business travel and tourism, global supply chains, commodities, and loss of confidence.", [["loss of confidence", "DISEASE", 381, 399], ["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["containment measures", "TREATMENT", 153, 173], ["business closures", "TREATMENT", 182, 199], ["Economic", "OBSERVATION_MODIFIER", 17, 25]]], ["The initial direct impact of the shutdowns could be a decline in the level of output of between one-fifth to one-quarter in many economies, with consumer expenditure potentially dropping by around one-third.", [["a decline", "PROBLEM", 52, 61], ["decline", "OBSERVATION_MODIFIER", 54, 61], ["economies", "OBSERVATION", 129, 138]]], ["This is far greater than anything experienced during the 2008 financial crisis.", [["greater", "OBSERVATION_MODIFIER", 12, 19]]], ["Nonetheless, it is clear that the impact of the shutdowns imposed on many economies will weaken short-term growth prospects substantially, equivalent to a decline in annual GDP growth of up to 2 percentage points for each month that strict containment measures are imposed.", [["GDP", "CHEMICAL", 173, 176], ["GDP", "CHEMICAL", 173, 176], ["GDP", "SIMPLE_CHEMICAL", 173, 176], ["a decline in annual GDP growth", "PROBLEM", 153, 183], ["strict containment measures", "TREATMENT", 233, 260], ["clear", "OBSERVATION", 19, 24], ["GDP", "OBSERVATION_MODIFIER", 173, 176], ["growth", "OBSERVATION_MODIFIER", 177, 183], ["containment", "OBSERVATION", 240, 251]]], ["If the shutdown continued uninterrupted for 3 months, with no offsetting factors, annual GDP growth could be between 4 and 6 percentage points lower than it otherwise might have been.", [["GDP", "CHEMICAL", 89, 92], ["GDP", "SIMPLE_CHEMICAL", 89, 92], ["annual GDP growth", "TEST", 82, 99]]], ["However, the worst potential impacts may be offset by measures such as the USD$5 trillion in fiscal spending the G20 countries agreed to inject into the global economy at their summit on March 26, 2020.Economic and social impact of COVID-19The Covid-19 epidemic and measures to counteract it are likely to disproportionally affect poorer people.", [["people", "ORGANISM", 338, 344], ["people", "SPECIES", 338, 344], ["COVID", "TEST", 232, 237], ["The Covid", "TREATMENT", 240, 249]]], ["The OECD's \"How's Life?\" 2020 shows that overall, 36% of people in OECD countries are financially vulnerable, meaning they would lack the financial assets needed to avoid falling into poverty if they were to lose 3 months of their income.", [["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63]]], ["These workers often work on short contracts, sometimes with weak or no social protections, with limited options for working remotely, and with risks of job loss and forgone earnings if they have to remain away from their place of work due to illness, quarantine, or government-mandated closures of specific activities.", [["illness", "DISEASE", 242, 249], ["illness", "PROBLEM", 242, 249]]], ["Anti-virus measures will affect them significantly since they are often employed in occupations demanding a high degree of contact with a wide range of clients, such as restaurants, taxis, and delivery services.Economic and social impact of COVID-19Measures to compensate people and firms for lost earnings are being introduced to alleviate the situation.", [["people", "ORGANISM", 272, 278], ["people", "SPECIES", 272, 278], ["Anti-virus measures", "TREATMENT", 0, 19], ["COVID", "TREATMENT", 241, 246]]], ["These can include postponement of taxes and debt repayments and government paid leave for people in countries which do not have paid sick leave.", [["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96]]], ["But in countries where there are short-term contracts, and poorer people have few savings, no amount of monetary stimulus will re-energize demand.", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72]]], ["The poor will be hardest hit in countries such as Indonesia, Mexico, and Brazil, with up to 50% or higher of the population employed in the informal sector and few channels through which any aid could reach such people.", [["people", "ORGANISM", 212, 218], ["people", "SPECIES", 212, 218]]], ["Oxfam estimates that the economic crisis caused by Covid-19 could push half a billion people into poverty (Oxfam 2020).", [["Covid-19", "CHEMICAL", 51, 59], ["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["the economic crisis", "PROBLEM", 21, 40]]], ["However, conditional cash transfers were scaled up very effectively following the 2008 global financial crisis; even in the Least Developed Countries, food for work programs and other forms of social protection can provide some relief.", [["work programs", "TREATMENT", 160, 173], ["social protection", "TREATMENT", 193, 210]]], ["As to the supply side of the economy, firms that have had to reduce their activities will take time to restart production and to contribute to global supply chains.Economic and social impact of COVID-19In the longer term, two impacts could be especially serious.", [["global supply chains", "PROBLEM", 143, 163], ["COVID", "TREATMENT", 194, 199]]], ["The Covid-19 pandemic has reminded us bluntly of the fragility of some of our most basic human-made systems.", [["human", "ORGANISM", 89, 94], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94]]], ["Shortages of masks, tests, ventilators, and other essential items have left frontline workers and the general population dangerously exposed to the disease itself.", [["tests", "TEST", 20, 25], ["ventilators", "TREATMENT", 27, 38], ["the disease itself", "PROBLEM", 144, 162], ["disease", "OBSERVATION", 148, 155]]], ["At a wider level, we have witnessed the cascading collapse of entire production, financial, and transportation systems, due to a vicious combination of supply and demand shocks.Economic and social impact of COVID-19China's merchandise trade was down 17% in the first 2 months of the year.", [["COVID-19China", "CHEMICAL", 207, 220], ["the cascading collapse", "PROBLEM", 36, 58], ["demand shocks", "TREATMENT", 163, 176], ["COVID-19China's merchandise trade", "TREATMENT", 207, 240], ["cascading", "OBSERVATION_MODIFIER", 40, 49], ["collapse", "OBSERVATION", 50, 58]]], ["While trade may rebound when the situation improves, there may be longer term, structural effects: firms may retreat from globalization, seeking shortened supply chains and suppliers located in countries that seem less prone to disruption.", [["shortened supply chains", "PROBLEM", 145, 168]]], ["This would have consequences for production structures, jobs, and income in different parts of the world.", [["production structures", "PROBLEM", 33, 54]]], ["This is worrying when international cooperation is literally vital in coordinating the response to Covid-19 and future systemic threats.", [["Covid", "TEST", 99, 104]]], ["The international financial system is already seeing the impacts of Covid-19, with increased volatility and sharp drops in share prices.", [["Covid", "TEST", 68, 73], ["increased volatility", "PROBLEM", 83, 103], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["volatility", "OBSERVATION_MODIFIER", 93, 103], ["sharp", "OBSERVATION_MODIFIER", 108, 113], ["drops", "OBSERVATION_MODIFIER", 114, 119]]], ["If these falls are the beginning of a longer downward trend, there will be a direct negative wealth impact on asset holders.", [["these falls", "PROBLEM", 3, 14]]], ["Further easing of monetary policies by central banks (especially by the European Central Bank where deposit rates are already negative) may reinforce the income effect for pensioners or push savers to higher-risk investments.", [["monetary policies", "TREATMENT", 18, 35], ["central banks", "OBSERVATION", 39, 52]]], ["On the other hand, low interest rates may further fuel inflation in assets that are considered safe havens (e.g., real estate, gold, government bonds) making inequalities in wealth worse.Economic and social impact of COVID-19Once again, the shadow of 2008 falls over the outlook today.", [["COVID-19Once", "CHEMICAL", 217, 229], ["COVID", "TREATMENT", 217, 222]]], ["The IMF's Global Debt Database shows that total global debt (public plus private) reached USD$188 trillion at the end of 2018, up by USD$3 trillion compared to 2017 (and up by over USD$90 trillion from 2007).", [["Debt Database", "TEST", 17, 30]]], ["The global average debt-to-GDP ratio (weighted by each country's GDP) edged up to 226% in 2018, 1\u00bd percentage points above the previous year (IMF 2020).", [["GDP", "SIMPLE_CHEMICAL", 27, 30], ["The global average debt", "TEST", 0, 23], ["GDP ratio", "TEST", 27, 36], ["global", "OBSERVATION_MODIFIER", 4, 10], ["average", "OBSERVATION_MODIFIER", 11, 18]]], ["Despite efforts to reduce fiscal deficits, many governments still have high levels of debt following their interventions to deal with the financial crisis and its aftermath, and sovereign spreads for some countries are starting to widen.", [["fiscal deficits", "PROBLEM", 26, 41], ["their interventions", "TREATMENT", 101, 120], ["the financial crisis", "PROBLEM", 134, 154]]], ["In advanced economies, IMF data show that the corporate debt ratio has gradually increased since 2010 and it is now at the same level as in 2008, the previous peak.", [["IMF data", "TEST", 23, 31], ["the corporate debt ratio", "TEST", 42, 66], ["gradually", "OBSERVATION_MODIFIER", 71, 80], ["increased", "OBSERVATION_MODIFIER", 81, 90]]], ["In several major economies debt is, or was, increasingly used for financial risk-taking (to fund distribution of dividends, share buybacks, and mergers and acquisitions).", [["several", "OBSERVATION_MODIFIER", 3, 10], ["major", "OBSERVATION_MODIFIER", 11, 16], ["economies", "OBSERVATION", 17, 26]]], ["Much of the debt is high speculative-grade debt, and a significant fraction of corporate debt is now rated BBB, the lowest investment grade rating.", [["BBB", "MULTI-TISSUE_STRUCTURE", 107, 110], ["high", "OBSERVATION_MODIFIER", 20, 24], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["fraction", "OBSERVATION_MODIFIER", 67, 75]]], ["Global household debt is over USD$47 trillion, compared to USD$35 trillion going into the 2008 crisis.Complex system view on the Covid-19 outbreakIn a linear, Newtonian world, actions cause predictable reactions.", [["the Covid", "TEST", 125, 134], ["predictable reactions", "PROBLEM", 190, 211]]], ["Today's complex system of environmental, socio-political, and economic systems, however, is constantly being reconfigured by human behavior and is simultaneously constantly affecting that behavior.", [["human", "ORGANISM", 125, 130], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130]]], ["In such a world, a small change can be transmitted and amplified by the interconnectedness of the system to have enormous consequences, far beyond the time, place, and scale of the initial perturbation.", [["a small change", "PROBLEM", 17, 31], ["small", "OBSERVATION_MODIFIER", 19, 24], ["change", "OBSERVATION", 25, 31], ["enormous", "OBSERVATION_MODIFIER", 113, 121], ["consequences", "OBSERVATION", 122, 134]]], ["In 2007-2008, problems in a national home loans market escalated into a financial crisis that almost destroyed the global banking system.", [["a financial crisis", "PROBLEM", 70, 88], ["global banking", "OBSERVATION", 115, 129]]], ["The consequences of the 2008 crisis were still being felt 10 years later because it provoked an economic recession that in turn caused political and social upheaval.", [["an economic recession", "PROBLEM", 93, 114], ["economic recession", "OBSERVATION", 96, 114]]], ["The Covid-19 crisis is another illustration of how systems change each other.", [["The Covid", "TEST", 0, 9]]], ["The initial cause, as in previous coronavirus outbreaks, was transmission from animals to humans of a virus.", [["coronavirus", "DISEASE", 34, 45], ["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["humans", "SPECIES", 90, 96], ["previous coronavirus outbreaks", "PROBLEM", 25, 55], ["a virus", "PROBLEM", 100, 107]]], ["When we look in more detail at how this happened, we will probably find that a range of social, economic, and environmental changes contributed to creating conditions where zoonosis could become so damaging-for example, changing land-use patterns and agricultural practices.", [["zoonosis", "DISEASE", 173, 181], ["creating conditions", "PROBLEM", 147, 166], ["agricultural practices", "TREATMENT", 251, 273]]], ["We could argue that the 2020 health crisis was made far worse by the 2008 financial crisis, or more precisely, the austerity measures that left many health systems without the basic resources such as protective clothing needed to cope with a sudden, unexpected upsurge in the number of patients.Complex system view on the Covid-19 outbreakCovid-19 also shows how subjective factors such as trust in institutions and willingness to follow their advice and instructions, or the sentiment of belonging to a community, can influence how a disaster unfolds.", [["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 286, 294], ["protective clothing", "TREATMENT", 200, 219], ["the Covid", "TEST", 318, 327]]], ["A full understanding of such factors requires an approach based on integrative economics, which calls on the insights and methods of the range of disciplines needed to paint a realistic picture of how the economic system is shaped and helps shape the larger \"system of systems\" it is part of.", [["such factors", "PROBLEM", 24, 36], ["an approach", "TREATMENT", 46, 57]]], ["Furthermore, systems thinking allows us to identify the key drivers, interactions, and dynamics of the economic, social, and environmental nexus that policy seeks to shape, and to select points of intervention in a selective, adaptive way.", [["intervention", "TREATMENT", 197, 209]]], ["Critically, this allows us to emphasize the importance of system resilience to a variety of shocks and stresses, allowing systems to recover from lost functionality and adapt to new realities regarding international economics, societal needs, and human behavior, as well as the risks of a more unpredictable climate.Complex system view on the Covid-19 outbreakFor example, the nuclear power industry in OECD countries relies on a safety philosophy known as \"integrated defence in depth.\"", [["nuclear", "ANATOMY", 377, 384], ["human", "ORGANISM", 247, 252], ["human", "SPECIES", 247, 252], ["human", "SPECIES", 247, 252], ["the Covid", "TEST", 339, 348]]], ["This framework requires consideration of not just reactor design and hardware performance but also the human and organizational elements (e.g., emergency response organizations) necessary for safe reactor operation (NEA 2016) .", [["human", "ORGANISM", 103, 108], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["hardware performance", "TEST", 69, 89], ["emergency response organizations", "TREATMENT", 144, 176], ["safe reactor operation", "TREATMENT", 192, 214]]], ["This framework, consistent with integrative economics, assesses overall system resilience, while recognizing that one must consider a variety of complex, interconnected variables.", [["consistent with", "UNCERTAINTY", 16, 31]]], ["Most electricity systems are, as a result, resilient by law: mandatory levels of additional dispatchable capacity are kept in reserve should the output of some technologies, or individual plants, become variable.Complex system view on the Covid-19 outbreakFerguson et al. (2020) of Imperial College, London provided simulations of Covid-19\u2032s diffusion which indicated that the United Kingdom's health service would be overwhelmed and might face 500,000 deaths if the government took no action.", [["deaths", "DISEASE", 453, 459], ["additional dispatchable capacity", "PROBLEM", 81, 113], ["the output", "TEST", 141, 151]]], ["Using a similar modeling approach, simulations for the United States suggested 2.2 million deaths if no actions were taken.", [["deaths", "DISEASE", 91, 97]]], ["Epidemiologist Joshua Epstein from New York University outlined the global spread of pandemics with a focus on Covid-19, in which the interaction between the infection dynamics (created by the pandemic) and the social dynamics (created by fear) produce volatile outcomes.", [["pandemics", "DISEASE", 85, 94], ["infection", "DISEASE", 158, 167], ["pandemics", "PROBLEM", 85, 94], ["Covid", "TEST", 111, 116], ["the infection dynamics", "PROBLEM", 154, 176], ["global", "OBSERVATION_MODIFIER", 68, 74], ["spread", "OBSERVATION_MODIFIER", 75, 81], ["infection", "OBSERVATION", 158, 167]]], ["Individuals contract fear through contact with the disease-infected (the sick), the fear-infected (the scared), and those infected with both fear and disease (the sick and scared).", [["fear-infected", "DISEASE", 84, 97], ["fear and disease", "DISEASE", 141, 157], ["the disease", "PROBLEM", 47, 58], ["disease", "PROBLEM", 150, 157], ["infected", "OBSERVATION", 59, 67], ["infected", "OBSERVATION", 89, 97]]], ["Scared individuals-whether sick or not-withdraw from circulation with a certain probability, which affects the course of the disease epidemic proper.", [["Scared individuals", "PROBLEM", 0, 18], ["disease", "OBSERVATION", 125, 132]]], ["If individuals recover from fear and return to circulation, the disease dynamics become rich, and include multiple waves of infection, such as occurred in the 1918 Influenza Pandemic (Epstein 2014) .", [["infection", "DISEASE", 124, 133], ["Influenza Pandemic", "DISEASE", 164, 182], ["fear", "PROBLEM", 28, 32], ["the disease dynamics", "PROBLEM", 60, 80], ["multiple waves of infection", "PROBLEM", 106, 133], ["infection", "OBSERVATION", 124, 133]]], ["The two epidemics, contagion and fear, operate in tandem and the behavior of individuals is changed.", [["The two epidemics", "PROBLEM", 0, 17], ["two", "OBSERVATION_MODIFIER", 4, 7], ["epidemics", "OBSERVATION", 8, 17]]], ["The movements in capital markets engendered by the change in decisions of market participants, who were originally affected neither by the virus nor by fear of it, may set off an epidemic of market movements.", [["participants", "SPECIES", 81, 93], ["movements", "OBSERVATION_MODIFIER", 4, 13]]], ["This can lead, as we have observed recently, to a crash of unprecedented proportions.Strategies and policies to increase resilienceSo, how should we deal with the considerable shock that Covid-19 places upon international markets, public health, social activity, and governance?", [["shock", "DISEASE", 176, 181]]], ["How can we address the cognitive and especially behavioral effects of fear at the individual and collective level which can trigger substantial slowdowns in economic activity, as well as the systemic effects that strain various sectors of international trade and governance?Strategies and policies to increase resilienceTwo overarching philosophies and methodologies are available for stakeholders to draw upon.", [["the cognitive", "PROBLEM", 19, 32], ["substantial", "OBSERVATION_MODIFIER", 132, 143], ["overarching philosophies", "OBSERVATION", 324, 348]]], ["As the basis of conventional risk management (i.e., to prepare for and absorb shocks), this option is politically appealing at the onset, as it offers the possibility that unacceptable risks may be mitigated before they cause serious problems.", [["conventional risk management", "TREATMENT", 16, 44], ["absorb shocks", "TREATMENT", 71, 84], ["serious problems", "PROBLEM", 226, 242]]], ["3 In a world of rapid feedback loops and increasingly nested systems where cascading failures are inevitable, however, such options might be ineffective at protecting economic and social systems and calming perturbations, or would be ruinously expensive to implement to the extent needed to assure policymakers and other stakeholders of adequate protection (Michel-Kerjan 2012; .Strategies and policies to increase resilienceThe second approach is one that accepts the inherently uncertain, unpredictable, and even random nature of systemic threats and addresses them through building system resilience.", [["rapid feedback loops", "PROBLEM", 16, 36], ["increasingly nested systems", "PROBLEM", 41, 68], ["cascading failures", "PROBLEM", 75, 93]]], ["Rather than rely solely upon the ability of system operators to prevent, avoid, withstand, and absorb any and all threats, resilience emphasizes the importance of recovery and adaptation in the aftermath of disruption.", [["system operators", "TREATMENT", 44, 60], ["disruption", "PROBLEM", 207, 217]]], ["Resilience acknowledges that massive disruptions can and will happen-in the future, for example, climate disruption will likely compound other shocks like pandemics-and it is essential that core systems have the capacity for recovery and adaptation to ensure their survival into the future, and even take advantage of new or revealed opportunities following the crises to improve the system through broader systemic changes.", [["massive disruptions", "PROBLEM", 29, 48], ["pandemics", "PROBLEM", 155, 164], ["the crises", "PROBLEM", 358, 368], ["broader systemic changes", "PROBLEM", 399, 423], ["massive", "OBSERVATION_MODIFIER", 29, 36], ["disruptions", "OBSERVATION", 37, 48], ["systemic", "OBSERVATION", 407, 415]]], ["4 This is sometimes characterized as not just bouncing back, but \"bouncing forward\" (Linkov et al. 2018a, b; Ganin et al. 2016 Ganin et al. , 2017 .Strategies and policies to increase resilienceCovid-19 is the latest instance of an unpredictable shock to interconnected systems, where international recovery will have vast implications for future economic, social, and governmental activity.", [["shock", "DISEASE", 246, 251], ["resilienceCovid", "TEST", 184, 199], ["an unpredictable shock", "PROBLEM", 229, 251]]], ["Resilience must become a core philosophy within system management and operation to ensure we are able to continue to function despite disruptions like Covid-19, and are able not only to adapt and improve in its aftermath, but to seize upon new or revealed opportunities.", [["system management", "TREATMENT", 48, 65], ["operation", "TREATMENT", 70, 79], ["disruptions", "PROBLEM", 134, 145], ["Covid", "TEST", 151, 156]]], ["5 Interconnectivity between systems is one of the structuring and determining features of our modern world, which is becoming ever more complex and dynamic.", [["more complex", "OBSERVATION_MODIFIER", 131, 143]]], ["This is a product of economic opportunity as well as global political interconnectedness, and has brought considerable benefits to much of the global population.", [["political interconnectedness", "OBSERVATION", 60, 88]]], ["An instinctive reaction to the Covid-19 outbreak would be to limit or reduce such interconnectedness, yet such sweeping policy changes would not better protect countries or international markets against future systemic threats.", [["An instinctive reaction", "PROBLEM", 0, 23], ["the Covid", "TREATMENT", 27, 36]]], ["Instead, an emphasis upon developing resilience within the international economic system is a necessary evolution for a post-Covid-19 world, where systems are designed to facilitate recovery and adaptation in the aftermath of disruption.Strategies and policies to increase resilienceComplementing risk-based approaches with resiliencebased approaches for management of epidemics, as well as for other systemic threats, is a necessity.", [["disruption", "PROBLEM", 226, 236], ["resiliencebased approaches", "TREATMENT", 324, 350], ["management", "TREATMENT", 355, 365], ["epidemics", "PROBLEM", 369, 378], ["disruption", "OBSERVATION", 226, 236]]], ["There is an awareness that the systemic threats modern societies face are increasingly difficult to model, and are often too complex to be solved for the \"optimal response\" using traditional approaches of risk assessment that focus primarily upon system hardness and ability to absorb threats before breaking.", [["risk assessment", "TEST", 205, 220], ["systemic", "OBSERVATION_MODIFIER", 31, 39]]], ["The new approach to resilience will focus on the ability of a system to anticipate, absorb, recover from, and adapt to a wide array of systemic threats (see Figure 1) . identify systemic threats and review the analytical and governance approaches and strategies to manage these threats (including epidemics) and build resilience to contain their impacts.", [["governance approaches", "TREATMENT", 225, 246], ["epidemics", "PROBLEM", 297, 306], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["This aims to help policymakers build safeguards, buffers and ultimately resilience to physical, economic, social and environmental shocks.Strategies and policies to increase resilienceFundamentally, Covid-19 is a multi-system problem.", [["physical, economic, social and environmental shocks", "DISEASE", 86, 137], ["Covid", "TEST", 199, 204], ["a multi-system problem", "PROBLEM", 211, 233], ["multi-system", "OBSERVATION_MODIFIER", 213, 225], ["problem", "OBSERVATION", 226, 233]]], ["Beginning with a slow yet unchecked spread of disease on a global scale, it quickly disrupted hospital systems and associated resource and labor requirements.", [["a slow yet unchecked spread of disease", "PROBLEM", 15, 53], ["labor requirements", "PROBLEM", 139, 157], ["slow", "OBSERVATION_MODIFIER", 17, 21], ["unchecked", "OBSERVATION_MODIFIER", 26, 35], ["spread", "OBSERVATION_MODIFIER", 36, 42], ["disease", "OBSERVATION", 46, 53]]], ["Simultaneously, as socioeconomic activity waned per government orders for quarantine and shelter-in-place, systemic disruption spread beyond the public health domain and into energy (fossil fuels), economics and finance, and even the broader political systems of various states.", [["quarantine", "TREATMENT", 74, 84], ["shelter", "TREATMENT", 89, 96], ["systemic disruption", "PROBLEM", 107, 126], ["systemic", "ANATOMY", 107, 115], ["disruption", "OBSERVATION", 116, 126]]], ["The loss of functionality triggered by this single disruption origin is one that requires robust recovery to minimize extensive and even permanent multisystem losses and damages (see Fig. 1 )-a lesson learned from the aftermath of the Great Recession.Recovery and adaptation in the aftermath of disruptionsRecovery and adaptation in the aftermath of disruptions is a requirement for interconnected 21st century economic, industrial, social, and health-based systems, and resilience is an increasingly crucial part of strategies to avoid systemic collapse (Merad and Trump 2020) .", [["The loss of functionality", "PROBLEM", 0, 25], ["permanent multisystem losses and damages", "PROBLEM", 137, 177], ["systemic collapse", "PROBLEM", 537, 554], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["multisystem losses", "OBSERVATION", 147, 165], ["Great Recession", "OBSERVATION", 235, 250], ["collapse", "OBSERVATION", 546, 554]]], ["Based on OECD reports and the resilience literature, specific recommendations for building resilience to contain epidemics and other systemic threats include:Recovery and adaptation in the aftermath of disruptions\u2022 Design systems, including infrastructure, supply chains, economic, financial, and public health systems, to be resilient, i.e., recoverable and adaptable. \u2022 Develop methods for quantifying resilience so that tradeoffs between a system's efficiency and resilience can be made explicit and can guide investments. \u2022 Control system complexity to minimize cascading failures resulting from unexpected disruption by decoupling unnecessary connections across infrastructure and making necessary connections controllable and visible. \u2022 Manage system topology by designing appropriate connections and communications across interconnected infrastructure. \u2022 Add resources and redundancies in system-crucial components to ensure functionality.", [["building resilience", "TREATMENT", 82, 101], ["epidemics", "PROBLEM", 113, 122], ["Design systems", "PROBLEM", 215, 229], ["economic, financial, and public health systems", "PROBLEM", 272, 318], ["a system's efficiency", "TREATMENT", 441, 462], ["cascading failures", "PROBLEM", 566, 584], ["unexpected disruption", "PROBLEM", 600, 621], ["decoupling unnecessary connections across infrastructure", "PROBLEM", 625, 681], ["chains", "OBSERVATION_MODIFIER", 264, 270], ["cascading failures", "OBSERVATION", 566, 584]]], ["This system brings together market expertise (mostly from FAO) and policy knowledge (mostly from OECD), a Market Information Group (country representatives, mandated to ensure timely exchange of market insights), and a Rapid Response Forum (senior country representatives, supported by IOs, tasked with addressing emergency situations in real time -to avoid a crisis, or at least mitigate its severity).", [["a crisis", "PROBLEM", 358, 366]]], ["AMIS proved its value by averting a near-crisis in its first year of operation, and is active at this moment monitoring markets and policies, and engaging with countries to facilitate informed decision-making and avoidance of bad policy choices.Recovery and adaptation in the aftermath of disruptions\u2022 Develop real-time decision support tools integrating data and automating selection of management alternatives based on explicit policy trade-offs in real time.Recovery and adaptation in the aftermath of disruptionsProcedurally, a complement to such resilience-based approaches is included in the International Risk Governance Centre's Guidelines for the Governance of Systemic Risks (IRGC 2018).", [["disruptions", "PROBLEM", 289, 300], ["management alternatives", "TREATMENT", 388, 411], ["operation", "OBSERVATION", 69, 78], ["active", "OBSERVATION_MODIFIER", 87, 93]]], ["The IRGC highlights a multi-step procedure to identify, analyze, and govern systemic risks, as well as better prepare affected systems for such risks by mitigating possible threats and transitioning the system toward one of resiliency-by-design.", [["a multi-step procedure", "TREATMENT", 20, 42]]], ["As a cyclical process, the IRGC's process for the governance of systemic risk includes:Recovery and adaptation in the aftermath of disruptions1.", [["a cyclical process", "PROBLEM", 3, 21], ["the IRGC's process", "TREATMENT", 23, 41]]], ["Co-develop management strategies dealing with each scenario.", [["Co-develop management strategies", "TREATMENT", 0, 32]]], ["Address unanticipated barriers and sudden critical shifts.", [["sudden critical shifts", "PROBLEM", 35, 57]]], ["Decide, test, and implement strategies.", [["test", "TEST", 8, 12]]], ["Monitor, learn from, review, and adapt.Recovery and adaptation in the aftermath of disruptionsThe purpose of IRGC's exercise is not to generate a deterministic model that applies to any and all systems-this is neither possible nor helpful.", [["IRGC's exercise", "TREATMENT", 109, 124]]], ["Instead, it is designed to produce more introspective, collaborative, and multi-system viewpoints regarding the threats that may be lingering along the peripheries of our systems, as well as where our system's critical functions or resilience challenges should be improved within future strategic management opportunities.Recovery and adaptation in the aftermath of disruptionsAn example of applying similar approaches to disease epidemics is presented in Massaro et al (2018) .", [["resilience challenges", "TREATMENT", 232, 253], ["strategic management", "TREATMENT", 287, 307], ["disease epidemics", "PROBLEM", 422, 439]]], ["The methodological resilience framework discussed above was applied to the analysis of the spread of infectious diseases across connected populations.", [["infectious diseases", "DISEASE", 101, 120], ["the analysis", "TEST", 71, 83], ["infectious diseases", "PROBLEM", 101, 120], ["infectious", "OBSERVATION", 101, 111]]], ["Massaro et al. monitor the system-level response to the epidemic by introducing a definition of engineering resilience that compounds both the disruption caused by the restricted travel and social distancing and the incidence of the disease.", [["the system", "TEST", 23, 33], ["engineering resilience", "TREATMENT", 96, 118], ["the disease", "PROBLEM", 229, 240], ["disease", "OBSERVATION", 233, 240]]], ["They confirm that intervention strategies, such as restricting travel and encouraging self-initiated social distancing, reduce the risk to individuals of contracting the disease.", [["intervention strategies", "TREATMENT", 18, 41], ["the disease", "PROBLEM", 166, 177], ["disease", "OBSERVATION", 170, 177]]], ["There is, though, a price to pay in terms of population mobility that will inevitably have repercussions on critical functionality, thus making the system less resilient, unless this is factored in to lockdowns, curfews, and other responses.Recovery and adaptation in the aftermath of disruptionsSo although containment measures are unavoidable to slow down the epidemic's progression, such measures may drive the system into negative health and economic outcomes.", [["containment measures", "TREATMENT", 308, 328]]], ["Multiple dimensions of a socio-technical system must be considered in epidemic management.", [["a socio-technical system", "TREATMENT", 23, 47], ["epidemic management", "TREATMENT", 70, 89], ["dimensions", "OBSERVATION_MODIFIER", 9, 19]]], ["For Covid-19, this implies that countries should resist the temptation to self-isolate from their international partners in an attempt to build national self-reliance.", [["Covid", "TEST", 4, 9]]], ["Viruses do not respect borders or administrative silos and the response to them has to be international and inter-sectoral.", [["Viruses", "PROBLEM", 0, 7]]], ["Fig. 1 COVID-19 disruption as a multi-system challenge.", [["a multi-system challenge", "TREATMENT", 30, 54]]], ["Where the threats, exploited vulnerabilities, and consequences of COVID-19 continue to manifest around the globe, extensive consideration must be given not only to how risk is absorbed and mitigated, but how affected systems will recover, adapt, and preferably \"bounce forward\" toward a more ideal system state (after Governments are considering a wide variety of political and economic policies to safeguard and recover economic and societal functions lost due to the Covid-19 pandemic.", [["COVID", "TEST", 66, 71], ["the Covid", "TEST", 465, 474], ["pandemic", "PROBLEM", 478, 486], ["globe", "ANATOMY", 107, 112]]], ["It will be important to frame strategic opportunities to shape intermediate and future policy in a manner that not only preserves normatively beneficial systems and recovers from this crisis, but also frames national and international economic systems.", [["this crisis", "PROBLEM", 179, 190]]], ["Any policy decisions in the short term will shape not only the nature of economic recovery in the next year, but the economic and political priorities of economic globalization as well.", [["economic globalization", "TREATMENT", 154, 176]]], ["6 Policy choices made for the recovery will also have a strong influence on the world's ability to avert dangerous climate change, as well as to become more resilient to the climate impacts already locked in.Recovery and adaptation in the aftermath of disruptionsIn recovering from the Covid-19 shock, policymakers can use economic models and other analytical resources to assess the efficiency of different regulatory policies discussed in Box 1.", [["shock", "DISEASE", 295, 300], ["economic models", "TREATMENT", 323, 338], ["other analytical resources", "TREATMENT", 343, 369]]], ["The immediate health, economic, and social needs are of critical importance, but developing strategic priorities and building resilience in national and regional responses to the crises will be equally important.", [["the crises", "PROBLEM", 175, 185]]], ["In both cases, policy interventions and priorities to address Covid-19 must incorporate principles of system resilience to systemic disruption now, for not doing so will limit socioeconomic recovery for the next decade.Recovery and adaptation in the aftermath of disruptionsSystems thinking is the most powerful tool we have at our disposal to accomplish this task, so long as it is part of a trilogy completed by anticipation and resilience.", [["policy interventions", "TREATMENT", 15, 35], ["Covid", "TEST", 62, 67], ["systemic disruption", "PROBLEM", 123, 142]]], ["On a theoretical level, systems thinking shows that crises are an intrinsic characteristic of complex systems such as public health or financial markets.", [["crises", "PROBLEM", 52, 58], ["crises", "OBSERVATION", 52, 58]]], ["Policymakers must be prepared for this eventual failure, even if preparation does not appear to be cost effective until after the crisis has happened.", [["this eventual failure", "PROBLEM", 34, 55], ["the crisis", "PROBLEM", 126, 136]]], ["The excuse that dangers are clear only in hindsight does not stand up to objective scrutiny.", [["clear", "OBSERVATION", 28, 33]]], ["Major simulation exercises in OECD countries predicted accurately how a crisis like Covid-19 could unfold, 7 but they were not acted upon, or at least not sufficiently, judging by what has happened.Recovery and adaptation in the aftermath of disruptionsNo two crises are identical, but they can all offer useful lessons for the next time.", [["two crises", "PROBLEM", 256, 266], ["two", "OBSERVATION_MODIFIER", 256, 259], ["crises", "OBSERVATION", 260, 266]]], ["Some countries, such as Korea, drew on past experience to react quickly to the new coronavirus threat.", [["coronavirus", "DISEASE", 83, 94], ["coronavirus", "ORGANISM", 83, 94]]], ["Korea was helped by the fact that its hospital system has a high number of intensive care beds, indeed higher than many health system managers would consider cost-efficient.", [["intensive care beds", "TREATMENT", 75, 94]]], ["But extra capacity increases resilience.", [["extra capacity", "PROBLEM", 4, 18], ["capacity", "OBSERVATION_MODIFIER", 10, 18], ["increases", "OBSERVATION_MODIFIER", 19, 28]]], ["In health and other physical domains, an emphasis on resilience can be easily recognized as cost effective, given the enormous costs of investing in the infrastructures and other resources that would be needed to prevent planetary emergencies such as serious floods, droughts, or other disasters provoked by climate change .Recovery and adaptation in the aftermath of disruptionsResilience is also a safe option in intangible domains such as financial systems.", [["floods", "DISEASE", 259, 265], ["droughts", "DISEASE", 267, 275], ["a safe option", "TREATMENT", 398, 411]]], ["Plenty of people saw the present financial crisis coming and many experts pointed to debt as a major contributing factor to system fragility.", [["people", "ORGANISM", 10, 16], ["people", "SPECIES", 10, 16], ["system fragility", "PROBLEM", 124, 140]]], ["A policy approach based on systems thinking would accept that although we do not know what the trigger of the next crisis will be, we do know it will come and that certain factors can make it more likely and more damaging, and that there are better policy options than waiting for it to happen and then paying for bailouts.Recovery and adaptation in the aftermath of disruptionsFinally, a systems approach will help \"break down silos\".", [["A policy approach", "TREATMENT", 0, 17], ["a systems approach", "TREATMENT", 387, 405]]], ["It can quickly spread to other systems that at first sight seem to be unconnected.", [["unconnected", "OBSERVATION", 70, 81]]], ["In a world where an ecosystem in a Chinese province can trigger a global economic crisis, we have to abandon our traditional, linear, compartmentalized way of making and applying policy, and cooperate pragmatically at local to international levels.", [["a global economic crisis", "PROBLEM", 64, 88]]], ["7 For example, Crimson Contagion in the US or Exercise Cygnus in the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 69, 71], ["the US", "TEST", 36, 42]]], ["6 Just as in advanced economies, governments in developing countries need to take swift action; however, their institutional and fiscal capacities are limited.", [["advanced", "OBSERVATION_MODIFIER", 13, 21], ["economies", "OBSERVATION", 22, 31]]], ["The crisis has exposed an aspect of fiscal policy in developing countries that was previously less examined: their resilience.", [["The crisis", "PROBLEM", 0, 10], ["crisis", "OBSERVATION", 4, 10]]], ["Timely international coordination to enable developing countries to face the crisis with the economic packages needed will be fundamental in the short-to medium-term.", [["the crisis", "PROBLEM", 73, 83], ["the economic packages", "TREATMENT", 89, 110]]], ["The financial pressure that economic packages will put on fiscal systems should not be under-estimated.", [["The financial pressure", "TREATMENT", 0, 22], ["economic packages", "TREATMENT", 28, 45], ["fiscal systems", "TREATMENT", 58, 72], ["pressure", "OBSERVATION_MODIFIER", 14, 22]]], ["Most developing countries face high levels of informality -both workers and firms -requiring innovative channels to reach the vulnerable population in times of crisis.Box 1.", [["Box 1", "GENE_OR_GENE_PRODUCT", 167, 172], ["innovative channels", "TREATMENT", 93, 112], ["crisis", "PROBLEM", 160, 166]]], ["Policy response Identify interventions to improve business recovery post-Covid-19.", [["Covid", "TEST", 73, 78]]], ["Funding should be prioritized based on immediate needs for economic recovery at the system level, including a consideration of local demand, of the regional /global supply chain, and of the impact of the region in question on regional, state, and global economy.", [["economic recovery", "TREATMENT", 59, 76], ["local demand", "TREATMENT", 127, 139], ["local demand", "OBSERVATION", 127, 139], ["regional", "ANATOMY_MODIFIER", 148, 156], ["global", "OBSERVATION_MODIFIER", 158, 164], ["supply chain", "OBSERVATION", 165, 177], ["global", "OBSERVATION_MODIFIER", 247, 253], ["economy", "OBSERVATION", 254, 261]]], ["Any low-interest loans or targeted investments/disbursements should be targeted here, rather than prioritizing businesses or industries with social or economic net negatives/ harms to broader society (i.e., high downstream costs with low immediate benefits via exploitative wages and sending money outside of the local economy).Box 1.", [["Box 1", "GENE_OR_GENE_PRODUCT", 328, 333], ["low", "OBSERVATION_MODIFIER", 4, 7]]], ["This principle is evident in global supply chains, surely one of the most efficient components of the international economy.", [["global", "OBSERVATION_MODIFIER", 29, 35], ["supply", "OBSERVATION_MODIFIER", 36, 42], ["chains", "OBSERVATION_MODIFIER", 43, 49], ["most", "OBSERVATION_MODIFIER", 69, 73], ["efficient", "OBSERVATION_MODIFIER", 74, 83], ["components", "OBSERVATION_MODIFIER", 84, 94], ["international economy", "OBSERVATION", 102, 123]]], ["The French Minister for the Economy, Bruno Le Maire, argues that that there will be a before and after Covid-19 for the world economic system: \"We need to draw all the conclusions from this epidemic on the way globalization is organized, and notably value chains\" (Le Maire 2020).", [["Covid", "TEST", 103, 108]]], ["When your highly optimized workflow is disrupted by shocks such as Covid-19, maybe just-in-time needs a dose of just-in-case.Box 1.", [["Box 1", "GENE_OR_GENE_PRODUCT", 125, 130]]], ["27 million people viewed the talk in which he made this comment, but as he noted in 2020, nobody in power heard the message.", [["people", "ORGANISM", 11, 17], ["people", "SPECIES", 11, 17]]], ["We are now in the midst of a systemic upheaval.", [["a systemic upheaval", "TREATMENT", 27, 46]]], ["In the spirit of Gates' call, international policymaking should look to better anticipate, prepare for, and build resilience for future crises.Box 1.", [["Box 1", "GENE_OR_GENE_PRODUCT", 143, 148], ["future crises", "PROBLEM", 129, 142]]], ["Strategic policy interventions for COVID-19The radical uncertainty associated with complex systems makes it impossible to predict where the next crisis will come from; nevertheless, this should not stop us learning the lessons of the past to prepare a systemic response for the future.", [["COVID-19", "CHEMICAL", 35, 43], ["COVID", "TEST", 35, 40], ["complex systems", "PROBLEM", 83, 98], ["radical uncertainty", "OBSERVATION", 47, 66]]], ["One lesson from Covid-19 is that crises do not repeat themselves.", [["Covid", "TEST", 16, 21]]], ["The fact that we were able to contain previous coronavirus crises such as SARS led to a sense of complacency in some instances about our ability to contain any future crisis.", [["coronavirus crises", "DISEASE", 47, 65], ["SARS", "DISEASE", 74, 78], ["coronavirus", "ORGANISM", 47, 58], ["previous coronavirus crises", "PROBLEM", 38, 65], ["SARS", "PROBLEM", 74, 78], ["any future crisis", "PROBLEM", 156, 173]]], ["In systemic terms, this is not a shock, with all that implies of a sudden, unexpected occurrence, but more like a stress.", [["shock", "DISEASE", 33, 38], ["a shock", "PROBLEM", 31, 38], ["systemic terms", "OBSERVATION", 3, 17], ["shock", "OBSERVATION", 33, 38]]], ["Systems analysis teaches us that stresses such as global warming are non-linear.", [["global warming", "TREATMENT", 50, 64]]], ["The system may continue to function more or less normally for a long period and only degrade slowly, but it can then reach a tipping point from which it cannot recover, and collapse can then be extremely rapid.", [["collapse", "PROBLEM", 173, 181], ["collapse", "OBSERVATION", 173, 181], ["rapid", "OBSERVATION_MODIFIER", 204, 209]]], ["Covid-19 shows that we have to act now, because we simply don't know how changes in one system may evolve and impact other systems, or in this case how a mutation in a virus could cripple the world economy.", [["Covid", "TEST", 0, 5], ["a mutation", "PROBLEM", 152, 162], ["a virus", "PROBLEM", 166, 173]]], ["We can anticipate, however, that serious damage to a natural system, such as biodiversity loss, or significant changes, such as sea level rise or increased occurrence of extreme weather, will have serious impacts on economic and social systems too.", [["biodiversity loss", "DISEASE", 77, 94], ["serious damage to a natural system", "PROBLEM", 33, 67], ["biodiversity loss", "PROBLEM", 77, 94], ["significant changes", "PROBLEM", 99, 118], ["sea level rise", "PROBLEM", 128, 142], ["significant", "OBSERVATION_MODIFIER", 99, 110]]], ["Further, as we recover and reconfigure systems for a brighter future, we must be cognizant of the fact that future systemic shocks may arise from any number of origins or industries, with no reasonable wayConclusionsEconomic analysis is often the most important tool for policymaking, but given that the socioeconomic system is changing and self-organizing itself in a way which is difficult, if not impossible, to reconcile with existing theory, economics has to change too.", [["future systemic shocks", "TREATMENT", 108, 130], ["Economic analysis", "TEST", 216, 233]]], ["In an increasingly complex and interdependent system, the aggregate phenomena that emerge do so as a reflection of the interaction between all the participants.", [["participants", "SPECIES", 147, 159], ["the aggregate phenomena", "PROBLEM", 54, 77], ["increasingly", "OBSERVATION_MODIFIER", 6, 18], ["complex", "OBSERVATION", 19, 26], ["interdependent system", "OBSERVATION", 31, 52], ["aggregate phenomena", "OBSERVATION", 58, 77]]], ["The system is constantly evolving and is neither in, nor converging toward, a steady state.", [["constantly", "OBSERVATION_MODIFIER", 14, 24], ["evolving", "OBSERVATION", 25, 33]]], ["Policy cannot be based on extrapolations from the past or analysis of the behavior of an isolated individual.ConclusionsSystem-analysis models have to improve too, to better integrate real-world dynamics such as social and behavioral heterogeneity.", [["analysis models", "TEST", 127, 142]]], ["This will help to represent social dynamics and complex collective decision-making and facilitate the evaluation of the effectiveness of policies and their systemic impacts.", [["the evaluation", "TEST", 98, 112]]], ["A promising approach is to integrate existing modeling tools from different fields, for example linking environmental models with economic growth and trade models.", [["economic growth and trade models", "PROBLEM", 130, 162]]], ["This extends the boundaries of what is modeled and allows for broader ranges of interactions to assess policy interventions.", [["policy interventions", "TREATMENT", 103, 123]]], ["Going beyond the integration of existing tools may involve pioneering applications and innovative methodologies and tools in several areas, including explicit accounting for uncertainty, multiple agents with strategic interactions, bounded rationality, including consumption preferences and consumer choices, and network effects linked to complex interconnectedness and systemic risks.ConclusionsA fundamental challenge to governing systemic risk is understanding the system as a complex network of individual and institutional actors with different and often conflicting interests, values, and worldviews.", [["pioneering applications", "TREATMENT", 59, 82], ["innovative methodologies", "TEST", 87, 111], ["systemic risks", "OBSERVATION", 370, 384]]], ["Superimposed on this governance network are the potential risk events with ill-defined chains or networks of interrelated consequences and impacts.", [["ill-defined chains", "PROBLEM", 75, 93]]]], "34acf621a791371e3264624336987cbf58f3729b": [["In the UK, a drop in recruitment and retention of qualified nursing staff, as well as a rise in patient acuity, have been identified as main reasons for this workforce crisis [3] .", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["a rise in patient acuity", "PROBLEM", 86, 110], ["drop", "OBSERVATION_MODIFIER", 13, 17], ["recruitment", "OBSERVATION_MODIFIER", 21, 32]]], ["The Rising Pressure report by the Health Foundation in 2017 showed that there was a 0.2% drop in the number of registered nurses, with a median leaver rate of around 15% in National Health Service (NHS) organisations [4] .", [["Rising", "OBSERVATION_MODIFIER", 4, 10], ["Pressure", "OBSERVATION_MODIFIER", 11, 19]]], ["However, these systems come under extraordinary strain when hospital and community services are placed under 'atypical' conditions, such as those witnessed during the recent Covid-19 outbreak.BackgroundA review of systematic reviews of determinants of nurses' intention to leave, found that the majority of included studies made a distinction between individual and organisational determinants of intention to leave.", [["the recent Covid", "TEST", 163, 179], ["studies", "TEST", 316, 323]]], ["Individual determinants include age, gender, marital status, educational attainment, stress, burnout, commitment, job satisfaction, low serum cholesterol, weight and sleep disturbance [7] .", [["serum", "ANATOMY", 136, 141], ["burnout", "DISEASE", 93, 100], ["cholesterol", "CHEMICAL", 142, 153], ["sleep disturbance", "DISEASE", 166, 183], ["cholesterol", "CHEMICAL", 142, 153], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["cholesterol", "SIMPLE_CHEMICAL", 142, 153], ["low serum cholesterol", "PROBLEM", 132, 153], ["sleep disturbance", "PROBLEM", 166, 183]]], ["Organisational determinants have centred on malfunctioning management and lack of supervision [8] .", [["malfunctioning management", "TREATMENT", 44, 69]]], ["For instance, individual studies by Larrabee et al., have shown that job dissatisfaction is predictive of both the intention to leave as well as actual turnover [9] .BackgroundWhilst several studies have sought to address the range of predictors of intention to leave, some have furthered the field by use of a theoretical approach.", [["individual studies", "TEST", 14, 32], ["a theoretical approach", "TREATMENT", 309, 331]]], ["The findings showed that lack of fairness and ethical leadership can have particularly bad consequences on nurses during difficult times such as the COVID-19 pandemic [13] .BackgroundPrevalence of job dissatisfaction among RNs was further highlighted through findings of a cross-sectional survey of 488 hospitals across Europe and the United States, which explored the level of dissatisfaction among RNs and associated outcomes.", [["the COVID", "TEST", 145, 154]]], ["It found that job dissatisfaction was highest in Greece (56%), followed by Ireland (42%) and England (39%).", [["job dissatisfaction", "PROBLEM", 14, 33]]], ["Notably, a higher patient to nurse ratio (more than 10:1 in Greece and more than 8:1 for the latter two), as well as poor work environment, was reported in these countries [14] .BackgroundA recent review of systematic reviews, exploring interventions to reduce adult nursing turnover, concluded that more high-quality primary research is needed to inform decision-making by human resource managers and organisations to improve retention strategies.", [["patient", "ORGANISM", 18, 25], ["human", "ORGANISM", 374, 379], ["patient", "SPECIES", 18, 25], ["human", "SPECIES", 374, 379], ["human", "SPECIES", 374, 379], ["interventions", "TREATMENT", 237, 250], ["retention strategies", "TREATMENT", 427, 447]]], ["The study included 9 systematic reviews in total.", [["The study", "TEST", 0, 9]]], ["The main reasons for reviews being in the moderate rather than strong evidence category were the lack of publication of a review protocol, unclear search strategy performed, the failure to have two reviewers check the selection and data extraction and not providing a list of both included and excluded primary studies.", [["a review protocol", "TEST", 120, 137], ["data extraction", "TEST", 232, 247], ["primary studies", "TEST", 303, 318], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["More high-quality research would allow a better understanding the current main causes of RNs dissatisfaction based on primary research and is therefore pivotal to address this issue [15] .BackgroundThe aim of this study was to undertake a secondary analysis of a large UK wide data set in order to assess a set of self-reported individual and organisational predictors of nurses' satisfaction/ dissatisfaction.", [["RNs dissatisfaction", "PROBLEM", 89, 108], ["this study", "TEST", 209, 219], ["dissatisfaction", "PROBLEM", 394, 409]]], ["These data were collected during 2017, ahead of recent global pandemic conditions.", [["recent global pandemic conditions", "PROBLEM", 48, 81], ["pandemic conditions", "OBSERVATION", 62, 81]]], ["Research about the determinants of dissatisfaction, as one of the predictors of nurses' intention to leave is becomes even more relevant during a pandemic crisis such as COVID-19.BackgroundWhilst we recognise that there are many factors involved in nurses' intention to leave, we have used the data available to us.", [["a pandemic crisis", "PROBLEM", 144, 161], ["COVID", "TEST", 170, 175]]], ["In this study, we cannot predict 'intention to leave' but we are exploring job satisfaction as one of the previously known determinants of the intention to leave within a cohort of adult acute RNs.MethodsThis study presents findings from a secondary analysis of an online-based cross-sectional survey of registered nurses from across the UK developed and administered by the RCN in May 2017 [16] .", [["this study", "TEST", 3, 13], ["Methods", "TREATMENT", 197, 204], ["This study", "TEST", 204, 214], ["a secondary analysis", "TEST", 238, 258]]], ["The RCN is the UK's largest professional nursing body consisting of 450,000 members of registered and non-registered nursing and health care staff.", [["largest", "OBSERVATION_MODIFIER", 20, 27]]], ["From this, we initially developed a framework, and subsequently a thematic analysis, of the qualitative data.", [["a thematic analysis", "TEST", 64, 83], ["the qualitative data", "TEST", 88, 108]]], ["Definitions of abductive reasoning vary, however, all recognise it as a process where there is a cyclical and creative movement between the formulation of hypotheses and observed phenomena [17, 18] .", [["a cyclical and creative movement", "PROBLEM", 95, 127]]], ["While some identify the challenges of utilising abduction in qualitative studies [19] , it is a form of reasoning well suited to mixed methods research as it develops claims supported from both deductive and inductively sourced evidence, in situations where the research is not driven exclusively by theory or by data [20] .Study populationIn May 2017, a staff survey of RN's was carried out by the Royal College of Nursing (RCN).", [["utilising abduction", "TEST", 38, 57], ["qualitative studies", "TEST", 61, 80]]], ["The sample therefore consisted of both RCN members and non-members across the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 78, 80]]], ["For the purpose of analysis, we identified from the data base and then included adult acute care nurses, which comprised 7040 RNs in total.", [["analysis", "TEST", 19, 27]]], ["In the UK, adult acute care covers all aspects of medical and surgical hospital in-patient care for those over 18 years of age but does not usually include in-patient mental health care.", [["patient", "ORGANISM", 83, 90], ["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 83, 90], ["patient", "SPECIES", 159, 166], ["acute", "OBSERVATION_MODIFIER", 17, 22]]], ["In order to provide a clear research focus on a specific group of RNs, we excluded RNs from the community, children's nursing, mental health nursing and learning disabilities sectors.", [["learning disabilities", "DISEASE", 153, 174], ["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115]]], ["These settings will be analysed in subsequent pieces of work.", [["These settings", "TREATMENT", 0, 14]]], ["As a result, we were unable to carry out our analysis at the level of hospital and NHS trusts or consider the impact of demographics.Data sharing agreement and ethicsBefore work commenced, a data sharing agreement was obtained between The University of Sheffield and the RCN.", [["our analysis", "TEST", 41, 53]]], ["However, respondents were in fact reporting on feeling Demoralised, which is a much stronger sentiment.Measured outcomesWe aimed to test all independent variables available from the survey that have been identified in previous literature as determinants of nurse job dissatisfaction and demoralisation.", [["demoralisation", "DISEASE", 287, 301], ["demoralisation", "PROBLEM", 287, 301]]], ["The dependent variable was tested against all available independent variables in Table 1 .Measured outcomesRespondents were also requested to respond to an open question asking them to describe and/or give examples of their last shift and any concerns or challenges they were able to observe.", [["dependent", "OBSERVATION_MODIFIER", 4, 13], ["variable", "OBSERVATION_MODIFIER", 14, 22]]], ["There was no word limit set on the length of replies to the open response question.", [["no", "UNCERTAINTY", 10, 12]]], ["These varied considerably in length and the amount of detail provided from a couple of sentences to 1-2 paragraphs.", [["varied", "OBSERVATION_MODIFIER", 6, 12], ["considerably", "OBSERVATION_MODIFIER", 13, 25], ["length", "OBSERVATION_MODIFIER", 29, 35], ["amount", "OBSERVATION_MODIFIER", 44, 50]]], ["Due to the large amount of data from 1747 responses, 400 pages, we randomly sampled 10 pages of data for the analysis.", [["the analysis", "TEST", 105, 117], ["large", "OBSERVATION_MODIFIER", 11, 16], ["amount", "OBSERVATION_MODIFIER", 17, 23]]], ["This resulted in descriptive, narrative data from 368 individuals (20%) in total.", [["narrative data", "TEST", 30, 44]]], ["While no formal test of data saturation was performed, a member of the team checked the emerging coding against a further 10 pages of data and no new codes were noted.", [["formal test of data saturation", "TEST", 9, 39]]], ["In addition, Braun & Clarke suggest that for qualitative analysis of open question survey responses, a sample size of over 100 respondents is required for a large project [21] .", [["qualitative analysis", "TEST", 45, 65]]], ["We are therefore confident that with the responses from 368 individuals, and from checking an additional 10% of the data, that data saturation was achieved.Data analysisAn explanatory analysis was used to draw conclusions about the findings from the survey.", [["the data", "TEST", 112, 120], ["that data saturation", "TEST", 122, 142], ["explanatory analysis", "TEST", 172, 192], ["the survey", "TEST", 246, 256]]], ["In the first part of the analysis, we conducted univariate analysis with independent variables from the survey in order to assess the relationship and best model for predicting job dissatisfaction and demoralisation.", [["demoralisation", "DISEASE", 201, 215], ["the analysis", "TEST", 21, 33], ["univariate analysis", "TEST", 48, 67], ["the survey", "TEST", 100, 110], ["predicting job dissatisfaction", "PROBLEM", 166, 196], ["demoralisation", "PROBLEM", 201, 215]]], ["A normality test showed that data was normally distributed for all responses.", [["A normality test", "TEST", 0, 16]]], ["We identified determinants that were most associated with affecting demoralisation.", [["affecting demoralisation", "PROBLEM", 58, 82], ["most associated with", "UNCERTAINTY", 37, 57]]], ["From this point, a set of categories based on the findings from the regression modelling were used as an initial framework to organise and explore the qualitative data.", [["the qualitative data", "TEST", 147, 167]]], ["Specifically, narratives around what led to dissatisfaction and feeling demoralised within this data set were considered.", [["dissatisfaction", "PROBLEM", 44, 59]]], ["Quirkos (v2.3) was used to assist in this phase of the analysis.Data analysisFor the qualitative analysis, responses were analysed from 368 respondents who were representative of the overall respondents in terms of their clinical setting e.g. medicine, surgery.", [["Quirkos", "TEST", 0, 7], ["the analysis", "TEST", 51, 63], ["Data analysis", "TEST", 64, 77], ["the qualitative analysis", "TEST", 81, 105], ["surgery", "TREATMENT", 253, 260]]], ["No analysis was performed to break down findings by these two clinical settings.", [["analysis", "PROBLEM", 3, 11]]], ["Three researchers [SR, TR, MS] coded the responses.Data analysisThe final stage of analysis was to more fully integrate the two data sets.", [["Data analysis", "TEST", 51, 64]]], ["Following processes of abduction [17] , we aimed to understand the complexity of the interrelationships that exist between our data sets and the interpretations of them.", [["abduction", "TEST", 23, 32]]], ["We did this in order to integrate surface (semantic) and deep (latent) structures of a phenomenon; in this case understanding the determinants of job satisfaction.", [["surface", "ANATOMY", 34, 41], ["deep (latent) structures of a phenomenon", "PROBLEM", 57, 97], ["deep", "ANATOMY_MODIFIER", 57, 61]]], ["In practice, this process was achieved by research team meetings to iteratively align the quantitative and qualitative data sets and their analysis while simultaneously incorporating previous empirical work into these critical discussions.", [["their analysis", "TEST", 133, 147]]], ["Again, in line with abduction, this allowed the juxtaposition of what is familiar with that not so familiar in order to generate robust explanations (that can be further tested) [17] .Data analysisFor reasons of flow and clarity, the results are presented as the two separate data sets and the more integrative analytical work is presented in the discussion.ResultsInitially there were 7040 Adult Acute RNs in our sample.", [["Data analysis", "TEST", 184, 197], ["Acute", "OBSERVATION_MODIFIER", 397, 402]]], ["The respondents who chose not to respond to this question could therefore not be included in the analysis.", [["the analysis", "TEST", 93, 105]]], ["As a result, in total, 1747 valid cases were in the final analysis.ResultsThe overall model was statistically significant x 2 (6) = 959,519, p < 0.001, predicting 82.7% of all cases.ResultsMissed care (p < 0.001), lack of adequate support and supervision (p < 0.001), understaffed shift (p = 0.001), inability to take a break (p < 0.001), worked overtime (p < 0.001), action taken when concerns were raised (p < 0.001), were all significantly related to demoralisation.ResultsRespondents who reported missed care, that is having to leave necessary care undone, were five times more likely to report being Demoralised (OR [5.02] 95% CI: 3.67, 6.38).", [["demoralisation", "DISEASE", 454, 468], ["the final analysis", "TEST", 48, 66], ["demoralisation", "PROBLEM", 454, 468], ["CI", "TEST", 632, 634]]], ["The RNs were 4.8 times more likely to be demoralised if there was a lack of support (OR [4.8] , 95% CI: 3.67, 6.38).", [["CI", "TEST", 100, 102]]], ["Perceived high absence/sickness, percentage of temporary staff on the shift and number of patients seen, were excluded from the model.Qualitative findingsResponses were analysed from 368 respondents who were representative of the overall respondents in terms of their clinical setting e.g. medicine, surgery.Qualitative findingsNo analysis was performed to break down findings by these two clinical settings.", [["absence/sickness", "DISEASE", 15, 31], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["Perceived high absence/sickness", "PROBLEM", 0, 31], ["Qualitative findings", "PROBLEM", 134, 154], ["surgery", "TREATMENT", 300, 307], ["Qualitative findings", "PROBLEM", 308, 328], ["analysis", "PROBLEM", 331, 339], ["sickness", "OBSERVATION", 23, 31]]], ["Further analysis revealed four main themes; Staffing Issues, Lack of Support, Risk, and Personal Impact (see Fig. 1 ).", [["Further analysis", "TEST", 0, 16], ["main", "OBSERVATION_MODIFIER", 31, 35]]], ["We describe each of the four themes below, using extracts from the data set to illuminate and confirm theme meanings.", [["the data", "TEST", 63, 71]]], ["It is important to note that the analysis here, like the quantitative analysis, focused on dissatisfaction and demoralisation.", [["the analysis", "TEST", 29, 41], ["the quantitative analysis", "TEST", 53, 78], ["demoralisation", "PROBLEM", 111, 125]]], ["Positive data, particularly relating to the first two themes, was also present and likely reflects the experiences of those 36% of RN's who did not report feeing demoralised.Staffing issuesAll respondents discussed staffing issues in their daily work and the challenges faced as a result.", [["Staffing issues", "PROBLEM", 174, 189]]], ["They spoke about a lack of adequate staff numbers, which resulted in higher than manageable patient to nurse ratios, and of the detrimental impact of this for both patients and staff:Staffing issues'We are chronically understaffed, and I feel this regularly has a negative impact on patient care and staff wellbeing.", [["patient", "ORGANISM", 92, 99], ["patients", "ORGANISM", 164, 172], ["patient", "ORGANISM", 283, 290], ["patient", "SPECIES", 92, 99], ["patients", "SPECIES", 164, 172], ["patient", "SPECIES", 283, 290], ["Staffing issues", "PROBLEM", 183, 198]]], ["We have patients that deteriorate quickly as well as a number of confused and high falls risk patients.", [["falls", "DISEASE", 83, 88], ["patients", "ORGANISM", 8, 16], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 94, 102], ["confused", "PROBLEM", 65, 73]]], ["I believe the lack of staff contributes to not being able to provide the highest level of care.'Staffing issuesAn aspect of this theme is the reference to personal, physical and emotional consequences of maintaining one's professional role under such conditions and how these impact upon the quality of care provided:Staffing issues'All staff are human and can only take so much of doing more than their workload.", [["human", "ORGANISM", 347, 352], ["human", "SPECIES", 347, 352], ["human", "SPECIES", 347, 352], ["Staffing issues", "PROBLEM", 317, 332]]], ["People end up being off sick due to exhaustion and stress.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["exhaustion", "PROBLEM", 36, 46], ["stress", "PROBLEM", 51, 57]]], ["Bottom line is understaffing to save money is as good as a chocolate tea pot.", [["chocolate tea", "CHEMICAL", 59, 72], ["tea", "ORGANISM_SUBDIVISION", 69, 72]]], ["This posed a separate set of challenges due to the temporary nurse's lack of familiarity with the ward and the patients:Staffing issues'I have to work with a different nurse every shift.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119]]], ["They aren't allowed to use certain pieces of equipment such as blood sugar monitoring or infusion pumps.'Staffing issuesThis theme demonstrates the challenging situations faced by RNs in their daily work.", [["blood", "ANATOMY", 63, 68], ["sugar", "CHEMICAL", 69, 74], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["sugar", "SIMPLE_CHEMICAL", 69, 74], ["certain pieces of equipment", "TREATMENT", 27, 54], ["blood sugar monitoring", "TEST", 63, 85], ["infusion pumps", "TREATMENT", 89, 103], ["Staffing issues", "PROBLEM", 105, 120]]], ["It demonstrates the complexity of this issue that leads to feelings of frustration and despair due to a lack of staff who are adequately trained and familiar with the ward setting.Failures in leadership and Organisational supportThis theme describes the negative feelings attributed to a lack of support from hospital management, as experienced by respondents.", [["frustration", "PROBLEM", 71, 82], ["despair", "PROBLEM", 87, 94], ["Organisational support", "TREATMENT", 207, 229], ["hospital management", "TREATMENT", 309, 328]]], ["This lack of support was experienced in a range of ways from simple disregard to being made to feel incompetent and even blamed for the poor state of patient care.", [["patient", "ORGANISM", 150, 157], ["patient", "SPECIES", 150, 157]]], ["The disregard encountered by RN's was not only for themselves but also, they felt, extended to a disregard for patient's needs:Failures in leadership and Organisational support'I feel our patients are behind us, but I do feel that upper management are disengaged with patients & staff's real concerns and issues.'Failures in leadership and Organisational supportThis apparent disconnect and disregard led to struggles with respondents trying to secure necessary staff or develop systems to help cope with excess workload.", [["patient", "ORGANISM", 111, 118], ["patients", "ORGANISM", 188, 196], ["upper", "ORGANISM_SUBDIVISION", 231, 236], ["patients", "ORGANISM", 268, 276], ["patient", "SPECIES", 111, 118], ["patients", "SPECIES", 188, 196], ["patients", "SPECIES", 268, 276], ["Organisational support'", "TREATMENT", 154, 177], ["Organisational support", "TREATMENT", 340, 362]]], ["Such efforts were often undermined by managers leaving respondents disempowered and dissatisfied:Failures in leadership and Organisational support'Our site manager is unable to help us and refuses to let us save beds the night before knowing that we have these patients coming in.'", [["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 261, 269]]], ["'I have seen a large number of staff leave due to the pressures of being understaffed and the ward manager not helping on the ward.", [["large", "OBSERVATION_MODIFIER", 15, 20]]], ["Nurses feel quite negative about matrons as they are not seen to do anything about understaffing.'Failures in leadership and Organisational supportAt its worst, this disregard of concerns, and struggle to get support in providing quality patient care, was reflected back on the respondents in ways that led to stress, blame and feelings of professional vulnerability:Failures in leadership and Organisational support'Staff are made to feel incompetent by management when things are not done.", [["patient", "ORGANISM", 238, 245], ["patient", "SPECIES", 238, 245], ["Organisational support", "TREATMENT", 125, 147]]], ["Went home from that shift feeling sad for the patients, angry with the management, absolutely exhausted and dreading the next shift.'", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["the management", "TREATMENT", 67, 81]]], ["And yet the threat of disciplinary action hangs over nurses if anything goes wrong. [\u2026] We don't challenge and yet we are being challenged by the government and hospital bosses.'Failures in leadership and Organisational supportWhat is being described in this theme are broken relationships between respondents in the clinical area and those senior managers they rely on to provide practical and emotional support in delivering safe and effective care.", [["practical and emotional support", "TREATMENT", 381, 412]]], ["Rather than being heard by those with the ability to help, many respondents report a perceived lack of action, or worse, actions that challenge their commitment and leave them feeling intimidated and demoralised.Risk to self/othersThe understaffing and lack of support noted above generate risks to both the respondents and the patients they care for.", [["patients", "ORGANISM", 328, 336], ["patients", "SPECIES", 328, 336]]], ["In this theme, respondents give detailed accounts of the ways in which necessary care is left undone and the risk this poses to patients as well as the risks that they face during their day-to-day work.", [["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136]]], ["Examples provided point to the immediate risks to patient well-being and to the subsequent impact on the wider health care system.", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57]]], ["As well as describing observations about the increased risk of adverse events to patients, RNs described risks to themselves.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["adverse events", "PROBLEM", 63, 77]]], ["They noted that whilst they tried to care for their patients, their own health and safety was not prioritised and was therefore at risk.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["They often described putting themselves in situations where their own safety was being jeopardized:Risk to self/others'I received a needle stick injury at work.", [["a needle stick injury", "PROBLEM", 130, 151]]], ["Patient who was needle phobic knocked needle into me.", [["Patient", "ORGANISM", 0, 7], ["Patient", "SPECIES", 0, 7]]], ["I was unable to follow correct procedures after injury.", [["injury", "PROBLEM", 48, 54]]], ["No staff cover for me to go to A&E straight away (I had to go 2 days later-waited 3hrs to be seen) to have procedural blood tests done.'Risk to self/othersRespondents noted the primary and secondary impact of not being afforded enough resources to carry out the care they aspire to.", [["blood", "ANATOMY", 118, 123], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["procedural blood tests", "TEST", 107, 129]]], ["The primary impact is noted in relation to patient care, with a secondary consequence for themselves:Risk to self/others'I am feeling sick with stress and fear for patient safety.'", [["patient", "ORGANISM", 43, 50], ["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 43, 50], ["patient", "SPECIES", 164, 171], ["stress", "PROBLEM", 144, 150]]], ["The respondents spoke about being in situations where they had to make choices between their own safety, versus the safety of their patients.", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140]]], ["The situation described below is an example where highly vulnerable patients, and a vulnerable staff member, were left riskexposed by chronic under-resourcing:Risk to self/others'When I left work there was no night nurse to hand over to for the 2 bays of patients I was looking after, should have been one bay and a side room.", [["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 255, 263], ["left", "ANATOMY_MODIFIER", 114, 118], ["chronic", "OBSERVATION_MODIFIER", 134, 141]]], ["I'm 36 weeks pregnant in an acute respiratory ward.", [["acute", "OBSERVATION_MODIFIER", 28, 33], ["respiratory ward", "OBSERVATION", 34, 50]]], ["This left 2 nurses looking after 35 patients.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["left", "ANATOMY_MODIFIER", 5, 9]]], ["4 of which are high dependency on NIV.Not safe!'This theme demonstrates the awareness of a heightened risk of adverse outcomes when staffing resources are short.", [["high dependency", "PROBLEM", 15, 30], ["NIV", "TREATMENT", 34, 37], ["high dependency", "OBSERVATION", 15, 30]]], ["Respondents recounted not only awareness of times when they were failing to deliver adequate patient care but also of the times when they had to make choices between safe patient care and their own wellbeingusually erring toward neglecting their own wellbeing and putting patients first.", [["patient", "ORGANISM", 93, 100], ["patient", "ORGANISM", 171, 178], ["patients", "ORGANISM", 272, 280], ["patient", "SPECIES", 93, 100], ["patient", "SPECIES", 171, 178], ["patients", "SPECIES", 272, 280], ["safe patient care", "TREATMENT", 166, 183]]], ["This compromise between the patients care and safety and their own wellbeing led to mental distress, anxiety and extreme feeling of dissatisfaction; in short, it had a significant personal impact for these nurses.Personal impactThe three themes described above point to a set of resource and organisational conditions that often resulted in the failure to deliver the best care.", [["distress", "DISEASE", 91, 99], ["anxiety", "DISEASE", 101, 108], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["the patients care", "TREATMENT", 24, 41], ["mental distress", "PROBLEM", 84, 99], ["anxiety", "PROBLEM", 101, 108], ["extreme feeling of dissatisfaction", "PROBLEM", 113, 147], ["organisational conditions", "TREATMENT", 292, 317], ["the failure", "PROBLEM", 341, 352], ["failure", "OBSERVATION", 345, 352]]], ["Collectively, these have huge personal impact on the respondents with concomitant consequences for their wellbeing and job satisfaction.", [["huge", "OBSERVATION_MODIFIER", 25, 29]]], ["Respondents described strong feelings of despair and being demoralised and highlighted how these feelings about their job impacted both their personal and their professional lives:Personal impact'Emotionally exhausted after shift, being in a bad mood to family, crying at home because of the pressures.", [["despair", "PROBLEM", 41, 48], ["the pressures", "TEST", 288, 301]]], ["Feeling physically unwell during shift as no time to rest/take break for air or drink of water.", [["unwell", "OBSERVATION", 19, 25]]], ["Busy workdays are good and can make you feel energised and positive but being overstretched on every single shift and worrying about mistakes being made is exhausting.'Personal impactThey described scenarios which lead them to consider ways in which they can leave or change their professions.Personal impactThey also described scenarios which had led their colleagues to leave the profession:Personal impact'We stated that 2 registered nurses to look after 19 patients (11 of whom were post-operative) and 10 of whom needed discharging later in the day\u2026 I have been qualified for one year and I have already started the process of going into a different career.", [["patients", "ORGANISM", 461, 469], ["patients", "SPECIES", 461, 469]]], ["The negative experiences during their working hours diffuses into their after-work hours impacting their personal and home life to an extent that they are struggling to deal with.", [["negative", "OBSERVATION", 4, 12]]], ["The situations which form an overall experience leave them feeling a sense of despair and hopelessness; these then form the basis for their intentions to leave.", [["hopelessness", "DISEASE", 90, 102], ["despair", "PROBLEM", 78, 85], ["hopelessness", "PROBLEM", 90, 102]]], ["The quote below draws together findings from the first three themes showing how they collectively build to create strong feelings of dissatisfaction and demoralisation that impact on personal life:Personal impact'Some days nursing affects my whole life.", [["demoralisation", "DISEASE", 153, 167], ["dissatisfaction", "PROBLEM", 133, 148]]], ["I try my hardest to give my best to my patients, but every day is like spinning plates and it feels like if my concerns are raised to managers then I am to blame for not coping or managing my workload properly.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["We have a high sickness rate, so we are down on staff and we have a high turnover of staff as people are always leaving.'Personal impactUltimately, as this quote and theme suggest, intentions to leave may become actions once the personal and professional situation becomes unmanageable and the losses become far more than benefits of doing a job that they describe as one that they once loved.Summary of findingsThe results from the survey show that nurses were most likely to feel demoralised if they missed care, followed by if they reported lack of support and Lack of action when concerns are raised.", [["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100], ["a high sickness rate", "PROBLEM", 8, 28], ["high sickness", "OBSERVATION_MODIFIER", 10, 23]]], ["Being Unable to take a break, Understaffing, and Having to work overtime were also significant factors.Summary of findingsQualitative findings demonstrate significant concerns about inadequate staffing and how this leads to demoralisation and dissatisfaction when safe and effective care cannot be provided.", [["demoralisation", "DISEASE", 224, 238], ["inadequate staffing", "PROBLEM", 182, 201], ["significant", "OBSERVATION_MODIFIER", 155, 166]]], ["These feeling are compounded by a lack of managerial support which can lead to feelings of stress, blame and professional vulnerability.", [["managerial support", "TREATMENT", 42, 60], ["stress", "PROBLEM", 91, 97]]], ["Staff often have to make choices between risks to the patient and risk to their own wellbeing.", [["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61]]], ["In such situations nurses tend to prioritise patients.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["The inability to provide quality care, have concerns addressed by management, take breaks and finish on time take a personal toll on nurses leading them to consider leaving the job and the profession.DiscussionResults here provide a picture of the factors that generated demoralisation among nurses in the UK in the period leading up to the COVID-19 pandemic.", [["the COVID", "TEST", 337, 346], ["pandemic", "PROBLEM", 350, 358]]], ["A recent review of the experience of nurses during epidemics associated with respiratory conditions, revealed that the quality of leadership and organisational factors, as well as staffing resources, leading into such events has a significant impact upon how the health care system is able to perform [22] .", [["respiratory conditions", "PROBLEM", 77, 99]]], ["With this in mind, our paper is useful in being in a position to describe the conditions many nurses were working under at the time of the Covid-19 pandemic onset, and from which we can begin to understand the healthcare system's operational performance during these events.DiscussionWhile our quantitative data showed that leaving necessary care undone and lack of support were the factors most likely to impact on feeling demoralised (and therefore on job dissatisfaction), the qualitative data suggest a strong emphasis on adequate staffing.", [["our quantitative data", "TEST", 290, 311], ["the qualitative data", "TEST", 476, 496]]], ["On closer consideration, it becomes apparent that it is not understaffing per se that is the main issue of concern but the consequences of this and the lack of support to avoid or prevent these consequences.", [["support", "TREATMENT", 160, 167]]], ["The primary focus of the nurse is on the ability to provide safe and effective patient care and dissatisfaction and feeling demoralised occurs when this cannot be achieved and those in more senior positions do not respond to their expressed concerns.", [["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["safe and effective patient care", "TREATMENT", 60, 91], ["dissatisfaction", "PROBLEM", 96, 111]]], ["Given that missed care has been seen as the mediator linking lower registered nurse staffing levels with increased patient mortality [23] , it seems no surprise that not being able to provide adequate care is one of the greatest predictors of job dissatisfaction among the respondents [24] .DiscussionIn light of our findings of the impact of missed care on dissatisfaction and feeling demoralised, any approach aimed at increasing RNs' satisfaction and retention should focus on interventions which allow RN's to provide safe and effective nursing care.", [["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["interventions", "TREATMENT", 480, 493], ["safe and effective nursing care", "TREATMENT", 522, 553]]], ["In addition to evidence that understaffing increases the occurrence of missed care and therefore job satisfaction, Senek et al. have recently demonstrated that ensuring adequate staffing numbers by covering rota gaps only with temporary staff (agency and bank staff) does not necessarily lower the occurrence of missed care [25] .", [["adequate", "OBSERVATION_MODIFIER", 169, 177]]], ["This temporary deployment means that they are often not familiar with the setting, staff or patient groups they are working with.", [["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99]]], ["Therefore, in order to ensure that RNs can achieve a satisfactory level of quality care provision, it is not only adequate staffing levels but also the right type of permanent staff, which allows for continuity of care and team building that can reduce the occurrence of missed care.", [["right", "ANATOMY_MODIFIER", 152, 157]]], ["These also link into another important finding, that of the choices nurses are forced to make when staffing levels are low, support is lacking and patient care is therefore at risk.", [["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154], ["staffing levels", "TEST", 99, 114]]], ["Missing breaks and working overtime are resorted to in order to ensure necessary patient care is not missed, or at least to minimise the amount that is missed.", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["Missing breaks", "PROBLEM", 0, 14]]], ["In this way, they represent a secondary, but still important, mechanism in generating job dissatisfaction by forcing nurses to choose between their own needs and those of their patients.", [["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["secondary", "OBSERVATION", 30, 39]]], ["This resonates with previous findings which showed that nurses' inability to take breaks was due to patient load, unpredictability of patient needs and reluctance to burden other nurses [26] .DiscussionCollectively, the inability to provide quality care, have concerns addressed by management, take breaks and finish on time take a personal toll on nurses.", [["patient", "ORGANISM", 100, 107], ["patient", "ORGANISM", 134, 141], ["patient", "SPECIES", 100, 107], ["patient", "SPECIES", 134, 141], ["previous findings", "TEST", 20, 37]]], ["Similar findings have been reported where psychological disempowerment of RNs resulted in job dissatisfaction, lack of organisational trust and staff nurse burnout [27, 28] .", [["burnout", "DISEASE", 156, 163], ["job dissatisfaction", "PROBLEM", 90, 109]]], ["They further note that when managers lead with kindness and respect, and in ways that demonstrate ethical leadership [12, 13] , it is more likely that staff also demonstrate the same behaviour towards the patients.", [["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["more likely", "UNCERTAINTY", 134, 145]]], ["Importantly, they also linked this to nonhierarchical leadership styles and management that was respectful and patient-centred [32] .DiscussionWe have reported on the level of RNs work morale before the COVID-19 pandemic.", [["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["management", "TREATMENT", 76, 86], ["the COVID", "TEST", 199, 208], ["pandemic", "PROBLEM", 212, 220]]], ["For instance, during and following the Severe Acute Respiratory Syndrome (SARS) outbreak, Taiwanese RNs reported high levels of stress, even more so in moderate-risk areas than those working in high-risk areas [33] .", [["Acute Respiratory Syndrome", "DISEASE", 46, 72], ["SARS", "DISEASE", 74, 78], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 35, 72], ["SARS) outbreak", "PROBLEM", 74, 88], ["high levels of stress", "PROBLEM", 113, 134], ["Severe", "OBSERVATION_MODIFIER", 39, 45], ["Acute", "OBSERVATION_MODIFIER", 46, 51], ["Respiratory Syndrome", "OBSERVATION", 52, 72], ["moderate", "OBSERVATION_MODIFIER", 152, 160]]], ["A crosssectional survey reported that nearly 8% of the nurses thought they should not care for SARS patients and considered resignation, mainly due to increased work stress and perceived risk of fatality.", [["SARS", "DISEASE", 95, 99], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["A crosssectional survey", "TEST", 0, 23], ["increased work stress", "PROBLEM", 151, 172], ["fatality", "PROBLEM", 195, 203]]], ["These findings are important in view of the current COVID-19 pandemic and any future impending outbreaks [34] .", [["the current COVID", "TEST", 40, 57]]], ["Prior to the COVID-19 pandemic, UK RNs intention to leave rates were reported to be between 30 and 50%.", [["the COVID", "TEST", 9, 18]]], ["The evidence-base from studies on SARS and Middle Eastern Respiratory Syndrome (MERS) epidemic outbreaks in South Korea [35] suggests that this phenomenon is exacerbated in a deadly disease outbreak.", [["SARS", "DISEASE", 34, 38], ["Middle Eastern Respiratory Syndrome", "DISEASE", 43, 78], ["MERS", "DISEASE", 80, 84], ["SARS", "PROBLEM", 34, 38], ["Middle Eastern Respiratory Syndrome", "PROBLEM", 43, 78], ["this phenomenon", "PROBLEM", 139, 154], ["a deadly disease outbreak", "PROBLEM", 173, 198], ["base", "ANATOMY_MODIFIER", 13, 17], ["Middle", "ANATOMY_MODIFIER", 43, 49], ["Respiratory Syndrome", "OBSERVATION", 58, 78]]], ["Currently, in the UK, concerns over safety, reported lack of personal protective equipment and high fatality rate of health care professionals will further increase work-related stress during the COVID-19 pandemic.", [["personal protective equipment", "TREATMENT", 61, 90], ["the COVID", "TEST", 192, 201], ["pandemic", "PROBLEM", 205, 213]]], ["The unprecedented crisis caused by the pandemic may therefore have a further negative impact on nurse retention.LimitationsThe variables that were tested from the survey were mainly job-related, interpersonal, and organisational factors.", [["The unprecedented crisis", "PROBLEM", 0, 24], ["the survey", "TEST", 159, 169], ["interpersonal, and organisational factors", "PROBLEM", 195, 236], ["unprecedented", "OBSERVATION_MODIFIER", 4, 17], ["crisis", "OBSERVATION", 18, 24]]], ["The personal and individual factors such as age, gender and level of experience were not available to us and could therefore not be included in the analysis.", [["the analysis", "TEST", 144, 156]]], ["Similarly, we cannot be sure that the qualitative data represents an accurate spread of views from across the adult nursing population.Future direction of researchIt seems clear that further research is needed to address the root causes of RN's dissatisfaction.", [["root", "ANATOMY", 225, 229], ["the qualitative data", "TEST", 34, 54], ["RN's dissatisfaction", "PROBLEM", 240, 260], ["clear", "OBSERVATION", 172, 177]]], ["Our data shows that RNs feel that there is limited recognition of the wider issue of understaffing and, when the issue is raised, they are often intimidated into continuing to work under these difficult conditions.", [["Our data", "TEST", 0, 8]]], ["In this instance, we have demonstrated their issues with management, but we recognise that RNs are part of a health care team that consists of many different roles.", [["management", "TREATMENT", 57, 67]]], ["However, these issues will forever remain if RNs are experiencing severe workloads and poor staffing levels that put their patients at risk due to missed care [36] .", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["severe workloads", "PROBLEM", 66, 82], ["poor staffing levels", "PROBLEM", 87, 107]]], ["For this to be dealt with effectively, it is not enough to train more people to be nurses when the dissatisfaction and the leaving-rate is high for those who are currently in the profession.ConclusionA high proportion of feeling demoralised and dissatisfied was reported by registered nurses and was most likely to occur as a result of missed care and lack of support and action when concerns were raised about this.", [["people", "ORGANISM", 70, 76], ["people", "SPECIES", 70, 76], ["the dissatisfaction", "PROBLEM", 95, 114], ["most likely", "UNCERTAINTY", 300, 311]]], ["Whilst some of these findings are consistent with those from previous studies, their level of impact and the mechanisms by which they cause a detrimental effect on nurses' moral and job satisfaction have not previously been fully discussed.", [["previous studies", "TEST", 61, 77], ["consistent with", "UNCERTAINTY", 34, 49]]], ["Addressing the issues highlighted here will be important in addressing the root causes of RN dissatisfaction and thereby improving retention and reducing the high turnover rate among nurses.", [["root", "ANATOMY", 75, 79], ["RN dissatisfaction", "PROBLEM", 90, 108]]]], "2931e39d77013eeb7a9709309e3f55215d9ea4e8": [["It emerged even the best national public health care systems before a huge trouble.", [["a huge trouble", "PROBLEM", 68, 82]]], ["COVID 19 is a mass causalities event per definition: a situation when the amount of the acute care patients overwhelmed emergency medical services resources, such as personnel and equipment.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["a mass causalities", "PROBLEM", 12, 30], ["mass", "OBSERVATION", 14, 18]]], ["For \"war plan\", the intelligence is crucial.IntroductionDaily data about the coronavirus pandemic, including the number of new cases and deaths, is collected internationally.", [["coronavirus pandemic", "DISEASE", 77, 97], ["deaths", "DISEASE", 137, 143], ["coronavirus", "ORGANISM", 77, 88]]], ["The use of these data makes possible the modelling of the international disease spread.", [["these data", "TEST", 11, 21], ["the international disease spread", "PROBLEM", 54, 86]]], ["However, due to the limited reliability of morbidity and mortality statistics, it is still questionable whether current databases may be used to assess the patterns of the epidemic and its prognosis.IntroductionMoreover, neither the significant percentage of asymptomatic virus-infected people nor the real number of recovered patients has not been well-established.", [["people", "ORGANISM", 287, 293], ["patients", "ORGANISM", 327, 335], ["people", "SPECIES", 287, 293], ["patients", "SPECIES", 327, 335], ["morbidity", "PROBLEM", 43, 52], ["asymptomatic virus", "PROBLEM", 259, 277], ["significant", "OBSERVATION_MODIFIER", 233, 244], ["percentage", "OBSERVATION_MODIFIER", 245, 255], ["asymptomatic", "OBSERVATION_MODIFIER", 259, 271], ["virus", "OBSERVATION", 272, 277]]], ["Nevertheless, despite the limited and uncertain data, the mathematic modelling of the pandemic's progression is crucial for predicting the possible future spread, preparing the next steps to combat it, and correctly evaluating the efficacy of governmental public health measures already performed.IntroductionOne of the most important information components is the possibility to develop the highgrade accuracy matemathics model of epidemics progression allowing the medical care providers to organize better the national resources.IntroductionAdequate modelling also establishes a framework for future evaluation of this and other pandemics.IntroductionThis paper describes novel infectious disease modelling, covering many aspects of COVID-19 dynamics.Material and Methods :For statistical analysis of coronavirus incidence dynamics, data from the World Health Organization (1) and from Johns Hopkins University (2) from 01.01.2020 to 04.", [["coronavirus", "ORGANISM", 804, 815], ["the pandemic's progression", "PROBLEM", 82, 108], ["governmental public health measures", "TREATMENT", 243, 278], ["future evaluation", "TEST", 596, 613], ["novel infectious disease modelling", "PROBLEM", 675, 709], ["COVID", "TEST", 736, 741], ["statistical analysis", "TEST", 780, 800], ["coronavirus incidence dynamics", "PROBLEM", 804, 834], ["infectious", "OBSERVATION", 681, 691]]], ["17 .2020 was collected.Material and Methods :There are many infectious disease spread models, such as SIR, SEIRD, and SEIHR.", [["many infectious disease spread models", "PROBLEM", 55, 92], ["many", "OBSERVATION_MODIFIER", 55, 59], ["infectious", "OBSERVATION", 60, 70]]], ["Most of them use differential equation systems (continuous time) or differen\u0441\u0435 equations (discrete time) for describing population dynamics with different characteristics in relation to infection (3 In the simplest SIR-model, the entire population is divided into three groups: Susceptible (S), Infected (I) and Removed (R) (8) The SIR model is a homogeneous Markov chain with a single absorbing state R, which can be imagined as a graph with the states of the S, I, R process and with the transitions between the states.", [["infection", "DISEASE", 186, 195], ["differential equation systems", "TEST", 17, 46], ["differen\u0441\u0435 equations", "PROBLEM", 68, 88], ["infection", "PROBLEM", 186, 195], ["a graph", "TEST", 430, 437], ["infection", "OBSERVATION", 186, 195], ["homogeneous", "OBSERVATION_MODIFIER", 347, 358], ["Markov chain", "OBSERVATION", 359, 371]]], ["However, in this case, the value of variable I (where patients with latent signs should be included) will not be the same as the I values from the statistics.Material and Methods :Since, at the early stages of an epidemic, the number of S susceptible patients is unproportionally much higher than the number of actually ill patients, and the rate of recovery is less than the rate of infection, the SIR-model defines the S value as constant.", [["infection", "DISEASE", 384, 393], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 251, 259], ["patients", "ORGANISM", 324, 332], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 251, 259], ["patients", "SPECIES", 324, 332], ["latent signs", "PROBLEM", 68, 80], ["infection", "PROBLEM", 384, 393], ["epidemic", "OBSERVATION", 213, 221], ["much higher", "OBSERVATION_MODIFIER", 280, 291], ["infection", "OBSERVATION", 384, 393]]], ["Thus, at the initial stage of an epidemic's development, the dynamics of infection can be represented as follows:Material and Methods :where m = \u03b2S = const.Material and Methods :However, model (1) is unable to recognize the nonmonotonic changes of process dynamics (for example, resulting from quarantine measures).", [["infection", "DISEASE", 73, 82], ["an epidemic's development", "PROBLEM", 30, 55], ["infection", "PROBLEM", 73, 82], ["quarantine measures", "TREATMENT", 294, 313], ["epidemic", "OBSERVATION_MODIFIER", 33, 41], ["infection", "OBSERVATION", 73, 82]]], ["In general, the SIR model describes the ending of the epidemic, as a process of exhausting the extent of group S, assuming in advance that the total population will be infected.Material and Methods :Most other modelling systems use Markov models that have all the above-mentioned disadvantages.", [["the total population", "TREATMENT", 139, 159], ["infected", "PROBLEM", 168, 176], ["infected", "OBSERVATION", 168, 176]]], ["The proposed bifurcation models that include the sudden increases in incidence at certain stages of the epidemic (11) are regression models and do not explain the reasons for such bifurcations.Material and Methods :We propose that the prevalence of coronavirus infected population can exist in one of two states.", [["coronavirus infected", "DISEASE", 249, 269], ["coronavirus", "ORGANISM", 249, 260], ["the sudden increases", "PROBLEM", 45, 65], ["coronavirus infected population", "PROBLEM", 249, 280], ["bifurcation", "OBSERVATION_MODIFIER", 13, 24], ["sudden", "OBSERVATION_MODIFIER", 49, 55], ["increases", "OBSERVATION_MODIFIER", 56, 65], ["certain stages", "OBSERVATION_MODIFIER", 82, 96], ["epidemic", "OBSERVATION_MODIFIER", 104, 112], ["do not explain", "UNCERTAINTY", 144, 158], ["coronavirus", "OBSERVATION_MODIFIER", 249, 260], ["infected", "OBSERVATION", 261, 269]]], ["The number of cases is low and is kept constant in time at the initial low-infection stage of the disease.", [["low-infection", "DISEASE", 71, 84], ["the disease", "PROBLEM", 94, 105], ["number", "OBSERVATION_MODIFIER", 4, 10], ["low", "OBSERVATION_MODIFIER", 23, 26], ["infection", "OBSERVATION", 75, 84], ["disease", "OBSERVATION", 98, 105]]], ["The viral epidemic goes to an exponential stage with very high incidence later.", [["The viral epidemic", "PROBLEM", 0, 18], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["epidemic", "OBSERVATION", 10, 18]]], ["The coronavirus pandemic may be interpreted as the biological analogue of a well-known physics phenomenon, first-order phase transition.", [["coronavirus pandemic", "DISEASE", 4, 24], ["coronavirus", "ORGANISM", 4, 15], ["coronavirus", "SPECIES", 4, 15], ["The coronavirus pandemic", "PROBLEM", 0, 24], ["a well-known physics phenomenon", "PROBLEM", 74, 105], ["coronavirus pandemic", "OBSERVATION", 4, 24]]], ["An example of such a phase transition is the condensation of a substance from gaseous to liquid state, when the density of gas molecules increases sharply from some critical temperature or pressure.", [["a phase transition", "PROBLEM", 19, 37], ["gas molecules", "PROBLEM", 123, 136], ["gas molecules", "OBSERVATION", 123, 136], ["increases", "OBSERVATION_MODIFIER", 137, 146], ["sharply", "OBSERVATION_MODIFIER", 147, 154], ["pressure", "OBSERVATION_MODIFIER", 189, 197]]], ["A \"soft\" system with a small height and a small half-width of a potential barrier easily alters its phase state.", [["A \"soft\" system", "PROBLEM", 0, 15], ["a small height", "PROBLEM", 21, 35], ["soft\"", "OBSERVATION_MODIFIER", 3, 8], ["small", "OBSERVATION_MODIFIER", 23, 28], ["height", "OBSERVATION_MODIFIER", 29, 35], ["small", "OBSERVATION_MODIFIER", 42, 47], ["half-width", "OBSERVATION_MODIFIER", 48, 58]]], ["On the contrary, a \"tough\" system with a high potential barrier and a high half-width value of a potential barrier will last quite some time in this condition.Material and Methods :The transition from a stable state with low incidence to an epidemic state will occur when some critical value of x r of incidents is reached.", [["stable", "OBSERVATION_MODIFIER", 203, 209]]], ["The ecological potential of the population morbidity F(x) will be defined as follows: consider a long time series of coronavirus cases since the first patient.", [["coronavirus", "DISEASE", 117, 128], ["coronavirus", "ORGANISM", 117, 128], ["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["coronavirus cases", "PROBLEM", 117, 134]]], ["These events will be responsible for the state of the low-incidence population.", [["the low-incidence population", "PROBLEM", 50, 78]]], ["The other part of the events will have values close to x 2 , the state of epidemic.Material and Methods :Finally, a small proportion of the events will have values close to the critical value of x r .", [["epidemic", "PROBLEM", 74, 82], ["small", "OBSERVATION_MODIFIER", 116, 121]]], ["When, rarely, there are many cases close to this value , there is a high rate of system transfer from x 1 toMaterial and Methods :If the proportion of people with this disease is low, and the proportion of time when the population is observed with a slightly higher incidence compared to x 1 is small, then condition x 1 can be said to be stable.", [["people", "ORGANISM", 151, 157], ["people", "SPECIES", 151, 157], ["this disease", "PROBLEM", 163, 175], ["a slightly higher incidence", "PROBLEM", 248, 275], ["small", "OBSERVATION_MODIFIER", 295, 300], ["stable", "OBSERVATION_MODIFIER", 339, 345]]], ["The potential function of F(x) can be represented as the reverse function of the daily infection incidents' density distribution function.", [["infection", "DISEASE", 87, 96], ["F(x)", "GENE_OR_GENE_PRODUCT", 26, 30], ["the daily infection", "PROBLEM", 77, 96]]], ["In a state of initial stage of epidemic with low incidence, the number of cases will be near the x 1 and value of F(x 1 ) will be small.", [["low incidence", "OBSERVATION_MODIFIER", 45, 58], ["small", "OBSERVATION_MODIFIER", 130, 135]]], ["If we consider the epidemic development as a first-order phase transition, this population will be near the critical value of x r number of patients for a very short time, and the value of the function F(x r ) will be large.Material and Methods :The process of the pandemic's growth can be considered as an analogue to a second order phase transition, in which the connection of the system's integral characteristics (the order parameter w, varying from 0 to 1) to the impact of the external factor Y is described by the (12, 13) .", [["patients", "ORGANISM", 140, 148], ["external factor Y", "PROTEIN", 483, 500], ["patients", "SPECIES", 140, 148], ["the pandemic's growth", "TREATMENT", 261, 282], ["large", "OBSERVATION", 218, 223]]], ["In this version of the second order phase transition model, the role of the external factor Y is significant from the pandemic's absolute beginning on the planet and w(T) is the portion of countries with coronavirus incidents at time T.Material and Methods :To simulate the processes of coronavirus dynamics in an epidemic state, we will use data on the current daily incidence of disease [I(t)-I(t-1)].", [["coronavirus incidents", "DISEASE", 204, 225], ["coronavirus", "ORGANISM", 204, 215], ["coronavirus", "ORGANISM", 287, 298], ["external factor Y", "PROTEIN", 76, 93], ["coronavirus", "SPECIES", 287, 298], ["the second order phase transition model", "TREATMENT", 19, 58], ["coronavirus dynamics", "PROBLEM", 287, 307], ["disease", "PROBLEM", 381, 388], ["coronavirus", "OBSERVATION", 287, 298]]], ["Since the n population in different countries can vary greatly -from billions to tens of thousands, we obtained, as comparable data for each country, indicators of relative current incidence introduced asMaterial and Methods :To reduce the variance, the value of ln p(t) will be considered instead p(t).Material and Methods :Under the assumption that the reported incidence on day t, after the onset of the epidemic, depends both on the duration of the t epidemic since the beginning of its exponential stage and on the disease in k of the previous days.", [["the epidemic", "PROBLEM", 403, 415], ["the disease", "PROBLEM", 516, 527], ["epidemic", "OBSERVATION", 407, 415]]], ["Then, in the logarithmic scale, you can use the ADL (k,1) (autoregressive distributed lag) -model (14) .Material and Methods :where p(t) -relative morbidity, t -duration of the exponential phase of the epidemic (number of days since its beginning), a 1 , a 2 , b -odds, k -the order of autogressing, \u03b5(t) -noise.Material and Methods :Equation (2) can be considered as a regression with the available values of the current relative morbidity, the relative morbidity during the previous days, and the duration of time since the beginning of the exponential epidemic stage.", [["relative morbidity", "PROBLEM", 138, 156], ["morbidity", "OBSERVATION", 147, 156], ["morbidity", "OBSERVATION", 455, 464]]], ["The easiest way to estimate k is to calculate the partial autocorrelation function (PACF) of the simulated time series and to determine the number of PACF members that are significantly different from zero (15) .", [["PACF", "GENE_OR_GENE_PRODUCT", 150, 154], ["PACF members", "PROTEIN", 150, 162]]], ["For states with different populations and different levels of morbidity, critical numbers are very close when the exponential phase of the epidemic begins (Table 1) .", [["different populations", "PROBLEM", 16, 37], ["morbidity", "PROBLEM", 62, 71]]], ["The peak function of F(x) accounts for the critical number of cases = 30.", [["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["Thus, this means that the epidemic is probably going to an exponential phase when the number of infected is between 20 to 30 people in a country.", [["people", "SPECIES", 125, 131], ["infected", "OBSERVATION", 96, 104]]], ["It is possible on next step to calculate the change in time of incidence within large territories or the planet as a whole, using the second order phase transition model.", [["the second order phase transition model", "TREATMENT", 130, 169]]], ["Dynamics of the relative coronavirus incidence for the United States (1 -lag phase; 2 -exponential phase).Material and Methods :As the epidemic develops in a single country, the following phases may be identified: -lag-phase, when a consistently low number of cases is recorded over a long period (1 -2 people per country); -exponential phase, when the relative number of cases (the number of cases per inhabitant) increases exponentially over time; -stabilization and fading phase, when the relative number of cases does not change over time and later begins to decrease.Material and Methods :As shown in Fig. 6 , the lag-phase of the disease lasted from January 23 (the date on which the first patient was recorded, according to WHO) until March 6, after which the disease went into an exponential phase, which can be approximated by the equationMaterial and Methods :is the estimated relative number of cases).", [["coronavirus", "ORGANISM", 25, 36], ["patient", "ORGANISM", 696, 703], ["people", "SPECIES", 303, 309], ["patient", "SPECIES", 696, 703], ["the disease", "PROBLEM", 632, 643], ["the disease", "PROBLEM", 763, 774], ["coronavirus", "OBSERVATION", 25, 36], ["disease", "OBSERVATION", 636, 643], ["disease", "OBSERVATION", 767, 774]]], ["The ADL model may be used to more accurately approximate incidence data.", [["The ADL model", "TREATMENT", 0, 13]]], ["To estimate the order of the autocorrelation member in equation (2), a partial autocorrelation function (PACF) of a number of statistical data differentials and exponential equations {ln p(t)h(t)} was calculated.", [["exponential equations", "TEST", 161, 182]]], ["It has shown in Fig. 7 , that the order k of the autocorrelation function in (2) equals 2 and, therefore, it is possible to write the equation of the morbidity dynamics:Equation ratios (3) can be interpreted as the susceptibility of magnitude ln p(t) to change values ln p(t-1), ln p(t-2) and t:If the susceptibilities (4) are positive, then with the growth of ln p(t-1), ln p(t-2), relative contamination rates b(t) also grow.", [["the autocorrelation function", "TEST", 45, 73], ["Equation ratios", "TEST", 169, 184], ["values ln p", "TEST", 261, 272], ["ln p(t-2)", "TEST", 279, 288], ["the susceptibilities", "TEST", 298, 318], ["Fig", "OBSERVATION_MODIFIER", 16, 19], ["ln", "ANATOMY", 279, 281], ["ln", "ANATOMY", 372, 374]]], ["With negative values of (4), relative infection rates fall.Equation ratios (3) can be interpreted as the susceptibility of magnitude ln p(t) to change values ln p(t-1), ln p(t-2) and t:The calculations showed that, not only for the U.S., but also for other countries, the order k of autoregression for model (3) may be adopted equal to 2.", [["infection", "DISEASE", 38, 47], ["relative infection rates fall", "PROBLEM", 29, 58], ["Equation ratios", "TEST", 59, 74], ["values", "TEST", 151, 157], ["The calculations", "TEST", 185, 201], ["negative values", "OBSERVATION_MODIFIER", 5, 20], ["infection", "OBSERVATION", 38, 47], ["ln", "ANATOMY", 169, 171]]], ["The calculated data for the parameters of the ADL model for the exponential phase of the disease in the United States are presented in Table 2 .", [["The calculated data", "TEST", 0, 19], ["the ADL model", "TREATMENT", 42, 55], ["disease", "OBSERVATION", 89, 96]]], ["The values of a 1 > 1 can be characterized as a parameter proportional to the relative number of latent and manifest cases at the moment (t-1).", [["The values", "TEST", 0, 10]]], ["As can be seen from Table 2 , the determination factor R 2 \u2248 0.95 for the ADL model is higher than the R 2 \u2248 0.85 for a simple exponential model (Fig. 6) .", [["the determination factor", "TEST", 30, 54], ["the ADL model", "TEST", 70, 83], ["higher", "OBSERVATION_MODIFIER", 87, 93]]], ["Temporary series of data on relative morbidity and model calculations by (3) is synphasse.", [["model calculations", "TEST", 51, 69]]], ["This is seen on the cross-correlation function (Fig. 9 ).", [["the cross-correlation function", "TEST", 16, 46]]], ["In a number of countries, the disease intensity begins to decrease, and a monotonic exponential model cannot describe this process.", [["the disease intensity", "PROBLEM", 26, 47], ["disease", "OBSERVATION", 30, 37], ["decrease", "OBSERVATION_MODIFIER", 58, 66]]], ["Fig. 10 shows data on the incidence of coronavirus in Russia.", [["coronavirus", "DISEASE", 39, 50], ["coronavirus", "ORGANISM", 39, 50], ["coronavirus", "PROBLEM", 39, 50], ["coronavirus", "OBSERVATION", 39, 50]]], ["Table 3 shows the calculations of the ADL model's parameters model to describe the epidemic in Russia.", [["the ADL model's parameters model", "TREATMENT", 34, 66]]], ["As shown in Table 3 and Fig. 10 , the ADL model describes very well the development dynamics of the disease in Russia.", [["disease", "OBSERVATION", 100, 107]]], ["As shown in Table 3 , the susceptibility a2 is negative for all countries, that is, with an increase in ln p(t-2), the number of infected on day t decreases.", [["susceptibility a2", "DNA", 26, 43], ["the susceptibility a2", "TEST", 22, 43], ["negative", "OBSERVATION", 47, 55], ["increase", "OBSERVATION_MODIFIER", 92, 100], ["ln", "OBSERVATION", 104, 106], ["infected", "OBSERVATION", 129, 137]]], ["Susceptibility b has a positive sign for Russia (to a greater extent) and for Israel (to a lesser extent), which can be interpreted as an increase in incidence over time.", [["Russia", "PROBLEM", 41, 47], ["greater extent", "OBSERVATION_MODIFIER", 54, 68], ["lesser extent", "OBSERVATION_MODIFIER", 91, 104], ["increase", "OBSERVATION_MODIFIER", 138, 146]]], ["Small values of coefficient a1 for Russia and Korea could indicate a weak effect of the number of infected the previous day on the current incidence.Equation ratios (3) can be interpreted as the susceptibility of magnitude ln p(t) to change values ln p(t-1), ln p(t-2) and t:Using the values of the parameters of the model (3) for individual countries, we can give a short-term prognosis of incidence.", [["Equation ratios", "TEST", 149, 164], ["values", "TEST", 241, 247], ["weak", "OBSERVATION_MODIFIER", 69, 73], ["infected", "OBSERVATION", 98, 106], ["ln", "ANATOMY", 259, 261]]], ["Indicators of the quality of the forecast can be defined as the difference between the data ln p (t) of the official statistics of morbidity and forecast calculations (Table 5 ).", [["forecast calculations", "TEST", 145, 166]]], ["The minus sign in Table 5 means that the incidence data is less than the predicted estimates.", [["the incidence data", "TEST", 37, 55], ["minus", "OBSERVATION_MODIFIER", 4, 9]]], ["Such ratios observed for Korea and Russia, and it is presumed that their slight decrease in incidence compared to the model may be due to quarantine measures.", [["Such ratios", "TEST", 0, 11], ["quarantine measures", "TREATMENT", 138, 157], ["slight", "OBSERVATION_MODIFIER", 73, 79], ["decrease", "OBSERVATION_MODIFIER", 80, 88], ["may be due to", "UNCERTAINTY", 124, 137], ["quarantine", "OBSERVATION", 138, 148]]], ["The same is true for data during the week from 04.09 to 04.16 in Israel.DiscussionFrom the point of view of phase transition, the transition from x 1 to x 2 can occur in two ways:Discussion-With large enough fluctuations of the system state, the value of which exceeds the height of the potential barrier, the system can spontaneously move from one state to another; or -Under the influence of an external field, one of the local minimum potential functions can disappear, and the system will \"fall\" into the only remaining state.DiscussionThe analysis of morbidity dynamics raises the question of whether the observed dynamics of the pandemic have some common properties or are individual to each country.", [["morbidity dynamics", "PROBLEM", 556, 574]]], ["Thus, we consider the dynamics of the disease onset (the date of the first patient) in different countries.DiscussionAs an indicator of the pandemic's development, we introduce a variable -the parameter These patterns of the disease spread need to take into account when planning how to fight the pandemic.DiscussionTo describe the behavior of a bistable system, three characteristic times can be entered - Many questions were reffered immediately to the public health systems worldwide with burst of COVID 19 pandemics.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["the disease onset", "PROBLEM", 34, 51], ["a variable -the parameter", "TREATMENT", 177, 202], ["the disease spread", "PROBLEM", 221, 239], ["disease", "OBSERVATION", 225, 232]]], ["Even advanced national care systems found itself unprepared to \"tsunami -like\" growing amount of corona virus patients.", [["corona virus", "ORGANISM", 97, 109], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["corona virus patients", "PROBLEM", 97, 118], ["corona virus", "OBSERVATION", 97, 109]]], ["The major efforts are being made in achieving of adequate medical staff, equipment, drugs and etc. However, the basic strategy planning of every single country is depends on prognostic epidemiologic modelling while the strict monitoring of the rapidly changed parameters.", [["drugs", "TREATMENT", 84, 89]]], ["The mathematical models were created by scientists in order to predict the course of the outbreak and identify governmental interventions that could be effective in decrease of epidemics progression.DiscussionThree possible approaches for such modeling may be considered.", [["governmental interventions", "TREATMENT", 111, 137], ["epidemics progression", "PROBLEM", 177, 198], ["decrease", "OBSERVATION_MODIFIER", 165, 173]]], ["The first approach is to model the available data using non-linear regression (for example, the agent-based model (16) .DiscussionUsing this method allows obtaining accurate estimates of existing data and give a short-term forecast of incidence, but it is difficult to describe the mechanisms of the pandemic.DiscussionMost coronavirus spread models use various versions of the SIR-model (for example, SEIR-models (17, 18, 19) .", [["the pandemic", "PROBLEM", 296, 308], ["SEIR-models", "TEST", 402, 413]]], ["In this case, the problem is the size estimation of the S-group.", [["size", "OBSERVATION_MODIFIER", 33, 37]]], ["If we accept that the entire country's population should be attributed to this group, then, based on the SIR-models, it should be concluded that the pandemic will stop only when the majority of the population becomes ill (20, 21) .", [["ill", "DISEASE", 217, 220], ["ill", "OBSERVATION_MODIFIER", 217, 220]]], ["Moreover, the SIR-models do not raise the question of theConclusions:The model is very simple in terms of the data necessary for the calculations.", [["the calculations", "TEST", 129, 145], ["very", "OBSERVATION_MODIFIER", 82, 86], ["simple", "OBSERVATION_MODIFIER", 87, 93]]], ["However, the determination coefficient of model R 2 is very high and exceeds 0.95 for most countries.", [["the determination coefficient", "TEST", 9, 38], ["model R 2", "TEST", 42, 51], ["high", "OBSERVATION_MODIFIER", 60, 64]]], ["The model permits the accurate prediction of the pandemics dynamics at intervals of up to 10 days.Conclusions:The ADL model allows describing nonmonotonic changes in relative infection over the time, and providing to governments and health care decision makers the possibility to predict the outcomes of their decisions on public health.", [["infection", "DISEASE", 175, 184], ["nonmonotonic changes", "PROBLEM", 142, 162], ["relative infection", "PROBLEM", 166, 184], ["relative", "OBSERVATION_MODIFIER", 166, 174], ["infection", "OBSERVATION", 175, 184]]]], "PMC5639607": [["IntroductionLiterature stresses the importance of social factors in HIV/AIDS epidemics, and the potential impact of emerging biomedicine \u2018and its attendant opportunities and (perhaps unintended) social consequences\u2019 (Friedman, Kippax, Phaswana-Mafuya, Rossi, & Newman, 2006, p.", [["HIV/AIDS", "DISEASE", 68, 76], ["HIV", "ORGANISM", 68, 71], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 68, 71]]], ["Although an extensive literature exists on progress toward visions of ultimate eradication (see Burman, Aphane, & Delobelle, 2016), challenges such as ongoing societal stigma (Gilbert, 2016), poor infrastructure and treatment delivery issues (Koto & Maharaj, 2016) and continued risk-taking behaviours (Ngidi, Moyo, Zulu, Adam, & Krishna, 2016) persist.", [["poor infrastructure", "PROBLEM", 192, 211], ["treatment delivery issues", "TREATMENT", 216, 241], ["extensive", "OBSERVATION_MODIFIER", 12, 21], ["literature", "OBSERVATION", 22, 32]]], ["This article makes the argument that certain recent developments in knowledge management enabled by technological advances offer hope for the ultimate eradication of HIV/AIDS, and offers insights into how these novel developments might contribute to this end.", [["HIV/AIDS", "DISEASE", 166, 174], ["HIV", "ORGANISM", 166, 169], ["HIV", "SPECIES", 166, 169], ["knowledge management", "TREATMENT", 68, 88], ["HIV/AIDS", "TREATMENT", 166, 174]]], ["HIV/AIDS, however, is not alone among a host of global disease threats.", [["HIV/AIDS", "DISEASE", 0, 8], ["HIV", "ORGANISM", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV/AIDS", "PROBLEM", 0, 8], ["global disease threats", "PROBLEM", 48, 70], ["disease", "OBSERVATION", 55, 62]]], ["Rapidly spreading antibiotic resistance heralds a post-antibiotic era (Gallagher, 2015), or antibiotic apocalypse (Ash, 1996); a world in which childbirth, even minor surgery, minor injuries and exposure to tuberculosis or other bacterial infections can be life-threatening.", [["injuries", "DISEASE", 182, 190], ["tuberculosis", "DISEASE", 207, 219], ["bacterial infections", "DISEASE", 229, 249], ["Rapidly spreading antibiotic resistance", "TREATMENT", 0, 39], ["minor surgery", "TREATMENT", 161, 174], ["minor injuries", "PROBLEM", 176, 190], ["tuberculosis", "PROBLEM", 207, 219], ["other bacterial infections", "PROBLEM", 223, 249], ["antibiotic resistance", "OBSERVATION", 18, 39], ["tuberculosis", "OBSERVATION", 207, 219], ["bacterial", "OBSERVATION_MODIFIER", 229, 238], ["infections", "OBSERVATION", 239, 249]]], ["Similarly, climate change has been discussed in apocalyptic terms, or as a phenomena that, if not addressed, can result in large-scale loss of life (Feinberg & Willer, 2011), and HIV antiretroviral resistance (Herman, 2016) might also have catastrophic consequences if it follows the same trend as that associated with antibiotic resistance.", [["HIV", "SPECIES", 179, 182], ["HIV", "SPECIES", 179, 182], ["catastrophic consequences", "PROBLEM", 240, 265], ["antibiotic resistance", "TREATMENT", 319, 340], ["large", "OBSERVATION_MODIFIER", 123, 128]]], ["Knowledge management has to date, however, failed to offer outright solutions to these problems.", [["outright solutions", "TREATMENT", 59, 77], ["these problems", "PROBLEM", 81, 95]]], ["This paper argues, however, that in light of recent technological advances, knowledge management and social sciences theory development can now offer an important complement to the \u2018natural\u2019 sciences processes of scientific research, with important implications for research problem-solving.IntroductionCertain reasons for the inadequate responses to these emerging threats have been mooted.", [["knowledge management", "TREATMENT", 76, 96]]], ["There are other reasons for failure to address apocalyptic threats, and many other crises (not to mention global conflict) which might qualify for apocalyptic status, or have high potential human life costs.", [["human", "ORGANISM", 190, 195], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 190, 195], ["failure", "PROBLEM", 28, 35], ["apocalyptic threats", "PROBLEM", 47, 66], ["many other crises", "PROBLEM", 72, 89]]], ["Whereas denial (Feinberg & Willer, 2011) might be one form of response to such imminent and serious threats, it is argued in this paper that another more useful response to these challenges is emerging, according to different literatures.IntroductionThis response is broadly categorised here as a trend in research and collaborative problem-solving termed probabilistic innovation, or innovative problem-solving processes which seek to dramatically increase the probability of solving problems through harnessing economies of scale in knowledge management.", [["innovative problem", "PROBLEM", 385, 403], ["solving processes", "PROBLEM", 404, 421], ["solving problems", "PROBLEM", 477, 493], ["knowledge management", "TREATMENT", 535, 555]]], ["The key characteristic of this body of literature can be described as a focus on dramatically increasing the global intensity of collaborations between problem-solvers.", [["global", "OBSERVATION_MODIFIER", 109, 115], ["intensity", "OBSERVATION_MODIFIER", 116, 125]]], ["Further, this literature suggests bottlenecks to innovative research capacity can also have their roots in human behaviour and systems of researchers.IntroductionFollowing Kuhn\u2019s (1962) arguments that paradigms change only as the shared values and norms of researchers change places social science at the heart of constraints to innovation in scientific research, rather than the reductionist logics which frame scientific progress as a function of purely natural science theory.", [["roots", "ANATOMY", 98, 103], ["heart", "ANATOMY", 305, 310], ["human", "ORGANISM", 107, 112], ["heart", "ORGAN", 305, 310], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["paradigms change", "PROBLEM", 201, 217], ["heart", "ANATOMY", 305, 310]]], ["In relation to the failure of Newtonian theory to integrate new theory development into its core, Lakatos (1970) argues that scientific progress can be constrained by the failure of theoretical frameworks to be responsive to new ideas, and that the structure of academic processes can hold back innovation.IntroductionFurther, \u2018academic market failures\u2019 in academic research are commonplace (Dewald, Thursby, & Anderson, 1986), as constraints to innovative research and to the progress of science itself exist within the processes by which academic research is published and disseminated (Bornmann, 2010, 2011).", [["Newtonian theory", "TREATMENT", 30, 46], ["the failure of theoretical frameworks", "PROBLEM", 167, 204], ["disseminated", "OBSERVATION_MODIFIER", 575, 587]]], ["Empirical research in certain instances has been found to be associated with biases (Henrion & Fischhoff, 1986), including \u2018file drawer bias\u2019 where studies failing to reject the null hypothesis literally remain in \u2018file drawers\u2019 (De Long & Lang, 1992) and serious concern has long existed across many scientific disciplines about the processes by which science is disseminated, in that theoretical innovation can be constrained by gatekeepers (Peters & Ceci, 1982).", [["the null hypothesis", "PROBLEM", 174, 193], ["disseminated", "OBSERVATION_MODIFIER", 364, 376]]], ["Notwithstanding bias in theory testing methods, dissemination of theory for fair criticism and contestation is perhaps a necessary condition for the progression of science.IntroductionLongstanding evidence suggests social effects in the academic publication system can constrain innovative idea generation.", [["theory testing methods", "TEST", 24, 46], ["a necessary condition", "PROBLEM", 119, 140], ["social effects", "OBSERVATION", 215, 229]]], ["161) documents a \u2018tendency for humans to seek out, attend to, and sometime embellish experiences that support or \u201cconfirm\u201d their beliefs,\u2019 which has led to a bias against the dissemination of new perspectives, which is fundamentally at odds with Popper\u2019s (1972) notions of falsification, which require theoretical ideas to disseminate prior to their testing, or to provide opportunities for empirical falsification.", [["humans", "ORGANISM", 31, 37], ["humans", "SPECIES", 31, 37], ["humans", "SPECIES", 31, 37], ["falsification", "PROBLEM", 273, 286], ["their testing", "TEST", 344, 357], ["empirical falsification", "PROBLEM", 391, 414], ["falsification", "OBSERVATION", 273, 286]]], ["Serious issues related to the resistance of academics themselves to scientific discovery Campanario (2009) seem to support Kuhn\u2019s (1962) and Lakatos\u2019s (1970) seminal arguments that constraints to scientific innovation can primarily have roots in human behaviour, and that social science has an important role in addressing these problems.", [["roots", "ANATOMY", 237, 242], ["roots", "ORGANISM_SUBDIVISION", 237, 242], ["human", "ORGANISM", 246, 251], ["human", "SPECIES", 246, 251], ["human", "SPECIES", 246, 251], ["Serious issues", "PROBLEM", 0, 14], ["seminal arguments", "TREATMENT", 158, 175]]], ["Campanario (2009, pp. 550, 560) argues that the \u2018important topic of scientists\u2019 resistance to scientific discovery\u2019 is under-researched, as case studies show that \u2018scientists with something truly original to communicate often have to fight against the silence, the lack of interest, and as a result the absence of citations and recognition.\u2019IntroductionThis research therefore seeks to identify and articulate a stream of literature which argues a new paradigm in research problem-solving is emerging, on the back of emergent technologies which enable new opportunities, and that this emerging body of theory has important implications for HIV research as it places social science research as an important complement to natural science in problem-solving.", [["HIV", "SPECIES", 640, 643], ["emergent technologies", "TREATMENT", 517, 538], ["HIV research", "TREATMENT", 640, 652]]], ["The theoretical contribution of this article is therefore in its identification and delineation of boundary conditions to research problem-solving theory.", [["boundary conditions", "PROBLEM", 99, 118]]], ["Clear and practical examples are also offered to support the arguments made here, and the paper also makes a contribution in offering a review with important insights for practitioners involved in different aspects of HIV research.IntroductionIt is therefore argued here that this movement to maximise collaborative engagement between stakeholders, members of the problem-solving crowd and all manner of those affected by a problem effectively represents a paradigm shift in problem-solving, and that social media and technological advances, including big data Manyika et al. (2011) have enabled a potential for problem-solving hitherto relatively untapped.", [["HIV", "ORGANISM", 218, 221], ["HIV", "SPECIES", 218, 221], ["HIV research", "TREATMENT", 218, 230]]], ["The big data era has increased the transparency and usability of information (Manyika et al., 2011), and offers the potential for fundamental disruption in science and particularly in biological discovery (Swan, 2013).", [["fundamental disruption in science", "PROBLEM", 130, 163], ["transparency", "OBSERVATION_MODIFIER", 35, 47], ["disruption", "OBSERVATION", 142, 152]]], ["There is perhaps hope of a curative paradigm in science (outright cures for disease, albeit less profitable for pharma firms) and hope of advances in social science that can solve problems like global warming at the source, or in terms of human behaviour.IntroductionHowever, within a scientific context of dramatically increased information and data proliferation, as \u2018the breakneck pace of genome-technology development has revolutionised bioscience research\u2019 (Hayden, 2014, p.", [["human", "ORGANISM", 239, 244], ["human", "SPECIES", 239, 244], ["human", "SPECIES", 239, 244], ["a curative paradigm", "TREATMENT", 25, 44], ["disease", "PROBLEM", 76, 83], ["data proliferation", "PROBLEM", 346, 364]]], ["294) and information accumulation rates exceed predictions of Moore\u2019s Law, transmission to problem-solving outcomes is lacking (from big data to \u2018big\u2019 knowledge); the missing portion of the contribution of big data to global problem-solving equation may be what humans uniquely contribute, or complex and tacit (Nonaka, 1994) problem-solving knowledge creation.", [["humans", "ORGANISM", 262, 268], ["humans", "SPECIES", 262, 268], ["humans", "SPECIES", 262, 268], ["solving equation", "TREATMENT", 233, 249]]], ["It is argued in this paper that developing a stream of literature, or a field, explicitly focused on maximising human collaborations (as a dimension of knowledge management) could act as a counterpoint to the rapidly burgeoning field of big data and information management and enable a curative paradigm in health as well as more effective problem-solving in social science.", [["human", "ORGANISM", 112, 117], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["knowledge management", "TREATMENT", 152, 172], ["information management", "TREATMENT", 250, 272], ["a curative paradigm", "TREATMENT", 284, 303]]], ["This paper seeks to identify and link literature in support of this objective, and to make an argument that this literature may usefully be synthesised under the banner of an emerging field, namely probabilistic innovation, driven by a social movement toward the democratisation of knowledge (and therefore science, medicine and social science).IntroductionProbabilistic innovation theory, with its knowledge management \u2018lens,\u2019 focuses on the human dimension of problem-solving, predicting that exponential increases in problem-solving inputs can decisively increase probabilities of solving complex yet inherently \u2018solvable\u2019 problems (where the solution to such problems is realistically a function of problem-solving attention).", [["human", "ORGANISM", 443, 448], ["human", "SPECIES", 443, 448], ["human", "SPECIES", 443, 448], ["exponential", "OBSERVATION_MODIFIER", 495, 506], ["increases", "OBSERVATION_MODIFIER", 507, 516]]], ["However, the extent to which higher volumes of human problem-solving inputs transmit to problem-solving outputs is difficult to predict.", [["human", "ORGANISM", 47, 52], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["human problem", "PROBLEM", 47, 60], ["solving outputs", "PROBLEM", 96, 111], ["higher", "OBSERVATION_MODIFIER", 29, 35], ["volumes", "OBSERVATION_MODIFIER", 36, 43]]], ["This paper therefore argues that this knowledge problem (lack of knowledge of how to increase this transmission factor) is a critically important research question in all fields related to catastrophic social problems, for the following reasons.Introduction", [["catastrophic social problems", "PROBLEM", 189, 217], ["catastrophic", "OBSERVATION_MODIFIER", 189, 201]]]], "PMC7497562": [["Tensions: athlete as commodity versus athlete as communityIn observing early decision-making processes during the current pandemic that proposed that mega-sporting events continue as planned, a tension emerged between maintaining \u2018athlete as commodity\u2019 within a lucrative commercial industry, while recognising and promoting \u2018athlete as community\u2019 in a world that requires social cooperation to mitigate the impact of covid-19.", [["mega-sporting events", "PROBLEM", 150, 170]]]], "72d96332952747fa2604cb3cf5150fc88dbd2b85": [["Nowadays headache disorders represent a great impact on the sanitary system, and in fact the WHO currently reports that the worldwide prevalence among adults of current headache disorder is estimated to be around 50%; moreover, in Global Burden of Disease Study, headache disorders collectively were reported as the third highest cause of years lost due to disability.", [["headache disorders", "DISEASE", 9, 27], ["headache disorder", "DISEASE", 169, 186], ["Burden of Disease", "DISEASE", 238, 255], ["headache disorders", "DISEASE", 263, 281], ["disability", "DISEASE", 357, 367], ["headache disorders", "PROBLEM", 9, 27], ["current headache disorder", "PROBLEM", 161, 186], ["Disease Study", "TEST", 248, 261], ["headache disorders", "PROBLEM", 263, 281], ["disability", "PROBLEM", 357, 367], ["great", "OBSERVATION_MODIFIER", 40, 45], ["Global", "OBSERVATION_MODIFIER", 231, 237], ["Burden", "OBSERVATION_MODIFIER", 238, 244], ["Disease", "OBSERVATION", 248, 255]]], ["The most common headache disorders are migraine, tension-type headache (TTH) and trigeminal autonomic cephalalgias (TACs).", [["trigeminal autonomic cephalalgias", "ANATOMY", 81, 114], ["headache", "DISEASE", 16, 24], ["migraine", "DISEASE", 39, 47], ["tension-type headache", "DISEASE", 49, 70], ["TTH", "DISEASE", 72, 75], ["trigeminal autonomic cephalalgias", "DISEASE", 81, 114], ["TACs", "DISEASE", 116, 120], ["trigeminal autonomic cephalalgias", "CANCER", 81, 114], ["The most common headache disorders", "PROBLEM", 0, 34], ["migraine", "PROBLEM", 39, 47], ["tension-type headache (TTH)", "PROBLEM", 49, 76], ["trigeminal autonomic cephalalgias", "PROBLEM", 81, 114], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["trigeminal", "ANATOMY", 81, 91], ["autonomic cephalalgias", "OBSERVATION", 92, 114]]], ["Moreover, in many recent studies, headache is reported as one of the most frequent admitting symptoms to the emergency department, even if it has been well stated that the ED is a suboptimal place for headache treatment, suggesting that an urgent admission to a headache centre should be preferred even in the acute headache attacks [1] .", [["headache", "DISEASE", 34, 42], ["headache", "DISEASE", 201, 209], ["headache", "DISEASE", 262, 270], ["headache", "DISEASE", 316, 324], ["headache", "PROBLEM", 34, 42], ["admitting symptoms", "PROBLEM", 83, 101], ["headache treatment", "TREATMENT", 201, 219], ["a headache centre", "PROBLEM", 260, 277], ["the acute headache attacks", "PROBLEM", 306, 332]]]]}